This search looks for keywords in all of the website’s content. Search tips
Filter by
- Abasaglar (previously Abasria)(0)
- Abecma(0)
- Abevmy(0)
- Abilify(0)
- Abilify Maintena(0)
- Abilify MyCite(0)
- Abiraterone Accord(0)
- Abiraterone Krka(0)
- Abiraterone Mylan(0)
- Ablavar (previously Vasovist)(0)
- ABP 710(0)
- Abraxane(0)
- Abrysvo(0)
- Abseamed(0)
- Absenor(2)
- Abylqis(0)
- Accofil(0)
- Aclasta(0)
- Acnemine(1)
- Acneson(1)
- Acomplia(0)
- Acrelcombi(1)
- Acrescent(0)
- Actelsar HCT(0)
- Acticam(0)
- Actionis(0)
- Activyl(0)
- Activyl Tick Plus(0)
- Actocalcio D3(1)
- Actonel(1)
- Actonel Combi D(1)
- Actos(0)
- Actraphane(0)
- Actrapid(0)
- Adakveo(1)
- Adasuve(0)
- Adcetris(0)
- Adcirca (previously Tadalafil Lilly)(0)
- Adempas(0)
- Adenuric(0)
- Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals)(0)
- Adlumiz(0)
- Adrovance(0)
- AdTab (previously Lotilaner Elanco)(0)
- Adtralza(0)
- Aduhelm(0)
- Advagraf(0)
- Advasure(0)
- Advate(0)
- Advexin(0)
- Advocate(0)
- Adynovi(0)
- Aerinaze(1)
- Aerius(0)
- Aerivio Spiromax(0)
- Afastural(1)
- Afinitor(0)
- Aflunov(0)
- Afstyla(0)
- Aftovaxpur DOE(0)
- Agamree(0)
- Agenerase(0)
- Agilus(0)
- Aimovig(0)
- Airexar Spiromax(0)
- Aivlosin(0)
- Ajovy(0)
- Akeega(0)
- Akynzeo(0)
- Albrioza(0)
- Alcort(0)
- Aldara(0)
- Aldurazyme(0)
- Alecensa(0)
- Alendronic Acid / Colecalciferol Mylan(0)
- Alimta(0)
- Aliqopa(0)
- Alisade(0)
- Alkindi(0)
- Allex(0)
- Alli (previously Orlistat GSK)(0)
- Alofisel(0)
- Aloperidin(1)
- Aloxi(0)
- Alpheon(0)
- Alpivab(0)
- Alprolix(0)
- Alsitek(0)
- Altargo(0)
- Altuvoct(0)
- Alunbrig(0)
- Alvedon(1)
- Alymsys(0)
- Ambirix(0)
- Ambrisentan Mylan(0)
- Ambrisentan Zentiva(0)
- Ameluz(0)
- Amfepramon-Hormosan(1)
- Amgevita(0)
- Amglidia(0)
- Amias(1)
- Amifampridine SERB(0)
- Amlodipine / Valsartan Mylan(0)
- Amlodipine Pfizer(1)
- Amlodipino(1)
- Amlor(1)
- Ammonaps(1)
- Amsparity(0)
- Amunovax(1)
- Amversio(0)
- Amvuttra(0)
- Amyvid(0)
- Anagastra(1)
- Anagrelide Viatris (previously Anagrelide Mylan)(0)
- Angiosan(2)
- Angiox(0)
- Anoro Ellipta (previously Anoro)(0)
- Antiadiposo(1)
- Antra(1)
- Apealea(0)
- Apidra(0)
- Apixaban Accord(0)
- Apoquel(0)
- Apralan(0)
- Apremilast Accord(0)
- Apretude(0)
- Aprovel(0)
- Aptivus(0)
- Apton(1)
- Aquilda(0)
- Aquipta(0)
- Aqumeldi(0)
- Aranesp(0)
- Arava(0)
- Aredia(1)
- Arepanrix(0)
- Arexvy(0)
- Ariclaim(0)
- Arikayce(0)
- Arikayce liposomal(0)
- Aripiprazole Accord(0)
- Aripiprazole Mylan(0)
- Aripiprazole Mylan Pharma (previously Aripiprazole Pharmathen)(0)
- Aripiprazole Sandoz(0)
- Aripiprazole Zentiva(0)
- Arixtra(0)
- Armanor(1)
- Armisarte (previously Pemetrexed Actavis)(0)
- Arsenic trioxide Accord(0)
- Arsenic trioxide medac(0)
- Arsenic trioxide Mylan(0)
- Artesunate Amivas(0)
- Arti-Cell Forte(0)
- Artiss(1)
- Artobend(0)
- Arxxant(0)
- Arzerra(0)
- Aservo EquiHaler(0)
- Asimtufii(0)
- Aspaveli(0)
- AstraZeneca(1)
- Atacand Zid(1)
- Atarax(1)
- Atazanavir Krka(0)
- Atazanavir Mylan(0)
- Atectura Breezhaler(0)
- Atorvastatin(4)
- Atorvastatina(3)
- Atorvastatina Nostrum(1)
- Atorvastatina Parke-Davis(1)
- Atorvastatina Pharmacia(1)
- Atosiban SUN(0)
- Atriance(0)
- Atripla(0)
- ATryn(0)
- Aubagio(0)
- Aulin(1)
- Avaglim(0)
- Avalox(1)
- Avamys(0)
- Avandamet(0)
- Avandia(0)
- Avastin(0)
- Avelox(1)
- Avonex(0)
- Avuloxil(0)
- Awiqli(0)
- Axumin(0)
- Axura(0)
- Aybintio(0)
- Ayvakyt(0)
- Azacitidine Accord(0)
- Azacitidine betapharm(0)
- Azacitidine Celgene(0)
- Azacitidine Kabi(0)
- Azacitidine Mylan(0)
- Azarga(0)
- Azilect(0)
- Azomyr(0)
- Azopt(0)
- Balaxur(0)
- Balimek(0)
- Bamlanivimab and etesevimab for COVID-19(0)
- Baqsimi(0)
- Baraclude(0)
- Bavencio(0)
- Baycox Iron(0)
- Becloneb(1)
- Beclospin and Sanasthmax(1)
- Begedina(0)
- Bekemv(0)
- Belatamin 100 mg/ml solution for injection(0)
- Belatamin vet. 100 mg/ml solution for injection(0)
- Belviq(0)
- Bemfola(0)
- Bemrist Breezhaler(0)
- BeneFIX(0)
- Benepali(0)
- Benlysta(0)
- Beovu(0)
- Beprana(0)
- Beriplast P(1)
- Berny Adulti(1)
- Beromun(0)
- Besponsa(0)
- Besremi(0)
- Betaferon(0)
- Betmiga(0)
- Bevespi Aerosphere(0)
- Bexsero(0)
- Bextra(0)
- Beyfortus(0)
- Bezalip(1)
- Biferonex(0)
- Biktarvy(0)
- Bimervax(0)
- Bimzelx(0)
- BindRen(0)
- Binocrit(0)
- Biocaine(1)
- Biograstim(0)
- Biopoin(0)
- BiResp Spiromax(0)
- Blectifor(0)
- Blenrep(0)
- Blincyto(0)
- Blitzima(0)
- Blopresid(1)
- Blopress(1)
- Blopress Comp(1)
- Blopress Plus(1)
- Bluevac BTV (previously known as Bluevac BTV8)(0)
- Bondenza (previously Ibandronic Acid Roche)(0)
- Bondronat(0)
- Bonefos(1)
- Bonqat(0)
- Bonviva(0)
- Bortezomib Accord(0)
- Bortezomib Fresenius Kabi(0)
- Bortezomib Hospira(0)
- Bortezomib Sun(0)
- Bosatria(0)
- Bosulif(0)
- Bovalto Ibraxion(0)
- Bovela(0)
- Bovilis Blue-8(0)
- Bovilis BTV8(0)
- Bovilis Cryptium(0)
- Bovilis Nasalgen-C(0)
- Bovimec B(0)
- Braftovi(0)
- Bravecto(0)
- Bravecto Plus(0)
- Bretaris Genuair(0)
- Breyanzi(0)
- Bridion(0)
- Brilence(0)
- Brilique(0)
- Brimica Genuair(0)
- Brinavess(0)
- Brineura(0)
- Brintellix(0)
- Briumvi(0)
- Briviact (in Italy: Nubriveo)(0)
- Broadline(0)
- Bronchitol(0)
- BroPair Spiromax(0)
- Brucellin Aquilon(0)
- Brukinsa(0)
- BTVPUR(0)
- BTVPUR AlSap 1(0)
- BTVPUR AlSap 2-4(0)
- BTVPUR Alsap 8(0)
- Buccolam(0)
- Budesonide/Formoterol Teva(0)
- Budesonide/Formoterol Teva Pharma B.V.(0)
- Bufal(1)
- Busilvex(0)
- Busulfan Fresenius Kabi(0)
- Buvidal(0)
- Byannli (previously Paliperidone Janssen-Cilag International)(0)
- Bydureon(0)
- Byetta(0)
- Byfavo(0)
- Bylvay(0)
- Byooviz(0)
- Cabazitaxel Accord(0)
- Cabazitaxel Teva(0)
- Cablivi(0)
- Cabometyx(0)
- Caelyx pegylated liposomal(0)
- Calmaderm(1)
- Calquence(0)
- Camcevi(0)
- Camzyos(0)
- Canakinumab Novartis(0)
- Cancidas (previously Caspofungin MSD)(0)
- Canef(1)
- Canesten(1)
- Canigen L4(0)
- CaniLeish(0)
- Capecitabine Accord(0)
- Capecitabine Medac(0)
- Capecitabine SUN(0)
- Capecitabine Teva(0)
- Caprelsa(0)
- Carbaglu(0)
- Carbamazepina Tillomed(1)
- Carbamazepin Tillomed(1)
- Cardalis(0)
- Cardene IV(1)
- Cardiol(1)
- Cardiol XL(1)
- Cardioxane(1)
- Cardopal Start(1)
- Cardyl(4)
- Carmustine medac (previously Carmustine Obvius)(0)
- Carvykti(0)
- Casgevy(0)
- Caspofungin Accord(0)
- Catiolanze(0)
- Cavoley(0)
- Cayston(0)
- Cazitel Plus and Prazitel Plus(0)
- CEA-Scan(0)
- Cefenil(0)
- Cefortam(1)
- Ceftiocyl(0)
- Ceftiomax(0)
- Ceftiosan(0)
- Cefuroxima Allen(1)
- Cefuroxima Duncan(1)
- Cefuroxima Solasma(1)
- Cegfila (previously Pegfilgrastim Mundipharma)(0)
- Celdoxome pegylated liposomal(0)
- CellCept(0)
- Celldemic(0)
- Celsentri(0)
- Celsunax(0)
- Celvapan(0)
- Cemay(0)
- Cepedex(0)
- Cephaguard DC(0)
- Cephaguard IV IM 4.5%(0)
- Ceplene(0)
- Ceprotin(0)
- Cerdelga(0)
- Cerenia(0)
- Cerepro(0)
- Cerezyme(0)
- Certifect(0)
- Cervarix(1)
- Cetrotide(0)
- Cevaxel(0)
- Cevenfacta(0)
- Champix(0)
- Chanaxin(0)
- Chanhold(0)
- Chenodeoxycholic acid Leadiant (previously known as Chenodeoxycholic acid sigma-tau)(0)
- Cheristin(0)
- Chloe(1)
- Cholestagel(0)
- Cholib(0)
- ChondroCelect(0)
- Cialis(0)
- Ciambra(0)
- Cibinqo(0)
- Cilazapril Teva(1)
- Cimalgex(0)
- Cimzia(0)
- Cinacalcet Accordpharma(0)
- Cinacalcet Mylan(0)
- Cinqaero(0)
- Cinryze(0)
- Circadin(0)
- CircoMax(0)
- CircoMax Myco(0)
- Circovac(0)
- Citovirax(1)
- Clairette(1)
- Clevor(0)
- Clomicalm(0)
- Clopidogrel/Acetylsalicylic acid Teva(0)
- Clopidogrel / Acetylsalicylic acid Viatris (previously Clopidogrel / Acetylsalicylic acid Mylan)(0)
- Clopidogrel/Acetylsalicylic acid Zentiva (previously DuoCover)(0)
- Clopidogrel 1A Pharma(0)
- Clopidogrel Acino(0)
- Clopidogrel Acino Pharma(0)
- Clopidogrel Acino Pharma GmbH(0)
- Clopidogrel BGR (previously Zylagren)(0)
- Clopidogrel BMS(0)
- Clopidogrel DURA(0)
- Clopidogrel HCS(0)
- Clopidogrel Hexal(0)
- Clopidogrel Krka(0)
- Clopidogrel Krka d.d. (previously Zopya)(0)
- Clopidogrel Qualimed(0)
- Clopidogrel ratiopharm(0)
- Clopidogrel ratiopharm GmbH(0)
- Clopidogrel Sandoz(0)
- Clopidogrel TAD(0)
- Clopidogrel Taw Pharma (previously Clopidogrel Mylan)(0)
- Clopidogrel Teva (hydrogen sulphate)(0)
- Clopidogrel Teva Generics B.V.(0)
- Clopidogrel Teva Pharma(0)
- Clopidogrel Teva Pharma (previously Clopidogrel HCS)(0)
- Clopidogrel Teva Pharma B.V.(0)
- Clopidogrel Viatris (previously Clopidogrel Taw Pharma)(0)
- Clopidogrel Zentiva (previously Clopidogrel Winthrop)(0)
- Clynav(0)
- Co-Inhibace(1)
- Coagadex(0)
- CoAprovel(0)
- Cobactan(0)
- Cobactan 4.5%(0)
- Cobactan DC intramam Susp. Ad us. Vet(0)
- Cobactan DC suspension intramammaire(0)
- Cobactan IV 4.5% A.U.V.(0)
- Cobactan IV IM 4.5%(0)
- Cobactan Vet.(0)
- CoKenzen(1)
- Cokiera(0)
- Coliprotec F4(0)
- Coliprotec F4/F18(0)
- Colobreathe(1)
- Columvi(0)
- Combimarv(0)
- Combisyn Lactating Cow(0)
- Combivir(0)
- Cometriq(0)
- Comfortis(0)
- Comfyde(0)
- Comirnaty(0)
- Competact(0)
- Comtan(0)
- Comtess(0)
- Conbriza(0)
- Conet(1)
- Constella(0)
- Contacera(0)
- Controloc(1)
- Controloc Control(0)
- Contusugene Ladenovec Gendux(0)
- Convenia(0)
- Convival Chrono(2)
- Convulex(2)
- Convulsofin Tabletten(1)
- Copalia(0)
- Copalia HCT(0)
- Copiktra(0)
- Corbilta (previously Levodopa/Carbidopa/Entacapone Sandoz)(0)
- Cordinate(2)
- Corlentor(0)
- Corlentor and Procoralan(1)
- Corluxin(0)
- Cortaderm(0)
- Cortavance(0)
- Cosentyx(0)
- Cotellic(0)
- Cotronak(0)
- COVID-19 Vaccine (inactivated, adjuvanted) Valneva(0)
- Coxatab(0)
- Coxevac(0)
- Cozaar IC(1)
- Cozaar Startpakkle(1)
- Cranoc(1)
- Credelio(0)
- Credelio Plus(0)
- Cresemba(0)
- Crixivan(0)
- Crysvita(0)
- Cubicin(0)
- Cufence(0)
- Cuprior(0)
- Cuprymina(0)
- CureVac’s COVID-19 vaccine (CVnCoV)(0)
- Curocef(1)
- Curoxim(1)
- Curoxima(1)
- Curoxime(1)
- Curoxim Monovial(1)
- Cyanokit(0)
- Cylatron(0)
- Cyltezo(0)
- Cymbalta(0)
- Cymevan(1)
- Cyprest(1)
- Cyprodiol(1)
- Cyramza(0)
- Cyrdanax(1)
- Cystadane(0)
- Cystadrops(0)
- Cystagon(0)
- Cytopoint(0)
- Dabigatran Etexilate Accord(0)
- Dabigatran Etexilate Leon Farma(0)
- Dacogen(0)
- Dafiro(0)
- Dafiro HCT(0)
- Daklinza(0)
- Daliresp(0)
- Dalzad(2)
- Danifos Adulti(1)
- Dany's BienenWohl(0)
- Dapagliflozin Viatris(0)
- Daptomycin Hospira(0)
- Daquiran(0)
- Daronda(1)
- Daronrix(0)
- Darunavir Krka(0)
- Darunavir Krka d.d.(0)
- Darunavir Mylan(0)
- Darzalex(0)
- Dasatinib Accord(0)
- Dasatinib Accordpharma(0)
- Dasselta(0)
- DaTSCAN(0)
- Daurismo(0)
- Daxas(0)
- Daxocox(0)
- Dectomax 1%(0)
- Dectomax 1% Injectable Solution(0)
- Dectomax 1% Injektionslösung für Rinder und Schafe(0)
- Dectomax 5 mg/ml pour-on Solution for cattle(0)
- Dectomax 10 mg/ml solution for injection for cattle sheep and pigs(0)
- Dectomax Injectable Solution for Cattle and Sheep(0)
- Dectomax solution injectable(0)
- Dectomax Vet(0)
- Dectova(0)
- Deferasirox Accord(0)
- Deferasirox Mylan(0)
- Deferiprone Lipomed(0)
- Defitelio(0)
- Degarelix Accord(0)
- Delepsine(2)
- Delstrigo(0)
- Deltyba(0)
- Denagard 450 mg/g(0)
- Denagard vet 450 mg/g(0)
- Dengvaxia(0)
- Depakin(1)
- Depakine(2)
- Depakote(1)
- Depamag(1)
- Depamide(1)
- Depo-Eligard(1)
- DepoCyte(0)
- Deprakine(2)
- Descovy(0)
- Deseril(1)
- Desernil(1)
- Desloratadine Actavis(0)
- Desloratadine Krka(0)
- Desloratadine ratiopharm(0)
- Desloratadine Teva(0)
- Destara(0)
- Dexamethasone Taw(0)
- Dexdomitor(0)
- Dexdor(0)
- Dexmedetomidine Accord(0)
- Dexrazoxane Cyathus(1)
- Dexxience(0)
- Diacomit(0)
- Diane 35(1)
- Dianette(1)
- Dicural(0)
- Didronel(1)
- Dificlir(0)
- Digardil(1)
- Digaril Prolib(1)
- Dimethyl fumarate Accord(0)
- Dimethyl fumarate Mylan(0)
- Dimethyl fumarate Neuraxpharm(0)
- Dimethyl fumarate Polpharma(0)
- Dimethyl fumarate Teva(0)
- Dimherity(0)
- Diovan Cardio(2)
- Diovane(2)
- Diplexil(2)
- Dipromal(2)
- Diractin(0)
- Ditelos(0)
- Divence Penta(0)
- Divence Tetra(0)
- Docefrez(0)
- Docetaxel Accord(0)
- Docetaxel Kabi(0)
- Docetaxel Mylan(0)
- Docetaxel SUN(0)
- Docetaxel Teva(0)
- Docetaxel Teva Pharma(0)
- Docetaxel Zentiva (previously Docetaxel Winthrop)(0)
- DogStem(0)
- Doptelet(0)
- Doribax(0)
- Dotarem(1)
- Dovato(0)
- Dovobet(1)
- Dovprela (previously Pretomanid FGK)(0)
- Doxirobe(0)
- Doxolipad(0)
- Doxorubicin Hydrochloride Tillomed(0)
- Doxorubicin SUN(0)
- Doxycycline Dophama(0)
- Doxylin Vet(0)
- Doxymed 50(0)
- Doxy Ort 50%(0)
- Draxxin(0)
- Dropcys(0)
- Drovelis(0)
- Duaklir Genuair(0)
- Duavive(0)
- Dukoral(0)
- Duloxetine Boehringer Ingelheim(0)
- Duloxetine Lilly(0)
- Duloxetine Mylan(0)
- Duloxetine Sandoz(0)
- Duloxetine Zentiva(0)
- DuoCover(0)
- DuoPlavin(0)
- DuoResp Spiromax(0)
- DuoTrav(0)
- Dupixent(0)
- Dutrebis(0)
- Duzallo(0)
- Dynastat(0)
- Dynepo(0)
- Dynorm(1)
- Dynorm Plus(1)
- Dyrupeg(0)
- Dzuveo(0)
- Easotic(0)
- Ebglyss(0)
- Ebilfumin(0)
- Ebixa(0)
- Ebvallo(0)
- Ebymect(1)
- Ecalta(0)
- Ecansya (previously Capecitabine Krka)(0)
- EchoGen(0)
- Ecokinase(0)
- Econor(0)
- Ecoporc Shiga(0)
- Edarbi(0)
- Edistride(2)
- Edovin(4)
- Edurant(0)
- Efavirenz/Emtricitabine/Tenofovir disoproxil Krka(0)
- Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan(0)
- Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva(0)
- Efavirenz Teva(0)
- Effentora(0)
- Efficib(0)
- Efgratin(0)
- Eficur(0)
- Efient(0)
- Efmody(0)
- Egranli(0)
- Egrifta(0)
- Ekesivy(0)
- Ekistol(1)
- Eklira Genuair(0)
- Eladynos(0)
- Elaprase(0)
- Elebrato Ellipta(0)
- Elelyso(0)
- Elfabrio(0)
- Eligard(1)
- Eligard Depot(1)
- Eligard Mensua(1)
- Eligard Semestral(1)
- Eligard Trimestral(1)
- Eliquis(0)
- Elityran 1 Month Depot (Dps)(1)
- Elityran 3 Month Depot (Dps)(1)
- ellaOne(1)
- Ellefore(0)
- Elmiron(0)
- Elmisol(0)
- Elobact(1)
- Elocta(0)
- Elonva(0)
- Elrexfio(0)
- Elsep(1)
- Elucirem(0)
- Eluracat(0)
- Elzonris(0)
- Emadine(0)
- Emblaveo(0)
- Emdocam(0)
- Emend(0)
- Emerflu(0)
- Emgality(0)
- Empliciti(0)
- Emselex(0)
- Emtricitabine/Tenofovir disoproxil Krka(0)
- Emtricitabine/Tenofovir disoproxil Krka d.d.(0)
- Emtricitabine/Tenofovir disoproxil Mylan(0)
- Emtricitabine/Tenofovir disoproxil Zentiva(0)
- Emtriva(0)
- Enanton Depot Dual(1)
- Enanton Depot Set(1)
- Enantone(1)
- Enantone L.P(1)
- Enantone Lp(1)
- Enantone Monats-Depot(1)
- Enaxozar(1)
- Enbrel(0)
- EnCyzix(0)
- EndolucinBeta(0)
- Enerzair Breezhaler(0)
- Enhertu(0)
- Enjaymo(0)
- Enpaxiq(0)
- Enrylaze(0)
- Enspryng(0)
- Entacapone Orion(0)
- Entacapone Teva(0)
- Entecavir Accord(0)
- Entecavir Viatris (previously Entecavir Mylan)(0)
- Enteroporc Coli(0)
- Enteroporc Coli AC(0)
- Enthryv(0)
- Entolimod TMC(0)
- Entresto(0)
- Entyvio(0)
- Enurev Breezhaler(0)
- Envarsus(0)
- Enviage(0)
- Enyglid(0)
- Enzepi(0)
- Epclusa(0)
- Eperzan(0)
- Epidyolex(0)
- Epilim(2)
- Episalvan(0)
- Episenta(2)
- Epival(2)
- Epivir(0)
- Epjevy(0)
- Epoetin Alfa Hexal(0)
- Epoprostenol(1)
- Eporatio(0)
- Epostim(0)
- Eprinex - Lösung zum Auftragen auf die Haut für Rinder(0)
- Eprinex Pour-On for beef and dairy cattle(0)
- Eprinex pour-on vet(0)
- Eprinex pour on pour bovins(0)
- Eprinex Vet(0)
- Eptifibatide Accord(0)
- Epysqli(0)
- Equanil and other trade names(1)
- Equidacent(0)
- Equilis Prequenza(0)
- Equilis Prequenza Te(0)
- Equilis StrepE(0)
- Equilis Te(0)
- Equilis West Nile(0)
- Equioxx(0)
- Equip WNV (previously Duvaxyn WNV)(0)
- Equisolon(0)
- Equitend(0)
- Eravac(0)
- Erbitux(0)
- Erelzi(0)
- Ergenyl(2)
- Eribulin Baxter(0)
- Erivedge(0)
- Erleada(0)
- Erlotinib Accord(0)
- Ertapenem Hospira(0)
- Ertapenem SUN(0)
- Ervebo(0)
- Eryseng(0)
- Eryseng Parvo(0)
- Esbriet(0)
- Esmya(2)
- Espa-Valept(2)
- Esperoct(0)
- Estradiol Wolff(1)
- Ethinylestradiol-Drospirenone 24+4(1)
- Ethyl Eicosapent soft gelatin capsules(0)
- Eucreas(0)
- Eupantol(1)
- Eurartesim(0)
- Eurican Herpes 205(0)
- Eurican L4(0)
- Eurifel RCP FeLV(0)
- Evalon(0)
- Evanovo(0)
- Evant(0)
- Evarrest(0)
- Evenity(0)
- Evicel(0)
- Evicto(0)
- Eviplera(0)
- Evista(0)
- Evkeeza(0)
- Evoltra(0)
- Evotaz(0)
- Evotopin(0)
- Evra(0)
- Evrenzo(0)
- Evrysdi(0)
- Evusheld(0)
- Exalief(0)
- Exblifep(0)
- Excenel(0)
- Exelon(0)
- Exforge(0)
- Exforge HCT(0)
- Exitel Plus(0)
- Exjade(0)
- Exkivity(0)
- Exondys(0)
- Exparel liposomal(0)
- Extavia(0)
- Exubera(0)
- Exulett(0)
- Exviera(0)
- Exzolt(0)
- Eylea(0)
- Fabhalta(0)
- Fablyn(0)
- Fabrazyme(0)
- Factive(0)
- Faldaprevir Boehringer Ingelheim(0)
- Famciclovir-Sandoz(1)
- Famciclovir-SB(1)
- Famciclovir-SB Zoster(1)
- Fampridine Accord(0)
- Fampyra(0)
- Famvir Zoster and Oravir(1)
- Fanaptum(0)
- Fansamac(1)
- Fareston(0)
- Farydak(0)
- Fasenra(0)
- Faslodex(0)
- Fastum(1)
- Fasturtec(0)
- Fatrovax RHD(0)
- Febseltiq(0)
- Febuxostat Krka(0)
- Febuxostat Viatris (previously Febuxostat Mylan)(0)
- Felisecto Plus(0)
- Felpreva(0)
- Femar(1)
- Fémara(1)
- Feminil(1)
- Fendrix(0)
- Fenofibrato Pensa(1)
- Fenofibrato Ranbaxy(1)
- Feraccru(0)
- Feraheme(0)
- Ferriprox(0)
- Fertavid(0)
- Fetcroja(0)
- Fevaxyn Pentofel(0)
- Fexeric(0)
- Fiasp(0)
- Filgrastim Hexal(0)
- Filgrastim ratiopharm(0)
- Filspari(0)
- Filsuvez(0)
- Fingolimod Accord(0)
- Fingolimod Mylan(0)
- Finlee(0)
- Fintepla(0)
- Firazyr(0)
- Firdapse (previously Zenas)(0)
- Firmagon(0)
- Flebogamma DIF (previously Flebogammadif)(0)
- Flexicam(0)
- Flexyess(1)
- Flixabi(0)
- Flofera(2)
- Fluad Paediatric(0)
- Fluad Tetra(0)
- Flucelvax Tetra(0)
- Fluconazole(1)
- Fluenz(0)
- Fluenz Tetra(0)
- Flurbiprofeno Geiser(1)
- Flurbiprofen Sejmet(1)
- Flutiform(1)
- Flutiformo(2)
- Fluvastatina(1)
- Fluvastatin Novartis(1)
- Flynpovi(0)
- Focetria(0)
- Foclivia(0)
- Folcepri(0)
- Folotyn(0)
- Fomicyt(1)
- Forcaltonin(0)
- Forceris(0)
- Foresto(0)
- Formodual(1)
- Forsteo(0)
- Fortacin(0)
- Fortekor Plus(0)
- Fortovase(0)
- Forxiga(1)
- Fosamax(1)
- Fosavance(0)
- Foscan(0)
- Fosfocin(1)
- Fosfocina(1)
- Fosfocine(1)
- Fosfopharm(1)
- Fosfuro(1)
- Fosmol(1)
- Foster(1)
- Fostrofemge(1)
- Fotivda(0)
- Fractal(1)
- Frontpro (previously known as Afoxolaner Merial)(0)
- Fruzaqla(0)
- Fulphila(0)
- Fulvestrant Mylan(0)
- Fumomo 50(1)
- Fungata(1)
- Fungitraxx(0)
- Fungoral(1)
- Fungustatin(1)
- Fuzeon(0)
- Fycompa(0)
- Fyzoclad(0)
- Gabbrocol(0)
- Gabbrovet(0)
- Gado-MRT ratiopharm(1)
- Gadovist(1)
- Galafold(0)
- Galantamina(1)
- Galantamina Ciclum(1)
- Galantamine Tiefenbacher(1)
- Galastad(1)
- Galatnax xl(1)
- Gallimune Flu H5N9 (i)(0)
- Galliprant(0)
- Galvus(0)
- Gamifant(0)
- Ganfort(0)
- Ganirelix Gedeon Richter(0)
- Gardasil(1)
- Gardasil 9(1)
- Garenoxacin mesylate(0)
- Garsun(0)
- Gastromotal(0)
- Gavreto(0)
- Gazyvaro(0)
- Gefitinib Mylan(0)
- Gefzuris(0)
- GeGant(0)
- Gelisia(1)
- Gemesis(0)
- Genasense(0)
- Gencebok(0)
- Genoptol(1)
- Genotonorm(1)
- Genotropin(1)
- Genvoya(0)
- GHRYVELIN (previously Macimorelin Aeterna Zentaris)(0)
- Giapreza(0)
- Gilenya(0)
- Ginecrin Depot(1)
- Giotrif(0)
- Givlaari(0)
- Glazidim(1)
- Glidipion (previously Pioglitazone Actavis Group)(0)
- Glimepiride Pfizer(1)
- Glimepiride tablets 2 mg(1)
- Glimepiride tablets 3 mg(1)
- Glimepiride tablets 4 mg(1)
- Glimepirid Pfizer(1)
- Gliolan(0)
- Glivec(0)
- Glubrava(0)
- Glustin(0)
- Glybera(0)
- Glyxambi(0)
- GONAL-f(0)
- Gonazon(0)
- GoResp Digihaler (previously Budesonide/Formoterol Teva Pharma B.V.)(0)
- Gosacin(1)
- Goserelin Cell Pharm(1)
- Goserelin Novosis(1)
- Granpidam(0)
- Granupas (previously Para-aminosalicylic acid Lucane)(0)
- Graspa(0)
- Grastofil(0)
- Grasustek(0)
- Grepid(0)
- Gripovac 3(0)
- Gumbohatch(0)
- Gynofostrome(1)
- Halagon(0)
- Halaven(0)
- Haldol-Janssen(1)
- Haldol - Janssen Decanoat Depot(1)
- Haldol Decanoas(1)
- Haldol Decanoat(1)
- Haldol Decanoato(1)
- Haldol Depot(1)
- Halimatoz(0)
- Halocur(0)
- Harvoni(0)
- Havrix and associated names(1)
- HBVaxPro(0)
- Hefiya(0)
- Helicobacter Test INFAI(0)
- Helixate NexGen(0)
- Hemangiol(0)
- HemAryo(0)
- Hemgenix(0)
- Hemlibra(0)
- Hepacare(0)
- Heparesc(0)
- Hepcludex(0)
- Heplisav(0)
- Heplisav B(0)
- Hepsera(0)
- Herceptin(0)
- Hervelous(0)
- Herwenda(0)
- Herzuma(0)
- Hetlioz(0)
- Hexacima(0)
- Hexaquin(2)
- Hexavac(0)
- Hexyon(0)
- Hiprabovis IBR Marker Live(0)
- Hirobriz Breezhaler(0)
- Hizentra(0)
- Holoclar(0)
- HopGuard Gold(0)
- Hopveus(0)
- Horse Allo 20(0)
- HorStem(0)
- Hukyndra(0)
- Hulio(0)
- Humalog(0)
- Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech(0)
- HumaSPECT(0)
- Humatrope(1)
- Humenza(0)
- Humira(0)
- Hyalograft C autograft(0)
- Hycamtin(0)
- Hydrocortisone aceponate Ecuphar (previously Cortacare)(0)
- Hyftor(0)
- HyQvia(0)
- Hyrimoz(0)
- Hytacand(1)
- Iasibon(0)
- Ibaflin(0)
- Ibandronic acid Accord(0)
- Ibandronic Acid Hexal(0)
- Ibandronic Acid Sandoz(0)
- Ibandronic Acid Teva(0)
- Iblias(1)
- Ibrance(0)
- Ibuprofen/Diphenhydramine Hydrochloride Wyeth(0)
- Ibuprofen Fresenius Kabi 400 mg oplossing voor infusie(1)
- Ibuprofen Fresenius Kabi 400 mg solution pour perfusion(1)
- Ibuprofen Gen.Orph(0)
- Ibuprofen Kabi(1)
- Ibuprofen Kabi 400 mg(1)
- Ibuprofen Kabi 400 mg oldatos infúzió(1)
- Ibuprofen Kabi 400 mg raztopina za infundiranje(1)
- Ibuprofen Kabi 400 mg soluţie perfuzabilă(1)
- Ibuprofen Kabi 400 mg Solution for Infusion(1)
- Ibuprofeno Kabi 400 mg solución para perfusion(1)
- Icandra (previously Vildagliptin / metformin hydrochloride Novartis)(0)
- Icatibant Accord(0)
- Iclusig(1)
- Idacio(0)
- Idefirix(0)
- Idelvion(0)
- IDflu(0)
- Idhifa(0)
- Iffeza(1)
- Ifirmacombi(0)
- Ifirmasta (previously Irbesartan Krka)(0)
- Ifo-Cell(1)
- Ifo-Cell N(1)
- Ifo-Cell N 2000(1)
- Ifosfamide Eg(1)
- Ikervis(0)
- Ilaris(0)
- Ilumetri(0)
- Imagify(0)
- Imatinib Accord(0)
- Imatinib Actavis(0)
- Imatinib Koanaa(0)
- Imatinib medac(0)
- Imatinib Teva(0)
- Imatinib Teva B.V.(0)
- Imbarkyd(0)
- Imbruvica(0)
- Imcivree(0)
- Imfinzi(0)
- Imipem(1)
- Imjudo(0)
- Imlygic(0)
- ImmunoGam(0)
- Imnovid (previously Pomalidomide Celgene)(0)
- Imoxat(0)
- Imprida(0)
- Imprida HCT(0)
- Improvac(0)
- Impulsor(0)
- Imraldi(0)
- Imrestor(0)
- Imvanex(0)
- Inaqovi(0)
- Inbrija(0)
- Incellipan(0)
- Incivo(0)
- Increlex(0)
- Incresync(0)
- Increxxa(0)
- Incruse Ellipta (previously Incruse)(0)
- Incurin(0)
- Indimacis 125(0)
- Inductos(1)
- Infanrix HepB(0)
- Infanrix Hexa(0)
- Infanrix Penta(0)
- Infectofos(1)
- Infergen(0)
- Infeur Adulti(1)
- Infinia(0)
- Inflacam(0)
- Inflectra(0)
- Ingelvac CircoFLEX(0)
- Ingelvac PCV FLEX(0)
- Inhibace(1)
- Inhibace Plus(1)
- Inhixa(0)
- Inibace(1)
- Inipomp(1)
- Inlyta(0)
- Innovair and associated names(1)
- Innovax-ILT(0)
- Innovax-ILT-IBD(0)
- Innovax-ND-H5(0)
- Innovax-ND-IBD(0)
- Innovax-ND-ILT(0)
- INOmax(0)
- Inovelon(0)
- Inpremzia(0)
- Inrebic(0)
- Instanyl(0)
- Insulatard(0)
- Insulin aspart Sanofi(0)
- Insulin Human 30/70 Mix Marvel(0)
- Insulin Human Long Marvel(0)
- Insulin Human Rapid Marvel(0)
- Insulin Human Winthrop(0)
- Insulin lispro Sanofi(0)
- Insuman(0)
- Intanza(0)
- Integrilin(0)
- Intelence(0)
- Interfos(1)
- Intrarosa(0)
- Intrinsa(0)
- IntronA(0)
- Intuniv(0)
- Inuxair(1)
- Invanz(0)
- Invega(0)
- Invirase(0)
- Invokana(1)
- Ioa(0)
- Ionsys(0)
- Ipique(0)
- Iplex(0)
- Ipreziv(0)
- Irbesartan/Hydrochlorothiazide Teva(0)
- Irbesartan BMS(0)
- Irbesartan Hydrochlorothiazide BMS(0)
- Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)(0)
- Irbesartan Teva(0)
- Irbesartan Zentiva (previously Irbesartan Winthrop)(0)
- Iressa(0)
- Iscover(0)
- Isemid(0)
- Isentress(0)
- Isomarv medium(0)
- Issarlos(0)
- Istin(1)
- Istodax(0)
- Isturisa(0)
- Ivabradine Accord(0)
- Ivabradine Anpharm(0)
- Ivabradine JensonR(0)
- Ivabradine Zentiva(0)
- Ivemend(0)
- Ivomec-Eprinex Pour On voor vlees- en melkvee(0)
- Ivozall(0)
- Ixempra(0)
- Ixense(0)
- Ixiaro(0)
- IXinity(0)
- Izba(0)
- Jakavi(0)
- Jalra(0)
- Janacti(0)
- Janumet(0)
- Januvia(0)
- Jardiance(1)
- Javlor(0)
- Jayempi(0)
- Jaypirca(0)
- Jcovden (previously COVID-19 Vaccine Janssen)(0)
- Jemperli(0)
- Jentadueto(0)
- Jenzyl(0)
- Jeraygo(0)
- Jesduvroq(0)
- Jetrea(0)
- Jevtana(0)
- Jinarc(0)
- Jivadco(0)
- Jivi(0)
- Joicela(0)
- Jorveza(0)
- Joulferon(0)
- Jubbonti(0)
- Juluca(0)
- Justor(1)
- Jylamvo(1)
- Jyseleca(0)
- Kadcyla(0)
- Kaftrio(0)
- Kalbitor(0)
- Kaletra(0)
- Kalpress(1)
- Kalpress Cardio(2)
- Kalydeco(0)
- Kanjinti(0)
- Kantos(1)
- Kanuma(0)
- Kapruvia(0)
- Karbamazepina Tillomed(1)
- Karbamazepin Tillomed(1)
- Karvea(0)
- Karvezide(1)
- Kauliv(0)
- Kengrexal(0)
- Kentera (previously Oxybutynin Nicobrand)(0)
- Kentlim(1)
- Kenzen(1)
- Kepivance(0)
- Kepnetic(0)
- Keppra(0)
- Kerendia(0)
- Kesimpta(0)
- Ketabel vet. 100 mg/ml solution for injection(0)
- Ketek(0)
- Ketoconazole AID-SCFM(0)
- Ketoconazole HRA(0)
- Ketum(1)
- Kevatril(1)
- Kevzara(0)
- Kexxtone(0)
- Keytruda(0)
- Kiacta(0)
- Kigabeq(0)
- Kimmtrak(0)
- Kineret(0)
- Kinpeygo(0)
- Kinzalkomb(0)
- Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)(0)
- Kiovig(0)
- Kirsty (previously Kixelle)(0)
- Kisplyx(0)
- Kisqali(0)
- Kivexa(0)
- Klebrocid 3-Monats-Depot(1)
- Klebrocid Depot Zweikammerspritze(1)
- Klisyri(0)
- Kogenate Bayer(0)
- Kolbam(0)
- Komboglyze(0)
- Koselugo(0)
- Kovaltry(0)
- Krazati(0)
- Kriptazen(0)
- Kromeya(0)
- Krystexxa(0)
- Kuvan(0)
- Kymriah(0)
- Kynamro(0)
- Kyndrisa(0)
- Kyntheum(0)
- Kyomarc(0)
- Kyprolis(0)
- Labazenit(0)
- Lacosamide Accord(0)
- Lacosamide Adroiq(0)
- Lacosamide Pain UCB Pharma(0)
- Lacosamide UCB(0)
- Lagevrio(0)
- Lamivudine/Zidovudine Teva(0)
- Lamivudine Teva(0)
- Lamivudine Teva Pharma B.V.(0)
- Lamzede(0)
- Lantus(0)
- Lartruvo(1)
- Latanoprost Pharmacia & Upjohn(1)
- Latuda(0)
- Laventair Ellipta (previously Laventair)(0)
- Ledaga(0)
- Ledertrexate(1)
- Leflunomide Actavis(1)
- Leflunomide Apotex(1)
- Leflunomide medac(0)
- Leflunomide ratiopharm(0)
- Leflunomide Teva(0)
- Leflunomide Zentiva (previously Leflunomide Winthrop)(0)
- Leganto(0)
- Lemtrada(1)
- Lenalidomide Accord(0)
- Lenalidomide Celgene Europe(0)
- Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto)(0)
- Lenalidomide Krka d.d.(0)
- Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka)(0)
- Lenalidomide Mylan(0)
- Lentogest(1)
- Lenvima(0)
- Leposit Prolib(1)
- Leptilan(2)
- Leptoprol(1)
- Leqvio(0)
- Lerin(1)
- Lescol Depot(1)
- Lescol Exel(1)
- Lescol LP(1)
- Lescol MR(1)
- Lescol Prolib(1)
- Lescol XL(1)
- Letifend(0)
- Leucofeligen FeLV/RCP(0)
- Leucogen(0)
- Leugon(1)
- LeukoScan(0)
- Leuprex 3(1)
- Leupro-Sandoz 1-Monats-Depot(1)
- Leupro-Sandoz 3-Monats-Depot(1)
- Leuprol(1)
- Leuprolin Ratiopharm(1)
- Leuprone 1-Monatsdepot(1)
- Leuprone 3-Monatsdepot(1)
- Leuprorelin 1-Month Depot Gp-Pharm(1)
- Leuprorelina Gp-Pharm(1)
- Leuprorelina Trimestral Sandoz(1)
- Leuproreline Sandoz(1)
- Leuprorelin Hexal(1)
- Leuprorelin Sandoz(1)
- Leuprostin(1)
- Levemir(0)
- Levetiracetam Accord(0)
- Levetiracetam Actavis(0)
- Levetiracetam Actavis Group(0)
- Levetiracetam Hospira(0)
- Levetiracetam ratiopharm(0)
- Levetiracetam Sun(0)
- Levetiracetam Teva(0)
- Levitra(0)
- Levodopa/Carbidopa/Entacapone Orion(0)
- Levofloxacin(1)
- Levonelle/Postinor and Levodonna(1)
- Levviax(0)
- Lextemy(0)
- Lexylan(0)
- Libertek(0)
- Libmeldy(0)
- Libmyris(0)
- Librela(0)
- Libtayo(0)
- Lidocaïne / Prilocaïne 5% Focus, Crème(1)
- Lifmior(0)
- Linhaliq(0)
- Linoladiol(1)
- Linoladiol Estradiol(1)
- Linoladiol N(1)
- Lipanor(1)
- Lipanthyl(1)
- Lipaxan(1)
- Lipaxin(1)
- Lipitor(3)
- Liposit(1)
- Liprimar(4)
- Liprolog(0)
- Litak(0)
- Litfulo(0)
- Livensa(0)
- Livmarli(0)
- Livogiva(0)
- Livtencity(0)
- Lixiana(0)
- Loargys(0)
- Locametz(0)
- Locatim (previously Serinucoli)(0)
- Locol(1)
- Lodipressin(0)
- Logastric(1)
- Lojuxta(0)
- Lokelma(0)
- Longrange(0)
- Lonquex(0)
- Lonsurf(0)
- Loortan(1)
- Loortan Cardio Start(1)
- Lopid(1)
- Lopinavir/Ritonavir Mylan(0)
- Lortaan(1)
- Lortaar IC(1)
- Lorviqua(0)
- Lorzaar(1)
- Lorzaar Protect(1)
- Lorzaar start(1)
- Lorzaar Varipharmstart(1)
- Losaprex(1)
- Losec Forte(1)
- Lotilaner Elanco(0)
- Lotimax(0)
- Loulla(0)
- Loxen(1)
- Loxicom(0)
- Loxifan(1)
- Loxitab(0)
- Lucentis(0)
- Lucrin(1)
- Lucrin Depot(1)
- Lucrin Pds Depot(1)
- Lucrin Pds Depot 1 Maand(1)
- Lucrin Pds Depot 3 Maanden(1)
- Lucrin Pds Depot 6 Maanden(1)
- Lumark(0)
- Lumeblue (previously known as Methylthioninium chloride Cosmo)(0)
- Lumevoq(0)
- Lumigan(0)
- Luminity(0)
- Lumoxiti(0)
- Lumykras(0)
- Lunivia(0)
- Lunsumio(0)
- Lupkynis(0)
- Lupron Depo(1)
- Lusduna(0)
- Lutathera(0)
- Lutetium (177Lu) chloride Billev (previously Illuzyce)(0)
- Lutholaz(0)
- Lutrate 1 Month Depot(1)
- Lutrate 3 Month Depot(1)
- Lutrate Depo(1)
- Lutrate Depot(1)
- Lutrate Depot Trimestral(1)
- Luveniq(0)
- Luveris(0)
- Luxceptar(0)
- Luxturna(0)
- Lydaxx(0)
- Lydisilka(0)
- Lyfnua(0)
- Lymetel(1)
- Lymphoseek(0)
- Lympreva(0)
- Lynparza(0)
- Lyrica(0)
- LysaKare(0)
- Lysodren(0)
- Lytenava(0)
- Lytgobi(0)
- Lyumjev (previously Liumjev)(0)
- Lyxumia(0)
- M-M-RVaxPro(0)
- MabCampath(0)
- MabThera(0)
- Maci(1)
- Macugen(0)
- Magnegita(1)
- Magnevist(1)
- Marixino (previously Maruxa)(0)
- Marker lebend(0)
- Masican(0)
- Masipro(0)
- Masivet(0)
- Masiviera(0)
- Mastu S(1)
- Matever(0)
- Mavenclad(0)
- Maviret(0)
- Maxolon(1)
- Maxomat(1)
- Maxtrex(1)
- Mayzent(0)
- Medicinal Oxygen Air Liquide Sante(0)
- Megestrol Alkermes(0)
- Mekinist(0)
- Mektovi(0)
- Melatonin Neurim(0)
- Melosus(0)
- Melovem(0)
- Meloxidolor(0)
- Meloxidyl(0)
- Meloxivet(0)
- Meloxoral(0)
- Memantine Accord(0)
- Memantine FGK(0)
- Memantine LEK(0)
- Memantine Merz(0)
- Memantine Mylan(0)
- Memantine ratiopharm(0)
- MenQuadfi(0)
- Mentocaína Spray(1)
- Menveo(0)
- Mepact(0)
- Mepsevii(0)
- Mersarex(0)
- Metacam(0)
- Metalyse(0)
- Metex(1)
- Methylthioninium chloride Proveblue(0)
- Metoject(1)
- Mevlyq(0)
- Mhyosphere PCV ID(0)
- Micardis(0)
- MicardisPlus(0)
- Micotil(0)
- Micotil - Injektionslösung für Rinder(0)
- Micotil 300 inj. ad us. vet.(0)
- Micotil Injection(0)
- Micropakine L.P.(2)
- Miglustat Dipharma(0)
- Miglustat Gen.Orph(0)
- Milnacipran Pierre Fabre Medicament(0)
- Mimpara(0)
- Minerva(1)
- Minjuvi(0)
- MiPet Easecto(0)
- Miplyffa(0)
- Mirapexin(0)
- Mirataz(0)
- Mircera(0)
- Mirvaso(0)
- Miten(1)
- Miten Cardio(2)
- Mixtard(0)
- Modasomil(1)
- Modigraf(0)
- Modiodal(1)
- Mometamax Ultra(0)
- Mometasone Furoato Sandoz 50(1)
- Mometasone Sandoz(1)
- Mometasone Sandoz 50(1)
- Mommox(1)
- Monopina(1)
- Monotard(0)
- Montadiol(1)
- Monural(1)
- Monuril(1)
- Monurol(1)
- Mopral(1)
- Mounjaro(0)
- Movectro(0)
- Moventig(0)
- Movymia(0)
- Mozobil(0)
- MS-H Vaccine(0)
- Mulpleo (previously Lusutrombopag Shionogi)(0)
- Mulsevo(0)
- Multaq(0)
- MultiHance(1)
- Muscoril and Coltramyl(1)
- Mvabea(0)
- Mvasi(0)
- Myalepta(0)
- Mycamine(0)
- Mycapssa(0)
- Myclausen(0)
- Mycograb(0)
- Mycophenolate mofetil Teva(0)
- Myfenax(0)
- Mylotarg(0)
- Myocet liposomal (previously Myocet)(0)
- Myolastan and generics(1)
- Myozyme(0)
- Mysildecard(0)
- Mysimba(1)
- n/a(1)
- Naglazyme(0)
- Namuscla(0)
- Nasometi(1)
- Nasym(0)
- Natalizumab Elan Pharma(0)
- Natpar(0)
- Naveruclif(0)
- Naxcel(0)
- Neffy(0)
- Nemdatine(0)
- Nenad(0)
- Neo-Lotan(1)
- Neoatricon(0)
- Neocepri(0)
- Neoclarityn(0)
- Neocolipor(0)
- Neofordex(0)
- Neoleish(0)
- NeoRecormon(0)
- NeoSpect(0)
- Neparvis(0)
- Nepexto(0)
- Neptra(0)
- Nerixia(1)
- Nerlynx(0)
- Nerventra(0)
- Nespo(0)
- Netvax(0)
- Neulasta(0)
- Neupopeg(0)
- Neupro(0)
- Neuraceq(0)
- NeuroBloc(0)
- Nevanac(0)
- Nevirapine Teva(0)
- Newflend ND H9(0)
- Nexavar(0)
- NexGard(0)
- NexGard Combo(0)
- Nexgard Spectra(0)
- Nexium Control(0)
- NexoBrid(0)
- Nexpovio(0)
- Nexviadyme(0)
- Nezglyal(0)
- Ngenla(0)
- Niapelf(0)
- Nicardipine Aguettant(1)
- Nicardipine Arrow(1)
- Nilemdo(0)
- Nimed(1)
- Nimenrix(0)
- Nimvastid(0)
- Ninlaro(0)
- Nintedanib Accord(0)
- Nisamox Lactating Cow(0)
- Nitisinone MDK (previously Nitisinone MendeliKABS)(0)
- Nityr(0)
- Nivador(1)
- Nivestim(0)
- Nivolumab BMS(0)
- Nizoral(1)
- Nobilis IB 4-91(0)
- Nobilis IB Primo QX(0)
- Nobilis Influenza H5N2(0)
- Nobilis Influenza H5N6(0)
- Nobilis Influenza H7N1(0)
- Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS(0)
- Nobilis OR Inac(0)
- Nobivac Bb(0)
- Nobivac DP Plus(0)
- Nobivac L4(0)
- Nobivac LeuFel(0)
- Nobivac LoVo L4(0)
- Nobivac Myxo-RHD(0)
- Nobivac Myxo-RHD Plus(0)
- Nobivac Piro(0)
- Nodetrip (previously Xeristar)(0)
- Nonafact(0)
- Nordimet(1)
- Norditropin(1)
- Norditropin FlexPro(1)
- Norditropin NordiFlex(1)
- Norditropin SimpleXx(1)
- Norlevo(1)
- Noroclav Lactating Cow(0)
- Norvir(0)
- Nouryant(0)
- Novaquin(0)
- Novem(0)
- Novimp and associated names(1)
- NovoEight(0)
- NovoMix(0)
- NovoNorm(0)
- NovoRapid(0)
- NovoSeven(0)
- Novosis Goserelin(1)
- NovoThirteen(0)
- Noxafil(0)
- Nplate(0)
- Nubeqa(0)
- Nucala(0)
- Nuceiva(0)
- Nuedexta(0)
- Nulibry(0)
- Nulojix(0)
- Numient(0)
- Nustendi(0)
- NutropinAq(0)
- Nuvaxovid(0)
- Nuwiq(0)
- Nuzyra(0)
- Nyracta(0)
- Nyvepria(0)
- Nyxoid(0)
- Nyxthracis (previously Obiltoxaximab SFL)(0)
- Obgemsa(0)
- Obizur(0)
- Obradon(3)
- Ocaliva(1)
- Ocrevus(0)
- Odefsey(0)
- Odomzo(0)
- Ofev(0)
- Ogivri(0)
- Ogluo(0)
- Okedi(0)
- Olansek(0)
- Olanzapine Apotex(0)
- Olanzapine Cipla (previously Olanzapine Neopharma)(0)
- Olanzapine Glenmark(0)
- Olanzapine Glenmark Europe(0)
- Olanzapine Mylan(0)
- Olanzapine Teva(0)
- Olazax(0)
- Olazax Disperzi(0)
- Olbetam(1)
- Olumiant(0)
- Olysio(0)
- Omblastys(0)
- Omeprazen(1)
- Omeprazole(1)
- Omidria(0)
- Omjjara(0)
- Omlyclo(0)
- Omniscan(1)
- Omnitrope(0)
- Omontys(0)
- Omvoh(0)
- Onbevzi(0)
- Onbrez Breezhaler(0)
- Oncaspar(0)
- Oncept IL-2(0)
- Oncept Melanoma(0)
- Oncophage(0)
- Ondexxya(0)
- Onduarp(0)
- Ongentys(0)
- Onglyza(0)
- Onivyde pegylated liposomal (previously known as Onivyde)(0)
- Onpattro(0)
- Onsenal(0)
- Onsior(0)
- Ontilyv(0)
- Ontozry(0)
- Ontruzant(0)
- Onureg(0)
- Onzeald(0)
- Opatanol(0)
- Opaxio(0)
- Opdivo(0)
- Opdualag(0)
- Opfolda(0)
- Opgenra(0)
- Oportuzumab monatox DLRC Pharma Services(0)
- Oprymea(0)
- Opsiria(0)
- Opsumit(0)
- Optaflu(0)
- Opticalcio D3(1)
- Optimark(1)
- Optinate Plus Ca&D(1)
- Optison(0)
- Optruma(0)
- Opulis(0)
- Opzelura(0)
- OraNera(0)
- Orathecin(0)
- Oraxim(1)
- orBec(0)
- Orbeos(4)
- Orencia(0)
- Orepaxam(0)
- Orfadin(0)
- Orfiril(2)
- Orgalutran(0)
- Orgovyx(0)
- Orkambi(0)
- Orlaam(0)
- Orladeyo(0)
- Orlept(1)
- Orphacol(0)
- Orplatna(0)
- Orserdu(0)
- Orudis(1)
- Osigraft(0)
- Oslif Breezhaler(0)
- Osseor(0)
- Osurnia(0)
- Otezla(0)
- Ovaleap(0)
- Ovitrelle(0)
- OvuGel(0)
- Oxapex(0)
- Oxbryta(0)
- Oxervate(0)
- Oxlumo(0)
- Oxmax(0)
- Oxybee(0)
- Oxyglobin(0)
- Oyavas(0)
- Ozawade(0)
- Ozempic(0)
- Ozespa(0)
- Ozurdex(0)
- Paccal Vet(0)
- Padcev(0)
- Paglitaz(0)
- Palforzia(0)
- Palladia(0)
- Palonosetron Accord(0)
- Palonosetron Hospira(0)
- Palynziq(0)
- Panacur AquaSol(0)
- Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune)(0)
- Pandemic Influenza Vaccine H5N1 Baxter AG(0)
- Pandemrix(0)
- Panretin(1)
- Pantec(1)
- Pantecta(4)
- Pantecta Control(0)
- Pantipp(1)
- Panto-Byk-20 / 40 / IV(1)
- Pantoc(1)
- Pantoloc(1)
- Pantoloc Control(0)
- PantoLomberg(1)
- Pantopan(1)
- Pantorc(1)
- Pantozol(1)
- Pantozol Control(0)
- Panzim(1)
- Paracomb(1)
- Parapres(1)
- Parapres Plus(1)
- Parareg(0)
- Parfenac(1)
- Parfenoide(1)
- Parofor(0)
- Parsabiv(0)
- Parsaclisib Incyte Biosciences Distribution B.V.(0)
- Parvoduk(0)
- Patrex(0)
- Paxene(0)
- Paxlovid(0)
- Pazenir(0)
- PecFent(0)
- Pedea(0)
- Pedmarqsi(0)
- Pegasys(0)
- PegIntron(0)
- Pelgraz(0)
- Pelmeg(0)
- Pelzont(0)
- Pemazyre(0)
- Pemetrexed Accord(0)
- Pemetrexed Baxter(0)
- Pemetrexed ditromethamine Hospira(0)
- Pemetrexed Fresenius Kabi(0)
- Pemetrexed Krka(0)
- Pemetrexed Lilly(0)
- Pemetrexed medac(0)
- Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited)(0)
- Pemetrexed Pfizer (previously Pemetrexed Hospira)(0)
- Pemetrexed Sandoz(0)
- Pepaxti(0)
- Peptazol(1)
- Pergoveris(0)
- Perjeta(0)
- Petilin(2)
- Pexion(0)
- Peyona (previously Nymusa)(0)
- Pheburane(0)
- Phelinun(0)
- Phesgo(0)
- PhotoBarr(0)
- Picato(1)
- Pifeltro(0)
- PigFlor Once(0)
- Pinzaar(1)
- Pioglitazone Accord(0)
- Pioglitazone Actavis(0)
- Pioglitazone Krka(0)
- Pioglitazone ratio(0)
- Pioglitazone ratiopharm(0)
- Pioglitazone ratiopharm GmbH(0)
- Pioglitazone Teva(0)
- Pioglitazone Teva Generics(0)
- Pioglitazone Teva Pharma(0)
- Piqray(0)
- Pirfenidone axunio (previously Pirfenidone AET)(0)
- Pirfenidone Viatris(0)
- Pirsue(0)
- Pixuvri(0)
- Plavix(0)
- Please see Annex I(0)
- Plegridy(0)
- Plenadren(0)
- Plerixafor Accord(0)
- Pletal(1)
- Plivensia(0)
- Pluvicto(0)
- Politrate(1)
- Politrate Depot(1)
- Polivy(0)
- Pomalidomide Viatris(0)
- Pombiliti(0)
- Ponvory(0)
- Porcilis AR-T DF(0)
- Porcilis ColiClos(0)
- Porcilis PCV(0)
- Porcilis PCV ID(0)
- Porcilis PCV M Hyo(0)
- Porcilis Pesti(0)
- Porcilis Porcoli Diluvac Forte (previously Porcilis Porcoli)(0)
- Porcimec P(0)
- Portrazza(0)
- Posaconazole Accord(0)
- Posaconazole AHCL(0)
- Posaconazole SP(0)
- Posatex(0)
- Possia(0)
- Potactasol(0)
- Poteligeo(0)
- Poulvac E. coli(0)
- Poulvac Flufend H5N3 RG(0)
- Poulvac Procerta HVT-IBD(0)
- Prac-tic(0)
- Pradaxa(0)
- Praluent(0)
- Pramipexole Accord(0)
- Pramipexole Teva(0)
- Prandin(0)
- Prasugrel Viatris (previously Prasugrel Mylan)(0)
- Pravafenix(0)
- Praxbind(0)
- Prazical Plus(0)
- Pregabalin Accord(0)
- Pregabalin Mylan(0)
- Pregabalin Mylan Pharma(0)
- Pregabalin Pfizer(0)
- Pregabalin Sandoz(0)
- Pregabalin Sandoz GmbH(0)
- Pregabalin Zentiva(0)
- Pregabalin Zentiva k.s.(0)
- PreHevbri(0)
- Preotact(0)
- Prepandemic Influenza Vaccine (H5N1) (Split Virion, Inactivated, Adjuvanted) GlaxoSmithKline Biologicals(0)
- Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics(0)
- Prepandrix(0)
- Prevenar(0)
- Prevenar 13(0)
- Prevenar 20 (previously Apexxnar)(0)
- Prevencor(4)
- Prevexxion RN(0)
- Prevexxion RN+HVT(0)
- Prevexxion RN+HVT+IBD(0)
- Previcox(0)
- Prevomax(0)
- Prevymis(0)
- Prexige(1)
- Prezista(0)
- Prialt(0)
- Primavax(0)
- Primaxin(1)
- Primesin(1)
- Primovist(1)
- Primperan(1)
- Priorix(1)
- Priorix Tetra(1)
- Pristiqs(0)
- Pritor(0)
- PritorPlus(0)
- Privigen(0)
- Procard(1)
- Procomvax(0)
- Procoralan(0)
- Procox(0)
- Procren Depot(1)
- Procren Depot Pds(1)
- Procrin Mensual(1)
- Procrin Semestral(1)
- Procrin Trimestral(1)
- Proctosan(1)
- Procysbi(0)
- Profender(0)
- Progesterone Retard Pharlon(1)
- ProHance(1)
- Prohippur(0)
- Prolevare(0)
- Prolia(0)
- Proluton Depot(1)
- ProMeris(0)
- ProMeris Duo(0)
- Prometax(0)
- Prontax(0)
- ProQuad(0)
- Prostap 3 Dcs(1)
- Prostap 6 Dcs(1)
- Prostaplant(1)
- Prostap Sr Dcs(1)
- Protaphane(0)
- Protelos(0)
- ProteqFlu(0)
- ProteqFlu-Te(0)
- Proteq West Nile(0)
- Protopic(0)
- Protopy(0)
- Provarivax(1)
- Provas(2)
- Provenge(0)
- Provigil(1)
- ProZinc(0)
- Pruban(0)
- Puldysa(0)
- Pulsaflox(0)
- Pumarix(0)
- Puregon(0)
- Purevax FeLV(0)
- Purevax Rabies(0)
- Purevax RC(0)
- Purevax RCCh(0)
- Purevax RCP(0)
- Purevax RCPCh(0)
- Purevax RCPCh FeLV(0)
- Purevax RCP FeLV(0)
- Pylclari(0)
- Pylobactell(0)
- Pylori-Chek(0)
- Pyrukynd(0)
- Pyzchiva(0)
- Qaialdo(0)
- Qalsody(0)
- Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron)(0)
- Qdenga(0)
- Qinlock(0)
- Qinprezo(0)
- Qizenday(0)
- Qsiva(0)
- Qtern(0)
- Qtrilmet(0)
- Quadramet(0)
- Quadrisol(0)
- Quinsair(1)
- Quintanrix(0)
- Quixidar(0)
- Quixil(1)
- Quofenix(0)
- Qutavina(0)
- Qutenza(0)
- Quviviq(0)
- R.O.R. Vax(1)
- Rabigen SAG2(0)
- Rabitec(0)
- Racanda(1)
- Radicava(0)
- Ralbior(1)
- Ralenova(1)
- Raligize(0)
- Raloxifene Teva(0)
- Raltegravir Viatris(0)
- Ramelteon(0)
- Ramvocid(0)
- Ranexa (previously Latixa)(0)
- Ranivisio(0)
- Rapamune(0)
- Rapidnorm(1)
- Rapilysin(0)
- Rapiscan(0)
- Raplixa(0)
- Raptiva(0)
- Rasagiline Mylan(0)
- Rasagiline ratiopharm(0)
- Rasilamlo(0)
- Rasilez(0)
- Rasilez HCT(0)
- Rasitrio(0)
- Rasival(0)
- Ratacand(1)
- Ratacand Plus(1)
- Ratioepo(0)
- Ratiograstim(0)
- Ravicti(0)
- Raxone(0)
- Raylumis(0)
- Rayoqta(0)
- Rayvow(0)
- Rayzon(0)
- Readycef(0)
- Reagila(0)
- Reasanz(0)
- Rebetol(0)
- Rebif(0)
- Reblozyl(0)
- Recarbrio(0)
- Recocam(0)
- Reconcile(0)
- Recothrom(0)
- Recuvyra(0)
- Redomex(1)
- Redomex Diffucaps(1)
- ReFacto AF(0)
- Refixia(0)
- Refludan(0)
- Regenon(1)
- Regenon Retard(1)
- Regkirona(0)
- Regranex(0)
- Rekambys(0)
- Rekovelle(0)
- Relistor(0)
- Relvar Ellipta(0)
- Remicade(0)
- Removab(0)
- Remsima(0)
- Renagel(0)
- RenuTend(0)
- Renvela(0)
- Repaglinide Accord(0)
- Repaglinide Krka(0)
- Repaglinide Sun(0)
- Repaglinide Teva(0)
- Repatha(0)
- Replagal(0)
- ReproCyc ParvoFLEX(0)
- Repso(0)
- Resolor(0)
- Respiporc Flu3(0)
- Respiporc FLUpan H1N1(0)
- Respivac TRT(0)
- Respreeza(0)
- Restaysis(0)
- Retaane(0)
- Retacrit(0)
- Retisert(0)
- Retsevmo(0)
- Revasc(0)
- Revatio(0)
- Revestive(0)
- Revinty Ellipta(0)
- RevitaCAM(0)
- Revlimid(0)
- Revolade(0)
- Rexxolide(0)
- Reyataz(0)
- Rezolsta(0)
- Rezzayo(0)
- Rheumocam(0)
- Rhiniseng(0)
- Rhinobovin(0)
- Rhinobovin Marker Attenuato(0)
- Rhinobovin Marker live(0)
- RhinobovinMarker Viva(0)
- Rhinobovin Marker Viva Marcada(0)
- Rhokiinsa(0)
- Rhucin(0)
- Riarify (previously CHF 5993 Chiesi Farmaceutici S.p.A.)(0)
- Ribavirin BioPartners(0)
- Ribavirin Mylan (previously Ribavirin Three Rivers)(0)
- Ribavirin Teva(0)
- Ribavirin Teva Pharma B.V.(0)
- Ribomustin(1)
- Rienso(0)
- Rifun(1)
- Rilonacept Regeneron (previously Arcalyst)(0)
- Riltrava Aerosphere(0)
- Rilutek(0)
- Riluzole Zentiva(0)
- Rimmyrah(0)
- Rinvoq(0)
- Riprazo(0)
- Riprazo HCT(0)
- Riquent(0)
- Ristaben(0)
- Ristempa(0)
- Ristfor(0)
- Ritemvia(0)
- Ritonavir Mylan(0)
- Rituximab Mabion(0)
- Rituzena (previously Tuxella)(0)
- Rivaroxaban Accord(0)
- Rivaroxaban Viatris (previously Rivaroxaban Mylan)(0)
- Rivastigmine 1 A Pharma(0)
- Rivastigmine 3M Health Care Ltd(0)
- Rivastigmine Actavis(0)
- Rivastigmine Hexal(0)
- Rivastigmine Sandoz(0)
- Rivastigmine Teva(0)
- Rixathon(0)
- Rixil(2)
- Riximyo(0)
- Rixubis(0)
- Rizmoic(0)
- RoActemra(0)
- Robaxisal compuesto(1)
- Roclanda(0)
- Roctavian(0)
- Rolufta Ellipta (previously Rolufta)(0)
- Ronapreve(0)
- Rotarix(0)
- Rotashield(0)
- RotaTeq(0)
- Roteas(0)
- Rotigotine Mylan(0)
- Rouvax(1)
- Rozlytrek(0)
- Rubraca(1)
- Ruconest(0)
- Rukobia(0)
- Ruvise(0)
- Ruxience(0)
- Rxulti(0)
- Rybelsus(0)
- Rybrevant(0)
- Rydapt(0)
- Rydene(1)
- Ryeqo(0)
- Rystiggo(0)
- Ryzneuta(0)
- Ryzodeg(0)
- Sabervel(0)
- Saizen(1)
- Samsca(0)
- Sancuso(0)
- Saphnelo(0)
- Sapropterin Dipharma(0)
- Sarclisa(0)
- Saroten 2ml(1)
- Saroten Retard(1)
- Saroten retard Tabs(1)
- Saroten Tabs(1)
- Sarotex(1)
- Sarotex Retard(1)
- Sarotex Retard 25(1)
- Sarotex Retard 50(1)
- Savene(0)
- Saxenda(0)
- Scandicaine(1)
- Scemblix(0)
- Scenesse(0)
- Scintimun(0)
- Sebivo(0)
- SecreFlo(0)
- Sedadex(0)
- See annex I(0)
- Seebri Breezhaler(0)
- Seffalair Spiromax(0)
- Segluromet(0)
- Selan(1)
- Selincro(0)
- Semglee(0)
- Semintra(0)
- Senshio(0)
- Senstend(0)
- Senvelgo(0)
- Sepioglin(0)
- Serenase(1)
- Serenase Dekanoat(1)
- Serenase Depot(1)
- Sevelamer carbonate Winthrop (previously Sevelamer carbonate Zentiva)(0)
- SevoFlo(0)
- Sevohale (previously known as Sevocalm)(0)
- Sevsury(0)
- Shingrix(0)
- Sialanar(0)
- Sibnayal(0)
- Sifrol(0)
- Signifor(0)
- Siklos(0)
- Silapo(0)
- Sildenafil Actavis(0)
- Sildenafil FGK(0)
- Sildenafil ratiopharm(0)
- Sildenafil Teva(0)
- Sileo(0)
- Silgard(1)
- Silodosin Recordati(0)
- Silodyx(0)
- Silomat(1)
- Simbrinza(0)
- Simparica(0)
- Simparica Trio(0)
- Simponi(0)
- Simulect(0)
- Simvastatin Vale pharmaceuticals(1)
- Sinerem(0)
- Sirturo(0)
- Sitagliptin / Metformin hydrochloride Accord(0)
- Sitagliptin / Metformin hydrochloride Mylan(0)
- Sitagliptin / Metformin hydrochloride Sun(0)
- Sitagliptin Accord(0)
- Sitagliptin SUN(0)
- Sitoiganap(0)
- Sivextro(0)
- Sixantone(1)
- Sixmo(0)
- Skelid(1)
- Skilarence(0)
- Skyclarys(0)
- Skycovion(0)
- Skyrizi(0)
- Skysona(0)
- Skytrofa (previously Lonapegsomatropin Ascendis Pharma)(0)
- Slentrol(0)
- Slenyto(0)
- Sliwens(0)
- Sogroya(0)
- Sohonos(0)
- Solensia(0)
- Soliris(0)
- Solithromycin Triskel EU Services(0)
- Soludox 433 mg/g(0)
- Soludox 500 mg/g(0)
- Soludox Vet(0)
- Solufos(1)
- Solumarv(0)
- Solvetan(1)
- Solymbic(0)
- Somac(1)
- Somac Control(0)
- Somadril(1)
- SomaKit TOC(0)
- Somatropin Biopartners(0)
- Somavert(0)
- Somnena(0)
- Sonata(0)
- Sondelbay(0)
- SonoVue(0)
- Sorafenib Accord(0)
- Sortis(1)
- Sotyktu(0)
- Sovaldi(1)
- Sovrima(0)
- Spanidin(0)
- Spectrila(0)
- Spedra(0)
- Spevigo(0)
- Spexotras(0)
- Spherox(0)
- Spikevax (previously COVID-19 Vaccine Moderna)(0)
- Spinraza(0)
- Spironolactone Ceva(0)
- Spravato(0)
- Sprimeo(0)
- Sprimeo HCT(0)
- Sprycel(0)
- Stabox 15% LA(0)
- Stalevo(0)
- Staquis(0)
- Starlix(0)
- Startvac(0)
- Stayveer(0)
- Steglatro(0)
- Steglujan(0)
- Stelara(0)
- Stelfonta(0)
- Stimufend(0)
- Stivarga(0)
- Stocrin(0)
- Strangvac(0)
- Strantel Plus(0)
- Strensiq(0)
- Stresam(1)
- Stresnil(0)
- Striascan(0)
- Stribild(0)
- Strimvelis(0)
- Stronghold(0)
- Stronghold Plus(0)
- Suboxone(0)
- Sugammadex Adroiq(0)
- Sugammadex Amomed(0)
- Sugammadex Fresenius Kabi(0)
- Sugammadex Lorien(0)
- Sugammadex Mylan(0)
- Sugammadex Piramal(0)
- Suiseng Diff/A(0)
- Suliqua(0)
- Sumatriptan Galpharm(0)
- Sunitinib Accord(0)
- Sunlenca(0)
- Sunosi(0)
- Supemtek(0)
- Suprelorin(0)
- Surfaxin(0)
- Sustiva(0)
- Susvimo(0)
- Sutent(0)
- Suvaxyn Aujeszky 783 + O/W(0)
- Suvaxyn Circo(0)
- Suvaxyn Circo+MH RTU(0)
- Suvaxyn CSF Marker(0)
- Suvaxyn PCV(0)
- Suvaxyn PRRS MLV(0)
- Sycrest(0)
- Syfovre(0)
- Sylvant(0)
- Symbioflor E. Coli(1)
- Symbioflor Escherichia(1)
- Symbioflor® 2(1)
- Symkevi(0)
- Symtuza(0)
- Symural(1)
- Synagis(0)
- Synchroplan(0)
- Synflorix(0)
- Synjardy(1)
- Synordia(0)
- Synulox comp. vet(0)
- Synulox Endomammario(0)
- Synulox LC(0)
- Syvazul BTV(0)
- Tabrecta(0)
- Tacforius(0)
- TachoSil(0)
- Tadalafil Lilly(0)
- Tadalafil Mylan(0)
- Tafinlar(0)
- Tagrisso(0)
- Tahor(4)
- Takhzyro(0)
- Talavir(1)
- Talmanco (previously Tadalafil Generics)(0)
- Taltz(0)
- Taluvian(0)
- Talvey(0)
- Talzenna(0)
- Tamiflu(0)
- Tandemact(0)
- Tarceva(0)
- Tareg(2)
- Targocid(1)
- Targretin(1)
- Tasermity(0)
- Tasigna(0)
- Tasmar(0)
- Tavlesse(0)
- Tavneos(0)
- Taxespira (previously Docetaxel Hospira UK Limited )(0)
- Taxotere(0)
- Tazobac(1)
- Tazocel(1)
- Tazonam(1)
- Teboneva(1)
- Tecartus(0)
- Tecentriq(0)
- Tecfidera(0)
- Tecnemab K1(0)
- Tecovirimat SIGA(0)
- Tecvayli(0)
- Tegsedi(0)
- Teicomid(1)
- Tekinex(0)
- Tekturna(0)
- Telmisartan Actavis(0)
- Telmisartan Teva(0)
- Telmisartan Teva Pharma(0)
- Telzir(0)
- Temodal(0)
- Temomedac(0)
- Temozolomide Accord(0)
- Temozolomide Hexal(0)
- Temozolomide Sandoz(0)
- Temozolomide Sun(0)
- Temozolomide Teva(0)
- Temybric Ellipta(0)
- Tenacid(1)
- Tenecteplase Boehringer Ingelheim Pharma GmbH Co. KG(0)
- Tenkasi (previously Orbactiv)(0)
- Tenofovir disoproxil Mylan(0)
- Tenofovir disoproxil Zentiva(0)
- Tenuate Retard(1)
- Tepadina(0)
- Tepkinly(0)
- Tepmetko(0)
- Teriflunomide Accord(0)
- Teriflunomide Mylan(0)
- Teriparatide Cinnagen(0)
- Teriparatide Sun(0)
- Terrosa(0)
- Tesavel(0)
- Teslascan(0)
- Tessie(0)
- Tevabone(1)
- Tevagrastim(0)
- Tevimbra(0)
- Texzor(4)
- Teysuno(0)
- Tezspire(0)
- Thalidomide BMS (previously Thalidomide Celgene)(0)
- Thalidomide Lipomed(0)
- Thelin(0)
- Theraloc(0)
- Theryttrex(0)
- Thiotepa Riemser(0)
- Thorinane(0)
- Thymanax(0)
- Thyrogen(0)
- Tiamutin 45%(0)
- Tibolinia(1)
- Tibolon Aristo(1)
- Tibsovo(0)
- Tidhesco(0)
- Tigecycline Accord(0)
- Tikosyn(0)
- Tilexim(1)
- Timolol sifi 1 mg/g gel oftalmico(1)
- Tisseel(1)
- Tissucol(1)
- Tivicay(0)
- Tizveni(0)
- Tobi Podhaler(0)
- Tofidence(0)
- Tolucombi(1)
- Tolura(0)
- Tolvaptan Accord(0)
- Tookad(0)
- Topotecan Actavis(0)
- Topotecan Eagle(0)
- Topotecan Hospira(0)
- Topotecan SUN(0)
- Topotecan Teva(0)
- Torisel(0)
- Torvast(4)
- Totalip(4)
- Toujeo (previously Optisulin)(0)
- Tovanor Breezhaler(0)
- Toviaz(0)
- Tracleer(0)
- Tractocile(0)
- Trajenta(0)
- Translarna(0)
- Trasylol(1)
- Travatan(0)
- Trazec(0)
- Trazimera(0)
- Trecondi(0)
- Tredaptive(0)
- Trelegy Ellipta(0)
- Tremelimumab AstraZeneca(0)
- Tremfya(0)
- Trenantone(1)
- Trenantone-Gyn(1)
- Treprostinil SciPharm Sàrl(0)
- Trepulmix(0)
- Tresiba(0)
- Trevaclyn(0)
- Trevicta (previously Paliperidone Janssen)(0)
- Triacelluvax(0)
- Trifexis(0)
- Triflucan(1)
- Trilocur(0)
- Trilorale(0)
- Trimbow(0)
- Trisenox(0)
- Tritanrix HepB(0)
- Triumeq(0)
- Trivivac(1)
- Trixeo Aerosphere(0)
- Trizivir(0)
- Trobalt(0)
- Trocoxil(0)
- Trodelvy(0)
- Trogarzo(0)
- Trovan(0)
- Trovan IV(0)
- Truberzi(0)
- Trudexa(0)
- Truleva(0)
- Trulicity(0)
- Trumenba(0)
- Truqap(0)
- TruScient(0)
- Truvada(0)
- Truvelog Mix 30(0)
- Truxima(0)
- Trydonis(0)
- Tukysa(0)
- Tulatrixx(0)
- Tulaven(0)
- Tulinovet(0)
- Tulissin(0)
- Turalio(0)
- Turvel(0)
- Turvel IV(0)
- Tuznue(0)
- Twinrix Adult(0)
- Twinrix Paediatric(0)
- Twynsta(0)
- Tybost(0)
- Tyenne(0)
- Tygacil(0)
- Tylmasin(0)
- Tyruko(0)
- Tysabri(1)
- Tyvaso(0)
- Tyverb(0)
- Ubac(0)
- Ucedane(0)
- Udenyca(0)
- Ulcotenal(1)
- Ulipristal Acetate Gedeon Richter(0)
- Ultibro Breezhaler(0)
- Ultifend ND IBD(0)
- Ultomiris(0)
- Ultratard(0)
- Ulunar Breezhaler(0)
- Unituxin(0)
- UpCard(0)
- Upkanz(0)
- Uplizna(0)
- Uprima(0)
- Upstaza(0)
- Uptravi(0)
- Uridoz(1)
- Urifos(1)
- Urinex(1)
- Urofast(1)
- Uromaste(1)
- Urorec(0)
- Uroseptic(1)
- Uzpruvo(0)
- Vaborem(0)
- Vabysmo(0)
- Vaditon(1)
- Vaditon Prolib(1)
- Vafseo(0)
- Valaciclovir Allen(1)
- Valberg(1)
- Valdoxan(0)
- Valdyn(0)
- Valdyn (previously Kudeq)(0)
- Valepil(1)
- Valepil and Valhel(1)
- Valhel PR(1)
- Valherpes(1)
- Valpal(1)
- Valpro and Valprolek(1)
- Valsartan Novartis(2)
- Valtropin(0)
- Vanflyta(0)
- Vaniqa(0)
- Vantavo (previously Alendronate sodium and colecalciferol, MSD)(0)
- Vantobra(0)
- Vantobra (previously Tobramycin PARI)(0)
- Vargatef(0)
- Varilrix(1)
- Varivax(1)
- VarroMed(0)
- Varuby(0)
- Vasonase(1)
- Vastarel(1)
- Vaxchora(0)
- Vaxelis(0)
- Vaxneuvance(0)
- Vaxxitek HVT+IBD(0)
- Vaxzevria (previously COVID-19 Vaccine AstraZeneca)(0)
- Vazkepa(0)
- Vectarion(1)
- Vectibix(0)
- Vectormune FP ILT(0)
- Vectormune FP ILT + AE(0)
- Vectormune ND(0)
- Vectra 3D(0)
- Vectra Felis(0)
- Vedrop(0)
- Vegzelma(0)
- Vekacia(0)
- Veklury(0)
- Velactis(0)
- Velcade(0)
- Velmetia(0)
- Velosulin(0)
- Velphoro(0)
- Velsipity(0)
- Veltassa(0)
- Vemlidy(0)
- Venclyxto(0)
- Ventavis(0)
- Venvia(0)
- Veoza(0)
- Vepacel(0)
- Vepured(0)
- Veraflox(0)
- VeraSeal(0)
- Veraseal(0)
- Verkazia(0)
- Verquvo(0)
- Versican Plus DHPPi(0)
- Versican Plus DHPPi/L4(0)
- Versican Plus DHPPi/L4R(0)
- Versican Plus L4(0)
- Versican Plus Pi(0)
- Versican Plus Pi/L4(0)
- Versican Plus Pi/L4R(0)
- Versiguard SARS CoV2(0)
- Verzenios(0)
- Vetadoxi 50(0)
- Veyvondi(0)
- Vfend(0)
- Viagra(0)
- Vibativ(0)
- Victoza(0)
- Victrelis(0)
- Vidaza(0)
- VidPrevtyn Beta(0)
- Viekirax(0)
- Vigil(1)
- Vihuma(0)
- Vijoice(0)
- Vildagliptin / Metformin hydrochloride Accord(0)
- Vimizim(0)
- Vimpat(0)
- Vipdomet(0)
- Vipidia(0)
- Viracept(0)
- Viraferon(0)
- ViraferonPeg(0)
- Viramune(0)
- Virbacef(0)
- Virbagen Omega(0)
- Viread(0)
- Vistide(0)
- Visudyne(0)
- Vitekta(0)
- Vitragan(0)
- Vitrakvi(0)
- Vitrasert Implant(0)
- Vitravene(0)
- Vivanza(0)
- Vivjoa(0)
- Vizamyl(0)
- Vizarsin(0)
- Vizimpro(0)
- Vocabria(0)
- Vokanamet(1)
- Volibris(0)
- Voncento(0)
- Voraxaze(0)
- Voriconazole Accord(0)
- Voriconazole Hikma (previously Voriconazole Hospira)(0)
- Vorinostat MSD(0)
- Vosevi(0)
- Votrient(0)
- Votubia(0)
- Voxical Plus(0)
- Voxzogo(0)
- Voydeya(0)
- Vpriv(0)
- Vueway(0)
- Vumerity(0)
- Vydura(0)
- Vyepti(0)
- Vylaer Spiromax(0)
- Vyndaqel(0)
- Vynfinit(0)
- Vynpenta (previously AvacopanChemoCentryx)(0)
- Vyvgart(0)
- Vyxeos liposomal (previously known as Vyxeos)(0)
- Wakix(0)
- Waylivra(0)
- Wegovy(0)
- Wezenla(0)
- Wilzin(0)
- Winfuran(0)
- Wyost(0)
- Xadago(0)
- Xagrid(0)
- Xalatan 50 mikrogramov/ml kaplijice za oko, raztopina(1)
- Xalkori(0)
- Xaluprine (previously Mercaptopurine Nova Laboratories)(0)
- Xapit(0)
- Xarator(4)
- Xarelto(0)
- Xegafri(0)
- Xelevia(0)
- Xeljanz(2)
- Xeloda(1)
- Xenical(0)
- Xenleta(0)
- Xenpozyme(0)
- Xeplion(0)
- Xerava(0)
- Xermelo(0)
- Xevudy(0)
- Xgeva(0)
- Xiapex(0)
- Xigduo(2)
- Xigris(0)
- Xiidra(0)
- Xiliarx(0)
- Ximelagatran 36 mg film coated tablets(0)
- Ximluci(0)
- Xofigo(1)
- Xofluza(0)
- Xolair(0)
- Xospata(0)
- Xoterna Breezhaler(0)
- Xromi(0)
- Xtandi(0)
- Xultophy(0)
- Xydalba(0)
- Xyndari(0)
- Xyrem(0)
- Yargesa(0)
- Yarvitan(0)
- Yaz 24+4(1)
- Yellox(0)
- Yentreve(0)
- Yervoy(0)
- Yesafili(0)
- Yescarta(0)
- Yondelis(1)
- Yorvipath(0)
- Ypozane(0)
- Yselty(0)
- Ytracis(0)
- Yttriga(0)
- Yuflyma(0)
- YURVAC RHD(0)
- Zabdeno(0)
- Zactima(0)
- Zactran(0)
- Zafiride(0)
- Zalasta(0)
- Zalmoxis(0)
- Zaltrap(0)
- Zalviso(0)
- Zanil Fluke Drench(0)
- Zanil Fluke Drench 34 mg/ml Oral Suspension(0)
- Zanil Suspension(0)
- Zarator(4)
- Zartra(0)
- Zarzio(0)
- Zavesca(0)
- Zavicefta(0)
- Zebinix(0)
- Zeffix(0)
- Zeftera (previously Zevtera)(0)
- Zefylti(0)
- Zejula(0)
- Zektayos - Hepjuvo(0)
- Zelboraf(0)
- Zeleris(0)
- Zelitrex(1)
- Zelnorm(0)
- Zemdri(0)
- Zemfirza(0)
- Zenalpha(0)
- Zenapax(0)
- Zenhale(0)
- Zepatier(0)
- Zeposia(0)
- Zerbaxa(0)
- Zercepac(0)
- Zerene(0)
- Zerit(0)
- Zessly(0)
- Zeulide(1)
- Zevalin(0)
- Ziagen(0)
- Zienam(1)
- Ziextenzo(0)
- Zilbrysq(0)
- Zimbus Breezhaler(0)
- Zimulti(0)
- Zinadol(1)
- Zinbryta(2)
- Zinforo(0)
- Zinnat(1)
- Zinocep(1)
- Zinocep Vena(1)
- Zinplava(0)
- Zioxtenzo(0)
- Zipos(1)
- Zirabev(0)
- Zoely(1)
- Zokinvy(0)
- Zoledronic Acid Accord(0)
- Zoledronic acid Actavis(0)
- Zoledronic Acid Hospira(0)
- Zoledronic acid medac(0)
- Zoledronic acid Mylan(0)
- Zoledronic acid Teva(0)
- Zoledronic acid Teva Generics(0)
- Zoledronic acid Teva Pharma(0)
- Zolgensma(0)
- Zolsketil pegylated liposomal(0)
- Zoltum(1)
- Zolvix(0)
- Zomacton(1)
- Zomarist(0)
- Zometa(0)
- Zondar(1)
- Zonegran(0)
- Zonisamide Mylan(0)
- Zontivity(0)
- Zoonotic Influenza Vaccine Seqirus(0)
- Zoref(1)
- Zostavax(0)
- Ztalmy(0)
- Zubrin(0)
- Zubsolv(0)
- Zulvac 1 Bovis(0)
- Zulvac 1 Ovis(0)
- Zulvac 1+8 Bovis(0)
- Zulvac 1+8 Ovis(0)
- Zulvac 8 Bovis(0)
- Zulvac 8 Ovis(0)
- Zulvac BTV(0)
- Zulvac SBV(0)
- Zunrisa(0)
- Zuprevo(0)
- Zurampic(0)
- Zurcal(1)
- Zurcale(1)
- Zurcazol(1)
- Zutectra(0)
- Zyclara(0)
- Zycortal(0)
- Zydax(0)
- Zydelig(1)
- Zykadia(0)
- Zyllt(0)
- Zynlonta(0)
- Zynquista(0)
- Zynrelef(0)
- Zynteglo(1)
- Zynyz(0)
- Zypadhera(0)
- Zyprexa(0)
- Zyprexa Velotab(0)
- Zyrona(1)
- Zytiga(0)
- Елигард(1)
- Лутрат Депо(1)
- (1-methyl-2-nitro-1H-imidazole-5-yl)methyl N,N'-bis(2-bromoethyl) phosphorodiamidate [TH-302](0)
- (1aR,12bS)-8-Cyclohexyl-N-(dimethylsulfamoyl)-11-methoxy-1a-(((1R,5S)-3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,12b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide hydrochloride (BMS-791325)(0)
- (1R,2R)-2-[4-(5-methyl-1H-pyrazol-3-yl) benzoyl]-N-(4-oxo-6,7-dihydro-5H-pyrazolo [1,5-a]pyrazin-3-yl)cyclohexanecarboxamide (AZD5718)(0)
- (1R,2R,3S,4S,5R,6S)-cyclohexane-1,2,3,4,5,6-hexayl-hexakis (dihydrogen phosphate)(0)
- (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy- 10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,- 14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]- oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyldimethyl-phosphinate (MK-8669, or AP23573)(0)
- (1R,2S,5S)-N-((1S)-1-Cyano-2-((3S)-2-oxopyrrolidin-3-yl)ethyl)-3-((2S)-3,3-dimethyl-2-(2,2,2- trifluoroacetamido)butanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide(0)
- (1R,3S,5R)-2-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromo-3- methylpyridin-2-yl)-5-methyl-2-azabicyclo[3.1.0]hexane-3-carboxamide (ALXN2050)(0)
- (1R, 4S, 5S, 6S)-4-[[(2s)-2-amino-4-(methylthio)-1-oxobutyl]amino]-2-thiabicyclo[3.1.0]hexane-4,6-dicarboxylic acid,2,2-dioxide, monohydrate (LY2140023)(0)
- (1S,3S)-3-({2-methyl-6-[1-methyl-5-({[methyl(propyl)carbamoyl]oxy}methyl)-1H-1,2,3-triazol-4-yl]pyridin-3-yl}oxy)cyclohexane-1-carboxylic acid (BMS-986278)(0)
- (1S, 3S, 4R)-4-[(3aS, 4R, 5S,7aS)-4-(aminomethyl)-7a-methyl-1-methylidene-octahydro-1H-inden-5-yl]-3-(hydroxymethyl)-4-methylcyclohexan-1-ol (acetic acid salt)(0)
- (2-Hydroxyethyl)trimethylammonium 3-[2-fluoro-5-(2,3-difluoro-6-methoxybenzyloxy)-4- methoxyphenyl]-2,4-dioxo-1,2,3,4-tetrahydrothieno[3,4-d]pyrimidine-5-carboxylate(0)
- ( 2R)-2-Amino-1-[3-( {2-[p-( 4-{3-[ (3,S-diamino-6-chloro-2-pyrazinyl)ca rbonyl ]guanidino }butyl )phenoxy ]ethyl}{ 3-[ ( 2R)-2-am ino-6-guanidinohexanoyla mino] propyl }amino )propylamino ]-6-guanidino-1-hexanone hexahydrochloride(0)
- (2R,3S,5R)-2-(2,5-Difluorophenyl)-5-[2,6-dihydro-2-(methylsulfonyl)pyrrolo[3,4-c]pyrazol-5(4H)-yl]tetrahydro-2H-pyran-3-amine (MK-3102)(0)
- ( 2S )-2-[ [ 2-[ ( 4S)-4-( difluo romethyl )-2-oxo-oxazol idin-3-yl ]-5 ,6-dihydro i midazo [ 1,2- d] [ 1,4 ]benzoxazepin-9-yl]amino ]propanamide(0)
- (2S) 4 [2 methoxyethyl [4 (5,6,7,8 tetrahydro 1,8 naphthyridin 2 yl)butyl] amino] 2 (quinazolin 4 ylamino)butanoic acid(0)
- (2S,3R,4R,5S,6R)-2-(4-Chloro-3-{3-[(S)-(tetrahydrofuran-3-yl)oxy]-benzyl}-phenyl)-6-hydroxymethyltetrahydro-pyran-3,4,5-triol(0)
- (2S,4R)-1-(2-(3-acetyl-5-(2-methylpyrimidin-5-yl)-1H-indazol-1-yl)acetyl)-N-(6-bromopyridin-2-yl)-4- fluoropyrrolidine-2-carboxamide (ACH-0144471)(0)
- (2S,4S)-2-(4-Carboxyphenyl)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-1-ium chloride―water (1/1) (LNP023)(0)
- (3aR,4S,7aR)-octahydro-4-hydroxy-4-[(3-methylphenyl)ethynyl]-1H-indole-1-carboxylic acid methyl ester(0)
- (3S,7S)-22-(3-(((2-((5-(2-Carboxyethyl)-2-hydroxybenzyl)(carboxymethyl)amino)ethyl)(carboxymethyl)amino)methyl)-4-hydroxyphenyl)-5,13,20-trioxo-4,6,12,19-tetraazadocosane-1,3,7-tricarboxylic acid (PSMA-11)(0)
- (3Z,5S)-5-(hydroxymethyl)-1-[(2'-methyl[1,1'-biphenyl]-4-yl)-carbonyl]-3-pyrrolidinone-O-methyloxime(0)
- (4R,5R)-1-[[4-[[4-[3,3-dibutyl-7-(dimethylamino)-2,3,4,5-tetrahydro-4-hydroxy-1,1-dioxido-1-benzothiepin-5-yl]phenoxy]methyl]phenyl]methyl]-4-aza-1-azoniabicyclo[2.2.2]octane chloride(0)
- (6aR,10aR)-1-Hydroxy-6,6-dimethyl-3-(2-methyl-2-octanyl)-6a,7,10,10a-tetrahydro-6H- benzo[c]chromene-9-carboxylic acid (lenabasum)(0)
- (11beta,17beta)-17-hydroxy-11-[4-(methylsulfonyl)phenyl]-17-(pentafluoroethyl)estra-4,9-dien-3-one(0)
- (14S)-8-[3-(2-{dispiro[2.0.2^(4).1^(3)]heptan-7-yl}ethoxy)-1H-pyrazol-1-yl]-12,12-dimethyl- 2lambda^(6)-thia-3,9,11,18,23-penta-azatetracyclo[17.3.1.1^(11,14).0^(5,10)]tetracosa- 1(22),5,7,9,19(23),20-hexaene-2,2,4-trione calcium salt hydrate / tezacaftor / deutivacaftor (VX-121/ TEZ/D-IVA)(0)
- (232 - 232’),(235 - 235’)-bis(disulfide) with immunoglobulin G4 anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain) disulfide with human-Mus musculus monoclonal OG1950 kappa-chain(0)
- (E)-4-(2-(6-(2-(2-(2-[18F]fluoroethoxy)ethoxy)ethoxy)pyridin-3-yl)vinyl)-N-methylbenzenamine(0)
- (E)-4-[(5-Phenyl-1,3,4-thiadiazol-2-yl)oxy]-1-azoniatricyclo[3.3.1.13,7] decane 3,4-dicarboxy-3-hydroxybutanoate hydrate (ABT-126)(0)
- (R)-1-(1-acryloylpiperidin-3-yl)-4-amino-3-(4-phenoxyphenyl)-1H-imidazo[4,5-c]pyridin-2(3H)-one (SAR442168)(0)
- (R)-2-(1-(6-Amino-5-chloropyrimidine-4-carboxamido)ethyl)-N-(5-chloro-4-(trifluoromethyl)pyridin-2-yl)thiazole-5-carboxamide (DAY101)(0)
- (R)-2-[3-({Benzoxazol-2-yl[3-(4-methoxyphenoxy)propyl]amino}methyl)phenoxy]butanoic acid(0)
- (R)-3(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrilephosphate(0)
- (R)-7-Chloro-benzo[b]thiophene-2-carboxylic acid (1-aza-bicyclo[2.2.2]oct-3-yl)-amide hydrochloride hydrate (EVP-6124)(0)
- (R)-azasetron (besilate) (SENS-401)(0)
- (R)-N-({5-[3-(2,5-Difluorophenyl)-2-(2,3-dihydro-1H-benzimidazol-2-ylidene)-3- oxopropanoyl]-2-fluorophenyl}sulfonyl)-2-hydroxypropanimidamide(0)
- (R)-tetrahydrofuran-3-yl 4-(6-(5-(4-ethoxy-1-isopropylpiperidin-4-yl) pyridin-2-yl)pyrrolo[1,2- b]pyridazin-4-yl)piperazine-1-carboxylate sesquisuccinate (IPN60130)(0)
- (RS)-Bacoflen(0)
- (S)-1-{5-Phenyl-4-[(pyridin-2-ylmethyl)-amino]-thieno[2,3-d]pyrimidin-2-yl}-piperidine-3-carboxylic acid (2-hydroxy-ethyl)-amide(0)
- (S)-2-(5-((3-ethoxypyridin-2-yl)oxy)pyridin-3-yl)-N-(tetrahydrofuran 3 yl) pyrimidine-5-carboxamide (PF-06865571)(0)
- (S)-2-hydroxy-6-((4-(2-(2-hydroxyethyl) nicotinoyl) morpholin-3-yl) methoxy) benzaldehyde (GBT021601)(0)
- (S)-3-(OH)-desazadesferrithiocin-polyether, magnesium salt (FBS0701)(0)
- (S)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropane-2-yl)-1H-pyrazole-4-carboxamide(0)
- (S)-6-hydroxy-2,5,7,8-tetramethyl-N-((R)-piperidin-3-yl)chroman-2-carboxamide hydrochloride (KH176)(0)
- (S)-lactic acid(0)
- (S)-methoprene(0)
- (S)-N-(1-amino-4-(dimethylamino)-1-oxobutan-2-yl)-5-(2,4-difluorophenoxy)-1-isobutyl-1H-indazole- 6-carboxamide(0)
- (S)-Pyrrolidine-2-carboxylic acid compound with (2S,3R,4R,5S,6R)-2-(3-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)methyl)-4-ethylphenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol (2:1) ( LIK066)(0)
- (Z)-N-(3-bromo-4- fluorophenyl)-N-hydroxy-4-(2-(sulfamoylamino)ethylamino)-1,2,5-oxadiazole-3-carboximidamide(0)
- 1,4-dihydro-1-[(2R)-2-(2-methoxyphenyl)-2-[(tetrahydro-2H-pyran-4-yl)oxy]ethyl]-α,α,5-trimethyl-6-(2-oxazolyl)-2,4-dioxo-thieno[2,3-d]pyrimidine-3(2H)-acetic acid (GS-0976)(0)
- 1-(2R,5R)-5-ethynyl-5-(hydroxymethyl)-2,5-dihydro-2-furanyl)-5-methyl-2,4(1H,3H)-pyrimidinedione (BMS-986001)(0)
- 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol sodium salt(0)
- 1-propanol(0)
- 1-[ 4-bromo-5-[ 1-ethyl-7-( methylamino )-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl ]-2-fluorophenyl]-3-(0)
- 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one(0)
- 1H-Indole-6-carboxylic acid, 2,3-dihydro-3-[[[4-[methyl[(4-methyl-1-piperazinyl)acetyl]amino]phenyl]amino]phenylmethylene]-2-oxo-, methyl ester, (3Z)-, monoethanesulfonate(0)
- 1H-Isoindol-1-one,2-[[1-[2-(4-fluorophenyl)-2-oxoethyl]-4-piperidinyl]methyl]-2,3-dihydro-,hydrochloride, hydrate (1:1:2) (MIN-101)(0)
- 2'-MOE antisense oligonucleotide targeting apoC-III (ISIS 678354)(0)
- 2'-O-(2-methoxyethyl) phosphorothioate antisense oligonucleotide targeting CD49d RNA (ATL1102)(0)
- 2,6-Bis-{(1-napthalenyl-3,6-disulfonic acid)-oxyacetamido}-2,6-bis-2,6-bis-2,6-bis-(2,6-diamino-hexanoylamino)-2,6-diamino-hexanoic acid (diphenylmethyl)-amide, polysodium salt(0)
- 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[C]isoxazolo[4,5-e]azepin-4-yl) acetamide monohydrate(0)
- 2-(2-(3-Butoxy-phenyl)-ethylamino)-N,N-dimethyl-acetamide hydrochloride(0)
- 2-(3-(1-carboxy-5-[(6-[18F]fluoropyridine-3-carbonyl)-amino]-pentyl)-ureido)-pentanedioic acid(0)
- 2-(6-azaspiro[2.5]octan-6-yl)-N-[2-(4,4-difluoropiperidin-1-yl)-6-methylpyrimidin-4-yl]- 4-[(2- hydroxyethanesulfonyl)amino]benzamide hydrochloride(0)
- 2-Amino-N-(4-hydroxybicyclo[2.2.2]octan-1-yl)-5-(4-((1R,5S)-3- (tetrahydro-2H-pyran-4-yl)-3-azabicyclo[3.1.0]hexan-1- yl)phenyl)nicotinamide fumarate dihydrate (INCB-00928)(0)
- 2-hydroxypropyl-ß-cyclodextrin (HP-ß-CD)(0)
- 2-iminobiotin(0)
- 2-propanol(0)
- 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid tris(hydroxymethyl)aminomethane salt (1:1) (PF-06882961)(0)
- 2-[4-Methoxy-3-(2-m-tolyl-ethoxy)-benzoylamino]-indan-2-carboxylic acid(0)
- 2-[[2-ethyl-6-[4-[2-(3-hydroxyazetidin-1-yl)-2-oxoethyl]piperazin-1-yl]-8-methylimidazo[1,2-a]pyridin-3-yl](methyl)amino]-4-(4-fluorophenyl)-1,3-thiazole-5-carbonitrile(0)
- 2-[[8-chloro-3-[(4-chlorophenyl)methyl]-4-(difluoromethoxy)-2-ethyl-5-quinolinyl]oxy]acetic acid Llysine salt (GB001)(0)
- 2-{(3S)-7-fluoro-4-[(3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)carbonyl]-3,4-dihydro-2H-1,4-benzoxazin-3-yl}-N-methylacetamide (AZD9977)(0)
- 2-{4-[4-(4-{5-[(1S)-1-amino-1-(4-fluorophenyl) ethyl]pyrimidin-2-yl}piperazin-1-yl)pyrrolo[2,1-f] [1,2,4]triazin-6-yl]-1H-pyrazol-1-yl}ethan-1-ol(0)
- 2’-O-(2-methoxyethyl) modified antisense oligonucleotide targeting glial fibrillary acidic protein pre-mRNA (ION373)(0)
- 2’-O-(2’-methoxyethyl) modified antisense oligonucleotide targeting prekallikrein mRNA (ISIS 721744)(0)
- 3,4-dimethoxy-N-methylbenzohydroxamic(0)
- 3,4-dimethoxy-N-methylbenzohydroxamic acid (Custodiol-N)(0)
- 3,4-dimethyl-N-(2-phenyl-1H-pyrrolo[2,3-b]pyridin-5-yl)-1H-pyrazole-5-carboxamide(0)
- 3,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl((2S,3R,4R,5R)-2,3,4,5,6- pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)-carbamimidoyl)pyrazine-2-carboxamide/Sodium chloride solution 4.2% (P-1037 inhalation solution)(0)
- 3,6-diamino-2,5-bis{N-[(1R)-1-carboxy-2-hydroxyethyl]carbamoyl}pyrazine (MB-102)(0)
- 3-(((1S,2S,3R)-2,3-difluoro-1-hydroxy-7-(methylsulfonyl)-2,3-dihydro-1H-inden-4-yl)oxy)-5- fluorobenzonitrile(0)
- 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile (TD-1473)(0)
- 3-(1,3-benzodioxol-5-yl)-5-(3-bromophenyl)-1H-pyrazole(0)
- 3-(1H-indol-3-yl)-4-(2-(4-methyl-1-piperazinyl)-4-quinazolinyl)-1H-pyrrole-2,5-dione acetate(1:1)(0)
- 3-(3-(3,5-Dimethyl-1H-pyrazol-4-yl)propoxy)-4-fluorobenzoic acid(0)
- 3-[4-(4-Aminopiperidin-1-yl)-3-(3,5-difluorophenyl)quinolin-6-yl]-2-hydroxybenzonitrile (CRN00808)(0)
- 3-[5-[(1R,2S)-2-(2,2-difluoropropanoylamino)-1-(2,3-dihydro-1,4-benzodioxin-6-yl)propoxy]indazol-1- yl]-N-[(3R)-tetrahydrofuran-3-yl]benzamide (AZD7594)(0)
- 3-[[4-[(1S)-1-[4-(4-tert-butylphenyl)-3,5-dimethyl-phenoxy]-4,4,4-trifluorobutyl]benzoyl]amino]propanoic acid(0)
- 3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-3-[[5-chloro-1-[3-(methylsulfonyl)propyl]-1H-indol-2-yl]methyl]-1-(2,2,2-trifluoroethyl)-1,3-dihydro-2H-imidazo[4,5-c]pyridine-2-one (JNJ-53718678)(0)
- 4-0-(ß-D-galactopiranosyl)-D-xylopyranose(0)
- 4-Amino-2-butoxy-8-[3-(pyrrolidin-1-ylmethyl)benzyl]-7,8-dihydropteridin-6(5H)-one (GS-9620)(0)
- 4-Hydroxy-n-(2-hydroxyethyl)-butyramide(0)
- 4-[3-(Methylsulfonyl)phenyl]-1-propylpiperidine x HC1 (pridopidine hydrochloride)(0)
- 4-[4-({4-[({2-[(3S)-2,6-dioxopiperidin-3-yl]-1-oxo-2,3-dihydro-1H-isoindol-4-yl}oxy)methyl]phenyl}methyl)piperazin-1-yl]-3-fluorobenzonitrile(0)
- 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-transcyclohexanol (CC-930)(0)
- 4-{[(1R,2s,3S,5s,7s)-5-Hydroxy-2-adamantyl]amino}-1H-pyrrolo[2,3-b]pyridine-5-carboxamide monohydrobromide (JNJ-54781532-AAD)(0)
- 5 fluorouracil(0)
- 5 fluorouracil (topical application)(0)
- 5%-Δ9-tetrahydrocannabinol standardised Cannabis extract(0)
- 5, 7-dihydroxy-2-[3-hydroxy-4-methoxy-2-(2-methyl-2-propenyl) phenyl]-6, 8-bis (2-methyl-2-propenyl)-4H-chromen-4-one(0)
- 5-(4,6-Dimethyl-1H-benzimidazol-2-yl)-4-methyl-N-[3-(1-methyl-4-piperidinyl)propyl]-2-pyrimidinamine 2,3-dihydroxybutanedioate hydrate (1:0.5:4) (JNJ-38518168)(0)
- 5-(4-cyclopropyl-1H-imidazol-1-yl)-2-fluoro-N-(6-(4-isopropyl-4H-1,2,4-triazol-3-yl)pyridi-2-yl)-4-methylbenzamide(0)
- 5-(4-Fluoro-1-benzothiophen-2-yl)-8-methyl-1,9-dihydro-2H-[1,3]oxazolo[4,5-H][2,3]benzodiazepin-2-one (S44819)(0)
- 5-aminolevulinic acid, hydrochloride(0)
- 5-aminolevulinic acid hydrochloride(0)
- 5’-capped mRNA encoding HPV16 oncoprotein E6 and E7(0)
- 6 fluoro-7-(2-fluoro-6-hydroxyphenyl)-(1M)-1-[4-methyl-2-(propan-2-yl)pyridin-3-yl]-4-[(2S)-2- methyl-4-(prop-2-enoyl)piperazin-1-yl]pyrido[2,3-d]pyrimidin-2(1H)-one(0)
- 6,7-dihydro-5H-pyrrolo[1,2-c] imidazol-5-yl) - (benzo derivative)(0)
- 6-mercaptopurine monohydrate(0)
- 7-(2-Methoxy-3,5-dimethylpyridin-4-yl)-1-[(3S)-tetrahydrofuran-3-yl]-1,5-dihydro-4H-pyrazolo[4,3-c]quinolin-4-one maleate(0)
- 9-valent HPV vaccine (types 6, 11, 16, 18, 31, 33, 45, 52 and 58)(1)
- 13-valent pneumococcal polysaccharide conjugate vaccine: pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F; diphtheria CRM197 conjugate(0)
- 13C-urea(0)
- 17 beta-estradiol(0)
- 17-allylamino-17-demethoxygeldanamycin hydroquinone, hydrochloride(0)
- 18-(p-[131I]-iodophenyl)octadecyl phosphocholine(0)
- 177Lu-PSMA-617(0)
- 224 Radium adsorbed in calcium carbonate microparticles(0)
- 449-thioether with 1,1’-[2-[11,11-bis[15-bromo-11,11-bis[(2-bromo-2-methyl- 1-oxopropoxy)methyl]-15-methyl-3,7,14-trioxo-9,13-dioxa-2,6-diazahexadec-1-yl]-44-(3-mercapto- 2,5-dioxo-1-pyrrolidinyl)-4,8,26,42-tetraoxo-2,13,16,19,22,29,32,35,38-nonaoxa-5,9,25,41- tetraazatetratetracont-1-yl]-2-[(2-bromo-2-methyl-1-oxopropoxy)methyl]-1,3-propanediyl] bis(2- bromo-2-methylpropanoate) core 9-arm star compd. with 4-hydroxy-N,N,N,10-tetramethyl-9-oxo- 3,5,8-trioxa-4-phosphaundec-10-en-1-aminium inner salt 4-oxide homopolymer (KSI-301)(0)
- A/Astrakhan/3212/2020 (H5N8)-like strain (CBER-RG8A) (clade 2.3.4.4b)(0)
- A/California/7/2009 influenza-like virus strain(0)
- A/Darwin/6/2021(H3N2)-like strain (A/Darwin/11/2021, wild type) / A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) / B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021) / B/Phuket/3073/2013-like virus (B/Singapore/INFTT-16-0610/2016, wild type)(0)
- A/Darwin/9/2021 (H3N2) - like strain (A/Darwin/6/2021, IVR-227) / A/Victoria/4897/2022 (H1N1) pdm09-like strain (A/Victoria/4897/2022, IVR-238) / B/Phuket/3073/2013-like strain (B/Phuket/3073/2013, BVR-1B) / Influenza virus B/Austria/1359417/2021-like strain (B/Austria/1359417/2021, BVR-26)(0)
- A/Darwin/9/2021 (H3N2) - like strain (A/Norway/16606/2021, MEDI 355293) / A/Victoria/2570/2019 (H1N1)pdm09 - like strain (A/Victoria/1/2020, MEDI 340505) / B/Austria/1359417/2021 - like strain (B/Austria/1359417/2021, MEDI 355292) / B/Phuket/3073/2013 - like strain (B/Phuket/3073/2013, MEDI 306444)(0)
- A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)(0)
- abacavir(0)
- abacavir (as sulfate)(0)
- abacavir (as sulfate) / lamivudine / zidovudine(0)
- abacavir sulfate / dolutegravir sodium / lamivudine(0)
- abaloparatide(0)
- Abatacept(0)
- abatacept(0)
- abelacimab(0)
- abemaciclib(0)
- abicipar pegol(0)
- abiraterone(0)
- abiraterone acetate(0)
- Abrilumab(0)
- Abrocitinib(1)
- abrocitinib(1)
- Acalabrutinib(0)
- acalabrutinib(0)
- acamprosate(0)
- acarbose(0)
- acebutolol(0)
- aceclofenac(0)
- acemetacin(0)
- acenocoumarol(0)
- Acetyl-cysteine(0)
- Acetyl-L-leucine ((s)-(acetylamino)-4-methylpentanoic acid) (IB1001)(0)
- Acetylcysteine(0)
- Acetylsalicylic acid(0)
- acetyl salicylic acid(0)
- acetylsalicylic acid(0)
- aciclovir(1)
- Aciclovir(0)
- acipimox(1)
- acitretin(1)
- aclidinium(0)
- aclidinium bromide(0)
- Acotiamide(0)
- Adagrasib(0)
- adagrasib(0)
- adalimumab(0)
- Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; (ABBV-154)(0)
- Adalimumab conjugated with (4S)-4-[2-(2-bromoacetamido)acetamido]-5-{3-[(4-{(4aR,4bS,5S,6aS,6bS,8R,9aR,10aS,10bS)-5-hydroxy-4a,6a-dimethyl-2-oxo-6b-[(phosphonooxy)acetyl]-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H,8H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8-yl}phenyl)methyl] anilino}-5-oxopentanoic acid; ABBV-154(0)
- adapalene(1)
- Adavosertib(0)
- adefovir dipivoxil(0)
- Adeno-associated viral vector serotype 8 containing the human glucose-6-phosphatase gene (DTX401)(0)
- Adeno-associated viral vector serotype 8 containing the human MTM1 gene (resamirigene bilparvovec)(0)
- Adeno-associated viral vector serotype 8 containing the human RPGR gene(0)
- Adeno-associated viral vector serotype 9 containing human sulfamidase gene(0)
- Adeno-associated viral vector serotype rh.10 expressing beta-galactosidase (LYS-GM101)(0)
- Adeno-associated virus, serotype 9 (AAV9)-based non-replicating, self-complementary recombinant vector containing an expression cassette for the human ASPA transgene (scAAV9-CB6-hASPAopt)(0)
- Adeno-associated virus serotype 2 encoding human aromatic L-amino acid decarboxylase(0)
- Adeno-associated virus vector serotype 1 containing the human GRN gene(0)
- adenosine(0)
- adenovirus-mediated Herpes simplex virus-thymidine kinase gene(0)
- Adenovirus associated viral vector serotype 2 containing the human RPE65 gene(0)
- Adenovirus encoding vascular endothelial growth factor C(0)
- adenovirus type 26 encoding the SARS-CoV-2 spike glycoprotein (Ad26.COV2-S)(0)
- adjuvanted bluetongue virus vaccine(0)
- adjuvanted inactivated vaccine against avian influenza virus type A, subtype H5(0)
- adjuvanted inactivated vaccine against avian influenza virus type A, subtype H7(0)
- adjuvanted inactivated vaccine against Ornithobacterium rhinotracheale serotype A(0)
- adjuvanted inactivated vaccine against porcine circovirus(0)
- adjuvanted inactivated vaccine against porcine circovirus type 2(0)
- adjuvanted inactivated vaccine against porcine circovirus type 2 in piglets(0)
- adjuvanted inactivated vaccine for cattle against Staphylococcus aureus, coliforms and coagulase-negative staphylococci(0)
- Adjuvanted vaccine against classical swine fever(0)
- adjuvanted vaccine against necrotic enteritis of chickens due to Clostridium perfringens(0)
- adjuvanted vaccine against progressive atrophic rhinitis in piglets(0)
- Adjuvanted vaccine against tetanus(0)
- adrenaline (epinephrine)(1)
- Adrenaline (epinephrine)(0)
- adrenaline (tartrate)(1)
- adsorbed hepatitis B surface antigen produced in recombinant yeast cells (Saccharomyces cerevisiae)(0)
- aducanumab(0)
- afamelanotide(0)
- Afamitresgene autoleucel(0)
- afatinib(0)
- Aficamten(0)
- aflibercept(0)
- afoxolaner(0)
- A fully humanized immunoglobulin G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation 3 (CD3) receptor complex and G Protein Coupled Receptor Family C Group 5 Member D (GPRC5D) (JNJ-64407564)(0)
- agalsidase alfa(0)
- agalsidase beta(0)
- Agomelatine(0)
- ajmaline(0)
- alanine(0)
- alatrofloxacin mesilate(0)
- albendazole(0)
- Albiglutide(0)
- albiglutide(0)
- Albumin interferon alfa-2b(0)
- albutrepenonacog alfa(0)
- Aldafermin(0)
- alder pollen(0)
- aldesleukin(0)
- Alectinib(0)
- alectinib(0)
- alectinib hydrochloride(0)
- alemtuzumab(1)
- alendronate(0)
- alendronate sodium trihydrate(0)
- alendronic acid(3)
- alendronic acid (as sodium alendronate trihydrate)(1)
- alendronic acid (as sodium trihydrate)(0)
- alfacalcidol(1)
- alfentanil(0)
- alfuzosin(0)
- alglucosidase alfa(0)
- Alicaforsen(0)
- alipogene tiparvovec(0)
- Alirocumab(0)
- alirocumab(0)
- Alisitol(0)
- aliskiren(1)
- aliskiren hemifumarate(1)
- Aliskiren hemifumarate(0)
- Alisporivir(0)
- alitretinoin(1)
- alitretinoin (oral use)(0)
- alizapride(0)
- Allantoin(0)
- Allergen extract of Phleum pratense pollen(0)
- Allergen extract of Secale cereale pollen(0)
- allergen for therapy: betula verrucosa (sublingual use)(0)
- allergen for therapy: Dactylis Glomerata L., Phleum Pratense L., Anthoxanthum Odoratum L., Lolium Perenne L., Poa Pratensis L. (sublingual tablet)(0)
- allergen for therapy: Phleum Pratense(0)
- Allogeneic, ex vivo expanded, umbilical cord blood-derived, haematopoietic CD34+progenitor cells (CF)(0)
- Allogeneic, non-expanded, umbilical cord blood-derived, haematopoietic mature myeloid and lymphoid cells (NF)(0)
- Allogeneic B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T cell(0)
- Allogeneic bone marrow derived mesenchymal stromal cells, ex-vivo expanded (MC0518)(0)
- allogeneic equine adipose-derived mesenchymal stem cells(0)
- Allogeneic ex vivo expanded umbilical cord blood cells(0)
- allogeneic glioma tumor cell lysates (inactivated)(0)
- allogeneic glioma tumor cells (inactivated)(0)
- Allogeneic haptenised and irradiated cell lysates derived from glioma(0)
- Allogeneic haptenised and irradiated cells derived from glioma(0)
- Allogeneic human neural stem cells genetically modified to express c-MycERTAM, a c-Myc and modified oestrogen receptor fusion protein (CTX0E03)(0)
- Allogeneic Mesenchymal Precursor Cells (rexlemestrocel-L)(0)
- Allogeneic skin-derived ATP-binding cassette, sub-family B, member 5 (ABCB5)-positive mesenchymal stem cells (allo-APZ2-EB)(0)
- Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)(0)
- allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)(0)
- Allopregnanolone(0)
- allopurinol(0)
- almagate(0)
- almitrine(1)
- almotriptan(0)
- Alnuctamab(0)
- Alnus glutinosa(0)
- alogliptin(1)
- alogliptin benzoate(1)
- Alpelisib(0)
- alpelisib(0)
- Alpha-1 antitrypsin(0)
- Alpha-1 proteinase inhibitor(0)
- alpha-1-antitrypsin(0)
- alpha-ketoglutaric acid(0)
- alpha-R-lipoic acid choline ester tosilate(0)
- alpha1-proteinase inhibitor (human)(0)
- alpha1-proteinase inhibitor (human)(0)
- Alpha Connexin C-terminal 1 peptide(0)
- Alpha tocotrienol quinone(0)
- alprazolam(0)
- alprostadil(0)
- Alteplase(1)
- alteplase(0)
- altizide(0)
- altrenogest(0)
- aluminium hydroxide adsorbed(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extract of Phleum pratense pollen(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergen extracts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (50/50)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) (1/5) each(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (cultivated rye) pollen (50/50)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (Grasses-Mix) and Secale cereale (Cultivated Rye) pollen (75/25)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of equal amounts of Phleum pratense pollen and Secale cereale (cultivated rye) pollen (50/50)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and poa pratensis pollen (grasses-mix) and birch, alder and hazel pollen (tree-mix) (50/50)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis pollen (grasses-mix) and birch pollen (50/50)(0)
- Aluminium hydroxide adsorbed, depigmented glutaraldehyde polymerised, allergic extract of Phleum pratense pollen(0)
- alverine(0)
- amantadine(0)
- Amantadine (hydrochloride)(0)
- ambrisentan(0)
- ambroxol(1)
- amfepramome(1)
- amfepramone(1)
- amifampridine(0)
- amifampridine phosphate(0)
- amikacin(0)
- Amikacin sulfate(0)
- amino acid combinations(0)
- aminocaproic acid(1)
- aminosalicylate sodium(0)
- Aminosalicylic acid(0)
- amiodarone(0)
- amisulpride(0)
- amitraz(0)
- amitriptyline(1)
- amitriptyline hydrochloride(0)
- amitriptylinoxide(0)
- amivantamab(0)
- amlodipine(9)
- amlodipine (as amlodipine besilate)(1)
- amlodipine (as besylate)(0)
- Amlodipine (besilate)(0)
- amlodipine besilate(3)
- Amlodipine besilate(2)
- Amlodipine camsylate(0)
- amorolfine(0)
- amoxicillin(3)
- Amoxicillin trihydrate(1)
- ampicillin(0)
- ampicillin trihydrate(0)
- amprenavir(0)
- amsacrine(0)
- anacetrapib(0)
- Anagrelide(0)
- anagrelide(0)
- Anagrelide hydrochloride(0)
- anakinra(0)
- anamorelin(0)
- anamorelin hydrochloride(0)
- anastrozole(2)
- Anastrozole(0)
- Andecaliximab(0)
- andexanet alfa(0)
- androstanolone(0)
- andusomeran(0)
- angiotensin II(0)
- Angiotensin II (LJPC-501)(0)
- Angiotensin II acetate(0)
- anidulafungin(0)
- anifrolumab(0)
- aniracetam(0)
- Anthoxanthum odoratum L.(0)
- anthrax vaccine(0)
- anti-(human vascular endothelial growth factor A) (human-Mus musculus monoclonal OG1950 gamma-4-chain)(0)
- Anti-alpha-synuclein human monoclonal antibody(0)
- Anti-alpha synuclein monoclonal antibody (BIIB054)(0)
- Anti-BAFF monoclonal antibody (LY2127399)(0)
- Anti-C1s Humanized IgG4 Monoclonal Antibody(0)
- Anti-C1s Humanized IgG4 Monoclonal Antibody (BIVV020)(0)
- Anti-CD3 mAb conjugated to ricin toxin A chain(0)
- Anti-CD7 mAb conjugated to ricin toxin A chain(0)
- Anti-CD40L humanized monoclonal antibody (SAR441344)(0)
- anti-CD40L humanized monoclonal antibody (SAR441344)(0)
- Anti-CD123 IgG1 humanised monoclonal antibody conjugated to N1-(2-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)ethyl)-N6-((S)-1-(((S)-1-((3-((((S)-8-methoxy-6-oxo-11,12,12a,13-tetrahydro-6H-benzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)-5-((((S)-8-methoxy-6-oxo-12a,13-dihydro-6Hbenzo[5,6][1,4]diazepino[1,2-a]indol-9-yl)oxy)methyl)phenyl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)adipamide(0)
- Anti-IL-7Rα monoclonal antibody (S95011/ OSE-127)(0)
- Anti-IL-17A/F nanobody (MK 1095)(0)
- Anti-IL-21 humanized immunoglobulin G1-kappa monoclonal antibody (BOS161721)(0)
- anti-melanoma mab fragments(0)
- Anti-mucosal addressin cell adhesion molecule antibody (SHP647)(0)
- Anti-neonatal Fc receptor human monoclonal antibody(0)
- Anti-neonatal Fe receptor human monoclonal antibody {M281)(0)
- Anti-PD1 humanized monoclonal antibody of the IgG4/kappa class (MK-3475) (pembrolizumab)(0)
- Anti-sclerostin human monoclonal antibody (AMG785)(0)
- Anti-TGFbeta fully human monoclonal antibody (NIS793)(0)
- anti-T lymphocyte immunoglobulin for human use, horse(0)
- Anti-VEGF and anti-DLL4 dual variable domain immunoglobulin (ABT-165)(0)
- Antigen of pre-pandemic strain A/Vietnam/1203/2004 propagated in Vero cells(0)
- Anti proprotein convertase subtilisin kexin type 9 humanized monoclonal antibody (PF-04950615)(0)
- Antisense oligonucleotide (30-mer) with nucleotide sequence 5′-GTAATTGCGGCAAGAAGAATTGTTTCTGTC-3′(CODA001)(0)
- Antithrombin alfa(0)
- antithrombin alfa(0)
- antithrombin iii(0)
- AP214 Acetate (Αcetyl-(Lys)6-α-MSH, acetate salt)(0)
- apalutamide(0)
- Apis mellifera (801)(0)
- Apis mellifera venom(0)
- Apixaban(0)
- apixaban(0)
- Apolipoprotein A-1(0)
- apomorphine(0)
- apomorphine hydrochloride(0)
- apraglutide(0)
- apramycin sulfate(0)
- apremilast(0)
- Aprepitant(0)
- aprepitant(0)
- aprocitentan(0)
- aprotinin(2)
- Aqueous allergen extract of birch(0)
- Aqueous allergen extract of pollen from Phleum pratense(0)
- Aqueous extract of grass pollen from Dactylis glomerata, Festuca pratensis, Holcus lanatus, Lolium perenne, Phleum pratense and Poa pratensis(0)
- arachis hypogaea extract(0)
- arcitumomab(0)
- Arfolitixorin(0)
- argatroban(0)
- arginine(0)
- argipressin(0)
- Argon(0)
- arimoclomol(0)
- arimoclomol citrate(0)
- aripiprazole(0)
- Aripiprazole monohydrate(0)
- Arpraziquantel(0)
- arpraziquantel(0)
- Arsenic trioxide(0)
- arsenic trioxide(0)
- arsenous anhydride(1)
- Artemether(0)
- Artenimol(0)
- artenimol(0)
- artesunate(0)
- articaine (hydrochloride)(1)
- Arzoxifene(0)
- Asciminib(0)
- asciminib(0)
- asciminib hydrochloride(0)
- ascorbic acid(0)
- asenapine(0)
- asenapine (as maleate) (0)
- Asenapine maleate(0)
- asfotase alfa(0)
- ASMF(0)
- asparaginase(0)
- aspartic acid(0)
- asunaprevir(0)
- Asundexian(0)
- Atacicept(0)
- Ataluren(0)
- ataluren(0)
- atazanavir(1)
- atazanavir (as sulfate)(0)
- atazanavir (sulfate)(0)
- atazanavir sulfate(1)
- atenolol(0)
- atezolizumab(0)
- atidarsagene autotemcel(0)
- atogepant(0)
- atomoxetine(1)
- atomoxetine (hydrochloride)(0)
- atorvastatin(6)
- atorvastatin (calcium trihydrate)(0)
- atorvastatin (L-lysine salt)(0)
- Atorvastatin calcium(0)
- atosiban(0)
- atosiban (as acetate)(0)
- atovaquone(0)
- atracurium(0)
- Atrasentan (hydrochloride)(0)
- Atropine (sulfate)(0)
- Atropine sulfate(0)
- atrovastatin(0)
- attenuated Chlamydophila felis (905 strain)(0)
- attenuated feline panleucopenia virus (PLI IV)(0)
- attenuated feline rhinotracheitis herpesvirus (FHV F2 strain)(0)
- attenuated live rabies vaccine virus, strain SPBN GASGAS(0)
- Aumolertinib(0)
- Autologous bone marrow-derived cardiopoietic stem cells(0)
- Autologous bone marrow-derived mononuclear cell enriched white blood cells(0)
- Autologous CD3+CD4+CD25+CD127-FoxP3+ polyclonal regulatory T cells ex vivo expanded(0)
- Autologous CD4+ and CD8+ T cells genetically modified with a lentiviral vector encoding a B cell maturation antigen-specific chimeric antigen receptor (JCARH125)(0)
- Autologous CD4+ and CD8+ T cells transduced with lentiviral vector encoding a chimeric antigen receptor (CAR) directed against CD19 and preserving the T cell phenotype of the leukapheresis starting material (YTB323)(0)
- Autologous CD4+ and CD8+ T cells transduced with lentiviral vector encoding a chimeric antigen receptor (CAR) directed against human B cell maturation antigen (BCMA) and preserving the T cell phenotype of the leukapheresis starting material (PHE885)(0)
- Autologous CD34+ cell enriched population that contains haematopoietic stem cells transduced with lentiviral vector encoding the βA-T87Q-globin gene(1)
- Autologous CD34+ cells encoding ARSA gene(0)
- Autologous CD34+ cells transduced ex-vivo with retroviral vector (GIADAl) containing human adenosine deaminase gene from cDNA(0)
- Autologous CD34+ cells transduced with lentiviral vector containing the human Wiskott Aldrich Syndrom Protein gene(0)
- Autologous CD34+ cells transduced with lentiviral vector encoding the human beta-globin gene(0)
- Autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with lentiviral vector that encodes for the human Wiskott Aldrich Syndrome (WAS) cDNA sequence(0)
- autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence(0)
- autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human adenosine deaminase (ADA) cDNA sequence from human haematopoietic stem/progenitor (CD34+) cells(0)
- Autologous CD34+enriched cells from patients with Fanconi anaemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene (PGK-FANCA-WPRE)(0)
- Autologous CD34+ haematopoietic stem cells transduced ex vivo with a lentiviral vector encoding for the human Beta 2 Integrin/CD18 gene(0)
- Autologous CD34+ haematopoietic stem cells transduced with lentiviral vector encoding the human βA-T87Q-globin gene(0)
- Autologous CD34+ hematopoietic stem and progenitor cells (HSPCs) genetically modified with the lentiviral vector IDUA LV, encoding for the human α-L-iduronidase (IDUA) gene (OTL-203)(0)
- Autologous CD34+ hematopoietic stem cells transduced ex vivo with EFS lentiviral vector encoding for the human adenosine deaminase gene(0)
- autologous CD34+ hematopoietic stem cells with a CRISPR-edited erythroid enhancer region of the BCL11A gene(0)
- autologous cultured chondrocytes(1)
- Autologous dendritic cells activated by transient exposure to killed prostate cancer cells ex vivo(0)
- Autologous dendritic cells pulsed with allogeneic tumour cell lysate(0)
- autologous glioma tumor cell lysates (inactivated)(0)
- autologous glioma tumor cells (inactivated)(0)
- autologous haematopoietic stem cells transduced with lentiviral vector Lenti-D encoding the human ATP-binding cassette, sub-family D (ALD), member 1 (ABCD1) from cDNA(0)
- Autologous haptenised and irradiated cell lysates derived from glioma(0)
- Autologous haptenised and irradiated cells derived from glioma(0)
- autologous human chondrocytes in vitro expanded(0)
- Autologous human T cells genetically modified ex-vivo with a lentiviral vector encoding a chimeric antigen receptor (CAR) for B-cell maturation antigen (BCMA) (JNJ-68284528)(0)
- Autologous oral mucosal epithelial cells(0)
- autologous peripheral-blood mononuclear cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor (sipuleucel-T)(0)
- autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor(0)
- Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti-CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (brexucabtagene autoleucel)(0)
- Autologous peripheral blood T cells CD4 and CD8 selected and CD3 and CD28 activated transduced with retroviral vector expressing anti CD19 CD28/CD3-zeta chimeric antigen receptor and cultured (KTE-X19)(0)
- Autologous selected renal cells(0)
- Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel)(0)
- Autologous T lymphocyte-enriched population of cells transduced with a lentiviral vector encoding a chimeric antigen receptor targeting human B cell maturation antigen with 4-1BB and CD3-zeta intracellular signalling domains (CT053)(0)
- Autologous tumour-derived immunoglobulin idiotype coupled to keyhole limpet hemocyanin(0)
- Autologous tumour-infiltrating lymphocytes (LN-144/LN-145)(0)
- Autologous tumour-infiltrating lymphocytes (TILs) isolated from a patient's cancer tissue and expanded ex vivo (ITIL-168)(0)
- Avacopan(0)
- avacopan(0)
- Avadomide(0)
- Avalglucosidase alfa(0)
- avanafil(0)
- Avapritinib(0)
- avapritinib(0)
- Avatrombopag(0)
- avatrombopag(0)
- avatrombopag maleate(0)
- avelumab(0)
- Avexitide (acetate)(0)
- avian infectious bronchitis(0)
- avian infectious bronchitis virus strain D388(0)
- avian infectious bursal disease(0)
- avian infectious bursal disease vaccine (live)(0)
- avian infectious laryngotracheitis and Marek’s disease vaccine (live)(0)
- avian metapneumovirus(0)
- avian reovirus and egg drop syndrome virus vaccine (inactivated)(0)
- Avibactam(0)
- avibactam(0)
- Avibactam (AVI)(0)
- avibactam sodium(0)
- Aviptadil(0)
- avizafone (hydrochloride)(0)
- Avotermin(0)
- Axicabtagene ciloleucel(0)
- axicabtagene ciloleucel(0)
- axitinib(0)
- azacitidine(0)
- azagly-nafarelin(0)
- azaperone(0)
- azathioprine(0)
- AZD8233 sodium, PCSK9-targeted, antisense oligonucleotide (ASO)(0)
- azelastine(0)
- Azelastine (hydrochloride)(0)
- azilsartan(1)
- Azilsartan medoxomil(1)
- azilsartan medoxomil(1)
- azithromycin(1)
- Azithromycin(0)
- Azithromycin (monohydrate)(0)
- azithromycin (ocular use formulations)(0)
- azithromycin dihydrate(1)
- Aztreonam(0)
- aztreonam(0)
- Aztreonam (ATM)(0)
- aztreonam lysine(0)
- babesia canis, inactivated(0)
- babesia rossi, inactivated(0)
- bacillus calmette-guérin (BCG)(0)
- bacillus clausii multi-antibioresistant spores(0)
- Baclofen(0)
- bacterial DNA plasmid containing LACK gene from Leishmania infantum(0)
- bacterial lysate of haemophilus influenzae(0)
- Balaglitazone(0)
- Balixafortide(0)
- Balovaptan(0)
- Baloxavir marboxil(0)
- baloxavir marboxil(0)
- bambuterol(0)
- Bamlanivimab(0)
- Bardoxolone methyl(0)
- bardoxolone methyl(0)
- Baricitinib(1)
- baricitinib(1)
- barium selenate(0)
- basiliximab(0)
- Basmisanil(0)
- Batiraxcept(0)
- Batoclimab(0)
- batoclimab(0)
- bazedoxifene(0)
- B cell maturation antigen antibody-drug conjugate comprised of an immunoglobulin G1 humanized antibody conjugated covalently to the dibenzocyclooctyne noncleavable linker maytansinoid warhead (BMS-986352)(0)
- becaplermin(0)
- beclometason(0)
- beclometasone(1)
- beclometasone dipropionate(2)
- Beclometasone dipropionate(0)
- bedaquiline(0)
- bedaquiline fumarate(0)
- bedinvetmab(0)
- begelomab(0)
- belantamab mafodotin(0)
- belatacept(0)
- belimumab(0)
- Bemarituzumab(0)
- bemiparin(0)
- Bempedoic acid(0)
- bempedoic acid(0)
- Bempedoic acid (ETC-1002)(0)
- Bempegaldesleukin(0)
- benazepril(1)
- benazepril hydrochloride(0)
- bendamustine(1)
- bendamustine hydrochloride(0)
- bendroflumethiazide(0)
- benfluorex(1)
- Benralizumab(0)
- benralizumab(0)
- benserazide(0)
- Bentracimab(0)
- benzalkonium chloride(0)
- Benzamide, 4-[4-[[2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohexen-1-yl]methyl]-1-piperazinyl]-N-[[4-[[(1R)-3-(4-morpholinyl)-1-[(phenylthio)methyl] propyl]amino]-3-[(trifluoromethyl)sulfonyl]phenyl] sulfonyl] (ABT-263)(0)
- benzathine benzylpenicillin(0)
- benzocaine(0)
- benzoyl peroxide(1)
- benzydamine(0)
- benzydamine (hydrochloride)(0)
- Benzylamine derivative of benzofuran (BCX9930)(0)
- benzyl nicotinate(0)
- Benzylpenicillin(0)
- benzylpenicilloyl octa- L-lysine(0)
- Bepirovirsen(0)
- beractant(0)
- Beremagene geperpavec(0)
- Berotralstat(0)
- berotralstat(0)
- berotralstat dihydrochloride(0)
- besilesomab(0)
- beta-alanine(0)
- betadex clathrate(0)
- betahistine(0)
- betahistine dihydrochloride(1)
- betaine(0)
- Betaine anhydrous(0)
- betaine anhydrous(0)
- betamethasone(1)
- betamethasone acetate(0)
- betamethasone dipropionate clotrimazole(0)
- Betamethasone valerate(0)
- betamethasone valerate(0)
- betaxolol(0)
- bethanechol(0)
- betibeglogene autotemcel(1)
- Betrixaban(0)
- betrixaban(0)
- betrixaban maleate(0)
- Betula alba(0)
- Betulae cortex(0)
- Betula pendula(0)
- Betula verrucosa(0)
- bevacizumab(0)
- Bexagliflozin(0)
- bexarotene(1)
- bezafibrate(1)
- Bezlotoxumab(0)
- bezlotoxumab(0)
- BI 425809(0)
- bicalutamide(2)
- biclotymol(0)
- bictegravir(0)
- Bilastine(0)
- bimatoprost(0)
- bimekizumab(0)
- binimetinib(0)
- Bintrafusp alfa(0)
- Biotin(0)
- biperiden(0)
- birch, hazel and alder allergen extracts(0)
- birch bark(0)
- birch bark extract(0)
- birch pollen(0)
- Birch pollen extract (Betula verrucosa)(0)
- Bis-choline tetrathiomolybdate(0)
- Bismuth (subcitrate)(0)
- Bismuth subcitrate potassium(0)
- Bisoctrizole(0)
- bisoprolol(0)
- bisoprolol (fumarate)(0)
- bisoprolol fumarate(1)
- Bisoprolol fumarate(0)
- Bispecific antibody binding to clotting factor IX and X (Mim8)(0)
- Bispecific T-cell engager antibody with a single-chain fragment crystallizable moiety that binds to B cell maturation antigen surface receptor on tumour cells and the cluster of differentiation 3 receptor on Tcells(0)
- Bitopertin(0)
- bituminosulphonate (sodium)(0)
- Bivalent anti-human myostatin adnectin recombinant human IgG1-Fc fusion protein (RO7239361)(0)
- bivalent HPV vaccine (types 16, 18)(1)
- Bivalirudin(0)
- bivalirudin(0)
- bivalrudin(0)
- bleomycin(1)
- blinatumomab(0)
- BLU-667(0)
- bluetongue-virus serotype-1 antigen(0)
- bluetongue-virus serotype-2 antigen(0)
- bluetongue-virus serotype-4 antigen(0)
- bluetongue virus serotype 8(0)
- bluetongue virus serotype 8 antigen(0)
- Bluetongue virus vaccine (inactivated) (multistrain: 1 strain out of a set of 3)(0)
- Bluetongue virus vaccine (inactivated) (multistrain: 1-2 strains out of a set of 3)(0)
- bluetongue virus vaccine (inactivated) serotype 8(0)
- bluetongue virus vaccine, serotype 8 (inactivated)(0)
- bluetongue virus vaccine serotypes 1 or 4 or 8 [inactivated](0)
- Boceprevir(0)
- boceprevir(0)
- Bordetella pertussis (inactivated)(0)
- Bordetella pertussis antigen: Filamentous Haemagglutinin(0)
- Bordetella pertussis antigen: Pertactin(0)
- Bordetella pertussis antigen: Pertussis toxoid(0)
- Bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin)(0)
- Bordetella pertussis antigens: pertussis toxoid, filamentous haemagglutinin, pertactin, fimbriae Types 2 and 3(0)
- Bordetella pertussis antigens Pertussis Toxoid Filamentous Haemagglutinin(0)
- bortezomib(0)
- bosentan(1)
- Bosentan(0)
- bosentan (as monohydrate)(0)
- bosentan monohydrate(0)
- Bosutinib(0)
- bosutinib(0)
- bosutinib (as monohydrate)(0)
- Botulinum Neurotoxin Type A(0)
- botulinum neurotoxin type a (150 kd) free from complexing proteins(0)
- Botulinum toxin, Type A(0)
- botulinum toxin a(0)
- botulinum toxin a - haemagglutinin complex(0)
- Botulinum toxin type A(0)
- botulinum toxin type a(0)
- botulinum toxin type B(0)
- Botulinum toxin type E(0)
- bovine aprotinin(0)
- bovine aprotinin, calcium chloride(0)
- bovine aprotinin, human fibrinogen(0)
- Bovine concentrated lactoserum containing specific immunoglobulins G against E. coli F5 (K99) adhesin(0)
- bovine coronavirus, strain CA25, live(0)
- bovine Herpes Virus type 1 (BHV-1), strain Difivac (IBR-Marker Virus, gE-negative), modified live (attenuated) virus(0)
- bovine lung phospholipid(0)
- bovine parainfluenza 3 virus (inactivated) and bovine respiratory syncytial virus vaccine(0)
- Bovine parainfluenza virus 3, strain SF-4 Reisinger, Inactivated,Bovine respiratory syncytial virus, strain LYM-56, Live,Bovine viral diarrhoea virus 1, E2 recombinant protein,Bovine viral diarrhoea virus 2, E2 recombinant protein,Infectious bovine rhinotracheitis virus, strain CEDDEL, gE- tk- double-gene deleted, Live,(0)
- Bovine respiratory syncytial virus, strain LYM-56, Live / Infectious bovine rhinotracheitis virus, strain CEDDEL, gE- tk- double-gene deleted, Live / Bovine parainfluenza virus 3, strain SF-4 Reisinger, Inactivated / Bovine viral diarrhoea virus 1, E2 recombinant protein / Bovine viral diarrhoea virus 2, E2 recombinant protein(0)
- bovine respiratory syncytial virus vaccine (live)(0)
- bovine viral diarrhoea vaccine (modified live)(0)
- bovine viral diarrhoea virus type 1 and type 2 (subunit recombinant)(0)
- branaplam(0)
- Brazikumab(0)
- Brensocatib(0)
- Brentuximab vedotin(0)
- brentuximab vedotin(0)
- brexpiprazole(0)
- Brexucabtagene autoleucel(0)
- Briakinumab(0)
- brigatinib(0)
- brimonidine(0)
- brimonidine tartrate(0)
- Brincidofovir(0)
- brinzolamide(0)
- Brivaracetam(0)
- brivaracetam(0)
- Brivudine(0)
- brodalumab(0)
- Brolucizumab(0)
- brolucizumab(0)
- bromazepam(0)
- bromfenac(0)
- bromfenac sodium sesquihydrate(0)
- bromhexine(1)
- bromocriptine(2)
- Bromocriptine (mesilate)(0)
- bromperidol(0)
- brotizolam(0)
- Brucella abortus, strain AQ1302, protein extract(0)
- Bruton’s tyrosine kinase inhibitor(0)
- bucelipase alfa(0)
- budesonide(3)
- Budesonide(0)
- budesonide, micronised(0)
- bufexamac(1)
- buflomedil(1)
- Bulevirtide(0)
- bulevirtide(0)
- Bulevirtide acetate(0)
- Bumetanide(0)
- bupivacaine(0)
- buprenorphine(0)
- Buprenorphine hydrochloride(0)
- bupropion(2)
- bupropion hydrochloride(1)
- Burosumab(0)
- burosumab(0)
- buserelin(0)
- buspirone(0)
- busulfan(0)
- Butafosfan(0)
- butoconazole(0)
- C1 inhibitor (human)(0)
- cabazitaxel(0)
- cabergoline(1)
- Cabotegavir sodium(0)
- Cabotegravir(0)
- cabotegravir(0)
- cabozantinib(0)
- cabozantinib (s)-malate(0)
- Cadazolid(0)
- caffeine(1)
- Caffeine(0)
- Caffeine citrate(0)
- caffeine citrate(0)
- Cagrilintide(0)
- Calcifediol(0)
- calcipotriol(1)
- Calcipotriol(0)
- Calcipotriol hydrate(0)
- calcitonin(2)
- calcitonin salmon(0)
- calcitriol(0)
- calcium(2)
- Calcium (citrate)(0)
- Calcium, N,N'-1,2-ethanediylbis[N-[[3-(hydroxy-2-methyl-5-[(phosphonooxy)methyl]-4-pyridinyl]methyl]glycine] manganese complexes(0)
- Calcium carbonate(4)
- calcium carbonate(0)
- calcium chloride(0)
- calcium chloride (dihydrate)(0)
- calcium chloride, aprotinin(0)
- calcium chloride dihydrate(0)
- calcium folinate(1)
- Calcium lactate gluconate(1)
- calcium salts(0)
- calcium valproate(0)
- Camellia sinensis(0)
- Camidanlumab tesirine(0)
- camlipixant(0)
- camphor(1)
- canagliflozin(2)
- Canakinumab(0)
- canakinumab(0)
- canarypox virus expressing feline leukemia virus, live(0)
- candesartan(5)
- Candesartan(0)
- candesartan (cilexetil)(0)
- candesartan cilexetil(1)
- Candesartan cilexetil(0)
- cangrelor(0)
- Cangrelor (tetrasodium)(0)
- Canine distemper vaccine (live, attenuated) and canine parvovirus vaccine (live, recombinant)(0)
- canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus(0)
- canine distemper virus, strain CDV Bio 11/A, canine adenovirus type 2, strain CAV-2 Bio 13, canine parvovirus type 2b, strain CPV-2b Bio 12/B, canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (all live attenuated), Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, strain MSLB 1090, L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091...(0)
- canine distemper virus, strain CDV Bio 11/A, canine adenovirus type 2, strain CAV-2 Bio 13, canine parvovirus type 2b, strain CPV-2b Bio 12/B and canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (all live attenuated)(0)
- Canine herpes vaccine (inactivated subunit)(0)
- Canine herpesvirus (F205 strain) antigens(0)
- Canine leishmaniasis vaccine (recombinant protein)(0)
- Canine leptospirosis vaccine (inactivated)(0)
- canine parainfluenza type-2 virus, strain CPiV-2 Bio 15 (live attenuated)(0)
- Canine parainfluenza type 2 virus, strain CPiV-2 Bio 15 (live attenuated), Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, strain MSLB 1090 and L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 (all inactivated)(0)
- canine parainfluenza virus(0)
- canine parainfluenza virus, leptospira and rabies virus(0)
- canine parainfluenza virus, leptospira and rabies virus.(0)
- canine parainfluenza virus and Leptospira(0)
- Cannabidiol(0)
- cannabidiol(0)
- capecitabine(1)
- capivasertib(0)
- Caplacizumab(0)
- caplacizumab(0)
- Capmatinib(0)
- capmatinib(0)
- capmatinib dihydrochloride monohydrate(0)
- capromorelin tartrate(0)
- capsaicin(0)
- Capsici acris(0)
- captopril(2)
- carbamazepin(1)
- Carbamazepine(0)
- Carbetocin(0)
- carbidopa(1)
- carbidopa monohydrate(0)
- carbocisteine(1)
- carbomers(0)
- carboplatin(0)
- carboprost(0)
- carfilzomib(0)
- carglumic acid(0)
- cariprazine(0)
- Cariprazine (hydrochloride)(0)
- cariprazine hydrochloride(0)
- Carisbamate(0)
- carisoprodol(1)
- carmustine(0)
- carmustine (implant)(0)
- Carmustine (powder and solvent for solution for infusion)(0)
- carmustine (powder and solvent for solution for infusion)(0)
- Carotuximab(0)
- carrageenin(0)
- carteolol(0)
- Carvedilol(0)
- Casirivimab(0)
- casirivimab(0)
- Casopitant(0)
- caspofungin(0)
- caspofungin (as acetate)(0)
- caspofungin acetate(0)
- Catequentinib(0)
- Cathine (hydrochloride)(0)
- catridecacog(0)
- Catumaxomab(0)
- catumaxomab(0)
- CD19-directed genetically modified autologous cell-based product consisting of purified CD4+ T cells (CD4+ cells)(0)
- CD19-directed genetically modified autologous cell-based product consisting of purified CD8+ T-cells (CD8+ cells)(0)
- Cebranopadol(0)
- cedazuridine(0)
- Cedazuridine, decitabine(0)
- cediranib maleate(0)
- cefadroxil(0)
- cefazolin(0)
- cefepime(0)
- cefepime dihydrochloride monohydrate(0)
- Cefiderocol(0)
- cefiderocol(0)
- cefiderocol sulfate tosilate(0)
- cefodizime(0)
- cefoperazone(0)
- cefoperazone / sulbactam(0)
- cefotaxime(0)
- cefovecin(0)
- cefovecin (as sodium salt)(0)
- cefpodoxime(1)
- cefpodoxime proxetil(1)
- cefprozil(0)
- cefquinome(0)
- Ceftaroline fosamil(0)
- ceftaroline fosamil(0)
- ceftazidime(1)
- Ceftazidime(0)
- ceftazidime pentahydrate(0)
- ceftibuten(0)
- ceftiofur(0)
- ceftobiprole(0)
- ceftobiprole medocaril(0)
- Ceftobiprole medocaril (sodium)(0)
- Ceftolozane(0)
- ceftolozane(0)
- ceftolozane sulfate(0)
- Ceftriaxone(2)
- cefuroxime (as axetil)(1)
- cefuroxime axetil(1)
- cefuroxime sodium(1)
- celecoxib(2)
- Celecoxib(0)
- celiprolol(0)
- Cell-associated live recombinant turkey herpesvirus (strain HVP360), expressing the fusion protein of ND virus and the VP2 protein of IBD virus(0)
- Cell-associated live recombinant turkey herpesvirus (strain HVT/ILT-138), expressing the glycoproteins gD and gI of infectious laryngotracheitis virus(0)
- Cell-associated live recombinant turkey herpesvirus (strain HVT/NDV/ILT) expressing the fusion protein of newcastle disease virus and the glycoproteins gD and gI of infectious laryngotracheitis virus(0)
- Cell-free solution of lysed Escherichia coli culture, strain Laves(0)
- Cemdisiran(0)
- Cemiplimab(0)
- cemiplimab(0)
- Cendakimab(0)
- Cenegermin(0)
- cenegermin(0)
- Cenerimod(0)
- Cenicriviroc(0)
- cenobamate(0)
- Censavudine(0)
- Ceralasertib(0)
- cereal pollen(0)
- ceritinib(0)
- cerivastatin(1)
- cerliponase alfa(0)
- Certolizumab pegol(0)
- certolizumab pegol(0)
- certoparin(0)
- cetirizine(1)
- cetirizine pseudoephedrine(0)
- Cetrelimab(0)
- cetrorelix(0)
- cetrorelix (as acetate)(0)
- cetuximab(0)
- cetylpyridine(0)
- Cevostamab(0)
- ChAdOx1-SARS-COV-2(0)
- characterised viable autologous cartilage cells expanded ex vivo expressing specific marker proteins(0)
- Chemically modified extract of grass pollen from Holcus lanatus, Phleum pratense and Poa pratensis(0)
- Chemically modified recombinant human sulfamidase(0)
- Chenodeoxycholic acid(0)
- chenodeoxycholic acid(0)
- Chikungunya Virus Virus-Like Particle Vaccine / aluminum hydroxide(0)
- Chimeric antibody to mesothelin (MORAB-009)(0)
- Chimeric fibril-reactive IgG1k monoclonal antibody 11-1F4(0)
- Chimeric monoclonal anti-Shiga toxin antibodies cαStx1 and cαStx2(0)
- Chimeric murine-human anti Interleukin 6 monoclonal antibody(0)
- chimeric yellow fever dengue virus serotype 1 (live, attenuated)(0)
- chimeric yellow fever dengue virus serotype 2 (live, attenuated)(0)
- chimeric yellow fever dengue virus serotype 3 (live, attenuated)(0)
- chimeric yellow fever dengue virus serotype 4 (live, attenuated)(0)
- Chimpanzee Adenovirus encoding the SARS CoV 2 Spike glycoprotein (ChAdOx1-S)(0)
- chlordiazepoxide(0)
- chlorhexidine(0)
- chlorhexidine diacetate(1)
- chlorhexidine digluconate(0)
- Chlorhexidine gluconate(0)
- chlormadinone(2)
- chlormadinone acetate(0)
- Chlormethine(0)
- chlormethine(0)
- chlormezanone(1)
- Chloroprocaine hydrochloride(0)
- Chloroquine(0)
- chloroquine phosphate(0)
- chlorphenamine maleate(0)
- Chlorphenoxamine hydrochloride(0)
- chlorpromazine(0)
- chlorquinaldol(0)
- chlortalidone(0)
- chlortetracycline hydrochloride(0)
- cholecalciferol(0)
- cholera vaccine (inactivated, oral)(0)
- Cholera vaccine, live attenuated, oral (strain CVD 103-HgR)(0)
- cholera vaccine, oral, live(0)
- cholic acid(0)
- choline alfoscerate(0)
- chondrogenic induced equine allogeneic peripheral blood-derived mesenchymal stem cells(0)
- Chondroitin sulfate(0)
- choriogonadotropin alfa(0)
- ciclesonide(1)
- ciclosporin(3)
- cidofovir(0)
- cilastatin(1)
- cilastatin sodium(0)
- cilazapril(4)
- cilengitide(0)
- cilgavimab(0)
- Cilgavimab (AZD1061)(0)
- Cilofexor(0)
- cilostazol(1)
- ciltacabtagene autoleucel(0)
- cimicifuga racemosa (L.) nutt., rhizoma(0)
- cimicoxib(0)
- cinacalcet(0)
- cinacalcet hydrochloride(0)
- cineole(1)
- cinolazepam(0)
- cinoxacin(1)
- Cipaglucosidase alfa(0)
- cipaglucosidase alfa(0)
- ciprofibrate(1)
- ciprofloxacin(6)
- Ciprofloxacin(0)
- ciprofloxacin hydrochloride(0)
- cisapride(1)
- cisatracurium(0)
- Cisplatin(0)
- citalopram(1)
- citral(1)
- citric acid(0)
- citric acid (as citric acid anhydrous)(0)
- Citrulline malate(0)
- Cladribine(0)
- cladribine(0)
- clarithromycin(0)
- clascoterone(0)
- classical swine fever vaccine (live recombinant)(0)
- Classical Swine Fever Virus (CSFV) -E2 subunit antigen(0)
- clavulanate(0)
- clavulanic acid(1)
- Clazakizumab(0)
- Clazosentan(0)
- clebopride(0)
- clenbuterol(0)
- clevidipine(0)
- Clevidipine butyrate(0)
- clindamycin(0)
- clindamycin hydrochloride(1)
- Clindamycin phosphate(0)
- clioquinol(0)
- clobazam(1)
- clobenzorex(1)
- clobetasol(0)
- clobutinol(1)
- clodronic acid(1)
- clofarabine(0)
- Clomipramine(0)
- clomipramine hydrochloride(0)
- clonazepam(1)
- Clonidine(0)
- Clonidine hydrochloride(0)
- clopidogrel(3)
- clopidogrel (as besilate)(0)
- clopidogrel (as hydrobromide)(0)
- clopidogrel (as hydrochloride)(0)
- clopidogrel (as hydrogen sulfate)(0)
- Clopidogrel (bisulfate)(0)
- clopidogrel besilate(0)
- clopidogrel hydrochloride(1)
- clopidogrel hydrogen sulfate(0)
- clorsulon(0)
- closantel(0)
- clostridioides difficile(0)
- Clostridioides difficile toxoid A(0)
- Clostridioides difficile toxoid B(0)
- Clostridium-perfringens-type-A alpha toxoid(0)
- clostridium botulinum neurotoxin type A(1)
- Clostridium Botulinum neurotoxin type A (150 kD), free from complexing proteins(0)
- Clostridium botulinum neurotoxin type A (150 kD), free of complexing proteins(0)
- Clostridium botulinum toxin type A, purified neurotoxin(0)
- Clostridium botulinum type A neurotoxin complex(1)
- Clostridium collagenase(0)
- Clostridium difficile toxin A human monoclonal antibody(0)
- Clostridium difficile toxin B human monoclonal antibody(0)
- Clostridium perfringens, type A, alpha toxoid(0)
- CLOSTRIDIUM PERFRINGENS TYPE C, BETA1 TOXOID / Clostridium perfringens, type A, alpha toxoid / Clostridium perfringens, type A, beta2 toxoid / Escherichia coli, fimbrial adhesin F4ab / Escherichia coli, fimbrial adhesin F4ac / Escherichia coli, fimbrial adhesin F5 / Escherichia coli, fimbrial adhesin F6(0)
- Clostridium perfringens type C / Escherichia coli F4ab / E. coli F4ac / E. coli F5 / E. coli F6 / E. coli LT(0)
- Clostridium perfringens vaccine (inactivated)(0)
- clostridium perfringens vaccine, inactivated(0)
- Clostridium tetani toxoid / Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus(0)
- clotiazepam(0)
- clotrimazole(1)
- clozapine(1)
- Cluster of differentiation 40 (CD40) ligand antagonist comprising two identical Tn3 modules fused to human serum albumin, with each Tn3 module being an engineered form of the third fibronectin type III protein domain of human Tenascin C (VIB4920)(0)
- Co-crystal of tramadol (hydrochloride)(0)
- Coagulation Factor VIIa (Recombinant)(0)
- cobicistat(0)
- Cobimetinib(0)
- cobimetinib(0)
- cobimetinib hemifumarate(0)
- cobolimab(0)
- Coccidiosis vaccine live for chickens(0)
- codeine(1)
- Codeine(0)
- codeine camphosulphonate(0)
- codeine camphosulphonate / sodium benzoate, codeine camphosulphonate / sulfogaiacol / grindelia soft extract(0)
- colchicine(0)
- colecalciferol(5)
- colesevelam(0)
- colesevelam (as hydrochloride)(0)
- Colesevelam hydrochloride(0)
- colestilan(0)
- Colistimethate sodium(1)
- colistimethate sodium(1)
- colistin(0)
- Colistin sulfate(0)
- collagenase Clostridium histolyticum(0)
- concentrate of proteolytic enzymes enriched in bromelain(0)
- Concentrate of proteolytic enzymes in bromelain(0)
- Concizumab(0)
- Conestat alfa(0)
- conestat alfa(0)
- Conjugated Estrogens(0)
- Copanlisib(0)
- copanlisib(0)
- Copanlisib dihydrochloride(0)
- copper (64Cu) chloride(0)
- corifollitropin alfa(0)
- corticorelin(0)
- Corticotropin(0)
- Corylus avellana(0)
- Cosibelimab(0)
- Cotadutide(0)
- Covalently closed DNA plasmids coding for cytomegalovirus phosphoprotein 65 and glycoprotein B genes (ASP0113)(0)
- COVID-19 mRNA vaccine(0)
- COVID-19 vaccine (Ad26.COV2-S (recombinant))(0)
- COVID-19 vaccine (Ad26.COV2-S [recombinant])(0)
- COVID-19 Vaccine (ChAdOx1-S [recombinant])(0)
- COVID-19 vaccine (ChAdOx1-S [recombinant]) (AZD1222)(0)
- COVID-19 vaccine (inactivated, adjuvanted, adsorbed)(0)
- COVID-19 Vaccine (recombinant, adjuvanted)(0)
- CpG 1018/Alum-adjuvanted recombinant SARS-CoV-2 Trimeric Spike (S) protein subunit vaccine (SCB- 2019)(0)
- Crinecerfont(0)
- Crisaborole(0)
- crisaborole(0)
- crisantaspase(0)
- Crizanlizumab(1)
- crizanlizumab(1)
- crizotinib(0)
- cromoglicic acid(0)
- Crovalimab(0)
- Cryptosporidium parvum, glycoprotein gp40(0)
- cryptosporidium parvum, glycoprotein gp40(0)
- Culture expanded autologous chondrocytes(0)
- CX-024414 (single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2)(0)
- Cyanocobalamin(0)
- cyanocobalamin(0)
- cyclizine(0)
- Cyclophosphamide(0)
- cyproheptadine(0)
- cyproterone(2)
- cyproterone / ethinylestradiol(0)
- Cysteamine hydrochloride(0)
- cysteine(0)
- cystine(0)
- cytarabine(0)
- cytomegalovirus immunoglobulin(0)
- D-Sorbitol (PXT3003)(0)
- dabigatran etexilate(0)
- Dabigatran etexilate mesilate(0)
- Dabrafenib(0)
- dabrafenib(0)
- dabrafenib mesilate(0)
- Dabrafenib mesylate(0)
- dacarbazine(1)
- daclatasvir(1)
- Daclatasvir(0)
- daclatasvir dihydrochloride(1)
- daclizumab(2)
- dacomitinib(0)
- dacomitinib monohydrate(0)
- Dactylis glomerata L.(0)
- dalbavancin(0)
- dalbavancin hydrochloride(0)
- Dalcetrapib(0)
- dalteparin sodium(0)
- Damoctocog alfa pegol(0)
- damoctocog alfa pegol(0)
- danaparoid(0)
- Danicopan(0)
- danofloxacin(0)
- danofloxacin mesilate(0)
- dantrolene sodium, hemiheptahydrate(0)
- dantrolene sodium hemiheptahydrate(0)
- dapagliflozin(3)
- dapagliflozin propanediol monohydrate(3)
- Dapirolizumab pegol(0)
- dapivirine(0)
- dapoxetine(1)
- daprodustat(0)
- daptomycin(0)
- Daratumumab(0)
- daratumumab(0)
- darbepoetin alfa(0)
- Daridorexant(0)
- daridorexant(0)
- daridorexant hydrochloride(0)
- darifenacin hydrobromide(0)
- darolutamide(0)
- darunavir(0)
- darvadstrocel(0)
- dasabuvir(1)
- Dasabuvir(0)
- Dasabuvir (sodium monohydrate)(0)
- dasabuvir sodium(1)
- dasatinib(0)
- dasatinib (anhydrous)(1)
- Dasiglucagon(0)
- dasiprotimut-t(0)
- daunorubicin(0)
- daunorubicin hydrochloride(0)
- DaxibotulinumtoxinA(0)
- decitabine(0)
- defatted powder of Arachis hypogaea L., semen (peanuts)(0)
- deferasirox(0)
- Deferiprone(0)
- deferiprone(0)
- Deferoxamine (mesylate)(0)
- defibrotide(0)
- degarelix(0)
- degarelix acetate(0)
- Delafloxacin(0)
- delafloxacin(0)
- delafloxacin meglumine(0)
- Delamanid(0)
- delamanid(0)
- Delandistrogene moxeparvovec(0)
- delapril(1)
- Deleobuvir(0)
- Delgocitinib(0)
- Delolimogene mupadenorepvec(0)
- delta-9-tetrahydrocannabinol(0)
- deltamethrin(0)
- demeclocycline(0)
- dengue tetravalent vaccine (live, attenuated)(0)
- Dengue virus, serotype 2, expressing Dengue virus, serotype 1, surface proteins, live, attenuated(0)
- Dengue virus, serotype 2, expressing Dengue virus, serotype 3, surface proteins, live, attenuated(0)
- Dengue virus, serotype 2, expressing Dengue virus, serotype 4, surface proteins, live, attenuated(0)
- Dengue virus, serotype 2, live, attenuated(0)
- denosumab(0)
- Deoxycholic acid(0)
- Depemokimab(0)
- depigmented glutaraldehyde polymerised(0)
- depreotide(0)
- depreotide trifluoroacetate(0)
- deproteinised hemoderivative of calf blood(0)
- Derivative of (3S,3'S,3a'S,10a'S)-3'-phenyl-3',3a',10',10a'-tetrahydro-1'H-spiro[indoline-3,2'- pyrrolo[2',3':4,5]pyrrolo[1,2-b]indazol]-2-one(0)
- Derivative of 3‐phenyl‐3H,4H,6H,7H‐pyrano[3,4‐d]imidazol‐4‐one(0)
- Derivative of 4,4'-(1-methylene)-bisbenzonitrile(0)
- Derivative of 4H-pyrazolo[3,4-d]pyrimidin-4-one(0)
- Derivative of 6-[2-(pyridin-2-yl)phenoxy]methyl}-1,2,3,4-tetrahydroisoquinoline(0)
- Derivative of pyrrolopyrimidine(0)
- Dermatophagoides farina(0)
- Dermatophagoides farinae(0)
- Dermatophagoides pteronyssinus(0)
- Dersimelagon(0)
- desfluran(0)
- desflurane(0)
- desirudin(0)
- desloratadine(2)
- deslorelin acetate(0)
- desmopressin(1)
- desogestrel(2)
- desoxycortone(0)
- desoxycortone pivalate(0)
- Desvenlafaxine succinate monohydrate(0)
- detomidine(0)
- Deucravacitinib(0)
- deucravacitinib(0)
- dexamethasone(2)
- dexamethasone (SHP640)(0)
- Dexamethasone (sodium phosphate)(0)
- dexamethasone acetate(0)
- dexamethasone phosphate(0)
- Dexamethasone sodium phosphate encapsulated in human autologous erythrocytes(0)
- dexamfetamine(1)
- dexchlorpheniramine(0)
- dexfenfluramine(1)
- dexibuprofen(1)
- dexketoprofen(0)
- Dexketoprofen (trometamol)(0)
- dexlansoprazole(0)
- dexmedetomidine(0)
- Dexmedetomidine hydrochloride(0)
- dexpanthenol xylometazoline(0)
- dexrazoxane(2)
- dexrazoxane hydrochloride(0)
- dextromethorphan(0)
- Dextromethorphan (hydrobromide)(0)
- dextromethorphan hydrobromide(0)
- dextropropoxyphene(1)
- Dezamizumab(0)
- diacerein(1)
- Diacerein(0)
- diacerin(0)
- Diamorphine(0)
- diamorphine hydrochloride(0)
- dibotermin alfa(1)
- diclofenac(3)
- Diclofenac (potassium)(0)
- Diclofenac (sodium)(0)
- diclofenac sodium(1)
- Diclofenac sodium(0)
- Diclofenamide(0)
- didanosine(1)
- dienogest(2)
- Dienogest(0)
- Difelikefalin(0)
- difelikefalin(0)
- difloxacin(0)
- difloxacin hydrochloride(0)
- Dihomo-y-linolenic acid(0)
- Dihomo-γ-linolenic acid (DS107)(0)
- dihydroergocristine(1)
- dihydroergocryptine(2)
- dihydroergotamine(1)
- dihydroergotoxine(1)
- diltiazem(0)
- Diltiazem (hydrochloride)(0)
- Dimeric protein comprised of two disulfide-linked monomers, each being a fully human fusion protein consisting of a modified extracellular domain of the human activin receptor type IIA fused to the fragment crystallizable domain of human IgG1 Fc including the hinge region, CH2 and CH3 domains (KER-050)(0)
- dimethanesulfonate(0)
- dimethyl fumarate(0)
- Dimethyl sulfoxide(0)
- dinoprost(0)
- dinoprostone(0)
- dinotefuran(0)
- dinotefuran, permethrin, and pyriproxyfen(0)
- Dinutuximab(0)
- dinutuximab(0)
- Dinutuximab beta(0)
- dinutuximab beta(0)
- Dipalmitoylphosphatidylcholine(0)
- diphenhydramine hydrochloride(0)
- diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type-b (Hib) conjugate vaccine (adsorbed)(0)
- diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) vaccine (adsorbed)(0)
- Diphtheria (D), tetanus (T), pertussis (whole cell) (Pw), hepatitis B (rDNA) (HBV), Haemophilus type b (HIB) and Neisseria meningitidis group A and C (MenAC) conjugate vaccine (adsorbed)(0)
- diphtheria (D), tetanus (T), pertussis (whole cell) (Pw) and hepatitis B (rDNA) (HBV) vaccine (adsorbed)(0)
- diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant) and Haemophilus influenzae type b conjugate vaccine, adjuvanted(0)
- diphtheria, tetanus, acellular pertussis and hepatitis B recombinant, adsorbed vaccine(0)
- diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus influenzae type b conjugate vaccine (adsorbed)(0)
- diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inactivated) and Haemophilus type b conjugate vaccine (adsorbed)(0)
- diphtheria, tetanus, pertussis (whole cell), hepatitis B (rDNA) and Haemophilus influenzae type B conjugate vaccine (absorbed)(0)
- diphtheria, tetanus and hepatitis B (rDNA) vaccine (adsorbed)(0)
- diphtheria, tetanus and pertussis (acellular, component) vaccine (adsorbed)(0)
- diphtheria / tetanus / pertussis (acellular, component) / poliomyelitis (inactivated) / haemophilus type b conjugate vaccine (adsorbed)(0)
- diphtheria tetanus pertussis and poliomyelitis inactivated vaccine(0)
- diphtheria tetanus pertussis and poliomyelitis inactivated vaccine reduce antigens content(0)
- diphtheria tetanus vaccines(0)
- diphtheria toxin interleukin-3 Fusion Protein(0)
- Diphtheria toxoid(0)
- diphtheria vaccine(0)
- diptheria(0)
- dipyridamole(1)
- dirlotapide(0)
- diroximel fumarate(0)
- Diroximel fumarate (BIIB098)(0)
- Dirucotide acetate(0)
- disulfide with human-Mus musculus monoclonal OG1950 kappa-chain(0)
- DL-camphor(0)
- DNA, d(P-thio)([2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]rG-G-T-T-A-m5C-A-T-G-A-A-[2'-0-(2-methoxyethyl)]rA-[2'-0-(2-methoxyethyl)]m5rU-[2'-0-(2-methoxyethyl)]m5rC-[2'-0-(2-methoxyethy l)]m5rC-[2'-0-(2-methoxyethyl)]m5rC), sodium salt(0)
- DNA plasmid encoding HPV type 16 consensus E6 and E7 proteins (pGX3001)(0)
- DNA plasmid encoding HPV type 18 consensus E6 and E7 proteins (pGX3002)(0)
- Dobutamine(0)
- docetaxel(1)
- docetaxel trihydrate(0)
- Docosahexaenoic acid(0)
- docosanol(0)
- dodecafluoropentane(0)
- dofetilide(0)
- dolutegravir(0)
- Dolutegravir (DTG)(0)
- dolutegravir sodium(0)
- Domagrozumab(0)
- domperidone(2)
- donepezil(1)
- donepezil hydrochloride(1)
- Dopamine(0)
- Dopamine (hydrochloride)(0)
- Dopamine hydrochloride(0)
- doramectin(0)
- doravirine(0)
- doripenem(0)
- Doripenem monohydrate(0)
- dornase alpha(0)
- dorzolamide(0)
- dostarlimab(0)
- Doxazosin(5)
- doxazosin(0)
- doxazosin (mesylate)(0)
- Doxecitine(0)
- doxorubicin(0)
- doxorubicin hydrochloride(0)
- doxorubicin hydrochloride, liposomal(0)
- Doxribtimine(0)
- Doxycycline(0)
- doxycycline(0)
- doxycycline hyclate(0)
- doxycycline monohydrate(1)
- doxylamine(0)
- Doxylamine (succinate)(0)
- Drisapersen(0)
- Dronabinol(0)
- dronedarone(0)
- drospirenone(6)
- drotaverine hydrochloride(0)
- drotrecogin alfa (activated)(0)
- dry extract from birch bark (DER 5-10 : 1), extraction solvent n-heptane 95% (w/w)(0)
- dulaglutide(0)
- duloxetine(0)
- duloxetine hydrochloride(0)
- dupilumab(0)
- Durlobactam / sulbactam (SUL-DUR)(0)
- durvalumab(0)
- Dusquetide(0)
- dutasteride(1)
- duvelisib(0)
- E. coli adhesin F4 (F4ab, F4ac, F4ad)(0)
- E. coli adhesin F5(0)
- E. coli adhesin F6(0)
- E. coli adhesin F41(0)
- E. coli verotoxoid vaccine (inactivated recombinant)(0)
- E2 glycoprotein of classical swine fever virus(0)
- ebastine(1)
- ebola vaccine (Ad26.ZEBOV-GP [recombinant])(0)
- Ebola vaccine (MVA-BN-Filo [recombinant])(0)
- Ebola Zaire Vaccine (rVSV∆G-ZEBOV-GP, live)(0)
- Ecallantide (recombiant inhibitor of human plasma kallikrein)(0)
- econazole(0)
- econazole nitrate(0)
- Ecopipam (hydrochloride)(0)
- Eculizumab(0)
- eculizumab(0)
- edaravone(0)
- edotreotide(0)
- edoxaban(0)
- edoxaban tosilate(0)
- efalizumab(0)
- Efanesoctocog alfa(0)
- efanesoctocog alfa(0)
- Efavaleukin alfa(0)
- efavirenz(0)
- efbemalenograstim alfa(0)
- Efgartigimod alfa(0)
- efgartigimod alfa(0)
- Efinaconazole(0)
- Eflapegrastim(0)
- Eflornithine(0)
- eflornithine(0)
- eflornithine (hydrochloride monohydrate)(0)
- Eflornithine hydrochloride(0)
- Efmorocotocog alfa(0)
- efmoroctocog alfa(1)
- Efpeglenatide(0)
- Efruxifermin(0)
- Eftilagimod alpha(0)
- eftrenonacog alfa(0)
- efungumab(0)
- EGFR-cMET bispecific antibody(0)
- Eimeria acervulina, strain 003(0)
- eimeria acervulina, strain 003(0)
- Eimeria acervulina, strain 044, Live(0)
- Eimeria acervulina, strain 044, live / Eimeria maxima, strain 013, live / Eimeria praecox, strain 007, live / Eimeria tenella, strain 004, live(0)
- eimeria brunetti, strain 034(0)
- Eimeria maxima, strain 013(0)
- eimeria maxima, strain 013(0)
- Eimeria maxima, strain 013, Live(0)
- Eimeria mitis, strain 006(0)
- eimeria necatrix, strain 033(0)
- Eimeria praecox, strain 007(0)
- Eimeria praecox, strain 007, Live(0)
- Eimeria tenella, strain 004(0)
- eimeria tenella, strain 004(0)
- Eimeria tenella, strain 004, Live(0)
- elacestrant(0)
- Elacytarabine(0)
- Eladocagene exuparvovec(0)
- eladocagene exuparvovec(0)
- Elafibranor(0)
- Elagolix(0)
- elasomeran(0)
- elasomeran / davesomeran(0)
- elasomeran / imelasomeran(0)
- Elasomeran / imelasomeran Elasomeran(0)
- elbasvir(0)
- Eleclazine(0)
- eletriptan(1)
- elexacaftor(0)
- Eliapixant(0)
- eliglustat(0)
- Eliglustat (tartrate)(0)
- elivaldogene autotemcel(0)
- Elobixibat(0)
- Elocalcitol(0)
- elosulfase alfa(0)
- Elotuzumab(0)
- elotuzumab(0)
- elranatamab(0)
- Eltrombopag(0)
- eltrombopag(0)
- Eluxadoline(0)
- eluxadoline(0)
- elvitegravir(0)
- Emactuzumab(0)
- Emapalumab(0)
- emapalumab(0)
- emedastine(0)
- emedastine difumarate(0)
- Emicizumab(0)
- emicizumab(0)
- emiplacel(0)
- Emixustat (hydrochloride)(0)
- emodepside(0)
- empagliflozin(3)
- Emricasan(0)
- emtricitabine(0)
- enalapril(2)
- Enalapril (maleate)(0)
- Enalapril maleate(0)
- Enasidenib(0)
- encequidar(0)
- enclomifene(0)
- enclomifene citrate(0)
- Encorafenib(0)
- encorafenib(0)
- enflicoxib(0)
- Enfortumab vedotin(0)
- enfortumab vedotin(0)
- enfuvirtide(0)
- Enmetazobactam(0)
- enmetazobactam(0)
- enoxacin(1)
- enoxaparin(1)
- enoxaparin sodium(0)
- Enpatoran(0)
- enrofloxacin(0)
- ensartinib(0)
- entacapone(1)
- Entecavir(0)
- entecavir(0)
- entecavir monohydrate(0)
- Entinostat Polymorph B(0)
- Entolimod(0)
- Entospletinib(0)
- Entrectinib(0)
- entrectinib(0)
- enzalutamide(0)
- Enzastaurin (hydrochloride)(0)
- Enzastaurin hydrochloride(0)
- Epcoritamab(0)
- epcoritamab(0)
- ephedrine(0)
- ephedrine hydrochloride(1)
- epinastine(0)
- epinephrine(0)
- epirubicin(0)
- eplerenone(0)
- Eplivanserin hemifumarate(0)
- Eplontersen(0)
- epoetin alfa(0)
- epoetin beta(0)
- epoetin delta(0)
- epoetin theta(0)
- epoetin zeta(0)
- epoprostenol(1)
- Epratuzumab(0)
- eprinomectin(0)
- eprinomectin, fipronil, praziquantel, (S)-methoprene(0)
- eprosartan(1)
- Eprotirome(0)
- eptacog alfa (activated)(0)
- Eptacog alfa pegol (activated)(0)
- Eptacog beta (activated)(0)
- eptifibatide(0)
- Eptinezumab(0)
- eptinezumab(0)
- eptotermin alfa(0)
- Equine allogeneic mesenchymal stem cells(0)
- Equine immunoglobulin F(ab')2 fragments targeting Shiga toxin(0)
- equine influenza (live recombinant) and tetanus vaccine(0)
- equine influenza-virus strains: A/equine-2/South Africa/4/03, A/equine-2/Newmarket/2/93(0)
- equine influenza-virus strains: A/equine-2/South Africa/4/03, A/equine-2/Newmarket/2/93, tetanus toxoid(0)
- Equine influenza vaccine (live recombinant)(0)
- equine umbilical cord-derived mesenchymal stem cells(0)
- equine umbilical cord mesenchymal stem cells(0)
- eravacycline(0)
- Erdafitinib(0)
- Erdosteine(0)
- erenumab(0)
- ergotamine(0)
- Eribulin(0)
- eribulin(0)
- Eribulin mesylate(0)
- Eritoran(0)
- erlotinib(0)
- ertapenem(0)
- ertapenem sodium(0)
- Ertugliflozin(0)
- ertugliflozin(0)
- ertugliflozin l-pyroglutamic acid(0)
- Erysipelothrix rhusiopathiae(0)
- Erysipelothrix rhusiopathiae, strain R32E11 (inactivated)(0)
- erythromycin(0)
- erythromycin estolate(0)
- esafoxolaner(0)
- Escherichia coli, type 08, strain K87 (live)(0)
- Escherichia coli aroA gene deleted, type O78, strain EC34195 (live)(0)
- escherichia coli bacteria (cells and autolysate)(1)
- Escherichia coli J5 inactivated(0)
- escherichia coli lysate(0)
- escitalopram(3)
- escitalopram oxalate(1)
- Esketamine(0)
- esketamine(0)
- Esketamine (hydrochloride)(0)
- esketamine hydrochloride(0)
- eslicarbazepine acetate(0)
- esomeprazole(1)
- esomeprazole magnesium(1)
- esomeprazole magnesium trihydrate(0)
- esomeprazole sodium(0)
- essential oils of pine needle, eucalyptus and turpentine(1)
- Estetrol(0)
- estetrol(0)
- estetrol monohydrate(0)
- estradiol(4)
- estradiol /prednisolone(0)
- estradiol hemihydrate(0)
- Estradiol valerate(0)
- Estriol(0)
- estriol(0)
- eszopiclone(0)
- etanercept(0)
- Etarfolatide(0)
- Etelcalcetide(0)
- etelcalcetide(0)
- etelcalcetide hydrochloride(0)
- eteplirsen(0)
- Etesevimab(0)
- Ethanol(0)
- ethinylestradiol(6)
- ethinyl estradiol(5)
- Ethinyl estradiol(0)
- ethinylestradiol (as betadex clathrate)(0)
- ethinylestradiol bethadex clathrate(0)
- ethosuximide(0)
- etidronate(0)
- etidronic acid(1)
- etifoxine(1)
- etirinotecan pegol(0)
- etomidate(0)
- etonogestrel(3)
- etoposide(1)
- etoposide phosphate(1)
- etoricoxib(4)
- etoxybamide(0)
- Etranacogene dezaparvovec(0)
- etranacogene dezaparvovec(0)
- Etrasimod(0)
- Etrasimod arginine(0)
- Etrasimod L-arginine(0)
- Etravirine(0)
- etravirine(0)
- Etripamil(0)
- Etrolizumab(0)
- Evacetrapib(0)
- Evenamide(0)
- everolimus(0)
- Evinacumab(0)
- evinacumab(0)
- Evobrutinib(0)
- Evolocumab(0)
- evolocumab(0)
- Evoncabtagene pazurgedleucel(0)
- Exagamglogene autotemcel(0)
- exametazime(0)
- exanatide(0)
- Exebacase(0)
- exemestane(0)
- exenatide(0)
- Exon 45 specific phosphorothioate oligonucleotide(0)
- Exon 53 specific phosphorothioate oligonucleotide(0)
- Expanded autologous bone marrow-derived osteoblastic cells(0)
- Expanded human autologous mesenchymal adult stem cells extracted from adipose tissue (CX-401)(0)
- ExPEC9V(0)
- ex vivo expanded autologous human corneal epithelial cells containing stem cells(0)
- Ex vivo expanded autologous human corneal epithelium cells containing stem cells(0)
- Ex vivo expanded autologous human keratinocytes containing epidermal stem cells genetically modified with a gamma-retroviral (RV) vector expressing the full-length LAMB3 cDNA (Hologene 5)(0)
- Ezeprogind(0)
- Ezetimibe(0)
- ezetimibe(0)
- F(ab’)2 fragments of equine antirabies immunoglobulin(0)
- F4ab (K88ab) fimbrial adhesin(0)
- F4ac (K88ac) fimbrial adhesin(0)
- F5 (K99) fimbrial adhesin(0)
- F6 (987P) fimbrial adhesin(0)
- Factor VIII Inhibitor Bypassing Activity(0)
- factor XIII(0)
- faldaprevir(0)
- famciclovir(1)
- Famotidine(0)
- Fampridine(0)
- fampridine(0)
- famtozinameran and tozinameran(0)
- Faricimab(0)
- faricimab(0)
- Fasinumab(0)
- Fasudil hydrochloride(0)
- Favezelimab(0)
- Fc- and CDR-modified humanised monoclonal antibody against C5 (ravulizumab)(0)
- febantel(0)
- febuxostat(0)
- fedratinib(0)
- fedratinib dihydrochloride monohydrate(0)
- felbamate(0)
- feline calicivirosis, feline viral rhinotrachieitis, feline infectious enteritis (feline panleucopenia) vaccine (live), feline leukaemia vaccine (inactivated)(0)
- feline calicivirus, strain 255, inactivated(0)
- feline interleukin-2 recombinant canarypox virus (vCP1338 virus)(0)
- Feline leukaemia vaccine (inactivated)(0)
- feline leukaemia virus recombinant canarypox virus (vCP97)(0)
- feline panleucopenia virus, strain PLI IV, live(0)
- feline rhinotracheitis virus, strain C27, antigen(0)
- felodipine(1)
- FeLV recombinant canarypox virus (vCP97)(0)
- fenbendazole(0)
- fenbutrazate(1)
- Fenebrutinib(0)
- fenfluramine(1)
- Fenfluramine hydrochloride(0)
- fenofibrate(2)
- fenoterol(1)
- fenproporex(1)
- fenspiride(1)
- fentanyl(4)
- fentanyl (transdermal patches, solution for injection - nationally authorised product only)(0)
- fentanyl citrate(1)
- Fentanyl citrate(0)
- fentanyl hydrochloride(0)
- ferric carboxymaltose(1)
- ferric citrate coordination complex(0)
- ferric maltol(0)
- Ferric pyrophosphate citrate(0)
- Ferucarbotran(0)
- Ferumoxytol(0)
- ferumoxytol(0)
- fesoterodine(0)
- fesoterodine fumarate(0)
- Fevipiprant(0)
- Fexapotide (friflutate)(0)
- fexinidazole(0)
- fexofenadine(1)
- fexofenadine hydrochloride(1)
- fezolinetant(0)
- Fianlimab(0)
- fibrin(2)
- Fibrinogen(0)
- Fibrinogen (human plasma-derived)(0)
- Fibroblast activation protein alpha-targeted interleukin 2 variant immunocytokine(0)
- fibronectin(0)
- fidanacogene elaparvovec(0)
- fidaxomicin(0)
- filamentous haemagglutinin(0)
- filgotinib(1)
- filgotinib maleate(1)
- filgrastim(0)
- Finasteride(0)
- Finerenone(0)
- finerenone(0)
- Fingolimod(0)
- fingolimod(0)
- fingolimod hydrochloride (0)
- fipronil(0)
- fipronil / amitraz / (S)-methoprene(0)
- firocoxib(0)
- Fish oil(0)
- Five component acellular pertussis [Purified Pertussis Toxoid (PT), Purified Filamentous Haemagglutinin (FHA), Purified Fimbriae Types 2 and 3 (FIM), and Purified Pertactin (PRN)](0)
- flecainide(0)
- Flibanserin(0)
- Florbetaben(0)
- florbetaben (18F)(0)
- florbetaben (18F)(0)
- florbetapir (18F)(0)
- florfenicol(0)
- Flortaucipir F18(0)
- Flosfluridine tidoxil(0)
- flubendazole(0)
- Fluciclovine (18F)(0)
- fluciclovine (18F)(0)
- flucloxacillin(0)
- fluconazole(3)
- flucytosine(1)
- Flucytosine(0)
- fludarabine(0)
- fludeoxyglucose (18F)(1)
- flumazenil(0)
- flumequin(1)
- flumequine(0)
- flumethrin(0)
- flunarizine(0)
- flunisolide(1)
- flunitrazepam(0)
- flunixin(0)
- Fluocinolone acetonide(0)
- fluorescein(0)
- Fluoride 18-labelled Prostate-Specific Membrane Antigen-1007 ([18F]PSMA-1007)(0)
- Fluorine (18F) PSMA-1007(0)
- Fluorocholine (18F)(0)
- fluorodopa (18F)(0)
- Fluoroestradiol (18F)(0)
- fluoromisonidazole (18F)(0)
- Fluoroquinolones(0)
- fluorouracil(1)
- Fluorouracil(0)
- fluoxetine(4)
- flupirtine(2)
- fluralaner(0)
- flurbiprofen(1)
- flurpiridaz (18F)(0)
- flutamide(0)
- flutemetamol (18F)(0)
- fluticasone(5)
- fluticasone furoate(1)
- fluticasone propionate(3)
- fluvastatin(1)
- fluvoxamine(2)
- folic acid(0)
- follitropin alfa(0)
- follitropin beta(0)
- follitropin delta(0)
- fomivirsen(0)
- fondaparinux sodium(0)
- Fordadistrogene movaparvovec(0)
- formaldehyde-inactivated whole-cell bacterial vaccine containing three strains of Actinobacillus pleuropneumoniae (serotypes 2, 9 and 11) and one strain of Pasteurella multocida (serotype A)(0)
- formic acid(0)
- formoterol(0)
- Formoterol (fumarate)(0)
- formoterol fumarate(3)
- formoterol fumarate dihydrate(0)
- Forodesine hydrochloride(0)
- fosamprenavir(0)
- fosamprenavir calcium(0)
- fosaprepitant(0)
- foscarnet(0)
- fosdenopterin(0)
- Fosdenopterin (ORGN001)(0)
- fosdenopterin hydrobromide dihydrate(0)
- fosfomycin(0)
- fosfomycin calcium(1)
- fosfomycin disodium(1)
- fosfomycin sodium(1)
- fosfomycin trometamol(1)
- fosinopril(1)
- fosmetpantotenate(0)
- Fosnetupitant(0)
- fosphenytoin(0)
- Fostamatinib(0)
- fostamatinib(0)
- Fostamatinib disodium(0)
- fostemsavir(0)
- fostemsavir (tromethamine)(0)
- fostemsavir trometamol(0)
- fowlpox, avian infectious laryngotracheitis vaccine (live, recombinant) and avian encephalomyelitis vaccine (live)(0)
- Fowlpox and avian infectious laryngotracheitis vaccine (live, recombinant)(0)
- Freeze-dried allergen extract of Betula pendula pollen(0)
- Freeze-dried culture of Lactobacillus casei subspecies rhamnosus Döderleini (Lcr35)(0)
- fremanezumab(0)
- frovatriptan(0)
- Frovatriptan (succinate monohydrate)(0)
- frunevetmab(0)
- Fruquintinib(0)
- fruquintinib(0)
- Fully human IgG1 RB-1 YTE anti-RSV F monoclonal antibody (MK-1654)(0)
- fulvestrant(0)
- fumarate(0)
- furosemide(1)
- Furosemide(0)
- furosemide-spironolactone(0)
- fusafungine(1)
- fusidic acid(0)
- Fusion protein composed of the first 2 immunoglobulin (Ig)-like domains of the human ROBO2 fused to human IgG1 Fc (PF-06730512)(0)
- Futibatinib(0)
- futibatinib(0)
- gabapentin(1)
- gadobenic acid(3)
- gadobutrol(3)
- Gadobutrol(0)
- gadodiamide(2)
- gadofosveset trisodium(0)
- gadopentetic acid(2)
- Gadopiclenol(0)
- Gadoquatrane (BAY 1747846)(0)
- gadoteric acid(2)
- gadoteric acid (IV and intravascular formulations)(0)
- gadoteridol(2)
- gadoversetamide(1)
- gadoxetic acid(2)
- gadoxetic acid disodium(0)
- galantamine(1)
- Galcanezumab(0)
- galcanezumab(0)
- Gallium (68Ga)(0)
- Gallium (68Ga) chloride(0)
- gallium (68Ga) chloride(0)
- Gallium 68-labelled Prostate-Specific Membrane Antigen-11 (68Ga-PSMA-11)(0)
- galsulfase(0)
- gamithromycin(0)
- Ganaxolone(0)
- ganaxolone(0)
- ganciclovir(1)
- ganirelix(0)
- ganirelix acetate(0)
- Gantenerumab(0)
- Garadacimab(0)
- gasiloxe(0)
- GBP510(0)
- Gefapixant(0)
- gefapixant(0)
- gefapixant (citrate)(0)
- Gefapixant (citrate salt)(0)
- gefitinib(0)
- gemcitabine(1)
- Gemcitabine (hydrochloride)(0)
- gemfibrozil(2)
- gemtuzumab ozogamicin(0)
- Genetically modified Mycobacterium bovis BCG(0)
- genetically modified recombinant Shiga-toxin-2e antigen(0)
- genetically modified replication-incompetent herpes simplex virus-1 expressing collagen VII (beremagene geperpavec)(0)
- genetically modified Shiga-toxin-2e antigen(0)
- gentamicin(0)
- gentamicin (systemic use)(0)
- gentamicin sulfate(0)
- Gepotidacin(0)
- Germanium (68Ge) chloride(0)
- germanium (68Ge) chloride(0)
- gestodene(1)
- Gevokizumab(0)
- gilteritinib(0)
- Gilteritinib (as fumarate)(0)
- gilteritinib fumarate(0)
- gimeracil(1)
- Giroctocogene fitelparvovec(0)
- Givinostat(0)
- Givosiran(0)
- givosiran(0)
- Glasdegib(0)
- glasdegib(0)
- Glasdegib maleate(0)
- glatiramer(0)
- glecaprevir(0)
- Glepaglutide(0)
- Gliadin protease(0)
- glibenclamide(0)
- gliclazide(0)
- glimepiride(2)
- glipizide(0)
- Glofitamab(0)
- glofitamab(0)
- Glu-NH-CO-NH-Lys-(Ahx)-[N,N9-bis[2-hydroxy-5-(carboxyethyl) benzyl]ethylenediamine-N,N9-diacetic acid (PSMA11-HBED-CC) (HBED Trasis)(0)
- Glucagon(0)
- glucagon(0)
- Glucagon analogue linked to a human immunoglobulin Fc fragment(0)
- glucarpidase(0)
- glucosamine(0)
- glucosamine hydrochloride(1)
- Glucosamine hydrochloride(0)
- glucose(0)
- glucose anhydrous(0)
- glucose monohydrate(0)
- glutamic acid(0)
- Glutamine(0)
- Glutathione(0)
- glycerol(0)
- Glycerol phenylbutyrate(0)
- glycerol phenylbutyrate(0)
- glyceryl trinitrate(0)
- glycine(0)
- glycopyrronium(0)
- Glycopyrronium bromide(0)
- glycopyrronium bromide(0)
- glycopyrronium bromide (CHF 5993)(0)
- Gold (Au)(0)
- Golidocitinib(0)
- Golimumab(0)
- golimumab(0)
- Gonadotropin releasing factor (GnRF) analogue-protein conjugate(0)
- goserelin(3)
- gozetotide(0)
- granisetron(1)
- granisetron (other formulations except for transdermal patch)(0)
- grapiprant(0)
- grass pollen(0)
- Grass pollen allergen extract from Dactylis glomerata L., Anthoxanthum odoratum L., Lolium perenne L., Poa prantensis L. and Phleum pratense L.(0)
- grazoprevir(0)
- grindelia soft extract(0)
- grindelia tincture(0)
- Guadecitabine(0)
- guanfacine(0)
- guanfacine hydrochloride(0)
- Guselkumab(0)
- guselkumab(0)
- H-Tyr-Gly-Arg-Lys-Lys-Arg-Arg-Gln-Arg-Arg-Arg-Lys-Leu-Ser-Ser-Ile-Glu-Ser-Asp-Val-OH(YGRKKRRQRRRKLSSIESDV)(0)
- haemagglutinin filamentous(0)
- Haemoglobin glutamer-200 (bovine)(0)
- haemoglobin glutamer-200 (bovine)(0)
- haemophilus influenzae(0)
- Haemophilus influenzae type b polysaccharide(0)
- Haemophilus influenzae type B polysaccharide (polyribosylribitol phosphate)(0)
- Haemophilus influenzae type b polysaccharide (Polyribosylribitol Phosphate) conjugated to Tetanus protein(0)
- Haemophilus influenzae type b polysaccharide conjugated to tetanus protein(0)
- Haemophilus type b and Meningococcal group C conjugate vaccine(1)
- haemophilus type b and meningococcal group c conjugate vaccine(0)
- haemophilus type b conjugate vaccine(0)
- haemophilus type b conjugate vaccine (adsorbed)(0)
- haemophilus type b conjugate vaccines(0)
- haemophilus B conjugate (meningococcal protein conjugate) and hepatitis B (recombinant) vaccine(0)
- half-life extended bispecific T-cell engager (BiTE) antibody construct that binds to prostate-specific membrane antigen and cluster of differentiation 3, with a single chain fragment crystallizable moiety(0)
- halofantrine(0)
- halofuginone(0)
- halofuginone lactate(0)
- haloperidol(1)
- haloperidol decanoate(1)
- hazel pollen(0)
- Hemoglobin betafumaril (bovine)(0)
- Heparin (sodium)(0)
- heparin sodium(0)
- hepatitis a(0)
- hepatitis a (inactivated) / typhoid polysaccharide vaccine (adsorbed)(0)
- hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)(0)
- hepatitis A vaccines(0)
- hepatitis A virus (inactivated)(0)
- hepatitis A virus (inactivated, adsorbed)(1)
- Hepatitis B (rDNA) surface antigen adjuvanted(0)
- hepatitis B, recombinant surface antigen(0)
- hepatitis B recombinant vaccine, adsorbed(1)
- hepatitis B surface antigen(0)
- hepatitis B surface antigen (rDNA)(0)
- Hepatitis B Surface Antigen, recombinant(0)
- hepatitis B surface antigen produced in yeast cells(0)
- hepatitis B surface antigens recombinant (S, pre-S1, pre-S2) adsorbed on aluminium hydroxide [produced on genetically engineered murine (C127I) cells](0)
- hepatitis B vaccine (recombinant DNA)(0)
- hepatitis A (inactivated) and hepatitis B (rDNA) (HAB) vaccine (adsorbed)(0)
- hepatitis A virus (inactivated)(0)
- hepatitis B (rDNA) vaccine (adjuvanted, adsorbed)(0)
- hepatitis B recombinant surface antigen(0)
- hepatitis B surface antigen recombinant(0)
- Herpes simplex 1 virus thymidine kinase and truncated low affinity nerve growth factor receptor transfected donor lymphocytes(0)
- herpes zoster vaccine (recombinant, adjuvanted)(0)
- Heterologous human adult liver-derived progenitor cells(0)
- hexaminolevulinate(0)
- hexaminolevulinate hydrochloride(0)
- hexoprenaline(1)
- hexoprenaline sulfate(0)
- Histamine dihydrochloride(0)
- histamine dihydrochloride(0)
- histidine(0)
- histrelin acetate(1)
- HIV-1 Maturation Inhibitor (GSK3640254)(0)
- House dust mites allergen extracts(0)
- Human, recombinant, non-fucosylated IgG1k monoclonal antibody targeting OX-40 receptor on activated T cells (rocatinlimab)(0)
- Human-cell-line recombinant human factor VIII (human-cl rhFVIII)(0)
- Human-papillomavirus-type-6 L1 protein(0)
- human-papillomavirus-type-11 L1 protein(0)
- human-papillomavirus-type-16 L1 protein(0)
- human-papillomavirus-type-18 L1 protein(0)
- human-papillomavirus-type-31 L1 protein(0)
- human-papillomavirus-type-33 L1 protein(0)
- human-papillomavirus-type-45 L1 protein(0)
- human-papillomavirus-type-52 L1 protein(0)
- human-papillomavirus-type-58 L1 protein(0)
- human albumin, denatured(1)
- Human alpha1-proteinase inhibitor(0)
- human anti-d immunoglobulin(0)
- Human anti-interleukin-15 (IL-15) monoclonal antibody(0)
- Human autologous mesenchymal adult stem cells extracted from adipose tissue(0)
- Human chorionic gonadotrophin(0)
- Human ciliary neurotrophic factor(0)
- human clottable protein containing mainly fibrinogen and fibronectin, calcium chloride(0)
- human coagulation factor IX(0)
- human coagulation factor VII(0)
- Human coagulation factor VIII(1)
- human coagulation factor VIII (inhibitor bypassing fraction)(0)
- Human Coagulation Factor VIII (rDNA)(0)
- human coagulation factor VIII / human von willebrand factor(1)
- Human coagulation factor X(0)
- human coagulation factor X(0)
- human coagulation factor XIII(0)
- human coagulation factor XIII, human fibrinogen(0)
- Human dermal fibroblasts cultured on bioresorbable polyglactin mesh (ABH001)(0)
- Human donor haematopoietic stem and progenitor cells (HSPC) that have been treated ex vivo with the protein transduction domain of the HIV-1 transactivation protein fused to MYC transcription factor (TBX-1400)(0)
- human factor XIII(0)
- human factor xiii(0)
- human fibrinogen(0)
- human fibrinogen, human thrombin(0)
- Human fibrinogen concentrate (BT524)(0)
- human hemin(0)
- human hepatitis B immunoglobulin(1)
- Human heterologous liver cells(0)
- human heterologous liver cells(0)
- human IgG1 monoclonal antibody specific for human interleukin-1 alpha(0)
- Human IgG4 monoclonal antibody against BCMA and CD3 (ABBV-383)(0)
- human IgG4-based bispecific antibody binding to both B-cell maturation antigen (BCMA) and cluster of differentiation 3 (CD3) (REGN5458)(0)
- Human immunoglobulin (Ig) G4-variant monoclonal antibody that binds and neutralizes soluble human interleukin (IL-) 33(0)
- Human immunoglobulin G1 constant region - human ectodysplasin-A1 receptor-binding domain fusion protein(0)
- Human immunoglobulin G2 isotype antibody to IL-33R(0)
- human insulin(0)
- human insulin (rDNA)(0)
- Humanised Antibody Targeting the Inducible T cell Co-Stimulatory receptor(0)
- Humanised chimeric antibody with a humanised H chain and a chimeric (mouse V-domain, human C-domain) L chain against epidermal growth factor receptor conjugated to maleimidocaproyl monomethylauristatin F (ABT-414)L chain against epidermal growth factor receptor conjugated to maleimidocaproylmonomethylauristatin F (ABT-414)(0)
- Humanised IgG2 monoclonal antibody against interleukin-6 (RO7200220)(0)
- Humanised IgG2k Fc-modified bispecific antibody against CD3 and BCMA (PF-06863135)(0)
- Humanised IgG4 monoclonal antibody against extracellular tau (BMS-986168)(0)
- Humanised KLB/FGFR1c monoclonal antibody (MK-3655)(0)
- Humanised recombinant IgG4, Anti-PD-1 monoclonal antibody (CS1003)(0)
- Humanized anti-CD19, Fc engineered, monoclonal antibody (XmAb5871)(0)
- Humanized antibody targeting B cell maturation antigen conjugated with maleimidocaproyl monomethyl auristatin F(0)
- Humanized IgG1, kappa anti-serum amyloid A and anti-AL amyloid antibody(0)
- Humanized immunoglobulin (lg) G4 proline, alanine, alanine (IgG4 PAA) based bispecific antibody directed against cluster of differentiation (CD) 3 receptor complex and B-cell maturation antigen (BCMA)(0)
- Humanized monoclonal antibody of IgG1 sub-type targeting the human SEMA3A polypeptide(0)
- Humanized monoclonal antibody of IgG1 subtype targeting NRP1(0)
- Humanized recombinant IgG4 anti-human tau antibody(0)
- Human monoclonal antibody targeting Staphylococcus aureus alpha-toxin (tosatoxumab)(0)
- Human Neutrophil Elastase Inhibitor (CHF6333)(0)
- human normal immunoglobulin(3)
- Human normal immunoglobulin(0)
- human normal immunoglobulin (IVIg)(0)
- Human normal immunoglobulin (LFB-IgSC)(0)
- human normal immunoglobulin (SCIg)(0)
- Human Papillomavirus1 Type 6 L1 protein(0)
- Human Papillomavirus1 Type 11 L1 protein(0)
- human papillomavirus1 type 16 L1 protein(0)
- Human Papillomavirus1 Type 18 L1 protein(0)
- human papillomavirus 9-valent vaccine (recombinant, adsorbed)(0)
- human papillomavirus type 6 L1 protein(0)
- human papillomavirus type 11 L1 protein(0)
- human papilloma virus type 16 E6 001-032(0)
- Human Papilloma Virus Type 16 E6 019-050(0)
- Human Papilloma Virus Type 16 E6 041-065(0)
- human papilloma virus type 16 E6 055-080(0)
- Human papilloma virus type 16 E6 071-095(0)
- Human Papilloma Virus Type 16 E6 085-109(0)
- human papilloma virus type 16 E6 091-122(0)
- Human Papilloma Virus Type 16 E6 109-140(0)
- Human Papilloma Virus Type 16 E6 127-158(0)
- Human Papilloma Virus Type 16 E7 001-035(0)
- Human Papilloma Virus Type 16 E7 022-056(0)
- human papilloma virus type 16 E7 064-098(0)
- human papillomavirus type 16 L1 protein(0)
- human papillomavirus type 18 L1 protein(0)
- human papillomavirus vaccine [types 6, 11, 16, 18, 31, 33, 45, 52, 58] (recombinant, adsorbed)(0)
- human papillomavirus vaccine [types 6, 11, 16, 18] (recombinant, adsorbed)(0)
- human papillomavirus vaccine [types 16, 18] (recombinant, adjuvanted, adsorbed)(0)
- human plasma (pooled and treated for virus inactivation)(0)
- Human plasma derived C1-inhibitor (OCTA-C1-INH)(0)
- human plasma protease C1 inhibitor(0)
- Human plasma proteins(0)
- human protein C(0)
- human prothrombin complex(0)
- human rabies immunoglobulin(0)
- Human recombinant follicle-stimulating hormone (FE 999049)(0)
- Human recombinant interleukin-2(0)
- human rotavirus, live attenuated(0)
- human tetanus immunoglobulin(0)
- human thrombin(0)
- human thrombin, aprotinin(0)
- human von willebrand factor(1)
- hydrochlorothiazide(8)
- hydrochlorothiazide/valsartan(0)
- hydrochlorothiazide moexipril(0)
- hydrocortisone(1)
- hydrocortisone (hemisuccinate)(0)
- hydrocortisone aceponate(0)
- Hydrogen Peroxide(0)
- hydromorphone(1)
- Hydromorphone (hydrochloride)(0)
- hydroquinidine(0)
- hydroxocobalamin(0)
- hydroxycarbamide(0)
- Hydroxychloroquine(0)
- hydroxyethyl salicylate(0)
- hydroxyethyl starch(3)
- hydroxyprogesterone(1)
- hydroxypropyl-β-cyclodextrin(0)
- hydroxyzine(1)
- hydroxyzine chloride(0)
- hydroxyzine pamoate(0)
- hyoscine(0)
- hypericum perforatum L., herba(0)
- Ianalumab(0)
- ibafloxacin(0)
- Ibalizumab(0)
- ibalizumab(0)
- ibandronic acid(1)
- Iberdomide(0)
- Ibodutant(0)
- Ibrexafungerp(0)
- Ibrexafungerp citrate(0)
- ibritumomab tiuxetan(0)
- Ibrutinib(0)
- ibrutinib(0)
- ibuprofen(5)
- Ibuprofen(0)
- Ibuprofen (sodium dihydrate)(0)
- ibuprofen lysine(0)
- Ibutamoren mesilate(0)
- ibutilide(0)
- icatibant(0)
- icatibant acetate(0)
- icodextrin(1)
- Icosabutate(0)
- Icosapent(0)
- Icosapent ethyl(0)
- icosapent ethyl(0)
- Icosasodium{26-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]-14,14-bis{[(3-{6-[(2-acetamido-2-deoxy-β-D-galactopyranosyl)oxy]hexyl}amino)-3-oxopropoxy)]methyl}-8,12,19-trioxo-16-oxa-7,13,20-triazahexacosyl}2′-O-(2-methoxyethyl...(0)
- idarubicin(0)
- idarucizumab(0)
- Idasanutlin(0)
- idebenone(0)
- idecabtagene vicleucel(0)
- Idelalisib(1)
- idelalisib(1)
- idursulfase(0)
- ifosfamide(1)
- igovomab(0)
- iloperidone(0)
- iloprost(0)
- imatinib(0)
- imatinib mesilate(0)
- Imdevimab(0)
- imdevimab(0)
- imepitoin(0)
- Imetelstat(0)
- IMG-2789(0)
- imidacloprid(0)
- imidapril(1)
- imiglucerase(0)
- imipenem(1)
- imipenem monohydrate(0)
- imipramine(0)
- imiquimod(0)
- Imlifidase(0)
- imlifidase(0)
- Immunoglobulin G1 anti-SORT1 human monoclonal antibody(0)
- Immunoglobulin G4 [449-cysteine](0)
- inactivated adjuvanted vaccine against bluetongue virus serotype 2 and 4 infections(0)
- inactivated bluetongue serotype 1+8 vaccine(0)
- inactivated bluetongue virus, serotype-1(0)
- inactivated bluetongue virus, serotype 1(0)
- Inactivated bluetongue virus, serotype 1, strain ALG2006/01 E1(0)
- inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01(0)
- inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1 RP(0)
- Inactivated bluetongue virus, serotype 4, strain BTV-4/SPA-1/2004(0)
- inactivated bluetongue virus, serotype 8(0)
- Inactivated bluetongue virus, serotype 8, strain BEL2006/01(0)
- inactivated bluetongue virus, serotype 8, strain btv-8/bel2006/02(0)
- inactivated bluetongue virus, serotypes 1 and 8(0)
- inactivated Bordetella bronchiseptica, strain 833CER(0)
- inactivated Bordetella bronchiseptica cells(0)
- inactivated Bordetella pertussis(0)
- inactivated Bovine Viral Diarrhoea (BVD) type 1 virus, cytopathogenic strain 5960(0)
- inactivated chimaeric flavivirus strain YF-WN(0)
- inactivated Coxiella burnetii vaccine(0)
- inactivated Coxiella burnetii vaccine, strain Nine Mile(0)
- inactivated feline calicivirosis antigens (FCV 431 and G1 strains)(0)
- inactivated feline calicivirus(0)
- inactivated feline Chlamydophila felis(0)
- inactivated feline leukaemia virus(0)
- inactivated feline panleukopenia virus(0)
- inactivated feline panleukopenia virus, calicivirus, rhinotracheitis virus, leukaemia virus and Chlamydophila felis(0)
- inactivated feline rhinotracheitis virus(0)
- Inactivated fimbrial adhesins of Escherichia coli F4ab(0)
- Inactivated fimbrial adhesins of Escherichia coli F4ac(0)
- Inactivated fimbrial adhesins of Escherichia coli F5(0)
- Inactivated fimbrial adhesins of Escherichia coli F6(0)
- inactivated Histophilus somni Bailie strain(0)
- inactivated IBR virus(0)
- inactivated immunological veterinary medicinal product containing Leptospira interrogans, serogroup Canicola, serovar Canicola, strain 16070, L. interrogans, serogroup icterohaemorrhagiae, serovar icterohaemorrhagiae, strain 16069, L. interrogans, serogroup Grippotyphosa, serovar Grippotyphosa, strain Grippo Mal 1540, L. interrogans, serogroup Australis, serovar Bratislava, strain(0)
- inactivated influenza-A virus(0)
- inactivated influenza-A virus / swine(0)
- Inactivated Leptospira strains: L. interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000); L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001); L. interrogans serogroup Australis serovar Bratislava (strain As-05-073); L. kirschneri serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)(0)
- inactivated leptospire vaccine(0)
- Inactivated Mycoplasma hyopneumoniae, strain P-5722-3(0)
- Inactivated patients own (autologous) microorganism (Escherichia coli, Candida spp., Enterococcus spp., Streptococcus spp., Staphylococcus spp., Prevotella intermedia, Fusobacterium nucleatum and others)(0)
- Inactivated poliomyelitis vaccine (Vero) – Type 1 (Mahoney), Type 2 (MEF-1) and Type 3 (Saukett)(0)
- Inactivated poliovirus: type 1 (Mahoney strain)(0)
- Inactivated poliovirus: type 2 (MEF-1 strain)(0)
- Inactivated poliovirus: type 3 (Saukett strain)(0)
- Inactivated poliovirus type 1 (Brunhilde)Inactivated poliovirus type 2 (MEF-1)Inactivated poliovirus type 3 (Saukett)(0)
- inactivated porcine actinobacillosis vaccine(0)
- inactivated porcine circovirus type 2 (PCV2)(0)
- inactivated porcine circovirus vaccine(0)
- Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strainV-1037(0)
- Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 ORF2 protein(0)
- Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (ORF2) protein(0)
- Inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b ORF2 protein(0)
- Inactivated Schmallenberg virus, strain BH80/11-4(0)
- Inactivated Type 1 Poliovirus (Mahoney)(0)
- Inactivated Type 2 Poliovirus (MEF-1)(0)
- inactivated type 2 poliovirus (MEF 1)(0)
- Inactivated Type 3 Poliovirus (Saukett)(0)
- inactivated vaccine against bluetongue virus serotypes 1 and 8(0)
- inactivated vaccine against foot-and-mouth disease(0)
- inactivated vaccine to prevent progressive and non-progressive atrophic rhinitis in pigs(0)
- inactivated West Nile virus, strain VM-2(0)
- inactivated whole avian influenza virus antigen of H5 subtype (strain H5N6, A/duck/Potsdam/2243/84)(0)
- inactivated whole avian influenza virus antigen of H5N2 subtype (strain A/duck/Potsdam/1402/86)(0)
- inactivated whole avian influenza virus antigen of H7N1 subtype (strain, A/CK/Italy/473/99)(0)
- inactivated whole cell concentrate of Mycoplasma hyopneumoniae strain 11(0)
- inactivated whole cell suspension of Ornithobacterium rhinotracheale serotype A, strain B3263/91(0)
- Inclacumab(0)
- inclisiran(0)
- Inclisiran sodium(0)
- indacaterol(0)
- Indacaterol (acetate)(0)
- indacaterol acetate(0)
- indacaterol maleate(0)
- Indapamide(0)
- indapamide (hemihydrate)(0)
- indinavir(0)
- indinavir sulfate ethanolate(0)
- indium (111In) pentetate(0)
- indium (In-111) chloride(0)
- indium (In-111) oxine(0)
- indobufen(0)
- indometacin(0)
- indoramin(0)
- indoxacarb(0)
- Inebilizumab(0)
- inebilizumab(0)
- Infectious bovine rhinotracheitis vaccine (inactivated)(0)
- Infectious bursal disease and Marek's disease vaccine (live recombinant)(0)
- Infigratinib(0)
- infigratinib(0)
- Infigratinib monophosphate(0)
- infliximab(0)
- Influenza A virus/human strain: A/Jena/VI5258/2009 (H1N1)pdm09, inactivated(0)
- Influenza A virus subtype H1N1 haemagglutinin, recombinant(0)
- Influenza A virus subtype H3N2 haemagglutinin, recombinant(0)
- Influenza B virus Victoria lineage haemagglutinin, recombinant(0)
- Influenza B virus Yamagata lineage haemagglutinin, recombinant(0)
- influenza vaccine(0)
- influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)(0)
- influenza vaccine (H1N1)v (whole virion, Vero cell derived, inactivated)(0)
- influenza vaccine (live attenuated, nasal)(0)
- influenza vaccine (split virion, inactivated)(0)
- influenza vaccine (split virion, inactivated) (non centrally authorised products)(0)
- Influenza vaccine (split virion, inactivated, prepared in cell cultures)(0)
- influenza vaccine (surface antigen, inactivated)(0)
- influenza vaccine (surface antigen, inactivated, adjuvanted)(0)
- influenza vaccine (surface antigen, inactivated, prepared in cell cultures)(0)
- influenza vaccine (whole virion, inactivated) containing antigen of: A/Vietnam/1203/2004 (H5N1)(0)
- influenza vaccine, purified antigen(1)
- influenza vaccine H1N1v (surface antigen, inactivated, adjuvanted)(0)
- influenza virus (inactivated, split) of the following strains:A/California/7/2009 (H1N1)pdm09 - like strain (A/California/7/2009, NYMC X-179A)A/Hong Kong/4801/2014 (H3N2) - like strain (A/Hong Kong/4801/2014, NYMC X-263B)B/Brisbane/60/2008 - like strain (B/Brisbane/60/2008, wild type)(0)
- Influenza virus (whole virion, inactivated), containing antigen of: A/Vietnam/1203/2004 (H5N1)(0)
- Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen(0)
- Influenza virus H1 haemagglutinin(0)
- influenza virus H3 haemagglutinin(0)
- influenza virus haemagglutinin from strain B Victoria lineage(0)
- influenza virus haemagglutinin from strain B Yamagata lineage (expressed as virus-like particle [VLP])(0)
- Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H1N1)(0)
- Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain A (H3N2)(0)
- Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain B (Victoria lineage)(0)
- Influenza virus inactivated split virion (haemagglutinin and neuraminidase) of strain B (Yamagata lineage)(0)
- Influenza virus surface antigens (haemagglutinin) of strain A (H1N1)(0)
- influenza virus surface antigens (haemagglutinin) of strain A (H3N2)(0)
- influenza virus surface antigens (haemagglutinin) of strain B (Yamagata lineage)(0)
- influenza virus surface antigens (haemagglutinin) of strain B (Victoria lineage)(0)
- influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains:A/California/7/2009 (H1N1)pdm09 - like strain(A/Brisbane/10/2010, wild type)A/Switzerland/9715293/2013 (H3N2) - like strain(A/South Australia/55/2014, wild type)B/Phuket/3073/2013–like strain(B/Utah/9/2014, wild type)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, of the following strains: A/Solomon Islands/3/2006 (H1N1)-like strain (A/Solomon Islands/3/2006, IVR-145); A/Wisconsin/67/2005 (H3N2)-like strain (A/Wisconsin/67/2005, NYMC X161B); B/Malaysia/2506/2004-like strain (B/Malaysia/2506/2004)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase), inactivated, trivalent(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/California/7/2009 (H1N1)-derived strain used NYMC X-181(0)
- influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: A/turkey/Turkey/1/05 (H5N1)-like strain (NIBRG-23)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H1N1)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A (H3N2)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H1N1Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H3N2Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/H5N1(0)
- influenza virus surface antigens (haemagglutinin and neuraminidase) of strain A/Viet Nam/1194/2004 (H5N1)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Victoria lineage) [QIVc](0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of strain B (Yamagata lineage)(0)
- Influenza virus surface antigens (haemagglutinin and neuraminidase) of the following strains: A/(H1N1), A/(H3N2), B/Yamagata lineage, B/Victoria lineage(0)
- influenza virus surface antigens, inactivated: A/Viet Nam/1194/2004 (H5N1)(0)
- Influenza virus surface antigens - A/turkey/Turkey/1/05 (H5N1)(0)
- Influenza virus type A, H1N1(0)
- influenza virus type A, H3N2(0)
- Influenza Virus Type A, H3N2Influenza Virus Type A, H1N1Influenza Virus Type B(0)
- influenza virus type B, Victoria lineage(0)
- influenza virus type B, Yamagata lineage(0)
- Ingenol mebutate(1)
- ingenol mebutate(1)
- inosine dimepranol acedoben(0)
- inosine pranobex(0)
- inotersen(0)
- inotersen sodium(0)
- Inotuzumab ozogamicin(0)
- inotuzumab ozogamicin(0)
- Insulin 287(0)
- insulin aspart(0)
- insulin degludec(0)
- Insulin detemir(0)
- insulin detemir(0)
- Insulin efsitora alfa(0)
- insulin glargine(0)
- insulin glulisine(0)
- Insulin human(0)
- insulin human(0)
- Insulin human (NTRA-2112)(0)
- Insulin human (RDNA)(0)
- insulin human (rDNA)(0)
- Insulin icodec(0)
- insulin lispro(0)
- Insulin lispro (BC222)(0)
- Insulin peglispro(0)
- insulin porcine(0)
- interferon (omega)(0)
- interferon alfa-2a(0)
- interferon alfa-2b(0)
- interferon alfacon-1(0)
- interferon alpha-2a(0)
- Interferon alpha 2b(0)
- interferon beta-1a(0)
- interferon beta-1b(0)
- Interferon gamma(0)
- Invimestrocel(0)
- In vitro expanded autologous human articular chondrocytes(0)
- iodine(0)
- iodine (131-I) murine IgG1 monoclonal antibody against B7-H3 (131I-omburtamab)(0)
- Iodine (131I) iobenguane(0)
- iodine (131I) omburtamab(0)
- iodixanol(0)
- iodocasein(1)
- ioflupane (123I)(0)
- ioflupane (123i)(0)
- ioflupane (123l)(0)
- Ioforminol(0)
- iohexol(0)
- iomeprol(0)
- iopamidol(0)
- iopromide(0)
- ioxaglic acid(0)
- Ipatasertib(0)
- Ipilimumab(0)
- ipilimumab(0)
- ipratropium(0)
- ipratropium salbutamol(0)
- Iptacopan(0)
- Iptacopan hydrochloride monohydrate(0)
- irbesartan(4)
- irbesartan hydrochloride(2)
- irinotecan(0)
- irinotecan anhydrous free-base(0)
- irinotecan hydrochloride trihydrate(0)
- iron(0)
- Iron(iii) ion(0)
- iron (III) ion(0)
- Iron, aqua carbonate hydroxy oxo starch sucrose complex(0)
- iron dextran(1)
- Iron hydroxyethyl amylopectin heptonate(0)
- iron isomaltoside(1)
- iron sucrose(2)
- Iron sucrose(0)
- Isatuximab(0)
- isatuximab(0)
- isavuconazole(0)
- Isavuconazonium sulfate(0)
- Iscalimab(0)
- Islatravir(0)
- Isoflurane(0)
- Isoleucin(0)
- isoleucine(0)
- isoniazid(0)
- isopropyl alcohol(0)
- isotretinoin(4)
- isotretinoin (oral formulations)(0)
- isotretinoin (topical formulations)(0)
- isoxsuprine(1)
- Istradefylline(0)
- istradefylline(0)
- Itacitinib(0)
- itopride(0)
- itraconazole(1)
- Itraconazole(0)
- ivabradine(1)
- ivabradine hydrochloride(0)
- ivacaftor(0)
- ivacaftor / tezacaftor/ potassium (benzenesulfonyl)({[6-(3-{2-[1-(trifluoromethyl)cyclopropyl]ethoxy}-1H-pyrazol-1-yl)-2-[(4S)-2,2,4-trimethylpyrrolidin-1-yl]pyridin-3-yl]carbonyl})azanide (VX-659)(0)
- Ivermectin(0)
- ivermectin(0)
- Ivosidenib(0)
- ivosidenib(0)
- Ixazomib(0)
- ixazomib(0)
- ixazomib citrate(0)
- ixekizumab(0)
- Izaflortaucipir (18F)(0)
- Izencitinib(0)
- Japanese-encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells)(0)
- Japanese encephalitis vaccine (inactivated, adsorbed)(0)
- Japanese encephalitis virus, inactivated (attenuated strain SA14-14-2 grown in vero cells)(0)
- ketamine(0)
- ketamine (hydrochloride)(0)
- ketobemidone(0)
- ketoconazole(1)
- Ketoconazole(0)
- ketoprofen(2)
- ketorolac(0)
- ketorolac trometamol (OMS302)(0)
- ketotifen(0)
- klebsiella ozaenae(0)
- klebsiella pneumoniae(0)
- L-5-methyltetrahydrofolic acid, calcium salt(0)
- L-arginine hydrochloride(0)
- L-Asparaginase(0)
- L-asparaginase encapsulated in erythrocytes(0)
- L-carnitine(0)
- L-Cysteine, L-leucyl-L-α-glutamyl-L-α-glutamyl-L-lysyl-L-lysylglycyl-L-asparaginyl-L-tyrosyl-L-valyl-L-valyl-L-threonyl-L-α -aspartyl-L-histidyl-S-[1-[(4-carboxycyclohexyl)methyl]-2,5-dioxo-3-pyrrolidinyl]-, complex with keyhole limpet haemocyanin(0)
- L-Cysteinyl-L-prolyl-L-alanyl-L-valyl-L-lysyl-L-arginyl-L-aspartyl-L-valyl-L-aspartyl-L-leucyl-L-phenylalanyl-L-leucyl-L-threonine, acetate salt(0)
- L-glutamyl-L-glutaminyl-L-valyl-L-alanyl-Lglutaminyl-L-tyrosyl-L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanine, acetate salt(0)
- L-Lactic acid(0)
- L-lysine hydrochloride(0)
- L-lysyl-L-alanyl-L-leucyl-L-prolyl-L-valyl-L-valyl-L-leucyl-L-glutamyl-L-asparaginyl-L-alanyl-L-arginyl-L-isoleucyl-L-leucyl-L-lysyl-L-asparaginyl-L-cysteinyl-L-valine, acetate salt...(0)
- L-Pyr-L-Glu-L-Gln-L-Leu-L-Glu-L-Arg-L-Ala-L-Leu-L-Asn-L-Ser-L-Ser(0)
- L. interrogans serogroup Australis serovar Bratislava (strain As-05-073)(0)
- L. interrogans serogroup Icterohaemorrhagiae serovar Copenhageni (strain Ic-02-001)(0)
- L. kirschneri serogroup Grippotyphosa serovar Dadas (strain Gr-01-005)(0)
- labetalol(0)
- lacidipine(0)
- lacosamide(0)
- lactic acid(0)
- lactitol(0)
- Lactobacillus reuteri (IBP-9414)(0)
- lactobionic acid(0)
- lactulose(0)
- Lacutamab(0)
- Ladarixin(0)
- lademirsen(0)
- lamivudine(0)
- lamotrigine(1)
- lanadelumab(0)
- Lanadelumab (DX-2930)(0)
- landiobloc(0)
- landiolol(0)
- Landiolol (hydrochloride)(0)
- lanreotide(0)
- Lanreotide acetate(0)
- Lansoprazole(7)
- lansoprazole(0)
- lanthanum(0)
- Lanthanum carbonate hydrate(0)
- lapatinib(0)
- Lapatinib ditosilate monohydrate(0)
- laquinimod(0)
- Laquinimod (sodium)(0)
- laronidase(0)
- laropiprant(1)
- Larotrectinib(0)
- larotrectinib(0)
- larotrectinib sulfate(0)
- Larvae of Lucilia sericata(0)
- lasmiditan(0)
- lasmiditan succinate(0)
- lasofoxifene(0)
- Lasofoxifene tartrate(0)
- latanoprost(1)
- Latanoprost(0)
- latanoprost / netarsudil(0)
- Latozinemab(0)
- lavender oil(0)
- lazertinib (mesilate)(0)
- Lebrikizumab(0)
- ledipasvir(1)
- ledispavir(1)
- Lefamulin(0)
- lefamulin(0)
- lefamulin acetate(0)
- leflunomide(1)
- Leishmania infantum excreted secreted proteins(0)
- Lenacapavir(0)
- lenacapavir(0)
- Lenacapavir sodium(0)
- lenadogene nolparvovec(0)
- lenalidomide(0)
- lenalidomide hydrochloride hydrate(0)
- lenalidomide hydrochloride monohydrate(0)
- Leniolisib(0)
- lenograstim(0)
- Lentiviral vector containing the human ABCA4 gene(0)
- Lenvatinib(0)
- lenvatinib(0)
- lenvatinib mesilate(0)
- lepirudin(0)
- Leptospira interrogans, serogroup Australis, serovar Bratislava, strain As-05-073, Inactivated,Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated,Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated,Leptospira kirschneri, serogroup Grippotyphosa, serovar Dadas, strain GR-01-005, Inactivated,(0)
- leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, inactivated / leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, inactivated / leptospira interrogans, serogroup Australis, serovar Bratislava, strain As-05-073, inactivated / leptospira kirschneri, serogroup Grippotyphosa, serovar Dadas, strain GR-01-005, inactivated(0)
- Leptospira interrogans serogroup Australis serovar Bratislava, strain MSLB 1088, L. interrogans serogroup Icterohaemorrhagiae serovar Icterohaemorrhagiae, strain MSLB 1089, L. interrogans serogroup Canicola serovar Canicola, strain MSLB 1090, L. kirschneri serogroup Grippotyphosa serovar Grippotyphosa, strain MSLB 1091 (all inactivated)(0)
- Leptospira interrogans serogroup Canicola serovar Portland-vere (strain Ca-12-000)(0)
- lercanidipine(0)
- Leriglitazone(0)
- leriglitazone(0)
- leriglitazone hydrochloride(0)
- Lerodalcibep(0)
- lesinurad(0)
- Letermovir(0)
- letermovir(0)
- letrozole(1)
- leucine(0)
- leuprorelin(1)
- Leuprorelin(0)
- leuprorelin (depot formulations)(0)
- leuprorelin mesilate(0)
- levacetylmethadol(0)
- Levamisole (hydrochloride)(0)
- levetiracetam(1)
- levobunolol(0)
- levobupivacaine(0)
- levocabastine(0)
- levocetirizine(0)
- levocetirizine (dihydrochloride)(0)
- levodopa(1)
- levofloxacin(2)
- levofloxacin/dexamethasone (ocular use)(0)
- Levofloxacin hemihydrate(0)
- Levomenthol(0)
- levomenthol(0)
- levomethadone(0)
- Levomilnacipran(0)
- levonorgestrel(4)
- levonorgestrel/ethinylestradiol, ethinylestradiol (combination pack)(0)
- levosalbutamol(0)
- Levosimendan(0)
- levothyroxine(0)
- Levothyroxine (sodium)(0)
- levothyroxine sodium(1)
- lidocaine(3)
- Lidocaine (hydrochloride monohydrate)(0)
- lidocaine hydrochloride(0)
- Lifitegrast(0)
- ligelizumab(0)
- linaclotide(0)
- linagliptin(1)
- lincomycin(0)
- Linear single strand of deoxyribonucleic acid (encoding human retinitis pigmentosa GTPase regulator [RPGR]) packaged in a recombinant adeno-associated virus protein capsid of serotype 5 (AAV5-hRKp.RPGR)(0)
- Linerixibat(0)
- linezolid(0)
- linzagolix choline(0)
- lipegfilgrastim(0)
- liposomal ciclosporin A (L-CsA)(0)
- Liposomal vinorelbine (tartrate)(0)
- Lipoteichoic acid from Biofilm Adhesion Component of Streptococcus uberis, strain 5616(0)
- Liquid ethanolic extract 30 per cent (w/w) of Allium cepa L. (fresh bulb) and Citrus limon (L.) Burm. f. (fresh fruit)(0)
- liraglutide(0)
- lisdexamfetamine(0)
- Lisdexamfetamine dimesilate(0)
- lisdexamfetamine dimesylate(0)
- lisinopril(5)
- lisinopril (dihydrate)(0)
- Lisocabtagene maraleucel(0)
- lisocabtagene maraleucel(0)
- lisuride(1)
- Litoxetine (benzoate)(0)
- Live, attenuated, chimeric dengue virus, serotype 1(0)
- Live, attenuated, chimeric dengue virus, serotype 2(0)
- Live, attenuated, chimeric dengue virus, serotype 2 (DENV2)(0)
- live, attenuated, chimeric dengue virus, serotype 3(0)
- Live, attenuated, chimeric dengue virus, serotype 4(0)
- Live, attenuated, dengue virus, serotype 1 (DENV1)(0)
- Live, attenuated, dengue virus, serotype 3 (DENV3)(0)
- Live, attenuated, dengue virus, serotype 4 (DENV4)(0)
- live, attenuated Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus inactivated(0)
- live, attenuated Canine distemper virus, canine adenovirus, canine parvovirus, canine parainfluenza virus inactivated and Leptospira(0)
- live, attenuated dengue virus, serotype 2(0)
- Live-attenuated La Reunion strain of chikungunya virus (VLA1553)(0)
- Live aroA gene deleted Escherichia coli, type 078, strain EC34195(0)
- live attenuated, chimeric dengue virus, serotype 4(0)
- live attenuated Aujeszky's disease virus(0)
- live attenuated avian infectious bronchitis virus variant strain 4-91(0)
- live attenuated bovine respiratory syncytial virus (BRSV), strain Lym-56(0)
- Live attenuated canine distemper virus strain Onderstepoort: 105.1 – 106.5 TCID50(0)
- live attenuated infectious bursal disease virus (IBDV), strain 1052(0)
- live attenuated Muscovy duck parvovirus(0)
- Live attenuated poliovirus type 1(0)
- Live attenuated poliovirus type 3(0)
- live attenuated PRRS virus strain DV(0)
- live attenuated rabies virus, SAG2 strain(0)
- live attenuated vaccine against avian infectious bronchitis(0)
- live attenuated varicella virus (OKA strain)(1)
- live attenuated yellow fever virus(1)
- live avian infectious bronchitis virus, strain D388(0)
- Live bacterium B. thetaiotaomicron(0)
- live Bordetella bronchiseptica bacteria strain B-C2(0)
- live deletion-mutant Streptococcus equi strain TW928(0)
- live feline calicivirus (strain F9)(0)
- live feline panleucopenia virus(0)
- live feline viral rhinotracheitis virus (strain F2)(0)
- live gE- tk- double-gene-deleted bovine herpes virus type 1, strain CEDDEL: 106.3–107.3 CCID50(0)
- live gene-deleted vaccine for intramuscular use for active immunisation of cattle against infectious bovine rhinotracheitis(0)
- live infectious bursal disease virus, strain V877(0)
- live myxoma-vectored rabbit-haemorrhagic-disease virus strain 009(0)
- Live myxoma vectored RHD virus strain 009(0)
- Live myxoma vectored RHD virus strain MK1899(0)
- live Newcastle disease virus, VG/GA strain(0)
- live non-pathogenic Escherichia coli O8:K87(0)
- Live non-pathogenic Escherichia coli O141:K94 (F18ac) and O8:K87 (F4ac)(0)
- Live recombinant canine parvovirus strain 630a: 105.1 – 106.7 TCID50(0)
- Live Recombinant E2 gene-deleted bovine viral diarrhoea virus containing classical swine fever virus E2 gene (CP7_E2alf)(0)
- live recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus (rFP-LT) and avian encephalomyelitis virus, strain Calnek 1143 (AE)(0)
- Live recombinant Marek’s disease (MD) virus, serotype 1, strain RN1250(0)
- Live recombinant Marek’s disease virus, serotype 1, strain RN1250; Live recombinant turkey herpesvirus, expressing the VP2 protein of infectious bursal disease virus, strain vHVT013-69(0)
- live vaccine against Bordetella bronchiseptica in cats(0)
- live vaccine against rabies(0)
- live vaccine against Streptococcus equi(0)
- Livoletide(0)
- lixisenatide(0)
- Lixivaptan(0)
- Locatim, oral solution for neonatal calves less than 12 hours of age(0)
- lokivetmab(0)
- Lolium perenne(0)
- Lolium perenne L.(0)
- lomefloxacin(1)
- Lomitapide(0)
- lomitapide(0)
- lomustine(0)
- Lonafarnib(0)
- lonafarnib(0)
- Lonapegsomatropin(0)
- lonapegsomatropin(0)
- Loncastuximab tesirine(0)
- loncastuximab tesirine(0)
- lonoctocog alfa(0)
- loperamide(0)
- lopinavir(0)
- loratadine(4)
- lorazepam(0)
- Lorcaserin(0)
- Lorlatinib(0)
- lorlatinib(0)
- lormetazepam(0)
- lornoxicam(1)
- losartan(3)
- Losartan potassium(0)
- lotilaner(0)
- lotilaner / milbemycin oxime(0)
- lovastatin(0)
- loxapine(0)
- loxoprofen (sodium hydrate)(0)
- LT toxoid(0)
- Lubiprostone(0)
- lucerastat(0)
- Lumacaftor(0)
- lumacaftor(0)
- Lumasiran(0)
- Lumasiran (ALN-GO1)(0)
- Lumasiran sodium(0)
- lumefantrin(0)
- lumefantrine(0)
- Lumicitabine(0)
- lumiracoxib(2)
- lurasidone(0)
- Lurasidone hydrochloride(0)
- Lurbinectedin(0)
- Luspatercept(0)
- luspatercept(0)
- Lusutrombopag(0)
- lusutrombopag(0)
- lutetium (177 Lu) chloride(0)
- lutetium (177Lu)(0)
- lutetium (177Lu) chloride(0)
- Lutetium (177Lu) edotreotide(0)
- lutetium (177Lu) oxodotreotide(0)
- lutetium (177Lu) vipivotide tetraxetan(0)
- lutropin alfa(0)
- lysine(0)
- Lysine acetate(0)
- lysine acetylsalicylate(0)
- lysine monohydrate(0)
- Macimorelin(0)
- macimorelin(0)
- macimorelin acetate(0)
- Macitentan(0)
- macitentan(0)
- Macrogol 3350(0)
- macrogol 4000(0)
- macrogol 4000 combinations(0)
- MAGE-A3 recombinant protein(0)
- magnesium acetate(0)
- magnesium acetate tetrahydrate(0)
- magnesium chloride(0)
- magnesium chloride (hexahydrate)(0)
- magnesium chloride hexahydrate(0)
- magnesium hydroxide(0)
- Magnesium lactate dihydrate Tramadol (hydrochloride)(0)
- magnesium sulfate(0)
- magnesium sulfate heptahydrate(0)
- magnesium sulfate heptahydrate (BLI800)(0)
- magnesium sulphate(0)
- Magrolimab(0)
- Malic acid(0)
- mangafodipir(0)
- mangafodipir trisodium(0)
- Manganese chloride tetrahydrate(0)
- manidipine(0)
- manidipine, delapril(0)
- Mannheimia haemolytica biotype A serotype A1, inactivated cell free suspension containing leukotoxoid Ph. Eur.(0)
- mannitol(0)
- maralixibat(0)
- Maralixibat chloride(0)
- maraviroc(0)
- marbofloxacin(0)
- Marek's disease vaccine (live recombinant)(0)
- Marek's disease vaccine, Newcastle disease vaccine & infectious laryngotracheitis vaccine (live recombinant)(0)
- Marek’s disease virus, strain RN1250, live(0)
- Maribavir(0)
- maribavir(0)
- Marizomib(0)
- maropitant(0)
- maropitant citrate(0)
- Marstacimab(0)
- Marzeptacog alfa (activated)(0)
- masitinib(0)
- Masitinib mesilate(0)
- masitinib mesilate(0)
- matrix-applied characterised autologous cultured chondrocytes(1)
- matrix applied characterised autologous cultured chondrocytes(1)
- Matrix applied characterised autologous cultured chondrocytes(0)
- Mavacamten(0)
- mavacamten(0)
- mavacoxib(0)
- Maximum three of the following purified, inactivated foot-and-mouth disease virus strains: O1 Manisa ≥ 6 PD50*; O1 BFS ≥ 6 PD50*; O Taiwan 3/97 ≥ 6 PD50*; A22 Iraq ≥ 6 PD50*; A24 Cruzeiro ≥ 6 PD50*; A Turkey 14/98 ≥ 6 PD50*; Asia 1 Shamir ≥ 6 PD50*; SAT2 Saudi Arabia ≥ 6 PD50*; * PD50 – 50% protective dose in cattle as described in Ph. Eur. monograph 0063.(0)
- mazindol(1)
- measles, mumps, rubella and varicella vaccine (live)(0)
- measles, mumps and rubella vaccine (live)(1)
- measles vaccine (live attenuated)(0)
- measles virus Enders’ Edmonston strain (live, attenuated)(0)
- Measles virus Schwarz strain (live, attenuated)(0)
- Mecasermin(0)
- mecasermin(0)
- Mecasermin rinfabate(0)
- medetomidine(0)
- medetomidine hydrochloride(0)
- Medium-chain triglycerides(0)
- medroxyprogesterone acetate(0)
- mefenorex(1)
- mefloquine(0)
- melatonin(0)
- Meldonium dihydrate(0)
- meloxicam(0)
- meloxicam (HTX-011)(0)
- melphalan(0)
- melphalan flufenamide(0)
- Melphalan flufenamide hydrochloride(0)
- melphalan hydrochloride(0)
- memantine(0)
- memantine hydrochloride(0)
- meningococcal group A, C, W-135 and Y conjugate vaccine(0)
- meningococcal group a and c polysaccharide vaccine(0)
- Meningococcal group A oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenA-CRM) Meningococcal group C oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenC-CRM) Meningococcal group W-135 oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenW-CRM) Meningococcal group Y oligosaccharide conjugated to Corynebacterium diphteriae CRM197 protein (MenY-CRM)(0)
- meningococcal group A oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein(0)
- meningococcal group B Vaccine (rDNA, component, adsorbed)(0)
- meningococcal group b vaccine (recombinant, adsorbed)(0)
- meningococcal group c conjugate vaccine(0)
- meningococcal group C oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein(0)
- meningococcal group c polysaccharide conjugate vaccine(0)
- meningococcal groups A, C, W-135 and Y conjugate vaccine(0)
- meningococcal group W-135 oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein(0)
- meningococcal group Y oligosaccharides conjugated to corynebacterium diphtheriae CRM197 protein (MenABCWY)(0)
- menotrophin(0)
- Menotropin(0)
- menthol(1)
- mepivacaine(1)
- mepivacaine hydrochloride(0)
- Mepolizumab(0)
- mepolizumab(0)
- meprobamate(1)
- mequitazine(0)
- mercaptamine(0)
- mercaptamine bitartrate(0)
- mercaptamine hydrochloride(0)
- mercaptopurine(0)
- Mercaptopurine monohydrate(0)
- meropenem(1)
- Meropenem(0)
- meropenem trihydrate(0)
- Mesalazine(0)
- Messenger RNA encoding Cas9 and single guide RNA targeting the human TTR gene(0)
- mesterolone(0)
- metaflumizone(0)
- metamizole(1)
- metamizole sodium(0)
- metamizol sodium(0)
- metformin(5)
- Metformin(0)
- metformin hydrochloride(4)
- methacetin (13C)(0)
- Methacholine chloride(0)
- methadone(1)
- methionine(0)
- methocarbamol(1)
- methohexital(0)
- Methotrexate(1)
- methotrexate(1)
- Methoxyflurane(0)
- Methoxy polyethylene glycol-epoetin beta(0)
- methoxy polyethylene glycol-epoetin beta(0)
- methylaminolevulinate(0)
- Methyl aminolevulinate hydrochloride(0)
- methylnaltrexone bromide(0)
- methylphenidate(1)
- Methylphenidate (hydrochloride)(0)
- methylphenidate hydrochloride(2)
- methylphenobarbital(0)
- methylprednisolone(1)
- methylprednisolone acetate(0)
- methylprednisolone hydrogen succinate(0)
- methyl salicylate(0)
- methylthioninium chloride(0)
- methysergide(1)
- metoclopramide(2)
- metoclopramide hydrochloride(1)
- metoprolol(0)
- metoprolol (tartrate)(0)
- Metreleptin(0)
- metreleptin(0)
- Metronidazole(0)
- Metronidazole (benzoate)(0)
- metyrapone(0)
- mexiletine hcl(0)
- Mexiletine hydrochloride(0)
- mianserine(1)
- micafungin(0)
- Miconazole(0)
- miconazole nitrate(0)
- midazolam(2)
- Midazolam Hydrochloride(0)
- midodrine(0)
- Midostaurin(0)
- midostaurin(0)
- mifamurtide(0)
- mifepristone(1)
- migalastat(0)
- Migalastat hydrochloride(0)
- Miglitol(0)
- miglustat(0)
- MIJ821(0)
- milbemycin oxime(0)
- milnacipran(1)
- milrinone(0)
- minocycline(0)
- minoxidil(0)
- mipomersen sodium(0)
- Mirabegron(0)
- mirabegron(0)
- Miridesap(0)
- Mirikizumab(0)
- mirikizumab(0)
- mirtazapine(2)
- Mirvetuximab soravtansine(0)
- misoprostol(0)
- misoprostol (gastrointestinal indication)(0)
- misoprostol (gynaecological indication - termination of pregnancy)(0)
- Mitapivat(0)
- mitapivat(0)
- mitapivat sulfate(0)
- Mitotane(0)
- mitotane(0)
- mitoxantrone(1)
- mitratapide(0)
- mivacurium(0)
- Mixture of 2 synthetic double-stranded N-Acetyl-galactosamine conjugated siRNA oligonucleotides that are directed against hepatitis B virus (JNJ-73763989)(0)
- Mixture of 2 synthetic double-stranded N-acetyl-galactosamine conjugated siRNA oligonucleotides that are directed against the hepatitis B virus (JNJ-73763989)(0)
- Mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis (Grasses-Mix) and Secale cereale (50/50) allergen extracts(0)
- Mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis (Grasses-Mix) and Secale cereale (75/25) allergen extracts(0)
- Mixture of Phleum pratense, Dactylis glomerata, Festuca elatior, Lolium perenne and Poa pratensis allergen extracts(0)
- Mixture of Phleum pratense and Secale cereale allergen extracts(0)
- mizalostine(1)
- mizolastine(0)
- mobocertinib(0)
- moclobemide(0)
- modafinil(1)
- Modakafusp Alfa(0)
- Modified allergen extract of birch pollen(0)
- Modified allergen extract of pollen from Phleum pratense(0)
- Modified human papillomavirus capsid protein conjugated to the near-infrared dye silicate(5-),bis[N-[3- [(hydroxy-.kappa.O)dimethylsilyl]propyl]-3-sulfo-N,N-bis(3-sulfopropyl)-1-propanaminiumato(4-)][6- [[[3-[(29H,31H-phthalocyanin-yl-.kappa.N29,.kappa.N30,.kappa.N31,.kappa.N32)oxy]propoxy] carbonyl]amino]hexanoato(3-)]-, sodium (1:5)(0)
- modified live bovine viral diarrhoea virus type 1, non-cytopathic parent strain KE-9 and modified live bovine viral diarrhoea virus type 2, non-cytopathic parent strain NY-93(0)
- Modified live porcine respiratory and reproductive syndrome virus(0)
- modified vaccinia Ankara - Bavarian Nordic (MVA-BN) virus(0)
- Modified Vaccinia Ankara - Bavarian Nordic virus (smallpox)(0)
- moexipril(1)
- Mogamulizumab(0)
- mogamulizumab(0)
- Molgramostim(0)
- Molibresib(0)
- Molidustat (sodium)(0)
- Molnupiravir(0)
- molnupiravir(0)
- Momelotinib(0)
- momelotinib(0)
- Momelotinib dihydrochloride monohydrate(0)
- mometasone(0)
- Mometasone (furoate) (QVM149)(0)
- Mometasone (furoate monohydrate)(0)
- mometasone furoate(2)
- Mometasone furoate(0)
- Monalizumab(0)
- monensin(0)
- monensin (as monensin sodium)(0)
- monepantel(0)
- Monoclonal IgG1 anti-influenza A antibody(0)
- Monovalent, live, recombinant, replication-incompetent adenoviral serotype 26 vectored vaccine expressing the full length glycoprotein of the Ebola virus Mayinga variant [Ad26.ZEBOV](0)
- Monovalent, recombinant, replication-incompetent human adenovirus serotype 26-vectored vaccine encoding the pre-fusion conformation-stabilised F protein derived from the RSV A2 strain(0)
- monovalent and multivalent measles, mumps, rubella and varicella vaccines (live)(1)
- montelukast(1)
- Montelukast sodium(0)
- moraxella catarrhalis(0)
- moroctocog alfa(1)
- morphine(1)
- Morphine (hydrochloride)(0)
- morphine sulphate(1)
- Mosunetuzumab(0)
- mosunetuzumab(0)
- Motavizumab(0)
- Moxetumomab pasudotox(0)
- moxetumomab pasudotox(0)
- moxidectin(0)
- moxifloxacin(7)
- Moxifloxacin hydrochloride(0)
- moxonidine(0)
- mugwort pollen(0)
- Multivalent, live, recombinant, non-replicating in human cells, Modified Vaccinia Ankara vectored vaccine, expressing the EBOV Mayinga glycoprotein, the Sudan virus Gulu GP, the Marburg virus Musoke GP, and the Taï Forest virus nucleoprotein [MVA-BN-Filo](0)
- Multivalent pneumococcal polysaccharide conjugate to carrier protein (SP0202)(0)
- mumps virus Jeryl Lynn (level B) strain (live, attenuated)(0)
- Mumps virus RIT 4385 strain, derived from Jeryl Lynn strain (live, attenuated)(0)
- mupirocin(0)
- mycophenolate mofetil(0)
- mycophenolic acid(0)
- Mycoplasma hyopneumoniae, strain 7304 (Nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated(0)
- Mycoplasma hyopneumoniae and porcine circovirus vaccine (inactivated, recombinant)(0)
- mycoplasma hyopneumoniae vaccine (inactivated)(0)
- Mycoplasma synoviae (live)(0)
- Mycoplasma synoviae strain MS-H(0)
- myxomatosis and rabbit haemorrhagic viral disease vaccine (live recombinant)(0)
- N(2)-L-alanyl-L-glutamine(0)
- N-(3-cyano-4-fluorophenyl)-1-methyl-4-[[(2S)-1,1,1-trifluoro-2-propanyl]sulfamoyl]-1H-pyrrole-2- carboxamide (JNJ-56136379)(0)
- N-(6-(((2R,3S)-3,4-dihydroxybutan-2-yl)oxy)-2-((4-fluorobenzyl)thio)pyrimidin-4-yl)-3-methylazetidine-1-sulfonamide (RIST-4721)(0)
- N-(trans-3-(5-((R)-1-hydroxyethyl)-1,3,4-oxadiazol-2-yl) cyclobutyl)-3-phenylisoxazole-5-(0)
- n-acetyl-histidine (monohydrate)(0)
- N-Acetyl-L-Cysteine (corresponds to L-Cysteine), L-Alanine, L-Alanyl-L-Glutamine (corresponds to L-Alanine and L-Glutamine), L-Arginine, Glycine, Glycyl-L-Tyrosine (corresponds to Glycine and L-Tyrosine), L-Histidine, L-Isoleucine, L-Leucine, L-Lysine acetate (corresponds to L-Lysine), LMethionine, L-Phenylalanine, L-Proline, L-Serine, Taurine, L-Threonine, L-Tryptophan, L-Valine(0)
- N-benzyl-2-(5-(4-(2-morpholinoethoxy)phenyl) pyridin-2-yl) acetamide (KX2-391)(0)
- N-hydroxy-5-methylfuran-2-sulfonamide (BMS-986231)(0)
- N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide dihydrochloride monohydrate (SAR302503A)(0)
- N-[(1R)-1-(1H-indol-3-ylmethyl)pentyl]-2-(4-methylpiperazin-1-yl)thiazole-5-carboxamide (UCB0599)(0)
- N-[4-(3-amino-1H-indazol-4 yl)phenyl]-N1-(2-fluoro-5-methylphenyl) urea (ABT-869)(0)
- N-[5-(4-Bromophenyl)-6-[2-[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-sulfamide(0)
- N-{2-(2,3-Difluorobenzylthio)-6-[(2R,3S)-3,4-dihydroxybut-2-yloxy]pyrimidin-4-yl}azetidine-1-sulfonamide (AZD5069)(0)
- N-{4-chloro-2-[(1-oxido-4-pyridinyl)carbonyl]phenyl}-4-(1,1-dimethylethyl) benzenesulfonamide, sodium salt(0)
- N. meningitidis serogroup C polysaccharide conjugated to tetanus toxoid(0)
- N. meningitidis serogroup W polysaccharide conjugated to tetanus toxoid (MenACYW)(0)
- N. meningitidis serogroup Y polysaccharide conjugated to tetanus toxoid(0)
- N2’-Deacetyl-N2’-[4-methyl-4-(oxobutyldithio)-1-oxopentyl]-maytansine-hu769_4D4 Antibody(0)
- nabumetone(0)
- nadifloxacin(0)
- Nadofaragene firadenovec(0)
- nadroparin(0)
- nafarelin(0)
- naftidrofuryl(1)
- naftifine(0)
- nalbuphine(0)
- Naldemedine(0)
- naldemedine(0)
- Naldemedine tosilate(0)
- Nalfurafine hydrochloride(0)
- nalidixic acid(1)
- nalmefene(0)
- Nalmefene hydrochloride dihydrate(0)
- Naloxegol(0)
- naloxegol(0)
- naloxegol oxalate(0)
- naloxone(0)
- naloxone (hydrochloride)(0)
- naloxone hydrochloride(1)
- Naloxone hydrochloride dihydrate(0)
- naltrexone(1)
- Naltrexone(0)
- naltrexone hydrochloride(1)
- Namilumab(0)
- Nanobody directed towards the fusion protein of human respiratory syncytial virus (ALX-0171)(0)
- naproxcinod(0)
- naproxen(0)
- naproxen (sodium)(0)
- naratriptan(0)
- Narsoplimab(0)
- natalizumab(1)
- nateglinide(0)
- navitoclax(0)
- nebivolol(1)
- nebivolol (hydrochloride)(0)
- necitumumab(0)
- Nedosiran(0)
- nefopam(0)
- nefopam (hydrochloride)(0)
- Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid(0)
- Neisseria meningitidis group A polysaccharide conjugated to tetanus toxoid carrier protein (MenABCWY)(0)
- Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid(0)
- Neisseria meningitidis group C polysaccharide conjugated to tetanus toxoid carrier protein(0)
- Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid(0)
- Neisseria meningitidis group W-135 polysaccharide conjugated to tetanus toxoid carrier protein(0)
- Neisseria meningitidis group W polysaccharide conjugated to tetanus toxoid(0)
- Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid(0)
- Neisseria meningitidis group Y polysaccharide conjugated to tetanus toxoid carrier protein(0)
- Neisseria meningitidis serogroup A polysaccharide conjugated to tetanus toxoid(0)
- Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily A; Neisseria meningitidis serogroup B fHbp (recombinant lipidated fHbp (factor H binding protein)) subfamily B(0)
- Neisseria meningitidis serogroup B fHbp subfamily A(0)
- Neisseria meningitidis serogroup B fHbp subfamily B(0)
- Neisseria meningitidis serogroup B Protein-based active substance(0)
- Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily A; Escherichia coli)(0)
- Neisseria meningitidis serogroup B recombinant lipoprotein (rLP2086; subfamily B; Escherichia coli)(0)
- nelarabine(0)
- nelfinavir(0)
- Nemolizumab(0)
- Nemtabrutinib(0)
- neomycin(0)
- neomycin sulfate(0)
- Neonatal piglet colibacillosis (recombinant, inactivated)(0)
- Neonatal piglet colibacillosis vaccine (inactivated)(0)
- Neonatal piglet colibacillosis vaccine (recombinant, inactivated)(0)
- neostigmine(0)
- nepafenac(0)
- neratinib(0)
- neridronic acid(1)
- Netarsudil(0)
- netarsudil(0)
- Netarsudil mesilate(0)
- netilmicin(0)
- netupitant(0)
- nevirapine(0)
- Newcastle disease(0)
- Newcastle disease, infectious bursal disease and Marek's disease vaccine (live recombinant)(0)
- Newcastle disease and Marek’s disease vaccine (live recombinant)(0)
- niaouli(1)
- nicardipine(1)
- nicergoline(1)
- niclosamide(0)
- nicoboxil(0)
- nicorandil(1)
- nicotinic acid(1)
- nifedipine(1)
- Nifedipine(0)
- niflumic(0)
- niflumic acid(0)
- nifuroxazide(0)
- Nifurtimox(0)
- nifurtoinol(0)
- nilotinib(0)
- nilutamide(0)
- nimesulide(3)
- nimesulide (systemic formulations)(0)
- nimesulide (topical formulations)(0)
- Nimodipine(0)
- nimotuzumab(0)
- nintedanib(0)
- Nipocalimab(0)
- Niraparib(0)
- niraparib(0)
- Niraparib (tosilate monohydrate)(0)
- Niraparib tosilate monohydrate(0)
- nirmatrelvir(0)
- Nirogacestat hydrobromide(0)
- Nirsevimab(0)
- nirsevimab(0)
- nitisinone(0)
- nitrazepam(0)
- nitrendipine(0)
- Nitric oxide(0)
- nitric oxide(0)
- nitrofurantoin(0)
- nitrous oxide(0)
- nitroxinil(0)
- nivolumab(0)
- nomegestrol(2)
- Nomegestrol(0)
- Nomegestrol acetate(1)
- nomegestrol acetate(0)
- Non-pathogenic bacterial lysate of Escherichia coli and Enterococcus faecalis(0)
- Nonacog alfa(0)
- nonacog alfa(0)
- Nonacog beta pegol(0)
- nonacog beta pegol(0)
- Nonacog gamma(0)
- nonacog gamma(0)
- nonivamide(0)
- norelgestromin(1)
- norepinephrine(0)
- norethisterone(0)
- norethisterone acetate(1)
- norfloxacin(2)
- norgestimate(1)
- Norovirus GI.1 virus-like particle antigen(0)
- norovirus GII.4 virus-like particle antigen(0)
- norpseudoephedrine(1)
- nortriptyline(0)
- Norursodeoxycholic acid(0)
- Nusinersen(0)
- nusinersen(0)
- nusinersen sodium(0)
- nystatin(0)
- nyxthracis(0)
- Obecabtagene autoleucel(0)
- Obefazimod(0)
- Obeticholic acid(1)
- obeticholic acid(1)
- Obidoxime (chloride)(0)
- Obiltoxaximab(0)
- obiltoxaximab(0)
- Obinutuzumab(0)
- obinutuzumab(0)
- oblimersen(0)
- Ociperlimab(0)
- oclacitinib maleate(0)
- ocrelizumab(0)
- ocreotide(2)
- ocriplasmin(0)
- octenidine(0)
- octenidine dihydrochloride(0)
- octocog alfa(2)
- Octocog alfa(1)
- octreotide(0)
- Octreotide acetate(0)
- Odanacatib(0)
- Odevixibat(0)
- odevixibat(0)
- Odronextamab(0)
- oestrogens conjugated(0)
- Ofatumumab(0)
- ofatumumab(0)
- ofloxacin(1)
- ofloxacin (systemic use)(0)
- Ofloxacin (topical use)(0)
- Ofranergene obadenovec(0)
- olanzapine(0)
- olanzapine pamoate(0)
- Olaparib(0)
- olaparib(0)
- Olaratumab(1)
- olaratumab(1)
- oleclumab(0)
- Olenasufligene relduparvovec(0)
- Olesoxime(0)
- Olinciguat(0)
- Olipudase alfa(0)
- olipudase alfa(0)
- olive oil(0)
- olmesartan(2)
- Olmesartan medoxomil(0)
- olodaterol(0)
- Olodaterol (hydrochloride)(0)
- Olokizumab(0)
- olopatadine(0)
- Olopatadine (hydrochloride) (GSP 301 NS)(0)
- olopatadine hydrochloride(0)
- Olpasiran(0)
- olsalazine(0)
- omacetaxine mepesuccinate(0)
- Omadacycline(0)
- omalizumab(0)
- Omaveloxolone(0)
- Ombitasvir(1)
- ombitasvir(1)
- Ombrabulin(0)
- Omecamtiv mecarbil(0)
- Omega-3 fatty acid ethyl esters(1)
- Omega-3-acid (85% ethyl esters of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in a ratio of 0.9-1.5)(0)
- omega-3-acid-ethyl esters(0)
- omega-3-acid ethyl esters 90(0)
- Omega-3-carboxylic acids(0)
- omeprazole(2)
- Onasemnogene abeparvovec(0)
- onasemnogene abeparvovec(0)
- ondansetron(0)
- Ondansetron (hydrochloride)(0)
- One of the following inactivated bluetongue virus strains:Inactivated bluetongue virus, serotype 1, strain BTV-1/ALG2006/01 E1Inactivated bluetongue virus, serotype 8, strain BTV-8/BEL2006/02Inactivated bluetongue virus, serotype 4, strain SPA-1/2004(0)
- opicapone(0)
- Opicinumab(0)
- opium(0)
- Oportuzumab monatox(0)
- oportuzumab monatox(0)
- orbifloxacin(0)
- oritavancin(0)
- oritavancin (diphosphate)(0)
- orlistat(1)
- ornithine(0)
- ornithine hydrochloride(0)
- orphenadrine (citrate)(0)
- orthophenylphenol(0)
- Orvepitant(0)
- osaterone acetate(0)
- oseltamivir(0)
- Oseltamivir (phosphate)(0)
- Osilodrostat(0)
- osilodrostat(0)
- Osilodrostat phosphate(0)
- osimertinib(0)
- Osimertinib (as mesilate)(0)
- osimertinib mesilate(0)
- ospemifene(0)
- Otenaproxesul(0)
- oteracil(1)
- Oteseconazole(0)
- outer membrane protein complex of Neisseria meningitidis (outer membrane protein complex of the B11 strain of Neisseria meningitidis subgroup B)(0)
- outer membrane vesicles (OMV) from n. meningitidis strain NZ 98/254(0)
- Outer Membrane Vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 measured as amount of total protein containing the PorA P1.4(0)
- outer membrane vesicles from neisseria meningitidis group b (strain nz 98/254)(0)
- oxalic acid dehydrate(0)
- oxalic acid dihydrate(0)
- oxalic acid dihydrate / formic acid(0)
- oxaliplatin(0)
- Oxalobacter formigenes strain HC-1(0)
- oxatomide(0)
- oxcarbazepine(0)
- oxolinic acid(0)
- oxybutynin(0)
- oxyclozanide(0)
- oxycodone(1)
- Oxycodone (hydrochloride)(0)
- oxycodone hydrochloride(1)
- oxygen(0)
- oxymetazoline(0)
- Oxymetazoline hydrochloride(0)
- oxytetracycline hydrochloride(0)
- Oxytocin(0)
- oxytocin (systemic use)(0)
- ozanimod(0)
- Ozanimod (hydrochloride)(0)
- ozanimod hydrochloride(0)
- Ozenoxacin(0)
- paclitaxel(1)
- Pacritinib(0)
- padeliporfin(0)
- padeliporfin di-potassium(0)
- Pagibaximab(0)
- Palbociclib(0)
- palbociclib(0)
- palifermin(0)
- paliperidone(0)
- paliperidone palmitate(0)
- palivizumab(0)
- Palonosetron(0)
- palonosetron(0)
- palonosetron hydrochloride(0)
- Palopegteriparatide(0)
- palopegteriparatide(0)
- Palovarotene(0)
- palovarotene(0)
- pamidronate(0)
- pamidronic acid(1)
- Pamiparib(0)
- Pamrevlumab(0)
- pancreas powder(0)
- pancuronium(0)
- pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted)(0)
- Pandemic influenza vaccine (H1N1) (split virion, inactivated, adjuvanted), containing antigen equivalent to Influenza A/California/7/2009(0)
- pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)(0)
- pandemic influenza vaccine (H5N1) (live attenuated, nasal)(0)
- pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)(0)
- pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) (0)
- Pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)(0)
- pandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)(0)
- pandemic influenza vaccine (H5N1) (whole virion, inactivated, prepared in cell culture)(0)
- pandemic influenza vaccine (whole virion, inactivated, adjuvanted)(0)
- Pandemic live attenuated influenza virus (H5N1)(0)
- panitumumab(0)
- panobinostat(0)
- Panobinostat as panobinostat lactate salt(0)
- panobinostat lactate anhydrous(0)
- pantoprazole(5)
- Para-aminosalicylic acid(0)
- para-aminosalicylic acid(0)
- paracetamol(4)
- paracetamol (IV formulation)(0)
- Paraffin liquid(0)
- parathyroid hormone(0)
- parathyroid hormone (rDNA)(0)
- parecoxib(0)
- parecoxib sodium(0)
- paricalcitol(0)
- paritaprevir(1)
- paromycin(0)
- paroxetine(2)
- Parsaclisib(0)
- parsaclisib(0)
- Parsaclisib (as hydrochloride)(0)
- Parsaclisib (hydrochloride)(0)
- Parsaclisib hydrochloride(0)
- pasireotide(0)
- patent blue V sodium(0)
- Patidegib(0)
- patiromer(0)
- Patiromer calcium(0)
- patiromer sorbitex calcium(0)
- patisiran(0)
- patisiran sodium(0)
- Patritumab deruxtecan(0)
- Patupilone(0)
- Paullinia cupana Kunth(0)
- pazopanib(0)
- Peanut allergen extract(0)
- Peanut flour(0)
- pefloxacin(1)
- pegaptanib(0)
- Pegaptanib sodium(0)
- pegaspargase(0)
- Pegbovigrastim(0)
- Pegcetacoplan(0)
- pegcetacoplan(0)
- pegfilgrastim(0)
- peginesatide(0)
- peginterferon alfa-2a(0)
- peginterferon alfa-2b(0)
- peginterferon beta-1a(0)
- Peginterferon lambda-1a(0)
- pegloticase(0)
- Pegunigalsidase alfa(0)
- pegunigalsidase alfa(0)
- Pegvaliase(0)
- pegvaliase(0)
- Pegvisomant(0)
- pegvisomant(0)
- pegvorhyaluronidase alpha(0)
- PEGylated-fibroblast growth factor 21 (BMS-986036)(0)
- Pegylated proline-interferon alpha-2b(0)
- Pegylated recombinant factor VIIa(0)
- Pegzilarginase(0)
- pelargonium reniforme curt. / radix(0)
- pelargonium sidoides dc(0)
- pelargonium sidoides dc and-or pelargonium reniforme curt-radix(0)
- Pemafibrate(0)
- Pembrolizumab(0)
- pembrolizumab(0)
- pemetrexed(0)
- pemetrexed diacid monohydrate(0)
- pemetrexed disodium(0)
- pemetrexed disodium hemipentahydrate(0)
- pemetrexed disodium heptahydrate(0)
- pemetrexed ditromethamine(0)
- pemigatinib(0)
- penciclovir(0)
- pentamidine(0)
- pentosan polysulfate sodium(0)
- pentoxyverine(0)
- peppermint oil(0)
- Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain(0)
- Peptide derivative of glucagon-like-peptide 1 and glucagon with fatty acid side chain (BI 456906)(0)
- Peptide KLBPVQLWV / Peptide SMPPPGTRV / Peptide YLQLVFGIEV / Peptide RLLQETELV / Peptide YLSGADLNL / Peptide LLTFWNPPV / Peptide IMIGHLVGV / Peptide KVAEIVHFL / Peptide KVFGSLAFV / Pan HLA DR-binding epitope D-Ala-Lys-Cha-Val-Ala-Ala-Trp-Thr-Leu-Lys-Ala-Ala-D-Ala (OSE2101)(0)
- Peramivir(0)
- peramivir(0)
- perampanel(0)
- Perflubutane(0)
- perflutren(0)
- pergolide(1)
- perindopril(3)
- Perindopril (arginine)(0)
- perindopril (arginine)(0)
- Perindopril (tosilate)(0)
- perindopril arginine(0)
- Perindopril erbumine(0)
- perindopril tert-butylamine(0)
- permethrin(0)
- perphenazine(0)
- pertactin(0)
- pertussis(0)
- pertussis (acellular, component)(0)
- pertussis (acellular, component) vaccine (adsorbed), diphtheria(0)
- pertussis (acellular, component) vaccine (adsorbed) reduced antigens contents(0)
- pertussis filamentous haemagglutinin(0)
- pertussis haemagglutin filamentous(0)
- pertussis pertactin(0)
- pertussis toxin(0)
- pertussis toxoid(0)
- pertuzumab(0)
- pethidine(0)
- Pevonedistat(0)
- Pexastimogene devacirepvec(0)
- Pexidartinib(0)
- Pexiganan (acetate)(0)
- phenazone(0)
- phendimetrazine(1)
- pheniramine maleate(0)
- phenmetrazine(1)
- Phenobarbital(0)
- phenobarbital(0)
- phenol(0)
- phenoxyethanol(0)
- phenoxymethylpenicillin(1)
- phentermine(1)
- phentolamine mesilate(0)
- Phenyl- and piperidin-containing derivative of amiloride (BI 443651)(0)
- phenylalanine(0)
- phenylephrine(0)
- phenylephrine (ophthalmic formulations)(0)
- phenylephrine hydrochloride(0)
- phenylpropanolamine(0)
- phenytoin(0)
- Phleum pratense(0)
- Phleum pratense allergen extract(0)
- Phleum pratense L.(0)
- phloroglucinol(0)
- phloroglucinol trimethylphloroglucinol(0)
- pholcodine(2)
- Pholcodine(0)
- Phospholipid esters from herring roe (HRO350)(0)
- physostigmine(0)
- pibrentasvir(0)
- Piflufolastat (18F)(0)
- piflufolastat (18F)(0)
- pilocarpine(0)
- Pilocarpine (hydrochloride)(0)
- Pimavanserin(0)
- pimecrolimus(1)
- pimobendan(0)
- Pimodivir(0)
- pioglitazone(2)
- pioglitazone hydrochloride(1)
- pipemidic acid(1)
- piperacillin(1)
- piperaquine phosphate anhydride(0)
- piperaquine tetraphosphate(0)
- pipobroman(0)
- piracetam(0)
- piretanide(0)
- Pirfenidone(0)
- pirfenidone(0)
- piribedil(0)
- pirlimycin(0)
- piroxicam(1)
- pirtobrutinib(0)
- pitavastatin(0)
- Pitavastatin (calcium)(0)
- pitolisant(0)
- pixantrone dimaleate(0)
- plasma fibronectin(0)
- Plasma kallikrein inhibitor(0)
- plasma protein fraction(0)
- plasminogen(0)
- Plasmodium falciparum and hepatitis B vaccine (recombinant, adjuvanted)(0)
- Plazomicin (sulfate)(0)
- Plerixafor(0)
- plerixafor(0)
- Plitidepsin(0)
- pneumococcal oligosaccharide serotype 18C(0)
- pneumococcal polysaccharide conjugate vaccine (13-valent, adsorbed)(0)
- Pneumococcal polysaccharide conjugate vaccine (15-valent, adsorbed)(0)
- pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)(0)
- pneumococcal polysaccharide conjugate vaccine (adsorbed)(0)
- Pneumococcal polysaccharide serotype 1(0)
- Pneumococcal polysaccharide serotype 1 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein(0)
- pneumococcal polysaccharide serotype 1- diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 3(0)
- pneumococcal polysaccharide serotype 3 - diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 4(0)
- pneumococcal polysaccharide serotype 4 - diphtheria CRM197 conjugate(0)
- pneumococcal polysaccharide serotype 4 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein(0)
- Pneumococcal polysaccharide serotype 5(0)
- pneumococcal polysaccharide serotype 5 - diphtheria CRM197 conjugate(0)
- pneumococcal polysaccharide serotype 5 conjugated to protein D (derived from non-typeable Haemophilus influenzae) carrier protein...(0)
- Pneumococcal polysaccharide serotype 6A(0)
- pneumococcal polysaccharide serotype 6A- diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 6B(0)
- pneumococcal polysaccharide serotype 6B - diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 7F(0)
- pneumococcal polysaccharide serotype 7F - diphtheria CRM197 conjugate(0)
- Pneumococcal Polysaccharide Serotype 8(0)
- Pneumococcal polysaccharide serotype 8(0)
- Pneumococcal Polysaccharide Serotype 9N(0)
- Pneumococcal polysaccharide serotype 9V(0)
- pneumococcal polysaccharide serotype 9V - diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 10A(0)
- Pneumococcal polysaccharide serotype 11A(0)
- Pneumococcal polysaccharide serotype 12F(0)
- Pneumococcal polysaccharide serotype 14(0)
- pneumococcal polysaccharide serotype 14 - diphtheria CRM197 conjugate(0)
- Pneumococcal Polysaccharide Serotype 15A(0)
- Pneumococcal polysaccharide serotype 15b(0)
- Pneumococcal Polysaccharide Serotype 15C(0)
- Pneumococcal Polysaccharide Serotype 16F(0)
- Pneumococcal Polysaccharide Serotype 17F(0)
- Pneumococcal polysaccharide serotype 18C(0)
- pneumococcal polysaccharide serotype 18C - diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 19A(0)
- pneumococcal polysaccharide serotype 19A - diphtheria CRM197 conjugate(0)
- Pneumococcal polysaccharide serotype 19F(0)
- pneumococcal polysaccharide serotype 19F - diphtheria CRM197 conjugate(0)
- Pneumococcal Polysaccharide Serotype 20(0)
- Pneumococcal Polysaccharide Serotype 22F(0)
- Pneumococcal polysaccharide serotype 22F(0)
- pneumococcal polysaccharide serotype 22F - diphtheria CRM197 conjugate(0)
- Pneumococcal Polysaccharide Serotype 23A(0)
- Pneumococcal Polysaccharide Serotype 23B(0)
- Pneumococcal polysaccharide serotype 23F(0)
- pneumococcal polysaccharide serotype 23F - diphtheria CRM197 conjugate(0)
- Pneumococcal Polysaccharide Serotype 24F(0)
- Pneumococcal Polysaccharide Serotype 31(0)
- Pneumococcal polysaccharide serotype 33F(0)
- pneumococcal polysaccharide serotype 33F – diphtheria CRM197 conjugate (15-valent pneumococcal polysaccharide conjugate vaccine [V114])(0)
- Pneumococcal Polysaccharide Serotype 35B(0)
- Pneumococcal polysaccharides individually biotinylated and complexed with a carrier protein (recombinant fusion construct of rhizavidin and Streptococcus pneumoniae derived proteins), 24-valent(0)
- Pneumococcal Polyssacharide Serotype 1 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 3 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 4 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 5 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 6A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 6B conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 7F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 8 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 9V conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 10A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 11A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 12F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 14 conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 15B conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 18C conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 19A conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 19F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 22F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 23F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- Pneumococcal Polyssacharide Serotype 33F conjugated to CRM197 carrier protein and adsorbed on aluminium Phosphate(0)
- pneumococcal saccharide conjugated vaccine, adsorbed(0)
- Poa pratensis(0)
- Poa pratensis L.(0)
- podophyllotoxin(0)
- polatuzumab vedotin(0)
- Polihexanide(0)
- poliomyelitis(0)
- poliomyelitis (inactivated)(0)
- poliomyelitis (inactivated) vaccine (adsorbed, reduced antigens(s) content)(0)
- poliovirus (inactivated) (type-1 (Mahoney strain), type-2 (MEF-1 strain), type-3 (Saukett strain))(0)
- poliovirus (inactivated) (type 1 (Mahoney strain), type 2 (MEF-1 strain), type 3 (Saukett strain))(0)
- poliovirus (inactivated): type 1 (Mahoney), type 2 (MEF-1), type 3 (Saukett) produced in Vero cells/ Haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) conjugated to meningococcal protein.(0)
- poliovirus (inactivated) type 1 (Mahoney) type 2 (MEF-1) type 3 (Saukett)(0)
- poliovirus (inactivated) type 1 (Mahoney strain) produced on Vero cells(0)
- poliovirus (inactivated) type 2 (MEF-1 strain) produced on Vero cells(0)
- poliovirus (inactivated) type 3 (Saukett strain) produced on Vero cells(0)
- poliovirus type 1(0)
- poliovirus type 1 / poliovirus type 3 (oral, live, attenuated) vaccine(0)
- poliovirus type 1 vaccine(0)
- poliovirus type 2(0)
- poliovirus type 2 vaccine(0)
- poliovirus type 3(0)
- poliovirus type 3 (oral, live, attenuated) vaccine(0)
- poliovirus type 3 vaccine(0)
- Pollen from Alnus glutinosa, Betula verrucosa and Corylus avellana(0)
- Pollen from Dactylis glomarata (8%), Lolium perenne (8%), Phleum pratense (8%), Poa pratensis (8%), Anthoxhantum odoratum (8%), Secale cereale (10%), Betula pendula (16.7%), Corylus avellana (16.6%) and Alnus glutinosa (16.6%)(0)
- Pollen from Dactylis glomarata (16%), Festuca pratensis (16%), Lolium perenne (16%), Phleum pratense (16%), Poa pratensis (16%), Secale cereale (20%)(0)
- Pollen from Dactylis glomarata (16%), Lolium perenne (16%), Phleum pratense (16%), Poa pratensis (16%), Anthoxhantum odoratum (16 %) and Secale cereale (20%)(0)
- Pollen from Dactylis glomarata, Lolium perenne, Phleum pratense, Poa pratensis and Anthoxhantum odoratum (20% each)(0)
- Pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale, Betula verrucosa, Corylus avellana and Alnus glutinosa(0)
- Pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Poa pratensis, Secale cereale and Artemisia vulgaris(0)
- Pollen from Dactylis glomerata, Festuca pratensis, Lolium perenne, Phleum pratense, Secale cereale (20% each)(0)
- Pollen from Dactylis glomerata, Lolium perenne, Phleum pratense, Festuca pratensis, Secale cereale(0)
- Pollen from Phleum pratense(0)
- poly (o-2-hydroxyethyl) starch(0)
- Poly(oxy-1,2-ethanediyl), alpha-hydro-omega-methoxy, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-teriparatide (2:1) (TransCon PTH)(0)
- Polyethylene glycol 3350(0)
- polygala syrup(0)
- Polymyxin B(0)
- polyribosylribitol phosphate (PRP) from Haemophilus influenzae type b as prp-ompc(0)
- polyribosylribitol phosphate from Haemophilus influenzae type b as PRP-OMPC(0)
- polystyrene sulfonate(0)
- Pomalidomide(0)
- pomalidomide(0)
- Ponatinib(1)
- ponatinib(1)
- ponesimod(0)
- Porcine circovirus and porcine enzootic pneumonia vaccine (inactivated)(0)
- porcine circovirus recombinant virus (CPCV) 1-2, inactivated(0)
- Porcine circovirus type 2 (PCV2) ORF2 subunit antigen, Mycoplasma hyopneumoniae J strain inactivated(0)
- porcine circovirus type 2 ORF2 protein(0)
- porcine circovirus type 2 ORF2 subunit antigen(0)
- Porcine circovirus vaccine (inactivated)(0)
- porcine circovirus vaccine (inactivated, recombinant)(0)
- Porcine circovirus vaccine (inactivated recombinant)(0)
- Porcine influenza vaccine (inactivated)(0)
- porcine pancreas enzymes(1)
- porcine parvovirosis vaccine (inactivated)(0)
- Porcine parvovirus, strain 27a, viral protein 2(0)
- porcine parvovirus, strain NADL-2 and Erysipelothrix rhusiopathiae, strain R32E11 (inactivated)(0)
- Porcine parvovirus and Erysipelothrix rhusiopathiae(0)
- porcine post-weaning diarrhoea vaccine (live)(0)
- porcine respiratory and reproductive syndrome virus, live(0)
- Porcine respiratory and reproductive syndrome virus vaccine (live)(0)
- porfimer(0)
- porfimer sodium(0)
- posaconazole(0)
- Posoleucel(0)
- potassium acetate(0)
- potassium bitartrate(0)
- potassium chloride(0)
- potassium chloride (NER1006)(0)
- potassium citrate(0)
- Potassium citrate monohydrated(0)
- potassium clavulanate(0)
- Potassium hydrogen carbonate(0)
- potassium hydrogen carbonate(0)
- potassium hydrogen carbonate (ADV7103)(0)
- potassium para aminobenzoate(0)
- potassium sulfate(0)
- potassium sulphate(0)
- povidone(0)
- Pozelimab(0)
- Pracinostat(0)
- Pradigastat(0)
- pradofloxacin(0)
- Pralatrexate(0)
- pralatrexate(0)
- pralsetinib(0)
- pramipexole(0)
- pramipexole dihydrochloride monohydrate(0)
- pramiracetam(0)
- Prasterone(0)
- prasterone(0)
- prasugrel(0)
- Prasugrel (hydrochloride)(0)
- prasugrel besilate(0)
- pravastatin(1)
- Pravastatin(0)
- Pravastatin sodium(0)
- praziquantel(0)
- Prednicarbate(0)
- Prednisolone(0)
- prednisolone metasulphobenzoate(0)
- prednisolone sodium phosphate(1)
- pregabalin(0)
- prepandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted)(0)
- prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)(0)
- Prepandemic influenza vaccine (H5N1) (whole virion, inactivated,prepared in cell culture)(0)
- Pretomanid(0)
- pretomanid(0)
- Pridopidine hydrochloride(0)
- prilocaine(2)
- primidone(0)
- Pritelivir (mesylate monohydrate)(0)
- procaine (hydrochloride)(0)
- Processed Nerve Allograft (human)(0)
- procyanidolic oligomers(0)
- progesterone(1)
- Progesterone(0)
- proguanil(0)
- proguanil hydrochloride(0)
- Prolgolimab(0)
- proline(0)
- promestriene(0)
- propafenone(0)
- Propan-2-yl (2S)-2-{[(S)-({(2R,3R,4R,5R)-5-[2-amino-6-(methylamino)-9H-purin-9-yl]-4-fluoro-3- hydroxy-4-methyloxolan-2-yl}methoxy)(phenoxy)phosphoryl]amino}propanoate; sulfuric acid (2:1) (AT-527 / RO7496998)(0)
- Propan-2-yl 2-[5-( acryloylamino )-4-{ [2-( dimethylamino )ethyl] ( methyl)amino }-2-methoxyanilino ]-4- ( 1 methyl-1 H-indol-3-yl)pyrimidine-5-carboxylate(0)
- propofol(0)
- propranolol(0)
- propranolol hydrochloride(0)
- propylhexedrine(1)
- Proteinase, metallo- (synthetic nociceptin receptor-binding) 1290102-81-6 (AGN214868)(0)
- protein dO (non-toxic deletion derivative of Pasteurella multocida dermonecrotic toxin)(0)
- proteolytic enzymes enriched in bromelain(0)
- prucalopride(0)
- Prucalopride succinate(0)
- prulifloxacin(1)
- pseudoephedrine(2)
- Pseudoephedrine(0)
- pseudophedrine sulfate(1)
- pUK-SPDV-poly2#1 DNA plasmid coding for salmon pancreas disease virus proteins(0)
- Purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 16 (recombinant CyaA-HPV16E7)(0)
- purified adenylate cyclase recombinant protein carrying subfragments of the early protein E7 antigen from human papillomavirus strain 18 (recombinant CyaA-HPV18E7)(0)
- Purified antigen fractions of inactivated split virion Influenza A/Indonesia/05/2005 (H5N1) like strain used (PR8-IBCDC-RG2)(0)
- Purified antigen fractions of inactivated split virion Influenza A/Indonesia/05/2005(H5N1) like strain used (PR8-IBCDC-RG2)(0)
- Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 (H5N1)(0)
- Purified antigen fractions of inactivated split virion Influenza A/Vietnam/1194/2004 (H5N1) like strain used (NIBRG-14)(0)
- Purified antigen fractions of inactivated split virion influenza virus type A, H1N1(0)
- purified diphtheria toxoid(0)
- Purified Diphtheria Toxoid (DTaP-IPV-HepB-PRP-T)(0)
- Purified Filamentous Haemagglutinin(0)
- purified fimbriae types 2 and 3(0)
- Purified inactivated rabies virus (WISTAR PM/WI 38-1503-3M strain)(0)
- purified p45 feline leukaemia virus envelope antigen(0)
- purified p45 FeLV-envelope antigen(0)
- purified pertactin(0)
- purified pertussis filamentous haemagglutinin(0)
- purified pertussis toxoid(0)
- Purified polyribosylribitol phosphate capsular polysaccharide of Haemophilus influenzae type b covalently bound to Tetanus protein (PRP-T)(0)
- purified Rp-45 FeLV-envelope antigen(0)
- Purified Tetanus Toxoid(0)
- pyrantel(0)
- pyrantel embonate(0)
- Pyridine-3-carboxamide derivative (K-161)(0)
- pyridoxine(0)
- pyridoxine (hydrochloride)(0)
- Pyrimidinyl-aminopyridine dual leucine zipper kinase inhibitor (GDC-0134)(0)
- pyriprole(0)
- pyriproxyfen(0)
- pyronaridine(0)
- quadrivalent HPV vaccine (types 6, 11, 16, 18)(1)
- Quadrivalent influenza vaccine (recombinant, prepared in cell culture)(0)
- quavonlimab(0)
- quetiapine(3)
- Quilizumab(0)
- quinagolide(0)
- quinapril(1)
- quinidine(0)
- quinidine sulfate(0)
- quinine(0)
- Quizartinib(0)
- quizartinib(0)
- Quizartinib dihydrochloride(0)
- quizartinib dihydrochloride(0)
- rAAV8 viral vector encoding the human UGT1A1 transgene (rAAV8-hUGT1A1)(0)
- rabbit anti-humanT-lymphocyte immunoglobulin(0)
- rabbit anti-human thymocyte(0)
- Rabbit haemorrhagic disease vaccine (inactivated)(0)
- Rabbit haemorrhagic disease vaccine (inactivated, recombinant)(0)
- Rabbit haemorrhagic disease virus, capsid protein antigen, recombinant(0)
- Rabbit hemorrhagic disease virus 2 VP1AB(0)
- Rabbit hemorrhagic disease virus VP1A(0)
- Rabeprazole(0)
- Rabeprazole (sodium)(0)
- rabies recombinant canarypox virus (vCP65)(0)
- rabies vaccine(0)
- Rabies vaccine (live, oral) for foxes and raccoon dogs(0)
- racecadotril(0)
- radium (223Ra) dichloride(1)
- radium Ra223 dichloride(1)
- rafoxanide(0)
- Ragweed pollen extract (Ambrosia artemisiifolia)(0)
- Ralinepag(0)
- Ralmitaront(0)
- raloxifene(0)
- raloxifene hydrochloride(0)
- Raltegravir(0)
- raltegravir(0)
- raltegravir potassium(0)
- Raltitrexed(0)
- ramipril(4)
- Ramipril(0)
- ramipril, amlodipine(0)
- ramipril, hydrochlorothiazide(0)
- Ramucirumab(0)
- ramucirumab(0)
- ranibizumab(0)
- ranitidine(1)
- ranolazine(0)
- rapibloc(0)
- raploc(0)
- rasagiline(0)
- rasagiline tartrate(0)
- rasburicase(0)
- Ravagalimab(0)
- ravulizumab(0)
- Raxibacumab(0)
- raxtozinameran(0)
- reassortant influenza virus (live attenuated) of the following strain: A/Vietnam/1203/2004 (H5N1) strain(0)
- Reassortant influenza virus (live attenuated) of the following strains:A/California/7/2009 (H1N1)pdm09 like strain, A/Victoria/361/2011 (H3N2) like strain, B/Massachusetts/2/2012 like strain(0)
- Rebisufligene etisparvovec(0)
- reboxetine(1)
- recombinant 10 kD culture filtrate protein(0)
- Recombinant adeno-associated viral (rAAV) vector expressing the human ornithine transcarbamylase (hOTC) gene(0)
- Recombinant Adenovirus type 26 (Ad26) encoding the glycoprotein (GP) of the Ebola virus Zaire (ZEBOV) Mayinga strain(0)
- Recombinant anti-human CD20 and anti-human CD3 monoclonal antibody (RO7082859; CD20 CD3 TCB)(0)
- Recombinant Bet v1 folding variant (rBet v1-FV)(0)
- Recombinant chimeric porcine circovirus 1 containing the porcine circovirus 2a open reading frame 2 protein, inactivated,Recombinant chimeric porcine circovirus 1 containing the porcine circovirus 2b open reading frame 2 protein, inactivated(0)
- recombinant cholera toxin B subunit(0)
- Recombinant Clostridioides difficile toxoid A(0)
- Recombinant Clostridioides difficile toxoid B(0)
- Recombinant COVID-19 subunit nanoparticle (adjuvanted with AS03) (GBP510)(0)
- Recombinant dimer of 6 kD early secretory antigenic target(0)
- recombinant fowlpox virus expressing the membrane fusion protein and the encapsidation protein of avian infectious laryngotracheitis virus, live(0)
- Recombinant Fusion Protein Linking Coagulation Factor VIIa with Albumin (rVIIa-FP; CSL689)(0)
- Recombinant fusion protein linking iduronate 2-sulfatase to engineered Fc with binding site for transferrin receptor (DNL310)(0)
- Recombinant Hepatitis B vaccine(0)
- Recombinant human acid ceramidase (RVT-801)(0)
- Recombinant human A disintegrin and metalloprotease with thrombospind type-1 motifs 13(0)
- recombinant human albumin fusion protein(0)
- Recombinant human anti-Rhesus D monoclonal antibody (LFB-R593)(0)
- Recombinant human antibody against activin type IIB receptors(0)
- Recombinant human antibody against the respiratory syncytial virus fusion protein (REGN2222)(0)
- Recombinant human beta-glucuronidase (rhGUS, UX003)(0)
- recombinant human C1 inhibitor(0)
- Recombinant human C1-inhibitor(0)
- Recombinant human epidermal growth factor(0)
- Recombinant human glutamic acid decarboxylase (rhGAD65)(0)
- Recombinant human granulocyte colony-stimulating factor – human immunoglobulin Fc fusion protein (rhG-CSF-Fc)(0)
- Recombinant human granulocyte colony stimulating factor(0)
- Recombinant human granulocyte colony stimulating factor coupled with recombinant human albumin fusion protein(0)
- Recombinant human growth hormone fused to hybrid Fc composed of the hinge region and N-terminal of CH2 domain of IgD and C-terminal of CH2 and full CH3 domain of IgG4(0)
- Recombinant human growth hormone modified by fusion with two hydrophilic polypeptide chains (VRS-317)(0)
- Recombinant human heparan-N-sulfatase(0)
- Recombinant human IgGlA monoclonal Fab antibody(0)
- recombinant human interferon alfa-2a(0)
- Recombinant humanised monoclonal antibody (IgG1, Kappa) to IL-5(0)
- Recombinant humanised monoclonal immunoglobulin G4, with specificity for human tau (UCB0107)(0)
- Recombinant humanized anti-alpha-synuclein IgG1 monoclonal antibody(0)
- Recombinant humanized anti-blood dendritic cell antigen 2 (BDCA2) monoclonal antibody (BIIB059)(0)
- Recombinant humanized anti-MMP9 monoclonal antibody IgG4 (GS-5745)(0)
- Recombinant human lecithin cholesterol acyltransferase(0)
- Recombinant human monoclonal antibody against growth differentiation factor 8 (REGN1033)(0)
- Recombinant human monoclonal antibody of the IgG1 class to insulin-like growth factor-1 receptor (RO4858696)(0)
- Recombinant human monoclonal antibody to GM-CSF (GSK3196165)(0)
- recombinant human monoclonal antibody to hsp(0)
- Recombinant human monoclonal antibody to human interleukin 17A (AIN457)(0)
- Recombinant human monoclonal antibody to the p40 subunit of human interleukin-12 and human interleukin-23 of the IgG1-class (ABT-874)(0)
- Recombinant human monoclonal IgG1 antibody directed against Programmed Death Ligand-1 (anti-PD-L1) (MSB0010718C)(0)
- recombinant human n-acetylgalactosamine-6-sulfatase(0)
- Recombinant human N-acetylgalactosamine-6-sulfatase (BMN110)(0)
- Recombinant human N-acetylglucosaminidase(0)
- Recombinant human nerve growth factor(0)
- recombinant inactivated avian influenza virus(0)
- Recombinant Influenza Hemagglutinin-strain A (H1N1 subtype)(0)
- Recombinant Influenza Hemagglutinin-strain A (H3N2 subtype)(0)
- Recombinant Influenza Hemagglutinin-strain B (Victoria lineage)(0)
- Recombinant Influenza Hemagglutinin-strain B (Yamagata lineage) (RIV4)(0)
- recombinant L-asparaginase(0)
- Recombinant modified human growth hormone(0)
- Recombinant Modified Vaccinia Ankara Bavarian Nordic Virus encoding the: Ebola virus Zaire (ZEBOV) Mayinga strain glycoprotein (GP); Ebola virus Sudan Gulu strain GP; Ebola virus Taï Forest strain nucleoprotein and the Marburg virus Musoke strain GP(0)
- Recombinant monoclonal antibody to sialic acid-binding Ig-like lectin 8 (AK002)(0)
- recombinant Neisseria meningitidis group B fHbp fusion protein(0)
- recombinant Neisseria meningitidis group B NadA protein(0)
- recombinant Neisseria meningitidis group B NHBA fusion protein(0)
- Recombinant Neisseria meningitidis serogroup B protein 1(0)
- Recombinant Neisseria meningitidis serogroup B protein 2(0)
- Recombinant Neisseria meningitidis serogroup B protein 3(0)
- recombinant neisseria meningitis group B Protein 287-953(0)
- recombinant neisseria meningitis group B Protein 936-741(0)
- recombinant neisseria meningitis group B Protein 961c(0)
- recombinant omega interferon of feline origin(0)
- Recombinant parathyroid hormone(0)
- Recombinant porcine factor VIII, B-domain deleted(0)
- Recombinant protein Q from Leishmania infantum MON-1(0)
- Recombinant respiratory syncytial virus pre-fusion F protein, adjuvanted with AS01E(0)
- Recombinant respiratory syncytial virus vaccine(0)
- Recombinant salmon calcitonin(0)
- recombinant salmon calcitonin(0)
- Recombinant SARS CoV2 spike protein(0)
- Recombinant Streptococcus equi protein CCE(0)
- Recombinant Streptococcus equi protein Eq85(0)
- Recombinant Streptococcus equi protein IdeE(0)
- Recombinant turkey herpesvirus, strain vhvt013-69, live(0)
- recombinant type-D Pasteurella-multocida toxin(0)
- Recombinant varicella zoster virus glycoprotein E(0)
- recombinant Verotoxin 2e of E. coli(0)
- recombinant vesicular stomatitis virus (strain indiana) with a deletion of the envelope glycoprotein, replaced with the zaire ebolavirus (strain kikwit 1995) surface glycoprotein(0)
- regadenoson(0)
- Regdanvimab(0)
- regdanvimab(0)
- regorafenib(0)
- Relamorelin(0)
- Relatlimab(0)
- relatlimab / nivolumab(0)
- Reldesemtiv(0)
- relebactam(0)
- relebactam (MK-7655A)(0)
- relebactam monohydrate(0)
- relugolix(0)
- remdesivir(0)
- Remibrutinib(0)
- remimazolam(0)
- Remimazolam (as besilate)(0)
- remimazolam besilate(0)
- repaglinide(1)
- Reparixin(0)
- Repotrectinib(0)
- Reslizumab(0)
- reslizumab(0)
- Resmetirom(0)
- Resminostat(0)
- resocortol butyrate(0)
- Respiratory Syncytial Virus (RSV) PreF3 recombinant Fusion protein/AS01(0)
- Respiratory syncytial virus, subgroup A, stabilized prefusion F protein / Respiratory syncytial virus, subgroup B, stabilized prefusion F protein(0)
- Respiratory Syncytial Virus PreF3 recombinant fusion protein (RSVPreF3)(0)
- Respiratory Syncytial Virus recombinant glycoprotein F stabilised in the pre-fusion conformation (RSVPreF3) produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology(0)
- Respiratory syncytial virus stabilised prefusion F subunit vaccine(0)
- Respiratory syncytial virus stabilised prefusion f subunit vaccine (RSVpreF)(0)
- Respiratory syncytial virus vaccine (bivalent, recombinant)(0)
- retapamulin(0)
- reteplase(0)
- Retifanlimab(0)
- retifanlimab(0)
- retigabine(0)
- Retinol (Vitamin A)(0)
- Retinyl Palmitate(0)
- Retosiban(0)
- reviparin(0)
- Revusiran(0)
- rezafungin(0)
- Rezafungin acetate(0)
- rhPSMA-7.3 (18F)(0)
- Ribavirin(0)
- ribavirin(0)
- Ribitol(0)
- Ribociclib(0)
- ribociclib(0)
- ribociclib succinate(0)
- Ridinilazole (hydrate)(0)
- rifampicin(0)
- Rifamycin(0)
- rifamyciun(0)
- rilmenidine(0)
- Rilonacept(0)
- rilonacept(0)
- rilpivirine(0)
- Rilpivirine (hydrochloride)(0)
- rilpivirine hydrochloride(0)
- riltozinameran and tozinameran(0)
- Riluzole(0)
- riluzole(0)
- Rilzabrutinib(0)
- Rimegepant(0)
- rimegepant(0)
- rimexolone(0)
- Rimiducid(0)
- rimonabant(0)
- riociguat(0)
- ripasudil(0)
- ripretinib(0)
- Risankizumab(0)
- risankizumab(0)
- Risdiplam(0)
- risdiplam(0)
- Risdiplam (RO7034067)(0)
- risedronate(0)
- risedronate sodium(2)
- Risedronate sodium(0)
- risedronic acid(1)
- risperidone(2)
- Risperidone(0)
- ritlecitinib(0)
- ritlecitinib tosilate(0)
- ritodrine(1)
- ritonavir(1)
- rituximab(0)
- rivaroxaban(0)
- rivastigmine(0)
- rivastigmine hydrogen tartrate(0)
- Rivoceranib (mesilate)(0)
- Rivogenlecleucel(0)
- rizatriptan(1)
- Rizatriptan(0)
- rizatriptan benzoate(1)
- robenacoxib(0)
- rocuronium(0)
- rofecoxib(1)
- roflumilast(0)
- Rogaratinib(0)
- rolapitant(0)
- Rolofylline(0)
- romidepsin(0)
- romifidine(0)
- romiplostim(0)
- Romosozumab(0)
- romosozumab(0)
- ropeginterferon alfa-2b(0)
- ropinirole(2)
- ropinirole hydrochloride(1)
- ropivacaine(0)
- rosiglitazone(0)
- Rosiglitazone Maleate(0)
- rosuvastatin(1)
- Rosuvastatin(0)
- Rosuvastatin (calcium)(0)
- rosuvastatin calcium(1)
- rotavirus serotype 1 reassortant, rotavirus serotype 2 reassortant, rotavirus serotype 3 rhesus, rotavirus serotype 4 reassortant(0)
- rotavirus serotype G1, serotype G2, serotype G3, serotype G4, serotype P1(0)
- rotavirus type G1(0)
- rotavirus type G2(0)
- rotavirus type G3(0)
- rotavirus type G4(0)
- rotavirus type P1A[8](0)
- rotavirus vaccine(0)
- rotavirus vaccine, live(0)
- rotigotine(0)
- Rovalpituzumab tesirine(0)
- Roxadustat(0)
- roxadustat(0)
- roxithromycin(0)
- Rozanolixizumab(0)
- rozanolixizumab(0)
- Rozibafusp alfa(0)
- RSV preF protein(0)
- RTS,S [Portion of P. falciparum circumsporozoite protein fused with hepatitis B surface antigen (RTS), and combined with hepatitis B surface antigen (S)](0)
- rubella vaccine(0)
- rubella virus Wistar RA 27/3 strain (live, attenuated)(0)
- Rubidium (82Rb)(0)
- Rubidium (82Rb) chloride(0)
- Rubitecan(0)
- rucaparib(1)
- Rucaparib camsylate(1)
- Rufinamide(0)
- rufinamide(0)
- rufloxacin(1)
- runrapiq(0)
- rupatadine(0)
- Rupatadine fumarate(0)
- rurioctocog alfa pegol(0)
- Rusfertide(0)
- ruxolitinib(0)
- ruxolitinib (as phosphate)(0)
- Ruxolitinib (phosphate)(0)
- ruxolitinib phosphate(0)
- rye pollen(0)
- sabatolimab(0)
- saccharomyces boulardii(0)
- Sacituzumab govitecan(0)
- sacituzumab govitecan(0)
- sacubitril(1)
- safinamide(0)
- safinamide methanesulfonate(0)
- salbutamol(3)
- salbutamol sulfate(0)
- salicylic acid(0)
- salmeterol(5)
- salmeterol xinafoate(0)
- Salmon pancreas disease vaccine (recombinant DNA plasmid)(0)
- samarium (153Sm) lexidronam pentasodium(0)
- samarium [153Sm] lexidronam pentasodium(0)
- sapropterin(0)
- Sapropterin dihydrochloride(0)
- saquinavir(0)
- sarilumab(0)
- Sarizotan (hydrochloride)(0)
- sarolaner(0)
- SARS-CoV-2 (Omicron XBB.1.5) recombinant spike protein(0)
- SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)(0)
- SARS-CoV-2 virus, beta-propiolactone inactivated adjuvanted with CpG 1018 (VLA2001)(0)
- SARS-CoV-2 virus recombinant spike (S) protein receptor binding domain (RBD) fusion heterodimer – B.1.351-B.1.1.7 strains(0)
- SARS-CoV2 prefusion Spike delta TM (CoV-2 preS dTM) adjuvanted with AS03(0)
- SARS CoV-2 (Original) recombinant spike protein(0)
- Sasanlimab(0)
- satoreotide trizoxetan(0)
- satralizumab(0)
- Savolitinib(0)
- savolitinib(0)
- saxagliptin(1)
- Saxagliptin(0)
- saxagliptin hydrochloride(1)
- scopolamine(0)
- sebelipase alfa(0)
- Secale cereale(0)
- Secretin(0)
- Secukinumab(0)
- secukinumab(0)
- Seladelpar(0)
- selamectin(0)
- Selatogrel(0)
- Selepressin(0)
- Selexipag(0)
- selexipag(0)
- Selinexor(0)
- selinexor(0)
- Selonsertib(0)
- Selpercatinib(0)
- selpercatinib(0)
- Seltorexant(0)
- Selumetinib(0)
- selumetinib(0)
- Selumetinib sulfate(0)
- selvacovatein(0)
- semaglutide(0)
- semuloparin sodium(0)
- Senaparib(0)
- sepofarsen(0)
- SER-109 (Eubacterial Spores, Purified Suspension, Encapsulated)(0)
- Serelaxin(0)
- serelaxin(0)
- serine(0)
- Serlopitant(0)
- serotype 26 adenovirus encoding mosaic 1 HIV-1 envelope protein (Ad26.Mos1.Env)(0)
- serotype 26 adenovirus encoding mosaic 1 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos1.Gag-Pol)(0)
- serotype 26 adenovirus encoding mosaic 2 HIV-1 group-specific antigen and polymerase proteins (Ad26.Mos2.Gag-Pol)(0)
- serotype 26 adenovirus encoding mosaic 2S HIV-1 envelope protein (Ad26.Mos2S.Env) [Ad26.Mos4.HIV](0)
- Serplulimab(0)
- sertindole(1)
- sertraline(2)
- setanaxib(0)
- Setmelanotide(0)
- setmelanotide(0)
- Setrusumab(0)
- sevelamer(0)
- sevelamer carbonate(0)
- sevelamer hydrochloride(0)
- Severe acute respiratory syndrome coronavirus 2 recombinant spike protein nanoparticle vaccine/ matrix-M1 adjuvant (NVX-CoV2373)(0)
- sevoflurane(0)
- shingles (herpes zoster) vaccine (live)(0)
- sialic acid(0)
- Sibeprenlimab(0)
- sibutramine(1)
- sildenafil(0)
- sildenafil citrate(0)
- silodosin(0)
- siltuximab(0)
- silver sulfadiazine(0)
- simeprevir(1)
- simeticone(0)
- simoctocog alfa(1)
- Simtuzumab(0)
- simvastatin(2)
- Single-stranded, 5’-capped messenger RNA (mRNA) produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2(0)
- Single-stranded, 5’-capped messenger RNA produced using a cell-free in vitro transcription from the corresponding DNA templates, encoding the viral spike (S) protein of SARS-CoV-2(0)
- Single-stranded 5' capped mRNA encoding the respiratory syncytial virus glycoprotein F stabilized in the prefusion conformation (mRNA-1345)(0)
- Single chain urokinase plasminogen activator (scuPA)(0)
- Single strain of non-genetically modified Prevotella histicola (EDP1815)(0)
- Sintilimab(0)
- siponimod(0)
- Siponimod (hemifumarate)(0)
- Siponimod fumaric acid(0)
- Sirolimus(0)
- sirolimus(0)
- sirukumab(0)
- sitagliptin(1)
- Sitagliptin (hydrochloride monohydrate)(0)
- sitagliptin fumarate(0)
- sitagliptin hydrochloride(0)
- sitagliptin hydrochloride monohydrate(0)
- sitagliptin phosphate monohydrate(0)
- sitaxentan sodium(0)
- sitravatinib (malate)(0)
- Sivopixant(0)
- Skeletal-muscle-derived cells(0)
- Skimmed cow's milk powder(0)
- Small interfering RNA targeting human TRPV1 mRNA(0)
- smallpox and monkeypox vaccine (Live Modified Vaccinia Virus Ankara)(0)
- Sodium acetate(0)
- sodium acetate trihydrate(0)
- Sodium alginate oligosaccharide(0)
- sodium ascorbate(0)
- Sodium benzoate(0)
- Sodium benzylpenilloate(0)
- sodium chloride(0)
- sodium citrate(0)
- sodium ferric gluconate(1)
- Sodium fluoride (18F)(0)
- sodium glycerophosphate(0)
- sodium glycerophosphate hydrated(0)
- sodium hydroxide(0)
- sodium iodide (131I)(0)
- sodium iron gluconate (parenteral preparations)(0)
- sodium lactate(0)
- sodium oxybate(1)
- Sodium phenylbutyrate(1)
- sodium phenylbutyrate(1)
- sodium salicylate(0)
- sodium sulfate(0)
- sodium sulfate (as sodium sulfate anhydrous)(0)
- sodium sulfate anhydrous(0)
- sodium sulphate(0)
- Sodium sulphate anhydrou(0)
- sodium tetradecyl sulfate(0)
- Sodium thiosulfate(0)
- sodium thiosulfate(0)
- sodium valproate(2)
- Sodium valproate(0)
- sodium zirconium cyclosilicate(0)
- Sofosbuvir(1)
- sofosbuvir(1)
- solifenacin(0)
- Solifenacin (succinate)(0)
- Solifenacin (succinate)(0)
- Solithromycin(0)
- Solriamfetol(0)
- solriamfetol(0)
- solriamfetol hydrochloride(0)
- Soluble human T cell receptor (TCR) directed against the glycoprotein 100 (gp100) melanoma antigen, linked to the single-chain variable fragment (ScFv) domain of the anti-cluster of differentiation 3 (CD3) antibody(0)
- Soluble yeast beta-1,3/1,6-glucan(0)
- Somapacitan(0)
- somapacitan(0)
- somatrogon(0)
- somatropin(5)
- sonidegib(0)
- sonidegib diphosphate(0)
- sorafenib(0)
- Sorafenib (as tosilate)(0)
- Sorafenib tosilate(0)
- Sotagliflozin(0)
- sotagliflozin(0)
- sotalol(0)
- sotatercept(0)
- Soticlestat(0)
- sotorasib(0)
- Sotrastaurin acetate(0)
- Sotrovimab(0)
- sotrovimab(0)
- soya bean oil(0)
- Soybean oil(0)
- Soybean phospholipids (oral use)(0)
- sparfloxacin(1)
- Sparsentan(0)
- Spartalizumab(0)
- spectinomycin(0)
- Spesolimab(0)
- spesolimab(0)
- spheroids of human autologous matrix-associated chondrocytes(0)
- spinosad(0)
- spiramycin(0)
- spiramycin adipate(0)
- spirapril(1)
- spironolactone(0)
- spironolactone metformin hydrochloride(0)
- Split influenza virus, inactivated (B/Victoria lineage)(0)
- split influenza virus, inactivated, containing antigen*: A/California/7/2009 (H1N1)v like strain (X-179A)*propagated in eggs.(0)
- Split influenza virus, inactivated, containing antigen: A/California/7/2009 (H1N1)v like strain (X-179A)(0)
- split influenza virus, inactivated, containing antigen: A/VietNam/1194/2004 (H5N1) like strain used (NIBRG-14)(0)
- Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), adjuvanted(0)
- Split influenza virus, inactivated containing antigen equivalent to A/California/7/2009 (H1N1)-like strain (A/California/7/2009 (NYMC X-179A)), non-adjuvanted(0)
- Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain(0)
- Split influenza virus, inactivated containing antigens equivalent to the A/H1N1-like strain / split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain / split influenza virus, inactivated containing antigens equivalent to the B-like strain(0)
- Split influenza virus, inactivated containing antigens equivalent to the A/H3N2-like strain(0)
- Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Victoria lineage)(0)
- Split influenza virus, inactivated containing antigens equivalent to the B-like strain (B/Yamagata lineage)(0)
- Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Victoria lineage)(0)
- Split influenza virus, inactivated containing antigens equivalent to the B-like strain (Yamagata lineage)(0)
- split influenza virus inactivated, containing antigen equivalent to A/California/07/2009 (H1N1)-derived strain used NYMC X-179A(0)
- staphylococcus aureus(0)
- Staphylococcus aureus (CP8) strain SP 140 inactivated, expressing slime-associated antigenic complex(0)
- stavudine(0)
- stiripentol(0)
- streptococcus aga(0)
- Streptococcus equi vaccine (recombinant proteins)(0)
- streptococcus mitis(0)
- streptococcus pneumoniae(0)
- streptococcus pyogenes(0)
- Streptococcus uberis vaccine (inactivated)(0)
- streptococcus viridans vaccine(0)
- strontium (89sr) chloride(0)
- strontium ranelate(1)
- strontium succinate(0)
- Sucroferric oxyhydroxide(0)
- sucroferric oxyhydroxide(0)
- sufentanil(0)
- sufentanil citrate(0)
- sugammadex(0)
- sugammadex sodium(0)
- Sugemalimab(0)
- Sulbactam(0)
- sulesomab(0)
- sulfadiazine(0)
- sulfadimethoxine(0)
- sulfadimidine sodium(0)
- sulfaguanidine(0)
- sulfamethizole(0)
- Sulfamethoxazole(0)
- sulfamethoxazole(0)
- sulfamethoxypyridazine(0)
- sulfametrole(0)
- sulfogaiacol(0)
- Sulindac(0)
- sulindac(0)
- sulphur hexafluoride(0)
- sulprostone(0)
- sultamicillin(0)
- sumatriptan(0)
- sumatriptan succinate(0)
- sunitinib(0)
- Sunvozertinib(0)
- Surotomycin(0)
- surufatinib(0)
- susoctocog alfa(1)
- sutimlimab(0)
- Suvecaltamide (hydrochloride)(0)
- suxamethonium(0)
- swine(0)
- synthetic analogue of eel calcitonin(0)
- Synthetic double-stranded siRNA oligonucleotide directed against antithrombin mRNA and covalently linked to a ligand containing three N-acetylgalactosamine residues (fitusiran)(0)
- Synthetic double-stranded siRNA oligonucleotide directed against p53 mRNA (QPI-1002)(0)
- Synthetic double-stranded siRNA oligonucleotide directed against transthyretin mRNA(0)
- Synthetic double-stranded siRNA oligonucleotide targeted against transthyretin mRNA, with six phosphorothioate linkages in the backbone, and nine 2’-fluoro and thirty-five 2’-O-methyl nucleoside residues in the sequence, which is covalently linked via a phosphodiester group to a ligand containing three N-acetylgalactosamine residues (ALN-65492)(0)
- Synthetic double-stranded small interfering RNA (siRNA) oligonucleotide specific to the mRNA of the caspase 2 gene(0)
- Synthetic hypericin(0)
- Synthetic peptide analogue of GnRF conjugated to diptheria toxoid(0)
- Synthetic ribonucleic acid oligonucleotide directed against superoxide dismutase 1 messenger ribonucleic acid (tofersen)(0)
- synthetic surfactant protein B analogue (CHF 5633)(0)
- synthetic surfactant protein C analogue(0)
- T-cell bispecific antibody targeting carcinoembryonic antigen expressed on tumor cells and CD3 epsilon chain present on T-cells(0)
- T-lymphocytes enriched leukocyte preparation depleted ex vivo of host host-alloreactive T cells using photodynamic treatment (ATIR101)(0)
- Tabalumab(0)
- Tabelecleucel(0)
- tabelecleucel(0)
- tacrolimus(2)
- tacrolimus monohydrate(0)
- tadalafil(0)
- tafamidis(0)
- Tafamidis meglumine(0)
- Tafasitamab(0)
- tafasitamab(0)
- Tafluprost(0)
- tagraxofusp(0)
- talazoparib(0)
- Taliglucerase alfa(0)
- taliglucerase alfa(0)
- talimogene laherparepvec(0)
- talquetamab(0)
- tamoxifen(0)
- tamsulosin(0)
- tamsulosine(0)
- tamsulosin hydrochloride(0)
- Tanezumab(0)
- tanezumab(0)
- taniborbactam(0)
- tapentadol(0)
- Tapentadol (hydrochloride)(0)
- Tapotoclax(0)
- Taranabant(0)
- Tarlatamab(0)
- Tartaric acid(0)
- tasimelteon(0)
- tasipimidine(0)
- tasonermin(0)
- Taspoglutide(0)
- taurine(0)
- tauroselcholic (75Se) acid(0)
- tauroselcholic [75Se] acid(0)
- Tauroursodeoxycholic acid(0)
- tavapadon(0)
- tazarotene(1)
- Tazarotene(0)
- tazobactam(1)
- tazobactam sodium(0)
- tebentafusp(0)
- technetium (99mTc) bicisate(0)
- technetium (99mTc) exametazime(0)
- technetium (99mTc) hynic-octeotide(0)
- technetium (99mtc) mebrofenin(0)
- technetium (99mTc) pertechnetate(0)
- technetium (99mTc) sestamibi(0)
- technetium (99mTc) tetrofosmin(0)
- Technetium (99mTc) trofolastat chloride(0)
- Teclistamab(0)
- teclistamab(0)
- Tecovirimat(0)
- Tecovirimat (monohydrate)(0)
- tecovirimat monohydrate(0)
- tedizolid (phosphate)(0)
- tedizolid phosphate(0)
- teduglutide(0)
- tegafur(1)
- tegaserod(0)
- teicoplanin(2)
- Teicoplanin(0)
- telaprevir(0)
- telavancin(0)
- Telavancin (hydrochloride)(0)
- telbivudine(0)
- Telcagepant(0)
- Telisotuzumab vedotin(0)
- Telitacicept(0)
- telithromycin(0)
- telmisartan(2)
- Telmisartan(1)
- telotristat ethyl(0)
- telotristat etiprate(0)
- Temelimab(0)
- temoporfin(0)
- temozolomide(0)
- Temsirolimus(0)
- temsirolimus(0)
- tenecteplase(0)
- tenofovir alafenamide(0)
- Tenofovir alafenamide (as fumarate)(0)
- tenofovir alafenamide fumarate(0)
- tenofovir disoproxil(0)
- tenofovir disoproxil (as fumarate)(0)
- tenofovir disoproxil (fumarate)(0)
- tenofovir disoproxil fumarate(0)
- tenofovir disoproxil maleate(0)
- tenofovir disoproxil phosphate(0)
- tenofovir disoproxil succinate(0)
- tenogenic primed equine allogeneic peripheral blood-derived mesenchymal stem cells(0)
- tenonitrozole(0)
- tenoxicam(0)
- Teplizumab(0)
- Tepotinib(0)
- tepotinib(0)
- Tepotinib hydrochloride monohydrate(0)
- tepoxalin(0)
- Teprotumumab(0)
- terazosin(0)
- terbinafine(0)
- Terbinafine hydrochloride(0)
- terbinafine hydrochloride(0)
- terbutaline(1)
- terfenadine(1)
- Terguride (hydrogenmaleate)(0)
- Teriflunomide(0)
- teriflunomide(0)
- teriparatide(0)
- terlipressin(1)
- Terlipressin(0)
- terpine(1)
- terpineol(1)
- tesamorelin(0)
- testosterone(1)
- Testosterone(0)
- testosterone undecanoate(0)
- testosterone undecylat(0)
- tetanus(0)
- tetanus protein(0)
- Tetanus toxoid(0)
- tetanus toxoid(0)
- tetanus toxoid adsorbed on aluminium hydroxide, hydrated(0)
- tetanus vaccine(0)
- tetanus vaccines(0)
- tetrabenazine(0)
- Tetrabenazine (ADV6979)(0)
- tetracaine(0)
- Tetracaine (hydrochloride)(0)
- tetracaine hydrochloride(0)
- tetracycline(0)
- Tetracycline (hydrochloride)(0)
- Tetracycline hydrochloride(0)
- tetrazepam(1)
- Tetrofosmin(0)
- tetryzoline(0)
- tezacaftor(0)
- tezepelumab(0)
- TGp1PTH1-34 L-Asparaginyl-L-glutaminyl-L-glutamyl-L-glutaminyl-L-valy1-L-seryl-L-prolyl-L-leucyl-L-tyrosyl-L-lysil-L-asparaginyl-L-arginyl-L-seryl-L-valyl-L-seryl-L-glutamyl-L-isoleucyl-L-glutaminyl-Lleucyl-L-methionyl-L-histidyl-L-asparaginyl-L-leucyl-L-glycyl-L-lysyl-L-histidyl-L-leucyl-Lasparaginyl-L-seryl-L-methionyl-L-glutamyl-L-arginyl-L-valyl-L-glutamyl-L-tryptophanyl-L-leucyl-L-arginyl-L-lysyl-L-lysyl-L-leucyl-L-glutamyl-L-asparty-L-valyl-L-histidyl-L-asparaginyl-Lphenylalanine-, acetate salt(0)
- Thalidomide(0)
- thalidomide(0)
- Theobroma cacao L.(0)
- theophylline(0)
- The whole range of unmanipulated autologous mononuclear cells derived from human umbilical cord blood (Hau-UCB-mnc)(0)
- thiamine(0)
- Thiamine (hydrochloride)(0)
- thiamine hydrochloride(1)
- thiamine nitrate(1)
- thiamphenicol(0)
- Thienopyrimidine Derivative(0)
- thiocolchicoside(1)
- thiopental(0)
- thiotepa(0)
- threonine(0)
- thrombin(0)
- thrombin, aprotinin(0)
- thrombin alfa(0)
- Thrombomodulin alfa(0)
- thyrotropin alfa(0)
- tiagabine(0)
- tiamulin hydrogen fumarate(0)
- tianeptine(0)
- tiapride(0)
- tibolone(1)
- Ticagrelor(0)
- ticagrelor(0)
- tick-borne encephalitis vaccine (inactivated)(0)
- ticlopidine(0)
- Tifacogin(0)
- Tigecycline(0)
- tigecycline(0)
- tigilanol tiglate(0)
- Tigolaner(0)
- tigolaner(0)
- Tigulixostat(0)
- Tildacerfont(0)
- tildipirosin(0)
- tildrakizumab(0)
- tilmanocept(0)
- tilmicosin(0)
- tilsotolimod(0)
- tiludronic acid(1)
- timolol(0)
- timolol maleate(1)
- Timrepigene emparvovec(0)
- tioconazole(0)
- tiotropium(0)
- Tiotropium bromide (monohydrate)(0)
- Tipifarnib(0)
- tipiracil(0)
- tipiracil hydrochloride(0)
- tipranavir(0)
- Tiprelestat(0)
- Tiragolumab(0)
- Tirasemtiv(0)
- tirbanibulin(0)
- Tirofiban(1)
- tirofiban(0)
- Tirzepatide(0)
- tirzepatide(0)
- tisagenlecleucel(0)
- Tislelizumab(0)
- tislelizumab(0)
- tisotumab vedotin(0)
- titanium dioxide(0)
- Tivantinib(0)
- tivozanib(0)
- tivozanib hydrochloride monohydrate(0)
- tixagevimab(0)
- Tixagevimab (AZD8895)(0)
- tixocortol(0)
- tixocortol pivalate(0)
- tizanidine(0)
- tobramycin(1)
- Tobramycin(0)
- toceranib(0)
- tocilizumab(0)
- tocofersolan(0)
- tocopherol(0)
- Tofacitinib(2)
- tofacitinib(2)
- tofacitinib citrate(0)
- Tofersen(0)
- tolcapone(0)
- Tolonium chloride(0)
- tolperisone(3)
- tolperisone hydrochloride(1)
- tolterodine(0)
- toltrazuril(0)
- Tolvaptan(0)
- tolvaptan(0)
- Tominersen(0)
- topiramate(2)
- Topiramate(0)
- topotecan(0)
- topotecan (as hydrochloride)(0)
- Torasemide(0)
- Torasemide anhydrous(0)
- toremifene(0)
- Toripalimab(0)
- Tozinameran(0)
- tozinameran(0)
- trabectedin(1)
- Tralokinumab(0)
- tralokinumab(0)
- tramadol(1)
- Tramadol(0)
- tramadol hydrochloride(1)
- Tramadol hydrochloride(0)
- trametinib(0)
- Trametinib (dimethyl sulfoxide)(0)
- Trametinib dimethyl sulfoxide(0)
- trandolapril(1)
- tranexamic acid(2)
- trastuzumab(0)
- trastuzumab deruxtecan(0)
- Trastuzumab duocarmazine(0)
- trastuzumab emtansine(0)
- travoprost(0)
- trazodone(0)
- Trazodone (hydrochloride)(0)
- Tremelimumab(0)
- tremelimumab(0)
- Trenonacog alfa(0)
- Treosulfan(0)
- treosulfan(0)
- Treprostinil(0)
- treprostinil(0)
- Treprostinil (palmitil)(0)
- Treprostinil diethanolamine(0)
- treprostinil diolamine(0)
- Treprostinil sodium(0)
- tretinoin(1)
- Tretinoin(0)
- triacetonamine tosilate(0)
- triamcinolone(0)
- Triamcinolone acetonide(0)
- triamterene(0)
- triazolam(0)
- triclabendazole(0)
- trientine(0)
- trientine dihydrochloride(0)
- Trientine tetrahydrochloride(0)
- Trifarotene(0)
- trifluridine(0)
- triglyceride combinations(0)
- Triglycerides medium-chain(0)
- Trilaciclib (dihydrochloride)(0)
- trilostane(0)
- trimegestone(0)
- Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C, adjuvanted with aluminium phosphate [Clade C gp140](0)
- Trimeric, recombinant HIV-1 envelope glycoprotein 140 of Clade C / trimeric, recombinant HIV-1 envelope glycoprotein 140 containing motifs of multiple HIV-1 variants, adjuvanted with aluminium phosphate [Clade C gp140/ Mosaic gp140](0)
- trimetazidine(4)
- Trimetazidine (dihydrochloride)(0)
- trimetazidine dihydrochloride(1)
- trimetazidine hydrochloride(1)
- trimethoprim(1)
- trimethylphloroglucinol(0)
- triprolidine(0)
- Triptorelin(0)
- triptorelin(0)
- Triptorelin acetate(0)
- Tris(hydroxymethyl)aminomethane trihydrate (PF-05221304-82)(0)
- Trivalent, seasonal, recombinant influenza hemagglutinin vaccine(0)
- Tropicamide(0)
- Tropifexor(0)
- Troriluzole hydrochloride(0)
- trovafloxacin(0)
- tryptophan(0)
- Tuberculin purified protein derivative(0)
- Tucatinib(0)
- tucatinib(0)
- tulathromycin(0)
- Tulobuterol(0)
- turkey herpes virus, expressing infectious bursal disease virus and avian infectious laryngotracheitis virus, strain HVT/IBD/ILT, live(0)
- turkey herpes virus, strain FC-126, expressing infectious bursal disease virus VP2 protein, live(0)
- Turkey herpesvirus, strain FC126, Live(0)
- Turkey herpes virus, strain HVT-IBD, expressing infectious bursal disease virus VP2 protein, live(0)
- Turkey herpesvirus, strain HVT-ND-H5 (cell-associated), expressing fusion protein gene of Newcastle disease virus and haemagglutinin gene of Avian influenza virus subtype H5(0)
- Turkey herpes virus, strain rHVT/ND/IBD, expressing the fusion protein of Newcastle disease virus and the VP2 protein of infectious bursal disease virus, live recombinant(0)
- turkey herpes virus, strain rHVT/ND expressing Newcastle disease virus, live(0)
- Turkey rhinotracheitis virus, strain 1062, live(0)
- turoctocog alfa(1)
- Turoctocog alfa pegol(0)
- turoctocog alfa pegol(0)
- turoctocog alpha(0)
- turpentine (essence oil)(0)
- turpentine oil(0)
- tylosin(0)
- tylosin tartrate(0)
- tylvalosin(0)
- typhoid polysaccharide vaccine(0)
- typhoid vaccine(0)
- tyrosine(0)
- Ublituximab(0)
- ublituximab(0)
- Ulimorelin(0)
- ulipristal(2)
- ulipristal acetate(3)
- Umbralisib tosylate(0)
- umeclidinium(0)
- umeclidinium bromide(0)
- upadacitinib(1)
- Upadacitinib (ABT-494)(0)
- Upifitamab rilsodotin(0)
- urapidil(0)
- urea(0)
- urea (13C)(0)
- Urofollitropin(0)
- urokinase(1)
- Ursodeoxycholic acid(0)
- Ursodoxicoltaurine(0)
- Ustekinumab(0)
- ustekinumab(0)
- vaborbactam(0)
- vaccine against babesiosis in dogs(0)
- vaccine against coccidiosis in chickens(0)
- vaccine against equine influenza and tetanus in horses(0)
- vaccine against equine influenza in horses(0)
- vaccine against feline leukaemia(0)
- vaccine against feline viral rhinotracheitis, calicivirosis, panleucopenia and leukaemia in cats(0)
- vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia, feline leukeamia and feline Chlamydophila infections(0)
- Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline Chlamydophila infections(0)
- Vaccine against feline viral rhinotracheitis, feline calicivirosis, feline panleucopenia and feline leukaemia(0)
- vaccine against feline viral rhinotracheitis, feline calicivirosis and feline Chlamydophila infections(0)
- vaccine against feline viral rhinotracheitis, feline calicivirosis and feline panleucopenia(0)
- vaccine against feline viral rhinotracheitis and feline calicivirosis(0)
- vaccine to aid in prevention of West Nile virus(0)
- Vaccine to prevent Leptospira infections in dogs(0)
- vaccine to provide passive immunity to the progeny against E. coli in pigs(0)
- vaccine to provide passive immunity to the progeny against Escherichia coli and Clostridium perfringens in pigs(0)
- Vadadustat(0)
- vadadustat(0)
- valaciclovir(1)
- Valaciclovir (hydrochloride)(0)
- valdecoxib(0)
- Valganciclovir(0)
- valine(0)
- valnemulin(0)
- Valoctocogene roxaparvovec(0)
- valoctocogene roxaparvovec(0)
- valpriomide(0)
- valproate(2)
- valproate bismuth(0)
- valproate magnesium(1)
- valproate pivoxil(0)
- valproate semisodium(2)
- valproic acid(4)
- Valproic acid(0)
- valpromide(2)
- valsartan(7)
- Vamorolone(0)
- vancomycin(1)
- Vancomycin(0)
- Vandetanib(0)
- vandetanib(0)
- vardenafil(0)
- varenicline(0)
- Varicella-zoster virus (inactivated)(0)
- varicella-zoster virus (live, attenuated)(0)
- varicella vaccine (live)(0)
- Varicella virus OKA strain (live, attenuated)(0)
- varicella zoster-immunoglobulin(0)
- vatinoxan hydrochloride(0)
- Vatiquinone(0)
- Vatreptacog alfa (activated)(0)
- vCP65 virus(0)
- vCP1338 virus(0)
- Vcp 2242 virus / Vcp1529 virus / Vcp1533 virus / vCP3011 virus(0)
- vecuronium bromide(0)
- vedaprofen(0)
- vedolizumab(0)
- velagliflozin(0)
- Velagliflozin L-proline monohydrate(0)
- velaglucerase alfa(0)
- Veliparib(0)
- velmanase alfa(0)
- velpatasvir(0)
- vemurafenib(0)
- Venetoclax(0)
- venetoclax(0)
- Venglustat(0)
- venlafaxine(4)
- Vepsitamab(0)
- veralipride(1)
- verapamil(0)
- Verdiperstat(0)
- Vericiguat(0)
- vericiguat(0)
- verinurad(0)
- Vernakalant hydrochloride(0)
- vernakalant hydrochloride(0)
- verteporfin(0)
- Vespula SPP. (802)(0)
- vestronidase alfa(0)
- Vibegron(0)
- vibegron(0)
- Vibostolimab(0)
- vibrio cholerae, strain cvd 103-hgr, live(0)
- vibrio cholerae 01(0)
- Vicriviroc maleate(0)
- vigabatrin(1)
- vilanterol(0)
- vilanterol trifenatate(0)
- vildagliptin(1)
- vildagliptin / metformin hydrochloride(0)
- Viltolarsen(0)
- Vimseltinib(0)
- vinflunine(0)
- vinorelbine(0)
- virus, live attenuated, measles, virus, live attenuated, mumps, virus, live attenuated, rubella, virus, live attenuated, varicella(0)
- Virus-like particle of SARS-CoV-2 spike protein (recombinant, adjuvant) (CoVLP)(0)
- vismodegib(0)
- Vitamin A (retinol and its esters)(0)
- vitamin D3(0)
- Voclosporin(0)
- voclosporin(0)
- Volanesorsen(0)
- volanesorsen(0)
- Volanesorsen sodium(0)
- Volasertib(0)
- Vonapanitase(0)
- vonicog alfa(0)
- Vonoprazan(0)
- von Willebrand factor(0)
- Vorapaxar(0)
- vorapaxar(0)
- vorapaxar sulfate(0)
- Vorasidenib (as hemicitrate, hemihydrate salt)(0)
- voretigene neparvovec(0)
- voriconazole(0)
- Vorinostat(0)
- Vortioxetine(0)
- vortioxetine(0)
- vosaroxin(0)
- Vosoritide(0)
- vosoritide(0)
- votumumab(0)
- Voxelotor(0)
- voxilaprevi(0)
- Vupanorse(0)
- vutrisiran(0)
- vutrisiran sodium(0)
- Wasp venom(0)
- West Nile fever vaccine (live recombinant)(0)
- West Nile recombinant canarypox virus (vCP2017 virus)(0)
- Whole-cell heat-inactivated bacterial strains of Escherichia coli, Klebsiella pneumoniae, Proteus vulgaris and Enterococcus faecalis(0)
- Whole virion, inactivated, containing antigen*: A/Vietnam/1194/2004 (H5N1)* produced in eggs(0)
- Whole virion influenza vaccine, inactivated containing antigen of strain A/California/07/2009 (H1N1)v(0)
- wild thyme(1)
- xevinapant(0)
- Xylazine(0)
- xylitol(0)
- xylometazoline(0)
- yellow fever vaccine (live)(0)
- Yellow fever virus, strain vYF-247(0)
- yttrium (90Y) chloride(0)
- yttrium [90Y] chloride(0)
- zafirlukast(0)
- zaleplon(0)
- Zamtocabtagene autoleucel(0)
- Zanamivir(0)
- Zandelisib(0)
- zanubrutinib(0)
- Zibotentan(0)
- ziconotide(0)
- zidebactam(0)
- zidovudine(0)
- Zilebesiran (sodium)(0)
- Ziltivekimab(0)
- Zilucoplan(0)
- zilucoplan(0)
- zinc(0)
- zinc gluconate(0)
- zinc oxide(0)
- zinc oxide, carrageenin(0)
- zinc oxide, titanium dioxide(0)
- Zinc sulfate(0)
- ziprasidone(0)
- zofenopril(3)
- Zolbetuximab(0)
- zoledronic acid(1)
- zoledronic acid monohydrate(0)
- Zoliflodacin(0)
- zolmitriptan(0)
- zolpidem(1)
- Zolpidem (tartrate)(0)
- zonisamide(0)
- zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted)(0)
- Zoonotic influenza vaccine (H5N8) (surface antigen, inactivated, adjuvanted)(0)
- Zorecimeran(0)
- Zuclopenthixol(0)
- zuranolone(0)
- Zuretinol (acetate)(0)
- [(3S)-6-({2',6'-Dimethyl-4'-[3-(methylsulfonyl) propoxy] biphenyl-3-yl}methoxy)-2,3-dihydro-1-benzofuran-3-yl]acetic acid hydrate (TAK-875)(0)
- [18F]CTT1057(0)
- [N-((2S,3R,3aS,3´R,4a´R,6S,6a´R,6b´S,7aR,12a´S,12b´S,Z)-3,6,11´,12b´-tetramethyl-2´,3a,3´,4,4´,4a´,5,5´,6,6´,6a´,6b´,7,7a,7´,8´,10´,12´,12a´,12b´-icosahydro-1´H,3Hspiro[furo[3,2-b]pyridine-2,9´-naphtho[2,1-a]azulene]-3´-yl)methanesulfonamide hydrochloride](0)
- Direct healthcare professional communication(116)
- Maximum residue limits(0)
- Opinions on maximum residue limits(0)
- Shortages(0)
- Herbal medicines(199)
- Medicines(2054)
- Opinions on medicines for use outside EU(16)
- Orphan designations(2937)
- Paediatric investigation plans(2803)
- Post-authorisation procedures for medicines(113)
- Periodic safety update report single assessments (PSUSA)(2152)
- (-)Referrals(448)
- Sortis(4)
- Diovan(3)
- Etoricoxib(3)
- Nimesulide(3)
- Arimidex(2)
- Celecoxib(2)
- Coversyl(2)
- Cozaar(2)
- Fibrinogencontaining solutions for sealant authorised for administration by spray application(2)
- Gadoliniumcontaining contrast agents(2)
- Genotropin(2)
- Hydroxyethyl starch solutions for infusion(2)
- Isotretinoin(2)
- Lumiracoxib(2)
- Norditropin(2)
- Octagam(2)
- Octegra(2)
- Prozac(2)
- Sibutramine(2)
- Valproate and related substances(2)
- Zinbryta(2)
- Actilyse(1)
- Actira(1)
- Activelle(1)
- Adakveo(1)
- Adartrel(1)
- Adrenaline autoinjectors(1)
- Aggrastat(1)
- Agopton(1)
- Agreal(1)
- Alcover and associated names(1)
- Alendronate HEXAL(1)
- Alkem(1)
- Almitrinecontaining medicines(1)
- Alvesco(1)
- Amaryl(1)
- Ambroxol and bromhexinecontaining medicines(1)
- Amfepramonecontaining medicinal products(1)
- Amlodipin Woerwag(1)
- Amlovita(1)
- Amoxil(1)
- AngiotensinIIreceptor antagonists sartans containing a tetrazole group(1)
- Anorectics(1)
- Antifibrinolytic medicines(1)
- Aprotinin(1)
- Arcoxia(1)
- Atacand(1)
- Atacand Plus(1)
- Augmentin(1)
- Avalox(1)
- Avelox(1)
- Azithromycincontaining medicinal products for systemic use(1)
- Bacterial lysatescontaining medicinal products indicated for respiratory conditions(1)
- Basiron AC and associated names(1)
- Baxter dialysis solutions(1)
- Belanette(1)
- Benfluorex(1)
- Betavert N(1)
- Bicaluplex(1)
- Bicalutamide 150 mg(1)
- Bifril Teoula Zofepril Zopranol(1)
- Bisphosphonates(1)
- Bleomycin(1)
- Botox(1)
- Bromocriptinecontaining medicines indicated in the prevention or suppression of physiological lactation postpartum(1)
- Budesonide Sandoz(1)
- Budesonide SUN(1)
- Bufexamac(1)
- Buflomedil(1)
- Bupropion hydrochloride(1)
- Calcichew D3(1)
- Calcichew D3 mite(1)
- Calcitonin(1)
- Calcitonins(1)
- Calcitugg(1)
- Calcium Sandoz(1)
- Canazole(1)
- Carbamazepin Tillomed(1)
- Cardiostad(1)
- Cardioxane(1)
- Cardoreg 4mg(1)
- Carisoprodol(1)
- Caustinerf arsenical and Yranicid arsenical(1)
- Ceftriaxone Tyrol Pharma(1)
- Cefuroximaxetil(1)
- Cerivastatin(1)
- Chlormezanone(1)
- Ciclosporin IDL(1)
- Cilostazolcontaining medicines(1)
- Ciprofloxacin Bayer(1)
- Ciprofloxacin Hikma(1)
- Ciprofloxacin Kabi(1)
- Ciprofloxacin Nycomed(1)
- Cisapride(1)
- Clenil and associated names(1)
- Clobutinol(1)
- Clopidogrel Orion(1)
- Clopidogrel Teva(1)
- Codeinecontaining medicinal products for the treatment of cough or cold in paediatric patients(1)
- Codeinecontaining medicines(1)
- Combined hormonal contraceptives(1)
- Corlentor and Procoralan(1)
- Cozaar Comp(1)
- Crestor 5 mg(1)
- Crestor and associated names(1)
- Cyklof(1)
- Cymevene(1)
- Cyproterone and ethinylestradiolcontaining medicines(1)
- Cyproteronecontaining medicinal products(1)
- Dacarbazine Faulding(1)
- Daivobet(1)
- Daruph and Anafezyn(1)
- Dexamed and associated names(1)
- Dexamethasone Alapis(1)
- Dexrazoxane(1)
- Dextropropoxyphene(1)
- Diacereincontaining medicines for oral administration(1)
- Diclofenaccontaining medicines(1)
- Diclofenac epolamine 50 mg tablets(1)
- Diclofenac Sodium Spray Gel 4%(1)
- Didanosine(1)
- Dienogest/ethinylestradiolcontaining medicinal products indicated in acne(1)
- Diflucan(1)
- Diotop capsules(1)
- Diovan Comp(1)
- Directacting antivirals indicated for treatment of hepatitis C interferonfree(1)
- Docetaxel Teva Generics(1)
- Domperidonecontaining medicines(1)
- Doxagamma 4mg(1)
- Doxastad 4 mg(1)
- Doxazosin "Winthrop" 4mg(1)
- Doxazosin Retard "Arrow" 4 mg(1)
- Durogesic and associated names(1)
- Ecazide(1)
- Efexor(1)
- Efexor depot(1)
- Elidel(1)
- Emergency contraceptives(1)
- EMLA cream and associated names(1)
- Engerix B(1)
- Ergot derivatives(1)
- Ergotderived dopamine agonists(1)
- Escitalopram(1)
- Esmya(1)
- Estradiolcontaining 001% w/w medicinal products for topical use(1)
- EthinylestradiolDrospirenone 24+4(1)
- Ethirfin(1)
- Etifoxinecontaining medicinal products(1)
- Etopophos(1)
- Extraneal(1)
- Factor VIII(1)
- Famvir(1)
- Femara(1)
- Fenspiride containing medicinal products(1)
- Fentanylratiopharm Matrixpflaster(1)
- FentanylratiopharmTTS(1)
- Fentrix(1)
- Fibrates(1)
- Flolan(1)
- Floxyfral(1)
- Fluconazol Tiefenbacher 50mg 100mg 150mg 200mg capsules hard(1)
- Fluorouracil and fluorouracil related substances capecitabine tegafur and flucytosine containing medicinal products(1)
- Fluoxetin NM(1)
- Flupirtinecontaining medicinal products(1)
- Flupirtinecontaining medicines(1)
- Flurbiprofen Geiser(1)
- Flutiform(1)
- Fortipan Combi D(1)
- Fortum(1)
- Fosfomycincontaining medicinal products(1)
- Furosemide Vitabalans(1)
- Fusafungine containing medicinal products for oromucosal and nasal use(1)
- Gadograf Gadovist(1)
- Galantamine Stada(1)
- Gelisia and associated names(1)
- Gemzar(1)
- Glimepirida ParkeDavis(1)
- Glucomed(1)
- Glucophage/Glucophage Forte/Risidon/Dianben(1)
- Gluscan 500(1)
- Goserelin Cell Pharm(1)
- GVK Biosciences(1)
- Haldol and associated names(1)
- Haldol Decanoate and associated names(1)
- Havrix(1)
- Human papillomavirus vaccines Cervarix Gardasil Gardasil 9 Silgard(1)
- Hydroxyethyl starch HES containing medicinal products(1)
- Hydroxyprogesteronecontaining medicinal products(1)
- Hydroxyzine(1)
- Hypnovel(1)
- Ibuprofen and dexibuprofencontaining medicines(1)
- Ibuprofen Kabi 400 mg Infusionslösung and associated names(1)
- Ibuprofen NVT(1)
- Iclusig(1)
- Iffeza(1)
- Ifosfamide solutions(1)
- Ikorel and Dancor(1)
- Implanon(1)
- Inductos(1)
- Inhaled corticosteroids containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease(1)
- Intravenous ironcontaining medicinal products(1)
- Intravenous nicardipine medicines(1)
- Iodocasein and thiaminecontaining medicinal products(1)
- Janus kinase inhibitors JAKi(1)
- Kantos Master(1)
- Ketoconazolecontaining medicines(1)
- Ketoprofene Ethypharm LP(1)
- Ketoprofen topical(1)
- Kogenate Bayer and Helixate NexGen(1)
- Kytril(1)
- Lamictal(1)
- Lansopon 15 mg and 30 mg(1)
- Lansoprazol AbZPharma 15 mg and 30 mg(1)
- Lansoprazol CTArzneimittel 15 mg and 30 mg(1)
- Lansoprazole(1)
- Lansoprazol HEXAL 15 mg and 30 mg(1)
- Lansoprazolratiopharm 15 mg and 30 mg(1)
- Lartruvo(1)
- Laurina(1)
- Lederfoline(1)
- Lemtrada(1)
- Leponex(1)
- Lescol(1)
- Leuprorelincontaining depot medicinal products(1)
- Levact(1)
- Levonelle 1500 microgram tablets and associated names(1)
- Levothyroxine Alapis(1)
- Lidocain/Prilocain Idetec and associated names(1)
- Linoladiol N and Linoladiol HN(1)
- Lipitor(1)
- Lisinopril Biochemie(1)
- Lisonorm(1)
- Lopid(1)
- Loratadine(1)
- Loratadine and pseudoephedrine(1)
- Loratadine Sandoz 10(1)
- Loraxin(1)
- Losec(1)
- Lovenox and associated names(1)
- Maci(1)
- Medicinal products containing lactose of bovine origin for IV/IM use in acute allergic reactions(1)
- Medicines studied at Cetero Research facility(1)
- Menitorix(1)
- Mephatrim(1)
- Meprobamate(1)
- Merisone and associated names(1)
- Meronem(1)
- Metamizole containing medicinal products(1)
- Metformin and metformincontaining medicines(1)
- Methadone medicinal products for oral use containing povidone(1)
- Methocarbamol / paracetamolcontaining medicinal products(1)
- Methotrexate containing medicinal products(1)
- Methylphenidate(1)
- Methylphenidate Hexal(1)
- Methylphenidate Sandoz(1)
- Methysergidecontaining medicines(1)
- Metoclopramidecontaining medicines(1)
- Micrazym and associated names(1)
- Micro Therapeutic Research(1)
- Mifepristone Linepharma(1)
- Mizollen(1)
- Modafinil(1)
- Modifiedreleased oral opioids(1)
- Mometasone Furoate Sandoz(1)
- Monovalent and multivalent measles mumps rubella and / or varicella vaccines(1)
- Motilium(1)
- Moxifloxacin(1)
- MultiHance(1)
- Myderison(1)
- Myoson and associated names(1)
- Mysimba(1)
- Naftidrofuryl(1)
- Nanotop and associated names(1)
- Nasolam and associated names(1)
- Nasonex(1)
- Neurontin(1)
- Nifedipine Pharmamatch 30 and 60 mg(1)
- Nomegestrol and chlormadinone(1)
- Norfloxacin(1)
- Norsed Combi D(1)
- Norvasc(1)
- Novantrone and associated names(1)
- Novimp(1)
- Novosis Goserelin(1)
- Numeta G13%E and Numeta G16%E emulsion for infusion(1)
- Ocaliva(1)
- Okrido(1)
- Omega3 acid ethyl esters containing medicinal products for oral in use in secondary prevention after myocardial infarction(1)
- Oracea(1)
- Orlistat(1)
- Oxynal Targin and associated names(1)
- Paclitaxel Hetero and associated names(1)
- Panexcell(1)
- Pantoprazole Bluefish(1)
- Pantoprazole Olinka EMEA/H/A29/1169(1)
- Pantoprazole Olinka EMEA/H/A29/1170(1)
- Paracetamol/Ibuprofen 500 mg/150 mg filmcoated tablets(1)
- Paracetamol modifiedrelease(1)
- Paroxetine(1)
- Perlinring and associated names(1)
- Pharmaceutics International Inc(1)
- Pholcodine(1)
- Pholcodinecontaining medicinal products(1)
- Picato(1)
- Pidolma(1)
- Piroxicam(1)
- Plendil and associated names(1)
- Polymyxincontaining medicines(1)
- Pravachol(1)
- Preflucel(1)
- Prevora(1)
- Priligy(1)
- Priorix(1)
- Prograf(1)
- Prokanazol(1)
- Protelos and Osseor(1)
- Protium(1)
- Pseudoephedrinecontaining medicinal products(1)
- Quinolone and fluoroquinolonecontaining medicinal products(1)
- Rambis and associated names(1)
- Ranitidinecontaining medicinal products(1)
- Rapinyl(1)
- Remeron(1)
- Reninangiotensinsystem RASacting agents(1)
- Renitec(1)
- Retinoidcontaining medicinal products(1)
- Rigevidon(1)
- Risperdal(1)
- Risperdal Consta(1)
- Roaccutane(1)
- Rocephin(1)
- Rofecoxib(1)
- Rubraca(1)
- Sabumalin(1)
- Salmeterol and Fluticasone Propionate(1)
- Sandimmun and associated names(1)
- Sandimmun Neoral and associated names(1)
- Sandostatin and associated names(1)
- Sandostatin LAR and associated names(1)
- Sanohex(1)
- Saroten and associated names(1)
- Scandonest and associated names(1)
- Seasonique and associated names(1)
- Semler(1)
- Septanest and associated names(1)
- Seretide Diskus(1)
- Seretide Evohaler(1)
- Seroquel / Seroquel XR and associated names(1)
- Seroquel XR(1)
- Serotoninspecific reuptake inhibitors and serotoninnoradrenaline reuptake inhibitors(1)
- Sertindole(1)
- SGLT2 inhibitors(1)
- SGLT2 inhibitors previously canagliflozin(1)
- Shortacting betaagonists(1)
- Simvastatin Vale(1)
- Singulair(1)
- Somatropin(1)
- Stamaril(1)
- Substances related to nicotinic acid(1)
- Symbioflor 2(1)
- Synapse(1)
- Synchron(1)
- SynerKinase and associated names(1)
- Talam(1)
- Targocid and associated names(1)
- Tavanic(1)
- Tazocin(1)
- Teicoplanin Hospira(1)
- Terfenadine(1)
- Terlipressincontaining medicinal products indicated in the treatment of hepatorenal syndrome(1)
- Terpenic derivatives(1)
- Testosteronecontaining medicines(1)
- Tetrazepamcontaining medicines(1)
- Thiocolchicosidecontaining medicines(1)
- Tibolona Aristo and Tibocina and associated names(1)
- Tienam(1)
- Tobramycin VVB and associated names(1)
- Tolperisone(1)
- Topamax(1)
- Topiramate(1)
- Tredaptive Pelzont and Trevaclyn(1)
- Trimetadizine ratiopharm(1)
- Trimetazidine(1)
- Tritace(1)
- Tritazide(1)
- Tysabri(1)
- Ulipristal acetate 5mg medicinal products(1)
- Uman Big(1)
- Valebo and associated names(1)
- Valproate(1)
- Valproat Ratiopharm Chrono(1)
- Valtrex(1)
- Vancomycincontaining medicines(1)
- Vantas(1)
- Varilrix(1)
- Vascace(1)
- Vascace Plus(1)
- Vepesid(1)
- Viani Diskus(1)
- Viani Evohaler(1)
- Vigabatrin(1)
- Vivaglobin(1)
- Xalatan(1)
- Xefo(1)
- Xeljanz(1)
- Xeomin(1)
- Xofigo(1)
- Yasminelle(1)
- Yaz 24+4(1)
- Yondelis(1)
- Yvidually(1)
- Zagam(1)
- Zestril(1)
- Zinacef(1)
- Zinnat(1)
- Zocord(1)
- Zofenil Zopranol Bifril(1)
- Zoloft(1)
- Zolpidemcontaining medicines(1)
- Zydelig(1)
- Zynteglo(1)
- Zyrtec(1)
- 1st EMEA/CPMP Workshop for Patients Organisations Information and Participation(0)
- 1st EMEA workshop for patients organisations on Orphan Medicinal Products(0)
- 1st EMEA workshop with health professionals and academia on orphan medicinal products(0)
- 2nd DIA/EMA Innovation Forum Is the EU regulatory framework ready(0)
- 2nd EMEA Workshop on Orphan Medicinal Products for patients representatives and learned societies(0)
- 2nd Joint DIA/EMA/CMDh conference on variations(0)
- 2nd meeting of the Committee for Orphan Medicinal Products(0)
- 3rd meeting of the Committee for Orphan Medicinal Products(0)
- 3Rs Working Party(0)
- 3Rs Working Party 3RsWP plenary meeting Public session on the 2023 work plan(0)
- 3Rs Working Party 3RsWP plenary meeting Public session on the 2024 work plan(0)
- 4th meeting of the Committee for Orphan Medicinal Products(0)
- 4year overview of pharmacovigilance activities in the EU shows robust and effective medicines safety system(0)
- 5aminolevulinic acid hydrochloride(0)
- 5th industry stakeholder platform Operation of EU pharmacovigilance legislation(0)
- 5th meeting of the Committee for Orphan Medicinal Products(0)
- 6th industry stakeholder platform Operation of EU pharmacovigilance legislation(0)
- 6th meeting of the Committee for Orphan Medicinal Products(0)
- 7th meeting of the Committee for Orphan Medicinal Products(0)
- 7th meeting of the committee for veterinary medicinal products(0)
- 8th meeting of the Committee for Orphan Medicinal Products(0)
- 8th meeting of the committee for veterinary medicinal products(0)
- 9th meeting of the Committee for Orphan Medicinal Products(0)
- 9th meeting of the committee for veterinary medicinal products(0)
- 10 years of the Healthcare Professionals Working Party(0)
- 10 years of the Patients and Consumers Working Party(0)
- 10th anniversary of European Medicines Agency EMA Healthcare Professionals HCPWP Working Party meeting(0)
- 10th anniversary of European Medicines Agencys Patients and Consumers Working Party PCWP(0)
- 10th ESVAC report shows continued decrease in sales of veterinary antibiotics(0)
- 10th meeting of the committee for veterinary medicinal products(0)
- 11th meeting of the Committee for Orphan Medicinal Products(0)
- 11th meeting of the committee for veterinary medicinal products(0)
- 11th stakeholder forum on the pharmacovigilance legislation(0)
- 12th meeting of the Committee for Orphan Medicinal Products(0)
- 12th meeting of the committee for veterinary medicinal products(0)
- 12th pharmacovigilance stakeholder forum(0)
- 13th industry stakeholder platform operation of European Union EU pharmacovigilance(0)
- 13th meeting of the Committee for Orphan Medicinal Products(0)
- 13th meeting of the committee for veterinary medicinal products(0)
- 14 March 2013 World Kidney Day Acute kidney injury stop kidney attack(0)
- 14th EudraVigilance information day Adversedrugreaction reporting in the European Union and highlights of the new pharmacovigilance legislation(0)
- 14th industry stakeholder platform operation of European Union EU pharmacovigilance(0)
- 14th Joint European Medicines Agency/European network for Health Technology Assessment dialogue meeting(0)
- 14th meeting of the Committee for Orphan Medicinal Products(0)
- 14th meeting of the committee for veterinary medicinal products(0)
- 15% decrease in sales of veterinary antibiotics in Europe(0)
- 15th EudraVigilance information day(0)
- 15th industry stakeholder platform operation of European Union EU pharmacovigilance(0)
- 15th Joint European Medicines Agency/European network for Health Technology Assessment dialogue meeting(0)
- 15th meeting of the Committee for Orphan Medicinal Products(0)
- 15th meeting of the committee for veterinary medicinal products(0)
- 16th industry stakeholder platform operation of European Union EU pharmacovigilance(0)
- 16th Joint European Medicines Agency/European network for Health Technology Assessment dialogue meeting(0)
- 16th meeting of the Committee for Orphan Medicinal Products(0)
- 16th meeting of the committee for veterinary medicinal products(0)
- 17th industry stakeholder platform operation of European Union EU pharmacovigilance(0)
- 17th meeting of the Committee for Orphan Medicinal Products(0)
- 17th meeting of the committee for veterinary medicinal products(0)
- 18th industry stakeholder platform operation of European Union EU pharmacovigilance(0)
- 18th meeting of the Committee for Orphan Medicinal Products(0)
- 18th meeting of the committee for veterinary medicinal products(0)
- 19th meeting of the Committee for Orphan Medicinal Products(0)
- 19th meeting of the committee for veterinary medicinal products(0)
- 20 years of sampling and testing programme for medicines authorised for the EU(0)
- 20th anniversary conference highlights(0)
- 20th meeting of the Committee for Orphan Medicinal Products(0)
- 20th meeting of the committee for veterinary medicinal products(0)
- 21st meeting of the Committee for Orphan Medicinal Products(0)
- 21st meeting of the committee for veterinary medicinal products(0)
- 22nd meeting of the committee for veterinary medicinal products(0)
- 23rd meeting of the Committee for Orphan Medicinal Products(0)
- 23rd meeting of the committee for veterinary medicinal products(0)
- 24th meeting of the Committee for Orphan Medicinal Products(0)
- 24th meeting of the committee for veterinary medicinal products(0)
- 25 Years of EMA building learning and adapting to new challenges(0)
- 25th meeting of the Committee for Orphan Medicinal Products(0)
- 25th meeting of the committee for veterinary medicinal products(0)
- 26th meeting of the Committee for Orphan Medicinal Products(0)
- 26th meeting of the committee for veterinary medicinal products(0)
- 27th meeting of the Committee for Orphan Medicinal Products(0)
- 27th meeting of the committee for veterinary medicinal products(0)
- 28 February 2013 Rare Disease Day Rare disorders without borders(0)
- 28th meeting of the Committee for Orphan Medicinal Products(0)
- 28th meeting of the committee for veterinary medicinal products(0)
- 29th meeting of the Committee for Orphan Medicinal Products(0)
- 29th meeting of the committee for veterinary medicinal products(0)
- 30th meeting of the Committee for Orphan Medicinal Products(0)
- 30th meeting of the committee for veterinary medicinal products(0)
- 31Hindol3yl424methyl1piperazinyl4quinazolinyl1Hpyrrole25dione acetate11(0)
- 31st meeting of the Committee for Orphan Medicinal Products(0)
- 31st meeting of the committee for veterinary medicinal products(0)
- 32nd meeting of the Committee for Orphan Medicinal Products(0)
- 32nd meeting of the committee for veterinary medicinal products(0)
- 33rd meeting of the Committee for Orphan Medicinal Products(0)
- 33rd meeting of the committee for veterinary medicinal products(0)
- 34th meeting of the Committee for Orphan Medicinal Products(0)
- 34th meeting of the committee for veterinary medicinal products(0)
- 35th meeting of the Committee for Orphan Medicinal Products(0)
- 35th meeting of the committee for veterinary medicinal products(0)
- 36th meeting of the Committee for Orphan Medicinal Products(0)
- 37th meeting of the Committee for Orphan Medicinal Products(0)
- 38th meeting of the Committee for Orphan Medicinal Products(0)
- 67th meeting of the Committee for Proprietary Medicinal Products CPMP(0)
- 68th meeting of the Committee for Proprietary Medicinal Products CPMP(0)
- 69th meeting of the Committee for Proprietary Medicinal Products CPMP(0)
- 70th meeting of the Committee for Proprietary Medicinal Products CPMP(0)
- 2005 EMEA/CHMP Workshop on Biomarkers(0)
- 2006 EMEA/EFPIA Workshop on Biomarkers(0)
- 2006 EMEA/IFAHEurope Info Day Stimulating innovation and managing risk in market access to the veterinary sector(0)
- 2006 EUSwiss GMP China Training Workshop(0)
- 2009 annual workshop of the European Network of Paediatric Research at the European Medicines Agency(0)
- 2009 EMEAIFAHEurope info day(0)
- 2009 European Medicines Agency minor use minor species info day Procedural advice for classification and incentives for veterinary medicinal products indicated for minor use minor species limited markets(0)
- 2009 H1N1 influenza pandemic(0)
- 2010 annual workshop of the European Network of Paediatric Research at the European Medicines Agency(0)
- 2010 European Medicines Agency / International Federation for Animal Health Europe info day(0)
- 2011 annual workshop of the European Network of Paediatric Research at the European Medicines Agency(0)
- 2011 European Medicines Agency/IFAHEurope Info Day(0)
- 2012 annual report on EudraVigilance published(0)
- 2012 annual workshop on the European Network of Paediatric Research at the European Medicines Agency EnprEMA(0)
- 2012 European Medicines Agency/International Federation for Animal Health Europe info day(0)
- 2012 European Union Good Clinical Practice Inspectors Working Group workshop(0)
- 2013 annual report on EudraVigilance over 1 million adverse reaction reports received and processed(0)
- 2013 annual workshop of the European Network of Paediatric Research at the European Medicines Agency(0)
- 2013 European Medicines Agency / International Federation for Animal Health Europe info day(0)
- 2015 European Union Good Clinical Practice Inspectors Working Group workshop(0)
- 2015 Forum on bioequivalence inspections(0)
- 2015 Pharmacovigilance Inspectors Working Group training course(0)
- 2016 annual workshop of the European network of paediatric research EnprEMA at the European Medicines Agency(0)
- 2016 European Union Good Clinical Practice Inspectors Working Group workshop(0)
- 2017 annual workshop of the European network of paediatric research at the European Medicines Agency EnprEMA(0)
- 2017 European Union Good Clinical Practice Inspectors Working Group workshop(0)
- 2017 Forum on bioequivalence inspections(0)
- 2017 Pharmacovigilance Inspectors Working Group training course(0)
- 2018 Annual workshop of the European Network of Paediatric Research at the European Medicines Agency EnprEMA(0)
- 2018 European Union Good Clinical Practice Inspectors Working Group workshop(0)
- 2019 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA EnprEMA(0)
- 2020 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA EnprEMA(0)
- 2020 European Union Good Clinical Practice Inspectors Working Group workshop(0)
- 2021 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA EnprEMA(0)
- 2022 annual meeting of the members and Coordinating Group of the European network of paediatric research at the EMA EnprEMA(0)
- 20112020 More than 40% decrease in sales of antimicrobials for use in animals(0)
- A(0)
- Aaron Sosa Mejia(0)
- Abasaglar previously Abasria(0)
- Abbott Laboratories Limited withdraws its marketing authorisation application for Ozespa briakinumab(0)
- Abdelaali Sarakha(0)
- Abdel Hafid El Bouyahyaoui(0)
- Abdul Karim Barakat(0)
- Abecma(0)
- Abeeda Ahmed(0)
- Abevmy(0)
- Abilify(0)
- Abilify Maintena(0)
- Abilify MyCite(0)
- Abiraterone Accord(0)
- Abiraterone acetate productspecific bioequivalence guidance(0)
- Abiraterone Krka(0)
- Abiraterone Mylan(0)
- Ablavar previously Vasovist(0)
- About this website(0)
- About us(0)
- ABP 710(0)
- Abraxane(0)
- Abrysvo(0)
- Abseamed(0)
- Absinthii herba(0)
- Abylqis(0)
- Academia(0)
- Academia developing medicines for rare diseases to receive free EMA scientific advice(0)
- Academia Info Day(0)
- Accelerated assessment(0)
- Accelerated assessment fasttracks Lenvima to benefit patients with thyroid cancer(0)
- Accelerated development of appropriate patient therapies a sustainable multistakeholder approach from research to treatment outcomes ADAPT SMART project kickoff meeting(0)
- Accelerating Clinical Trials in the EU ACT EU(0)
- Accelerating Clinical Trials in the EU ACT EU for better clinical trials that address patients needs(0)
- Accelerating Clinical Trials in the EU publication of 20222026 workplan(0)
- Accelerating stakeholder collaboration to enhance the clinical trials environment in the EU(0)
- Accessing key EMA information on human medicines(0)
- Access to documents(0)
- Access to EudraVigilance data(0)
- Accofil(0)
- Acenocoumarol productspecific bioequivalence guidance(0)
- Acipimox only to be used as additional or alternative treatment to reduce high triglyceride levels(0)
- Aclasta(0)
- A common data model in Europe Why Which How(0)
- Acomplia(0)
- Acrescent(0)
- Actelion withdraws its application for an extension of indication for Zavesca(0)
- Actelsar HCT(0)
- ACT EU Clinical Trials Analytics Workshop January 2024(0)
- ACT EU creating a better environment for clinical trials through collaboration(0)
- ACT EU multistakeholder meeting on decentralised clinical trials(0)
- ACT EU multistakeholder platform kickoff workshop(0)
- ACT EU PA04 Multistakeholder Workshop on ICH E6 R3 Public Consultation(0)
- ACT EU PA08 multistakeholder methodology workshop(0)
- ACT EU Training for noncommercial sponsors Transitioning trials to the CTR CTIS(0)
- Acticam(0)
- Action plan for herbal medicines 20102011(0)
- Actions to support the development of medicines for children(0)
- Active pharmaceutical ingredients Japan joins international collaboration on GMP inspections(0)
- Active substance master file procedure Scientific guideline(0)
- Active Substance Master File Working Group(0)
- Activities after orphan designation(0)
- Activities of former EMA Executive Director Thomas Lönngren(0)
- Activyl(0)
- Activyl Tick Plus(0)
- Actos(0)
- Actraphane(0)
- Actrapid(0)
- Adalsteinn Gudmundsson(0)
- Adam Andersson(0)
- Adamos Hadjipanayis(0)
- Adam Przybylkowski(0)
- Adapted vaccine targeting BA4 and BA5 Omicron variants and original SARSCoV2 recommended for approval(0)
- Adapting COVID19 vaccines to SARSCoV2 variants guidance for vaccine manufacturers(0)
- Adaptive pathways(0)
- Adaptive pathways a future approach to bring new medicines to patients(0)
- Adaptive pathways key learnings and next steps(0)
- Adaptive pathways workshop(0)
- Adaptogenic concept Scientific guideline(0)
- Adarsh Syla Kumar(0)
- Adasuve(0)
- Adcetris(0)
- Adcirca previously Tadalafil Lilly(0)
- Addendum on terms and concepts of pharmacogenomic features related to metabolism to the Guideline on the use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products Scientific guideline(0)
- Addendum to the guideline on the evaluation of medicinal products indicated for treatment of bacterial infections to address paediatricspecific clinical data requirements Scientific guideline(0)
- Addendum to the note for guidance on antiarrhythmics on atrial fibrillation and atrial flutter Scientific guideline(0)
- Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to address indicationspecific clinical data requirements Scientific guideline(0)
- Addendum to the note for guidance on evaluation of medicinal products indicated for treatment of bacterial infections to specifically address the clinical development of new agents to treat disease due to Mycobacterium Tuberculosis Scientific guideline(0)
- Additional manufacturing capacity for BioNTech/Pfizers COVID19 vaccine(0)
- Additional manufacturing capacity for Modernas COVID19 vaccine(0)
- Additional manufacturing site for COVID19 Vaccine Janssen(0)
- Additional measures to allow experts to focus on COVID19 activities(0)
- Additional monitoring information materials(0)
- Additional quality requirements for products intended for incorporation into animal feedingstuffs medicated premixes Scientific guideline(0)
- Addressing challenges of innovative cancer immunotherapy medicines(0)
- Addressing the potential impact of novel coronavirus disease COVID19 on medicines supply in the EU(0)
- Adela Núñez Velázquez(0)
- Adele Romani(0)
- Adempas(0)
- Adempas not for use in patients with pulmonary hypertension caused by idiopathic interstitial pneumonia(0)
- Adenovirusmediated Herpes simplex virusthymidine kinase gene(0)
- Adenuric(0)
- Adhatodae vasicae folium(0)
- Ad hoc CHMP Expert Group Meeting on Nanomedicines(0)
- Adhoc Management Board meeting on CTIS(0)
- Adhoc meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG(0)
- ADHOC working group meeting on herbal medicinal products 6 7 July 1998(0)
- AD HOC working group on herbal medicinal products meeting of the 2425 November 1997(0)
- Adina Pirvu(0)
- Adjupanrix previously Pandemic influenza vaccine H5N1 split virion inactivated adjuvanted GlaxoSmithKline Biologicals(0)
- Adjusol trimethoprim sulfa liquide and its associated names(0)
- Adjusted fees for applications to European Medicines Agency from 1 April 2012(0)
- Adjusted fees for applications to European Medicines Agency from 1 April 2013(0)
- Adjusted fees for applications to European Medicines Agency from 1 April 2015(0)
- Adjusted fees for applications to European Medicines Agency on 1 April 2011(0)
- Adjustment for baseline covariates in clinical trials Scientific guideline(0)
- Adjustment for crossover in estimating effects in oncology trials Scientific guideline(0)
- Adjuvants in vaccines for human use Scientific guideline(0)
- Adlumiz(0)
- Administration and Corporate Management(0)
- Adolfo Bandettini di Poggio(0)
- Adriana Ammassari(0)
- Adrian Fandiño Lopez(0)
- Adrian Llerena Ruiz(0)
- Adriano Friganovic(0)
- Adrian Post(0)
- Adrienn Horváth(0)
- Adrijana Ilić Martinac(0)
- Adrovance(0)
- AdTab previously Lotilaner Elanco(0)
- Adtralza(0)
- Aduhelm(0)
- Advagraf(0)
- Advanced therapies marketing authorisation(0)
- Advanced therapies postauthorisation(0)
- Advanced therapies research and development(0)
- Advanced therapy classification(0)
- Advanced therapy medicinal products Overview(0)
- Advanced therapy medicines towards increased development and patient access(0)
- Advancing international collaboration on COVID19 realworld evidence and observational studies(0)
- Advancing regulatory science in the EU midpoint report published(0)
- Advancing regulatory science in the EU new strategy adopted(0)
- Advasure(0)
- Advate(0)
- Advate / Rixubis(0)
- Adventitious agent safety of urinederived medicinal products Scientific guideline(0)
- Advexin(0)
- Advice on impacts of using antimicrobials in animals(0)
- Advice to sponsors on managing the impact of the war in Ukraine on clinical trials(0)
- Advisory functions(0)
- Advocate(0)
- Adynovi(0)
- Aerinaze(0)
- Aerius(0)
- Aerivio Spiromax(0)
- Aet Viispert(0)
- Afinitor(0)
- Aflunov(0)
- African Medicines Agency African Union(0)
- Afstyla(0)
- Aftovaxpur DOE(0)
- Agamree(0)
- Ágata Arias Sánchez(0)
- Agata Maria Krawczynska(0)
- Agata Mikolajewska(0)
- Agency in numbers(0)
- Agency internal and external IT systems offline from 26 November 1800 UK time to 29 November 0900 UK time(0)
- Agency releases new guidance on medicines based on stem cells(0)
- Agency sets out work priorities for 2011(0)
- Agenerase(0)
- Agilus(0)
- Agita Karklite(0)
- A global approach to regulatory flexibility to increase manufacturing capacity during COVID19(0)
- Agnes Gabriella Szadeczkyne Kelemen(0)
- Agnes Gyurasics(0)
- Ágnes Kalocsai(0)
- Agnès MamboleDema(0)
- Agnès Saint Raymond appointed to UN Commission on lifesaving commodities for women and children(0)
- Agnes Tunde Kollo Toth(0)
- Agni casti fructus(0)
- Agnieszka Barcikowska(0)
- Agnieszka Dzierwa(0)
- Agnieszka Kupecka(0)
- Agnieszka Przybyszewska(0)
- Agnieszka RogowskaJaśkowiak(0)
- Agnieszka Siutowicz(0)
- Agnieszka Wlazly(0)
- Agni Kapou(0)
- Agomelatine productspecific bioequivalence guidance(0)
- Agrimoniae herba(0)
- Agropyri repentis rhizoma(0)
- Agueda Antonia Galvez Gonzalez(0)
- Agustin Portela(0)
- Aida Hajdo(0)
- Aija Novika(0)
- Ailise Carleton(0)
- Aimad Torqui(0)
- Aimovig(0)
- Aina Jannicke Øvrebust(0)
- Aine McKenna(0)
- Ainis Dzalbs(0)
- Airexar Spiromax(0)
- Aisling Vesey(0)
- Aisling Walsh(0)
- Aitana Calvo(0)
- Aivlosin(0)
- Ajda Bedene(0)
- A joint meeting by TOPRA and the European Medicines Agency(0)
- Ajovy(0)
- Ajten Ademi Avduramani(0)
- Akeega(0)
- Akynzeo(0)
- Alain GEILLE(0)
- Alanine arginine aspartic acid cysteine/cystine glutamic acid glycine histidine isoleucine leucine lysine monohydrate methionine ornithine hydrochloride phenylalanine proline serine taurine threonine tryptophan tyrosine valine sod(0)
- Alan Sanh(0)
- Alar Irs(0)
- Alba Peña(0)
- Alba PerezVela(0)
- Alba RodriguezRius(0)
- Albena Hristova(0)
- Albena Yordanova(0)
- Albert Meisinger(0)
- Alberto Casaca(0)
- Alberto de Prado Lopez(0)
- Alberto Díaz(0)
- ALBERTO VAN HERCKENRODE SÁNCHEZ(0)
- Albert Stühler(0)
- Albert Vollaard(0)
- Albrioza(0)
- Alcon Laboratories UK Ltd withdraws its application to extend the marketing authorisation for Opatanol(0)
- Alcon Laboratories withdraws its application for RETAANE(0)
- Alcort(0)
- Aldara(0)
- Aldo Pietro Maggioni(0)
- Aldurazyme(0)
- Alecensa(0)
- Alectinib productspecific bioequivalence guidance(0)
- Alejandra Perez del Real de Agueda(0)
- ALEJANDRO BLASCO BARBERO(0)
- Alejandro isidoro Pérez Cabeza(0)
- Alejandro Montón Silva(0)
- ALEJANDRO PEREZ CARO(0)
- Alejandro Platt Orzáez(0)
- Alejandro Rodriguez(0)
- Aleksandar Knezevic(0)
- Aleksandra Karin(0)
- Alena Maruskova(0)
- Alendronic Acid / Colecalciferol Mylan(0)
- Alessandra Aldieri(0)
- Alessandra Chillà(0)
- Alessandra Marabello(0)
- Alessandra Ranuncoli(0)
- Alessandra Renieri(0)
- Alessandra Tamburella(0)
- Alessandro Ascione(0)
- Alessandro Assisi(0)
- Alessandro Loppini(0)
- Alessia Calzolari(0)
- Alessia Pochesci(0)
- Alessia Proietti(0)
- Alexander Braathen(0)
- Alexander Kammerlocher(0)
- Alexander Knieps(0)
- Alexander Weninger(0)
- Alexandra Branchu(0)
- Alexandra Demetriou(0)
- Alexandra Dettweiler(0)
- Alexandra Kamp(0)
- Alexandra KlabundeNegatsch(0)
- Alexandra Naunheim(0)
- Alexandra Raluca Bocan(0)
- ALEXANDRA VOULGARI(0)
- Alexandre Moreau(0)
- Alexandrina Preda(0)
- alexandru mihail simion(0)
- Alexis Jacquet(0)
- Alexis Viel(0)
- Alfonso Aguarón(0)
- Algina Burniene(0)
- Alia MichaelidouPatsia(0)
- Alice Bardin Laforge(0)
- Alice Bender(0)
- Alice Pornin(0)
- Alice Stack(0)
- Alicia Pérez González(0)
- Alicia SánchezCaro(0)
- Alicja Irena Lengowska(0)
- Alida Spruijt(0)
- Alimta(0)
- Alina Hoffmann(0)
- Alina Hoskins(0)
- Alina Rößner(0)
- Aline Hanouet(0)
- Aliqopa(0)
- Alisade(0)
- Aliskiren productspecific bioequivalence guidance(0)
- Alissa SIALA(0)
- Alkermes Pharma Ireland Limited withdraws its marketing authorisation application for Megestrol Alkermes megestrol(0)
- Alkindi(0)
- Allan Reinapae(0)
- Allergenic potency of herbal medicinal products containing soya or peanut protein Scientific guideline(0)
- Allergen products development for immunotherapy and allergy diagnosis in moderate to lowsized study populations Scientific guideline(0)
- Allergen products production and quality issues Scientific guideline(0)
- Allex(0)
- All herbal community lists(0)
- All herbal documents under consultation(0)
- Allii cepae bulbus(0)
- Allii sativi bulbus(0)
- Alli previously Orlistat GSK(0)
- Allogeneic ex vivo expanded umbilical cord blood cells(0)
- Allogenic mesenchymal stem cellbased products for veterinary use specific questions on tumorigenicity Scientific guideline(0)
- All premixes for medicated feedingstuff containing 40 g 100 g or 200 g tilmicosin per kg premix and administered to rabbits(0)
- Alma Moffett(0)
- Aloes folii succus siccatus(0)
- Alofisel(0)
- Alois Konertz(0)
- Aloxi(0)
- Alpha2adrenoreceptor agonists(0)
- Alpheon(0)
- Alpivab(0)
- Alprolix(0)
- Alsitek(0)
- Altargo(0)
- Althaeae radix(0)
- Altrenogest(0)
- Altuvoct(0)
- Aluminium hydroxide adsorbed depigmented glutaraldehyde polymerized allergenic extract of birch alder and hazel pollen(0)
- Aluminium hydroxide adsorbed depigmented glutaraldehyde polymerized allergic extract of birch pollen(0)
- Alunbrig(0)
- Aluvia(0)
- Alvar Per Olof Jansson(0)
- Alymsys(0)
- Amalia Papadaki(0)
- Amalie Clement(0)
- Amanda Camilleri(0)
- Amanda Hainzl(0)
- Amani AlSarraf(0)
- Amarilla BarcsayVeres(0)
- Amarin Neuroscience Ltd withdraws its marketing authorisation application for Ethyl Eicosapent Soft Capsules ethyl eicosapent(0)
- Ambirix(0)
- Ambrisentan Mylan(0)
- Ambrisentan Zentiva(0)
- Ambroxol and bromhexine expectorants safety information to be updated(0)
- Amedeo Manfrin(0)
- Amelia Cupelli(0)
- Ameluz(0)
- Amendments to the pharmacovigilance legislation new notification requirements for marketingauthorisation holders(0)
- Amendments to the pharmacovigilance legislation new notification requirements for marketingauthorisation holders and changes to scope of European safety referrals(0)
- amfepramone(0)
- Amgevita(0)
- Amglidia(0)
- Amifampridine SERB(0)
- Amina Taleb(0)
- Amlodipine / Valsartan Mylan(0)
- Amlodipine besilate / bisoprolol fumarate(0)
- Ammonaps(0)
- Amsparity(0)
- Amversio(0)
- Amvuttra(0)
- Amyvid(0)
- Ana Andre(0)
- Ana Babic Perhoc(0)
- Ana Baião(0)
- Ana Boban(0)
- Ana Catarina Fonseca(0)
- Ana Catarina Reis(0)
- Ana Civantos(0)
- Ana Claudia Figueiredo(0)
- Ana Dugonjic Okrosa(0)
- Ana Greiner(0)
- Anagrelide Viatris previously Anagrelide Mylan(0)
- Ana Isabel Olías Molero(0)
- Ana Jeroncic(0)
- Ana Kralj(0)
- Ana López de la Rica Manjavacas(0)
- Analysis of antimicrobial consumption and resistance JIACRA reports(0)
- ANAMARIA FRASINEANU(0)
- Ana Martinez Lamparero(0)
- Ana Martín Leal(0)
- Ana Mimoso(0)
- Ana Moreno Oliver(0)
- Ana Pardo González(0)
- Ana Paula Leandro(0)
- Ana Paula Martins(0)
- Ana Rita Martins(0)
- Ana Sagredo(0)
- Ana Santamartina Conde(0)
- Ana Sofia Diniz Martins(0)
- Anastasia Mountaki(0)
- Anastasios Makritis(0)
- Anastrozole(0)
- Ana Struwe(0)
- Ana Téllez Torres(0)
- Ana Zubec(0)
- Ancella Santos Quintano(0)
- Anders Bäcksholm(0)
- Anders Bucht(0)
- Anders Lignell(0)
- Andis Vilums(0)
- ANDRA SARGUNA(0)
- Andras Armväärt(0)
- András Biro(0)
- Andras DonasziIvanov(0)
- Andras Lakatos(0)
- Andras Mittner(0)
- Andrea Berghold(0)
- Andrea Boente Juncal(0)
- Andrea Caffo(0)
- Andrea Christina Golombiewski(0)
- Andrea CsehPálos(0)
- Andrea Erika Elsa Springer(0)
- Andrea Gaggioli(0)
- Andrea García Caballero(0)
- Andrea Hanson(0)
- Andrea Kugi(0)
- Andrea Laslop(0)
- Andrea Logreco(0)
- Andrea Margulis(0)
- Andrea Marzoll(0)
- Andrea Orthmann(0)
- Andrea Pizzini(0)
- Andrea Röhmer(0)
- Andreas Bonertz(0)
- Andreas Borjesson(0)
- Andreas Brandt(0)
- Andrea Schiller(0)
- Andreas James Schaeffer Senders(0)
- Andreas Kirisits(0)
- Andreas Krassnigg(0)
- Andreas Madinger(0)
- Andreas Merkle(0)
- Andreas Motitschke(0)
- Andreas Pott appointed Deputy Executive Director of European Medicines Agency(0)
- Andrea Sprick(0)
- Andrea Springer(0)
- Andreas Schieweck(0)
- Andreas Schoen(0)
- Andreas Scorilas(0)
- Andreas Sundgren(0)
- Andrea Thorhallsdottir(0)
- Andrea Weber(0)
- Andrea Winchenbach(0)
- Andre Berger(0)
- Andre Deschamps(0)
- Andreea Barbu(0)
- André Elferink(0)
- Andreia Mendes(0)
- Andreja Kranjc(0)
- Andreja Novak(0)
- André Luong(0)
- Andre Mangani(0)
- André SilvaPinto(0)
- Andreu Rico(0)
- Andria Eliadou(0)
- Andri Andreou(0)
- Andri Spanou Nicolaou(0)
- Andrographidis paniculatae folium(0)
- Androulla Stylianou(0)
- Andrzej Brudnowski(0)
- Andrzej Czeslawski(0)
- Andzelika NajdaBernatowicz(0)
- Ane Kvingedal(0)
- Aneta Hovorkova(0)
- Anete Sulce(0)
- Anette Bern(0)
- Anette Solli Karlsen(0)
- A new role for EMA in monitoring and mitigating critical medical device shortages during public health emergencies(0)
- Angela Bradshaw(0)
- Angela de Kleynen(0)
- Angela Del Vecchio(0)
- Angela Garau(0)
- Ángela Juárez La Casa(0)
- Angela Krackhardt(0)
- Angela Leburgue(0)
- Angela Pollicino(0)
- Angel Concheiro(0)
- Angelicae sinensis radix(0)
- Angelika Geroldinger(0)
- Angeliki Rompoti(0)
- Angelo Ferreira da Silva(0)
- Angelo Loris Brunetta(0)
- Angelo Molinaro(0)
- Angel Sainz Rodriguez(0)
- Angiox(0)
- Anika Therapeutics Srl withdraws its marketingauthorisation application for Hyalograft C autograft(0)
- Animal health professionals(0)
- Anisi aetheroleum(0)
- Anisi fructus(0)
- Anis Nouichi(0)
- anissa benlazar(0)
- Anita Bottger(0)
- Anita C Volkers(0)
- Anita Kovacsne dr Losonczi(0)
- Anita Nagy(0)
- Anita Piwowarczyk(0)
- Anita SeidnerGernig(0)
- Anita Simonds(0)
- Anita Wolfer(0)
- Anja Düchting(0)
- Anja Fog Rasmussen(0)
- Anja Hoffmeister(0)
- Anja Keber(0)
- Anja Kotschwar(0)
- Anja Schiel(0)
- Anja Schmidt(0)
- Anja Silke Christensen(0)
- Anja van Haren(0)
- Anke Blumberg(0)
- Anke Finnah(0)
- Anke Zobywalski(0)
- An Le(0)
- Annabelle Page(0)
- AnnaBettina Haidich(0)
- Anna Borioni(0)
- Anna Chioti(0)
- Anna Christina Albrecht(0)
- Anna Fordymacka(0)
- Anna Hajós(0)
- Anna Hillgren(0)
- Anna Jencz(0)
- Anna Jenny Charlotta Larsson(0)
- Anna Jonczyk(0)
- An Na Joo(0)
- Anna KajasteRudnitski(0)
- Anna Karin Belfrage(0)
- AnnaKarin Klocker(0)
- Anna Karin Rehnström(0)
- Anna Katalin Barane Gilicze(0)
- Anna Katsifi(0)
- Anna Kroupová(0)
- Anna Krueger(0)
- Anna Kubandová(0)
- Annalisa Capuano(0)
- Anna Locatelli(0)
- Anna Lundgren(0)
- Anna Mäkinen Salmi(0)
- Anna Mareková(0)
- Annamária MosolygóTelepó(0)
- Anna Maria Serrilli(0)
- Anna Maria Urbaniak(0)
- Anna Mari Lone(0)
- Anna Nickel(0)
- Anna Norberg(0)
- Anna Raslova(0)
- Annarita Villani(0)
- Anna Schölin(0)
- Anna Siira(0)
- Anna Sundlöv(0)
- Anna Tarzia(0)
- Anna Vikerfors(0)
- Anna von BonsdorffNikander(0)
- Anna WachnikŚwięcicka(0)
- Anna Werinder(0)
- Anna Westin(0)
- Anna Zadrozna(0)
- Ann Bylund(0)
- ann de guchtenaere(0)
- Anne Bausch(0)
- AnneBerit Erdal(0)
- AnneCecile Vuillemin(0)
- Anne Chardon(0)
- Anne Chevance(0)
- Anne Deicke(0)
- Anne Driheme(0)
- Anne Dybwad(0)
- Anne Engelhard(0)
- Anne Figenschou Soleng(0)
- Anne Fragne Nataf(0)
- Anne Hasle Buur(0)
- Anne Hess(0)
- AnneIsabelle Waechter(0)
- Anne Isabel Roth(0)
- Anne Junttonen(0)
- Anne Kleinau(0)
- Anne Kristine Hejlesen(0)
- Anne Kulseth Dahl(0)
- Anne Kærsgaard Mylin(0)
- Anne Laurent(0)
- Anne Lenaers(0)
- Anneloes van der Ree(0)
- Annely Aleksejev(0)
- Anne Malene Nissen(0)
- AnneMare de Vries(0)
- Anne Marie Ciobanu(0)
- AnneMarie Dalseg(0)
- Annemarie den Harder(0)
- AnneMarie Jacques(0)
- Anne Mathy(0)
- AnneMette Hoberg(0)
- Annemieke AartsmaRus(0)
- Anne Miermont(0)
- AnneNicole Kolbrueck(0)
- Anne Paavola(0)
- Anne Rath Petersen(0)
- Anne Rochtus(0)
- Anne Rousseau(0)
- Anneruth HuttingaGarling(0)
- Anne Sagnier(0)
- Anne Slomp(0)
- Anne Taams(0)
- Anne Timonen(0)
- Anne Torrez FloresLexmond(0)
- Anne Trappe(0)
- Annette Byrholt Hansen(0)
- Annette Cleveland Nielsen(0)
- Annette EdwardsLemburg(0)
- Annette Lommel(0)
- Anne Tungelund Larsen(0)
- Anne Vestrheim(0)
- Annex I variation applications content for live attenuated influenza vaccines(0)
- Annex to the European Commission guideline on Excipients in the labelling and package leaflet of medicinal products for human use(0)
- Annica Nordin(0)
- Annie George Chandy(0)
- Anniina Ritvanen(0)
- Annika Andersson(0)
- Annika Ekbom Schnell(0)
- Annika Folin(0)
- Annika Fredricsson(0)
- Annika Ridell(0)
- Ann Jans(0)
- AnnKathrin Strahl(0)
- AnnKristin Leuchs(0)
- Ann Marie Janson Lang(0)
- Ann Marie Totterman(0)
- Ann Neubert(0)
- Anno Faber(0)
- Annual bulletins on veterinary pharmacovigilance activities 200319(0)
- Annual Patients and Consumers Working Party PCWP and Healthcare Professionals Working Party HCPWP meeting with all eligible organisations(0)
- Annual report 2009 published "Agency achieved very good results in one of the most challenging years in its history"(0)
- Annual report 2011 shows continuously high level of activities(0)
- Annual report 2019 published(0)
- Annual report 2020 published(0)
- Annual report on deferrals(0)
- Annual reports and work programmes(0)
- Annual workshop of the European network of paediatric research at EMA EnprEMA(0)
- Annual workshop of the European network of paediatric research at the European Medicines Agency EnprEMA(0)
- Anoro Ellipta previously Anoro(0)
- Ansgar Arenz(0)
- Antero Kallio(0)
- Anthelmintic resistance Scientific guideline(0)
- Anthonie van der Wekken(0)
- Anthony Gerry Wilson(0)
- Anthony Nunn(0)
- Anthony Samuel(0)
- Anthony SerracinoInglott(0)
- Antiarrhythmics Scientific guideline(0)
- Antifraud strategy(0)
- Antigenics Therapeutics Limited withdraws its marketing authorisation application for Oncophage vitespen(0)
- Antimicrobial Advice Ad Hoc Expert Group(0)
- Antimicrobial resistance(0)
- Antimicrobial resistance European Medicines Agency provides advice on use of colistin and tigecycline in animals(0)
- Antimicrobial resistance European Medicines Agency releases draft advice on the impact on public health and animal health of the use of antibiotics in animals(0)
- Antimicrobial resistance in human medicine(0)
- Antimicrobial resistance in the environment considerations for current and future risk assessment of veterinary medicinal products Scientific guideline(0)
- Antimicrobial resistance in veterinary medicine(0)
- Antimicrobialresistance surveillance as postmarketing authorisation commitment Scientific guideline(0)
- Antimicrobials(0)
- Antimicrobial Sales and Use Platform(0)
- Antimicrobials Working Party(0)
- Antita Adriaens(0)
- Antiviral medicines for pandemic influenza(0)
- Antje Gerofke(0)
- Antoine Treff(0)
- Antonela Simunovic(0)
- Antonella Caselli(0)
- Antonella Isgrò(0)
- Antonella Romanini(0)
- Antonio Battisti(0)
- Antonio Clavenna(0)
- Antonio GomezOutes(0)
- Antonio Lopez Navas(0)
- António Matias(0)
- Antonio Portolés(0)
- Antonio Radoev(0)
- Antonius Ederveen(0)
- Antonius Johannes van der Stappen(0)
- Antti Hyvärinen(0)
- Antti Vierikko(0)
- Anu Puomila(0)
- Anya Staal(0)
- Aoibhinn Collery(0)
- AP214 Acetate ΑcetylLys6αMSH acetate salt(0)
- Apealea(0)
- Apidra(0)
- Apixaban Accord(0)
- Apixaban productspecific bioequivalence guidance(0)
- Aplidin(0)
- Apoquel(0)
- Appeal procedure for Orphan Medicinal Product designation(0)
- Appendix 1 to the guideline on clinical evaluation of diagnostic agents on imaging agents Scientific guideline(0)
- Appendix 1 to the guideline on the evaluation of anticancer medicinal products in man methodological consideration for using progressionfree survival PFS or diseasefree survival DFS in confirmatory trials Scientific guideline(0)
- Appendix 2 to the guideline on the evaluation of anticancer medicinal products in man the use of patientreported outcome PRO measures in oncology studies Scientific guideline(0)
- Appendix 4 to the guideline on the evaluation of anticancer medicinal products in man condition specific guidance Scientific guideline(0)
- Appendix IV of the guideline on the investigation on bioequivalence presentation of biopharmaceutical and bioanalytical data in module 271 Scientific guideline(0)
- Application guidance veterinary medicines(0)
- Application with 1 Metaanalyses 2 One pivotal study Scientific guideline(0)
- Applying for marketing authorisation orphan medicines(0)
- Applying for orphan designation(0)
- Applying for SME status(0)
- Applying regulatory science to neonates launch of the International Neonatal Consortium INC(0)
- APPM Respipharm(0)
- Approaches on how to consider excipients in the context of Regulation 2377/90 Scientific guideline(0)
- Approach to establish a pharmacological acceptable daily intake ADI Scientific guideline(0)
- A practical approach to effective lifecycle implementation of systems and processes for pharmaceutical manufacturing(0)
- Apremilast Accord(0)
- Apretude(0)
- Aprovel(0)
- Aptivus(0)
- Aqueous extract of grass pollen from Dactylis glomerata Festuca pratensis Holcus lanatus Lolium perenne Phleum pratense and Poa pratensis(0)
- Aquilda(0)
- Aquipta(0)
- Aqumeldi(0)
- Araceli Nunez Ventura(0)
- Arancha Camacho(0)
- Aranesp(0)
- Aránzazu GonzálezCanga(0)
- Aranzazu SanchoLopez(0)
- Arava(0)
- Archived versions of the European Medicines Agencys website(0)
- Archive of development of good pharmacovigilance practices(0)
- Arctii radix(0)
- Arendina Hissink(0)
- Arepanrix(0)
- Arexvy(0)
- Are you an SME interested in funding of Adverse Drug Reaction research through the European Commissions 7th Framework Programme(0)
- ARIADNA TIBAU MARTORELL(0)
- Arian Ahmeti(0)
- Arianna Ambrogi(0)
- Arianna Pisaneschi(0)
- Ariclaim(0)
- Arikayce(0)
- Arikayce liposomal(0)
- Ari Lehtola(0)
- Aripiprazole Accord(0)
- Aripiprazole Mylan(0)
- Aripiprazole Mylan Pharma previously Aripiprazole Pharmathen(0)
- Aripiprazole Sandoz(0)
- Aripiprazole Zentiva(0)
- Aristotelis Bamias(0)
- Arixtra(0)
- Arja Willman(0)
- Arkadiusz Lubas(0)
- Ark Therapeutics Ltd withdraws its marketing authorisation application for Cerepro sitimagene ceradenovec(0)
- Ark Therapeutics withdraws its marketing authorisation application for Cerepro(0)
- Armando Genazzani(0)
- Armando Magrelli(0)
- Armin Braun(0)
- Armin Koch(0)
- Armisarte previously Pemetrexed Actavis(0)
- Arnar Gudjonsson(0)
- Arne Broch Brantsæter(0)
- Arne Hein(0)
- Arnicae flos(0)
- Arno Terhechte(0)
- Arpad Szallasi(0)
- Arpida A/S withdraws its marketing authorisation application for Mersarex iclaprim(0)
- Arpraziquantel(0)
- Arsenic trioxide Accord(0)
- Arsenic trioxide medac(0)
- Arsenic trioxide Mylan(0)
- Artesunate Amivas(0)
- Arthur van Strien(0)
- ArtiCell Forte(0)
- ArtiCell Forte / RenuTend(0)
- Article 5 procedure Regulatory and procedural guidance(0)
- Article 53 opinions on any scientific matter human medicines(0)
- Article 1411 opinions on any scientific matter veterinary medicines(0)
- Artificial intelligence in medicine regulation(0)
- Artificial intelligence workplan to guide use of AI in medicines regulation(0)
- Artobend(0)
- Arunas Vaitkevicius(0)
- Arxxant(0)
- Arzerra(0)
- Arzoxifene(0)
- Åsa HerslöfBjörling(0)
- Åsa Kragh(0)
- Asa Kumlin Howell(0)
- Åsa Lindh(0)
- Åsa Tunon(0)
- Asenapine productspecific bioequivalence guidance(0)
- Aservo EquiHaler(0)
- Asimina Zisi(0)
- Asimtufii(0)
- Åslaug Helland(0)
- Aspa Karampela(0)
- Aspartame and phenylalanine(0)
- Aspaveli(0)
- Assessing dietary exposure to residues of veterinary medicines feed additives and pesticides in food of animal origin in the EU(0)
- Assessing the toxicological risk to human health and groundwater communities from veterinary pharmaceuticals in groundwater Scientific guideline(0)
- Assessing the toxicological risk to humans and the environment of veterinary pharmaceuticals in groundwater Scientific guideline(0)
- Assessment and control of DNA reactive mutagenic impurities in veterinary medicinal products Scientific guideline(0)
- Assessment of bioavailability of bound residues in food commodities of animal origin in the context of Council Regulation EEC No 2377/90 Scientific guideline(0)
- Assessment of cardiovascular safety profile of medicinal products Scientific guideline(0)
- Assessment of clinical safety and efficacy in the preparation of EU herbal monographs for wellestablished and traditional herbal medicinal products Scientific guideline(0)
- Assessment of genotoxicity of herbal substances/preparations Scientific guideline(0)
- Assessment of human dietary exposure to residues of veterinary medicines in the EU(0)
- Assessment of persistent bioaccumulative and toxic PBT or very persistent and very bioaccumulative vPvB substances in veterinary medicinal products(0)
- Assessment of persistent bioaccumulative and toxic PBT or very persistent and very bioaccumulative vPvB substances in veterinary medicinal products Scientific guideline(0)
- Assessment of SmPC section 51 A Guide for Assessors of Centralised Applications Scientific guideline(0)
- Assessment of the effect of antimicrobial substances on dairy starter cultures Scientific guideline(0)
- Assessment of the genotoxic potential of antisense oligodeoxynucleotides Scientific guideline(0)
- Assessment of the risk of transmission of animal spongiform encephalopathy agents by master seed materials used in the production of veterinary vaccines Scientific guideline(0)
- Assessment of the risk to public health from antimicrobial resistance due to the use of an antimicrobial veterinary medicinal product in foodproducing animals Scientific guideline(0)
- Assessment templates and guidance(0)
- Assessment templates and guidance Ancillary medicinal substances incorporated in a medical device(0)
- Assessment templates and guidance veterinary medicines(0)
- Assessment templates updated to include information on geriatric studies and new active substance claims(0)
- assia allalou(0)
- Asta Kubiliene(0)
- Astellas Pharma Europe BV withdraws its application for an extension of the indication for Qutenza capsaicin(0)
- Astellas withdraws its marketing authorisation application for Vibativ telavancin(0)
- AstraZeneca COVID19 vaccine review of very rare cases of unusual blood clots continues(0)
- AstraZenecas COVID19 vaccine benefits and risks in context(0)
- AstraZenecas COVID19 vaccine EMA finds possible link to very rare cases of unusual blood clots with low blood platelets(0)
- AstraZenecas COVID19 vaccine EMA to provide further context on risk of very rare blood clots with low blood platelets(0)
- AstraZeneca withdraws its application for Ximelagatran 36mg filmcoated tablets(0)
- AstraZeneca Withdraws its marketing authorisation application for Zactima vandetanib(0)
- Astrid Blok Hestbaek(0)
- Astrid Doutreluingne(0)
- Astrid Obmann(0)
- Astrid Schäfer(0)
- Astrid Schwantes(0)
- Astrid Thomas(0)
- Astrid Wiemann(0)
- A stronger role for EMA(0)
- Atazanavir Krka(0)
- Atazanavir Mylan(0)
- Atectura Breezhaler(0)
- Ate Duursma(0)
- Athanasia Kyrdi(0)
- Atorvastatin calcium(0)
- Atosiban SUN(0)
- Atriance(0)
- Atripla(0)
- ATryn(0)
- Attila Megyeri(0)
- Attila Sebe(0)
- Aubagio(0)
- Audrey Kinahan(0)
- Audrey Sultana(0)
- Audronis Lukosius(0)
- Audun Aukrust(0)
- Audun Haga(0)
- Augusto Fernandez(0)
- Aurélia de Fatima Mazon(0)
- Aurélie Demarcq(0)
- Aurélie Poll(0)
- Aurélie Vitores(0)
- Aurelija Ciegyte(0)
- Aurora María Rojo Sanchís(0)
- Australia(0)
- Authenticity verification for electronic certificates(0)
- Authorisation of medicines(0)
- Authorisation of veterinary medicinal products containing potential persistent bioaccumulative and toxic PBT or very persistent and very bioaccumulative vPvB substances Scientific guideline(0)
- Authorised uses of cancer medicine Yondelis unchanged following review of new data(0)
- Avaglim(0)
- Availability of critical medicines(0)
- Availability of medicines during COVID19(0)
- Availability of veterinary medicinal products extrapolation of maximum residue limits Scientific guideline(0)
- Availability of veterinary medicines(0)
- Availability of veterinary vaccines(0)
- Avamys(0)
- Avandamet(0)
- Avandia(0)
- Avastin(0)
- Avenae fructus(0)
- Avenae herba(0)
- Avian influenza bird flu(0)
- Avinew(0)
- A vision for use of realworld evidence in EU medicines regulation(0)
- Avoiding duplication of clinical trials in children(0)
- Avonex(0)
- Avotermin(0)
- Awareness session for SMEs on the reform of the EU pharmaceutical legislation(0)
- Awiqli(0)
- Axumin(0)
- Axura(0)
- Axxonis Pharma AG withdraws its marketing authorisation application for Nenad lisuride(0)
- Aybintio(0)
- Aynur Sert(0)
- Aysun Cetinyurek Yavuz(0)
- Ayvakyt(0)
- Azacitidine Accord(0)
- Azacitidine betapharm(0)
- Azacitidine Celgene(0)
- Azacitidine Kabi(0)
- Azacitidine Mylan(0)
- Azarga(0)
- Azilect(0)
- Azomyr(0)
- Azopt(0)
- Azra Selimovic(0)
- B(0)
- Babett Kobe(0)
- Babs Fabriek(0)
- Background to clinical data publication policy(0)
- Background to the CPMP Position Paper on possible preclinical studies to investigate addiction and dependence/withdrawal related to the use of selective serotonin uptake inhibitors SSRIs Scientific guideline(0)
- Background to the CPMP Position Paper on selective serotonin uptake inhibitors SSRIs and dependency/withdrawal reactions Scientific guideline(0)
- Bacterial lysate medicines for respiratory conditions to be used only for prevention of recurrent infections(0)
- Balaglitazone(0)
- Balaxur(0)
- Balimek(0)
- Balsamum peruvianum(0)
- Bamlanivimab and etesevimab for COVID19(0)
- Baqsimi(0)
- Baraclude(0)
- Barbara Attenni(0)
- Barbara Blaznik Marc(0)
- Barbara Bonamassa(0)
- Barbara Bridget Byrne Habic(0)
- Barbara Cerar(0)
- Barbara De Grimani(0)
- Barbara Gozlinska(0)
- Barbara Kovacic Bytyqi(0)
- Barbara Leonardi(0)
- Barbara Melmer(0)
- Barbara mostacci(0)
- Barbara Razinger(0)
- Barbara Schnierle(0)
- Barbara Schulte(0)
- Barbara Stubbe(0)
- Barbara Tucek(0)
- Barbara Yutzy(0)
- Bärbel Friedrichs(0)
- Bärbel Witte(0)
- Barbora Ladinova(0)
- Barbora Ptackova(0)
- Barbora Vodickova(0)
- Barjola Hodaj(0)
- Barry OHea(0)
- Bart de Keizer(0)
- Bart Denayer(0)
- Bashkim Sadiku(0)
- Bastian Hornung(0)
- Bas Wouters(0)
- Batches of the insulin medicine NovoMix 30 FlexPen and Penfill to be recalled(0)
- Batch potency testing of immunological veterinary medicinal product Scientific guideline(0)
- Bausch & Lomb Ireland withdraws its marketing authorisation application for Retisert(0)
- Bavencio(0)
- Baycox Iron(0)
- Bayer Schering Pharma withdraws its marketing authorisation application for Recothrom thrombin alfa(0)
- Bayovac IBR Marker Vivum(0)
- Baytril 10% oral solution(0)
- Baytril injectable(0)
- Baytril injectable and generics(0)
- Beata Berlinska(0)
- Beata Maria Jakline Ullrich(0)
- Beata Szabady(0)
- Beate Gasser(0)
- Beate Maichel(0)
- Beate Mosl(0)
- Beate Stadler(0)
- Beatrice Chelli(0)
- Beatrice Claudia Castiglioni(0)
- Béatrice LEROUX(0)
- Béatrice PANTERNE(0)
- Beatrice Rambaldi(0)
- Beatriz Corcho Corral(0)
- Beatriz Gutiérrez Eugenio(0)
- Beatriz López Hernández(0)
- Beatriz Martinez(0)
- Becoming a member of one of EMAs scientific advisory groups(0)
- Begedina(0)
- Begoña Pérez Valderrama(0)
- Bekemv(0)
- Belaïd Sekkali(0)
- Belen Gutierrez Soriano(0)
- Belviq(0)
- Bemfola(0)
- Bemrist Breezhaler(0)
- Benedicte Hay(0)
- Benedicte Koch(0)
- benedicte NEVEN(0)
- Benedikt Göttel(0)
- Benedikt Martin(0)
- Benefitrisk methodology(0)
- Benefitrisk review of Multaq started(0)
- Benefits of combined hormonal contraceptives CHCs continue to outweigh risks CHMP endorses PRAC recommendation(0)
- Benefits of Diane 35 and generics outweigh risks in specific patient group(0)
- Benefits of Diane 35 and its generics outweigh risks in certain patient groups PRAC recommendation endorsed by CMDh(0)
- Benefits of ifosfamide solutions continue to outweigh risks EMAs safety committee PRAC has concluded that the benefits of ifosfamide solutions for infusion(0)
- Benefits of medicines containing combination of methocarbamol and paracetamol continue to outweigh risks(0)
- BeneFIX(0)
- Benepali(0)
- Bengt Berglund(0)
- Bengt Persson(0)
- Benita Cullen(0)
- Benjamin Burrus(0)
- Benjamin Hofner(0)
- Benjamin Micallef(0)
- Benlysta(0)
- Benoit Courty(0)
- Benzalkonium chloride(0)
- Benzathine benzylpenicillin intended for administration to foodproducing species(0)
- Benzoic acid and benzoates(0)
- Benzyl alcohol(0)
- Beovu(0)
- Beprana(0)
- Berendina Maria van den Hoorn(0)
- Bergrún Tinna Magnúsdóttir(0)
- Bernadette Doyle(0)
- Bernadett Flora Kiss(0)
- Bernadett Murárik(0)
- Bernadett Pályi(0)
- Bernard Soler(0)
- Bernardus Oomen(0)
- Bernd Arents(0)
- BerndBodo Haas(0)
- Bernd Gansbacher(0)
- Bernhard Kerscher(0)
- Bernhard Kodritsch(0)
- Bernhard Lewe(0)
- Bernhard Majer(0)
- Bernhard Roppenser(0)
- Beromun(0)
- BERTA HERNANDEZ(0)
- Besponsa(0)
- Besremi(0)
- Best expertise vs conflicts of interests Striking the right balance(0)
- Best practices to fight antimicrobial resistance(0)
- Best use of medicines legislation to bring new antibiotics to patients and combat the resistance problem(0)
- Betaferon(0)
- Betamox LA 150 mg/ml suspension for injection and associated names and generics products thereof(0)
- Betmiga(0)
- Better identification of medicinal products(0)
- Better labelling of excipients for safe use of medicines(0)
- Better monitoring of biological medicines(0)
- Better protection of public health European Medicines Agency counts down to introduction of new pharmacovigilance legislation(0)
- Better safety for patients through EUfunded research(0)
- Better surveillance needed to fight spread of antimicrobial resistance in zoonotic infections(0)
- Better training tools recommended to support patients using adrenaline autoinjectors(0)
- Better use of EMA support tools and increased success rate for SME applications(0)
- Better veterinary medicines for healthier animals and people(0)
- Bettina Bryde Nielsen(0)
- Bettina Bücker(0)
- Bettina Digruber(0)
- Bettina Kartmann(0)
- Bettina Klug(0)
- Bettina Lange(0)
- Bettina Ziegele(0)
- Betulae folium(0)
- Bevespi Aerosphere(0)
- Bexsero(0)
- Bextra(0)
- Beyfortus(0)
- Biancamaria Bruno(0)
- Bianca Mulder(0)
- Bianca van Beugen(0)
- Biannual Big Data Steering Group and industry stakeholders meeting(0)
- Bibi Fatima Syed Shah(0)
- BichHang Pham(0)
- Biferonex(0)
- Big data(0)
- Big Data Steering Group and industry stakeholders meeting(0)
- Big Data strategy for veterinary medicines in the EU(0)
- Big data use for public health publication of Big Data Steering Group workplan 202225(0)
- Biktarvy(0)
- Bilateral interactions with nonEU regulators(0)
- Biljana Dimitrova(0)
- Biljana Strojmanovska(0)
- Biljana Temova(0)
- Bimervax(0)
- Bimzelx(0)
- BindRen(0)
- Bine Haase(0)
- Binocrit(0)
- Bioanalytical method validation Scientific guideline(0)
- Biocides for use in animal husbandry(0)
- Bioenvision Ltd withdraws its application for an extension of indication for Evoltra clofarabine(0)
- Biograstim(0)
- Biological and chemical threats(0)
- Biological guidelines(0)
- Biologicals active substance(0)
- Biologicals finished product(0)
- Biological substances other than immunologicals(0)
- Biologics Working Party(0)
- Biologics Working Party documents(0)
- BioPartners GmbH withdraws its application for Biferonex interferon beta1a(0)
- Biopoin(0)
- Biosimilar medicinal products containing recombinant granulocytecolony stimulating factor Annex to guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance nonclinical and clinical issues(0)
- Biosimilar Medicinal Products Working Party(0)
- Biosimilar medicines can be interchanged(0)
- Biosimilar medicines marketing authorisation(0)
- Biosimilar medicines Overview(0)
- Biostatistics(0)
- BiResp Spiromax(0)
- Birger Scholz(0)
- Birgit Ahrens(0)
- Birgit Barten(0)
- Birgit Donabauer(0)
- Birgit Döring(0)
- Birgit Gadatsch(0)
- Birgit Reinprecht(0)
- Birgit Schmauser(0)
- Birgitte Charlotte Faber(0)
- Birgitte Tiesjema(0)
- Birte Niemann(0)
- Bismuth subcitrate potassium / Metronidazole / Tetracycline hydrochloride(0)
- Bisoprolol fumarate / acetylsalicylic acid(0)
- Bjoern Cohrs(0)
- Bjoern Egil Olsen(0)
- Bjorg Overby(0)
- Björn Eriksson(0)
- Bjorn Jansson(0)
- Blanka Hirschlerova(0)
- Blaz Ferjanc(0)
- Blectifor(0)
- Blenrep(0)
- Blerina Kaza(0)
- Blincyto(0)
- Blitzima(0)
- Bluevac BTV previously known as Bluevac BTV8(0)
- BMWP/BWP Workshop on Immunogenicity Assessment of Therapeutic Proteins(0)
- Bogdan Frunzareanu(0)
- Bogdan Yavorov Kirilov(0)
- Bojana Divkovic(0)
- Bojana Stavar Mocnik(0)
- Bojan Batinic(0)
- Boje Kvorning Pires Ehmsen(0)
- Boldi folium(0)
- Bondenza previously Ibandronic Acid Roche(0)
- Bondronat(0)
- Bonqat(0)
- Bonviva(0)
- Boosting care for newborn babies in lowincome countries(0)
- Boosting the development of medicines for children(0)
- Boric acid and borates(0)
- Boris Kolar(0)
- Borja García LópezRey(0)
- Bortezomib(0)
- Bortezomib Accord(0)
- Bortezomib Fresenius Kabi(0)
- Bortezomib Hospira(0)
- Bortezomib Sun(0)
- Boryana Ivanova(0)
- Bosatria(0)
- Bosulif(0)
- Bosutinib productspecific bioequivalence guidance(0)
- Boudewijn Catry(0)
- Bovalto Ibraxion(0)
- Bovela(0)
- Bovilis Blue8(0)
- Bovilis BTV8(0)
- Bovilis BVD(0)
- Bovilis Cryptium(0)
- Bovilis NasalgenC(0)
- Bovimectin Injection and its associated names(0)
- Bozena Bürmen(0)
- Bozena GrabonSyrzistie(0)
- Bozenna DembowskaBaginska(0)
- Braftovi(0)
- Brain diseases in the elderly(0)
- Bravecto(0)
- Bravecto Plus(0)
- Brazil(0)
- Brenda Holingue(0)
- Brenda Valente(0)
- Bretaris Genuair(0)
- Brexit preparedness EMA to further temporarily scale back and suspend activities(0)
- Brexit regulatory preparedness for veterinary medicinal products in the centralised procedure(0)
- Brexitrelated guidance for companies(0)
- Brexit the United Kingdoms withdrawal from the European Union(0)
- Breyanzi(0)
- Brian Aylward(0)
- Brian Ward(0)
- Bridion(0)
- Briefing meetings of the EMA Innovation Task Force now open to veterinary medicines(0)
- Brigitte Anliker(0)
- Brigitte Brake(0)
- Brigitte Hauser(0)
- Brigitte Kuechler(0)
- Brigitte MauelWalbröl(0)
- Brigitte Mueller(0)
- Brigitte PoumerolDumas(0)
- Brigitte SchwarzerDaum(0)
- Brigitte Tarasiewicz(0)
- Brilence(0)
- Brilique(0)
- Brimica Genuair(0)
- Brinavess(0)
- Brineura(0)
- Brintellix(0)
- BristolMyers Squibb Pharma EEIG withdraws its marketing authorisationapplication for DuoCover(0)
- BristolMyers Squibb Pharma EEIG withdraws its marketing authorisation application for Ixempra(0)
- Britta Kuhn(0)
- Britta Martens(0)
- Britta Meyer(0)
- Britta Selzsam(0)
- Britta TofernReblin(0)
- Britta Wellnitz(0)
- Britt Duijndam(0)
- Briumvi(0)
- Briviact in Italy Nubriveo(0)
- Brivudine(0)
- Broadline(0)
- Bromfenac sodium sesquihydrate(0)
- Bronchitol(0)
- BroPair Spiromax(0)
- Brucellin Aquilon(0)
- Brukinsa(0)
- Bruna Dekic(0)
- Bruno Delafont(0)
- Bruno Quesnel(0)
- Bruno Sepodes(0)
- Bruno Spieldenner(0)
- Bruno Urbain(0)
- Bryan Deane(0)
- Brynjar Orvarsson(0)
- BTVPUR(0)
- BTVPUR AlSap 1(0)
- BTVPUR Alsap 8(0)
- BTVPUR AlSap 24(0)
- Buccolam(0)
- Budesonide/Formoterol Teva(0)
- Budesonide/Formoterol Teva Pharma BV(0)
- Budesonide / salmeterol xinafoate(0)
- Building a leaner more streamlined organisation(0)
- Bursae pastoris herba(0)
- Burt H Kroes(0)
- Busilvex(0)
- Business hours and holidays(0)
- Busulfan Fresenius Kabi(0)
- Buvidal(0)
- Buying medicines online(0)
- Buying veterinary medicines online(0)
- Byannli previously Paliperidone JanssenCilag International(0)
- Bydureon(0)
- Byetta(0)
- Byfavo(0)
- Bylvay(0)
- Byooviz(0)
- C(0)
- Cabazitaxel Accord(0)
- Cabazitaxel Teva(0)
- Cablivi(0)
- Cabometyx(0)
- Cabozantinib productspecific bioequivalence guidance(0)
- Caelyx pegylated liposomal(0)
- Çağrı Gürer(0)
- Calcipotriol hydrate / hydrocortisone(0)
- Calculation of dose factor to be submitted to the Union Product Database UPD Scientific guideline(0)
- Calendulae flos(0)
- Calendulae herba(0)
- Call for all sponsors to publish clinical trial results in EU database(0)
- Call for civil society members in Paediatric Committee(0)
- Call for civil society members of EMA Management Board(0)
- Call for civil society members to join two EMA committees(0)
- Call for companies to register their Industry Single Point of Contact iSPOC on supply and availability(0)
- Call for experts in anonymisation of clinical data(0)
- Call for expression of interest for civil society representatives to participate in the work of EMAs Paediatric Committee(0)
- Call for expression of interest for health professional and patient organisations representatives for the Paediatric Committee PDCO launched(0)
- Call for expression of interest for independent scientific experts to participate in the work of EMAs Safety Committee(0)
- Call for expressions of interest for civil society representatives to participate in work of Committee for Advanced Therapies(0)
- Call for expressions of interest for civil society representatives to participate in work of EMA(0)
- Call for expressions of interest for Committee for Orphan Medicinal Products COMP members positions representing patient organisations(0)
- Call for expressions of interest for patients organisations representatives to join Committee for Orphan Medicinal Products COMP(0)
- Call for expressions of interest to appoint patient and healthcareprofessional representatives as members of Paediatric Committee(0)
- Call for independent scientific experts to join EMAs Pharmacovigilance Risk Assessment Committee PRAC(0)
- Call for independent scientific experts to join EMAs Pharmacovigilance Risk Assessment Committee PRAC deadline extended(0)
- Call for patient organisation representatives to join the Committee for Orphan Medicines(0)
- Calls for civil society members for two EMA committees(0)
- Call to pool research resources into large multicentre multiarm clinical trials to generate sound evidence on COVID19 treatments(0)
- Calquence(0)
- Camcevi(0)
- Camelliae sinensis non fermentatum folium(0)
- Camilla Aertebjerg Baek(0)
- Camilla Birgitta Göktürk(0)
- Camilla Festa(0)
- Camilla Gigg(0)
- Camilla Ledin(0)
- Camilla Svensson(0)
- Camille DE KERVASDOUE(0)
- Camille Massaux(0)
- Camille Ramahefarivony(0)
- Camzyos(0)
- Canada(0)
- Canakinumab Novartis(0)
- Cancer(0)
- Cancer Medicines Forum December 2022(0)
- Cancer Medicines Forum February 2024(0)
- Cancer Medicines Forum June 2022(0)
- Cancer Medicines Forum June 2023(0)
- Cancer Medicines Forum kickoff meeting(0)
- Cancer Medicines Forum March 2023(0)
- Cancer medicines forum meeting 4 December 2023(0)
- Cancer Medicines Forum workshop April 2024(0)
- Cancidas previously Caspofungin MSD(0)
- Candesartan/Hydrochlorothiazide(0)
- Candesartan cilexetil(0)
- Canigen L4(0)
- CaniLeish(0)
- Can measuring anticoagulant activity and concentration in the body play a role in clinical use of medicines used to prevent blood clots(0)
- Cannabis flos(0)
- Can regulators influence the affordability of medicines(0)
- Caoimhin Concannon(0)
- Capecitabine Accord(0)
- Capecitabine Medac(0)
- Capecitabine productspecific bioequivalence guidance(0)
- Capecitabine SUN(0)
- Capecitabine Teva(0)
- Caprelsa(0)
- Capsici fructus(0)
- Capsicum/capsaicin containing herbal medicinal products Scientific guideline(0)
- Carbaglu(0)
- Carcinogenicity evaluation of medicinal products for the treatment of HIV infection Scientific guideline(0)
- Carcinogenic potential Scientific guideline(0)
- Cardalis(0)
- Cardiovascular diseases(0)
- Cardiovascular Working Party(0)
- Careers(0)
- Carglumic acid productspecific bioequivalence guidance(0)
- Caridad Pontes(0)
- Carina Bergman(0)
- Carina Simons(0)
- Carina Uhe(0)
- Carin Bergquist(0)
- Carine Condy(0)
- Carine Le Jaoen(0)
- Carisbamate(0)
- Carla Cofiño Fabres(0)
- Carla Garcia Berbegal(0)
- Carla Jonker(0)
- Carla Maione(0)
- Carla Marcella Caramella(0)
- Carla Torre(0)
- Carl Henrik Alm(0)
- Carline Terendij(0)
- Carlo Colosimo(0)
- Carlos Altuna Faus(0)
- Carlos ballesteros(0)
- Carlos Gomez Martin(0)
- Carmela Macchiarulo(0)
- carmel geoghegan(0)
- Carmen de la MorenaCriado(0)
- Carmen Díez Fernández(0)
- Carmen Gallego López Jurado(0)
- carmen maffettone(0)
- Carmen Pastor Alcaide(0)
- Carmen Purdel(0)
- Carmen Sara Maestro Nombela(0)
- Carmen Verge Gonzalez(0)
- Carmustine medac previously Carmustine Obvius(0)
- Carola de Beaufort(0)
- Carola Govenius(0)
- Carola Simmer(0)
- Carole Cousin(0)
- Carole FossetMartinetti(0)
- Carole Schummer(0)
- Carolien Hovenier(0)
- Carolien Versantvoort(0)
- Carolina Elisa Rodríguez Sanz(0)
- Carolina GarciaVidal(0)
- Carolina Gracia Iguacel(0)
- Carolina Prieto Fernandez(0)
- Caroline AuricheBenichou(0)
- Caroline Bitterlich(0)
- Caroline Coner(0)
- Caroline Gjestad(0)
- Caroline Guittré(0)
- Caroline Kleber(0)
- Caroline Le(0)
- Caroline LEROUX(0)
- Caroline Matko(0)
- Caroline Moermond(0)
- Caroline Muscat(0)
- Caroline Norén(0)
- Carolin Hand(0)
- Carolin Schulte(0)
- Carsten Levin(0)
- Carvi aetheroleum(0)
- Carvi fructus(0)
- Carvykti(0)
- Caryophylli floris aetheroleum(0)
- Caryophylli flos(0)
- Casgevy(0)
- Casopitant(0)
- Casparus Nooten(0)
- Casper Holmkvist Moos(0)
- Caspofungin Accord(0)
- Caspofungin acetate(0)
- Catarina Björklund(0)
- Catarina Eriksson(0)
- Catarina Wallen(0)
- CAT Documents(0)
- Categorisation of antibiotics used in animals promotes responsible use to protect public and animal health(0)
- Catharina Husteden(0)
- Catharina Scholl(0)
- Catherijne Knibbe(0)
- Catherine Byrne(0)
- Catherine Deguines(0)
- Catherine Milne(0)
- Catherine Neary(0)
- Catherine Planchon(0)
- Cathrine Berglund(0)
- Cathrine Wisbech(0)
- Catiolanze(0)
- CAT meeting archive 20092012(0)
- CAT meeting archive 20132016(0)
- CAT meeting archive 20172019(0)
- CAT members(0)
- Catophos 100 mg/ml+005 mg/ml solution for injection for horses cattle dogs and cats and associated names(0)
- CAT scientific workshop Reducing the number of laboratory animals used in tissueengineering research by restricting the variety of animal models(0)
- CattleMarker IBR Inactivated(0)
- CATTranslational Centre for Regenerative Medicine Leipzig collaborative workshop advancedtherapy medicinal products from bench to bedside Regulatory path for translation of research to commercial medicinal products(0)
- CAT Working parties and other groups(0)
- Cavoley(0)
- Cayston(0)
- CEAScan(0)
- Cecile Choquet(0)
- Cécile Dop(0)
- Cécile Lescrainier(0)
- Cécile Majesté(0)
- Cécile Taddeï(0)
- Cecilia Bäckman Persson(0)
- Cecilia Berg(0)
- Cecilia Fornum(0)
- Cecilie Dovey de la Cour(0)
- Cédric Maerckx(0)
- Cedric Muentener(0)
- Cegfila previously Pegfilgrastim Mundipharma(0)
- Celdoxome pegylated liposomal(0)
- Celebrating 20 years EMA launches anniversary book(0)
- Celeste Freire(0)
- Celgene Europe Limited withdraws its application for an extension of the indication for Revlimid lenalidomide(0)
- Celgene Europe Limited withdraws its marketing authorisation application for Lenalidomide Celgene Europe lenalidomide(0)
- Celia Caballero Estevez(0)
- Celia Cerrato Rivera(0)
- Celia Coelho Henriques(0)
- Celia Xiomara Bonkanka Tabares(0)
- Celien Muylaert(0)
- Céline Chartier(0)
- Celine Chu(0)
- Céline Delerme(0)
- Céline Jumeau(0)
- Celine Lorteau(0)
- Celine Simoneit(0)
- Celine Thiry(0)
- CellCept(0)
- Cell culture inactivated influenza vaccines Annex to note for guidance on harmonisation of requirements for influenza vaccines(0)
- Celldemic(0)
- CellSeed Europe Ltd withdraws its marketingauthorisation application for OraNera autologous oral mucosal epithelial cells(0)
- Cellular therapy module of the European Society for Blood & Marrow Transplantation EBMT Registry(0)
- Celsentri(0)
- Celsunax(0)
- Celvapan(0)
- Centaurii herba(0)
- Centellae asiaticae herba(0)
- Centralised procedure procedures(0)
- Central Nervous System Working Party(0)
- Central register of data processing records(0)
- Central repository for safety reports one year to go before mandatory use(0)
- Central repository to facilitate assessment of medicines safety reports(0)
- Cepedex(0)
- Cephalosporins(0)
- Ceplene(0)
- Ceprotin(0)
- Cerdelga(0)
- Cerdelga recommended for approval in type 1 Gaucher disease(0)
- Cerenia(0)
- Cerepro(0)
- Cerezyme(0)
- Certifect(0)
- Certification of medicinal products(0)
- Certification procedures for advanced therapies under development by micro small and mediumsized enterprises SMEs(0)
- Cervarix(0)
- Cetrotide(0)
- Cevazuril(0)
- Cevenfacta(0)
- Chair of EMAs committee for orphan medicines receives award for outstanding patient engagement(0)
- Chair of the European Network of Paediatric Research at EMA reelected(0)
- Chamomilla containing herbal medicinal products Scientific guideline(0)
- Chamomillae romanae flos(0)
- Champix(0)
- Chanaxin(0)
- Change management for the EudraVigilance system(0)
- Change of name of liposomal medicines at high risk of medication errors(0)
- Change of time zone due to EMAs relocation in March 2019(0)
- Changes in the Human Medicines Evaluation Unit and nomination of new Head of Unit(0)
- Changes to submission and assessment of maximum residue limits of veterinary medicines in foods(0)
- Changes to variation rules start to apply from 2 November 2012(0)
- Changing the invented name of a centrally authorised medicine questions and answers(0)
- Changing the invented name of a veterinary medicine(0)
- Changing the labelling and package leaflet Article 613 notifications(0)
- Changing the name or address of a sponsor(0)
- Chanhold(0)
- Chantal Britt(0)
- Chantal van de Schootbrugge(0)
- Charlotta Bergquist(0)
- Charlotta Lofberg(0)
- Charlotte Anderberg(0)
- Charlotte Backman(0)
- Charlotte de Wolf(0)
- Charlotte Geluk(0)
- Charlotte Hejl(0)
- Charlotte Lübow(0)
- Charlotte Roffiaen(0)
- Charlotte Selvais(0)
- Charlotte Smith Bonde(0)
- Charlotte Soderberg Nyhem(0)
- Charlotte Welsh(0)
- Chau Minh Tran(0)
- Chaya Gopie(0)
- Chelidonii herba(0)
- ChemGenex Europe SAS withdraws its marketing authorisation application for Tekinex omacetaxine mepesuccinate(0)
- Chemical structure and properties criteria to be considered for the evaluation of new active substance NAS status of chemical substances Scientific guideline(0)
- Chemical structure and properties criteria to be considered for the evaluation of new active substance NAS status of chemical substances Veterinary Scientific guideline(0)
- Chemistry of active substances(0)
- Chemistry of active substances chemistry of new active substances Scientific guideline(0)
- Chemistry of active substances for veterinary medicinal products Scientific guideline(0)
- Chemistry of new active substances(0)
- Chenodeoxycholic acid Leadiant previously known as Chenodeoxycholic acid sigmatau(0)
- Cheristin(0)
- Chiara Acone(0)
- Chiara Agrati(0)
- Chiara Nardis(0)
- Chiara Parisi(0)
- Chimeric antigen receptor CAR Tcell therapy registries workshop(0)
- Chimeric murinehuman anti Interleukin 6 monoclonal antibody(0)
- China(0)
- Chloé FREYCHE(0)
- Chloroprocaine hydrochloride(0)
- CHMP Chair reelected(0)
- CHMP confirms PRAC recommendations on Kogenate Bayer/Helixate NexGen(0)
- CHMP confirms recommendations for use of Zydelig(0)
- CHMP elects new chair and vicechair at its first meeting(0)
- CHMP endorses review finding no link between viral vector in Zynteglo and blood cancer(0)
- CHMP meeting archive 20012009(0)
- CHMP meeting archive 20102012(0)
- CHMP meeting archive 20132015(0)
- CHMP meeting archive 20162018(0)
- CHMP meeting on 8 September 2010 to discuss Avandia and Pandemrix(0)
- CHMP meeting on Paroxetine and other SSRIs(0)
- CHMP meeting to discuss Multaq on Friday 2 September(0)
- CHMP meets to discuss Avandia and Pandemrix(0)
- CHMP meets to discuss Multaq(0)
- CHMP members(0)
- CHMP opinions on consultation procedures(0)
- CHMP recommends authorisation of new treatment for phenylketonuria a rare inherited metabolic disease(0)
- CHMP recommends first oralonly treatment for sleeping sickness(0)
- CHMP reelects its Chair and ViceChair(0)
- CHMP Safety Working Partys response to the Paediatric Committee regarding the use of PEGylated drug products in the paediatric population Scientific guideline(0)
- CHMP SWP conclusions and recommendations on the use of genetically modified animal models for carcinogenicity assessment Scientific guideline(0)
- CHMP Working parties and other groups(0)
- CHMP working parties reorganised(0)
- Choice of a noninferiority margin Scientific guideline(0)
- Cholestagel(0)
- Cholib(0)
- Cholic acid(0)
- Cholic acid productspecific bioequivalence guidance(0)
- ChondroCelect(0)
- Christa Hackmann(0)
- Christa Huygh(0)
- Christa Siepmann(0)
- Christel Geiges(0)
- Christelle Bizimungu(0)
- Christelle Vechot(0)
- Christiaan Keijzer(0)
- Christian B Kit Roes(0)
- Christiane Rahn(0)
- Christian Gartner(0)
- Christian Gisselbrecht(0)
- Christian Kuhne(0)
- Christian Marx(0)
- Christian Mayer(0)
- Christian Merz(0)
- Christianne Reijnders(0)
- Christianne van Rekum(0)
- Christian PitotBelin(0)
- Christian Schoerner(0)
- Christian Spiteri(0)
- Christian Strueh(0)
- Christian Taylor(0)
- Christian von Linstow(0)
- Christian Wentzel(0)
- Christian Woloch(0)
- Christian Zoschke(0)
- Christina Bokorou(0)
- Christina Bredtmann(0)
- Christina Fadler(0)
- Christina Fasser(0)
- Christina Greko(0)
- Christina Højelse(0)
- Christina Meissner(0)
- Christina Reeb(0)
- Christina Sylvia Chrysostomou(0)
- Christina Thygesen Eltorp(0)
- Christina Tischer(0)
- Christina von der Heidt(0)
- Christine Dehn(0)
- Christine Diesinger(0)
- Christine Greiner(0)
- Christine Herrington(0)
- Christine Keipert(0)
- Christine Miras(0)
- Christine Monier(0)
- Christine Prendergast(0)
- Christine SchilhartWallisch(0)
- Christine Schwarz(0)
- Christine Siezen(0)
- Christine Vaculik(0)
- Christine van Hattem(0)
- Christin Olofsson(0)
- Christof Krummeich(0)
- Christof Schaefer(0)
- Christof Scheid(0)
- Christoph Bührer(0)
- Christophe Driesmans(0)
- Christophe Focke(0)
- Christophe GENISSET(0)
- Christophe Lahorte(0)
- Christopher Janich(0)
- Christopher Kjaer Cullum(0)
- Christopher Paul Kurz(0)
- Christoph Kefeder(0)
- Christoph Liebold(0)
- Christoph Male(0)
- Christoph Mueck(0)
- Christos Lionis(0)
- Chrysanthi Valasaki(0)
- Cialis(0)
- Ciambra(0)
- Ciara Kirke(0)
- Ciara Turley(0)
- Cibinqo(0)
- Cibinqo / Jyseleca / Olumiant / Rinvoq / Xeljanz(0)
- Cichorii intybi radix(0)
- Cimalgex(0)
- Cimicifugae rhizoma(0)
- Cimzia(0)
- Cinacalcet Accordpharma(0)
- Cinacalcet Mylan(0)
- Cindy Birck(0)
- Cinnamomi cortex(0)
- Cinnamomi corticis aetheroleum(0)
- Cinqaero(0)
- Cinryze(0)
- Cinzia Ciceroni(0)
- Cinzia DAmbrosio(0)
- Circadin(0)
- CircoMax(0)
- CircoMax Myco(0)
- Circovac(0)
- CIS bio international withdraw their application for Scintimun(0)
- Cisti cretici herba(0)
- Citri bergamiae aetheroleum(0)
- Civil society representatives wanted for EMAs Management Board and Pharmacovigilance Committee(0)
- Cladribine(0)
- Claire Beuneu(0)
- Claire de Severac(0)
- ClaireLi Ding(0)
- Clara Bosbach(0)
- Clara Dingert(0)
- Clare Foley(0)
- Clarification of Comirnaty dosage interval(0)
- Clarification on Sputnik V vaccine in the EU approval process(0)
- Classification of a product as intended for a limited market and eligibility for authorisation under Article 23 of Regulation EU 2019/6 Applications for limited markets(0)
- Classification of changes for veterinary medicines(0)
- Classification of changes questions and answers(0)
- Classifications as minoruseminorspecies and limitedmarket according to former EMA policy(0)
- Class waivers(0)
- Claudia Afonso(0)
- Claudia Baranyi(0)
- Claudia Bernardini(0)
- Claudia Colussi(0)
- Claudia ElRawas(0)
- Claudia Gramiccioni(0)
- Claudia Heinbuecher(0)
- Claudia Louati(0)
- Claudia Oesterwind(0)
- Claudia Pramesberger(0)
- Claudia Pressl(0)
- Claudia Reichelt(0)
- Claudia Reichmann(0)
- Claudia Riedel(0)
- CLAUDIA SPINA(0)
- Claus Bang Pedersen(0)
- Claus Stage(0)
- Clavudale 50mg tablet for cats and dogs(0)
- Clemens Mittmann(0)
- Clevor(0)
- Clinical and nonclinical evaluation during the consultation procedure on medicinal substances contained in drugeluting medicinalsubstanceeluting coronary stents Scientific guideline(0)
- Clinical aspects related to tissue engineered products Scientific guideline(0)
- Clinical assessment of fixed combinations of herbal substances/herbal preparations Scientific guideline(0)
- Clinical data for two more medicines now available online(0)
- Clinical data publication(0)
- Clinical Data Publication Policy 0070 relaunch EMA webinar(0)
- Clinical development of fibrinolytic medicinal products in the treatment of patients with ST segment elevation acute myocardial infarction STEMI Scientific guideline(0)
- Clinical development of fixed combination medicinal products Scientific guideline(0)
- Clinical development of medicinal products for the treatment of allergic rhinoconjunctivitis Scientific guideline(0)
- Clinical development of medicinal products for the treatment of autism spectrum disorder ASD Scientific guideline(0)
- Clinical development of medicinal products for the treatment of cystic fibrosis Scientific guideline(0)
- Clinical development of medicinal products for treatment of HIV infection Scientific guideline(0)
- Clinical development of medicinal products intended for the treatment of chronic primary immune thrombocytopenia Scientific guideline(0)
- Clinical development of medicinal products intended for the treatment of pain Scientific guideline(0)
- Clinical development of products for specific immunotherapy for the treatment of allergic diseases Scientific guideline(0)
- Clinical efficacy and safety alimentary tract and metabolism(0)
- Clinical efficacy and safety allergy/immunology(0)
- Clinical efficacy and safety antiinfectives for systemic use(0)
- Clinical efficacy and safety antineoplastic and immunomodulating agents(0)
- Clinical efficacy and safety biostatistics(0)
- Clinical efficacy and safety blood and bloodforming organs(0)
- Clinical efficacy and safety cardiovascular system(0)
- Clinical efficacy and safety dermatologicals(0)
- Clinical efficacy and safety general(0)
- Clinical efficacy and safety genitourinary system and sex hormones(0)
- Clinical efficacy and safety guidelines(0)
- Clinical efficacy and safety haematology and blood products including biotech alternatives(0)
- Clinical efficacy and safety nervous system(0)
- Clinical efficacy and safety radiopharmaceuticals and diagnostic agents(0)
- Clinical efficacy and safety respiratory system(0)
- Clinical efficacy and safety rheumatology/musculoskeletal system(0)
- Clinical evaluation of antifungal agents for the treatment and prophylaxis invasive fungal disease Scientific guideline(0)
- Clinical evaluation of diagnostic agents Scientific guideline(0)
- Clinical evaluation of direct acting antiviral agents intended for treatment of chronic hepatitis C Scientific guideline(0)
- Clinical evaluation of medicinal products intended for treatment of hepatitis B Scientific guideline(0)
- Clinical evaluation of medicinal products used in weight control addendum on weight control in children Scientific guideline(0)
- Clinical evaluation of medicinal products used in weight control Scientific guideline(0)
- Clinical evaluation of new vaccines Scientific guideline(0)
- Clinical investigation of antianginal medicinal products in stable angina pectoris Scientific guideline(0)
- Clinical investigation of corticosteroids intended for use on the skin Scientific guideline(0)
- Clinical investigation of hepatitis B immunoglobulins Scientific guideline(0)
- Clinical investigation of human antiD immunoglobulin for intravenous and/or intramuscular use Scientific guideline(0)
- Clinical investigation of human normal immunoglobulin for intravenous administration IVIg Scientific guideline(0)
- Clinical investigation of human normal immunoglobulin for subcutaneous and/or intramuscular administration SCIg/IMIg Scientific guideline(0)
- Clinical investigation of human plasmaderived von Willebrand factor products Scientific guideline(0)
- Clinical investigation of immunosuppressants for solid organ transplantation Scientific guideline(0)
- Clinical investigation of medicinal products for hormone replacement therapy of oestrogen deficiency symptoms in postmenopausal women Scientific guideline(0)
- Clinical investigation of medicinal products for prevention of stroke and systemic embolic events in patients with nonvalvular atrial fibrillation Scientific guideline(0)
- Clinical investigation of medicinal products for prevention of venous thromboembolism VTE in nonsurgical patients Scientific guideline(0)
- Clinical investigation of medicinal products for prevention of venous thromboembolism VTE in patients undergoing high VTErisk surgery Scientific guideline(0)
- Clinical investigation of medicinal products for the management of Crohns disease Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment and prevention of bipolar disorder Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of acute heart failure Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of acute stroke Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of amyotrophic lateral sclerosis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of asthma Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder ADHD Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of axial spondyloarthritis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of chronic constipation Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of Duchenne and Becker muscular dystrophy Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of gout Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of juvenile idiopathic arthritis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of multiple sclerosis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of obsessive compulsive disorder Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of psoriatic arthritis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of pulmonary arterial hypertension Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of sepsis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of systemic lupus erythematosus and lupus nephritis Scientific guideline(0)
- Clinical investigation of medicinal products for the treatment of venous thromboembolic disease Scientific guideline(0)
- Clinical investigation of medicinal products for treatment of migraine Scientific guideline(0)
- Clinical investigation of medicinal products for treatment of rheumatoid arthritis Scientific guideline(0)
- Clinical investigation of medicinal products including depot preparations in the treatment of schizophrenia Scientific guideline(0)
- Clinical investigation of medicinal products indicated for generalised anxiety disorder Scientific guideline(0)
- Clinical investigation of medicinal products indicated for panic disorder Scientific guideline(0)
- Clinical investigation of medicinal products indicated for the treatment of psoriasis Scientific guideline(0)
- Clinical investigation of medicinal products indicated for the treatment of social anxiety Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of chronic heart failure Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of chronic obstructive pulmonary disease COPD Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of depression Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of epileptic disorders Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of lipid disorders Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of Parkinsons disease Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of patients with acute respiratory distress syndrome Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of peripheralarterial occlusive disease Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment of urinary incontinence Scientific guideline(0)
- Clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus Scientific guideline(0)
- Clinical investigation of medicinal products to prevent development/slow progression of chronic renal insufficiency Scientific guideline(0)
- Clinical investigation of medicinal products used in the treatment of osteoarthritis Scientific guideline(0)
- Clinical investigation of medicines for the treatment of Alzheimers disease Scientific guideline(0)
- Clinical investigation of new medicinal products for the treatment of acute coronary syndrome Scientific guideline(0)
- Clinical investigation of plasmaderived antithrombin products Scientific guideline(0)
- Clinical investigation of plasmaderived fibrin sealant/haemostatic products Scientific guideline(0)
- Clinical investigation of recombinant and human plasmaderived factor IX products Scientific guideline(0)
- Clinical investigation of recombinant and human plasmaderived factor VIII products Scientific guideline(0)
- Clinical investigation of steroid contraceptives in women Scientific guideline(0)
- Clinical investigation of the pharmacokinetics of therapeutic proteins Scientific guideline(0)
- Clinical investigation on medicinal products in the treatment of hypertension Scientific guideline(0)
- Clinical pharmacology and pharmacokinetics(0)
- Clinical pharmacology and pharmacokinetics questions and answers(0)
- Clinical requirements for non replacement therapy in haemophilia A and B Scientific guideline(0)
- Clinical Trials Information System(0)
- Clinical Trials Information System CTIS bitesize talk Annual safety report ASR(0)
- Clinical Trials Information System CTIS bitesize talk Deferral rules and Public website(0)
- Clinical Trials Information System CTIS bitesize talk Document and personal data in CTIS(0)
- Clinical Trials Information System CTIS Bitesize Talk How to submit a transitional trial in CTIS(0)
- Clinical Trials Information System CTIS bitesize talk How to submit a transitional trial in CTIS(0)
- Clinical Trials Information System CTIS bitesize talk IMPDQ only submission(0)
- Clinical Trials Information System CTIS bitesize talk Initial clinical trial application(0)
- Clinical Trials Information System CTIS bitesize talk Modifications(0)
- Clinical Trials Information System CTIS bitesize talk Notifications Part 1(0)
- Clinical Trials Information System CTIS bitesize talk Notifications Part 2(0)
- Clinical Trials Information System CTIS bitesize talk Part Ionly applications and Part II requirements in CTIS(0)
- Clinical Trials Information System CTIS bitesize talk Requests for information(0)
- Clinical Trials Information System CTIS bitesize talk Training materials CTIS prerequisites and updates on transparency rules(0)
- Clinical Trials Information System CTIS bitesize talk Transitional trials and additional Member State concerned MSC application(0)
- Clinical Trials Information System CTIS bitesize talk User access and role management(0)
- Clinical Trials Information System CTIS demonstration for stakeholders(0)
- Clinical Trials Information System CTIS Information day(0)
- Clinical Trials Information System CTIS online training modules(0)
- Clinical Trials Information System CTIS Readiness for mandatory use of the Clinical Trials Regulation from 31 January 2023(0)
- Clinical Trials Information System CTIS sponsor end user training programme April 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme April 2024(0)
- Clinical Trials Information System CTIS sponsor end user training programme December 2023(0)
- Clinical Trials Information System CTIS sponsor end user training programme February 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme February 2023(0)
- Clinical Trials Information System CTIS sponsor end user training programme February 2024(0)
- Clinical Trials Information System CTIS sponsor end user training programme January 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme June 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme June 2023(0)
- Clinical Trials Information System CTIS sponsor end user training programme June 2024(0)
- Clinical Trials Information System CTIS sponsor end user training programme March 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme May 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme May 2023(0)
- Clinical Trials Information System CTIS sponsor end user training programme November 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme October 2023(0)
- Clinical Trials Information System CTIS sponsor end user training programme September 2022(0)
- Clinical Trials Information System CTIS sponsor end user training programme September 2023(0)
- Clinical Trials Information System CTIS Virtual information day(0)
- Clinical Trials Information System CTIS Walkin clinic(0)
- Clinical Trials Information System CTIS Walkin clinic 5 May 2022(0)
- Clinical Trials Information System CTIS Walkin clinic April 2022(0)
- Clinical Trials Information System CTIS Walkin clinic April 2023(0)
- Clinical Trials Information System CTIS Walkin clinic August 2022(0)
- Clinical Trials Information System CTIS Walkin clinic December 2023(0)
- Clinical Trials Information System CTIS Walkin clinic February 2023(0)
- Clinical Trials Information System CTIS Walkin clinic January 2023(0)
- Clinical Trials Information System CTIS Walkin clinic January 2024(0)
- Clinical Trials Information System CTIS Walkin clinic July 2023(0)
- Clinical Trials Information System CTIS Walkin clinic June 2022(0)
- Clinical Trials Information System CTIS Walkin clinic June 2023(0)
- Clinical Trials Information System CTIS Walkin clinic March 2022(0)
- Clinical Trials Information System CTIS Walkin clinic March 2023(0)
- Clinical Trials Information System CTIS Walkin clinic March 2024(0)
- Clinical Trials Information System CTIS Walkin clinic May 2022(0)
- Clinical Trials Information System CTIS Walkin clinic May 2023(0)
- Clinical Trials Information System CTIS Walkin clinic May 2024(0)
- Clinical Trials Information System CTIS Walkin clinic November 2022(0)
- Clinical Trials Information System CTIS Walkin clinic November 2023(0)
- Clinical Trials Information System CTIS Walkin clinic October 2022(0)
- Clinical Trials Information System CTIS Walkin clinic September 2022(0)
- Clinical Trials Information System CTIS Walkin clinic September 2023(0)
- Clinical Trials Information System CTIS Webinar 9 months on and going forward November 2022(0)
- Clinical Trials Information System CTIS webinar How sponsor organisations can prepare for CTIS(0)
- Clinical Trials Information System CTIS webinar Six months of CTIS and looking forward(0)
- Clinical Trials Information System reaches major milestone towards golive and application of the Clinical Trial Regulation(0)
- Clinical Trials Information System training and support(0)
- Clinical Trials Information System Webinar Last Year of Transition(0)
- Clinical Trials Information System Webinar Second Year of Transition(0)
- Clinical trials in human medicines(0)
- Clinical trials in small populations Scientific guideline(0)
- Clinical Trials Regulation(0)
- Clinical Trials Regulation progress on implementation(0)
- Clinical trials transition to new EU system one year left(0)
- Clinical trials with haematopoietic growth factors for the prophylaxis of infection following myelosuppressive or myeloablative therapy Scientific guideline(0)
- Clodagh Kearney(0)
- Clomicalm(0)
- Clopidogrel(0)
- Clopidogrel/Acetylsalicylic acid Teva(0)
- Clopidogrel / Acetylsalicylic acid Viatris previously Clopidogrel / Acetylsalicylic acid Mylan(0)
- Clopidogrel/Acetylsalicylic acid Zentiva previously DuoCover(0)
- Clopidogrel 1A Pharma(0)
- Clopidogrel Acino(0)
- Clopidogrel Acino Pharma(0)
- Clopidogrel Acino Pharma GmbH(0)
- Clopidogrel BGR previously Zylagren(0)
- Clopidogrel BMS(0)
- Clopidogrel DURA(0)
- Clopidogrel HCS(0)
- Clopidogrel Hexal(0)
- Clopidogrel Krka(0)
- Clopidogrel Krka dd previously Zopya(0)
- Clopidogrel Qualimed(0)
- Clopidogrel ratiopharm(0)
- Clopidogrel ratiopharm GmbH(0)
- Clopidogrel Sandoz(0)
- Clopidogrel TAD(0)
- Clopidogrel Taw Pharma previously Clopidogrel Mylan(0)
- Clopidogrel Teva Generics BV(0)
- Clopidogrel Teva hydrogen sulphate(0)
- Clopidogrel Teva Pharma(0)
- Clopidogrel Teva Pharma BV(0)
- Clopidogrel Teva Pharma previously Clopidogrel HCS(0)
- Clopidogrel Viatris previously Clopidogrel Taw Pharma(0)
- Clopidogrel Zentiva previously Clopidogrel Winthrop(0)
- Closamectin Pouron Solution and associated names(0)
- Closantel(0)
- Closer ties on medicines safety between EU and Japan(0)
- Closer ties on medicines safety between European and Canadian regulatory authorities(0)
- Clostridium collagenase(0)
- Cluster activities(0)
- Clynav(0)
- CMDh agrees to strengthen warnings on the use of valproate medicines in women and girls(0)
- CMDh confirms recommendations on restricting use of domperidonecontaining medicines(0)
- CMDh confirms that methylprednisolone injections containing lactose must not be given to patients allergic to cows milk proteins(0)
- CMDh endorses new advice to minimise risk of nextmorning impaired driving ability and mental alertness with zolpidem(0)
- CMDh endorses recommendations to restrict the use of diacereincontaining medicines(0)
- CMDh endorses restricted use of bromocriptine for stopping breast milk production(0)
- CMDh endorses revocation of authorisations for fusafungine sprays used to treat airway infections(0)
- CMDh endorses suspension of methadone oral solutions containing high molecular weight povidone(0)
- Cnici benedicti herba(0)
- Coagadex(0)
- CoAprovel(0)
- Cobactan DC and its associated names(0)
- Cobactan IV 45% powder and solvent for solution for injection and its associated names(0)
- Codeine not to be used in children below 12 years for cough and cold(0)
- Codevelopment of pharmacogenomic biomarkers and assays in the context of drug development Scientific guideline(0)
- Codex Alimentarius(0)
- Coglapix suspension for injection for pigs(0)
- Cokiera(0)
- Colae semen(0)
- Colchicine productspecific bioequivalence guidance(0)
- Colesevelam hydrochloride(0)
- Coliprotec F4(0)
- Coliprotec F4/F18(0)
- Colistin(0)
- Colistin combinations(0)
- Colistin oral(0)
- Collaboration on neonatal issues between researchers and the European Medicines Agency(0)
- Collaboration with academia to be reinforced(0)
- Collecting highquality data on antibiotic use in animals in support of the fight against antimicrobial resistance(0)
- Collecting highquality information on medicines through patient registries(0)
- Colobreathe(0)
- Colour change for insulin injection Fiasp to avoid mix ups with Tresiba(0)
- Columvi(0)
- Combimarv(0)
- Combimox Lactating Cow(0)
- Combination Species pectorales(0)
- Combined use of medicines affecting the reninangiotensin system RAS to be restricted CHMP endorses PRAC recommendation(0)
- Combisyn Lactating Cow(0)
- Combivir(0)
- Cometriq(0)
- Comfortis(0)
- Comfyde(0)
- Comirnaty(0)
- Comirnaty / Spikevax previously COVID19 Vaccine Moderna(0)
- Comirnaty and Spikevax EMA recommendations on extra doses and boosters(0)
- Comirnaty and Spikevax possible link to very rare cases of myocarditis and pericarditis(0)
- Comirnaty COVID19 vaccine EMA recommends approval for children aged 5 to 11(0)
- Comirnaty EMA recommends approval of adapted COVID19 vaccine targeting Omicron XBB15(0)
- Comments invited on concept paper on the need to revise the guideline on medicines to treat Alzheimers disease(0)
- Comments invited on draft reflection paper on data requirements for ironbased nanocolloidal products developed with reference to an innovator medicine(0)
- Comments invited on draft revised guideline on biosimilars(0)
- Comments invited on draft revised guideline on medicines for the treatment of hypertension(0)
- Comments invited on goodpharmacovigilancepractice module on reporting of adverse reactions(0)
- Comments invited on guidance on clinical investigation of medicines for the treatment of asthma(0)
- Comments invited on guideline for the demonstration of efficacy for veterinary medicines containing antimicrobials(0)
- Comments invited on joint EUJapan reflection paper on medicines delivered using nanosized block copolymer micelles(0)
- Comments invited on reflection paper on risk of antimicrobial resistance transfer from companion animals to humans(0)
- Comments invited on the ICH E2C R2 guideline on periodic benefitrisk evaluation report(0)
- Committee for Advanced Therapies activities streamlined(0)
- Committee for Advanced Therapies adopts first classification recommendation for an advanced therapy medicinal product(0)
- Committee for Advanced Therapies adopts fiveyear work programme to foster development of advanced therapies(0)
- Committee for Advanced Therapies CAT(0)
- Committee for Advanced Therapies CAT 15 June 2023(0)
- Committee for Advanced Therapies CAT 24 December 2020(0)
- Committee for Advanced Therapies CAT 24 December 2026(0)
- Committee for Advanced Therapies CAT 34 November 2016(0)
- Committee for Advanced Therapies CAT 34 November 2022(0)
- Committee for Advanced Therapies CAT 35 December 2025(0)
- Committee for Advanced Therapies CAT 35 November 2021(0)
- Committee for Advanced Therapies CAT 46 December 2019(0)
- Committee for Advanced Therapies CAT 46 December 2024(0)
- Committee for Advanced Therapies CAT 46 November 2020(0)
- Committee for Advanced Therapies CAT 46 November 2026(0)
- Committee for Advanced Therapies CAT 46 October 2017(0)
- Committee for Advanced Therapies CAT 46 October 2023(0)
- Committee for Advanced Therapies CAT 57 December 2018(0)
- Committee for Advanced Therapies CAT 57 November 2025(0)
- Committee for Advanced Therapies CAT 57 October 2022(0)
- Committee for Advanced Therapies CAT 67 December 2012(0)
- Committee for Advanced Therapies CAT 67 October 2016(0)
- Committee for Advanced Therapies CAT 68 December 2017(0)
- Committee for Advanced Therapies CAT 68 December 2023(0)
- Committee for Advanced Therapies CAT 68 November 2019(0)
- Committee for Advanced Therapies CAT 68 November 2024(0)
- Committee for Advanced Therapies CAT 68 October 2021(0)
- Committee for Advanced Therapies CAT 68 September 2017(0)
- Committee for Advanced Therapies CAT 68 September 2023(0)
- Committee for Advanced Therapies CAT 78 April 2011(0)
- Committee for Advanced Therapies CAT 79 December 2016(0)
- Committee for Advanced Therapies CAT 79 December 2022(0)
- Committee for Advanced Therapies CAT 79 November 2018(0)
- Committee for Advanced Therapies CAT 79 October 2020(0)
- Committee for Advanced Therapies CAT 79 October 2026(0)
- Committee for Advanced Therapies CAT 79 September 2022(0)
- Committee for Advanced Therapies CAT 89 December 2011(0)
- Committee for Advanced Therapies CAT 89 March 2012(0)
- Committee for Advanced Therapies CAT 89 November 2012(0)
- Committee for Advanced Therapies CAT 89 September 2016(0)
- Committee for Advanced Therapies CAT 810 December 2021(0)
- Committee for Advanced Therapies CAT 810 October 2025(0)
- Committee for Advanced Therapies CAT 810 September 2021(0)
- Committee for Advanced Therapies CAT 910 December 2010(0)
- Committee for Advanced Therapies CAT 910 February 2012(0)
- Committee for Advanced Therapies CAT 911 August 2023(0)
- Committee for Advanced Therapies CAT 911 January 2013(0)
- Committee for Advanced Therapies CAT 911 October 2019(0)
- Committee for Advanced Therapies CAT 911 October 2024(0)
- Committee for Advanced Therapies CAT 911 September 2020(0)
- Committee for Advanced Therapies CAT 911 September 2026(0)
- Committee for Advanced Therapies CAT 1011 December 2015(0)
- Committee for Advanced Therapies CAT 1011 February 2011(0)
- Committee for Advanced Therapies CAT 1011 March 2011(0)
- Committee for Advanced Therapies CAT 1011 November 2011(0)
- Committee for Advanced Therapies CAT 1012 April 2017(0)
- Committee for Advanced Therapies CAT 1012 August 2022(0)
- Committee for Advanced Therapies CAT 1012 May 2017(0)
- Committee for Advanced Therapies CAT 1012 May 2021(0)
- Committee for Advanced Therapies CAT 1012 October 2018(0)
- Committee for Advanced Therapies CAT 1012 September 2025(0)
- Committee for Advanced Therapies CAT 1112 August 2011(0)
- Committee for Advanced Therapies CAT 1112 December 2014(0)
- Committee for Advanced Therapies CAT 1112 February 2010(0)
- Committee for Advanced Therapies CAT 1112 March 2010(0)
- Committee for Advanced Therapies CAT 1112 May 2010(0)
- Committee for Advanced Therapies CAT 1112 November 2010(0)
- Committee for Advanced Therapies CAT 1112 October 2012(0)
- Committee for Advanced Therapies CAT 1113 April 2022(0)
- Committee for Advanced Therapies CAT 1113 August 2021(0)
- Committee for Advanced Therapies CAT 1113 July 2012(0)
- Committee for Advanced Therapies CAT 1113 June 2025(0)
- Committee for Advanced Therapies CAT 1113 May 2022(0)
- Committee for Advanced Therapies CAT 1113 May 2026(0)
- Committee for Advanced Therapies CAT 1113 September 2013(0)
- Committee for Advanced Therapies CAT 1113 September 2019(0)
- Committee for Advanced Therapies CAT 1113 September 2024(0)
- Committee for Advanced Therapies CAT 1213 April 2012(0)
- Committee for Advanced Therapies CAT 1213 December 2013(0)
- Committee for Advanced Therapies CAT 1213 January 2012(0)
- Committee for Advanced Therapies CAT 1213 May 2011(0)
- Committee for Advanced Therapies CAT 1213 May 2015(0)
- Committee for Advanced Therapies CAT 1213 November 2015(0)
- Committee for Advanced Therapies CAT 1214 August 2020(0)
- Committee for Advanced Therapies CAT 1214 July 2017(0)
- Committee for Advanced Therapies CAT 1214 July 2023(0)
- Committee for Advanced Therapies CAT 1214 September 2018(0)
- Committee for Advanced Therapies CAT 1314 February 2014(0)
- Committee for Advanced Therapies CAT 1314 January 2011(0)
- Committee for Advanced Therapies CAT 1314 March 2014(0)
- Committee for Advanced Therapies CAT 1314 November 2014(0)
- Committee for Advanced Therapies CAT 1314 October 2011(0)
- Committee for Advanced Therapies CAT 1314 September 2012(0)
- Committee for Advanced Therapies CAT 1315 July 2016(0)
- Committee for Advanced Therapies CAT 1315 July 2022(0)
- Committee for Advanced Therapies CAT 1315 March 2013(0)
- Committee for Advanced Therapies CAT 1315 March 2024(0)
- Committee for Advanced Therapies CAT 1315 November 2013(0)
- Committee for Advanced Therapies CAT 1316 August 2024(0)
- Committee for Advanced Therapies CAT 1415 February 2013(0)
- Committee for Advanced Therapies CAT 1415 January 2010(0)
- Committee for Advanced Therapies CAT 1415 July 2011(0)
- Committee for Advanced Therapies CAT 1415 June 2012(0)
- Committee for Advanced Therapies CAT 1415 October 2010(0)
- Committee for Advanced Therapies CAT 1416 April 2021(0)
- Committee for Advanced Therapies CAT 1416 April 2025(0)
- Committee for Advanced Therapies CAT 1416 August 2013(0)
- Committee for Advanced Therapies CAT 1416 February 2024(0)
- Committee for Advanced Therapies CAT 1416 July 2021(0)
- Committee for Advanced Therapies CAT 1416 June 2017(0)
- Committee for Advanced Therapies CAT 1416 March 2018(0)
- Committee for Advanced Therapies CAT 1416 May 2025(0)
- Committee for Advanced Therapies CAT 1516 April 2010(0)
- Committee for Advanced Therapies CAT 1516 April 2014(0)
- Committee for Advanced Therapies CAT 1516 February 2018(0)
- Committee for Advanced Therapies CAT 1516 January 2015(0)
- Committee for Advanced Therapies CAT 1516 July 2010(0)
- Committee for Advanced Therapies CAT 1516 May 2012(0)
- Committee for Advanced Therapies CAT 1516 May 2014(0)
- Committee for Advanced Therapies CAT 1516 October 2015(0)
- Committee for Advanced Therapies CAT 1516 September 2011(0)
- Committee for Advanced Therapies CAT 1517 April 2026(0)
- Committee for Advanced Therapies CAT 1517 February 2017(0)
- Committee for Advanced Therapies CAT 1517 February 2023(0)
- Committee for Advanced Therapies CAT 1517 July 2020(0)
- Committee for Advanced Therapies CAT 1517 July 2026(0)
- Committee for Advanced Therapies CAT 1517 June 2022(0)
- Committee for Advanced Therapies CAT 1517 March 2017(0)
- Committee for Advanced Therapies CAT 1517 May 2023(0)
- Committee for Advanced Therapies CAT 1617 April 2015(0)
- Committee for Advanced Therapies CAT 1617 April 2019(0)
- Committee for Advanced Therapies CAT 1617 August 2012(0)
- Committee for Advanced Therapies CAT 1617 January 2014(0)
- Committee for Advanced Therapies CAT 1617 July 2015(0)
- Committee for Advanced Therapies CAT 1617 June 2011(0)
- Committee for Advanced Therapies CAT 1617 June 2016(0)
- Committee for Advanced Therapies CAT 1617 October 2014(0)
- Committee for Advanced Therapies CAT 1617 September 2010(0)
- Committee for Advanced Therapies CAT 1618 February 2022(0)
- Committee for Advanced Therapies CAT 1618 July 2025(0)
- Committee for Advanced Therapies CAT 1618 June 2021(0)
- Committee for Advanced Therapies CAT 1618 March 2022(0)
- Committee for Advanced Therapies CAT 1618 October 2013(0)
- Committee for Advanced Therapies CAT 1718 July 2014(0)
- Committee for Advanced Therapies CAT 1718 June 2010(0)
- Committee for Advanced Therapies CAT 1718 March 2021(0)
- Committee for Advanced Therapies CAT 1718 September 2015(0)
- Committee for Advanced Therapies CAT 1719 April 2024(0)
- Committee for Advanced Therapies CAT 1719 February 2021(0)
- Committee for Advanced Therapies CAT 1719 January 2018(0)
- Committee for Advanced Therapies CAT 1719 January 2024(0)
- Committee for Advanced Therapies CAT 1719 July 2013(0)
- Committee for Advanced Therapies CAT 1719 July 2019(0)
- Committee for Advanced Therapies CAT 1719 July 2024(0)
- Committee for Advanced Therapies CAT 1719 June 2020(0)
- Committee for Advanced Therapies CAT 1719 June 2026(0)
- Committee for Advanced Therapies CAT 1819 April 2013(0)
- Committee for Advanced Therapies CAT 1819 February 2016(0)
- Committee for Advanced Therapies CAT 1819 January 2023(0)
- Committee for Advanced Therapies CAT 1819 June 2015(0)
- Committee for Advanced Therapies CAT 1819 September 2014(0)
- Committee for Advanced Therapies CAT 1820 April 2018(0)
- Committee for Advanced Therapies CAT 1820 February 2026(0)
- Committee for Advanced Therapies CAT 1820 January 2017(0)
- Committee for Advanced Therapies CAT 1820 January 2023(0)
- Committee for Advanced Therapies CAT 1820 July 2018(0)
- Committee for Advanced Therapies CAT 1820 March 2020(0)
- Committee for Advanced Therapies CAT 1820 March 2026(0)
- Committee for Advanced Therapies CAT 1820 May 2016(0)
- Committee for Advanced Therapies CAT 1820 May 2020(0)
- Committee for Advanced Therapies CAT 1920 February 2015(0)
- Committee for Advanced Therapies CAT 1920 June 2014(0)
- Committee for Advanced Therapies CAT 1920 March 2015(0)
- Committee for Advanced Therapies CAT 1921 April 2023(0)
- Committee for Advanced Therapies CAT 1921 February 2020(0)
- Committee for Advanced Therapies CAT 1921 February 2025(0)
- Committee for Advanced Therapies CAT 1921 January 2022(0)
- Committee for Advanced Therapies CAT 1921 June 2013(0)
- Committee for Advanced Therapies CAT 1921 June 2019(0)
- Committee for Advanced Therapies CAT 1921 June 2024(0)
- Committee for Advanced Therapies CAT 1921 March 2025(0)
- Committee for Advanced Therapies CAT 2021 April 2016(0)
- Committee for Advanced Therapies CAT 2022 February 2019(0)
- Committee for Advanced Therapies CAT 2022 January 2021(0)
- Committee for Advanced Therapies CAT 2022 June 2018(0)
- Committee for Advanced Therapies CAT 2022 March 2019(0)
- Committee for Advanced Therapies CAT 2122 January 2016(0)
- Committee for Advanced Therapies CAT 2123 January 2026(0)
- Committee for Advanced Therapies CAT 2223 March 2016(0)
- Committee for Advanced Therapies CAT 2223 March 2023(0)
- Committee for Advanced Therapies CAT 2224 April 2020(0)
- Committee for Advanced Therapies CAT 2224 January 2020(0)
- Committee for Advanced Therapies CAT 2224 January 2025(0)
- Committee for Advanced Therapies CAT 2224 May 2013(0)
- Committee for Advanced Therapies CAT 2224 May 2019(0)
- Committee for Advanced Therapies CAT 2224 May 2024(0)
- Committee for Advanced Therapies CAT 2325 January 2019(0)
- Committee for Advanced Therapies CAT 2325 May 2018(0)
- Committee for Advanced Therapies CAT 3031 October 2017(0)
- Committee for Advanced Therapies CAT 3031 October 2023(0)
- Committee for Advanced Therapies CAT and the German Society for Transfusion Medicine and Immunohaematology DGTI workshop on advancedtherapy medicinal products How to bring cellbased medicinal products successfully to the market(0)
- Committee for Advanced Therapies CAT and the International Society for Cellular Therapy ISCT workshop challenges and opportunities for a successful development and approval of advanced therapy medicinal products(0)
- Committee for Advanced Therapies CAT elects chair and vicechair(0)
- Committee for Advanced Therapies CAT expert meeting on scientific and regulatory considerations for adenoassociated viral vector AVVbased gene therapy(0)
- Committee for Advanced Therapies CAT meeting with interested parties(0)
- Committee for Advanced Therapies CAT meeting with interested parties May 2023(0)
- Committee for Advanced Therapies CAT workshop scientific and regulatory challenges of genetically modified cellbased cancer immunotherapy products(0)
- Committee for advanced therapies election of new chair overview of 2013 and looking ahead(0)
- Committee for Advanced TherapiesEuropean Society for Gene and Cell Therapy satellite workshop Advancedtherapy medicinal products(0)
- Committee for Advanced Therapies focus on incentives for SMEs and strengthened interaction with stakeholders(0)
- Committee for Advanced Therapies gives first certification opinion for advanced therapies medicinal product(0)
- Committee for Advanced Therapies issues first recommendation for certification of nonclinical data for an advanced therapy(0)
- Committee for Advanced Therapies reelects Christian Schneider as chair(0)
- Committee for Herbal Medicinal Products HMPC 0103 March 2021(0)
- Committee for Herbal Medicinal Products HMPC 0608 July 2020(0)
- Committee for Herbal Medicinal Products HMPC 10 May 2011(0)
- Committee for Herbal Medicinal Products HMPC 12 February 2016(0)
- Committee for Herbal Medicinal Products HMPC 24 March 2020(0)
- Committee for Herbal Medicinal Products HMPC 24 March 2026(0)
- Committee for Herbal Medicinal Products HMPC 24 November 2014(0)
- Committee for Herbal Medicinal Products HMPC 24 September 2012(0)
- Committee for Herbal Medicinal Products HMPC 30 June1 July 2014(0)
- Committee for Herbal Medicinal Products HMPC 30 May 31 May 2016(0)
- Committee for Herbal Medicinal Products HMPC 35 May 2021(0)
- Committee for Herbal Medicinal Products HMPC 45 April 2016(0)
- Committee for Herbal Medicinal Products HMPC 45 June 2018(0)
- Committee for Herbal Medicinal Products HMPC 45 May 2015(0)
- Committee for Herbal Medicinal Products HMPC 46 May 2020(0)
- Committee for Herbal Medicinal Products HMPC 46 May 2026(0)
- Committee for Herbal Medicinal Products HMPC 56 May 2010(0)
- Committee for Herbal Medicinal Products HMPC 56 May 2014(0)
- Committee for Herbal Medicinal Products HMPC 57 July 2021(0)
- Committee for Herbal Medicinal Products HMPC 57 May 2025(0)
- Committee for Herbal Medicinal Products HMPC 67 July 2015(0)
- Committee for Herbal Medicinal Products HMPC 68 July 2026(0)
- Committee for Herbal Medicinal Products HMPC 79 July 2025(0)
- Committee for Herbal Medicinal Products HMPC 89 July 2013(0)
- Committee for Herbal Medicinal Products HMPC 810 July 2019(0)
- Committee for Herbal Medicinal Products HMPC 910 March 2015(0)
- Committee for Herbal Medicinal Products HMPC 1011 March 2010(0)
- Committee for Herbal Medicinal Products HMPC 1012 May 2023(0)
- Committee for Herbal Medicinal Products HMPC 1112 July 2011(0)
- Committee for Herbal Medicinal Products HMPC 1112 July 2016(0)
- Committee for Herbal Medicinal Products HMPC 1112 March 2013(0)
- Committee for Herbal Medicinal Products HMPC 1112 November 2013(0)
- Committee for Herbal Medicinal Products HMPC 1113 January 2021(0)
- Committee for Herbal Medicinal Products HMPC 1213 September 2011(0)
- Committee for Herbal Medicinal Products HMPC 1314 January 2010(0)
- Committee for Herbal Medicinal Products HMPC 1314 May 2013(0)
- Committee for Herbal Medicinal Products HMPC 1315 January 2020(0)
- Committee for Herbal Medicinal Products HMPC 1315 March 2023(0)
- Committee for Herbal Medicinal Products HMPC 1315 May 2019(0)
- Committee for Herbal Medicinal Products HMPC 1415 January 2013(0)
- Committee for Herbal Medicinal Products HMPC 1415 July 2010(0)
- Committee for Herbal Medicinal Products HMPC 1416 January 2019(0)
- Committee for Herbal Medicinal Products HMPC 1516 September 2010(0)
- Committee for Herbal Medicinal Products HMPC 1617 September 2013(0)
- Committee for Herbal Medicinal Products HMPC 1618 May 2022(0)
- Committee for Herbal Medicinal Products HMPC 1618 November 2020(0)
- Committee for Herbal Medicinal Products HMPC 1618 November 2026(0)
- Committee for Herbal Medicinal Products HMPC 1718 July 2017(0)
- Committee for Herbal Medicinal Products HMPC 1719 July 2023(0)
- Committee for Herbal Medicinal Products HMPC 1719 March 2025(0)
- Committee for Herbal Medicinal Products HMPC 1719 November 2025(0)
- Committee for Herbal Medicinal Products HMPC 1819 September 2017(0)
- Committee for Herbal Medicinal Products HMPC 1820 July 2022(0)
- Committee for Herbal Medicinal Products HMPC 1820 March 2024(0)
- Committee for Herbal Medicinal Products HMPC 1820 November 2019(0)
- Committee for Herbal Medicinal Products HMPC 1820 November 2024(0)
- Committee for Herbal Medicinal Products HMPC 1820 September 2023(0)
- Committee for Herbal Medicinal Products HMPC 1920 November 2012(0)
- Committee for Herbal Medicinal Products HMPC 1920 November 2018(0)
- Committee for Herbal Medicinal Products HMPC 1920 September 2016(0)
- Committee for Herbal Medicinal Products HMPC 1921 January 2026(0)
- Committee for Herbal Medicinal Products HMPC 1921 September 2022(0)
- Committee for Herbal Medicinal Products HMPC 2021 November 2017(0)
- Committee for Herbal Medicinal Products HMPC 2022 January 2025(0)
- Committee for Herbal Medicinal Products HMPC 2022 November 2023(0)
- Committee for Herbal Medicinal Products HMPC 2022 September 2021(0)
- Committee for Herbal Medicinal Products HMPC 2122 May 2012(0)
- Committee for Herbal Medicinal Products HMPC 2122 November 2011(0)
- Committee for Herbal Medicinal Products HMPC 2122 November 2016(0)
- Committee for Herbal Medicinal Products HMPC 2123 November 2022(0)
- Committee for Herbal Medicinal Products HMPC 2123 September 2020(0)
- Committee for Herbal Medicinal Products HMPC 2123 September 2026(0)
- Committee for Herbal Medicinal Products HMPC 2224 July 2024(0)
- Committee for Herbal Medicinal Products HMPC 2224 November 2021(0)
- Committee for Herbal Medicinal Products HMPC 2224 September 2025(0)
- Committee for Herbal Medicinal Products HMPC 2324 January 2012(0)
- Committee for Herbal Medicinal Products HMPC 2324 July 2018(0)
- Committee for Herbal Medicinal Products HMPC 2324 November 2015(0)
- Committee for Herbal Medicinal Products HMPC 2325 January 2023(0)
- Committee for Herbal Medicinal Products HMPC 2325 September 2019(0)
- Committee for Herbal Medicinal Products HMPC 2325 September 2024(0)
- Committee for Herbal Medicinal Products HMPC 2425 March 2014(0)
- Committee for Herbal Medicinal Products HMPC 2425 November 2010(0)
- Committee for Herbal Medicinal Products HMPC 2425 September 2018(0)
- Committee for Herbal Medicinal Products HMPC 2426 January 2022(0)
- Committee for Herbal Medicinal Products HMPC 2627 January 2011(0)
- Committee for Herbal Medicinal Products HMPC 2627 March 2012(0)
- Committee for Herbal Medicinal Products HMPC 2627 March 2018(0)
- Committee for Herbal Medicinal Products HMPC 2728 January 2014(0)
- Committee for Herbal Medicinal Products HMPC 2728 January 2015(0)
- Committee for Herbal Medicinal Products HMPC 2728 March 2017(0)
- Committee for Herbal Medicinal Products HMPC 2729 May 2024(0)
- Committee for Herbal Medicinal Products HMPC 2829 September 2015(0)
- Committee for Herbal Medicinal Products HMPC 2830 March 2022(0)
- Committee for Herbal Medicinal Products HMPC 2930 January 2018(0)
- Committee for Herbal Medicinal Products HMPC 2930 May 2017(0)
- Committee for Herbal Medicinal Products HMPC 2930 September 2014(0)
- Committee for Herbal Medicinal Products HMPC 2931 January 2024(0)
- Committee for Herbal Medicinal Products HMPC 3031 January 2017(0)
- Committee for Herbal Medicinal Products HMPC 3031 March 2011(0)
- Committee for Medicinal Products for Human Use CHMP(0)
- Committee for Medicinal Products for Human Use CHMP 0710 December 2026(0)
- Committee for Medicinal Products for Human Use CHMP 0811 December 2025(0)
- Committee for Medicinal Products for Human Use CHMP 0912 December 2019(0)
- Committee for Medicinal Products for Human Use CHMP 0912 December 2024(0)
- Committee for Medicinal Products for Human Use CHMP 0912 November 2026(0)
- Committee for Medicinal Products for Human Use CHMP 0912 October 2023(0)
- Committee for Medicinal Products for Human Use CHMP 29 March 01 April 2016(0)
- Committee for Medicinal Products for Human Use CHMP 69 November 2017(0)
- Committee for Medicinal Products for Human Use CHMP 69 November 2023(0)
- Committee for Medicinal Products for Human Use CHMP 710 December 2020(0)
- Committee for Medicinal Products for Human Use CHMP 710 November 2016(0)
- Committee for Medicinal Products for Human Use CHMP 710 November 2022(0)
- Committee for Medicinal Products for Human Use CHMP 811 November 2021(0)
- Committee for Medicinal Products for Human Use CHMP 912 November 2020(0)
- Committee for Medicinal Products for Human Use CHMP 912 October 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1013 December 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1013 December 2018(0)
- Committee for Medicinal Products for Human Use CHMP 1013 November 2025(0)
- Committee for Medicinal Products for Human Use CHMP 1013 October 2016(0)
- Committee for Medicinal Products for Human Use CHMP 1013 October 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1114 April 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1114 December 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1114 December 2023(0)
- Committee for Medicinal Products for Human Use CHMP 1114 November 2019(0)
- Committee for Medicinal Products for Human Use CHMP 1114 November 2024(0)
- Committee for Medicinal Products for Human Use CHMP 1114 October 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1114 September 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1114 September 2023(0)
- Committee for Medicinal Products for Human Use CHMP 1215 December 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1215 December 2016(0)
- Committee for Medicinal Products for Human Use CHMP 1215 December 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1215 March 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1215 November 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1215 November 2018(0)
- Committee for Medicinal Products for Human Use CHMP 1215 October 2020(0)
- Committee for Medicinal Products for Human Use CHMP 1215 October 2026(0)
- Committee for Medicinal Products for Human Use CHMP 1215 September 2016(0)
- Committee for Medicinal Products for Human Use CHMP 1215 September 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1316 December 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1316 December 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1316 February 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1316 October 2025(0)
- Committee for Medicinal Products for Human Use CHMP 1316 September 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1417 August 2023(0)
- Committee for Medicinal Products for Human Use CHMP 1417 December 2015(0)
- Committee for Medicinal Products for Human Use CHMP 1417 February 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1417 January 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1417 March 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1417 November 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1417 October 2019(0)
- Committee for Medicinal Products for Human Use CHMP 1417 October 2024(0)
- Committee for Medicinal Products for Human Use CHMP 1417 September 2020(0)
- Committee for Medicinal Products for Human Use CHMP 1417 September 2026(0)
- Committee for Medicinal Products for Human Use CHMP 1518 August 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1518 December 2014(0)
- Committee for Medicinal Products for Human Use CHMP 1518 February 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1518 March 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1518 May 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1518 November 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1518 October 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1518 October 2018(0)
- Committee for Medicinal Products for Human Use CHMP 1518 September 2025(0)
- Committee for Medicinal Products for Human Use CHMP 1619 April 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1619 August 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1619 August 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1619 December 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1619 January 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1619 July 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1619 June 2025(0)
- Committee for Medicinal Products for Human Use CHMP 1619 May 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1619 May 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1619 November 2015(0)
- Committee for Medicinal Products for Human Use CHMP 1619 September 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1619 September 2019(0)
- Committee for Medicinal Products for Human Use CHMP 1619 September 2024(0)
- Committee for Medicinal Products for Human Use CHMP 1720 August 2026(0)
- Committee for Medicinal Products for Human Use CHMP 1720 February 2014(0)
- Committee for Medicinal Products for Human Use CHMP 1720 January 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1720 July 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1720 July 2023(0)
- Committee for Medicinal Products for Human Use CHMP 1720 March 2014(0)
- Committee for Medicinal Products for Human Use CHMP 1720 May 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1720 May 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1720 November 2014(0)
- Committee for Medicinal Products for Human Use CHMP 1720 October 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1720 September 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1720 September 2018(0)
- Committee for Medicinal Products for Human Use CHMP 1821 April 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1821 August 2025(0)
- Committee for Medicinal Products for Human Use CHMP 1821 February 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1821 January 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1821 July 2011(0)
- Committee for Medicinal Products for Human Use CHMP 1821 July 2016(0)
- Committee for Medicinal Products for Human Use CHMP 1821 July 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1821 June 2012(0)
- Committee for Medicinal Products for Human Use CHMP 1821 March 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1821 March 2024(0)
- Committee for Medicinal Products for Human Use CHMP 1821 May 2015(0)
- Committee for Medicinal Products for Human Use CHMP 1821 May 2026(0)
- Committee for Medicinal Products for Human Use CHMP 1821 November 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1821 October 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1922 April 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1922 April 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1922 April 2022(0)
- Committee for Medicinal Products for Human Use CHMP 1922 August 2013(0)
- Committee for Medicinal Products for Human Use CHMP 1922 August 2024(0)
- Committee for Medicinal Products for Human Use CHMP 1922 February 2018(0)
- Committee for Medicinal Products for Human Use CHMP 1922 February 2024(0)
- Committee for Medicinal Products for Human Use CHMP 1922 January 2015(0)
- Committee for Medicinal Products for Human Use CHMP 1922 July 2010(0)
- Committee for Medicinal Products for Human Use CHMP 1922 July 2021(0)
- Committee for Medicinal Products for Human Use CHMP 1922 June 2017(0)
- Committee for Medicinal Products for Human Use CHMP 1922 June 2023(0)
- Committee for Medicinal Products for Human Use CHMP 1922 March 2018(0)
- Committee for Medicinal Products for Human Use CHMP 1922 May 2014(0)
- Committee for Medicinal Products for Human Use CHMP 1922 May 2025(0)
- Committee for Medicinal Products for Human Use CHMP 1922 October 2015(0)
- Committee for Medicinal Products for Human Use CHMP 1922 September 2011(0)
- Committee for Medicinal Products for Human Use CHMP 2023 April 2015(0)
- Committee for Medicinal Products for Human Use CHMP 2023 April 2026(0)
- Committee for Medicinal Products for Human Use CHMP 2023 August 2012(0)
- Committee for Medicinal Products for Human Use CHMP 2023 February 2017(0)
- Committee for Medicinal Products for Human Use CHMP 2023 February 2023(0)
- Committee for Medicinal Products for Human Use CHMP 2023 January 2014(0)
- Committee for Medicinal Products for Human Use CHMP 2023 July 2015(0)
- Committee for Medicinal Products for Human Use CHMP 2023 July 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2023 July 2026(0)
- Committee for Medicinal Products for Human Use CHMP 2023 June 2011(0)
- Committee for Medicinal Products for Human Use CHMP 2023 June 2016(0)
- Committee for Medicinal Products for Human Use CHMP 2023 June 2022(0)
- Committee for Medicinal Products for Human Use CHMP 2023 March 2017(0)
- Committee for Medicinal Products for Human Use CHMP 2023 October 2014(0)
- Committee for Medicinal Products for Human Use CHMP 2023 September 2010(0)
- Committee for Medicinal Products for Human Use CHMP 2124 February 2022(0)
- Committee for Medicinal Products for Human Use CHMP 2124 July 2014(0)
- Committee for Medicinal Products for Human Use CHMP 2124 July 2025(0)
- Committee for Medicinal Products for Human Use CHMP 2124 June 2010(0)
- Committee for Medicinal Products for Human Use CHMP 2124 June 2021(0)
- Committee for Medicinal Products for Human Use CHMP 2124 March 2022(0)
- Committee for Medicinal Products for Human Use CHMP 2124 May 2012(0)
- Committee for Medicinal Products for Human Use CHMP 2124 October 2013(0)
- Committee for Medicinal Products for Human Use CHMP 2124 September 2015(0)
- Committee for Medicinal Products for Human Use CHMP 2225 April 2013(0)
- Committee for Medicinal Products for Human Use CHMP 2225 April 2014(0)
- Committee for Medicinal Products for Human Use CHMP 2225 April 2024(0)
- Committee for Medicinal Products for Human Use CHMP 2225 April 2025(0)
- Committee for Medicinal Products for Human Use CHMP 2225 February 2016(0)
- Committee for Medicinal Products for Human Use CHMP 2225 February 2021(0)
- Committee for Medicinal Products for Human Use CHMP 2225 January 2018(0)
- Committee for Medicinal Products for Human Use CHMP 2225 January 2024(0)
- Committee for Medicinal Products for Human Use CHMP 2225 July 2013(0)
- Committee for Medicinal Products for Human Use CHMP 2225 July 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2225 July 2024(0)
- Committee for Medicinal Products for Human Use CHMP 2225 June 2015(0)
- Committee for Medicinal Products for Human Use CHMP 2225 June 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2225 June 2026(0)
- Committee for Medicinal Products for Human Use CHMP 2225 March 2021(0)
- Committee for Medicinal Products for Human Use CHMP 2225 May 2023(0)
- Committee for Medicinal Products for Human Use CHMP 2225 September 2014(0)
- Committee for Medicinal Products for Human Use CHMP 2326 April 2018(0)
- Committee for Medicinal Products for Human Use CHMP 2326 April 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2326 February 2015(0)
- Committee for Medicinal Products for Human Use CHMP 2326 February 2026(0)
- Committee for Medicinal Products for Human Use CHMP 2326 January 2017(0)
- Committee for Medicinal Products for Human Use CHMP 2326 January 2023(0)
- Committee for Medicinal Products for Human Use CHMP 2326 July 2018(0)
- Committee for Medicinal Products for Human Use CHMP 2326 June 2014(0)
- Committee for Medicinal Products for Human Use CHMP 2326 March 2015(0)
- Committee for Medicinal Products for Human Use CHMP 2326 March 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2326 March 2026(0)
- Committee for Medicinal Products for Human Use CHMP 2326 May 2016(0)
- Committee for Medicinal Products for Human Use CHMP 2426 April 2023(0)
- Committee for Medicinal Products for Human Use CHMP 2427 February 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2427 February 2025(0)
- Committee for Medicinal Products for Human Use CHMP 2427 January 2022(0)
- Committee for Medicinal Products for Human Use CHMP 2427 June 2013(0)
- Committee for Medicinal Products for Human Use CHMP 2427 June 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2427 June 2024(0)
- Committee for Medicinal Products for Human Use CHMP 2427 March 2025(0)
- Committee for Medicinal Products for Human Use CHMP 2528 April 2016(0)
- Committee for Medicinal Products for Human Use CHMP 2528 February 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2528 January 2016(0)
- Committee for Medicinal Products for Human Use CHMP 2528 June 2018(0)
- Committee for Medicinal Products for Human Use CHMP 2528 March 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2528 May 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2529 January 2021(0)
- Committee for Medicinal Products for Human Use CHMP 2629 January 2026(0)
- Committee for Medicinal Products for Human Use CHMP 2729 May 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2730 January 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2730 January 2025(0)
- Committee for Medicinal Products for Human Use CHMP 2730 March 2023(0)
- Committee for Medicinal Products for Human Use CHMP 2730 May 2013(0)
- Committee for Medicinal Products for Human Use CHMP 2730 May 2024(0)
- Committee for Medicinal Products for Human Use CHMP 2830 April 2020(0)
- Committee for Medicinal Products for Human Use CHMP 2831 January 2019(0)
- Committee for Medicinal Products for Human Use CHMP 2831 May 2018(0)
- Committee for Medicinal Products for Human Use CHMP Biologics Working Party BWP stakeholders meeting on the Guideline on the requirements for quality documentation concerning biological investigational medicinal products IMP in clinical trials(0)
- Committee for Medicinal Products for Human Use CHMP Blood Products Working Party BPWP assessors training on blood products(0)
- Committee for Medicinal Products for Human Use CHMP Blood Products Working Party BPWP stakeholders meeting on normal immunoglobulin for intravenous administration IVIg guidance(0)
- Committee for Medicinal Products for Human Use elects new chair and vicechair(0)
- Committee for Medicinal Products for Veterinary Use CVMP 0305 December 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 0507 November 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 0507 November 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 0810 October 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 0810 October 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 13 December 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 14 16 May 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 24 December 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 24 June 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 December 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 June 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 May 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 November 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 November 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 November 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 October 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 35 October 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 46 December 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 46 November 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 46 November 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 46 November 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 46 October 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 46 October 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 April 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 December 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 December 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 February 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 March 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 May 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 November 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 October 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 September 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 57 September 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 67 October 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 December 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 December 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 December 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 March 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 May 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 November 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 November 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 October 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 October 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 September 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 68 September 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 December 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 December 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 February 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 July 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 June 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 November 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 November 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 October 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 October 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 79 September 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 April 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 April 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 April 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 December 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 December 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 February 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 January 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 July 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 March 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 November 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 November 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 November 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 October 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 September 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 September 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 810 September 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 April 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 August 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 December 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 February 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 March 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 November 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 October 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 October 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 September 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 911 September 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 April 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 August 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 December 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 February 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 February 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 January 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 July 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 June 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 March 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 March 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 May 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 May 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 May 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 September 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 September 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1012 September 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 April 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 April 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 December 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 February 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 February 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 January 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 July 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 July 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP1113 June 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 March 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 March 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 October 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 September 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1113 September 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 January 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 July 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 July 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 July 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 June 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 March 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1214 October 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 April 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 April 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 August 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 February 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 February 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 January 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 January 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 July 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 July 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 June 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 June 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 March 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 May 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1315 September 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1415 June 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 April 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 August 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 February 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 February 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 January 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 January 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 July 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 July 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 June 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 March 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 May 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1416 September 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1516 April 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1516 May 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1517 February 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1517 July 2025(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1517 June 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1517 June 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1517 March 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1617 February 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 April 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 February 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 January 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 January 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 July 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 July 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 July 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 June 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 June 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1618 March 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1718 January 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1718 March 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1719 April 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1719 January 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1719 July 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1719 May 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1819 January 2022(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1820 April 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1820 February 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1820 June 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1820 June 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1820 May 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1820 May 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1920 January 2021(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1921 April 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1921 February 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1921 January 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1921 June 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1921 March 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 1921 May 2026(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2122 May 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2123 April 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2123 January 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2123 March 2023(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2123 May 2024(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2224 January 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP 2325 May 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting 68 December 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 24 June 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 35 December 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 35 June 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 35 May 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 35 October 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 46 December 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 46 November 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 46 November 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 46 October 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 57 April 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 57 December 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 57 February 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 57 March 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 57 May 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 57 November 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 57 November 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 57 September 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 68 December 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 68 March 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 68 May 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 68 November 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 68 November 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 68 October 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 68 September 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 79 December 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 79 February 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 79 July 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 79 June 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 79 November 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 79 October 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 810 April 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 810 April 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 810 December 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 810 February 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 810 January 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 810 July 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 810 March 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 810 November 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 810 November 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 810 October 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 810 October 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 810 September 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 911 April 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 911 December 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 911 February 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 911 March 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 911 November 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 911 October 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 911 October 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 911 September 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1012 April 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1012 December 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1012 February 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1012 January 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1012 July 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1012 March 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1012 May 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1012 September 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1012 September 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 April 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 December 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 February 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1113 January 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 July 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 June 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 March 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 October 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 September 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1113 September 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1213 October 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1214 January 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1214 July 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1214 July 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1214 June 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1315 April 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1315 February 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1315 January 2015(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1315 July 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1315 June 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1315 March 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1315 May 2008(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1315 September 2011(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1416 February 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1416 January 2014(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1416 June 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1416 March 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1416 May 2012(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1416 May 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1416 September 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1516 April 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1517 June 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1517 March 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1618 February 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1618 January 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1618 July 2013(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1618 July 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1618 June 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1718 March 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1719 April 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1719 January 2017(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1719 July 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1719 May 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1820 February 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1820 June 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1820 May 2010(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1820 May 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1921 April 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1921 February 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP Meeting of 1921 January 2016(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1921 June 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 1921 March 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 2122 May 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 2123 April 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 2123 January 2020(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 2224 January 2019(0)
- Committee for Medicinal Products for Veterinary Use CVMP meeting of 2325 May 2018(0)
- Committee for Medicinal Products for Veterinary Use CVMP publishes new draft strategy on combating antimicrobial resistance(0)
- Committee for Medicinal Products for Veterinary Use holds 200th meeting(0)
- Committee for medicinal products for veterinary use Meeting of 4 to 6 October 2005(0)
- Committee for medicinal products for veterinary use Meeting of 6 to 7 September 2004(0)
- Committee for medicinal products for veterinary use Meeting of 6 to 8 December 2005(0)
- Committee for medicinal products for veterinary use Meeting of 6 to 8 September 2005(0)
- Committee for medicinal products for veterinary use Meeting of 7 9 November 2006(0)
- Committee for medicinal products for veterinary use Meeting of 7 to 9 December 2004(0)
- Committee for medicinal products for veterinary use Meeting of 8 to 10 February 2005(0)
- Committee for medicinal products for veterinary use Meeting of 8 to 10 March 2005(0)
- Committee for medicinal products for veterinary use Meeting of 8 to 10 November 2005(0)
- Committee for medicinal products for veterinary use Meeting of 9 to 11 November 2004(0)
- Committee for medicinal products for veterinary use Meeting of 10 12 July 2007(0)
- Committee for medicinal products for veterinary use Meeting of 10 to 12 October 2006(0)
- Committee for medicinal products for veterinary use Meeting of 11 to 13 May 2004(0)
- Committee for medicinal products for veterinary use Meeting of 12 14 December 2006(0)
- Committee for medicinal products for veterinary use Meeting of 12 14 June 2007(0)
- Committee for medicinal products for veterinary use Meeting of 12 to 13 July 2005(0)
- Committee for medicinal products for veterinary use Meeting of 12 to 14 April 2005(0)
- Committee for medicinal products for veterinary use Meeting of 12 to 14 October 2004(0)
- Committee for medicinal products for veterinary use Meeting of 12 to 14 September 2006(0)
- Committee for medicinal products for veterinary use Meeting of 13 15 March 2007(0)
- Committee for medicinal products for veterinary use Meeting of 13 to 15 July 2004(0)
- Committee for medicinal products for veterinary use Meeting of 14 to 15 April 2004(0)
- Committee for medicinal products for veterinary use Meeting of 14 to 15 June 2005(0)
- Committee for medicinal products for veterinary use Meeting of 14 to 16 February 2006(0)
- Committee for medicinal products for veterinary use Meeting of 14 to 16 March 2006(0)
- Committee for medicinal products for veterinary use Meeting of 15 to 17 June 2004(0)
- Committee for medicinal products for veterinary use Meeting of 16 18 January 2007(0)
- Committee for medicinal products for veterinary use Meeting of 16 to 18 May 2006(0)
- Committee for medicinal products for veterinary use Meeting of 17 to 18 January 2006(0)
- Committee for medicinal products for veterinary use Meeting of 17 to 18 May 2005(0)
- Committee for medicinal products for veterinary use Meeting of 18 to 20 April 2006(0)
- Committee for medicinal products for veterinary use Meeting of 18 to 20 July 2006(0)
- Committee for medicinal products for veterinary use Meeting of 20 to 22 June 2006(0)
- Committee for medicinal products for veterinary use Meeting of 68 November 2007(0)
- Committee for Medicinal Products for Veterinary Use Meeting of 810 December 2009(0)
- Committee for medicinal products for veterinary use Meeting of 911 December 2008(0)
- Committee for medicinal products for veterinary use Meeting of 911 October 2007(0)
- Committee for medicinal products for veterinary use Meeting of 1012 February 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1012 March 2009(0)
- Committee for Medicinal Products for Veterinary Use Meeting of 1012 November 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1112 January 2005(0)
- Committee for medicinal products for veterinary use Meeting of 1113 December 2007(0)
- Committee for medicinal products for veterinary use Meeting of 1113 March 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1113 November 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1113 September 2007(0)
- Committee for medicinal products for veterinary use Meeting of 1214 February 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1214 May 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1315 February 2007(0)
- Committee for medicinal products for veterinary use Meeting of 1315 January 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1315 October 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1415 May 2007(0)
- Committee for medicinal products for veterinary use Meeting of 1416 July 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1416 October 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1517 April 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1517 April 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1517 January 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1517 July 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1517 September 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1618 June 2009(0)
- Committee for medicinal products for veterinary use Meeting of 1618 September 2008(0)
- Committee for medicinal products for veterinary use Meeting of 1718 April 2007(0)
- Committee for medicinal products for veterinary use Meeting of 1719 June 2008(0)
- Committee for Medicinal Products for Veterinary Use reelects Dr Anja Holm as chair(0)
- Committee for Orphan Medicinal Products adopts 100th positive opinion on designation(0)
- Committee for Orphan Medicinal Products April 2004 meeting(0)
- Committee for Orphan Medicinal Products April 2005 meeting(0)
- Committee for Orphan Medicinal Products April 2006 meeting(0)
- Committee for Orphan Medicinal Products April 2007 Meeting(0)
- Committee for Orphan Medicinal Products Chair and Vicechair reelected(0)
- Committee for Orphan Medicinal Products COMP(0)
- Committee for Orphan Medicinal Products COMP 12 June 2010(0)
- Committee for Orphan Medicinal Products COMP 13 December 2020(0)
- Committee for Orphan Medicinal Products COMP 13 December 2026(0)
- Committee for Orphan Medicinal Products COMP 13 September 2015(0)
- Committee for Orphan Medicinal Products COMP 23 February 2010(0)
- Committee for Orphan Medicinal Products COMP 23 March 2010(0)
- Committee for Orphan Medicinal Products COMP 24 December 2025(0)
- Committee for Orphan Medicinal Products COMP 24 September 2014(0)
- Committee for Orphan Medicinal Products COMP34 November 2016(0)
- Committee for Orphan Medicinal Products COMP 34 September 2013(0)
- Committee for Orphan Medicinal Products COMP 35 December 2019(0)
- Committee for Orphan Medicinal Products COMP 35 December 2024(0)
- Committee for Orphan Medicinal Products COMP 35 November 2020(0)
- Committee for Orphan Medicinal Products COMP 35 November 2021(0)
- Committee for Orphan Medicinal Products COMP 35 November 2026(0)
- Committee for Orphan Medicinal Products COMP 35 October 2012(0)
- Committee for Orphan Medicinal Products COMP 35 October 2017(0)
- Committee for Orphan Medicinal Products COMP 35 October 2023(0)
- Committee for Orphan Medicinal Products COMP 45 May 2011(0)
- Committee for Orphan Medicinal Products COMP 45 September 2012(0)
- Committee for Orphan Medicinal Products COMP 46 December 2018(0)
- Committee for Orphan Medicinal Products COMP 46 February 2014(0)
- Committee for Orphan Medicinal Products COMP 46 November 2025(0)
- Committee for Orphan Medicinal Products COMP 46 October 2016(0)
- Committee for Orphan Medicinal Products COMP 46 October 2022(0)
- Committee for Orphan Medicinal Products COMP 56 December 2012(0)
- Committee for Orphan Medicinal Products COMP 56 February 2013(0)
- Committee for Orphan Medicinal Products COMP 56 January 2010(0)
- Committee for Orphan Medicinal Products COMP 56 May 2010(0)
- Committee for Orphan Medicinal Products COMP 56 November 2013(0)
- Committee for Orphan Medicinal Products COMP 56 October 2011(0)
- Committee for Orphan Medicinal Products COMP 57 December 2017(0)
- Committee for Orphan Medicinal Products COMP 57 December 2023(0)
- Committee for Orphan Medicinal Products COMP 57 November 2019(0)
- Committee for Orphan Medicinal Products COMP 57 November 2024(0)
- Committee for Orphan Medicinal Products COMP 57 October 2021(0)
- Committee for Orphan Medicinal Products COMP 57 September 2017(0)
- Committee for Orphan Medicinal Products COMP 57 September 2023(0)
- Committee for Orphan Medicinal Products COMP 67 April 2011(0)
- Committee for Orphan Medicinal Products COMP 67 December 2011(0)
- Committee for Orphan Medicinal Products COMP 67 July 2011(0)
- Committee for Orphan Medicinal Products COMP 67 November 2012(0)
- Committee for Orphan Medicinal Products COMP 67 October 2010(0)
- Committee for Orphan Medicinal Products COMP 67 September 2011(0)
- Committee for Orphan Medicinal Products COMP 68 December 2016(0)
- Committee for Orphan Medicinal Products COMP 68 December 2022(0)
- Committee for Orphan Medicinal Products COMP 68 November 2018(0)
- Committee for Orphan Medicinal Products COMP 68 October 2015(0)
- Committee for Orphan Medicinal Products COMP 68 October 2020(0)
- Committee for Orphan Medicinal Products COMP 68 October 2026(0)
- Committee for Orphan Medicinal Products COMP 68 September 2016(0)
- Committee for Orphan Medicinal Products COMP 68 September 2022(0)
- Committee for Orphan Medicinal Products COMP 78 April 2010(0)
- Committee for Orphan Medicinal Products COMP 78 December 2010(0)
- Committee for Orphan Medicinal Products COMP 78 February 2012(0)
- Committee for Orphan Medicinal Products COMP 78 July 2010(0)
- Committee for Orphan Medicinal Products COMP 78 March 2012(0)
- Committee for Orphan Medicinal Products COMP 78 September 2010(0)
- Committee for Orphan Medicinal Products COMP 79 December 2021(0)
- Committee for Orphan Medicinal Products COMP 79 January 2014(0)
- Committee for Orphan Medicinal Products COMP 79 January 2015(0)
- Committee for Orphan Medicinal Products COMP 79 November 2023(0)
- Committee for Orphan Medicinal Products COMP 79 October 2014(0)
- Committee for Orphan Medicinal Products COMP 79 October 2025(0)
- Committee for Orphan Medicinal Products COMP 79 September 2021(0)
- Committee for Orphan Medicinal Products COMP 89 April 2014(0)
- Committee for Orphan Medicinal Products COMP 89 February 2011(0)
- Committee for Orphan Medicinal Products COMP 89 January 2013(0)
- Committee for Orphan Medicinal Products COMP 89 June 2011(0)
- Committee for Orphan Medicinal Products COMP 89 March 2011(0)
- Committee for Orphan Medicinal Products COMP 89 November 2011(0)
- Committee for Orphan Medicinal Products COMP 810 December 2015(0)
- Committee for Orphan Medicinal Products COMP 810 July 2014(0)
- Committee for Orphan Medicinal Products COMP 810 November 2022(0)
- Committee for Orphan Medicinal Products COMP 810 October 2013(0)
- Committee for Orphan Medicinal Products COMP 810 October 2019(0)
- Committee for Orphan Medicinal Products COMP 810 October 2024(0)
- Committee for Orphan Medicinal Products COMP 810 September 2020(0)
- Committee for Orphan Medicinal Products COMP 810 September 2026(0)
- Committee for Orphan Medicinal Products COMP 910 December 2014(0)
- Committee for Orphan Medicinal Products COMP 910 November 2010(0)
- Committee for Orphan Medicinal Products COMP 911 July 2013(0)
- Committee for Orphan Medicinal Products COMP 911 October 2018(0)
- Committee for Orphan Medicinal Products COMP 911 September 2025(0)
- Committee for Orphan Medicinal Products COMP 1011 April 2017(0)
- Committee for Orphan Medicinal Products COMP 1011 December 2013(0)
- Committee for Orphan Medicinal Products COMP 1011 January 2012(0)
- Committee for Orphan Medicinal Products COMP 1011 July 2012(0)
- Committee for Orphan Medicinal Products COMP 1011 May 2012(0)
- Committee for Orphan Medicinal Products COMP 1012 February 2015(0)
- Committee for Orphan Medicinal Products COMP 1012 June 2014(0)
- Committee for Orphan Medicinal Products COMP 1012 June 2025(0)
- Committee for Orphan Medicinal Products COMP 1012 May 2021(0)
- Committee for Orphan Medicinal Products COMP 1012 May 2022(0)
- Committee for Orphan Medicinal Products COMP 1012 November 2015(0)
- Committee for Orphan Medicinal Products COMP 1012 September 2019(0)
- Committee for Orphan Medicinal Products COMP 1012 September 2024(0)
- Committee for Orphan Medicinal Products COMP 1012May 2017(0)
- Committee for Orphan Medicinal Products COMP 1112 April 2012(0)
- Committee for Orphan Medicinal Products COMP 1112 January 2011(0)
- Committee for Orphan Medicinal Products COMP 1112 June 2013(0)
- Committee for Orphan Medicinal Products COMP 1112 March 2014(0)
- Committee for Orphan Medicinal Products COMP 1113 April 2022(0)
- Committee for Orphan Medicinal Products COMP 1113 July 2016(0)
- Committee for Orphan Medicinal Products COMP 1113 July 2017(0)
- Committee for Orphan Medicinal Products COMP 1113 July 2023(0)
- Committee for Orphan Medicinal Products COMP 1113 May 2026(0)
- Committee for Orphan Medicinal Products COMP 1113 November 2014(0)
- Committee for Orphan Medicinal Products COMP 1113 September 2018(0)
- Committee for Orphan Medicinal Products COMP 1213 June 2012(0)
- Committee for Orphan Medicinal Products COMP 1213 March 2013(0)
- Committee for Orphan Medicinal Products COMP 1213 May 2015(0)
- Committee for Orphan Medicinal Products COMP 1214 July 2022(0)
- Committee for Orphan Medicinal Products COMP 1214 March 2024(0)
- Committee for Orphan Medicinal Products COMP 1314 May 2014(0)
- Committee for Orphan Medicinal Products COMP 1315 April 2021(0)
- Committee for Orphan Medicinal Products COMP 1315 February 2018(0)
- Committee for Orphan Medicinal Products COMP 1315 February 2024(0)
- Committee for Orphan Medicinal Products COMP 1315 July 2021(0)
- Committee for Orphan Medicinal Products COMP 1315 June 2017(0)
- Committee for Orphan Medicinal Products COMP 1315 June 2023(0)
- Committee for Orphan Medicinal Products COMP 1315 March 2018(0)
- Committee for Orphan Medicinal Products COMP 1315 May 2025(0)
- Committee for Orphan Medicinal Products COMP 1415 July 2015(0)
- Committee for Orphan Medicinal Products COMP 1415 March 2017(0)
- Committee for Orphan Medicinal Products COMP 1415 May 2013(0)
- Committee for Orphan Medicinal Products COMP 1416 April 2013(0)
- Committee for Orphan Medicinal Products COMP 1416 April 2025(0)
- Committee for Orphan Medicinal Products COMP 1416 April 2026(0)
- Committee for Orphan Medicinal Products COMP 1416 February 2017(0)
- Committee for Orphan Medicinal Products COMP 1416 February 2023(0)
- Committee for Orphan Medicinal Products COMP 1416 July 2020(0)
- Committee for Orphan Medicinal Products COMP 1416 July 2026(0)
- Committee for Orphan Medicinal Products COMP 1416 June 2016(0)
- Committee for Orphan Medicinal Products COMP 1416 June 2022(0)
- Committee for Orphan Medicinal Products COMP 1516 April 2013(0)
- Committee for Orphan Medicinal Products COMP 1517 April 2019(0)
- Committee for Orphan Medicinal Products COMP 1517 February 2022(0)
- Committee for Orphan Medicinal Products COMP 1517 July 2025(0)
- Committee for Orphan Medicinal Products COMP 1517 June 2021(0)
- Committee for Orphan Medicinal Products COMP 1517 March 2022(0)
- Committee for Orphan Medicinal Products COMP 1517 May 2023(0)
- Committee for Orphan Medicinal Products COMP 1618 April 2024(0)
- Committee for Orphan Medicinal Products COMP 1618 February 2016(0)
- Committee for Orphan Medicinal Products COMP 1618 February 2021(0)
- Committee for Orphan Medicinal Products COMP 1618 January 2018(0)
- Committee for Orphan Medicinal Products COMP 1618 January 2024(0)
- Committee for Orphan Medicinal Products COMP 1618 July 2019(0)
- Committee for Orphan Medicinal Products COMP 1618 July 2024(0)
- Committee for Orphan Medicinal Products COMP 1618 June 2015(0)
- Committee for Orphan Medicinal Products COMP 1618 June 2020(0)
- Committee for Orphan Medicinal Products COMP 1618 June 2026(0)
- Committee for Orphan Medicinal Products COMP 1618 March 2021(0)
- Committee for Orphan Medicinal Products COMP 1719 April 2018(0)
- Committee for Orphan Medicinal Products COMP 1719 February 2026(0)
- Committee for Orphan Medicinal Products COMP 1719 January 2017(0)
- Committee for Orphan Medicinal Products COMP 1719 January 2023(0)
- Committee for Orphan Medicinal Products COMP 1719 July 2018(0)
- Committee for Orphan Medicinal Products COMP 1719 March 2015(0)
- Committee for Orphan Medicinal Products COMP 1719 March 2020(0)
- Committee for Orphan Medicinal Products COMP 1719 March 2026(0)
- Committee for Orphan Medicinal Products COMP 1719 May 2016(0)
- Committee for Orphan Medicinal Products COMP 1820 April 2023(0)
- Committee for Orphan Medicinal Products COMP 1820 February 2020(0)
- Committee for Orphan Medicinal Products COMP 1820 February 2025(0)
- Committee for Orphan Medicinal Products COMP 1820 January 2022(0)
- Committee for Orphan Medicinal Products COMP 1820 June 2019(0)
- Committee for Orphan Medicinal Products COMP 1820 June 2024(0)
- Committee for Orphan Medicinal Products COMP 1820 March 2025(0)
- Committee for Orphan Medicinal Products COMP 1820 May 2020(0)
- Committee for Orphan Medicinal Products COMP 1921 April 2016(0)
- Committee for Orphan Medicinal Products COMP 1921 February 2019(0)
- Committee for Orphan Medicinal Products COMP 1921 January 2016(0)
- Committee for Orphan Medicinal Products COMP 1921 January 2021(0)
- Committee for Orphan Medicinal Products COMP 1921 June 2018(0)
- Committee for Orphan Medicinal Products COMP 1921 March 2019(0)
- Committee for Orphan Medicinal Products COMP 2022 January 2020(0)
- Committee for Orphan Medicinal Products COMP 2022 January 2026(0)
- Committee for Orphan Medicinal Products COMP 2123 April 2020(0)
- Committee for Orphan Medicinal Products COMP 2123 January 2025(0)
- Committee for Orphan Medicinal Products COMP 2123 March 2016(0)
- Committee for Orphan Medicinal Products COMP 2123 March 2023(0)
- Committee for Orphan Medicinal Products COMP 2123 May 2019(0)
- Committee for Orphan Medicinal Products COMP 2123 May 2024(0)
- Committee for Orphan Medicinal Products COMP 2224 January 2019(0)
- Committee for Orphan Medicinal Products COMP 2224 May 2018(0)
- Committee for Orphan Medicinal Products COMP 3031 October 2017(0)
- Committee for Orphan Medicinal Products COMP December highlights(0)
- Committee for Orphan Medicinal Products COMP elects new chair(0)
- Committee for Orphan Medicinal Products COMP January 2012 highlights(0)
- Committee for Orphan Medicinal Products COMP June 2012 highlights(0)
- Committee for Orphan Medicinal Products COMP May 2012 highlights(0)
- Committee for Orphan Medicinal Products December 2003 meeting(0)
- Committee for Orphan Medicinal Products December 2004 meeting(0)
- Committee for Orphan Medicinal Products December 2005 meeting(0)
- Committee for Orphan Medicinal Products December 2006 meeting(0)
- Committee for Orphan Medicinal Products elects new chair and vicechair(0)
- Committee for Orphan Medicinal Products February 2004 meeting(0)
- Committee for Orphan Medicinal Products February 2005 meeting(0)
- Committee for Orphan Medicinal Products February 2006 meeting(0)
- Committee for Orphan Medicinal Products February 2007 meeting(0)
- Committee for Orphan Medicinal Products January 2004 meeting(0)
- Committee for Orphan Medicinal Products January 2005 meeting(0)
- Committee for Orphan Medicinal Products January 2006 meeting(0)
- Committee for Orphan Medicinal Products January 2007 meeting(0)
- Committee for Orphan Medicinal Products July 2004 meeting(0)
- Committee for Orphan Medicinal Products July 2005 meeting(0)
- Committee for Orphan Medicinal Products July 2006 meeting(0)
- Committee for Orphan Medicinal Products July 2007 Meeting(0)
- Committee for Orphan Medicinal Products June 2004 meeting(0)
- Committee for Orphan Medicinal Products June 2005 meeting(0)
- Committee for Orphan Medicinal Products June 2006 meeting(0)
- Committee for Orphan Medicinal Products June 2007 Meeting(0)
- Committee for Orphan Medicinal Products March 2004 meeting(0)
- Committee for Orphan Medicinal Products March 2006 meeting(0)
- Committee for Orphan Medicinal Products March 2007 Meeting(0)
- Committee for Orphan Medicinal Products May 2004 meeting(0)
- Committee for Orphan Medicinal Products May 2005 meeting(0)
- Committee for Orphan Medicinal Products May 2006 meeting(0)
- Committee for Orphan Medicinal Products May 2008 meeting(0)
- Committee for Orphan Medicinal Products November 2003 meeting(0)
- Committee for Orphan Medicinal Products November 2004 meeting(0)
- Committee for Orphan Medicinal Products November 2005 meeting(0)
- Committee for Orphan Medicinal Products November 2006 meeting(0)
- Committee for Orphan Medicinal Products October 2003 meeting(0)
- Committee for Orphan Medicinal Products October 2004 meeting(0)
- Committee for Orphan Medicinal Products October 2005 meeting(0)
- Committee for Orphan Medicinal Products October 2006 meeting(0)
- Committee for Orphan Medicinal Products September 2004 Meeting(0)
- Committee for Orphan Medicinal Products September 2005 meeting(0)
- Committee for Orphan Medicinal Products September 2006 meeting(0)
- Committee for Orphan Medicinal Products September 2007 Meeting(0)
- Committee for Orphan Medicinal Products strengthened interactions with patients and international partners(0)
- Committee for orphan medicines overview of 2013 and looking ahead(0)
- Committee for paediatric medicinal products towards more and better information on the use of medicines for children(0)
- Committee for Proprietary Medicinal Products CPMP 9th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 10th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 11th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 12th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 13th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 14th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 15th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 16th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 17th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 18th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 19th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 20th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 21st plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 22nd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 23rd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 24th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 25th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 26th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 27th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 28th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 29th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 30th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 31st plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 32nd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 33rd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 34th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 35th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 36th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 37th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 38th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 39th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 40th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 41st plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 42nd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 43rd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 44th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 45th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 46th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 47th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 48th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 49th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 50th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 51st plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 52nd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 53rd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 54th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 55th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 56th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 57th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 58th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 59th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 60th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 61st plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 62nd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 63rd plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 64th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 65th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 66th plenary meeting(0)
- Committee for Proprietary Medicinal Products CPMP 2425 April 2001 meeting summary(0)
- Committee for Proprietary Medicinal Products CPMP meeting of 11 to 13 December 2001(0)
- Committee for Proprietary Medicinal Products CPMP meeting of 13 to 15 November 2001(0)
- Committee for Proprietary Medicinal Products CPMP meeting of 16 to 18 October 2001(0)
- Committee for Proprietary Medicinal Products CPMP meeting of 18 to 20 June 2001(0)
- Committee for Proprietary Medicinal Products CPMP meeting of 24 to 26 June 2001(0)
- Committee for Proprietary Medicinal Products CPMP meeting of 26 to 28 June 2001(0)
- Committee for veterinary medicinal products 36th meeting(0)
- Committee for veterinary medicinal products 37th meeting(0)
- Committee for veterinary medicinal products 38th meeting(0)
- Committee for veterinary medicinal products 39th meeting(0)
- Committee for veterinary medicinal products 40th meeting(0)
- Committee for veterinary medicinal products 41st meeting(0)
- Committee for veterinary medicinal products 42nd meeting(0)
- Committee for veterinary medicinal products 43rd meeting(0)
- Committee for veterinary medicinal products 44th meeting(0)
- Committee for veterinary medicinal products 45th meeting(0)
- Committee for veterinary medicinal products 46th meeting(0)
- Committee for veterinary medicinal products 47th meeting(0)
- Committee for veterinary medicinal products 48th meeting(0)
- Committee for Veterinary Medicinal Products 49th meeting(0)
- Committee for veterinary medicinal products 50th meeting(0)
- Committee for veterinary medicinal products 51st meeting(0)
- Committee for veterinary medicinal products 52nd meeting(0)
- Committee for veterinary medicinal products 53rd meeting(0)
- Committee for veterinary medicinal products 54th meeting(0)
- Committee for veterinary medicinal products 55th meeting(0)
- Committee for veterinary medicinal products 56th meeting(0)
- Committee for veterinary medicinal products 57th meeting(0)
- Committee for veterinary medicinal products 58th meeting(0)
- Committee for veterinary medicinal products 59th meeting(0)
- Committee for veterinary medicinal products 60th meeting(0)
- Committee for veterinary medicinal products 61st meeting(0)
- Committee for veterinary medicinal products 62nd meeting(0)
- Committee for veterinary medicinal products 63rd meeting(0)
- Committee for veterinary medicinal products 64th meeting(0)
- Committee for veterinary medicinal products 65th meeting(0)
- Committee for veterinary medicinal products 66th meeting(0)
- Committee for veterinary medicinal products 67th meeting(0)
- Committee for veterinary medicinal products 68th meeting(0)
- Committee for veterinary medicinal products 69th meeting(0)
- Committee for veterinary medicinal products 70th meeting(0)
- Committee for veterinary medicinal products 71st meeting(0)
- Committee for veterinary medicinal products 72nd meeting(0)
- Committee for veterinary medicinal products 73rd meeting(0)
- Committee for veterinary medicinal products 74th meeting(0)
- Committee for veterinary medicinal products 75th meeting(0)
- Committee for veterinary medicinal products 76th meeting(0)
- Committee for veterinary medicinal products 77th meeting(0)
- Committee for veterinary medicinal products 78th meeting(0)
- Committee for veterinary medicinal products 79th meeting(0)
- Committee for veterinary medicinal products 80th meeting(0)
- Committee for Veterinary Medicinal Products CVMP(0)
- Committee for Veterinary Medicinal Products CVMP 1517 March 2022(0)
- Committee for Veterinary Medicinal Products focus on reducing the risk of antimicrobial resistance and strengthening quality assurance(0)
- Committee for veterinary medicinal products guidelines(0)
- Committee for veterinary medicinal products Meeting of 1 to 3 October 2002(0)
- Committee for veterinary medicinal products Meeting of 8 to 9 April 2003(0)
- Committee for veterinary medicinal products Meeting of 9 to 10 December 2003(0)
- Committee for veterinary medicinal products Meeting of 10 to 12 December 2002(0)
- Committee for veterinary medicinal products Meeting of 10 to 12 February 2004(0)
- Committee for veterinary medicinal products Meeting of 11 to 13 February 2003(0)
- Committee for veterinary medicinal products Meeting of 11 to 13 March 2003(0)
- Committee for veterinary medicinal products Meeting of 11 to 13 November 2003(0)
- Committee for veterinary medicinal products Meeting of 12 to 14 November 2002(0)
- Committee for veterinary medicinal products Meeting of 13 to 14 May 2003(0)
- Committee for veterinary medicinal products Meeting of 13 to 15 January 2004(0)
- Committee for veterinary medicinal products Meeting of 14 to 16 January 2003(0)
- Committee for veterinary medicinal products Meeting of 14 to 16 October 2003(0)
- Committee for veterinary medicinal products Meeting of 16 to 17 September 2003(0)
- Committee for veterinary medicinal products Meeting of 16 to 18 March 2004(0)
- Committee for veterinary medicinal products Meeting of 17 to 19 June 2003(0)
- Committee for veterinary medicinal products Meeting of 22 to 24 July 2003(0)
- Committee highlights(0)
- Committee on Advanced Therapies CAT celebrates its first birthday(0)
- Committee on Herbal Medicinal Products approves fouryear work programme(0)
- Committee on Herbal Medicinal Products assessors training on quality for herbal medicinal products(0)
- Committee on Herbal Medicinal Products elects new chair and vicechair(0)
- Committee on herbal medicinal products Elects new chair and vicechair(0)
- Committee on Herbal Medicinal Products HMPC(0)
- Committee on Herbal Medicinal Products publishes its meeting agenda for the first time(0)
- Committees working parties and other groups(0)
- Communication@EMA how are we doing(0)
- Compagel(0)
- Companies stepping up efforts to ensure medicine supply post Brexit(0)
- Comparability of biotechnologyderived medicinal products after a change in the manufacturing process nonclinical and clinical issues Scientific guideline(0)
- Comparability of medicinal products containing biotechnologyderived proteins as active substance Annex on nonclinical and clinical issues(0)
- Compassionate use(0)
- COMP Documents(0)
- Competact(0)
- Complaints(0)
- Compliance marketing authorisation(0)
- Compliance of authorised equine influenza vaccines with OIE requirements Scientific guideline(0)
- Compliance of veterinary vaccines under the centralised procedure with veterinary vaccine monographs of the European Pharmacopoeia Scientific guideline(0)
- Compliance Overview(0)
- Compliance overview veterinary medicines(0)
- Compliance postauthorisation(0)
- Compliance postauthorisation veterinary medicines(0)
- Compliance research and development(0)
- COMP meeting archive 20072011(0)
- COMP meeting archive 20122014(0)
- COMP members(0)
- COMP Working parties and other groups(0)
- Comtan(0)
- Comtess(0)
- Conbriza(0)
- Concepcion BIURRUN(0)
- Concept paper for the development of a reflection paper on a tailored clinical approach in biosimilar development(0)
- Concept paper for the revision of residues guidelines to align with the definitions for withdrawal periods provided in Regulation EU 2019/6 Scientific guideline(0)
- Concept paper for the revision of scientific guidelines on limited market for veterinary medicinal products(0)
- Concept paper on a guideline for allergen products development in moderate to lowsized study populations Scientific guideline(0)
- Concept paper on development and lifecycle of personalised medicines and companion diagnostics(0)
- Concept paper on development of productspecific guidance on demonstration of bioequivalence released for a twomonth public consultation(0)
- Concept paper on fees for new pharmacovigilance activities released for public consultation(0)
- Concept paper on medicines to prevent HIV infection released for public consultation(0)
- Concept paper on pharmacovigilance implementing measures released for consultation(0)
- Concetta Quintarelli(0)
- Conditional marketing authorisation(0)
- Conditional marketing authorisations give patients access to important new medicines earlier(0)
- Conduct of bioequivalence studies for veterinary medicinal products Scientific guideline(0)
- Conduct of efficacy studies for intramammary products for use in cattle Scientific guideline(0)
- Conduct of efficacy studies for nonsteroidal antiinflammatory drugs NSAIDs Scientific guideline(0)
- Conduct of pharmacokinetic studies in target animal species Scientific guideline(0)
- Conference on Environmental Risk Assessment for Human and Veterinary Medicinal Products(0)
- Conference on the outcome of the evaluation of the European Medicines Agency(0)
- Confidentiality arrangement between EU and Brazilian regulatory authorities(0)
- Confidentiality arrangement between the EU and the Republic of Korea(0)
- Conflicts of interests revised EMA policy reflects more balanced approach(0)
- Congress Programme ESDP 2006 Tenth Biannual Congress(0)
- Conor OReilly(0)
- Consideration of adjuvants and preservatives under Council Regulation EEC No 2377/90 laying down a community procedure for the establishment of maximum residue limits of veterinary medicinal products in foodstuffs of animal origin Scientific guideline(0)
- Considerations given to designation of a single stereo isomeric form enantiomer a complex a derivative or a different salt or ester as new active substance in relation to the relevant reference active substance Scientific guideline(0)
- Constance McDaniel(0)
- CONSTANTIA HADJIDEMETRIOU(0)
- Constanze Goepfert(0)
- Constanze Wolf(0)
- Constella(0)
- Construction of new EMA building in Amsterdam on track(0)
- Consuelo Argumánez(0)
- Consuelo Mejías Pavón(0)
- Consuelo Pedrós(0)
- Consuelo Rubio Montejano(0)
- Consultation meeting with industry stakeholders on new scheme to support development of innovative medicines for unmet medical needs(0)
- Consultation meeting with stakeholders Request from the European Commission for advice on the impact on public and animal health of the use of antibiotics in animals(0)
- Consultation on draft guideline on quality requirements for medical devices in combination products(0)
- Consultation on revised guideline on medicines to treat Alzheimers disease(0)
- Consultation on revised policy on access to documents(0)
- Consultation on updated guideline on clinical development of medicines for treatment of HIV infection(0)
- Consultation procedure for ancillary medicinal substances in medical devices(0)
- Consumption of antimicrobials in animals reaches lowest level ever in Europe(0)
- Contacera(0)
- Contacting EMA postauthorisation(0)
- Contacts at the European Medicines Agency(0)
- Controloc Control(0)
- Control of impurities of pharmacopoeial substances compliance with the European Pharmacopoeia general monograph Substances for Pharmaceutical Use and general chapter Control of Impurities in Substances for Pharmaceutical Use Scientific guideline(0)
- Control of impurities of pharmacopoeial substances Scientific guideline(0)
- Control of the active substance in the finished product for immunological veterinary medicinal products IVMPs Scientific guideline(0)
- Contusugene Ladenovec Gendux(0)
- Convenia(0)
- Conversations on Cancer presents Living with Metastatic Breast Cancer(0)
- Conversations on Cancer Transforming Patient Lives by Therapeutic and Regulatory Innovations(0)
- Cookies(0)
- Cooperation between regulators and HTA bodies creates synergies(0)
- Cooperation on medicines regulation intensified(0)
- Coordinating bodies(0)
- Coordinating investigator signature of clinical study reports Scientific guideline(0)
- Coordination group for mutual recognition and decentralised procedures for veterinary medicinal products CMDv(0)
- Coordination Group for Mutual Recognition and Decentralised Procedures Human CMDh(0)
- Coordination of GCP inspections(0)
- Coordination of GLP inspections(0)
- Coordination of pharmacovigilance inspections(0)
- Copalia(0)
- Copalia HCT(0)
- Copiktra(0)
- CoraChristina Peters(0)
- Coralie DELIGNY(0)
- Coral Martinez(0)
- Corbilta previously Levodopa/Carbidopa/Entacapone Sandoz(0)
- Core management documents(0)
- Core SmPC and package leaflet for sodium iodide 131 I for therapeutic use Scientific guideline(0)
- Core summary for product characteristics for human albumin solution Scientific guideline(0)
- Core summary for product characteristics for human rabies immunoglobulin for intramuscular use Scientific guideline(0)
- Core summary of product characteristics and package leaflet for 68Ge/68Ga generator Scientific guideline(0)
- Core summary of product characteristics and package leaflet for gadopentetate dimeglumine Scientific guideline(0)
- Core summary of product characteristics for human antiD immunoglobulin for intravenous use Scientific guideline(0)
- Core summary of product characteristics for human fibrinogen products Scientific guideline(0)
- Core summary of product characteristics for human normal immunoglobulin for intravenous administration IVIg Scientific guideline(0)
- Core summary of product characteristics for human normal immunoglobulin for subcutaneous and intramuscular use Scientific guideline(0)
- Core summary of product characteristics for human plasma coagulation factor VII products Scientific guideline(0)
- Core summary of product characteristics for human plasmaderived and recombinant coagulation factor IX products Scientific guideline(0)
- Core summary of product characteristics for human plasmaderived and recombinant coagulation factor VIII products Scientific guideline(0)
- Core summary of product characteristics for human plasma derived antithrombin Scientific guideline(0)
- Core summary of product characteristics for human plasmaderived hepatitis B immunoglobulin for intramuscular use Scientific guideline(0)
- Core summary of product characteristics for human plasmaderived hepatitis B immunoglobulin for intravenous use Scientific guideline(0)
- Core summary of product characteristics for human plasma derived von Willebrand factor Scientific guideline(0)
- Core summary of product characteristics for human prothrombin complex products Scientific guideline(0)
- Core summary of product characteristics for human tetanus immunoglobulin for intramuscular use Scientific guideline(0)
- Core summary of product characteristics for human tickborne encephalitis immunoglobulin for intramuscular use Scientific guideline(0)
- Core summary of product characteristics for human varicella immunoglobulin for intramuscular use Scientific guideline(0)
- Core summary of product characteristics for plasmaderived fibrin sealant/haemostatic products Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for 99Mo/99mTc generator Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for fludeoxyglucose 18F Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for fluorodopa 18F Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for gadoteric acid Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for iopamidol 300 Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for iopamidol 370 Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for nanocolloidal technetium 99mTc albumin Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for radiopharmaceuticals Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for sodium fluoride 18F Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for technetium 99mTc macrosalb Scientific guideline(0)
- Core summary of product characteristics SmPC and package leaflet for technetium 99mTc sestamibi Scientific guideline(0)
- Core summary of products characteristics for human antiD immunoglobulin for intramuscular use Scientific guideline(0)
- Corina Spreitzer(0)
- Corlentor(0)
- Corluxin(0)
- Cornelia ArrasReiter(0)
- Cornelis Frank Tuinenburg(0)
- Cornelis Hendrik Rico Slingerland(0)
- Cornelis van Tilburg(0)
- Coronavirus disease COVID19(0)
- Cortaderm(0)
- Cortavance(0)
- Cosentyx(0)
- Cotellic(0)
- Cotronak(0)
- Council of Europes European Directorate for the Quality of Medicines and Healthcare EDQM and European Medicines Agency joint meeting on raw materials used for the production of cellbased and genetherapy products(0)
- Countdown to launch of new EudraVigilance System(0)
- Countries should reduce use of colistin in animals to decrease the risk of antimicrobial resistance(0)
- Courtney Davis(0)
- Court of Justice upholds EMAs approach to transparency(0)
- COVID19 Beware of falsified medicines from unregistered websites(0)
- COVID19 chloroquine and hydroxychloroquine only to be used in clinical trials or emergency use programmes(0)
- COVID19 developers of medicines or vaccines to benefit from free scientific advice(0)
- COVID19 EMA and Heads of Medicines Agencies update on molnupiravir(0)
- COVID19 EMA meetings with delegates and experts will be held virtually until end April 2020(0)
- COVID19 EMA recommends authorisation of antibody medicine Xevudy(0)
- COVID19 EMA recommends authorisation of two monoclonal antibody medicines(0)
- COVID19 EMA recommends conditional marketing authorisation for Paxlovid(0)
- COVID19 EMA sets up infrastructure for realworld monitoring of treatments and vaccines(0)
- COVID19 EMA starts rolling review of molnupiravir(0)
- COVID19 guidance evaluation and marketing authorisation(0)
- COVID19 guidance postauthorisation(0)
- COVID19 guidance research and development(0)
- COVID19 how EMA fasttracks development support and approval of medicines and vaccines(0)
- COVID19 information on veterinary medicines(0)
- COVID19 latest safety data provide reassurance about use of mRNA vaccines during pregnancy(0)
- COVID19 latest updates archive(0)
- COVID19 medicines(0)
- COVID19 medicines Article 18 and Article 53 reviews(0)
- COVID19 medicines that received EMA advice(0)
- COVID19 medicines under evaluation(0)
- COVID19 public health emergency of international concern 202023(0)
- COVID19 reminder of risk of serious side effects with chloroquine and hydroxychloroquine(0)
- COVID19 reminder of the risks of chloroquine and hydroxychloroquine(0)
- COVID19 Vaccine AstraZeneca benefits still outweigh the risks despite possible link to rare blood clots with low blood platelets(0)
- COVID19 Vaccine AstraZeneca PRAC investigating cases of thromboembolic events vaccines benefits currently still outweigh risks Update(0)
- COVID19 Vaccine AstraZeneca PRAC preliminary view suggests no specific issue with batch used in Austria(0)
- COVID19 Vaccine AstraZeneca Update on ongoing evaluation of blood clot cases(0)
- COVID19 Vaccine inactivated adjuvanted Valneva(0)
- COVID19 Vaccine Janssen assessment of very rare cases of unusual blood clots with low platelets continues(0)
- COVID19 Vaccine Janssen authorities in EU take steps to safeguard vaccine quality(0)
- COVID19 Vaccine Janssen EMA finds possible link to very rare cases of unusual blood clots with low blood platelets(0)
- COVID19 Vaccine Janssen EMA recommendation on booster dose(0)
- COVID19 Vaccine Janssen GuillainBarré syndrome listed as a very rare side effect(0)
- COVID19 vaccines development evaluation approval and monitoring(0)
- COVID19 vaccines key facts(0)
- COVID19 vaccine Spikevax approved for children aged 12 to 17 in EU(0)
- COVID19 vaccines studies for approval(0)
- COVID19 vaccine strain updates Global regulators agree on timing and data requirements(0)
- COVID19 vaccines update on ongoing evaluation of myocarditis and pericarditis(0)
- Coxatab(0)
- Coxevac(0)
- CPMP elects new chair and vicechair at its 100th meeting(0)
- CPMP list of herbal drugs with serious risks dated 1992 Scientific guideline(0)
- CPMP members(0)
- Craig Connolly(0)
- Crataegi folium cum flore(0)
- Creating electronic drug information for prescribing in the European Union(0)
- Credelio(0)
- Credelio Plus(0)
- Cresemba(0)
- CreutzfeldtJakob disease and advanced therapy medicinal products Scientific guideline(0)
- CreutzfeldtJakob disease and plasmaderived and urinederived medicinal products Scientific guideline(0)
- Crisis preparedness and management(0)
- Cristel Loeb(0)
- Cristiana Chelucci(0)
- Cristian Dan Georgescu(0)
- cristiano Colalto(0)
- Cristian Sampaolesi(0)
- CRISTINA BENITO SASTRE(0)
- Cristina Fernandez(0)
- Cristina Ferris Villanueva(0)
- Cristina Migali(0)
- Cristina Muñoz Madero(0)
- Cristina Pezzella(0)
- Criteria for determining that an active substance is essential when considered in the context of Article 372j of Regulation 2019/6(0)
- Criteria to be considered for the evaluation of new active substance NAS status of biological substances(0)
- Crixivan(0)
- Crizotinib productspecific bioequivalence guidance(0)
- Croatia becomes a new member of the European medicines network(0)
- Crysvita(0)
- Csaba Miskey(0)
- C Susana Rojo(0)
- CTI Life Sciences Ltd withdraws its marketing authorisation application for Opaxio paclitaxel poliglumex(0)
- CTIS Bitesize Talk Alternate IMPDQ and New guidance AxMP(0)
- CTIS Bitesize Talk How to submit a transitional trial in CTIS(0)
- Cubicin(0)
- Cucurbitae semen(0)
- Cufence(0)
- Cuprior(0)
- Cuprymina(0)
- Curcumae longae rhizoma(0)
- Curcumae xanthorrhizae rhizoma(0)
- CureVacs COVID19 vaccine CVnCoV(0)
- Current status of European Medicines Agency policy on publication of clinical data Stakeholder webinar(0)
- CVMP advisory notice to veterinary surgeons regarding the development of fibrosarcomas at sites of injection of veterinary medicinal products in cats Scientific guideline(0)
- CVMP Documents(0)
- CVMP Interested Parties meeting(0)
- CVMP interested parties meeting(0)
- CVMP meeting archive 20052012(0)
- CVMP meeting archive 20132015(0)
- CVMP meeting archive 20162018(0)
- CVMP members(0)
- CVMP recommendations on limited market classification and eligibility for authorisation under Article 23(0)
- CVMP strategy on antimicrobials 20212025(0)
- CVMP Working parties and other groups(0)
- Cyanokit(0)
- Cyberattack on EMA update 1(0)
- Cyberattack on EMA update 2(0)
- Cyberattack on EMA update 3(0)
- Cyberattack on EMA update 4(0)
- Cyberattack on EMA update 5(0)
- Cyberattack on EMA update 6(0)
- Cyberattack on the European Medicines Agency(0)
- Cyclodextrins(0)
- Cydectin TriclaMox(0)
- Cylatron(0)
- Cyltezo(0)
- Cymbalta(0)
- Cynarae folium(0)
- Cynthia Hüttner(0)
- cyproterone(0)
- Cyramza(0)
- cyrille krul(0)
- Cystadane(0)
- Cystadrops(0)
- Cystagon(0)
- Cystic fibrosis workshop Registries initiative(0)
- Cytopoint(0)
- D(0)
- Dabigatran Etexilate Accord(0)
- Dabigatran Etexilate Leon Farma(0)
- Dabigatran etexilate productspecific bioequivalence guidance(0)
- Dace Kalke(0)
- Dace Peiseniece(0)
- Dacogen(0)
- DADI PDF electronic application forms eAF training webinar(0)
- Dafiro(0)
- Dafiro HCT(0)
- Dagbjort Sigvaldadottir(0)
- Dag Jordbru(0)
- Dagmar Michalkova(0)
- Dagmar Pospisilova(0)
- Dagmar SchillingLeiss(0)
- Dagmar Sommer(0)
- Dagnija Arbidane(0)
- Daiana Vasilcanu(0)
- DAIGA OSINA(0)
- Daklinza(0)
- Dalcetrapib(0)
- Dalia Akramiene(0)
- Daliresp(0)
- Damien Bouchard(0)
- Damyana Stoyanova(0)
- Dana Gabriela Marin(0)
- Dana Halová(0)
- Danica Juricic Nahal(0)
- Daniela Elena Popa(0)
- Daniela Frangiosa(0)
- Daniela Gildemeister(0)
- Daniela Karra(0)
- Daniela Kuelbs(0)
- Daniela Ljubica(0)
- Daniela Loos(0)
- Daniela Motiu(0)
- Daniela Philadelphy(0)
- Daniela Plosceanu(0)
- Daniela Raneri(0)
- Daniela Reins(0)
- Daniela Valentova(0)
- Daniel Benesh(0)
- Daniel Bjermo(0)
- Daniel Dušek(0)
- Daniel Fernández Soto(0)
- Daniel Holy(0)
- Danielle Horst(0)
- Danielle Kramer(0)
- Daniel Roque(0)
- Danila Renzo(0)
- Danka Tesic(0)
- Danys BienenWohl(0)
- Dapagliflozin Viatris(0)
- Dapivirine Vaginal Ring 25 mg(0)
- Daptomycin Hospira(0)
- Daquiran(0)
- Dara Sevkan Akdag(0)
- Daria Szymanowicz(0)
- Darija Kos(0)
- Darija Kuruc Poje(0)
- Dario Fiorenza(0)
- Darío Ortiz de Orué Lucana(0)
- Dario Siciliano(0)
- Dario Trapani(0)
- Dariush Mokhtari(0)
- Darius Matusevicius(0)
- Dariusz Krajewski(0)
- Dariusz Sladowski(0)
- Dariusz WASYL(0)
- Darko Trumbetic(0)
- Daronrix(0)
- Darren Scully(0)
- Darunavir(0)
- Darunavir Krka(0)
- Darunavir Krka dd(0)
- Darunavir Mylan(0)
- DARWIN EU Advisory Board meeting 6 February 2023(0)
- DARWIN EU Advisory Board meeting 6 July 2022(0)
- DARWIN EU Advisory Board meeting 8 September 2022(0)
- DARWIN EU Advisory Board meeting 11 December 2023(0)
- DARWIN EU Advisory Board meeting 12 November 2021(0)
- DARWIN EU Advisory Board meeting 16 February 2022(0)
- DARWIN EU Advisory Board meeting 20 April 2022(0)
- DARWIN EU Advisory Board meeting 20 September 2021(0)
- DARWIN EU Advisory Board meeting 24 May 2023(0)
- DARWIN EU Advisory Board meeting 28 June 2021(0)
- DARWIN EU multistakeholder information webinar(0)
- DARWIN EU® continues expanding its capacity to deliver realworld data studies(0)
- DARWIN EU® has completed its first studies and is calling for new data partners(0)
- DARWIN EU® welcomes first data partners(0)
- Darzalex(0)
- Dasa Radosova(0)
- Dasatinib Accord(0)
- Dasatinib Accordpharma(0)
- Dasatinib productspecific bioequivalence guidance(0)
- Dasselta(0)
- Data Analysis and Real World Interrogation Network DARWIN EU(0)
- Data anonymisation workshop(0)
- Data exclusivity / Generics / Biosimilars Regulatory and procedural guidance(0)
- Data from patient registries to replace clinical trials in previously untreated haemophilia patients(0)
- Data integrity key to public health protection(0)
- Data Monitoring Committees issues Scientific guideline(0)
- Data monitoring committees Scientific guideline(0)
- Data on medicines ISO IDMP standards marketing authorisation(0)
- Data on medicines ISO IDMP standards Overview(0)
- Data on medicines ISO IDMP standards postauthorisation(0)
- Data on medicines ISO IDMP standards research and development(0)
- Data privacy in the age of big data(0)
- Data protection and privacy(0)
- Data quality framework for medicines regulation(0)
- Data requirements for adjuvants in vaccines for veterinary use Scientific guideline(0)
- Data requirements for applications for immunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation EU 2019/6 Scientific guideline(0)
- Data requirements for changes to the strain composition of authorised equine influenza vaccines in line with OIE recommendations Scientific guideline(0)
- Data requirements for immunological veterinary medicinal products intended for minor use or minor species Scientific guideline(0)
- Data requirements for intravenous ironbased nanocolloidal products developed with reference to an innovator medicinal product Scientific guideline(0)
- Data requirements for intravenous liposomal products developed with reference to an innovator liposomal product Scientific guideline(0)
- Data requirements for multistrain dossiers for inactivated veterinary vaccines Scientific guideline(0)
- Data requirements for swine influenza vaccines against pandemic H1N1 2009 influenza Scientific guideline(0)
- Data requirements for the replacement of established master seeds MS already used in authorised immunological veterinary medicinal products IVMPS by new master seed of the same origin Scientific guideline(0)
- Data requirements for vaccine antigen master files VAMF Scientific guideline(0)
- Data requirements for vaccine platform technology master files PTMF Scientific guideline(0)
- Data requirements for veterinary medicinal products intended to reduce the risk of transmission of vectorborne pathogens in dogs and cats Scientific guideline(0)
- Data requirements to support inuse stability claims for veterinary vaccines Scientific guideline(0)
- Data Standardisation Strategy stakeholder workshop(0)
- Data submission on authorised medicines Article 57(0)
- Data submission on investigational medicines guidance for clinical trial sponsors(0)
- Data to be provided in support of a request to include a substance in the list of substances considered as not falling within the scope of regulation EC No 470/2009 Scientific guideline(0)
- DaTSCAN(0)
- Daurismo(0)
- David Chauvier(0)
- David DEVOS(0)
- David Duguay(0)
- Davide Lonati(0)
- David Khan(0)
- David Monjas Piqueras(0)
- David Murphy(0)
- David Murphy elected new Chair of EMA Committee for Medicinal Products for Veterinary Use CVMP(0)
- David Olsen(0)
- David Ordonez del Valle(0)
- David Steindl(0)
- David Trigos Herraez(0)
- Daxas(0)
- Daxocox(0)
- Deadlines for placing paediatric medicines on the market(0)
- Declan Byrne(0)
- Declaration of herbal substances and herbal preparations in herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Declaration of storage conditions 1 in the product information of pharmaceutical veterinary medicinal products 2 for active substances Annex Scientific guideline(0)
- Declaration of storage conditions for medicinal products particulars and active substances Annex Scientific guideline(0)
- Declaration of the quantitative composition/potency labelling of biological medicinalproducts that contain modified proteins as active substance Scientific guideline(0)
- Dectomax injectable solution and its associated names(0)
- Dectova(0)
- Deeksha Ganga(0)
- Deepak Rai(0)
- Defect in Herceptin vials identified but supply for patients is maintained(0)
- Defect with Buccolam oral syringes(0)
- Deferasirox Accord(0)
- Deferasirox Mylan(0)
- Deferasirox productspecific bioequivalence guidance(0)
- Deferiprone Lipomed(0)
- Definition of a new biological active substance in terms of active passive immunity and immunomodulators which then constitute a new active ingredient in the context of part B of the Annex to Council Regulation EEC No 2309/93 Scientific guideline(0)
- Definition of substances capable of pharmacological action in the context of Council Directive 2001/82/EC as amended with particular reference to excipients and manufacturing materials Scientific guideline(0)
- Defitelio(0)
- Degarelix Accord(0)
- Deirdre Mannion(0)
- DELIA GOLETTI(0)
- Delphine Barbot(0)
- Delphine Urban(0)
- Delstrigo(0)
- Deltanil(0)
- Deltyba(0)
- Demetra Kyriakidou(0)
- Demonstrating significant benefit of orphan medicines(0)
- Demonstration of a possible impact of maternally derived antibodies on vaccine efficacy in young animals Scientific guideline(0)
- Demonstration of efficacy for veterinary medicinal products containing anticoccidial substances Scientific guideline(0)
- Demonstration of efficacy for veterinary medicinal products containing antimicrobial substances Scientific guideline(0)
- Demonstration of efficacy of ectoparasiticides Scientific guideline(0)
- Demonstration of palatability of veterinary medicinal products Scientific guideline(0)
- Demonstration of target animal safety and efficacy of veterinary medicinal products intended for use in farmed finfish Scientific guideline(0)
- Denagard 45%(0)
- Dengue Tetravalent Vaccine Live Attenuated Takeda(0)
- Dengvaxia(0)
- Denisa Houskova(0)
- Denisa Marilena Margina(0)
- Denisa Pahrova(0)
- Denise OMahony(0)
- Denise Tischner(0)
- Denis Lacombe(0)
- Denisse Mazilu(0)
- Denna Tabari(0)
- Dennis Lex(0)
- Dennis van Eijl(0)
- DepoCyte(0)
- Deputy Executive Director Noël Wathion retires after 25 years of service(0)
- Derk Reinders(0)
- Descovy(0)
- Description of composition of pegylated conjugated proteins in the summary of product characteristics Scientific guideline(0)
- Design modifications of gene therapy medicinal products during development Scientific guideline(0)
- Design of studies to evaluate the safety and efficacy of fish vaccines Scientific guideline(0)
- Design Space Creating a shared vision between industry and regulators(0)
- Desloratadine Actavis(0)
- Desloratadine Krka(0)
- Desloratadine ratiopharm(0)
- Desloratadine Teva(0)
- Despina Asprou(0)
- Despoina Makridaki(0)
- Dessislava IlievaTonova(0)
- Destara(0)
- Desvenlafaxine succinate monohydrate(0)
- Determination of withdrawal periods for edible tissue Scientific guideline(0)
- Determination of withdrawal periods for milk Scientific guideline(0)
- Determining the fate of veterinary medicinal products in manure Scientific guideline(0)
- Development and data requirements of potency tests for cellbased therapy products and the relation to clinical efficacy Scientific guideline(0)
- Development and manufacture of human medicinal products specifically designed for phage therapy Scientific guideline(0)
- Development and manufacture of lentiviral vectors Scientific guideline(0)
- Development and manufacture of synthetic peptides Scientific guideline(0)
- Development challenges for medicines for central nervous system disorders(0)
- Development of a guideline on preparation of herbal teas Scientific guideline(0)
- Development of a guideline on quality requirements of medicinal products containing a device component for delivery or use of the medicinal product Scientific guideline(0)
- Development of a guideline on the quality aspects of mRNA vaccines Scientific guideline(0)
- Development of a guideline on the safety of nanoparticles in the context of the establishment of maximum residue limits and veterinary marketing authorisations(0)
- Development of antibiotics for children towards a global approach(0)
- Development of a reflection paper on modern manufacturing techniques used for herbal preparations Scientific guideline(0)
- Development of a reflection paper on new analytical methods/technologies in the quality control of herbal medicinal products Scientific guideline(0)
- Development of a reflection paper on the availability and characteristics of diagnostic tests to improve the responsible use of antibiotics in animals(0)
- Development of blockcopolymermicelle medicinal products Scientific guideline(0)
- Development of CHMP guideline on dosing delivery of injectable liquids Scientific guideline(0)
- Development of live attenuated influenza vaccines(0)
- Development of medicinal products for the treatment of alcohol dependence Scientific guideline(0)
- Development of medicinal products for the treatment of posttraumatic stress disorder Scientific guideline(0)
- Development of medicines for rare diseases(0)
- Development of medicines to treat tuberculosis(0)
- Development of new medicinal products for the treatment of smoking Scientific guideline(0)
- Development of new medicinal products for the treatment of ulcerative colitis Scientific guideline(0)
- Development of the Clinical Trials Information System(0)
- Development of vaccinia virusbased vaccines against smallpox Scientific guideline(0)
- Development pharmaceutics for biotechnological and biological products Annex to note for guidance on development pharmaceutics Scientific guideline(0)
- Development pharmaceutics for veterinary medicinal products Scientific guideline(0)
- Development pharmaceutics Scientific guideline(0)
- Development production characterisation and specifications for monoclonal antibodies and related products Scientific guideline(0)
- Dexadreson(0)
- Dexamethasone(0)
- Dexamethasone Taw(0)
- Dexdomitor(0)
- Dexdor(0)
- Dexmedetomidine Accord(0)
- Dextrans(0)
- Dexxience(0)
- Dhurata Veseli(0)
- DIA/EFGCP/EMA better medicines for children annual conference(0)
- Diabetes(0)
- Diacomit(0)
- DIA Innovation Forum(0)
- Dialogue with Chinese authorities on medicine regulation(0)
- Diamorphine(0)
- Diamorphine hydrochloride(0)
- Diana Hartenstein(0)
- Diana Laura Bassula(0)
- Diana Leleckaite(0)
- Diana Litenboka(0)
- Diana Paegle(0)
- Diana Ráez Rodríguez(0)
- Diana Stepanyan(0)
- Diana Toteda(0)
- Diana van RietNales(0)
- Diane Farrugia(0)
- Diarmuid OCeilleachiar(0)
- Diby Olivier DIBY(0)
- Dick Heederik(0)
- Diclofenac use in animals poses a risk to European vultures(0)
- Dicural(0)
- Didier Hue(0)
- Diederica Claeys(0)
- Diego Alejandro Dri(0)
- Diego Nogales(0)
- Diego Pernas(0)
- Dienogest(0)
- Dienogest / ethinylestradiol as betadex clathrate / L5methyltetrahydrofolic acid calcium salt(0)
- Dienogest/ethinylestradiol can be used for acne after certain other treatments have failed(0)
- Dieter Deforce(0)
- Dieter Pullirsch(0)
- Dificlir(0)
- Digital application dataset integration DADI and Product Management Service PMS webinar Variations form for human medicinal products What will happen at golive(0)
- Digital application dataset integration DADI Q&A webinar variations form for human medicinal products(0)
- Digital application dataset integration DADI webinar common factors in the Fast Healthcare Interoperability Resources FHIR data standard for Article 572 and electronic application forms eAF(0)
- Dijana Derganc(0)
- Dimethyl fumarate Accord(0)
- Dimethyl fumarate Mylan(0)
- Dimethyl fumarate Neuraxpharm(0)
- Dimethyl fumarate Polpharma(0)
- Dimethyl fumarate productspecific bioequivalence guidance(0)
- Dimethyl fumarate Teva(0)
- Dimherity(0)
- Dimitar Roussinov(0)
- Dimitra Katsarou(0)
- Dimitrina Novakova(0)
- Dimitrios Athanasiou(0)
- Dimitrios Dimas(0)
- Dimitrios Filippou(0)
- Dimitrios Zafeiriou(0)
- Dina ApeleFreimane(0)
- Dina Habib Hanawy(0)
- Dina Lopes(0)
- Dina Sanctussy(0)
- Dina Schadel(0)
- DINCA VALENTIN(0)
- Dinko Vitezic(0)
- Dinolytic 125 mg/ml and 5 mg/ml solutions for injection and associated names and generic products thereof(0)
- Dino Soumpasis(0)
- Diractin(0)
- Directacting antivirals for hepatitis C EMA confirms recommendation to screen for hepatitis B(0)
- Direct animal healthcare professional communications(0)
- Direct healthcare professional communications(0)
- Dirk Luettkopf(0)
- Dirk Mentzer(0)
- Dirk Mergan(0)
- Dirk Ottersbach(0)
- Dirk Reinhardt(0)
- Dirk Van Roost(0)
- Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics(0)
- Disease areas in focus Cancer(0)
- Dissolution specification for generic oral immediate release products(0)
- Dissolution specification for generic oral immediate release products Scientific guideline(0)
- Ditelos(0)
- Ditte Søgaard(0)
- Ditte Zerlang Andersen(0)
- Divence Penta(0)
- Divence Tetra(0)
- Diyana Dimitrova(0)
- DNA and host cell protein impurities routine testing versus validation studies Scientific guideline(0)
- DNA vaccines(0)
- Docefrez(0)
- Docetaxel(0)
- Docetaxel Accord(0)
- Docetaxel Kabi(0)
- Docetaxel Mylan(0)
- Docetaxel SUN(0)
- Docetaxel Teva(0)
- Docetaxel Teva Pharma(0)
- Docetaxel Zentiva previously Docetaxel Winthrop(0)
- Document and information management procedures(0)
- Documents from advisory groups on clinicaltrial data(0)
- DogStem(0)
- Doina Plesca(0)
- Dolores Martin de SantaOlalla Llanes(0)
- Dolores Serrano(0)
- Dolovet Rifen(0)
- Dolutegravir productspecific bioequivalence guidance(0)
- Domenico Di Giorgio(0)
- Domingos de Carvalho Ferreira(0)
- Dominika Ciberej Andreánská(0)
- Dominik Dautovic(0)
- Dominik Friedrich(0)
- Dominik Langer(0)
- Dominique BremondGignac(0)
- Dominique Delforge(0)
- Dominique Garcia(0)
- Dominique Gaston(0)
- Dominique Masset(0)
- Dominique Ploin(0)
- Dominique Westphal(0)
- Donal OConnor(0)
- Donatella Gramaglia(0)
- Doptelet(0)
- Dóra Földesi(0)
- Dora Hermann(0)
- Doramectin(0)
- DOR BIOPHARMA UK Ltd withdraws marketing authorisation application for orBec beclomethasone dipropionate(0)
- Dorde Maksic(0)
- Doreen Fagan(0)
- Dore Peereboom(0)
- Doribax(0)
- Doris Franziska Oberle(0)
- Doris Höschele(0)
- Doris Lutz(0)
- Doris Sommer(0)
- Dorit Kirchhoff(0)
- Dorota Distlerova(0)
- Dorota Jagodzinska(0)
- Dorota Kornicka(0)
- Dorota Kurnik(0)
- Dorota Nowicka(0)
- Dorota Osiecka(0)
- Dorota Rojek(0)
- Dorothea Neubert(0)
- Dorte Fabricius Munksgaard(0)
- Dörte Thürmer(0)
- Dose review and adjustment of established veterinary antibiotics in the context summary of product characteristic SPC harmonisation Scientific guideline(0)
- Dossier requirements for anticancer medicinal products for dogs and cats Scientific guideline(0)
- Dossier structure and content for pandemicinfluenzavaccine marketingauthorisation application Scientific guideline(0)
- Dounia Bouzid(0)
- Douwe Postmus(0)
- Dovato(0)
- Dovprela previously Pretomanid FGK(0)
- Download medicine data(0)
- Doxirobe(0)
- Doxolipad(0)
- Doxorubicin Hydrochloride Tillomed(0)
- Doxorubicin SUN(0)
- Doxycycline 50% WSP(0)
- Doxycycline hyclate(0)
- Doxyfar 50%(0)
- Doxyprex 100mg Premix(0)
- Draft guideline on biosimilar medicines containing monoclonal antibodies released for consultation(0)
- Drafting meeting on the framework for the interaction between the Agency and Healthcare Professionals Organisations(0)
- Draft policy on publication and access to clinicaltrial data one month left to send comments(0)
- Draxxin(0)
- Dries Masure(0)
- Dries Reynders(0)
- Driton Bajramaj(0)
- Dronabinol(0)
- Dronedarone productspecific bioequivalence guidance(0)
- Dropcys(0)
- Drospirenone / ethinylestradiol betadex clathrate / L5methyltetrahydrofolic acid calcium salt(0)
- Drospirenone / ethinylestradiol bethadex clathrate(0)
- Drovelis(0)
- Dr Tomas Salmonson elected new chair of the Committee for Medicinal Products for Human Use CHMP(0)
- Drug Information Association / European Medicines Agency / Coordination Group for Mutual Recognition and Decentralised Procedures Human joint conference on variations(0)
- Duaklir Genuair(0)
- Duavive(0)
- Dukoral(0)
- Dulce Maria Lopez Alanon(0)
- Duloxetine Boehringer Ingelheim(0)
- Duloxetine Lilly(0)
- Duloxetine Mylan(0)
- Duloxetine Sandoz(0)
- Duloxetine Zentiva(0)
- DuoCover(0)
- DuoPlavin(0)
- DuoResp Spiromax(0)
- DuoTrav(0)
- Dupixent(0)
- Duration of protection achieved by veterinary vaccines Scientific guideline(0)
- Dusan Palic(0)
- Dutch authorities hand over final building to EMA in Amsterdam(0)
- Dutrebis(0)
- Duzallo(0)
- Dyax sa withdraws its marketing authorisation application for Kalbitor ecallantide(0)
- Dymphna Johanna Maria Asselbergs(0)
- Dynastat(0)
- Dynepo(0)
- Dyrupeg(0)
- Dzuveo(0)
- E(0)
- Eadaoin Griffin(0)
- Eamon O Murchu(0)
- Early dialogue between regulators and health technology assessment bodies key to medicines development(0)
- Early dialogue to support development of medicines for children(0)
- Early dialogue with regulators and HTA bodies(0)
- Easotic(0)
- East African Community looks to EMA as model for future regional agency(0)
- Eberhard Hildt(0)
- Ebglyss(0)
- Ebilfumin(0)
- Ebixa(0)
- Ebola(0)
- Ebola outbreak EMA to review experimental medicines to support treatment decisions(0)
- Ebru Karakoc Madsen(0)
- Ebvallo(0)
- Ebymect(0)
- Ecallantide(0)
- Ecalta(0)
- Ecansya previously Capecitabine Krka(0)
- ECDC and EMA collaborate on vaccine safety and effectiveness monitoring studies(0)
- ECDC and EMA highlight considerations for additional and booster doses of COVID19 vaccines(0)
- ECDC and EMA issue advice on fourth doses of mRNA COVID19 vaccines(0)
- ECDC and EMA update on COVID19(0)
- ECDC and EMA update recommendations on additional booster doses of mRNA COVID19 vaccines(0)
- ECDCEMA statement on booster vaccination with Omicron adapted bivalent COVID19 vaccines(0)
- Ece Gurpinar(0)
- Echinaceae angustifoliae radix(0)
- Echinaceae pallidae radix(0)
- Echinaceae purpureae herba(0)
- Echinaceae purpureae radix(0)
- EchoGen(0)
- Ecokinase(0)
- Ecomectin 187mg/g Oral Paste for Horses(0)
- Econor(0)
- Ecoporc Shiga(0)
- Edarbi(0)
- Edistride(0)
- Edita Skrupskiene(0)
- Edit Nagy(0)
- Edo Richard(0)
- Eduard Dolusic(0)
- Eduardo Daniel Herrera Reyes(0)
- Eduardo Olivas(0)
- Edurant(0)
- Edurne Lazaro(0)
- Edward Bojtor(0)
- Edward Hansen(0)
- Edward Laane(0)
- Edwige Haelterman(0)
- Edwige Haelterman Brenneisen(0)
- Edyta Harmasz(0)
- Edyta Sapierzyńska(0)
- Eeva Leinonen(0)
- Eeva Sofia Leinonen(0)
- Efavirenz/Emtricitabine/Tenofovir disoproxil Krka(0)
- Efavirenz/Emtricitabine/Tenofovir disoproxil Mylan(0)
- Efavirenz/Emtricitabine/Tenofovir disoproxil Zentiva(0)
- Efavirenz Teva(0)
- Efe Onaghinor(0)
- Effentora(0)
- Efficacy and target animal safety data requirements for applications for nonimmunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation EU 2019/6 Scientific guideline(0)
- Efficacy and target animal safety data requirements for applications for nonimmunological veterinary medicinal products intended for limited markets submitted under Article 23 of the Regulation EU 2019/6(0)
- Efficacy guidelines(0)
- Efficacy multidisciplinary(0)
- Efficacy pharmaceuticals(0)
- Efficacy veterinary limited markets(0)
- Efficacy Working Party(0)
- Efficacy Working Party documents(0)
- Efficacy Working Party EWP(0)
- Efficib(0)
- Efgratin(0)
- Efient(0)
- Efmody(0)
- Efstathios Nikolaidis(0)
- Eftychia Aravidou(0)
- Egberdina Botjes(0)
- Egbert Flory(0)
- Egle Audova(0)
- Egle Daniuleviciute(0)
- Egle Sulioke(0)
- Egranli(0)
- Egrifta(0)
- EIC / EMA Info Day Regulatory support for the development of innovative medicines and technologies(0)
- Eighteenth Meeting of the Management Board(0)
- Eighth industry stakeholder platform operation of the European Union EU pharmacovigilance legislation(0)
- Eighth Industry Standing Group ISG meeting(0)
- Eighth meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Eighth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicine(0)
- Eighth Meeting of the Management Board(0)
- Eighth stakeholders forum on the implementation of the pharmacovigilance legislation Building on two years of operation(0)
- Eight industry stakeholder platform on research and development support(0)
- Eight Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Eija Ahlholm(0)
- Eija Harjuketo(0)
- Eija Mikkonen(0)
- Eija Pelkonen(0)
- Eirik Grønevik(0)
- Eirini Apostolidou(0)
- Ekaterini Tiligada(0)
- Ekesivy(0)
- Eklira Genuair(0)
- Eladynos(0)
- Elaine Hynes(0)
- Elaprase(0)
- Eleanor Carey(0)
- Elebrato Ellipta(0)
- Electronic application form pilot to be extended to initial veterinary applications(0)
- Electronic application forms fully available for use(0)
- Electronicapplicationform termrequest webinar(0)
- Electronic Common Technical Document eCTD vendor workshop(0)
- Electronic product information ePI(0)
- Electronic product information for human medicines in the European Union key principles(0)
- Eleftheria Nikolaidi(0)
- Eleftheria Thomaidou(0)
- Elelyso(0)
- Elena Borsi(0)
- Elena Cvetanovska(0)
- Elena Franco Perez(0)
- Elena Giovani(0)
- Elena Grabski(0)
- Elena Kaisis(0)
- Elena Lucas Roldán(0)
- Elena María Brozos Vázquez(0)
- Elena Maria Vella(0)
- Elena Marin Rodriguez(0)
- Elena Marotta(0)
- Elena Martínez(0)
- Elena Matarangolo(0)
- Elena Rodionova(0)
- Elena Rodrigo Serrano(0)
- Elena Ruiz de la Torre(0)
- Elena Sanchez Pallares(0)
- elena zamagni(0)
- Eleni Georgiadou(0)
- Eleni Katsomiti(0)
- Eleni Petelos(0)
- Eleonora Agricola(0)
- Eleonora Gambineri(0)
- Eleonora Lekic(0)
- Eleonora Wijnans(0)
- Eleutherococci radix(0)
- Eleventh EMA human scientific committees working party with patients and consumers organisations PCWP meeting(0)
- Eleventh industry stakeholder platform on research and development support(0)
- Eleventh industry stakeholder platform on the operation of pharmacovigilance in the European Union(0)
- Eleventh meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines(0)
- Eleventh Meeting of the Management Board(0)
- Eleventh Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Elfabrio(0)
- Elfie Hörer(0)
- Elham Yousefi(0)
- ELIE SERRANO(0)
- Eligible healthcare professionals organisations(0)
- Eligible patients and consumers organisations(0)
- Eli Lilly withdraws its marketing authorisation application for ARXXANT(0)
- Elina Asikanius(0)
- Elina Jarho(0)
- Elina Rantala(0)
- Elina Rönnemaa(0)
- Elin Bjornhaug(0)
- Elin Blom(0)
- Eline Kuipers(0)
- Elin Lindhagen(0)
- Elin Magnusdottir(0)
- Elin Maria Bergsten(0)
- Elinor BouvyBerends(0)
- Eliquis(0)
- Elisabeth Balks(0)
- Elisabeth Begon(0)
- Elisabeth BojsenMøller Secher(0)
- Elisabeth de Vries(0)
- Elisabeth Fuerst(0)
- Elisabeth Hobacher(0)
- Elisabeth Johanne Rook(0)
- Elisabeth Kasilingam(0)
- Elisabeth Kooi(0)
- Elisabeth Maria Berghäll(0)
- Elisabeth Øya(0)
- Elisabeth Sanders(0)
- Elisabeth Strutzmann(0)
- Elisabeth Wischnitzki(0)
- Elisabetta Tribulato(0)
- Elisa Sulleiro(0)
- Elisa Vit(0)
- Elita Poplavska(0)
- Elizabeth Dunny(0)
- Elizabeth Jacoba Johanna Berm(0)
- Elizabeth Verschuurvan der Voort(0)
- Elizabeth Vroom(0)
- Eljona Chilku(0)
- Elke Röhrdanz(0)
- Elke Schwedinger(0)
- Elke Stahl(0)
- ellaOne(0)
- Ellefore(0)
- Ellen Lurje(0)
- Ellen Mc Grath(0)
- Ellen Pantke(0)
- Ellen Tennert(0)
- Elli Tyrkkö(0)
- Elly Vereyken(0)
- Elma OReilly(0)
- Elmer Schabel(0)
- Elmir Omerovic(0)
- Elmiron(0)
- Elmisol(0)
- Elocalcitol(0)
- Elocta(0)
- Elodie BOUSQUET(0)
- Eloise Buontempo(0)
- Elonva(0)
- Elrexfio(0)
- Elsa Grangier(0)
- Elsa Ivarsson(0)
- Els Beghein(0)
- Els Dewaele(0)
- Els Goetghebeur(0)
- Els Verschaeren(0)
- Elucirem(0)
- Eluracat(0)
- Elvira Bräuner(0)
- Elvira Rubio Esparza(0)
- Elvira ZimreGrabensteiner(0)
- Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil productspecific bioequivalence guidance(0)
- Elvitegravir productspecific bioequivalence guidance(0)
- Elysée Hille(0)
- Elżbieta Zembrzuska(0)
- Elzonris(0)
- EMA/131957/2023(0)
- EMA/235643/2017(0)
- EMA/CAT and Medical Devices Notified Body EMA/CATNB Collaboration Group(0)
- EMA/FDA/Health Canada joint workshop addressing unmet needs of children with pulmonary arterial hypertension(0)
- EMA/FDA analysis shows high degree of alignment in marketing application decisions between EU and US(0)
- EMA/FVE info session on restrictions for the use of certain antimicrobials in animals(0)
- EMA/FVE info session on restrictions of certain antimicrobials(0)
- EMA/HMA Big Data Stakeholder Forum 2022(0)
- EMA/OD/0000149115(0)
- EMA 25th anniversary symposium New approaches in patientfocused cancer drug development(0)
- EMA 2017 annual report published(0)
- EMA Account Management training webinar(0)
- EMA adopts first list of critical medicines for COVID19(0)
- EMA advice on use of colistin in animals to be updated(0)
- EMA advises against use of COVID19 Vaccine Janssen in people with history of capillary leak syndrome(0)
- EMA advises against use of ivermectin for the prevention or treatment of COVID19 outside randomised clinical trials(0)
- EMA advises companies on steps to take to avoid nitrosamines in human medicines(0)
- EMA advises continued use of medicines for hypertension heart or kidney disease during COVID19 pandemic(0)
- EMA advises on development plan for GSK Ebola vaccine(0)
- EMA alerts EU patients and healthcare professionals to reports of falsified Ozempic pens(0)
- EMA and Association of the European SelfMedication Industry AESGP annual bilateral meeting(0)
- EMA and Australian regulator strengthen collaboration in the area of orphan medicines(0)
- EMA and EATRIS webinar on navigating the regulatory requirements for advanced therapy medicinal products ATMPs(0)
- EMA and EATRIS webinar on support for academic and nonprofit ATMP developers(0)
- EMA and ECDC join forces for enhanced postmarketing monitoring of COVID19 vaccines in Europe(0)
- EMA and ECDC recommendations on heterologous vaccination courses against COVID19 mixandmatch approach can be used for both initial courses and boosters(0)
- EMA and ECDC statement on updating COVID19 vaccines to target new SARSCoV2 virus variants(0)
- EMA and ECDC update on COVID19(0)
- EMA and EORTC multistakeholder workshop on soft tissue and bone sarcoma(0)
- EMA and EU national competent authorities agree on action plan to address medication errors(0)
- EMA and EUnetHTA finalise joint work plan for 20172020(0)
- EMA and EUnetHTA step up interaction to align data requirements(0)
- EMA and EUnetHTA take stock of their cooperation(0)
- EMA and European Infrastructure for Translational Research EATRIS webinar on Scientific Advice for Advanced Therapy Medicinal Products ATMPs what and when to ask(0)
- EMA and European medicines regulatory network lift COVID19 business continuity status(0)
- EMA and European Organisation for Research and Treatment of Cancer EORTC workshop How can patientreported outcomes PRO and healthrelated quality of life HRQoL data inform regulatory decisions(0)
- EMA and FDA encourage use of innovative approaches in the development of medicines for Gaucher disease(0)
- EMA and FDA extend pilot programme for parallel assessment of qualitybydesign applications(0)
- EMA and FDA reinforce collaboration on patient engagement(0)
- EMA and heads of national competent authorities discuss consequences of Brexit(0)
- EMA and Health Canada publish clinical data used to support their authorisations of the Moderna COVID19 vaccine(0)
- EMA and Korean Ministry of Food and Drug Safety to share confidential COVID19 information(0)
- EMA and the EUnetHTA 21 consortium set priorities for their collaboration(0)
- EMA announces final steps for its clinicaltrial data policy(0)
- EMA annual report 2018 published(0)
- EMA annual report 2022 published(0)
- EMA appoints Chief Medical Officer(0)
- EMA business hours on Europe Day Monday 9 May(0)
- EMA business hours on Europe Day Tuesday 9 May(0)
- EMA business hours over All Saints Day and All Souls Day 1 and 2 November(0)
- EMA business hours over Ascension Day holidays 18 and 19 May(0)
- EMA business hours over Ascension Day holidays 26 and 27 May(0)
- EMA business hours over Assumption Day 15 August(0)
- EMA business hours over Easter holiday(0)
- EMA business hours over Easter holiday period(0)
- EMA business hours over holiday period(0)
- EMA business hours over Kings Day and Labour Day 27 April and 1 May(0)
- EMA business hours over Kings Day holiday(0)
- EMA business hours over Whit Monday 29 May(0)
- EMA business hours over Whit Monday holiday 6 June(0)
- EMA calls for highquality observational research in context of COVID19(0)
- EMA cancer symposium New approaches in patientfocused cancer medicine development(0)
- EMA celebrates 25 years advancing public and animal health(0)
- EMA celebrates ten years of its patients and consumers working party(0)
- EMA Clinical Trial Information System CTIS webinar dynamic demo of sponsor workspace(0)
- EMA closed 1 November 2019(0)
- EMA closed 2 November 2020(0)
- EMA closed 10 June 2019(0)
- EMA closed 12 November 2018(0)
- EMA closed 15 August 2019(0)
- EMA closed 1822 April 2019(0)
- EMA closed 3031 May 2019(0)
- EMA closed from 28 October to 3 November 2016(0)
- EMA commissions independent research to prepare for realworld monitoring of COVID19 vaccines(0)
- EMA Committee for Advanced Therapies elects Ilona Reischl as its new Chair(0)
- EMA Committee on Herbal Medicinal Products reelects Emiel van Galen as Chair(0)
- EMA completes review of inhaled corticosteroids for chronic obstructive pulmonary disease(0)
- EMA concludes defective device in ROCKET study does not impact Xareltos safety(0)
- EMA concludes review of Zinbryta and confirms further restrictions to reduce risk of liver damage(0)
- EMA concludes safety review of Uptravi(0)
- EMA conference "Regulatory science are regulators leaders or followers"(0)
- EMA confirms measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders(0)
- EMA confirms measures to minimise the risk of serious side effects with medicines containing pseudoephedrine(0)
- EMA confirms omega3 fatty acid medicines are not effective in preventing further heart problems after a heart attack(0)
- EMA confirms positive benefitrisk for antidepressant Valdoxan/Thymanax agomelatine(0)
- EMA confirms recommendation for nonrenewal of authorisation of Duchenne muscular dystrophy medicine Translarna(0)
- EMA confirms recommendation for nonrenewal of authorisation of multiple myeloma medicine Blenrep(0)
- EMA confirms recommendations to minimise ketoacidosis risk with SGLT2 inhibitors for diabetes(0)
- EMA confirms recommendations to minimise risk of brain infection PML with Tysabri(0)
- EMA confirms recommendation to withdraw marketing authorisations for amfepramone medicines(0)
- EMA confirms WeWork as new subtenant for 30 Churchill Place EMA also settles court case with Canary Wharf Group(0)
- EMA confirms withdrawal of two court cases concerning access to clinicaltrial data(0)
- EMA confirms Xeljanz to be used with caution in patients at high risk of blood clots(0)
- EMA considerations on COVID19 vaccine approval Scientific guideline(0)
- EMA COVID19 assessments OPEN to nonEU regulators(0)
- Emadine(0)
- EMAEFPIA Information Day 2011(0)
- EMA encourages companies to submit type I variations for 2023 in November 2023(0)
- EMA encourages tailored development of medicines for older people(0)
- EMA endorses use of dexamethasone in COVID19 patients on oxygen or mechanical ventilation(0)
- EMA ends rolling review of CVnCoV COVID19 vaccine following withdrawal by CureVac AG(0)
- EMA ends rolling review of the antibodies bamlanivimab and etesevimab for COVID19 following withdrawal by Lilly(0)
- EMA establishes Cancer Medicines Forum with academia to optimise cancer treatments in clinical practice(0)
- EMA establishes task force to take quick and coordinated regulatory action related to COVID19 medicines(0)
- EMA EudraVigilance information day(0)
- EMA evaluating data on booster dose of COVID19 vaccine Comirnaty(0)
- EMA evaluating data on booster dose of COVID19 vaccine Comirnaty in adolescents(0)
- EMA evaluating data on booster dose of COVID19 Vaccine Janssen(0)
- EMA evaluating data on booster dose of COVID19 vaccine Spikevax(0)
- EMA evaluating the use of COVID19 Vaccine Moderna in young people aged 12 to 17(0)
- EMA event supporting materials(0)
- EMA experts awarded for excellence in standards development(0)
- EMA explains its redaction rules(0)
- EMA facilitates early engagement with medicine developers to combat antimicrobial resistance(0)
- EMA fasttracks antidote to anticoagulant Pradaxa(0)
- EMA fasttracks enzyme replacement therapy for lysosomal acid lipase deficiency(0)
- EMA fasttracks new oral treatment for nonsmall cell lung cancer(0)
- EMA fasttracks treatment of multiple myeloma for approval in EU(0)
- EMA finalises opinion on presence of nitrosamines in medicines(0)
- EMA finds no evidence linking viral vector in Zynteglo to blood cancer(0)
- EMA gets ready for relocation decision(0)
- EMA getting ready for the publication of clinical data(0)
- EMA gives advice on the use of nonsteroidal antiinflammatories for COVID19(0)
- EMA gives guidance on safety monitoring of medicines used in children(0)
- EMA guidance supports development of new antibiotics(0)
- EMAhosted virtual meetings(0)
- EMA hosts workshop on adaptive pathways(0)
- EMAHTA workshop on parallel scientific advice in drug development takes place today(0)
- EMAHTA workshop on parallel scientific advice in drug development to take place tomorrow(0)
- EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting(0)
- EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting info session on antimicrobial resistance(0)
- EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting Workshop on social media(0)
- EMA Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP meeting with all eligible organisations(0)
- EMA identifies gaps in industry preparedness for Brexit(0)
- EMA implements new measures to minimise animal testing during medicines development(0)
- EMA in London 19952019(0)
- EMA issues advice on use of antibody combination bamlanivimab / etesevimab(0)
- EMA issues advice on use of Lagevrio molnupiravir for the treatment of COVID19(0)
- EMA issues advice on use of Paxlovid PF07321332 and ritonavir for the treatment of COVID19 rolling review starts in parallel(0)
- EMA issues advice on use of regdanvimab for treating COVID19(0)
- EMA issues advice on use of REGNCOV2 antibody combination casirivimab / imdevimab(0)
- EMA issues advice on use of sotrovimab VIR7831 for treating COVID19(0)
- EMA launches checklist to facilitate validation for initial marketing authorisation applications(0)
- EMA launches new corporate website(0)
- EMA launches pilot project on analysis of raw data from clinical trials(0)
- EMA launches the Regulatory Science Research Needs initiative(0)
- EMA Management Board discusses next steps after judgment of EU Civil Service Tribunal(0)
- EMA Management Board elects Christa WirthumerHoche as chair(0)
- EMA Management Board elects Lorraine Nolan as chair(0)
- EMA Management Board highlights of December 2014 meeting(0)
- EMA Management Board highlights of December 2015 meeting(0)
- EMA Management Board highlights of December 2016 meeting(0)
- EMA Management Board highlights of December 2017 meeting(0)
- EMA Management Board highlights of December 2018 meeting(0)
- EMA Management Board highlights of December 2019 meeting(0)
- EMA Management Board highlights of December 2020 meeting(0)
- EMA Management Board highlights of December 2021 meeting(0)
- EMA Management Board highlights of December 2022 meeting(0)
- EMA Management Board highlights of December 2023 meeting(0)
- EMA Management Board highlights of June 2015 meeting(0)
- EMA Management Board highlights of June 2016 meeting(0)
- EMA Management Board highlights of June 2017 meeting(0)
- EMA Management Board highlights of June 2022 meeting(0)
- EMA Management Board highlights of June 2023 meeting(0)
- EMA Management Board highlights of March 2015 meeting(0)
- EMA Management Board highlights of March 2016 meeting(0)
- EMA Management Board highlights of March 2017 meeting(0)
- EMA Management Board highlights of March 2018 meeting(0)
- EMA Management Board highlights of March 2019 meeting(0)
- EMA Management Board highlights of March 2020 meeting(0)
- EMA Management Board highlights of March 2021 meeting(0)
- EMA Management Board highlights of March 2022 meeting(0)
- EMA Management Board highlights of March 2023 meeting(0)
- EMA Management Board highlights of March 2024 meeting(0)
- EMA Management Board highlights of October 2014 meeting(0)
- EMA Management Board highlights of October 2015 meeting(0)
- EMA Management Board highlights of October 2016 meeting(0)
- EMA Management Board highlights of October 2017 meeting(0)
- EMA Management Board highlights of October 2018 meeting(0)
- EMA Management Board highlights of October 2019 meeting(0)
- EMA Management Board highlights of October 2022 meeting(0)
- EMA Management Board highlights of October 2023 meeting(0)
- EMA marks European Antibiotic Awareness Day(0)
- EMA mourns passing of Noël Wathion(0)
- EMA multistakeholder workshop on Acute Respiratory Distress Syndrome(0)
- EMA multistakeholder workshop on psychedelics Towards an EU regulatory framework(0)
- EMA multistakeholder workshop on qualification of novel methodologies(0)
- EMA now operating from Amsterdam(0)
- Emanuela Corsini(0)
- EMA organisational changes come into effect(0)
- EMA organises a second public meeting about the new COVID19 vaccines(0)
- EMA organises public meeting on COVID19 vaccines(0)
- EMA Paediatric Committee elects Brian Aylward as its new Chair(0)
- EMA pilot offers enhanced support to academic and nonprofit developers of advanced therapy medicinal products(0)
- EMA pilots scientific advice for certain highrisk medical devices(0)
- EMA prepares for Brexit(0)
- EMA preparing guidance to tackle COVID19 variants(0)
- EMA press briefing on human medicines highlights in 2023(0)
- EMA press briefing to inform on CHMP discussion on booster doses(0)
- EMA press briefing to update on analysis of data on Vaxzevria the COVID19 vaccine from AstraZeneca(0)
- EMA promotes consistent development of bioequivalence studies through productspecific guidance(0)
- EMA provides guidance on development of medicines to prevent stroke in patients with atrial fibrillation comments invited(0)
- EMA provides recommendations on compassionate use of remdesivir for COVID19(0)
- EMA public workshop on extrapolation of efficacy and safety in medicine development(0)
- EMA publishes 2013 annual report(0)
- EMA publishes annual report 2021(0)
- EMA publishes comments on Member States hosting bids(0)
- EMA publishes its work programme for 2014(0)
- EMA publishes report on workshop on regulatory options in the fight against antimicrobial resistance(0)
- EMA publishes safety monitoring plan and guidance on risk management planning for COVID19 vaccines(0)
- EMA raises awareness of clinical care recommendations to manage suspected thrombosis with thrombocytopenia syndrome(0)
- EMA ready to address challenges ahead(0)
- EMA ready to start assessment of Ebola vaccines and treatments as soon as data are made available(0)
- EMA receives application for conditional authorisation of first COVID19 treatment in the EU(0)
- EMA receives application for conditional marketing authorisation for Paxlovid PF07321332 and ritonavir for treating patients with COVID19(0)
- EMA receives application for conditional marketing authorisation of COVID19 mRNA vaccine BNT162b2(0)
- EMA receives application for conditional marketing authorisation of COVID19 Vaccine AstraZeneca(0)
- EMA receives application for conditional marketing authorisation of COVID19 Vaccine Janssen(0)
- EMA receives application for conditional marketing authorisation of Moderna COVID19 vaccine(0)
- EMA receives application for conditional marketing authorisation of Novavaxs COVID19 vaccine Nuvaxovid(0)
- EMA receives application for marketing authorisation for Lagevrio molnupiravir for treating patients with COVID 19(0)
- EMA receives application for marketing authorisation for Regkirona regdanvimab for treating patients with COVID19(0)
- EMA receives application for marketing authorisation for Ronapreve casirivimab / imdevimab for treatment and prevention of COVID19(0)
- EMA receives application for marketing authorisation for Xevudy sotrovimab for treating patients with COVID19(0)
- EMA receives application for marketing authorisation of Dexamethasone Taw for COVID19(0)
- EMA recommendations on DPD testing prior to treatment with fluorouracil capecitabine tegafur and flucytosine(0)
- EMA recommends 81 medicines for marketing authorisation in 2013(0)
- EMA recommends additional measures to prevent use of mycophenolate in pregnancy(0)
- EMA recommends aligning doses of metamizole medicines and their use during pregnancy and breastfeeding(0)
- EMA recommends approval for use of Kineret in adults with COVID19(0)
- EMA recommends approval for use of RoActemra in adults with severe COVID19(0)
- EMA recommends approval of adapted Nuvaxovid COVID19 vaccine targeting Omicron XBB15(0)
- EMA recommends approval of Bimervax as a COVID19 booster vaccine(0)
- EMA recommends approval of Comirnaty and Spikevax COVID19 vaccines for children from 6 months of age(0)
- EMA recommends approval of Imvanex for the prevention of monkeypox disease(0)
- EMA recommends approval of new treatment for platinumresistant ovarian cancer together with companion diagnostic(0)
- EMA recommends approval of second adapted Spikevax vaccine(0)
- EMA recommends approval of Spikevax for children aged 6 to 11(0)
- EMA recommends approval of treatment for attention deficit hyperactivity disorder(0)
- EMA recommends approval of VidPrevtyn Beta as a COVID 19 booster vaccine(0)
- EMA recommends authorisation of booster doses of Comirnaty from 12 years of age(0)
- EMA recommends authorisation of COVID19 medicine Evusheld(0)
- EMA recommends authorisation of Nuvaxovid for adolescents aged 12 to 17(0)
- EMA recommends availability of ellaOne emergency contraceptive without prescription(0)
- EMA recommends avoidance of certain hepatitis C medicines and amiodarone together(0)
- EMA recommends changes to prescribing information for vancomycin antibiotics(0)
- EMA recommends COVID19 Vaccine AstraZeneca for authorisation in the EU(0)
- EMA recommends COVID19 Vaccine Janssen for authorisation in the EU(0)
- EMA recommends COVID19 Vaccine Moderna for authorisation in the EU(0)
- EMA recommends expanding remdesivir compassionate use to patients not on mechanical ventilation(0)
- EMA recommends first COVID19 vaccine for authorisation in the EU(0)
- EMA recommends immediate suspension and recall of multiple sclerosis medicine Zinbryta(0)
- EMA recommends measures to ensure safe use of Keppra oral solution(0)
- EMA recommends measures to minimise risk of serious side effects with Janus kinase inhibitors for chronic inflammatory disorders(0)
- EMA recommends new safety measures for Zydelig(0)
- EMA recommends nonrenewal of authorisation of Duchenne muscular dystrophy medicine Translarna(0)
- EMA recommends nonrenewal of authorisation of multiple myeloma medicine Blenrep(0)
- EMA recommends Nuvaxovid for authorisation in the EU(0)
- EMA recommends restricting use of cancer medicine Rubraca(0)
- EMA recommends standard marketing authorisations for Comirnaty and Spikevax COVID19 vaccines(0)
- EMA recommends suspending the veterinary medicine Velactis used in dairy cows at the time of drying off(0)
- EMA recommends suspension of medicines due to unreliable studies from Micro Therapeutic Research Labs(0)
- EMA recommends suspension of medicines over flawed studies at Semler Research Centre(0)
- EMA recommends that Symbioflor 2 can continue to be used for irritable bowel syndrome(0)
- EMA recommends treatment for rare cancer in children(0)
- EMA recommends Valnevas COVID19 vaccine for authorisation in the EU(0)
- EMA recommends withdrawal of marketing authorisation for amfepramone medicines(0)
- EMA recommends withdrawal of marketing authorisation for cancer medicine Lartruvo(0)
- EMA recommends withdrawal of pholcodine medicines from EU market(0)
- EMA reelected as chair of ICMRA from October 2022(0)
- EMA regrets to learn of the passing of Dr Eric Abadie former CHMP Chair(0)
- EMA regular press briefing on COVID19(0)
- EMA regular press briefing on COVID19 and monkeypox(0)
- EMA regular press briefing on public health emergencies(0)
- EMA releases guidance on the use of pharmacogenomics to improve safety monitoring of medicines(0)
- EMA relocation updates(0)
- EMA reminds physicians to use Tecentriq with nabpaclitaxel for treating breast cancer(0)
- EMA reorganisation changes to handling of certain evaluation procedures for human medicines to be introduced from 1 April 2014(0)
- EMA responds to European Ombudsman(0)
- EMA response to the monkeypox public health emergency(0)
- EMA restricts use of Keytruda and Tecentriq in bladder cancer(0)
- EMA restricts use of multiple sclerosis medicine Zinbryta(0)
- EMA restricts use of prostate cancer medicine Xofigo(0)
- EMA reviewing cancer medicine docetaxel(0)
- EMA reviewing data on monoclonal antibody use for COVID19(0)
- EMA reviewing data on sabizabulin for COVID19(0)
- EMA reviewing medicines containing valsartan from Zhejiang Huahai following detection of an impurity some valsartan medicines being recalled across the EU(0)
- EMA reviewing new data on effectiveness of Lagevrio molnupiravir for the treatment of COVID19(0)
- EMA reviewing risk of dosing errors with methotrexate(0)
- EMA reviewing safety of Uptravi for pulmonary arterial hypertension updated*(0)
- EMA reviewing veterinary medicine Velactis(0)
- EMA review of data on paternal exposure to valproate(0)
- EMA review of Picato concludes medicines risks outweigh its benefits(0)
- EMA review of regdanvimab for COVID19 to support national decisions on early use(0)
- EMA review of Zinbryta confirms medicines risks outweigh its benefits(0)
- EMA reviews cancer medicine Zydelig(0)
- EMA roundtable with stakeholders on the 15year anniversary of the SME Regulation(0)
- EMAs Brexit plans ensure Agencys focus on medicines evaluation and supervision(0)
- EMAs Business Continuity Plan for Brexit published(0)
- EMAs Committee for Medicinal Products for Human Use CHMP elects new chair(0)
- EMA seeks views of public during its safety review of valproate(0)
- EMAs Emergency Task Force advises on intradermal use of Imvanex / Jynneos against monkeypox (0)
- EMA sets up task force on Zika virus(0)
- EMAs final opinion confirms restrictions on use of linear gadolinium agents in body scans(0)
- EMAs first public hearing giving EU citizens a voice to help reduce the risk of valproate(0)
- EMAs governance during the COVID19 public health emergency(0)
- EMAs Head of Human Medicines Development and Evaluation Patrick Le Courtois retires after 16 years of service(0)
- EMAs medical literature monitoring enters into full operation(0)
- EMAs Pharmacovigilance and Risk Assessment Committee PRAC elects new Chair(0)
- EMAs proactive publication of clinical data a success(0)
- EMAs procedural handling of safety review was complete and independent(0)
- EMAs safety committee continues investigation of COVID19 Vaccine AstraZeneca and thromboembolic events further update(0)
- EMA starts evaluating the use of Kineret in adult COVID19 patients at increased risk of severe respiratory failure(0)
- EMA starts evaluating use of COVID19 vaccine Comirnaty in children aged 5 to 11(0)
- EMA starts evaluating use of COVID19 vaccine Comirnaty in young people aged 12 to 15(0)
- EMA starts evaluating use of COVID19 vaccine Spikevax in children aged 6 to 11(0)
- EMA starts evaluating use of Olumiant in hospitalised COVID19 patients requiring supplemental oxygen(0)
- EMA starts evaluating use of RoActemra in hospitalised adults with severe COVID19(0)
- EMA starts evaluating use of Veklury in COVID19 patients not requiring supplemental oxygen(0)
- EMA starts first rolling review of a COVID19 vaccine in the EU(0)
- EMA starts new review of hydroxyethylstarch containing medicines(0)
- EMA starts review of cancer medicine Rubraca(0)
- EMA starts review of conditional marketing authorisation application for Skycovion COVID19 vaccine(0)
- EMA starts review of dexamethasone for treating adults with COVID19 requiring respiratory support(0)
- EMA starts review of meningioma risk with nomegestrol and chlormadinonecontaining medicines(0)
- EMA starts review of Paxlovid for treating patients with COVID19(0)
- EMA starts review of VIR7831 for treating patients with COVID19(0)
- EMA starts rolling review of Celltrion antibody regdanvimab for COVID19(0)
- EMA starts rolling review of COVID19 Vaccine HIPRA PHH1V(0)
- EMA starts rolling review of COVID19 Vaccine Vero Cell Inactivated(0)
- EMA starts rolling review of COVID19 vaccine Vidprevtyn(0)
- EMA starts rolling review of CureVacs COVID19 vaccine CVnCoV(0)
- EMA starts rolling review of Eli Lilly antibodies bamlanivimab and etesevimab for COVID19(0)
- EMA starts rolling review of Evusheld tixagevimab and cilgavimab(0)
- EMA starts rolling review of Janssens COVID19 vaccine Ad26COV2S(0)
- EMA starts rolling review of mRNA COVID19 vaccine by Moderna Biotech Spain SL(0)
- EMA starts rolling review of Novavaxs COVID19 vaccine NVXCoV2373(0)
- EMA starts rolling review of REGNCOV2 antibody combination casirivimab / imdevimab(0)
- EMA starts rolling review of remdesivir for COVID19(0)
- EMA starts rolling review of sotrovimab VIR7831 for COVID19(0)
- EMA starts rolling review of the Sputnik V COVID19 vaccine(0)
- EMA starts rolling review of Valnevas COVID19 vaccine VLA2001(0)
- EMA starts safety review of Janus kinase inhibitors for inflammatory disorders(0)
- EMA starts second rolling review of a COVID19 vaccine(0)
- EMA statement on ongoing review of GLP1 receptor agonists(0)
- EMA supports regulatory harmonisation in East Africa(0)
- EMA survey on initial marketing authorisation application 2016(0)
- EMA surveys pharma companies on their preparedness for Brexit(0)
- EMA suspends Picato as a precaution while review of skin cancer risk continues(0)
- EMAs work on new veterinary regulation advances(0)
- EMA systems disruption expected from 11 to 17 April(0)
- EMA takes further steps to address critical shortages of medicines in the EU(0)
- EMA takes note of the European Ombudsmans decision on presubmission activities(0)
- EMA takes yet another step in public engagement with its first public hearing(0)
- EMA Thalassaemia International Federation TIF bilateral meeting(0)
- EMA tightens rules on revolving door for committee members and experts(0)
- EMA to encourage use of scientific advice for postauthorisation safety studies(0)
- EMA to further clarify safety profile of human papillomavirus HPV vaccines(0)
- EMA to host workshop on prevention of product shortages due to manufacturing and quality problems(0)
- EMA to issue electronic certificates for medicines(0)
- EMA to launch new corporate website on 27 September 2018(0)
- EMA to provide guidance on avoiding nitrosamines in human medicines(0)
- EMA to relocate to Amsterdam the Netherlands(0)
- EMA to review Inductos(0)
- EMA to review ranitidine medicines following detection of NDMA(0)
- EMA to support development of vaccines and treatments for novel coronavirus disease COVID19(0)
- EMA to support establishment of the African Medicines Agency(0)
- EMA to work with stakeholders to improve the product information for EU medicines(0)
- EMA traineeship programme informative session(0)
- EMA update on metformin diabetes medicines(0)
- EMA update on shortages of antibiotics in the EU(0)
- EMA urgently reviewing multiple sclerosis medicine Zinbryta following cases of inflammatory brain disorders(0)
- EMA Veterinary Awareness Day(0)
- EMA Veterinary Medicines Info Day 2024(0)
- EMA virtual conference 25 years of advancing public and animal health(0)
- EMA virtual technical media briefing on the RNA technology(0)
- EMA virtual workshop on myocarditis post COVID19 vaccination(0)
- EMA warns that Noxafil tablets and oral suspension have different doses and are not interchangeable(0)
- EMA webinar for fact checkers Safety of COVID19 vaccines and therapeutics(0)
- EMA website briefly unavailable on 3 December 2020(0)
- EMA website briefly unavailable on 3 March(0)
- EMA website briefly unavailable on 8 March 2021(0)
- EMA website briefly unavailable on 9 December(0)
- EMA website briefly unavailable on 15 March 2021(0)
- EMA website briefly unavailable on 18 November(0)
- EMA website briefly unavailable on 20 December(0)
- EMA website briefly unavailable on 23 May(0)
- EMA website briefly unavailable on 25 July(0)
- EMA website briefly unavailable on 27 October(0)
- EMA website briefly unavailable on 29 November(0)
- EMA welcomes EU Commissioner for Health and Food Safety(0)
- EMA welcomes Italys Minister of Health Beatrice Lorenzin(0)
- EMA welcomes new Head of Information Management Division(0)
- EMA welcomes new Head of International Affairs(0)
- EMA working for every patient in Europe(0)
- EMA working on COVID19 and Brexit over holiday period(0)
- EMA working on COVID19 during closure on 1 and 2 November 2021(0)
- EMA working on COVID19 during closure on 13 and 14 May 2021(0)
- EMA working on COVID19 during closure on 24 May 2021(0)
- EMA working on COVID19 during closure on 27 April 2021(0)
- EMA working on COVID19 over holiday period(0)
- EMA workshop on prevention of product shortages due to manufacturing and quality problems takes place today(0)
- EMA workshop on the challenges in drug development regulation and clinical practice in hemoglobinopathies(0)
- EMA workshop on thrombosis with thrombocytopenia syndrome(0)
- EMA workshop with European Union pharmaceutical industry associations on the implementation of Article 572 second subparagraph of Regulation EC No 726/2004(0)
- Emblaveo(0)
- Emdocam(0)
- EMEA/DIA Joint Workshop on EMEA new Guidelines for development and approval of Biosimilars(0)
- EMEA/H/N/PSR/0001(0)
- EMEA/H/N/PSR/J/0002(0)
- EMEA/H/N/PSR/J/0003(0)
- EMEA/H/N/PSR/J/0005(0)
- EMEA/H/N/PSR/J/0006(0)
- EMEA/H/N/PSR/J/0008(0)
- EMEA/H/N/PSR/J/0015(0)
- EMEA/H/N/PSR/J/0023(0)
- EMEA/H/N/PSR/J/0031(0)
- EMEA/H/N/PSR/S/0009(0)
- EMEA/H/N/PSR/S/0016(0)
- EMEA/H/N/PSR/S/0017(0)
- EMEA/H/N/PSR/S/0025(0)
- EMEA/H/N/PSR/S/0028(0)
- EMEA/H/N/PSR/S/0029(0)
- EMEA/H/N/PSR/S/0033(0)
- EMEA/H/N/PSR/S/0035(0)
- EMEA/ICH Workshop on Viral/Vector Shedding(0)
- EMEA/IFAHEurope Info Day Balancing the benefits and risks of veterinary medicinal products(0)
- EMEA/IFAH Infoday latest developments in scientific review legislation and marketing authorisation procedures for veterinary medicines(0)
- EMEA/INFARMED/EXPERTISSUES joint workshop on cell based medicinal products(0)
- EMEA000005PIP0107M01(0)
- EMEA000006PIP0210(0)
- EMEA000006PIP0312(0)
- EMEA000007PIP0107M02(0)
- EMEA000007PIP0412(0)
- EMEA000008PIP0107(0)
- EMEA000012PIP0107M01(0)
- EMEA000013PIP0107M03(0)
- EMEA000014PIP0107M06(0)
- EMEA000015PIP0107M04(0)
- EMEA000016PIP0107M08(0)
- EMEA000017PIP0107(0)
- EMEA000018PIP0107M12(0)
- EMEA000018PIP0107M14(0)
- EMEA000019PIP0107(0)
- EMEA000019PIP0207M05(0)
- EMEA000019PIP0308(0)
- EMEA000019PIP0609M05(0)
- EMEA000019PIP0812M03(0)
- EMEA000019PIP1114(0)
- EMEA000020PIP0107M05(0)
- EMEA000024PIP0107(0)
- EMEA000025PIP0107M01(0)
- EMEA000026PIP0211(0)
- EMEA000027PIP0107(0)
- EMEA000032PIP0107M04(0)
- EMEA000035PIP0107M05(0)
- EMEA000035PIP0209M02(0)
- EMEA000036PIP0107M06(0)
- EMEA000042PIP0107(0)
- EMEA000043PIP0107(0)
- EMEA000044PIP0108(0)
- EMEA000045PIP0107(0)
- EMEA000049PIP0107M03(0)
- EMEA000052PIP0107M03(0)
- EMEA000054PIP0107M04(0)
- EMEA000055PIP0107M06(0)
- EMEA000056PIP0107M02(0)
- EMEA000056PIP0310M02(0)
- EMEA000057PIP0107M07(0)
- EMEA000058PIP0107(0)
- EMEA000059PIP0107(0)
- EMEA000060PIP0107M03(0)
- EMEA000060PIP0208M06(0)
- EMEA000060PIP0414M01(0)
- EMEA000060PIP0514M01(0)
- EMEA000060PIP0719(0)
- EMEA000060PIP0819(0)
- EMEA000060PIP0920(0)
- EMEA000062PIP0107(0)
- EMEA000063PIP0107M01(0)
- EMEA000064PIP0107(0)
- EMEA000065PIP0107M05(0)
- EMEA000067PIP0211M02(0)
- EMEA000069PIP0107M07(0)
- EMEA000069PIP0210M08(0)
- EMEA000069PIP0413M02(0)
- EMEA000069PIP0516(0)
- EMEA000071PIP0107(0)
- EMEA000074PIP0107(0)
- EMEA000078PIP0107M08(0)
- EMEA000081PIP0107M11(0)
- EMEA000084PIP0210(0)
- EMEA000085PIP0107(0)
- EMEA000087PIP0107M05(0)
- EMEA000092PIP0211(0)
- EMEA000093PIP0107M01(0)
- EMEA000093PIP0210(0)
- EMEA000095PIP0221(0)
- EMEA000097PIP0107(0)
- EMEA000100PIP0107M01(0)
- EMEA000104PIP0107(0)
- EMEA000110PIP0107(0)
- EMEA000115PIP0107M12(0)
- EMEA000115PIP0209M03(0)
- EMEA000116PIP0107M09(0)
- EMEA000117PIP0107M07(0)
- EMEA000117PIP0210M07(0)
- EMEA000118PIP0107M01(0)
- EMEA000118PIP0210M03(0)
- EMEA000118PIP0315(0)
- EMEA000118PIP0417(0)
- EMEA000120PIP0107M05(0)
- EMEA000124PIP0107M02(0)
- EMEA000126PIP0107(0)
- EMEA000127PIP0107M03(0)
- EMEA000128PIP0107M08(0)
- EMEA000128PIP0209M04(0)
- EMEA000130PIP0107(0)
- EMEA000132PIP0107M04(0)
- EMEA000139PIP0107M03(0)
- EMEA000142PIP0209M11(0)
- EMEA000144PIP0107M05(0)
- EMEA000145PIP0107M09(0)
- EMEA000145PIP0212M04(0)
- EMEA000149PIP0107M02(0)
- EMEA000150PIP0210(0)
- EMEA000153PIP0107M05(0)
- EMEA000156PIP0107M02(0)
- EMEA000157PIP0107M05(0)
- EMEA000160PIP0107M05(0)
- EMEA000170PIP0107M04(0)
- EMEA000170PIP0210M03(0)
- EMEA000170PIP0313M04(0)
- EMEA000171PIP0107(0)
- EMEA000172PIP0107M03(0)
- EMEA000174PIP0107M03(0)
- EMEA000176PIP0107M05(0)
- EMEA000178PIP0107M04(0)
- EMEA000181PIP0108M06(0)
- EMEA000181PIP0213M01(0)
- EMEA000183PIP0108M08(0)
- EMEA000183PIP0212M03(0)
- EMEA000184PIP0108M02(0)
- EMEA000184PIP0214(0)
- EMEA000184PIP0316(0)
- EMEA000185PIP0108M05(0)
- EMEA000189PIP0108(0)
- EMEA000189PIP0108M01(0)
- EMEA000191PIP0108M05(0)
- EMEA000192PIP0108(0)
- EMEA000194PIP0310(0)
- EMEA000196PIP0108M04(0)
- EMEA000198PIP0410(0)
- EMEA000200PIP0108M10(0)
- EMEA000205PIP0108M02(0)
- EMEA000205PIP0211M05(0)
- EMEA000207PIP0108M06(0)
- EMEA000216PIP0108(0)
- EMEA000222PIP0108M09(0)
- EMEA000225PIP0108(0)
- EMEA000228PIP0108M04(0)
- EMEA000234PIP0214(0)
- EMEA000235PIP0210M02(0)
- EMEA000236PIP0311(0)
- EMEA000236PIP0414(0)
- EMEA000236PIP0518(0)
- EMEA000237PIP0108M10(0)
- EMEA000239PIP0108M03(0)
- EMEA000245PIP0108M06(0)
- EMEA000249PIP0108(0)
- EMEA000249PIP0110(0)
- EMEA000250PIP0108M02(0)
- EMEA000251PIP0108(0)
- EMEA000252PIP0108(0)
- EMEA000253PIP0108(0)
- EMEA000254PIP0108(0)
- EMEA000265PIP0108M04(0)
- EMEA000265PIP0211M04(0)
- EMEA000266PIP0108M01(0)
- EMEA000268PIP0108(0)
- EMEA000275PIP0108(0)
- EMEA000278PIP0108M01(0)
- EMEA000279PIP0108M05(0)
- EMEA000281PIP0108M02(0)
- EMEA000282PIP0108M02(0)
- EMEA000284PIP0108M04(0)
- EMEA000287PIP0210(0)
- EMEA000288PIP0108M02(0)
- EMEA000290PIP0108M04(0)
- EMEA000292PIP0108M03(0)
- EMEA000293PIP0210M01(0)
- EMEA000294PIP0212M01(0)
- EMEA000297PIP0212M02(0)
- EMEA000298PIP0108M06(0)
- EMEA000300PIP0108M04(0)
- EMEA000301PIP0108M03(0)
- EMEA000302PIP0108M03(0)
- EMEA000306PIP0108M04(0)
- EMEA000308PIP0108M04(0)
- EMEA000308PIP0211M01(0)
- EMEA000309PIP0108M07(0)
- EMEA000309PIP0214(0)
- EMEA000309PIP0417M03(0)
- EMEA000309PIP0621(0)
- EMEA000309PIP0721(0)
- EMEA000309PIP0921(0)
- EMEA000310PIP0310M06(0)
- EMEA000311PIP0108M04(0)
- EMEA000311PIP0311M06(0)
- EMEA000311PIP0413M04(0)
- EMEA000311PIP0517M02(0)
- EMEA000311PIP0618(0)
- EMEA000312PIP0108M07(0)
- EMEA000315PIP0108(0)
- EMEA000315PIP0215M02(0)
- EMEA000316PIP0211M05(0)
- EMEA000316PIP0320(0)
- EMEA000317PIP0108M13(0)
- EMEA000317PIP0218M01(0)
- EMEA000319PIP0108M03(0)
- EMEA000322PIP0108M06(0)
- EMEA000325PIP0108M10(0)
- EMEA000328PIP0209(0)
- EMEA000329PIP0209M05(0)
- EMEA000332PIP0108M15(0)
- EMEA000332PIP0108M16(0)
- EMEA000332PIP0217M04(0)
- EMEA000334PIP0108M11(0)
- EMEA000335PIP0108M15(0)
- EMEA000339PIP0209M03(0)
- EMEA000341PIP0209M05(0)
- EMEA000341PIP0318(0)
- EMEA000342PIP0108M07(0)
- EMEA000343PIP0108(0)
- EMEA000344PIP0108(0)
- EMEA000347PIP0108M06(0)
- EMEA000347PIP0216M04(0)
- EMEA000347PIP0318(0)
- EMEA000347PIP0520(0)
- EMEA000351PIP0108(0)
- EMEA000352PIP0108M01(0)
- EMEA000353PIP0216M02(0)
- EMEA000362PIP0108M04(0)
- EMEA000365PIP0108M12(0)
- EMEA000366PIP0108M06(0)
- EMEA000366PIP0209M06(0)
- EMEA000366PIP0412(0)
- EMEA000366PIP0512M02(0)
- EMEA000367PIP0108M08(0)
- EMEA000368PIP0108(0)
- EMEA000369PIP0108(0)
- EMEA000370PIP0218M01(0)
- EMEA000371PIP0108(0)
- EMEA000371PIP0209(0)
- EMEA000371PIP0416(0)
- EMEA000373PIP0209M05(0)
- EMEA000377PIP0108(0)
- EMEA000380PIP0108M04(0)
- EMEA000380PIP0209M04(0)
- EMEA000380PIP0410(0)
- EMEA000380PIP0518(0)
- EMEA000380PIP0619M01(0)
- EMEA000380PIP0720(0)
- EMEA000380PIP0821(0)
- EMEA000380PIP0921(0)
- EMEA000384PIP0108(0)
- EMEA000389PIP0108M01(0)
- EMEA000391PIP0108M01(0)
- EMEA000394PIP0108M01(0)
- EMEA000395PIP0108(0)
- EMEA000397PIP0108(0)
- EMEA000398PIP0108(0)
- EMEA000399PIP0108(0)
- EMEA000402PIP0211M05(0)
- EMEA000402PIP0317M06(0)
- EMEA000404PIP0212(0)
- EMEA000406PIP0108M04(0)
- EMEA000408PIP0108M05(0)
- EMEA000408PIP0212(0)
- EMEA000409PIP0108M06(0)
- EMEA000410PIP0108M04(0)
- EMEA000411PIP0108(0)
- EMEA000412PIP0108M01(0)
- EMEA000414PIP0211(0)
- EMEA000420PIP0110(0)
- EMEA000425PIP0210M04(0)
- EMEA000428PIP0108M03(0)
- EMEA000429PIP0108M04(0)
- EMEA000430PIP0108M11(0)
- EMEA000431PIP0108M12(0)
- EMEA000433PIP0108(0)
- EMEA000434PIP0108M09(0)
- EMEA000435PIP0108(0)
- EMEA000436PIP0108(0)
- EMEA000439PIP0211(0)
- EMEA000440PIP0211M05(0)
- EMEA000444PIP0108(0)
- EMEA000452PIP0210M06(0)
- EMEA000454PIP0108M07(0)
- EMEA000455PIP0210M09(0)
- EMEA000456PIP0108M02(0)
- EMEA000457PIP0210M02(0)
- EMEA000458PIP0108(0)
- EMEA000459PIP0108M02(0)
- EMEA000461PIP0211M05(0)
- EMEA000463PIP0108M03(0)
- EMEA000463PIP0210(0)
- EMEA000464PIP0108(0)
- EMEA000464PIP0210(0)
- EMEA000465PIP0108(0)
- EMEA000467PIP0108M15(0)
- EMEA000468PIP0212M07(0)
- EMEA000469PIP0108M07(0)
- EMEA000470PIP0108M11(0)
- EMEA000471PIP0108M02(0)
- EMEA000478PIP0108M01(0)
- EMEA000478PIP0218(0)
- EMEA000479PIP0108M03(0)
- EMEA000480PIP0108M14(0)
- EMEA000482PIP0108M06(0)
- EMEA000485PIP0108M04(0)
- EMEA000486PIP0108M04(0)
- EMEA000487PIP0108(0)
- EMEA000488PIP0108(0)
- EMEA000488PIP0211(0)
- EMEA000491PIP0108M01(0)
- EMEA000492PIP0108M01(0)
- EMEA000493PIP0108M01(0)
- EMEA000494PIP0108M09(0)
- EMEA000495PIP0108M09(0)
- EMEA000496PIP0108M08(0)
- EMEA000498PIP0108M10(0)
- EMEA000499PIP0210M01(0)
- EMEA000499PIP0317(0)
- EMEA000499PIP0417(0)
- EMEA000499PIP0518(0)
- EMEA000500PIP0108M03(0)
- EMEA000506PIP0108M02(0)
- EMEA000510PIP0210M02(0)
- EMEA000511PIP0108M04(0)
- EMEA000512PIP0108(0)
- EMEA000513PIP0108(0)
- EMEA000514PIP0108(0)
- EMEA000515PIP0108(0)
- EMEA000516PIP0108(0)
- EMEA000517PIP0108(0)
- EMEA000520PIP0108M05(0)
- EMEA000520PIP0213M04(0)
- EMEA000524PIP0108(0)
- EMEA000525PIP0108M08(0)
- EMEA000527PIP0108(0)
- EMEA000527PIP0210(0)
- EMEA000527PIP0313(0)
- EMEA000527PIP0413M01(0)
- EMEA000527PIP0517(0)
- EMEA000530PIP0211(0)
- EMEA000533PIP0108M11(0)
- EMEA000534PIP0317(0)
- EMEA000548PIP0109M08(0)
- EMEA000550PIP0210M01(0)
- EMEA000551PIP0421M01(0)
- EMEA000552PIP010(0)
- EMEA000553PIP0109M05(0)
- EMEA000555PIP0109M06(0)
- EMEA000556PIP0109M02(0)
- EMEA000557PIP0109(0)
- EMEA000558PIP0109M02(0)
- EMEA000558PIP0210(0)
- EMEA000559PIP0109M04(0)
- EMEA000560PIP0215(0)
- EMEA000560PIP0315M01(0)
- EMEA000562PIP0109M01(0)
- EMEA000564PIP0109(0)
- EMEA000565PIP0109(0)
- EMEA000567PIP0109M05(0)
- EMEA000568PIP0109M06(0)
- EMEA000571PIP0109(0)
- EMEA000573PIP0109M05(0)
- EMEA000573PIP0213M03(0)
- EMEA000574PIP0212M03(0)
- EMEA000575PIP0109M03(0)
- EMEA000576PIP0109M14(0)
- EMEA000576PIP0211M04(0)
- EMEA000576PIP0312M06(0)
- EMEA000582PIP0109M03(0)
- EMEA000583PIP0109M08(0)
- EMEA000597PIP0210M09(0)
- EMEA000597PIP0315M05(0)
- EMEA000599PIP0109M07(0)
- EMEA000601PIP0109M06(0)
- EMEA000602PIP0212(0)
- EMEA000608PIP0109(0)
- EMEA000609PIP0109M03(0)
- EMEA000611PIP0109(0)
- EMEA000612PIP0109(0)
- EMEA000619PIP0210(0)
- EMEA000625PIP0109M03(0)
- EMEA000627PIP0109M04(0)
- EMEA000628PIP0109M04(0)
- EMEA000630PIP0209M05(0)
- EMEA000631PIP0109(0)
- EMEA000632PIP0109(0)
- EMEA000635PIP0109(0)
- EMEA000636PIP0109M07(0)
- EMEA000637PIP0109M01(0)
- EMEA000637PIP0210M07(0)
- EMEA000639PIP0209M02(0)
- EMEA000639PIP0316M02(0)
- EMEA000639PIP0419(0)
- EMEA000639PIP0519(0)
- EMEA000639PIP0620(0)
- EMEA000641PIP0109(0)
- EMEA000643PIP0220(0)
- EMEA000645PIP0109M08(0)
- EMEA000645PIP0318(0)
- EMEA000645PIP0420M02(0)
- EMEA000646PIP0109M01(0)
- EMEA000653PIP0109M05(0)
- EMEA000654PIP0109M02(0)
- EMEA000656PIP0109(0)
- EMEA000658PIP0108(0)
- EMEA000661PIP0109M07(0)
- EMEA000662PIP0209M05(0)
- EMEA000663PIP0109M03(0)
- EMEA000665PIP0109(0)
- EMEA000669PIP0109M02(0)
- EMEA000670PIP0109M02(0)
- EMEA000671PIP0109M10(0)
- EMEA000673PIP0109M09(0)
- EMEA000674PIP0211M01(0)
- EMEA000687PIP0109M02(0)
- EMEA000689PIP0109M11(0)
- EMEA000694PIP0109M08(0)
- EMEA000694PIP0214M03(0)
- EMEA000694PIP0317(0)
- EMEA000694PIP0418(0)
- EMEA000694PIP0520(0)
- EMEA000694PIP0620(0)
- EMEA000696PIP0210M08(0)
- EMEA000698PIP0210M01(0)
- EMEA000700PIP0210(0)
- EMEA000703PIP0109(0)
- EMEA000709PIP0109M05(0)
- EMEA000711PIP0109(0)
- EMEA000712PIP0109(0)
- EMEA000713PIP0210M05(0)
- EMEA000715PIP0211M06(0)
- EMEA000715PIP0311M06(0)
- EMEA000715PIP0513M05(0)
- EMEA000716PIP0109M05(0)
- EMEA000717PIP0213M02(0)
- EMEA000718PIP0109M06(0)
- EMEA000719PIP0210(0)
- EMEA000720PIP0109M02(0)
- EMEA000724PIP0211(0)
- EMEA000725PIP0109M03(0)
- EMEA000726PIP0109M02(0)
- EMEA000727PIP0109M06(0)
- EMEA000727PIP0109M07(0)
- EMEA000731PIP0109M03(0)
- EMEA000733PIP0212(0)
- EMEA000734PIP0109(0)
- EMEA000735PIP0109(0)
- EMEA000736PIP0109(0)
- EMEA000737PIP0109(0)
- EMEA000737PIP0211M02(0)
- EMEA000742PIP0109(0)
- EMEA000744PIP0109(0)
- EMEA000745PIP0109M03(0)
- EMEA000746PIP0109M04(0)
- EMEA000753PIP0111(0)
- EMEA000753PIP0216(0)
- EMEA000758PIP0109(0)
- EMEA000764PIP0109(0)
- EMEA000764PIP0211(0)
- EMEA000769PIP0109M08(0)
- EMEA000770PIP0211(0)
- EMEA000774PIP0109M03(0)
- EMEA000775PIP0109M02(0)
- EMEA000777PIP0109M05(0)
- EMEA000778PIP0212M01(0)
- EMEA000780PIP0109M06(0)
- EMEA000781PIP0109(0)
- EMEA000782PIP0109M04(0)
- EMEA000783PIP0109M06(0)
- EMEA000784PIP0211M01(0)
- EMEA000786PIP0109M02(0)
- EMEA000788PIP0211M11(0)
- EMEA000789PIP0109(0)
- EMEA000790PIP0109(0)
- EMEA000791PIP0109(0)
- EMEA000792PIP0109M01(0)
- EMEA000793PIP0109(0)
- EMEA000794PIP0109M01(0)
- EMEA000795PIP0109M01(0)
- EMEA000798PIP0109M03(0)
- EMEA000800PIP0109M01(0)
- EMEA000801PIP0316M01(0)
- EMEA000802PIP0109(0)
- EMEA000802PIP0211M01(0)
- EMEA000804PIP0109M02(0)
- EMEA000806PIP0109(0)
- EMEA000807PIP0109(0)
- EMEA000808PIP0109M01(0)
- EMEA000809PIP0109M01(0)
- EMEA000810PIP0109(0)
- EMEA000811PIP0109(0)
- EMEA000812PIP0109(0)
- EMEA000813PIP0109(0)
- EMEA000814PIP0109(0)
- EMEA000815PIP0109M01(0)
- EMEA000816PIP0210M03(0)
- EMEA000817PIP0211M01(0)
- EMEA000822PIP0109M01(0)
- EMEA000823PIP0110(0)
- EMEA000823PIP0210(0)
- EMEA000824PIP0109(0)
- EMEA000826PIP0109(0)
- EMEA000827PIP0109M05(0)
- EMEA000827PIP0311(0)
- EMEA000828PIP0109M09(0)
- EMEA000828PIP0416M03(0)
- EMEA000828PIP0517(0)
- EMEA000828PIP0618(0)
- EMEA000828PIP0721(0)
- EMEA000829PIP0109(0)
- EMEA000830PIP0210M02(0)
- EMEA000832PIP0110M05(0)
- EMEA000834PIP0110(0)
- EMEA000835PIP0110(0)
- EMEA000836PIP0110(0)
- EMEA000837PIP0110M02(0)
- EMEA000838PIP0110M02(0)
- EMEA000839PIP0110(0)
- EMEA000840PIP0110(0)
- EMEA000841PIP0110(0)
- EMEA000845PIP0110M02(0)
- EMEA000846PIP0110M01(0)
- EMEA000847PIP0110M01(0)
- EMEA000848PIP0110M02(0)
- EMEA000849PIP0110M01(0)
- EMEA000850PIP0110(0)
- EMEA000851PIP0110(0)
- EMEA000852PIP0110M01(0)
- EMEA000853PIP0110M01(0)
- EMEA000856PIP0110(0)
- EMEA000857PIP0110M01(0)
- EMEA000859PIP0110(0)
- EMEA000860PIP0110M01(0)
- EMEA000863PIP0110(0)
- EMEA000864PIP0110(0)
- EMEA000865PIP0110(0)
- EMEA000866PIP0110(0)
- EMEA000867PIP0110(0)
- EMEA000869PIP0110(0)
- EMEA000872PIP0110M03(0)
- EMEA000876PIP0110M01(0)
- EMEA000876PIP0211M01(0)
- EMEA000876PIP0314M05(0)
- EMEA000876PIP0515M05(0)
- EMEA000876PIP0615(0)
- EMEA000876PIP0715(0)
- EMEA000877PIP0317M04(0)
- EMEA000878PIP0211(0)
- EMEA000880PIP0211M04(0)
- EMEA000882PIP0311M05(0)
- EMEA000883PIP0110M05(0)
- EMEA000884PIP0110(0)
- EMEA000885PIP0110(0)
- EMEA000886PIP0110(0)
- EMEA000887PIP0110(0)
- EMEA000888PIP0110(0)
- EMEA000892PIP0110(0)
- EMEA000894PIP0110(0)
- EMEA000896PIP0110(0)
- EMEA000898PIP0110M02(0)
- EMEA000901PIP0110(0)
- EMEA000901PIP0210(0)
- EMEA000901PIP0316M02(0)
- EMEA000901PIP0417M02(0)
- EMEA000902PIP0110(0)
- EMEA000903PIP0110(0)
- EMEA000904PIP0110(0)
- EMEA000905PIP0110(0)
- EMEA000906PIP0110(0)
- EMEA000907PIP0110(0)
- EMEA000908PIP0110(0)
- EMEA000909PIP0110(0)
- EMEA000910PIP0110(0)
- EMEA000911PIP0110(0)
- EMEA000912PIP0110M06(0)
- EMEA000914PIP0110M05(0)
- EMEA000915PIP0110(0)
- EMEA000916PIP0110M07(0)
- EMEA000917PIP0110M04(0)
- EMEA000917PIP0211(0)
- EMEA000918PIP0110(0)
- EMEA000919PIP0110(0)
- EMEA000920PIP0110(0)
- EMEA000921PIP0110(0)
- EMEA000922PIP0110(0)
- EMEA000923PIP0110(0)
- EMEA000924PIP0110(0)
- EMEA000925PIP0110(0)
- EMEA000926PIP0110(0)
- EMEA000927PIP0110M07(0)
- EMEA000928PIP0110M01(0)
- EMEA000929PIP0110(0)
- EMEA000930PIP0110(0)
- EMEA000931PIP0110(0)
- EMEA000932PIP0110M02(0)
- EMEA000933PIP0110(0)
- EMEA000934PIP0110(0)
- EMEA000935PIP0110(0)
- EMEA000936PIP0110(0)
- EMEA000937PIP0110(0)
- EMEA000938PIP0110(0)
- EMEA000939PIP0110(0)
- EMEA000940PIP0110(0)
- EMEA000941PIP0110(0)
- EMEA000942PIP0110(0)
- EMEA000943PIP0110(0)
- EMEA000944PIP0110(0)
- EMEA000945PIP0110(0)
- EMEA000946PIP0110(0)
- EMEA000947PIP0110(0)
- EMEA000948PIP0110(0)
- EMEA000949PIP0110(0)
- EMEA000950PIP0110(0)
- EMEA000951PIP0110(0)
- EMEA000953PIP0110(0)
- EMEA000954PIP0110(0)
- EMEA000955PIP0110(0)
- EMEA000956PIP0110(0)
- EMEA000957PIP0110(0)
- EMEA000958PIP0110(0)
- EMEA000959PIP0110(0)
- EMEA000960PIP0110(0)
- EMEA000961PIP0110(0)
- EMEA000962PIP0110(0)
- EMEA000963PIP0110(0)
- EMEA000964PIP0110(0)
- EMEA000965PIP0110(0)
- EMEA000966PIP0110(0)
- EMEA000968PIP0211M05(0)
- EMEA000969PIP0110M06(0)
- EMEA000970PIP0110M01(0)
- EMEA000971PIP0110M03(0)
- EMEA000972PIP0110M05(0)
- EMEA000973PIP0110M03(0)
- EMEA000977PIP0110(0)
- EMEA000978PIP0110M01(0)
- EMEA000979PIP0110M02(0)
- EMEA000980PIP0110M07(0)
- EMEA000980PIP0215(0)
- EMEA000980PIP0418(0)
- EMEA000981PIP0110M04(0)
- EMEA000982PIP0110(0)
- EMEA000983PIP0110(0)
- EMEA000986PIP0110(0)
- EMEA000986PIP0213(0)
- EMEA000987PIP0110M04(0)
- EMEA000988PIP0110(0)
- EMEA000989PIP0110M02(0)
- EMEA000990PIP0210(0)
- EMEA000991PIP0110(0)
- EMEA000993PIP0110(0)
- EMEA000994PIP0110M01(0)
- EMEA000995PIP0110(0)
- EMEA000997PIP0110M06(0)
- EMEA000998PIP0110(0)
- EMEA001000PIP0110(0)
- EMEA001002PIP0110(0)
- EMEA001003PIP0110M02(0)
- EMEA001004PIP0110(0)
- EMEA001005PIP0110M01(0)
- EMEA001006PIP0110(0)
- EMEA001006PIP0215(0)
- EMEA001006PIP0316(0)
- EMEA001006PIP0518M01(0)
- EMEA001007PIP0110(0)
- EMEA001007PIP0215(0)
- EMEA001011PIP0110M01(0)
- EMEA001012PIP0110M01(0)
- EMEA001013PIP0110M01(0)
- EMEA001014PIP0110M01(0)
- EMEA001015PIP0110(0)
- EMEA001016PIP0110M01(0)
- EMEA001017PIP0110M01(0)
- EMEA001019PIP0110M05(0)
- EMEA001023PIP0110(0)
- EMEA001024PIP0110M02(0)
- EMEA001026PIP0110(0)
- EMEA001028PIP0110(0)
- EMEA001030PIP0110M10(0)
- EMEA001032PIP0110M05(0)
- EMEA001032PIP0217(0)
- EMEA001032PIP0319(0)
- EMEA001033PIP0211(0)
- EMEA001034PIP0110(0)
- EMEA001036PIP0110(0)
- EMEA001037PIP0211M05(0)
- EMEA001039PIP0110M02(0)
- EMEA001039PIP0212M04(0)
- EMEA001039PIP0317(0)
- EMEA001042PIP0211(0)
- EMEA001043PIP0110M03(0)
- EMEA001043PIP0216(0)
- EMEA001045PIP0110M02(0)
- EMEA001045PIP0218(0)
- EMEA001045PIP0418(0)
- EMEA001050PIP0110M05(0)
- EMEA001050PIP0218M01(0)
- EMEA001051PIP0110M03(0)
- EMEA001053PIP0110M03(0)
- EMEA001054PIP0110M03(0)
- EMEA001055PIP0110(0)
- EMEA001055PIP0221(0)
- EMEA001056PIP0212M01(0)
- EMEA001057PIP0110M01(0)
- EMEA001060PIP0110(0)
- EMEA001061PIP0110M03(0)
- EMEA001064PIP0110M03(0)
- EMEA001065PIP0110(0)
- EMEA001066PIP0110(0)
- EMEA001066PIP0211M03(0)
- EMEA001069PIP0110(0)
- EMEA001070PIP0110M02(0)
- EMEA001071PIP0212M02(0)
- EMEA001071PIP0314M01(0)
- EMEA001072PIP0110M04(0)
- EMEA001073PIP0214(0)
- EMEA001075PIP0110(0)
- EMEA001075PIP0415M04(0)
- EMEA001078PIP0110(0)
- EMEA001079PIP0110M06(0)
- EMEA001080PIP0110(0)
- EMEA001080PIP0318(0)
- EMEA001082PIP0211M03(0)
- EMEA001084PIP0110(0)
- EMEA001084PIP0211(0)
- EMEA001085PIP0110(0)
- EMEA001087PIP0212M03(0)
- EMEA001089PIP0213M03(0)
- EMEA001090PIP0111(0)
- EMEA001090PIP0221(0)
- EMEA001091PIP0215(0)
- EMEA001094PIP0110M04(0)
- EMEA001095PIP0212(0)
- EMEA001095PIP0319(0)
- EMEA001097PIP0110M02(0)
- EMEA001098PIP0110M01(0)
- EMEA001099PIP0211M01(0)
- EMEA001100PIP0110(0)
- EMEA001102PIP0110(0)
- EMEA001103PIP0110M03(0)
- EMEA001105PIP0110M06(0)
- EMEA001107PIP0110M04(0)
- EMEA001108PIP0215(0)
- EMEA001109PIP0110(0)
- EMEA001110PIP0110M01(0)
- EMEA001111PIP0110(0)
- EMEA001113PIP0110M06(0)
- EMEA001114PIP0110M03(0)
- EMEA001115PIP0110M08(0)
- EMEA001117PIP0110(0)
- EMEA001118PIP0110(0)
- EMEA001119PIP0212M08(0)
- EMEA001119PIP0319M03(0)
- EMEA001120PIP0110(0)
- EMEA001121PIP0110(0)
- EMEA001123PIP0111M03(0)
- EMEA001124PIP0110M05(0)
- EMEA001126PIP0110M03(0)
- EMEA001127PIP0211M02(0)
- EMEA001128PIP0110(0)
- EMEA001129PIP0111M05(0)
- EMEA001131PIP0111(0)
- EMEA001131PIP0212(0)
- EMEA001133PIP0111(0)
- EMEA001134PIP0111(0)
- EMEA001135PIP0111(0)
- EMEA001136PIP0111M02(0)
- EMEA001136PIP0219M01(0)
- EMEA001137PIP0111(0)
- EMEA001138PIP0211(0)
- EMEA001139PIP0111M02(0)
- EMEA001140PIP0215(0)
- EMEA001141PIP0111(0)
- EMEA001142PIP0111M04(0)
- EMEA001142PIP0216(0)
- EMEA001143PIP0111M04(0)
- EMEA001144PIP0111(0)
- EMEA001145PIP0110(0)
- EMEA001146PIP0111M07(0)
- EMEA001147PIP0111M07(0)
- EMEA001147PIP0220(0)
- EMEA001148PIP0111(0)
- EMEA001149PIP0111M07(0)
- EMEA001150PIP0213M04(0)
- EMEA001150PIP0322(0)
- EMEA001151PIP0111(0)
- EMEA001151PIP0217(0)
- EMEA001152PIP0216(0)
- EMEA001154PIP0111(0)
- EMEA001154PIP0215(0)
- EMEA001155PIP0111M03(0)
- EMEA001156PIP0111M07(0)
- EMEA001157PIP0111M02(0)
- EMEA001159PIP0212(0)
- EMEA001160PIP0111M03(0)
- EMEA001161PIP0211M02(0)
- EMEA001163PIP0111(0)
- EMEA001164PIP0111M06(0)
- EMEA001165PIP0111(0)
- EMEA001167PIP0211M01(0)
- EMEA001168PIP0111M03(0)
- EMEA001169PIP0111M05(0)
- EMEA001169PIP0213(0)
- EMEA001170PIP0111(0)
- EMEA001171PIP0111M02(0)
- EMEA001172PIP0111(0)
- EMEA001173PIP0111M01(0)
- EMEA001174PIP0212M02(0)
- EMEA001174PIP0318(0)
- EMEA001175PIP0111M04(0)
- EMEA001176PIP0111M06(0)
- EMEA001177PIP0111M06(0)
- EMEA001177PIP0220(0)
- EMEA001178PIP0111M06(0)
- EMEA001180PIP0111(0)
- EMEA001181PIP0111M06(0)
- EMEA001182PIP0111(0)
- EMEA001183PIP0213(0)
- EMEA001184PIP0111(0)
- EMEA001185PIP0111M08(0)
- EMEA001186PIP0111M03(0)
- EMEA001187PIP0111M04(0)
- EMEA001190PIP0111(0)
- EMEA001191PIP0111M03(0)
- EMEA001192PIP0111(0)
- EMEA001193PIP0111(0)
- EMEA001194PIP0111M05(0)
- EMEA001195PIP0111M05(0)
- EMEA001196PIP0111(0)
- EMEA001196PIP0217(0)
- EMEA001196PIP0321(0)
- EMEA001197PIP0111(0)
- EMEA001198PIP0111(0)
- EMEA001198PIP0216(0)
- EMEA001198PIP0317M04(0)
- EMEA001200PIP0111(0)
- EMEA001201PIP0111M02(0)
- EMEA001202PIP0213M04(0)
- EMEA001203PIP0214M02(0)
- EMEA001204PIP0111(0)
- EMEA001204PIP0214(0)
- EMEA001205PIP0219M02(0)
- EMEA001207PIP0111M01(0)
- EMEA001207PIP0219M01(0)
- EMEA001207PIP0320(0)
- EMEA001207PIP0622(0)
- EMEA001208PIP0111M03(0)
- EMEA001211PIP0111M02(0)
- EMEA001212PIP0111(0)
- EMEA001213PIP0212M02(0)
- EMEA001214PIP0111M11(0)
- EMEA001214PIP0217(0)
- EMEA001214PIP0419(0)
- EMEA001214PIP0519(0)
- EMEA001214PIP0620(0)
- EMEA001214PIP0721(0)
- EMEA001214PIP0821(0)
- EMEA001214PIP0921(0)
- EMEA001215PIP0111M07(0)
- EMEA001216PIP0112(0)
- EMEA001217PIP0111M08(0)
- EMEA001218PIP0111(0)
- EMEA001219PIP0111M06(0)
- EMEA001220PIP0111M07(0)
- EMEA001220PIP0316M02(0)
- EMEA001220PIP0519(0)
- EMEA001220PIP0720M01(0)
- EMEA001220PIP0820(0)
- EMEA001222PIP0111(0)
- EMEA001223PIP0111(0)
- EMEA001226PIP0111M01(0)
- EMEA001229PIP0111M03(0)
- EMEA001230PIP0111M05(0)
- EMEA001231PIP0213M09(0)
- EMEA001232PIP0111(0)
- EMEA001234PIP0111(0)
- EMEA001237PIP0111(0)
- EMEA001238PIP0112(0)
- EMEA001238PIP0220(0)
- EMEA001238PIP0321(0)
- EMEA001239PIP0111(0)
- EMEA001241PIP0213M01(0)
- EMEA001244PIP0111M02(0)
- EMEA001245PIP0111(0)
- EMEA001247PIP0111(0)
- EMEA001251PIP0111M05(0)
- EMEA001252PIP0111(0)
- EMEA001254PIP0111M02(0)
- EMEA001255PIP0111M03(0)
- EMEA001256PIP0212M02(0)
- EMEA001257PIP0111(0)
- EMEA001258PIP0111M08(0)
- EMEA001259PIP0213M02(0)
- EMEA001260PIP0111M02(0)
- EMEA001261PIP0111M07(0)
- EMEA001262PIP0112M03(0)
- EMEA001264PIP0112M02(0)
- EMEA001266PIP0112(0)
- EMEA001266PIP0214(0)
- EMEA001266PIP0419(0)
- EMEA001267PIP0112(0)
- EMEA001268PIP0112M05(0)
- EMEA001269PIP0112(0)
- EMEA001269PIP0214(0)
- EMEA001270PIP0112M05(0)
- EMEA001271PIP0112M01(0)
- EMEA001272PIP0213M01(0)
- EMEA001274PIP0112(0)
- EMEA001275PIP0112(0)
- EMEA001276PIP0112M02(0)
- EMEA001277PIP0112(0)
- EMEA001278PIP0112(0)
- EMEA001279PIP0112(0)
- EMEA001280PIP0112M05(0)
- EMEA001281PIP0112(0)
- EMEA001283PIP0112(0)
- EMEA001284PIP0112(0)
- EMEA001285PIP0112M02(0)
- EMEA001286PIP0112(0)
- EMEA001288PIP0112(0)
- EMEA001289PIP0112M01(0)
- EMEA001290PIP0112(0)
- EMEA001291PIP0112(0)
- EMEA001292PIP0112M01(0)
- EMEA001294PIP0112(0)
- EMEA001295PIP0112M01(0)
- EMEA001296PIP0112M04(0)
- EMEA001298PIP0112(0)
- EMEA001299PIP0112(0)
- EMEA001299PIP0317M01(0)
- EMEA001300PIP0112(0)
- EMEA001301PIP0112(0)
- EMEA001301PIP0212M04(0)
- EMEA001302PIP0112(0)
- EMEA001303PIP0112M04(0)
- EMEA001304PIP0213M05(0)
- EMEA001304PIP0317(0)
- EMEA001305PIP0112(0)
- EMEA001307PIP0112(0)
- EMEA001308PIP0112M02(0)
- EMEA001309PIP0112(0)
- EMEA001310PIP0112M03(0)
- EMEA001311PIP0112M01(0)
- EMEA001312PIP0112(0)
- EMEA001312PIP0219(0)
- EMEA001312PIP0319(0)
- EMEA001313PIP0112M13(0)
- EMEA001314PIP0112M01(0)
- EMEA001315PIP0216M02(0)
- EMEA001316PIP0112M01(0)
- EMEA001317PIP0112(0)
- EMEA001318PIP0112M04(0)
- EMEA001319PIP0112(0)
- EMEA001320PIP0112(0)
- EMEA001321PIP0112(0)
- EMEA001322PIP0112(0)
- EMEA001323PIP0112(0)
- EMEA001323PIP0212(0)
- EMEA001324PIP0112M01(0)
- EMEA001325PIP0112(0)
- EMEA001326PIP0112(0)
- EMEA001327PIP0112(0)
- EMEA001329PIP0112(0)
- EMEA001329PIP0213(0)
- EMEA001331PIP0112M02(0)
- EMEA001332PIP0112M06(0)
- EMEA001333PIP0213(0)
- EMEA001334PIP0112(0)
- EMEA001337PIP0112(0)
- EMEA001340PIP0112M03(0)
- EMEA001342PIP0112(0)
- EMEA001343PIP0112(0)
- EMEA001344PIP0112(0)
- EMEA001344PIP0217(0)
- EMEA001345PIP0112(0)
- EMEA001348PIP0112M01(0)
- EMEA001349PIP0112M03(0)
- EMEA001350PIP0213M04(0)
- EMEA001352PIP0112M01(0)
- EMEA001353PIP0112(0)
- EMEA001354PIP0112(0)
- EMEA001355PIP0112(0)
- EMEA001356PIP0212M04(0)
- EMEA001357PIP0112M02(0)
- EMEA001358PIP0112(0)
- EMEA001359PIP0112M03(0)
- EMEA001361PIP0112(0)
- EMEA001362PIP0112M03(0)
- EMEA001363PIP0112M01(0)
- EMEA001364PIP0112(0)
- EMEA001365PIP0112(0)
- EMEA001366PIP0112M02(0)
- EMEA001368PIP0112(0)
- EMEA001369PIP0112(0)
- EMEA001370PIP0213(0)
- EMEA001371PIP0112(0)
- EMEA001371PIP0221(0)
- EMEA001371PIP0322(0)
- EMEA001373PIP0112M04(0)
- EMEA001374PIP0112(0)
- EMEA001377PIP0112(0)
- EMEA001379PIP0112M06(0)
- EMEA001380PIP0112(0)
- EMEA001381PIP0112(0)
- EMEA001382PIP0112(0)
- EMEA001384PIP0112(0)
- EMEA001384PIP0217(0)
- EMEA001385PIP0112(0)
- EMEA001389PIP0112(0)
- EMEA001390PIP0112(0)
- EMEA001391PIP0112(0)
- EMEA001392PIP0112(0)
- EMEA001394PIP0112(0)
- EMEA001395PIP0112(0)
- EMEA001396PIP0112(0)
- EMEA001397PIP0112(0)
- EMEA001397PIP0213(0)
- EMEA001397PIP0314M06(0)
- EMEA001397PIP0417M01(0)
- EMEA001397PIP0517(0)
- EMEA001397PIP0617(0)
- EMEA001398PIP0213(0)
- EMEA001400PIP0112(0)
- EMEA001403PIP0112(0)
- EMEA001404PIP0112(0)
- EMEA001405PIP0112(0)
- EMEA001406PIP0112(0)
- EMEA001407PIP0112M03(0)
- EMEA001407PIP0215M05(0)
- EMEA001407PIP0320(0)
- EMEA001408PIP0112(0)
- EMEA001409PIP0112(0)
- EMEA001410PIP0112(0)
- EMEA001410PIP0217M04(0)
- EMEA001411PIP0112M04(0)
- EMEA001413PIP0113(0)
- EMEA001414PIP0112M01(0)
- EMEA001415PIP0221(0)
- EMEA001416PIP0112M03(0)
- EMEA001417PIP0112M04(0)
- EMEA001418PIP0113M02(0)
- EMEA001418PIP0113M05(0)
- EMEA001418PIP0115M01(0)
- EMEA001418PIP0215M03(0)
- EMEA001421PIP0112(0)
- EMEA001425PIP0113M05(0)
- EMEA001426PIP0113M02(0)
- EMEA001428PIP0113(0)
- EMEA001428PIP0315M02(0)
- EMEA001429PIP0113M07(0)
- EMEA001430PIP0113(0)
- EMEA001433PIP0113(0)
- EMEA001434PIP0113M03(0)
- EMEA001435PIP0216M01(0)
- EMEA001437PIP0113(0)
- EMEA001437PIP0219(0)
- EMEA001438PIP0113M01(0)
- EMEA001439PIP0113M03(0)
- EMEA001440PIP0113M03(0)
- EMEA001441PIP0113M03(0)
- EMEA001441PIP0215M02(0)
- EMEA001441PIP0317M02(0)
- EMEA001441PIP0520(0)
- EMEA001441PIP0721(0)
- EMEA001442PIP0113(0)
- EMEA001444PIP0113(0)
- EMEA001447PIP0112(0)
- EMEA001447PIP0221(0)
- EMEA001448PIP0113M03(0)
- EMEA001450PIP0113M01(0)
- EMEA001451PIP0113M01(0)
- EMEA001452PIP0113M04(0)
- EMEA001453PIP0113M01(0)
- EMEA001454PIP0315M02(0)
- EMEA001454PIP0518(0)
- EMEA001457PIP0113(0)
- EMEA001460PIP0113M05(0)
- EMEA001461PIP0113(0)
- EMEA001461PIP0214(0)
- EMEA001462PIP0113(0)
- EMEA001463PIP0113(0)
- EMEA001464PIP0113(0)
- EMEA001465PIP0113M05(0)
- EMEA001467PIP0113(0)
- EMEA001468PIP0113(0)
- EMEA001469PIP0113(0)
- EMEA001469PIP0217(0)
- EMEA001471PIP0113(0)
- EMEA001472PIP0113(0)
- EMEA001473PIP0113(0)
- EMEA001474PIP0113M01(0)
- EMEA001474PIP0216M02(0)
- EMEA001475PIP0113(0)
- EMEA001475PIP0213M02(0)
- EMEA001475PIP0317M03(0)
- EMEA001475PIP0420(0)
- EMEA001476PIP0113M01(0)
- EMEA001477PIP0113(0)
- EMEA001478PIP0113(0)
- EMEA001479PIP0113(0)
- EMEA001480PIP0113(0)
- EMEA001481PIP0113M04(0)
- EMEA001483PIP0113(0)
- EMEA001484PIP0113M01(0)
- EMEA001485PIP0113M01(0)
- EMEA001487PIP0113(0)
- EMEA001487PIP0215(0)
- EMEA001489PIP0113M02(0)
- EMEA001489PIP0219(0)
- EMEA001490PIP0113M02(0)
- EMEA001491PIP0113M02(0)
- EMEA001492PIP0113M01(0)
- EMEA001492PIP0218(0)
- EMEA001493PIP0218(0)
- EMEA001493PIP0318M01(0)
- EMEA001494PIP0113(0)
- EMEA001495PIP0113M01(0)
- EMEA001495PIP0221(0)
- EMEA001496PIP0113(0)
- EMEA001497PIP0113(0)
- EMEA001499PIP0113(0)
- EMEA001501PIP0113M07(0)
- EMEA001501PIP0213M07(0)
- EMEA001501PIP0315(0)
- EMEA001501PIP0419M02(0)
- EMEA001501PIP0520(0)
- EMEA001501PIP0620(0)
- EMEA001501PIP0720(0)
- EMEA001501PIP0820(0)
- EMEA001501PIP0921(0)
- EMEA001501PIP1121(0)
- EMEA001502PIP0113(0)
- EMEA001503PIP0113(0)
- EMEA001504PIP0113(0)
- EMEA001506PIP0214M01(0)
- EMEA001508PIP0113(0)
- EMEA001509PIP0113M02(0)
- EMEA001510PIP0113(0)
- EMEA001511PIP0213(0)
- EMEA001511PIP0314(0)
- EMEA001513PIP0113(0)
- EMEA001514PIP0113M01(0)
- EMEA001516PIP0113(0)
- EMEA001517PIP0113M01(0)
- EMEA001517PIP0214M03(0)
- EMEA001518PIP0319(0)
- EMEA001519PIP0113(0)
- EMEA001520PIP0113(0)
- EMEA001521PIP0113M06(0)
- EMEA001521PIP0218(0)
- EMEA001523PIP0214M02(0)
- EMEA001523PIP0318M02(0)
- EMEA001523PIP0419M01(0)
- EMEA001523PIP0519M01(0)
- EMEA001525PIP0113(0)
- EMEA001525PIP0221(0)
- EMEA001526PIP0113M05(0)
- EMEA001527PIP0113(0)
- EMEA001528PIP0113(0)
- EMEA001529PIP0214M03(0)
- EMEA001530PIP0113(0)
- EMEA001531PIP0113M04(0)
- EMEA001532PIP0113(0)
- EMEA001533PIP0113M02(0)
- EMEA001534PIP0113(0)
- EMEA001535PIP0113M01(0)
- EMEA001536PIP0113(0)
- EMEA001537PIP0113(0)
- EMEA001538PIP0113(0)
- EMEA001539PIP0113M05(0)
- EMEA001540PIP0113M01(0)
- EMEA001541PIP0113(0)
- EMEA001544PIP0113M02(0)
- EMEA001545PIP0113M02(0)
- EMEA001546PIP0113(0)
- EMEA001547PIP0113(0)
- EMEA001548PIP0113(0)
- EMEA001549PIP0214(0)
- EMEA001552PIP0113(0)
- EMEA001553PIP0113M02(0)
- EMEA001554PIP0113M03(0)
- EMEA001555PIP0113M04(0)
- EMEA001556PIP0113(0)
- EMEA001557PIP0113M06(0)
- EMEA001558PIP0113(0)
- EMEA001558PIP0214(0)
- EMEA001559PIP0113(0)
- EMEA001560PIP0113(0)
- EMEA001561PIP0113M02(0)
- EMEA001563PIP0215M01(0)
- EMEA001567PIP0113M03(0)
- EMEA001568PIP0314(0)
- EMEA001569PIP0113(0)
- EMEA001571PIP0113(0)
- EMEA001573PIP0113(0)
- EMEA001573PIP0217(0)
- EMEA001574PIP0113(0)
- EMEA001575PIP0113(0)
- EMEA001576PIP0113(0)
- EMEA001577PIP0214M05(0)
- EMEA001577PIP0317(0)
- EMEA001578PIP0113(0)
- EMEA001579PIP0113M05(0)
- EMEA001581PIP0113M03(0)
- EMEA001581PIP0216(0)
- EMEA001582PIP0113M10(0)
- EMEA001584PIP0113M06(0)
- EMEA001585PIP0113M05(0)
- EMEA001586PIP0113(0)
- EMEA001588PIP0113M02(0)
- EMEA001588PIP0318(0)
- EMEA001590PIP0113M04(0)
- EMEA001594PIP0213(0)
- EMEA001595PIP0113(0)
- EMEA001596PIP0217M02(0)
- EMEA001597PIP0113(0)
- EMEA001598PIP0113M03(0)
- EMEA001599PIP0113(0)
- EMEA001600PIP0113M02(0)
- EMEA001601PIP0113(0)
- EMEA001602PIP0113M01(0)
- EMEA001603PIP0113M01(0)
- EMEA001604PIP0113M03(0)
- EMEA001606PIP0214(0)
- EMEA001607PIP0113(0)
- EMEA001608PIP0113(0)
- EMEA001608PIP0221(0)
- EMEA001609PIP0114(0)
- EMEA001612PIP0114(0)
- EMEA001613PIP0114M04(0)
- EMEA001613PIP0220(0)
- EMEA001613PIP0421(0)
- EMEA001614PIP0113(0)
- EMEA001615PIP0113(0)
- EMEA001616PIP0113(0)
- EMEA001617PIP0114(0)
- EMEA001619PIP0316M01(0)
- EMEA001619PIP0417M01(0)
- EMEA001621PIP0114(0)
- EMEA001623PIP0114M05(0)
- EMEA001623PIP0320M01(0)
- EMEA001624PIP0114M05(0)
- EMEA001624PIP0219(0)
- EMEA001625PIP0114M06(0)
- EMEA001625PIP0221(0)
- EMEA001625PIP0321(0)
- EMEA001625PIP0422(0)
- EMEA001627PIP0114M02(0)
- EMEA001628PIP0114(0)
- EMEA001630PIP0114(0)
- EMEA001631PIP0114M04(0)
- EMEA001632PIP0114(0)
- EMEA001633PIP0114(0)
- EMEA001634PIP0114(0)
- EMEA001635PIP0317(0)
- EMEA001636PIP0114M03(0)
- EMEA001637PIP0113(0)
- EMEA001638PIP0114M02(0)
- EMEA001638PIP0221(0)
- EMEA001639PIP0217(0)
- EMEA001640PIP0114M06(0)
- EMEA001642PIP0220(0)
- EMEA001644PIP0214M03(0)
- EMEA001645PIP0114M04(0)
- EMEA001646PIP0114M02(0)
- EMEA001649PIP0221(0)
- EMEA001651PIP0114(0)
- EMEA001652PIP0114M04(0)
- EMEA001653PIP0114M02(0)
- EMEA001654PIP0114M04(0)
- EMEA001654PIP0217M01(0)
- EMEA001656PIP0114(0)
- EMEA001656PIP0219(0)
- EMEA001657PIP0114M01(0)
- EMEA001659PIP0115M06(0)
- EMEA001662PIP0114M05(0)
- EMEA001662PIP0317(0)
- EMEA001663PIP0114(0)
- EMEA001664PIP0215M05(0)
- EMEA001665PIP0114M06(0)
- EMEA001665PIP0217(0)
- EMEA001666PIP0114M01(0)
- EMEA001667PIP0114(0)
- EMEA001668PIP0114(0)
- EMEA001669PIP0114(0)
- EMEA001671PIP0114(0)
- EMEA001672PIP0114(0)
- EMEA001674PIP0114(0)
- EMEA001676PIP0114M05(0)
- EMEA001677PIP0114(0)
- EMEA001679PIP0114(0)
- EMEA001680PIP0114(0)
- EMEA001684PIP0114(0)
- EMEA001687PIP0114M06(0)
- EMEA001688PIP0316(0)
- EMEA001689PIP0114(0)
- EMEA001693PIP0114(0)
- EMEA001693PIP0220(0)
- EMEA001693PIP0321(0)
- EMEA001694PIP0114(0)
- EMEA001695PIP0114M05(0)
- EMEA001696PIP0114M02(0)
- EMEA001697PIP0114(0)
- EMEA001697PIP0214(0)
- EMEA001699PIP0114(0)
- EMEA001700PIP0114(0)
- EMEA001701PIP0114M02(0)
- EMEA001702PIP0114(0)
- EMEA001705PIP0215M03(0)
- EMEA001706PIP0114M03(0)
- EMEA001710PIP0214M07(0)
- EMEA001710PIP0317M03(0)
- EMEA001710PIP0417M03(0)
- EMEA001711PIP0114(0)
- EMEA001712PIP0215(0)
- EMEA001713PIP0214(0)
- EMEA001715PIP0114M04(0)
- EMEA001716PIP0217(0)
- EMEA001716PIP0318(0)
- EMEA001716PIP0419(0)
- EMEA001716PIP0520(0)
- EMEA001718PIP0114(0)
- EMEA001719PIP0114(0)
- EMEA001720PIP0114M02(0)
- EMEA001721PIP0114(0)
- EMEA001722PIP0114M02(0)
- EMEA001724PIP0114(0)
- EMEA001726PIP0114(0)
- EMEA001729PIP0114M01(0)
- EMEA001729PIP0218(0)
- EMEA001730PIP0215(0)
- EMEA001731PIP0114M03(0)
- EMEA001732PIP0215(0)
- EMEA001733PIP0215M02(0)
- EMEA001734PIP0114M06(0)
- EMEA001739PIP0216M01(0)
- EMEA001740PIP0114(0)
- EMEA001741PIP0114M05(0)
- EMEA001741PIP0216M02(0)
- EMEA001741PIP0316M03(0)
- EMEA001741PIP0417M02(0)
- EMEA001741PIP0517(0)
- EMEA001741PIP0618(0)
- EMEA001742PIP0114M01(0)
- EMEA001742PIP0216(0)
- EMEA001743PIP0114(0)
- EMEA001744PIP0114M02(0)
- EMEA001746PIP0115(0)
- EMEA001747PIP0115(0)
- EMEA001748PIP0115M01(0)
- EMEA001748PIP0218(0)
- EMEA001748PIP0319(0)
- EMEA001750PIP0115M06(0)
- EMEA001752PIP0115(0)
- EMEA001753PIP0215(0)
- EMEA001754PIP0115(0)
- EMEA001755PIP0115(0)
- EMEA001757PIP0215M03(0)
- EMEA001758PIP0115M02(0)
- EMEA001759PIP0115(0)
- EMEA001760PIP0115M03(0)
- EMEA001761PIP0115(0)
- EMEA001762PIP0115(0)
- EMEA001763PIP0115M01(0)
- EMEA001764PIP0315(0)
- EMEA001765PIP0215M04(0)
- EMEA001766PIP0115M04(0)
- EMEA001768PIP0215M03(0)
- EMEA001769PIP0115(0)
- EMEA001771PIP0115(0)
- EMEA001772PIP0115(0)
- EMEA001773PIP0115(0)
- EMEA001776PIP0115M01(0)
- EMEA001776PIP0217M01(0)
- EMEA001776PIP0317(0)
- EMEA001776PIP0417(0)
- EMEA001777PIP0115(0)
- EMEA001779PIP0115(0)
- EMEA001780PIP0115(0)
- EMEA001782PIP0115M03(0)
- EMEA001783PIP0215(0)
- EMEA001784PIP0115M04(0)
- EMEA001786PIP0115M02(0)
- EMEA001788PIP0115(0)
- EMEA001790PIP0115(0)
- EMEA001792PIP0115(0)
- EMEA001793PIP0115M03(0)
- EMEA001794PIP0216M05(0)
- EMEA001796PIP0316M02(0)
- EMEA001797PIP0115M01(0)
- EMEA001798PIP0216M01(0)
- EMEA001799PIP0319(0)
- EMEA001805PIP0115(0)
- EMEA001806PIP0318(0)
- EMEA001806PIP0419(0)
- EMEA001807PIP0215(0)
- EMEA001808PIP0317(0)
- EMEA001809PIP0115M03(0)
- EMEA001810PIP0115(0)
- EMEA001811PIP0215M04(0)
- EMEA001811PIP0320(0)
- EMEA001811PIP0421(0)
- EMEA001812PIP0115M01(0)
- EMEA001813PIP0115(0)
- EMEA001816PIP0115(0)
- EMEA001816PIP0215(0)
- EMEA001817PIP0115(0)
- EMEA001820PIP0115(0)
- EMEA001821PIP0115M06(0)
- EMEA001822PIP0115M01(0)
- EMEA001823PIP0115M02(0)
- EMEA001824PIP0115(0)
- EMEA001825PIP0115(0)
- EMEA001825PIP0115M04(0)
- EMEA001828PIP0115M03(0)
- EMEA001830PIP0115M02(0)
- EMEA001831PIP0115(0)
- EMEA001832PIP0115M02(0)
- EMEA001834PIP0216M01(0)
- EMEA001835PIP0115M05(0)
- EMEA001836PIP0115(0)
- EMEA001838PIP0115M03(0)
- EMEA001839PIP0115(0)
- EMEA001840PIP0115(0)
- EMEA001841PIP0115(0)
- EMEA001842PIP0215(0)
- EMEA001844PIP0115(0)
- EMEA001845PIP0115(0)
- EMEA001847PIP0115(0)
- EMEA001849PIP0115(0)
- EMEA001849PIP0215M04(0)
- EMEA001850PIP0115(0)
- EMEA001851PIP0115(0)
- EMEA001852PIP0115(0)
- EMEA001853PIP0115M02(0)
- EMEA001854PIP0115(0)
- EMEA001855PIP0115M02(0)
- EMEA001856PIP0216M02(0)
- EMEA001857PIP0115M01(0)
- EMEA001857PIP0220(0)
- EMEA001858PIP0216M03(0)
- EMEA001859PIP0215(0)
- EMEA001860PIP0316M08(0)
- EMEA001860PIP0416(0)
- EMEA001861PIP0115(0)
- EMEA001862PIP0115M02(0)
- EMEA001862PIP0219(0)
- EMEA001862PIP0320(0)
- EMEA001864PIP0115M07(0)
- EMEA001864PIP0219(0)
- EMEA001864PIP0319M01(0)
- EMEA001865PIP0216(0)
- EMEA001866PIP0115M04(0)
- EMEA001867PIP0115(0)
- EMEA001868PIP0216(0)
- EMEA001868PIP0316(0)
- EMEA001869PIP0115M02(0)
- EMEA001870PIP0115M02(0)
- EMEA001871PIP0115(0)
- EMEA001872PIP0115M02(0)
- EMEA001872PIP0219(0)
- EMEA001873PIP0115(0)
- EMEA001874PIP0115(0)
- EMEA001875PIP0218M03(0)
- EMEA001876PIP0115(0)
- EMEA001877PIP0115M02(0)
- EMEA001877PIP0317(0)
- EMEA001878PIP0115(0)
- EMEA001879PIP0115M03(0)
- EMEA001880PIP0219M03(0)
- EMEA001881PIP0115(0)
- EMEA001882PIP0216M02(0)
- EMEA001883PIP0317(0)
- EMEA001884PIP0215(0)
- EMEA001884PIP0318(0)
- EMEA001885PIP0115M01(0)
- EMEA001886PIP0115M01(0)
- EMEA001886PIP0215M01(0)
- EMEA001887PIP0115(0)
- EMEA001888PIP0115M01(0)
- EMEA001892PIP0115(0)
- EMEA001893PIP0115M02(0)
- EMEA001894PIP0115M01(0)
- EMEA001895PIP0115M01(0)
- EMEA001900PIP0217M06(0)
- EMEA001902PIP0115M04(0)
- EMEA001903PIP0115M01(0)
- EMEA001904PIP0217(0)
- EMEA001904PIP0318M02(0)
- EMEA001905PIP0115(0)
- EMEA001908PIP0115(0)
- EMEA001909PIP0115(0)
- EMEA001910PIP0115(0)
- EMEA001910PIP0320M01(0)
- EMEA001911PIP0115M04(0)
- EMEA001912PIP0115(0)
- EMEA001912PIP0216M02(0)
- EMEA001913PIP0218(0)
- EMEA001914PIP0115(0)
- EMEA001915PIP0115M03(0)
- EMEA001916PIP0115(0)
- EMEA001918PIP0115M02(0)
- EMEA001921PIP0116(0)
- EMEA001925PIP0219(0)
- EMEA001929PIP0116(0)
- EMEA001930PIP0116M04(0)
- EMEA001931PIP0116M02(0)
- EMEA001931PIP0219(0)
- EMEA001933PIP0116M01(0)
- EMEA001935PIP0116(0)
- EMEA001936PIP0116M01(0)
- EMEA001939PIP0316(0)
- EMEA001940PIP0116M04(0)
- EMEA001941PIP0116(0)
- EMEA001942PIP0116(0)
- EMEA001943PIP0116M07(0)
- EMEA001943PIP0220M01(0)
- EMEA001943PIP0320M01(0)
- EMEA001943PIP0420(0)
- EMEA001943PIP0521(0)
- EMEA001944PIP0116M03(0)
- EMEA001945PIP0116M03(0)
- EMEA001948PIP0116(0)
- EMEA001949PIP0116M04(0)
- EMEA001949PIP0218M02(0)
- EMEA001951PIP0116M02(0)
- EMEA001952PIP0116(0)
- EMEA001953PIP0116(0)
- EMEA001957PIP0219(0)
- EMEA001961PIP0116(0)
- EMEA001962PIP0116(0)
- EMEA001964PIP0116M04(0)
- EMEA001964PIP0219(0)
- EMEA001964PIP0321(0)
- EMEA001965PIP0116(0)
- EMEA001966PIP0116(0)
- EMEA001968PIP0116(0)
- EMEA001969PIP0116(0)
- EMEA001970PIP0217(0)
- EMEA001971PIP0216M04(0)
- EMEA001971PIP0318M02(0)
- EMEA001973PIP0116(0)
- EMEA001974PIP0116M02(0)
- EMEA001975PIP0116M02(0)
- EMEA001976PIP0218(0)
- EMEA001977PIP0216(0)
- EMEA001978PIP0116(0)
- EMEA001978PIP0219(0)
- EMEA001979PIP0116(0)
- EMEA001980PIP0116(0)
- EMEA001982PIP0116(0)
- EMEA001983PIP0116M01(0)
- EMEA001984PIP0220(0)
- EMEA001984PIP0320(0)
- EMEA001986PIP0116(0)
- EMEA001988PIP0116M01(0)
- EMEA001990PIP0116M05(0)
- EMEA001992PIP0216M01(0)
- EMEA001993PIP0116(0)
- EMEA001995PIP0116M03(0)
- EMEA001996PIP0216M01(0)
- EMEA001998PIP0116(0)
- EMEA001999PIP0217M01(0)
- EMEA002002PIP0116(0)
- EMEA002002PIP0217(0)
- EMEA002004PIP0116(0)
- EMEA002005PIP0116(0)
- EMEA002006PIP0116(0)
- EMEA002007PIP0217M02(0)
- EMEA002010PIP0116M03(0)
- EMEA002011PIP0116(0)
- EMEA002012PIP0116M03(0)
- EMEA002014PIP0116(0)
- EMEA002015PIP0116(0)
- EMEA002016PIP0216(0)
- EMEA002016PIP0319M02(0)
- EMEA002016PIP0420(0)
- EMEA002017PIP0116(0)
- EMEA002018PIP0216M05(0)
- EMEA002020PIP0116M01(0)
- EMEA002021PIP0116(0)
- EMEA002022PIP0116(0)
- EMEA002023PIP0116M06(0)
- EMEA002024PIP0116(0)
- EMEA002024PIP0222(0)
- EMEA002025PIP0419(0)
- EMEA002027PIP0217M01(0)
- EMEA002028PIP0116M03(0)
- EMEA002029PIP0116M03(0)
- EMEA002030PIP0116(0)
- EMEA002031PIP0116M03(0)
- EMEA002033PIP0116M03(0)
- EMEA002034PIP0116(0)
- EMEA002036PIP0116(0)
- EMEA002037PIP0116(0)
- EMEA002038PIP0116(0)
- EMEA002039PIP0116(0)
- EMEA002040PIP0116(0)
- EMEA002042PIP0116(0)
- EMEA002042PIP0220M01(0)
- EMEA002043PIP0116(0)
- EMEA002047PIP0116(0)
- EMEA002048PIP0218(0)
- EMEA002051PIP0216(0)
- EMEA002053PIP0116(0)
- EMEA002054PIP0116M03(0)
- EMEA002054PIP0218(0)
- EMEA002054PIP0320M02(0)
- EMEA002057PIP0116(0)
- EMEA002058PIP0116M01(0)
- EMEA002059PIP0116(0)
- EMEA002059PIP0219M01(0)
- EMEA002060PIP0217M01(0)
- EMEA002061PIP0116(0)
- EMEA002062PIP0116(0)
- EMEA002063PIP0116M02(0)
- EMEA002064PIP0116M03(0)
- EMEA002065PIP0116M03(0)
- EMEA002066PIP0120(0)
- EMEA002066PIP0220(0)
- EMEA002067PIP0217(0)
- EMEA002068PIP0116M04(0)
- EMEA002069PIP0217(0)
- EMEA002070PIP0116M07(0)
- EMEA002071PIP0116(0)
- EMEA002072PIP0116M01(0)
- EMEA002074PIP0116(0)
- EMEA002075PIP0116M03(0)
- EMEA002077PIP0116(0)
- EMEA002077PIP0116M05(0)
- EMEA002079PIP0116M03(0)
- EMEA002081PIP0116(0)
- EMEA002082PIP0116(0)
- EMEA002084PIP0116(0)
- EMEA002087PIP0116M01(0)
- EMEA002090PIP0116(0)
- EMEA002091PIP0116(0)
- EMEA002092PIP0116(0)
- EMEA002093PIP0217M01(0)
- EMEA002094PIP0116(0)
- EMEA002095PIP0116M01(0)
- EMEA002096PIP0116M03(0)
- EMEA002097PIP0116(0)
- EMEA002099PIP0116(0)
- EMEA002101PIP0218M01(0)
- EMEA002102PIP0116(0)
- EMEA002104PIP0116(0)
- EMEA002106PIP0116M02(0)
- EMEA002108PIP0116(0)
- EMEA002109PIP0116(0)
- EMEA002110PIP0117(0)
- EMEA002110PIP0217(0)
- EMEA002111PIP0117(0)
- EMEA002111PIP0217(0)
- EMEA002112PIP0116M01(0)
- EMEA002113PIP0116M01(0)
- EMEA002114PIP0116(0)
- EMEA002115PIP0117M05(0)
- EMEA002116PIP0117M01(0)
- EMEA002117PIP0117M02(0)
- EMEA002118PIP0117(0)
- EMEA002120PIP0117(0)
- EMEA002121PIP0319M01(0)
- EMEA002122PIP0217M01(0)
- EMEA002124PIP0117(0)
- EMEA002125PIP0117(0)
- EMEA002127PIP0117M01(0)
- EMEA002129PIP0217(0)
- EMEA002130PIP0117(0)
- EMEA002131PIP0117(0)
- EMEA002132PIP0117(0)
- EMEA002133PIP0117M03(0)
- EMEA002135PIP0117(0)
- EMEA002136PIP0117(0)
- EMEA002137PIP0117(0)
- EMEA002138PIP0117M01(0)
- EMEA002140PIP0117(0)
- EMEA002141PIP0117M03(0)
- EMEA002142PIP0117(0)
- EMEA002143PIP0117(0)
- EMEA002144PIP0117(0)
- EMEA002146PIP0117M04(0)
- EMEA002146PIP0218(0)
- EMEA002147PIP0217M01(0)
- EMEA002148PIP0117(0)
- EMEA002149PIP0117(0)
- EMEA002151PIP0117(0)
- EMEA002152PIP0117M03(0)
- EMEA002152PIP0217M01(0)
- EMEA002152PIP0319(0)
- EMEA002153PIP0117M01(0)
- EMEA002155PIP0117(0)
- EMEA002157PIP0117(0)
- EMEA002160PIP0117(0)
- EMEA002161PIP0117(0)
- EMEA002163PIP0117(0)
- EMEA002164PIP0117M02(0)
- EMEA002165PIP0218(0)
- EMEA002166PIP0117M06(0)
- EMEA002167PIP0117(0)
- EMEA002168PIP0117M04(0)
- EMEA002169PIP0117M02(0)
- EMEA002170PIP0117(0)
- EMEA002172PIP0217M02(0)
- EMEA002173PIP0117(0)
- EMEA002174PIP0117(0)
- EMEA002175PIP0117(0)
- EMEA002177PIP0117(0)
- EMEA002178PIP0117M01(0)
- EMEA002180PIP0219(0)
- EMEA002181PIP0117(0)
- EMEA002183PIP0117M01(0)
- EMEA002184PIP0117M01(0)
- EMEA002185PIP0217(0)
- EMEA002187PIP0117(0)
- EMEA002189PIP0117M03(0)
- EMEA002189PIP0319(0)
- EMEA002189PIP0420(0)
- EMEA 002191PIP0217(0)
- EMEA002192PIP0217(0)
- EMEA002194PIP0117(0)
- EMEA002195PIP0117(0)
- EMEA002196PIP0117(0)
- EMEA002197PIP0117(0)
- EMEA002198PIP0121(0)
- EMEA002199PIP0117(0)
- EMEA002200PIP0117(0)
- EMEA002200PIP0219(0)
- EMEA002202PIP0117(0)
- EMEA002202PIP0220(0)
- EMEA002203PIP0117(0)
- EMEA002204PIP0220(0)
- EMEA002205PIP0117M03(0)
- EMEA002206PIP0219(0)
- EMEA002207PIP0117(0)
- EMEA002208PIP0117M02(0)
- EMEA002209PIP0117M03(0)
- EMEA002211PIP0117(0)
- EMEA002212PIP0117(0)
- EMEA002213PIP0117(0)
- EMEA002214PIP0117M01(0)
- EMEA002215PIP0117M03(0)
- EMEA002217PIP0117M02(0)
- EMEA002218PIP0117(0)
- EMEA002220PIP0117(0)
- EMEA002221PIP0117(0)
- EMEA002222PIP0117(0)
- EMEA002223PIP0119(0)
- EMEA002224PIP0117(0)
- EMEA002226PIP0217(0)
- EMEA002229PIP0117M03(0)
- EMEA002229PIP0221(0)
- EMEA002231PIP0117(0)
- EMEA002232PIP0219M02(0)
- EMEA002233PIP0117M01(0)
- EMEA002234PIP0117(0)
- EMEA002238PIP0117M01(0)
- EMEA002239PIP0117(0)
- EMEA002239PIP0221(0)
- EMEA002240PIP0217M02(0)
- EMEA002242PIP0117(0)
- EMEA002242PIP0221(0)
- EMEA002243PIP0117M03(0)
- EMEA002243PIP0220(0)
- EMEA002244PIP0218(0)
- EMEA002246PIP0117M02(0)
- EMEA002247PIP0217(0)
- EMEA002247PIP0317(0)
- EMEA002248PIP0117(0)
- EMEA002249PIP0117(0)
- EMEA002250PIP0217M01(0)
- EMEA002252PIP0117(0)
- EMEA002254PIP0117(0)
- EMEA002255PIP0117(0)
- EMEA002257PIP0117(0)
- EMEA002257PIP0219(0)
- EMEA002258PIP0117(0)
- EMEA002259PIP0117(0)
- EMEA002261PIP0117(0)
- EMEA002263PIP0117(0)
- EMEA002264PIP0117(0)
- EMEA002266PIP0117(0)
- EMEA002267PIP0219(0)
- EMEA002267PIP0319(0)
- EMEA002268PIP0117(0)
- EMEA002268PIP0218M01(0)
- EMEA002268PIP0318(0)
- EMEA002269PIP0117M01(0)
- EMEA002270PIP0320(0)
- EMEA002270PIP0420(0)
- EMEA002272PIP0117(0)
- EMEA002274PIP0117(0)
- EMEA002275PIP0117(0)
- EMEA002276PIP0117(0)
- EMEA002282PIP0117M01(0)
- EMEA002283PIP0117M04(0)
- EMEA002284PIP0117(0)
- EMEA002285PIP0219M02(0)
- EMEA002287PIP0117M03(0)
- EMEA002291PIP0117(0)
- EMEA002292PIP0117(0)
- EMEA002293PIP0117(0)
- EMEA002296PIP0117M03(0)
- EMEA002298PIP0117M05(0)
- EMEA002299PIP0117(0)
- EMEA002302PIP0117(0)
- EMEA002303PIP0117M03(0)
- EMEA002304PIP0117(0)
- EMEA002305PIP0117M01(0)
- EMEA002306PIP0218(0)
- EMEA002307PIP0117M02(0)
- EMEA002308PIP0117M02(0)
- EMEA002309PIP0117(0)
- EMEA002310PIP0117(0)
- EMEA002310PIP0217(0)
- EMEA002311PIP0117M02(0)
- EMEA002312PIP0117M01(0)
- EMEA002317PIP0221(0)
- EMEA002318PIP0319(0)
- EMEA002319PIP0117M02(0)
- EMEA002320PIP0117M03(0)
- EMEA002321PIP0117(0)
- EMEA002322PIP0117(0)
- EMEA002323PIP0219(0)
- EMEA002324PIP0117M03(0)
- EMEA002326PIP0420(0)
- EMEA002329PIP0220M01(0)
- EMEA002330PIP0118M02(0)
- EMEA002331PIP0118(0)
- EMEA002333PIP0219(0)
- EMEA002335PIP0118(0)
- EMEA002338PIP0118(0)
- EMEA002338PIP0218(0)
- EMEA002338PIP0321(0)
- EMEA002340PIP0118(0)
- EMEA002341PIP0118M02(0)
- EMEA002342PIP0118M02(0)
- EMEA002342PIP0218M01(0)
- EMEA002342PIP0318(0)
- EMEA002343PIP0118(0)
- EMEA002344PIP0118(0)
- EMEA002344PIP0218M01(0)
- EMEA002345PIP0118(0)
- EMEA002347PIP0118(0)
- EMEA002349PIP0320(0)
- EMEA002350PIP0118M02(0)
- EMEA002350PIP0220(0)
- EMEA002350PIP0320(0)
- EMEA002350PIP0421(0)
- EMEA002351PIP0118(0)
- EMEA002352PIP0118(0)
- EMEA002353PIP0118(0)
- EMEA002354PIP0218M01(0)
- EMEA002356PIP0220M01(0)
- EMEA002358PIP0218M02(0)
- EMEA002358PIP0319(0)
- EMEA002359PIP0118M05(0)
- EMEA002360PIP0118M02(0)
- EMEA002360PIP0222(0)
- EMEA002361PIP0118(0)
- EMEA002362PIP0219M02(0)
- EMEA002363PIP0118(0)
- EMEA002364PIP0218(0)
- EMEA002364PIP0319(0)
- EMEA002365PIP0118(0)
- EMEA002366PIP0118(0)
- EMEA002367PIP0118(0)
- EMEA002369PIP0118M02(0)
- EMEA002370PIP0118(0)
- EMEA002370PIP0322(0)
- EMEA002374PIP0118(0)
- EMEA002375PIP0118(0)
- EMEA002375PIP0218(0)
- EMEA002376PIP0118(0)
- EMEA002376PIP0220(0)
- EMEA002377PIP0118(0)
- EMEA002378PIP0118(0)
- EMEA002380PIP0118(0)
- EMEA002381PIP0118(0)
- EMEA002383PIP0118M02(0)
- EMEA002384PIP0118(0)
- EMEA002385PIP0118(0)
- EMEA002387PIP0118(0)
- EMEA002387PIP0221(0)
- EMEA002389PIP0118(0)
- EMEA002391PIP0219(0)
- EMEA002392PIP0118M02(0)
- EMEA002393PIP0118(0)
- EMEA002395PIP0118(0)
- EMEA002396PIP0118(0)
- EMEA002397PIP0118M03(0)
- EMEA002398PIP0118(0)
- EMEA002399PIP0118M01(0)
- EMEA002400PIP0118(0)
- EMEA002401PIP0118(0)
- EMEA002402PIP0218(0)
- EMEA002403PIP0118(0)
- EMEA002405PIP0118(0)
- EMEA002406PIP0118(0)
- EMEA002407PIP0118(0)
- EMEA002410PIP0118(0)
- EMEA002413PIP0118(0)
- EMEA002414PIP0118(0)
- EMEA002416PIP0118(0)
- EMEA002418PIP0118M02(0)
- EMEA002419PIP0218(0)
- EMEA002420PIP0118(0)
- EMEA002421PIP0118(0)
- EMEA002423PIP0118(0)
- EMEA002424PIP0219(0)
- EMEA002425PIP0118(0)
- EMEA002427PIP0118M01(0)
- EMEA002428PIP0118(0)
- EMEA002428PIP0218(0)
- EMEA002430PIP0118(0)
- EMEA002431PIP0118(0)
- EMEA002431PIP0221(0)
- EMEA002432PIP0220(0)
- EMEA002435PIP0118M03(0)
- EMEA002436PIP0118(0)
- EMEA002438PIP0118(0)
- EMEA002438PIP0219M02(0)
- EMEA002439PIP0118(0)
- EMEA002440PIP0118M04(0)
- EMEA002441PIP0118(0)
- EMEA002442PIP0118(0)
- EMEA002443PIP0118M01(0)
- EMEA002443PIP0218(0)
- EMEA002444PIP0218(0)
- EMEA002447PIP0118M01(0)
- EMEA002448PIP0118M02(0)
- EMEA002449PIP0218M01(0)
- EMEA002450PIP0118(0)
- EMEA002451PIP0118M01(0)
- EMEA002451PIP0221(0)
- EMEA002452PIP0118(0)
- EMEA002455PIP0118(0)
- EMEA002456PIP0118(0)
- EMEA002457PIP0118(0)
- EMEA002460PIP0118(0)
- EMEA002461PIP0118(0)
- EMEA002462PIP0118(0)
- EMEA002463PIP0118M01(0)
- EMEA002464PIP0118(0)
- EMEA002465PIP0118(0)
- EMEA002468PIP0218(0)
- EMEA002468PIP0418(0)
- EMEA002469PIP0118(0)
- EMEA002470PIP0118(0)
- EMEA002471PIP0118(0)
- EMEA002472PIP0219(0)
- EMEA002472PIP0322(0)
- EMEA002474PIP0218M01(0)
- EMEA002475PIP0219M02(0)
- EMEA002477PIP0118(0)
- EMEA002479PIP0118M01(0)
- EMEA002480PIP0118(0)
- EMEA002484PIP0118(0)
- EMEA002485PIP0118(0)
- EMEA002486PIP0421(0)
- EMEA002487PIP0118(0)
- EMEA002488PIP0118(0)
- EMEA002489PIP0118(0)
- EMEA002491PIP0219(0)
- EMEA002492PIP0118M02(0)
- EMEA002493PIP0118M05(0)
- EMEA002496PIP0118(0)
- EMEA002497PIP0118(0)
- EMEA002499PIP0219(0)
- EMEA002500PIP0118(0)
- EMEA002501PIP0118M03(0)
- EMEA002503PIP0118(0)
- EMEA002504PIP0118(0)
- EMEA002506PIP0321(0)
- EMEA002507PIP0219(0)
- EMEA002509PIP0118(0)
- EMEA002510PIP0118(0)
- EMEA002511PIP0219(0)
- EMEA002512PIP0118(0)
- EMEA002514PIP0118(0)
- EMEA002515PIP0118(0)
- EMEA002516PIP0118(0)
- EMEA002516PIP0221(0)
- EMEA002519PIP0218(0)
- EMEA002519PIP0321(0)
- EMEA002520PIP0118(0)
- EMEA002521PIP0118(0)
- EMEA002522PIP0118(0)
- EMEA002524PIP0219(0)
- EMEA002525PIP0118(0)
- EMEA002526PIP0219(0)
- EMEA002527PIP0118(0)
- EMEA002530PIP0118(0)
- EMEA002531PIP0118(0)
- EMEA002532PIP0118M02(0)
- EMEA002533PIP0118(0)
- EMEA002535PIP0319(0)
- EMEA002535PIP0421(0)
- EMEA002536PIP0118M01(0)
- EMEA002537PIP0219(0)
- EMEA002539PIP0118(0)
- EMEA002540PIP0118(0)
- EMEA002541PIP0118(0)
- EMEA002542PIP0118(0)
- EMEA002542PIP0219(0)
- EMEA002542PIP0320(0)
- EMEA002544PIP0118M01(0)
- EMEA002545PIP0119M01(0)
- EMEA002546PIP0119(0)
- EMEA002547PIP0119(0)
- EMEA002548PIP0119(0)
- EMEA002549PIP0119(0)
- EMEA002551PIP0118(0)
- EMEA002552PIP0119(0)
- EMEA002553PIP0119(0)
- EMEA002554PIP0219(0)
- EMEA002555PIP0221(0)
- EMEA002557PIP0119(0)
- EMEA002558PIP0119(0)
- EMEA002559PIP0119(0)
- EMEA002559PIP0219(0)
- EMEA002559PIP0319(0)
- EMEA002559PIP0421(0)
- EMEA002559PIP0522(0)
- EMEA002559PIP0622(0)
- EMEA002560PIP0119(0)
- EMEA002561PIP0220(0)
- EMEA002562PIP0119(0)
- EMEA002563PIP0219M01(0)
- EMEA002564PIP0119(0)
- EMEA002565PIP0219(0)
- EMEA002566PIP0119(0)
- EMEA002567PIP0119(0)
- EMEA002568PIP0119(0)
- EMEA002569PIP0419(0)
- EMEA002570PIP0119(0)
- EMEA002571PIP0119(0)
- EMEA002572PIP0119(0)
- EMEA002572PIP0219M01(0)
- EMEA002573PIP0119(0)
- EMEA002575PIP0119(0)
- EMEA002575PIP0220(0)
- EMEA002575PIP0321(0)
- EMEA002576PIP0119(0)
- EMEA002577PIP0119(0)
- EMEA002578PIP0119(0)
- EMEA002580PIP0119(0)
- EMEA002581PIP0119(0)
- EMEA002582PIP0119M01(0)
- EMEA002582PIP0221(0)
- EMEA002583PIP0119(0)
- EMEA002585PIP0119(0)
- EMEA002586PIP0119M01(0)
- EMEA002587PIP0119(0)
- EMEA002588PIP0119(0)
- EMEA002593PIP0119(0)
- EMEA002594PIP0119(0)
- EMEA002594PIP0220(0)
- EMEA002594PIP0321(0)
- EMEA002595PIP0119(0)
- EMEA002597PIP0119M01(0)
- EMEA002597PIP0320(0)
- EMEA002597PIP0421(0)
- EMEA002597PIP0521(0)
- EMEA002597PIP0621(0)
- EMEA002597PIP0721(0)
- EMEA002597PIP0922(0)
- EMEA002598PIP0119(0)
- EMEA002599PIP0119M01(0)
- EMEA002600PIP0119M01(0)
- EMEA002600PIP0321(0)
- EMEA002600PIP0422(0)
- EMEA002601PIP0119(0)
- EMEA002606PIP0219(0)
- EMEA002608PIP0119(0)
- EMEA002615PIP0119(0)
- EMEA002617PIP0119(0)
- EMEA002617PIP0219(0)
- EMEA002618PIP0220(0)
- EMEA002618PIP0321(0)
- EMEA002619PIP0119(0)
- EMEA002622PIP0119(0)
- EMEA002623PIP0119(0)
- EMEA002626PIP0119(0)
- EMEA002627PIP0119(0)
- EMEA002627PIP0221(0)
- EMEA002628PIP0119(0)
- EMEA002629PIP0119(0)
- EMEA002631PIP0119M01(0)
- EMEA002632PIP0119(0)
- EMEA002633PIP0119(0)
- EMEA002634PIP0119M01(0)
- EMEA002635PIP0221(0)
- EMEA002636PIP0119(0)
- EMEA002640PIP0119(0)
- EMEA002641PIP0119(0)
- EMEA002642PIP0119M03(0)
- EMEA002643PIP0119M01(0)
- EMEA002644PIP0119M01(0)
- EMEA002645PIP0119(0)
- EMEA002645PIP0220(0)
- EMEA002645PIP0321(0)
- EMEA002646PIP0119(0)
- EMEA002647PIP0119(0)
- EMEA002648PIP0119(0)
- EMEA002649PIP0119(0)
- EMEA002649PIP0220(0)
- EMEA002650PIP0119(0)
- EMEA002651PIP0119(0)
- EMEA002652PIP0119(0)
- EMEA002653PIP0119(0)
- EMEA002654PIP0219(0)
- EMEA002655PIP0220(0)
- EMEA002656PIP0119(0)
- EMEA002657PIP0119(0)
- EMEA002658PIP0119(0)
- EMEA002661PIP0119(0)
- EMEA002662PIP0119(0)
- EMEA002663PIP0119(0)
- EMEA002664PIP0119(0)
- EMEA002665PIP0220(0)
- EMEA002668PIP0119(0)
- EMEA002669PIP0220(0)
- EMEA002671PIP0220(0)
- EMEA002672PIP0119(0)
- EMEA002676PIP0119(0)
- EMEA002677PIP0119M02(0)
- EMEA002678PIP0119(0)
- EMEA002679PIP0119(0)
- EMEA002681PIP0119M01(0)
- EMEA002681PIP0221(0)
- EMEA002682PIP0119(0)
- EMEA002684PIP0119(0)
- EMEA002684PIP0119M01(0)
- EMEA002684PIP0221(0)
- EMEA002685PIP0219M01(0)
- EMEA002686PIP0119(0)
- EMEA002687PIP0119(0)
- EMEA002690PIP0119(0)
- EMEA002690PIP0222(0)
- EMEA002691PIP0119(0)
- EMEA002691PIP0220(0)
- EMEA002692PIP0119(0)
- EMEA002693PIP0119(0)
- EMEA002694PIP0119(0)
- EMEA002694PIP0221(0)
- EMEA002695PIP0119(0)
- EMEA002696PIP0119(0)
- EMEA002696PIP0221(0)
- EMEA002696PIP0322(0)
- EMEA002698PIP0119(0)
- EMEA002698PIP0222(0)
- EMEA002698PIP0322(0)
- EMEA002700PIP0119(0)
- EMEA002700PIP0119M01(0)
- EMEA002702PIP0119(0)
- EMEA002703PIP0119(0)
- EMEA002705PIP0119(0)
- EMEA002705PIP0219(0)
- EMEA002705PIP0320(0)
- EMEA002706PIP0119M01(0)
- EMEA002707PIP0119M01(0)
- EMEA002708PIP0119(0)
- EMEA002708PIP0221(0)
- EMEA002709PIP0119M01(0)
- EMEA002710PIP0119(0)
- EMEA002712PIP0119M01(0)
- EMEA002713PIP0119M02(0)
- EMEA002713PIP0221(0)
- EMEA002714PIP0119(0)
- EMEA002716PIP0119(0)
- EMEA002717PIP0220(0)
- EMEA002718PIP0220(0)
- EMEA002720PIP0119(0)
- EMEA002721PIP0119(0)
- EMEA002721PIP0220(0)
- EMEA002721PIP0320(0)
- EMEA002722PIP0119M02(0)
- EMEA002723PIP0119M01(0)
- EMEA002724PIP0119M02(0)
- EMEA002725PIP0119(0)
- EMEA002726PIP0119M03(0)
- EMEA002727PIP0119M01(0)
- EMEA002730PIP0321(0)
- EMEA002730PIP0421M01(0)
- EMEA002732PIP0220(0)
- EMEA002734PIP0119(0)
- EMEA002735PIP0119(0)
- EMEA002735PIP0320M01(0)
- EMEA002737PIP0119(0)
- EMEA002739PIP0119(0)
- EMEA002740PIP0119(0)
- EMEA002741PIP0120M01(0)
- EMEA002743PIP0119(0)
- EMEA002744PIP0119(0)
- EMEA002745PIP0119(0)
- EMEA002745PIP0220(0)
- EMEA002746PIP0120(0)
- EMEA002747PIP0120(0)
- EMEA002748PIP0120(0)
- EMEA002749PIP0119M02(0)
- EMEA002750PIP0119(0)
- EMEA002751PIP0119(0)
- EMEA002751PIP0222(0)
- EMEA002752PIP0119(0)
- EMEA002753PIP0119(0)
- EMEA002754PIP0119(0)
- EMEA002755PIP0119M01(0)
- EMEA002756PIP0119M01(0)
- EMEA002757PIP0119(0)
- EMEA002757PIP0221(0)
- EMEA002758PIP0119M02(0)
- EMEA002759PIP0119(0)
- EMEA002760PIP0119(0)
- EMEA002761PIP0120(0)
- EMEA002762PIP0220(0)
- EMEA002763PIP0120(0)
- EMEA002765PIP0119(0)
- EMEA002765PIP0221(0)
- EMEA002766PIP0120(0)
- EMEA002766PIP0221(0)
- EMEA002768PIP0120(0)
- EMEA002769PIP0120(0)
- EMEA002772PIP0120(0)
- EMEA002773PIP0120(0)
- EMEA002775PIP0120(0)
- EMEA002776PIP0120M01(0)
- EMEA002777PIP0120(0)
- EMEA002778PIP0120M01(0)
- EMEA002779PIP0120(0)
- EMEA002780PIP0220(0)
- EMEA002781PIP0120(0)
- EMEA002783PIP0120(0)
- EMEA002784PIP0120(0)
- EMEA002785PIP0120(0)
- EMEA002786PIP0120(0)
- EMEA002789PIP0120(0)
- EMEA002790PIP0120(0)
- EMEA002791PIP0120(0)
- EMEA002792PIP0120(0)
- EMEA002794PIP0120(0)
- EMEA002795PIP0120(0)
- EMEA002795PIP0221M01(0)
- EMEA002796PIP0120(0)
- EMEA002797PIP0120(0)
- EMEA002798PIP0120(0)
- EMEA002798PIP0221(0)
- EMEA002798PIP0322(0)
- EMEA002799PIP0120(0)
- EMEA002800PIP0120(0)
- EMEA002802PIP0221(0)
- EMEA002805PIP0120(0)
- EMEA002807PIP0120M01(0)
- EMEA002808PIP0120(0)
- EMEA002811PIP0120(0)
- EMEA002812PIP0120(0)
- EMEA002812PIP0220M01(0)
- EMEA002814PIP0221M01(0)
- EMEA002815PIP0120(0)
- EMEA002816PIP0120(0)
- EMEA002817PIP0320(0)
- EMEA002817PIP0420(0)
- EMEA002818PIP0120(0)
- EMEA002819PIP0120(0)
- EMEA002821PIP0120(0)
- EMEA002822PIP0120(0)
- EMEA002823PIP0120(0)
- EMEA002824PIP0120(0)
- EMEA002825PIP0120(0)
- EMEA002826PIP0120M03(0)
- EMEA002827PIP0120(0)
- EMEA002831PIP0120(0)
- EMEA002832PIP0120(0)
- EMEA002834PIP0120(0)
- EMEA002835PIP0120(0)
- EMEA002836PIP0120(0)
- EMEA002837PIP0120(0)
- EMEA002839PIP0120M01(0)
- EMEA002840PIP0120(0)
- EMEA002840PIP0222(0)
- EMEA002841PIP0120(0)
- EMEA002842PIP0120(0)
- EMEA002843PIP0120(0)
- EMEA002843PIP0220(0)
- EMEA002844PIP0120(0)
- EMEA002845PIP0120(0)
- EMEA002846PIP0120(0)
- EMEA002846PIP0222(0)
- EMEA002849PIP0120(0)
- EMEA002850PIP0221(0)
- EMEA002852PIP0120(0)
- EMEA002853PIP0120(0)
- EMEA002854PIP0120(0)
- EMEA002856PIP0120(0)
- EMEA002859PIP0120(0)
- EMEA002860PIP0120(0)
- EMEA002861PIP0220M05(0)
- EMEA002862PIP0120M02(0)
- EMEA002863PIP0120(0)
- EMEA002864PIP0120(0)
- EMEA002866PIP0120(0)
- EMEA002867PIP0120(0)
- EMEA002868PIP0120(0)
- EMEA002869PIP0121(0)
- EMEA002869PIP0321(0)
- EMEA002871PIP0120(0)
- EMEA002873PIP0120(0)
- EMEA002875PIP0120(0)
- EMEA002876PIP0120(0)
- EMEA002877PIP0120(0)
- EMEA002879PIP0120(0)
- EMEA002880PIP0120M01(0)
- EMEA002881PIP0120M01(0)
- EMEA002882PIP0120(0)
- EMEA002884PIP0120(0)
- EMEA002885PIP0120(0)
- EMEA002886PIP0120M02(0)
- EMEA002887PIP0120(0)
- EMEA002888PIP0120(0)
- EMEA002889PIP0120(0)
- EMEA002889PIP0220(0)
- EMEA002890PIP0120(0)
- EMEA002891PIP0120(0)
- EMEA002892PIP0120(0)
- EMEA002893PIP0120M02(0)
- EMEA002894PIP0120(0)
- EMEA002895PIP0221(0)
- EMEA002896PIP0120(0)
- EMEA002897PIP0120(0)
- EMEA002899PIP0120M01(0)
- EMEA002900PIP0120M01(0)
- EMEA002901PIP0120(0)
- EMEA002902PIP0120(0)
- EMEA002903PIP0120(0)
- EMEA002903PIP0221(0)
- EMEA002903PIP0321(0)
- EMEA002904PIP0120(0)
- EMEA002905PIP0120(0)
- EMEA002906PIP0120(0)
- EMEA002907PIP0120M02(0)
- EMEA002908PIP0120(0)
- EMEA002909PIP0120(0)
- EMEA002910PIP0120(0)
- EMEA002913PIP0120(0)
- EMEA002915PIP0120M01(0)
- EMEA002917PIP0120(0)
- EMEA002918PIP0120(0)
- EMEA002919PIP0120(0)
- EMEA002919PIP0221(0)
- EMEA002920PIP0120(0)
- EMEA002921PIP0120(0)
- EMEA002923PIP0120(0)
- EMEA002925PIP0120M01(0)
- EMEA002926PIP0120(0)
- EMEA002927PIP0120(0)
- EMEA002927PIP0221(0)
- EMEA002930PIP0120(0)
- EMEA002931PIP0120(0)
- EMEA002932PIP0221(0)
- EMEA002933PIP0120(0)
- EMEA002934PIP0120(0)
- EMEA002935PIP0120M01(0)
- EMEA002936PIP0120(0)
- EMEA002937PIP0120(0)
- EMEA002938PIP0120(0)
- EMEA002939PIP0120(0)
- EMEA002940PIP0120(0)
- EMEA002940PIP0221(0)
- EMEA002941PIP0120M02(0)
- EMEA002942PIP0120(0)
- EMEA002942PIP0220(0)
- EMEA002943PIP0120(0)
- EMEA002944PIP0120(0)
- EMEA002945PIP0120(0)
- EMEA002945PIP0221(0)
- EMEA002946PIP0120(0)
- EMEA002947PIP0120(0)
- EMEA002948PIP0120(0)
- EMEA002949PIP0120(0)
- EMEA002950PIP0120(0)
- EMEA002952PIP0121(0)
- EMEA002954PIP0221(0)
- EMEA002955PIP0121(0)
- EMEA002956PIP0121(0)
- EMEA002957PIP0221(0)
- EMEA002959PIP0121(0)
- EMEA002960PIP0221(0)
- EMEA002961PIP0121M01(0)
- EMEA002962PIP0121(0)
- EMEA002963PIP0121(0)
- EMEA002964PIP0121M02(0)
- EMEA002965PIP0121M02(0)
- EMEA002966PIP0121(0)
- EMEA002967PIP0121(0)
- EMEA002968PIP0121(0)
- EMEA002969PIP0121(0)
- EMEA002970PIP0121(0)
- EMEA002971PIP0121(0)
- EMEA002973PIP0121(0)
- EMEA002974PIP0121(0)
- EMEA002975PIP0121(0)
- EMEA002976PIP0121(0)
- EMEA002976PIP0221(0)
- EMEA002977PIP0121(0)
- EMEA002978PIP0121(0)
- EMEA002979PIP0121(0)
- EMEA002979PIP0321(0)
- EMEA002981PIP0121(0)
- EMEA002982PIP0121(0)
- EMEA002983PIP0121(0)
- EMEA002984PIP0121(0)
- EMEA002986PIP0121(0)
- EMEA002987PIP0121(0)
- EMEA002988PIP0121(0)
- EMEA002989PIP0121M01(0)
- EMEA002992PIP0121(0)
- EMEA002994PIP0121(0)
- EMEA002995PIP0121(0)
- EMEA002996PIP0121(0)
- EMEA002997PIP0121(0)
- EMEA002997PIP0222(0)
- EMEA002999PIP0121(0)
- EMEA003001PIP0121(0)
- EMEA003002PIP0121(0)
- EMEA003003PIP0121(0)
- EMEA003004PIP0121(0)
- EMEA003005PIP0121(0)
- EMEA003006PIP0121(0)
- EMEA003007PIP0121(0)
- EMEA003008PIP0121(0)
- EMEA003009PIP0121(0)
- EMEA003010PIP0121(0)
- EMEA003015PIP0121(0)
- EMEA003016PIP0121(0)
- EMEA003017PIP0121(0)
- EMEA003018PIP0121(0)
- EMEA003020PIP0121(0)
- EMEA003021PIP0121(0)
- EMEA003023PIP0121(0)
- EMEA003026PIP0221(0)
- EMEA003028PIP0121(0)
- EMEA003030PIP0221(0)
- EMEA003031PIP0121(0)
- EMEA003032PIP0121M01(0)
- EMEA003034PIP0121(0)
- EMEA003035PIP0221(0)
- EMEA003036PIP0121(0)
- EMEA003037PIP0121(0)
- EMEA003038PIP0121(0)
- EMEA003039PIP0121(0)
- EMEA003040PIP0121(0)
- EMEA003040PIP0221(0)
- EMEA003041PIP0121(0)
- EMEA003042PIP0121(0)
- EMEA003043PIP0121(0)
- EMEA003044PIP0121(0)
- EMEA003045PIP0121(0)
- EMEA003046PIP0121(0)
- EMEA003047PIP0121(0)
- EMEA003048PIP0121(0)
- EMEA003049PIP0121(0)
- EMEA003051PIP0121(0)
- EMEA003051PIP0422(0)
- EMEA003051PIP0522(0)
- EMEA003052PIP0121(0)
- EMEA003053PIP0121(0)
- EMEA003058PIP0121(0)
- EMEA003059PIP0121(0)
- EMEA003061PIP0121(0)
- EMEA003062PIP0121(0)
- EMEA003063PIP0121(0)
- EMEA003064PIP0121(0)
- EMEA003065PIP0121(0)
- EMEA003066PIP0121(0)
- EMEA003068PIP0121(0)
- EMEA003069PIP0121(0)
- EMEA003070PIP0121(0)
- EMEA003071PIP0121(0)
- EMEA003072PIP0121(0)
- EMEA003075PIP0121(0)
- EMEA003076PIP0121(0)
- EMEA003077PIP0121(0)
- EMEA003081PIP0121M02(0)
- EMEA003082PIP0121(0)
- EMEA003083PIP0121(0)
- EMEA003084PIP0322(0)
- EMEA003085PIP0121(0)
- EMEA003087PIP0121(0)
- EMEA003091PIP0121(0)
- EMEA003094PIP0221(0)
- EMEA003096PIP0222(0)
- EMEA003097PIP0121(0)
- EMEA003098PIP0121(0)
- EMEA003100PIP0121(0)
- EMEA003101PIP0121(0)
- EMEA003104PIP0121(0)
- EMEA003105PIP0121(0)
- EMEA003106PIP0121(0)
- EMEA003107PIP0121(0)
- EMEA003108PIP0121(0)
- EMEA003109PIP0121(0)
- EMEA003112PIP0121(0)
- EMEA003114PIP0121(0)
- EMEA003115PIP0121(0)
- EMEA003116PIP0121(0)
- EMEA003117PIP0221(0)
- EMEA003119PIP0121M01(0)
- EMEA003120PIP0121(0)
- EMEA003121PIP0121(0)
- EMEA003122PIP0121M01(0)
- EMEA003125PIP0121(0)
- EMEA003125PIP0221(0)
- EMEA003127PIP0121(0)
- EMEA003132PIP0121(0)
- EMEA003133PIP0121(0)
- EMEA003134PIP0121(0)
- EMEA003135PIP0121(0)
- EMEA003137PIP0121(0)
- EMEA003138PIP0121(0)
- EMEA003144PIP0121(0)
- EMEA003145PIP0121(0)
- EMEA003146PIP0121(0)
- EMEA003147PIP0121(0)
- EMEA003148PIP0121(0)
- EMEA003149PIP0121(0)
- EMEA003151PIP0121(0)
- EMEA003152PIP0121(0)
- EMEA003153PIP0121(0)
- EMEA003155PIP0121(0)
- EMEA003156PIP0121(0)
- EMEA003156PIP0222(0)
- EMEA003157PIP0121(0)
- EMEA003158PIP0121(0)
- EMEA003159PIP0121(0)
- EMEA003160PIP0121(0)
- EMEA003162PIP0121(0)
- EMEA003162PIP0222(0)
- EMEA003164PIP0121(0)
- EMEA003165PIP0121(0)
- EMEA003166PIP0121(0)
- EMEA003167PIP0121(0)
- EMEA003168PIP0121(0)
- EMEA003169PIP0121(0)
- EMEA003170PIP0121M01(0)
- EMEA003171PIP0121(0)
- EMEA003172PIP0121(0)
- EMEA003173PIP0121(0)
- EMEA003174PIP0121(0)
- EMEA003174PIP0222(0)
- EMEA003175PIP0121(0)
- EMEA003177PIP0121(0)
- EMEA003178PIP0121(0)
- EMEA003179PIP0122(0)
- EMEA003181PIP0122(0)
- EMEA003182PIP0122(0)
- EMEA003183PIP0222(0)
- EMEA003186PIP0122(0)
- EMEA003187PIP0122(0)
- EMEA003189PIP0122M01(0)
- EMEA003190PIP0122(0)
- EMEA003191PIP0122(0)
- EMEA003193PIP0122(0)
- EMEA003196PIP0122(0)
- EMEA003198PIP0122(0)
- EMEA003199PIP0122(0)
- EMEA003200PIP0122(0)
- EMEA003202PIP0122(0)
- EMEA003204PIP0122(0)
- EMEA003205PIP0122(0)
- EMEA003206PIP0122(0)
- EMEA003207PIP0122(0)
- EMEA003210PIP0122(0)
- EMEA003211PIP0122(0)
- EMEA003212PIP0122(0)
- EMEA003214PIP0122(0)
- EMEA003215PIP0122(0)
- EMEA003217PIP0122(0)
- EMEA003218PIP0122(0)
- EMEA003219PIP0122(0)
- EMEA003223PIP0122(0)
- EMEA003224PIP0122(0)
- EMEA003226PIP0122(0)
- EMEA003227PIP0122(0)
- EMEA003228PIP0122(0)
- EMEA003229PIP0122(0)
- EMEA003230PIP0122(0)
- EMEA003231PIP0122(0)
- EMEA003234PIP0122(0)
- EMEA003235PIP0122(0)
- EMEA003236PIP0122(0)
- EMEA003237PIP0122(0)
- EMEA003238PIP0122(0)
- EMEA003239PIP0122(0)
- EMEA003240PIP0122(0)
- EMEA003241PIP0122(0)
- EMEA003243PIP0122(0)
- EMEA003245PIP0122(0)
- EMEA003246PIP0122(0)
- EMEA003248PIP0122(0)
- EMEA003250PIP0122(0)
- EMEA003252PIP0122(0)
- EMEA003255PIP0122(0)
- EMEA003260PIP0122(0)
- EMEA003261PIP0122(0)
- EMEA003262PIP0122(0)
- EMEA003269PIP0122(0)
- EMEA003272PIP0122(0)
- EMEA003273PIP0122(0)
- EMEA003275PIP0122(0)
- EMEA003278PIP0122(0)
- EMEA003281PIP0122(0)
- EMEA003282PIP0122(0)
- EMEA003285PIP0122(0)
- EMEA003289PIP0122(0)
- EMEA003291PIP0122(0)
- EMEA003292PIP0122(0)
- EMEA003292PIP0222(0)
- EMEA003294PIP0122(0)
- EMEA003295PIP0122(0)
- EMEA003298PIP0122(0)
- EMEA003308PIP0122(0)
- EMEA003309PIP0122(0)
- EMEA003310PIP0122(0)
- EMEA003311PIP0122(0)
- EMEA003317PIP0222(0)
- EMEA003320PIP0122(0)
- EMEA003330PIP0122(0)
- EMEA003334PIP0122(0)
- EMEA003337PIP0122(0)
- EMEA003339PIP0122(0)
- EMEA003340PIP0122(0)
- EMEA003341PIP0122(0)
- EMEA003342PIP0122(0)
- EMEA003380PIP0122(0)
- EMEA and EU accession countries meet ahead of enlargement(0)
- EMEA announces appointment of new Head of Unit for Human Medicines(0)
- EMEA announces composition of its scientific committees(0)
- EMEA announces new CPMP chairman and vicechairman(0)
- EMEA announces new Head of Unit for Communications and Networking(0)
- EMEA annual report shows 24 positive reviews for new human medicines in 2003 Agency proposes €108 million budget for 2005(0)
- EMEA annual report shows rise in applications for new medicines in 2004with further increases forecast for 2005 and 2006(0)
- EMEA brings in new openness measures and acts to encourage development of veterinary medicines(0)
- EMEA celebrates 10th anniversary(0)
- EMEA completes the review of recombinant factor VIII products and inhibitor development(0)
- EMEAcoordinated PROTECT project has been accepted for funding by the Innovative Medicines Initiative joint undertaking(0)
- EMEA Creates new Communications and Networking Unit(0)
- EMEA EFPIA info day(0)
- EMEAEFPIA Info day(0)
- EMEAEFPIA Quality by Design application workshop(0)
- EMEA EGA Info Day on Generic and Biosimilar Medicinal Products and the Centralised Procedure(0)
- EMEA forecasts modest increase in applications in its 2004 budget and Management Board elects new chairman(0)
- EMEA halfyear report for 2008 shows activities to be on target with a marked increase in the provision of scientific advice(0)
- EMEA implementation of electronic submissions statements of intent Scientific guideline(0)
- EMEA launches action plan for improvements for human medicines(0)
- EMEA launches consultation on the future of EU pharmaceutical guidelines(0)
- EMEA launches Eudra Vigilance training programme(0)
- EMEA Management Board adopts fee implementing rule and looks at the Agencys corporate governance(0)
- EMEA Management Board adopts the 2007 work programme and budget(0)
- EMEA Management Board adopts work programme for a busy year ahead and agrees to move towards greater transparency of its meetings(0)
- EMEA Management Board considers road map 2010 and welcomes increase in new applications for human medicines(0)
- EMEA Management Board considers the Agencys road map to 2010 and approves transparency proposal for orphan drugs(0)
- EMEA Management Board elects new chairman and sets out proposed work programme for 2004(0)
- EMEA Management Board moves for greater transparency(0)
- EMEAPDA Conference European GMP Current issues and future developments(0)
- EMEA public statement on fee reductions for designated orphan medicinal products(0)
- EMEA Public Statement on herbal medicinal products containing cimicifugae racemosae rhizoma Serious hepatic reactions(0)
- EMEA public statement on Refacto moroctocog alfa Introduction of a change to Refacto drug product specific activity specification increase of 20% in the amount of Refacto protein in each vial(0)
- EMEA public statement on Refludan Lepirudin Fatal anaphylactic reactions(0)
- EMEA public statement on Replaglinide NovoNorm/Prandin contraindication of concomitant use of Replaglinide and Gemfibrozil(0)
- EMEA Public Statement on review of recombinant Factor VIII FVIII products Advate Kogenate Bayer/Helixate NexGen Kogenate/Helixate Recombinate ReFacto and inhibitor development(0)
- EMEA Public Statement on the Recommendation to suspend the marketing authorisation for Orlaam Levaceetylmethadol in the European Union(0)
- EMEA public statement on the suspension of the marketing authorisation for Optison perflutren in the European Union(0)
- EMEA publishes first summaries of opinions for designated orphan medicines(0)
- EMEA recommends a new warning for epoetins for their use in cancer patients(0)
- EMEA recommends authorisation of first prepandemic influenza vaccine(0)
- EMEA recommends changes in the storage conditions for Neupro rotigotine(0)
- EMEA recommends information on lung cancer cases to be included inExubera product information(0)
- EMEA recommends new warnings and contraindications for ergotderived dopamine agonists(0)
- EMEA recommends new warnings and contraindications for rosiglitazone(0)
- EMEA recommends restricted use of oral norfloxacincontaining medicines in urinary infections(0)
- EMEA recommends strengthening warnings and contraindications for etoricoxibcontaining medicines used in the treatment of rheumatoid arthritis and ankylosing spondylitis(0)
- EMEA releases guidelines on development of medicines for Alzheimers disease and Parkinsons disease(0)
- EMEA releases recommendations for better information for patients(0)
- EMEA reports strong performance in regulatory and publichealth activities in 2007 the outlook for 2008 is even higher application numbers and a focus on advancedtherapy medicines(0)
- EMEA sets out its road map to 2010(0)
- EMEAs provision of information to the EMEAs stakeholders(0)
- EMEA statement on the safety of Ketek(0)
- EMEA strengthens handling of safety concerns for human medicines(0)
- EMEA Tenth Anniversary / Scientific conference A scientific perspective on the future of medicines(0)
- EMEA workshop on homeopathic medicinal products concludes to strengthen harmonisation but accept different national traditions(0)
- EMEA workshop on Monoclonal Antibodies(0)
- EMEA Workshop on Neonates Development of medicines for neonates needs multi disciplinary cooperation(0)
- EMEA Workshop on Pharmacovigilance Systems and Inspections for Veterinary Medicinal Products(0)
- Emelie Bergman Perland(0)
- Emend(0)
- Emer Cooke nominated as new EMA Executive Director(0)
- Emer Cookes endofyear message(0)
- Emer Cooke takes office as head of EMA(0)
- Emerflu(0)
- Emergency Task Force ETF(0)
- Emerging medicinal products from laboratory to patient use(0)
- Emese Prikidánovits(0)
- Emgality(0)
- Emiel Van Galen(0)
- Emiel van Galen elected as chair of the Committee for Herbal Medicinal Products(0)
- EMIL EMILSSON(0)
- Emil Hermansen(0)
- Emilia Mavrokordatou(0)
- Emiliano Gemma(0)
- Emilia Stoyanova(0)
- Emilie Birch Kristensen(0)
- Emilie Breton(0)
- Emilie Patras de Campaigno(0)
- Emilie Perez(0)
- Emilie VITTAZ(0)
- Emilio Benfenati(0)
- Emilio José Torres Bermúdez(0)
- Emil Schwan(0)
- Emily Hams(0)
- Emline LEON(0)
- Emma Beuzekom van(0)
- Emma Carroll(0)
- Emma Cassar Buontempo(0)
- Emma Fagan(0)
- Emma Louise Nautrup Ravn Stadsbjerg(0)
- Emmanuel LEMICHEZ(0)
- Emma Redondo(0)
- Emma van Beuzekom(0)
- Emmely de Vries(0)
- Empliciti(0)
- Emselex(0)
- Emtricitabine / rilpivirine / tenofovir disoproxil productspecific bioequivalence guidance(0)
- Emtricitabine/Tenofovir disoproxil Krka(0)
- Emtricitabine/Tenofovir disoproxil Krka dd(0)
- Emtricitabine/Tenofovir disoproxil Mylan(0)
- Emtricitabine/tenofovir disoproxil productspecific bioequivalence guidance(0)
- Emtricitabine/Tenofovir disoproxil Zentiva(0)
- Emtriva(0)
- Enbrel(0)
- ENCePP 10 years for excellence in medicines safety(0)
- ENCePP eregister reaches 100 postauthorisation studies(0)
- ENCePP guide on methodological standards in pharmacoepidemiology revised(0)
- ENCePP publishes the guide on methodological standards in pharmacoepidemiology(0)
- ENCePP releases for public consultation draft Guide on Methodological Standards in Pharmacoepidemiology(0)
- EnCyzix(0)
- End of year message from EMAs Executive Director(0)
- Endofyear message from EMAs Executive Director(0)
- EndolucinBeta(0)
- Endpoints in clinical studies with haematopoietic growth factors for mobilisation of autologous stem cells Scientific guideline(0)
- Ene Kenkmann(0)
- Enerzair Breezhaler(0)
- Engeline van Duijkeren(0)
- Enhancing consistency in wording of therapeutic indications to support healthcare decisionmaking(0)
- Enhertu(0)
- Enjaymo(0)
- Enpaxiq(0)
- EnprEMA Coordinating Group and networks meeting(0)
- EnprEMA Coordinating Group meeting(0)
- EnprEMA governance and meetings(0)
- EnprEMA meeting documents archive(0)
- EnprEMA priority activities(0)
- Enrico Costa(0)
- Enrico Mantel(0)
- Enrique Gallardo(0)
- EnroK(0)
- Enrylaze(0)
- Enspryng(0)
- Entacapone Comtess/Comtan Update of Product Information(0)
- Entacapone Orion(0)
- Entacapone Teva(0)
- Entecavir Accord(0)
- Entecavir productspecific bioequivalence guidance(0)
- Entecavir Viatris previously Entecavir Mylan(0)
- Enteroporc Coli(0)
- Enteroporc Coli AC(0)
- Enthryv(0)
- Entolimod TMC(0)
- Entresto(0)
- Entyvio(0)
- Enurace 50(0)
- Enurev Breezhaler(0)
- Envarsus(0)
- Enviage(0)
- Environmental impact assessment for veterinary medicinal products in support of the VICH guidelines GL6 and GL38 Scientific guideline(0)
- Environmental risk assessment for immunological veterinary medicinal products Scientific guideline(0)
- Environmental risk assessment for parasiticide veterinary medicinal products used in companion animals Scientific guideline(0)
- Environmental risk assessment of ectoparasiticidal veterinary medicinal products used in cats and dogs(0)
- Environmental risk assessment of herbal medicinal products Scientific guideline(0)
- Environmental risk assessment of medicinal products for human use Scientific guideline(0)
- Environmental risk assessment of veterinary medicinal products intended to be used in aquaculture Scientific guideline(0)
- Environmental risk assessment of veterinary medicines(0)
- Environmental risk assessments for medicinal products containing or consisting of genetically modified organisms GMOs Scientific guideline(0)
- Environmental Risk Assessment Working Party(0)
- Enyglid(0)
- Enzalutamide productspecific bioequivalence guidance(0)
- Enzepi(0)
- EPAR summaries for the public A further step for the provision of better information about medicines(0)
- Epclusa(0)
- Eperzan(0)
- Epidemiological data on blood transmissible infections Scientific guideline(0)
- Epidyolex(0)
- ePI information workshop and exploratory workshop(0)
- Epilobii herba(0)
- Episalvan(0)
- Epivir(0)
- Epjevy(0)
- Eplivanserin hemifumarate(0)
- Epoetin Alfa Hexal(0)
- Epoetin theta(0)
- Eporatio(0)
- Epostim(0)
- Epp Ülevaino(0)
- Eprinex pouron and its associated names(0)
- Eprotirome(0)
- Eptifibatide Accord(0)
- Epysqli(0)
- Equibactin vet(0)
- Equidacent(0)
- Equilis Prequenza(0)
- Equilis Prequenza Te(0)
- Equilis StrepE(0)
- Equilis Te(0)
- Equilis West Nile(0)
- Equimectin(0)
- Equioxx(0)
- Equip WNV previously Duvaxyn WNV(0)
- Equiseti herba(0)
- Equisolon(0)
- Equitend(0)
- Equivalence studies for the demonstration of therapeutic equivalence for locally applied locally acting products in the gastrointestinal tract Scientific guideline(0)
- Eraldo Donnarumma(0)
- Eravac(0)
- Erbitux(0)
- Erden Radoncic(0)
- Erelzi(0)
- eReporting(0)
- Eribulin Baxter(0)
- Eric Abadie resigns as chair of the CHMP(0)
- Erich Schneider(0)
- Eric Vermeulen(0)
- Erika Elisabet Gustafsson(0)
- Erika Fredriksson(0)
- Erika M Friedl(0)
- Erik Bergman(0)
- Erik den Hertog(0)
- Erik Hergarden(0)
- Erik Niks(0)
- Erik Peltomaa(0)
- Eritoran(0)
- Erivedge(0)
- Erleada(0)
- Erlotinib Accord(0)
- Erlotinib productspecific bioequivalence guidance(0)
- Erno Horváth(0)
- Ertapenem Hospira(0)
- Ertapenem SUN(0)
- Ervebo(0)
- Erwin Dreesen(0)
- Eryseng(0)
- Eryseng Parvo(0)
- Esa Heinonen(0)
- Esben Meldgaard Høgh Quistgaard(0)
- Esbriet(0)
- Eschscholziae herba(0)
- eSignature webinar(0)
- Esmya / Ulipristal Acetate Gedeon Richter(0)
- Esmya new measures to minimise risk of rare but serious liver injury(0)
- Esomeprazole magnesium/acetylsalisylic acid(0)
- Esomeprazole sodium Esomeprazole magnesium trihydrate(0)
- Esperanza GomezLucia(0)
- Esperoct(0)
- Essential work to combat the COVID19 pandemic to continue during EMAs closure on 1 June 2020(0)
- Essential work to combat the COVID19 pandemic to continue during EMAs closure on 27 April and on 1 May 2020(0)
- Essential work to combat the COVID19 pandemic to continue during EMAs Easter break from 9 to 13 April 2020(0)
- Establishing efficacy based on singlearm trials submitted as pivotal evidence in a marketing authorisation(0)
- Establishment of a guideline on the development and manufacture of synthetic oligonucleotides Scientific guideline(0)
- Establishment of maximum residue limits for milk considering the daily intake by children Scientific guideline(0)
- Establishment of maximum residue limits for Salmonidae and other fin fish Scientific guideline(0)
- Estela Pedreiro(0)
- Estelle Foeillet(0)
- Esther Brandon(0)
- Esther Broekman(0)
- Esther Cobo(0)
- Esther de Vries(0)
- Esther Lubberts(0)
- Esther Moyano Ramirez(0)
- Esther Rincón Gila(0)
- Esther Werner(0)
- Esther Zagwijn(0)
- estradiol(0)
- Estradiol valerate / Dienogest(0)
- eSubmission Gateway now live for all applications for human medicines to the European Medicines Agency(0)
- eSubmission Gateway or web client to become mandatory for all eCTD submissions through the centralised procedure in 2014(0)
- eSubmission Gateway referral procedures and paediatric submissions webinar(0)
- eSubmission Gateway release II and eSubmission web client now live for all applications for human medicines(0)
- eSubmission Gateway veterinary submission webinar(0)
- eSubmission gateway webinar(0)
- eSubmission web client for electronic submissions now available for registration(0)
- Eszter KollárNagy(0)
- Eszter Molnár(0)
- Eszter Volgyesine Horvath(0)
- Etanercept(0)
- ETF concludes that bivalent original/Omicron BA45 mRNA vaccines may be used for primary vaccination(0)
- ETF warns that monoclonal antibodies may not be effective against emerging strains of SARSCoV2(0)
- Ethanol(0)
- Ethanol content in herbal medicinal products and traditional herbal medicinal products used in children Scientific guideline(0)
- Ethical considerations for paediatric trials how can ethics committees in the European Member States and the Paediatric Committee at the European Medicines Agency work together(0)
- Ethical use of animals in medicine testing(0)
- Ethyl Eicosapent soft gelatin capsules(0)
- Etienne Schmitt(0)
- Etonogestrel and ethinylestradiol vaginal delivery system productspecific bioequivalence(0)
- EU/3/00/001(0)
- EU/3/00/002(0)
- EU/3/00/003(0)
- EU/3/00/004(0)
- EU/3/00/005(0)
- EU/3/00/006(0)
- EU/3/00/007(0)
- EU/3/00/008(0)
- EU/3/00/009(0)
- EU/3/00/010(0)
- EU/3/00/011(0)
- EU/3/00/012(0)
- EU/3/00/013(0)
- EU/3/00/014(0)
- EU/3/00/015(0)
- EU/3/00/016(0)
- EU/3/00/017(0)
- EU/3/01/018(0)
- EU/3/01/019(0)
- EU/3/01/020(0)
- EU/3/01/021(0)
- EU/3/01/022(0)
- EU/3/01/023(0)
- EU/3/01/024(0)
- EU/3/01/025(0)
- EU/3/01/026(0)
- EU/3/01/027(0)
- EU/3/01/028(0)
- EU/3/01/029(0)
- EU/3/01/030(0)
- EU/3/01/031(0)
- EU/3/01/032(0)
- EU/3/01/033(0)
- EU/3/01/034(0)
- EU/3/01/035(0)
- EU/3/01/036(0)
- EU/3/01/037(0)
- EU/3/01/038(0)
- EU/3/01/039(0)
- EU/3/01/040(0)
- EU/3/01/041(0)
- EU/3/01/042(0)
- EU/3/01/043(0)
- EU/3/01/044(0)
- EU/3/01/045(0)
- EU/3/01/046(0)
- EU/3/01/047(0)
- EU/3/01/048(0)
- EU/3/01/050(0)
- EU/3/01/051(0)
- EU/3/01/052(0)
- EU/3/01/053(0)
- EU/3/01/054(0)
- EU/3/01/055(0)
- EU/3/01/056(0)
- EU/3/01/057(0)
- EU/3/01/058(0)
- EU/3/01/059(0)
- EU/3/01/060(0)
- EU/3/01/061(0)
- EU/3/01/062(0)
- EU/3/01/063(0)
- EU/3/01/064(0)
- EU/3/01/065(0)
- EU/3/01/066(0)
- EU/3/01/067(0)
- EU/3/01/068(0)
- EU/3/01/069(0)
- EU/3/01/070(0)
- EU/3/01/071(0)
- EU/3/01/072(0)
- EU/3/01/073(0)
- EU/3/01/074(0)
- EU/3/01/075(0)
- EU/3/01/076(0)
- EU/3/01/077(0)
- EU/3/01/078(0)
- EU/3/01/079(0)
- EU/3/01/080(0)
- EU/3/01/081(0)
- EU/3/01/082(0)
- EU/3/01/083(0)
- EU/3/01/084(0)
- EU/3/02/085(0)
- EU/3/02/086(0)
- EU/3/02/087(0)
- EU/3/02/088(0)
- EU/3/02/089(0)
- EU/3/02/090(0)
- EU/3/02/091(0)
- EU/3/02/092(0)
- EU/3/02/093(0)
- EU/3/02/094(0)
- EU/3/02/095(0)
- EU/3/02/096(0)
- EU/3/02/097(0)
- EU/3/02/098(0)
- EU/3/02/099(0)
- EU/3/02/100(0)
- EU/3/02/101(0)
- EU/3/02/102(0)
- EU/3/02/103(0)
- EU/3/02/104(0)
- EU/3/02/105(0)
- EU/3/02/106(0)
- EU/3/02/107(0)
- EU/3/02/108(0)
- EU/3/02/109(0)
- EU/3/02/110(0)
- EU/3/02/111(0)
- EU/3/02/112(0)
- EU/3/02/113(0)
- EU/3/02/114(0)
- EU/3/02/115(0)
- EU/3/02/116(0)
- EU/3/02/117(0)
- EU/3/02/118(0)
- EU/3/02/119(0)
- EU/3/02/120(0)
- EU/3/02/121(0)
- EU/3/02/122(0)
- EU/3/02/123(0)
- EU/3/02/124(0)
- EU/3/02/125(0)
- EU/3/02/126(0)
- EU/3/02/127(0)
- EU/3/02/128(0)
- EU/3/02/129(0)
- EU/3/02/130(0)
- EU/3/02/131(0)
- EU/3/03/132(0)
- EU/3/03/133(0)
- EU/3/03/134(0)
- EU/3/03/135(0)
- EU/3/03/136(0)
- EU/3/03/137(0)
- EU/3/03/138(0)
- EU/3/03/139(0)
- EU/3/03/140(0)
- EU/3/03/141(0)
- EU/3/03/142(0)
- EU/3/03/143(0)
- EU/3/03/144(0)
- EU/3/03/145(0)
- EU/3/03/146(0)
- EU/3/03/147(0)
- EU/3/03/148(0)
- EU/3/03/149(0)
- EU/3/03/150(0)
- EU/3/03/151(0)
- EU/3/03/152(0)
- EU/3/03/153(0)
- EU/3/03/154(0)
- EU/3/03/155(0)
- EU/3/03/156(0)
- EU/3/03/157(0)
- EU/3/03/158(0)
- EU/3/03/159(0)
- EU/3/03/160(0)
- EU/3/03/161(0)
- EU/3/03/162(0)
- EU/3/03/163(0)
- EU/3/03/164(0)
- EU/3/03/165(0)
- EU/3/03/166(0)
- EU/3/03/167(0)
- EU/3/03/168(0)
- EU/3/03/169(0)
- EU/3/03/170(0)
- EU/3/03/171(0)
- EU/3/03/172(0)
- EU/3/03/173(0)
- EU/3/03/174(0)
- EU/3/03/175(0)
- EU/3/03/176(0)
- EU/3/03/177(0)
- EU/3/03/178(0)
- EU/3/03/179(0)
- EU/3/03/180(0)
- EU/3/03/181(0)
- EU/3/03/182(0)
- EU/3/03/183(0)
- EU/3/03/184(0)
- EU/3/03/185(0)
- EU/3/04/186(0)
- EU/3/04/187(0)
- EU/3/04/188(0)
- EU/3/04/189(0)
- EU/3/04/190(0)
- EU/3/04/191(0)
- EU/3/04/192(0)
- EU/3/04/193(0)
- EU/3/04/194(0)
- EU/3/04/195(0)
- EU/3/04/196(0)
- EU/3/04/197(0)
- EU/3/04/198(0)
- EU/3/04/199(0)
- EU/3/04/200(0)
- EU/3/04/201(0)
- EU/3/04/202(0)
- EU/3/04/203(0)
- EU/3/04/204(0)
- EU/3/04/205(0)
- EU/3/04/206(0)
- EU/3/04/207(0)
- EU/3/04/208(0)
- EU/3/04/209(0)
- EU/3/04/210(0)
- EU/3/04/211(0)
- EU/3/04/212(0)
- EU/3/04/213(0)
- EU/3/04/214(0)
- EU/3/04/215(0)
- EU/3/04/216(0)
- EU/3/04/217(0)
- EU/3/04/218(0)
- EU/3/04/219(0)
- EU/3/04/220(0)
- EU/3/04/221(0)
- EU/3/04/222(0)
- EU/3/04/223(0)
- EU/3/04/224(0)
- EU/3/04/225(0)
- EU/3/04/226(0)
- EU/3/04/227(0)
- EU/3/04/228(0)
- EU/3/04/229(0)
- EU/3/04/230(0)
- EU/3/04/231(0)
- EU/3/04/232(0)
- EU/3/04/233(0)
- EU/3/04/234(0)
- EU/3/04/235(0)
- EU/3/04/236(0)
- EU/3/04/237(0)
- EU/3/04/238(0)
- EU/3/04/239(0)
- EU/3/04/240(0)
- EU/3/04/241(0)
- EU/3/04/242(0)
- EU/3/04/243(0)
- EU/3/04/244(0)
- EU/3/04/245(0)
- EU/3/04/246(0)
- EU/3/04/247(0)
- EU/3/04/248(0)
- EU/3/04/249(0)
- EU/3/04/250(0)
- EU/3/04/251(0)
- EU/3/04/252(0)
- EU/3/04/253(0)
- EU/3/04/254(0)
- EU/3/04/255(0)
- EU/3/04/256(0)
- EU/3/04/257(0)
- EU/3/04/258(0)
- EU/3/04/259(0)
- EU/3/04/260(0)
- EU/3/05/261(0)
- EU/3/05/262(0)
- EU/3/05/263(0)
- EU/3/05/264(0)
- EU/3/05/265(0)
- EU/3/05/266(0)
- EU/3/05/267(0)
- EU/3/05/268(0)
- EU/3/05/269(0)
- EU/3/05/270(0)
- EU/3/05/271(0)
- EU/3/05/272(0)
- EU/3/05/273(0)
- EU/3/05/274(0)
- EU/3/05/275(0)
- EU/3/05/276(0)
- EU/3/05/277(0)
- EU/3/05/278(0)
- EU/3/05/279(0)
- EU/3/05/280(0)
- EU/3/05/281(0)
- EU/3/05/282(0)
- EU/3/05/283(0)
- EU/3/05/284(0)
- EU/3/05/285(0)
- EU/3/05/286(0)
- EU/3/05/287(0)
- EU/3/05/288(0)
- EU/3/05/289(0)
- EU/3/05/290(0)
- EU/3/05/291(0)
- EU/3/05/292(0)
- EU/3/05/293(0)
- EU/3/05/294(0)
- EU/3/05/295(0)
- EU/3/05/296(0)
- EU/3/05/297(0)
- EU/3/05/298(0)
- EU/3/05/299(0)
- EU/3/05/300(0)
- EU/3/05/301(0)
- EU/3/05/302(0)
- EU/3/05/303(0)
- EU/3/05/304(0)
- EU/3/05/305(0)
- EU/3/05/306(0)
- EU/3/05/307(0)
- EU/3/05/308(0)
- EU/3/05/309(0)
- EU/3/05/310(0)
- EU/3/05/311(0)
- EU/3/05/312(0)
- EU/3/05/313(0)
- EU/3/05/314(0)
- EU/3/05/315(0)
- EU/3/05/316(0)
- EU/3/05/317(0)
- EU/3/05/318(0)
- EU/3/05/319(0)
- EU/3/05/320(0)
- EU/3/05/321(0)
- EU/3/05/322(0)
- EU/3/05/323(0)
- EU/3/05/324(0)
- EU/3/05/325(0)
- EU/3/05/326(0)
- EU/3/05/327(0)
- EU/3/05/328(0)
- EU/3/05/329(0)
- EU/3/05/330(0)
- EU/3/05/331(0)
- EU/3/05/332(0)
- EU/3/05/333(0)
- EU/3/05/334(0)
- EU/3/05/335(0)
- EU/3/05/336(0)
- EU/3/05/337(0)
- EU/3/05/338(0)
- EU/3/05/339(0)
- EU/3/05/340(0)
- EU/3/05/341(0)
- EU/3/05/342(0)
- EU/3/05/343(0)
- EU/3/05/344(0)
- EU/3/05/345(0)
- EU/3/05/346(0)
- EU/3/05/347(0)
- EU/3/05/348(0)
- EU/3/06/349(0)
- EU/3/06/350(0)
- EU/3/06/351(0)
- EU/3/06/352(0)
- EU/3/06/353(0)
- EU/3/06/354(0)
- EU/3/06/355(0)
- EU/3/06/356(0)
- EU/3/06/357(0)
- EU/3/06/358(0)
- EU/3/06/359(0)
- EU/3/06/360(0)
- EU/3/06/361(0)
- EU/3/06/362(0)
- EU/3/06/363(0)
- EU/3/06/364(0)
- EU/3/06/365(0)
- EU/3/06/366(0)
- EU/3/06/367(0)
- EU/3/06/368(0)
- EU/3/06/369(0)
- EU/3/06/370(0)
- EU/3/06/371(0)
- EU/3/06/372(0)
- EU/3/06/373(0)
- EU/3/06/374(0)
- EU/3/06/375(0)
- EU/3/06/376(0)
- EU/3/06/377(0)
- EU/3/06/378(0)
- EU/3/06/379(0)
- EU/3/06/380(0)
- EU/3/06/381(0)
- EU/3/06/382(0)
- EU/3/06/383(0)
- EU/3/06/384(0)
- EU/3/06/385(0)
- EU/3/06/386(0)
- EU/3/06/387(0)
- EU/3/06/388(0)
- EU/3/06/389(0)
- EU/3/06/390(0)
- EU/3/06/391(0)
- EU/3/06/392(0)
- EU/3/06/393(0)
- EU/3/06/394(0)
- EU/3/06/395(0)
- EU/3/06/396(0)
- EU/3/06/397(0)
- EU/3/06/398(0)
- EU/3/06/399(0)
- EU/3/06/400(0)
- EU/3/06/401(0)
- EU/3/06/402(0)
- EU/3/06/403(0)
- EU/3/06/404(0)
- EU/3/06/405(0)
- EU/3/06/406(0)
- EU/3/06/407(0)
- EU/3/06/408(0)
- EU/3/06/409(0)
- EU/3/06/410(0)
- EU/3/06/411(0)
- EU/3/06/412(0)
- EU/3/06/413(0)
- EU/3/06/414(0)
- EU/3/06/415(0)
- EU/3/06/416(0)
- EU/3/06/417(0)
- EU/3/06/418(0)
- EU/3/06/419(0)
- EU/3/06/420(0)
- EU/3/06/421(0)
- EU/3/06/422(0)
- EU/3/06/423(0)
- EU/3/06/424(0)
- EU/3/06/425(0)
- EU/3/06/426(0)
- EU/3/06/427(0)
- EU/3/06/428(0)
- EU/3/06/429(0)
- EU/3/07/430(0)
- EU/3/07/431(0)
- EU/3/07/432(0)
- EU/3/07/433(0)
- EU/3/07/434(0)
- EU/3/07/435(0)
- EU/3/07/436(0)
- EU/3/07/437(0)
- EU/3/07/438(0)
- EU/3/07/439(0)
- EU/3/07/440(0)
- EU/3/07/441(0)
- EU/3/07/442(0)
- EU/3/07/443(0)
- EU/3/07/444(0)
- EU/3/07/445(0)
- EU/3/07/446(0)
- EU/3/07/447(0)
- EU/3/07/448(0)
- EU/3/07/449(0)
- EU/3/07/450(0)
- EU/3/07/451(0)
- EU/3/07/452(0)
- EU/3/07/453(0)
- EU/3/07/454(0)
- EU/3/07/455(0)
- EU/3/07/456(0)
- EU/3/07/457(0)
- EU/3/07/458(0)
- EU/3/07/459(0)
- EU/3/07/460(0)
- EU/3/07/461(0)
- EU/3/07/462(0)
- EU/3/07/463(0)
- EU/3/07/464(0)
- EU/3/07/465(0)
- EU/3/07/466(0)
- EU/3/07/467(0)
- EU/3/07/468(0)
- EU/3/07/469(0)
- EU/3/07/470(0)
- EU/3/07/471(0)
- EU/3/07/472(0)
- EU/3/07/473(0)
- EU/3/07/474(0)
- EU/3/07/475(0)
- EU/3/07/476(0)
- EU/3/07/477(0)
- EU/3/07/478(0)
- EU/3/07/479(0)
- EU/3/07/480(0)
- EU/3/07/481(0)
- EU/3/07/482(0)
- EU/3/07/483(0)
- EU/3/07/484(0)
- EU/3/07/485(0)
- EU/3/07/486(0)
- EU/3/07/487(0)
- EU/3/07/488(0)
- EU/3/07/489(0)
- EU/3/07/490(0)
- EU/3/07/491(0)
- EU/3/07/492(0)
- EU/3/07/493(0)
- EU/3/07/494(0)
- EU/3/07/495(0)
- EU/3/07/496(0)
- EU/3/07/497(0)
- EU/3/07/498(0)
- EU/3/07/499(0)
- EU/3/07/500(0)
- EU/3/07/501(0)
- EU/3/07/502(0)
- EU/3/07/503(0)
- EU/3/07/504(0)
- EU/3/07/505(0)
- EU/3/07/506(0)
- EU/3/07/507(0)
- EU/3/07/508(0)
- EU/3/07/509(0)
- EU/3/07/510(0)
- EU/3/07/511(0)
- EU/3/07/512(0)
- EU/3/07/513(0)
- EU/3/07/514(0)
- EU/3/07/515(0)
- EU/3/07/516(0)
- EU/3/07/517(0)
- EU/3/07/518(0)
- EU/3/07/519(0)
- EU/3/07/520(0)
- EU/3/07/521(0)
- EU/3/07/522(0)
- EU/3/07/523(0)
- EU/3/07/524(0)
- EU/3/07/525(0)
- EU/3/07/526(0)
- EU/3/08/527(0)
- EU/3/08/528(0)
- EU/3/08/529(0)
- EU/3/08/530(0)
- EU/3/08/531(0)
- EU/3/08/532(0)
- EU/3/08/533(0)
- EU/3/08/534(0)
- EU/3/08/535(0)
- EU/3/08/536(0)
- EU/3/08/537(0)
- EU/3/08/538(0)
- EU/3/08/539(0)
- EU/3/08/540(0)
- EU/3/08/541(0)
- EU/3/08/542(0)
- EU/3/08/543(0)
- EU/3/08/544(0)
- EU/3/08/545(0)
- EU/3/08/546(0)
- EU/3/08/547(0)
- EU/3/08/548(0)
- EU/3/08/549(0)
- EU/3/08/550(0)
- EU/3/08/551(0)
- EU/3/08/552(0)
- EU/3/08/553(0)
- EU/3/08/554(0)
- EU/3/08/555(0)
- EU/3/08/556(0)
- EU/3/08/557(0)
- EU/3/08/558(0)
- EU/3/08/559(0)
- EU/3/08/560(0)
- EU/3/08/561(0)
- EU/3/08/562(0)
- EU/3/08/563(0)
- EU/3/08/564(0)
- EU/3/08/565(0)
- EU/3/08/566(0)
- EU/3/08/567(0)
- EU/3/08/568(0)
- EU/3/08/569(0)
- EU/3/08/570(0)
- EU/3/08/571(0)
- EU/3/08/572(0)
- EU/3/08/573(0)
- EU/3/08/574(0)
- EU/3/08/575(0)
- EU/3/08/576(0)
- EU/3/08/577(0)
- EU/3/08/578(0)
- EU/3/08/579(0)
- EU/3/08/580(0)
- EU/3/08/581(0)
- EU/3/08/582(0)
- EU/3/08/583(0)
- EU/3/08/584(0)
- EU/3/08/585(0)
- EU/3/08/586(0)
- EU/3/08/587(0)
- EU/3/08/588(0)
- EU/3/08/589(0)
- EU/3/08/590(0)
- EU/3/08/591(0)
- EU/3/08/592(0)
- EU/3/08/593(0)
- EU/3/08/594(0)
- EU/3/08/595(0)
- EU/3/08/596(0)
- EU/3/08/597(0)
- EU/3/08/598(0)
- EU/3/08/599(0)
- EU/3/08/600(0)
- EU/3/08/601(0)
- EU/3/08/602(0)
- EU/3/08/603(0)
- EU/3/08/604(0)
- EU/3/08/605(0)
- EU/3/08/606(0)
- EU/3/08/607(0)
- EU/3/08/608(0)
- EU/3/08/609(0)
- EU/3/08/610(0)
- EU/3/08/611(0)
- EU/3/08/612(0)
- EU/3/09/613(0)
- EU/3/09/614(0)
- EU/3/09/615(0)
- EU/3/09/616(0)
- EU/3/09/617(0)
- EU/3/09/618(0)
- EU/3/09/619(0)
- EU/3/09/620(0)
- EU/3/09/621(0)
- EU/3/09/622(0)
- EU/3/09/623(0)
- EU/3/09/624(0)
- EU/3/09/625(0)
- EU/3/09/626(0)
- EU/3/09/627(0)
- EU/3/09/628(0)
- EU/3/09/629(0)
- EU/3/09/630(0)
- EU/3/09/631(0)
- EU/3/09/632(0)
- EU/3/09/633(0)
- EU/3/09/634(0)
- EU/3/09/635(0)
- EU/3/09/636(0)
- EU/3/09/637(0)
- EU/3/09/638(0)
- EU/3/09/639(0)
- EU/3/09/640(0)
- EU/3/09/641(0)
- EU/3/09/642(0)
- EU/3/09/643(0)
- EU/3/09/644(0)
- EU/3/09/645(0)
- EU/3/09/646(0)
- EU/3/09/647(0)
- EU/3/09/648(0)
- EU/3/09/649(0)
- EU/3/09/650(0)
- EU/3/09/651(0)
- EU/3/09/652(0)
- EU/3/09/653(0)
- EU/3/09/654(0)
- EU/3/09/655(0)
- EU/3/09/656(0)
- EU/3/09/657(0)
- EU/3/09/658(0)
- EU/3/09/659(0)
- EU/3/09/660(0)
- EU/3/09/661(0)
- EU/3/09/662(0)
- EU/3/09/663(0)
- EU/3/09/664(0)
- EU/3/09/665(0)
- EU/3/09/666(0)
- EU/3/09/667(0)
- EU/3/09/668(0)
- EU/3/09/669(0)
- EU/3/09/670(0)
- EU/3/09/671(0)
- EU/3/09/672(0)
- EU/3/09/673(0)
- EU/3/09/674(0)
- EU/3/09/675(0)
- EU/3/09/676(0)
- EU/3/09/677(0)
- EU/3/09/678(0)
- EU/3/09/679(0)
- EU/3/09/680(0)
- EU/3/09/681(0)
- EU/3/09/682(0)
- EU/3/09/683(0)
- EU/3/09/684(0)
- EU/3/09/685(0)
- EU/3/09/686(0)
- EU/3/09/687(0)
- EU/3/09/688(0)
- EU/3/09/689(0)
- EU/3/09/690(0)
- EU/3/09/691(0)
- EU/3/09/692(0)
- EU/3/09/693(0)
- EU/3/09/694(0)
- EU/3/09/695(0)
- EU/3/09/696(0)
- EU/3/09/697(0)
- EU/3/09/698(0)
- EU/3/09/699(0)
- EU/3/09/700(0)
- EU/3/09/701(0)
- EU/3/09/702(0)
- EU/3/09/703(0)
- EU/3/09/704(0)
- EU/3/09/705(0)
- EU/3/09/706(0)
- EU/3/09/707(0)
- EU/3/09/708(0)
- EU/3/09/709(0)
- EU/3/09/710(0)
- EU/3/09/711(0)
- EU/3/09/712(0)
- EU/3/09/713(0)
- EU/3/09/714(0)
- EU/3/09/715(0)
- EU/3/09/716(0)
- EU/3/09/717(0)
- EU/3/09/718(0)
- EU/3/09/719(0)
- EU/3/09/720(0)
- EU/3/09/721(0)
- EU/3/09/722(0)
- EU/3/09/723(0)
- EU/3/09/724(0)
- EU/3/09/725(0)
- EU/3/10/726(0)
- EU/3/10/727(0)
- EU/3/10/728(0)
- EU/3/10/729(0)
- EU/3/10/730(0)
- EU/3/10/731(0)
- EU/3/10/732(0)
- EU/3/10/733(0)
- EU/3/10/734(0)
- EU/3/10/735(0)
- EU/3/10/736(0)
- EU/3/10/737(0)
- EU/3/10/738(0)
- EU/3/10/739(0)
- EU/3/10/740(0)
- EU/3/10/741(0)
- EU/3/10/742(0)
- EU/3/10/743(0)
- EU/3/10/744(0)
- EU/3/10/745(0)
- EU/3/10/746(0)
- EU/3/10/747(0)
- EU/3/10/748(0)
- EU/3/10/749(0)
- EU/3/10/750(0)
- EU/3/10/751(0)
- EU/3/10/752(0)
- EU/3/10/753(0)
- EU/3/10/754(0)
- EU/3/10/755(0)
- EU/3/10/756(0)
- EU/3/10/757(0)
- EU/3/10/758(0)
- EU/3/10/759(0)
- EU/3/10/760(0)
- EU/3/10/761(0)
- EU/3/10/762(0)
- EU/3/10/763(0)
- EU/3/10/764(0)
- EU/3/10/765(0)
- EU/3/10/766(0)
- EU/3/10/767(0)
- EU/3/10/768(0)
- EU/3/10/769(0)
- EU/3/10/770(0)
- EU/3/10/771(0)
- EU/3/10/772(0)
- EU/3/10/773(0)
- EU/3/10/774(0)
- EU/3/10/775(0)
- EU/3/10/776(0)
- EU/3/10/777(0)
- EU/3/10/778(0)
- EU/3/10/779(0)
- EU/3/10/780(0)
- EU/3/10/781(0)
- EU/3/10/782(0)
- EU/3/10/783(0)
- EU/3/10/784(0)
- EU/3/10/785(0)
- EU/3/10/786(0)
- EU/3/10/787(0)
- EU/3/10/788(0)
- EU/3/10/789(0)
- EU/3/10/790(0)
- EU/3/10/791(0)
- EU/3/10/792(0)
- EU/3/10/793(0)
- EU/3/10/794(0)
- EU/3/10/795(0)
- EU/3/10/796(0)
- EU/3/10/797(0)
- EU/3/10/798(0)
- EU/3/10/799(0)
- EU/3/10/802(0)
- EU/3/10/803(0)
- EU/3/10/804(0)
- EU/3/10/805(0)
- EU/3/10/806(0)
- EU/3/10/807(0)
- EU/3/10/808(0)
- EU/3/10/809(0)
- EU/3/10/810(0)
- EU/3/10/811(0)
- EU/3/10/812(0)
- EU/3/10/813(0)
- EU/3/10/814(0)
- EU/3/10/815(0)
- EU/3/10/816(0)
- EU/3/10/817(0)
- EU/3/10/818(0)
- EU/3/10/819(0)
- EU/3/10/820(0)
- EU/3/10/821(0)
- EU/3/10/822(0)
- EU/3/10/823(0)
- EU/3/10/824(0)
- EU/3/10/825(0)
- EU/3/10/826(0)
- EU/3/10/827(0)
- EU/3/10/828(0)
- EU/3/10/829(0)
- EU/3/10/830(0)
- EU/3/10/831(0)
- EU/3/10/832(0)
- EU/3/10/833(0)
- EU/3/10/834(0)
- EU/3/10/835(0)
- EU/3/10/836(0)
- EU/3/10/837(0)
- EU/3/10/838(0)
- EU/3/10/839(0)
- EU/3/10/840(0)
- EU/3/10/841(0)
- EU/3/10/842(0)
- EU/3/10/843(0)
- EU/3/10/844(0)
- EU/3/10/845(0)
- EU/3/10/846(0)
- EU/3/10/847(0)
- EU/3/10/848(0)
- EU/3/11/849(0)
- EU/3/11/850(0)
- EU/3/11/851(0)
- EU/3/11/852(0)
- EU/3/11/853(0)
- EU/3/11/854(0)
- EU/3/11/855(0)
- EU/3/11/856(0)
- EU/3/11/857(0)
- EU/3/11/858(0)
- EU/3/11/859(0)
- EU/3/11/860(0)
- EU/3/11/861(0)
- EU/3/11/862(0)
- EU/3/11/863(0)
- EU/3/11/864(0)
- EU/3/11/865(0)
- EU/3/11/866(0)
- EU/3/11/867(0)
- EU/3/11/868(0)
- EU/3/11/869(0)
- EU/3/11/870(0)
- EU/3/11/871(0)
- EU/3/11/872(0)
- EU/3/11/873(0)
- EU/3/11/874(0)
- EU/3/11/875(0)
- EU/3/11/876(0)
- EU/3/11/877(0)
- EU/3/11/878(0)
- EU/3/11/879(0)
- EU/3/11/880(0)
- EU/3/11/881(0)
- EU/3/11/882(0)
- EU/3/11/883(0)
- EU/3/11/884(0)
- EU/3/11/885(0)
- EU/3/11/886(0)
- EU/3/11/887(0)
- EU/3/11/888(0)
- EU/3/11/889(0)
- EU/3/11/890(0)
- EU/3/11/891(0)
- EU/3/11/892(0)
- EU/3/11/893(0)
- EU/3/11/894(0)
- EU/3/11/895(0)
- EU/3/11/896(0)
- EU/3/11/897(0)
- EU/3/11/898(0)
- EU/3/11/899(0)
- EU/3/11/900(0)
- EU/3/11/901(0)
- EU/3/11/902(0)
- EU/3/11/903(0)
- EU/3/11/904(0)
- EU/3/11/905(0)
- EU/3/11/906(0)
- EU/3/11/907(0)
- EU/3/11/908(0)
- EU/3/11/909(0)
- EU/3/11/910(0)
- EU/3/11/911(0)
- EU/3/11/912(0)
- EU/3/11/913(0)
- EU/3/11/914(0)
- EU/3/11/915(0)
- EU/3/11/916(0)
- EU/3/11/917(0)
- EU/3/11/918(0)
- EU/3/11/919(0)
- EU/3/11/920(0)
- EU/3/11/921(0)
- EU/3/11/922(0)
- EU/3/11/923(0)
- EU/3/11/924(0)
- EU/3/11/925(0)
- EU/3/11/926(0)
- EU/3/11/927(0)
- EU/3/11/928(0)
- EU/3/11/929(0)
- EU/3/11/930(0)
- EU/3/11/931(0)
- EU/3/11/932(0)
- EU/3/11/933(0)
- EU/3/11/934(0)
- EU/3/11/935(0)
- EU/3/11/936(0)
- EU/3/11/937(0)
- EU/3/11/938(0)
- EU/3/11/939(0)
- EU/3/11/940(0)
- EU/3/11/941(0)
- EU/3/11/942(0)
- EU/3/11/943(0)
- EU/3/11/944(0)
- EU/3/11/945(0)
- EU/3/11/946(0)
- EU/3/11/947(0)
- EU/3/11/948(0)
- EU/3/12/949(0)
- EU/3/12/950(0)
- EU/3/12/951(0)
- EU/3/12/952(0)
- EU/3/12/953(0)
- EU/3/12/954(0)
- EU/3/12/955(0)
- EU/3/12/956(0)
- EU/3/12/957(0)
- EU/3/12/958(0)
- EU/3/12/959(0)
- EU/3/12/960(0)
- EU/3/12/961(0)
- EU/3/12/962(0)
- EU/3/12/963(0)
- EU/3/12/964(0)
- EU/3/12/965(0)
- EU/3/12/966(0)
- EU/3/12/967(0)
- EU/3/12/968(0)
- EU/3/12/969(0)
- EU/3/12/970(0)
- EU/3/12/971(0)
- EU/3/12/972(0)
- EU/3/12/973(0)
- EU/3/12/974(0)
- EU/3/12/975(0)
- EU/3/12/976(0)
- EU/3/12/977(0)
- EU/3/12/978(0)
- EU/3/12/979(0)
- EU/3/12/980(0)
- EU/3/12/981(0)
- EU/3/12/982(0)
- EU/3/12/983(0)
- EU/3/12/984(0)
- EU/3/12/985(0)
- EU/3/12/986(0)
- EU/3/12/987(0)
- EU/3/12/988(0)
- EU/3/12/989(0)
- EU/3/12/990(0)
- EU/3/12/991(0)
- EU/3/12/992(0)
- EU/3/12/993(0)
- EU/3/12/994(0)
- EU/3/12/995(0)
- EU/3/12/996(0)
- EU/3/12/997(0)
- EU/3/12/998(0)
- EU/3/12/999(0)
- EU/3/12/1000(0)
- EU/3/12/1001(0)
- EU/3/12/1002(0)
- EU/3/12/1003(0)
- EU/3/12/1004(0)
- EU/3/12/1005(0)
- EU/3/12/1006(0)
- EU/3/12/1007(0)
- EU/3/12/1008(0)
- EU/3/12/1009(0)
- EU/3/12/1010(0)
- EU/3/12/1011(0)
- EU/3/12/1012(0)
- EU/3/12/1013(0)
- EU/3/12/1014(0)
- EU/3/12/1015(0)
- EU/3/12/1016(0)
- EU/3/12/1017(0)
- EU/3/12/1018(0)
- EU/3/12/1019(0)
- EU/3/12/1020(0)
- EU/3/12/1021(0)
- EU/3/12/1022(0)
- EU/3/12/1023(0)
- EU/3/12/1024(0)
- EU/3/12/1025(0)
- EU/3/12/1026(0)
- EU/3/12/1027(0)
- EU/3/12/1028(0)
- EU/3/12/1029(0)
- EU/3/12/1030(0)
- EU/3/12/1031(0)
- EU/3/12/1032(0)
- EU/3/12/1033(0)
- EU/3/12/1034(0)
- EU/3/12/1035(0)
- EU/3/12/1036(0)
- EU/3/12/1037(0)
- EU/3/12/1038(0)
- EU/3/12/1039(0)
- EU/3/12/1040(0)
- EU/3/12/1041(0)
- EU/3/12/1042(0)
- EU/3/12/1043(0)
- EU/3/12/1044(0)
- EU/3/12/1045(0)
- EU/3/12/1046(0)
- EU/3/12/1047(0)
- EU/3/12/1048(0)
- EU/3/12/1049(0)
- EU/3/12/1050(0)
- EU/3/12/1051(0)
- EU/3/12/1052(0)
- EU/3/12/1053(0)
- EU/3/12/1054(0)
- EU/3/12/1055(0)
- EU/3/12/1056(0)
- EU/3/12/1057(0)
- EU/3/12/1058(0)
- EU/3/12/1059(0)
- EU/3/12/1060(0)
- EU/3/12/1061(0)
- EU/3/12/1062(0)
- EU/3/12/1063(0)
- EU/3/12/1064(0)
- EU/3/12/1065(0)
- EU/3/12/1066(0)
- EU/3/12/1067(0)
- EU/3/12/1068(0)
- EU/3/12/1069(0)
- EU/3/12/1070(0)
- EU/3/12/1071(0)
- EU/3/12/1072(0)
- EU/3/12/1073(0)
- EU/3/12/1074(0)
- EU/3/12/1075(0)
- EU/3/12/1076(0)
- EU/3/12/1077(0)
- EU/3/12/1078(0)
- EU/3/12/1079(0)
- EU/3/12/1080(0)
- EU/3/12/1081(0)
- EU/3/12/1082(0)
- EU/3/12/1083(0)
- EU/3/12/1084(0)
- EU/3/12/1085(0)
- EU/3/12/1086(0)
- EU/3/12/1087(0)
- EU/3/12/1088(0)
- EU/3/12/1089(0)
- EU/3/12/1090(0)
- EU/3/12/1091(0)
- EU/3/12/1092(0)
- EU/3/12/1093(0)
- EU/3/12/1094(0)
- EU/3/12/1095(0)
- EU/3/12/1096(0)
- EU/3/12/1097(0)
- EU/3/12/1098(0)
- EU/3/13/1099(0)
- EU/3/13/1100(0)
- EU/3/13/1101(0)
- EU/3/13/1102(0)
- EU/3/13/1103(0)
- EU/3/13/1104(0)
- EU/3/13/1105(0)
- EU/3/13/1106(0)
- EU/3/13/1107(0)
- EU/3/13/1108(0)
- EU/3/13/1109(0)
- EU/3/13/1110(0)
- EU/3/13/1111(0)
- EU/3/13/1112(0)
- EU/3/13/1113(0)
- EU/3/13/1114(0)
- EU/3/13/1115(0)
- EU/3/13/1116(0)
- EU/3/13/1117(0)
- EU/3/13/1118(0)
- EU/3/13/1119(0)
- EU/3/13/1120(0)
- EU/3/13/1121(0)
- EU/3/13/1122(0)
- EU/3/13/1123(0)
- EU/3/13/1124(0)
- EU/3/13/1125(0)
- EU/3/13/1126(0)
- EU/3/13/1127(0)
- EU/3/13/1128(0)
- EU/3/13/1129(0)
- EU/3/13/1130(0)
- EU/3/13/1131(0)
- EU/3/13/1132(0)
- EU/3/13/1133(0)
- EU/3/13/1134(0)
- EU/3/13/1135(0)
- EU/3/13/1136(0)
- EU/3/13/1137(0)
- EU/3/13/1138(0)
- EU/3/13/1139(0)
- EU/3/13/1140(0)
- EU/3/13/1141(0)
- EU/3/13/1142(0)
- EU/3/13/1143(0)
- EU/3/13/1144(0)
- EU/3/13/1145(0)
- EU/3/13/1146(0)
- EU/3/13/1147(0)
- EU/3/13/1148(0)
- EU/3/13/1149(0)
- EU/3/13/1150(0)
- EU/3/13/1151(0)
- EU/3/13/1152(0)
- EU/3/13/1153(0)
- EU/3/13/1154(0)
- EU/3/13/1155(0)
- EU/3/13/1156(0)
- EU/3/13/1157(0)
- EU/3/13/1158(0)
- EU/3/13/1159(0)
- EU/3/13/1160(0)
- EU/3/13/1161(0)
- EU/3/13/1162(0)
- EU/3/13/1163(0)
- EU/3/13/1164(0)
- EU/3/13/1165(0)
- EU/3/13/1166(0)
- EU/3/13/1167(0)
- EU/3/13/1168(0)
- EU/3/13/1169(0)
- EU/3/13/1170(0)
- EU/3/13/1171(0)
- EU/3/13/1172(0)
- EU/3/13/1173(0)
- EU/3/13/1174(0)
- EU/3/13/1175(0)
- EU/3/13/1176(0)
- EU/3/13/1177(0)
- EU/3/13/1178(0)
- EU/3/13/1179(0)
- EU/3/13/1180(0)
- EU/3/13/1181(0)
- EU/3/13/1182(0)
- EU/3/13/1183(0)
- EU/3/13/1184(0)
- EU/3/13/1185(0)
- EU/3/13/1186(0)
- EU/3/13/1187(0)
- EU/3/13/1188(0)
- EU/3/13/1189(0)
- EU/3/13/1190(0)
- EU/3/13/1191(0)
- EU/3/13/1192(0)
- EU/3/13/1193(0)
- EU/3/13/1194(0)
- EU/3/13/1195(0)
- EU/3/13/1196(0)
- EU/3/13/1197(0)
- EU/3/13/1198(0)
- EU/3/13/1199(0)
- EU/3/13/1200(0)
- EU/3/13/1201(0)
- EU/3/13/1202(0)
- EU/3/13/1203(0)
- EU/3/13/1204(0)
- EU/3/13/1205(0)
- EU/3/13/1206(0)
- EU/3/13/1207(0)
- EU/3/13/1208(0)
- EU/3/13/1209(0)
- EU/3/13/1210(0)
- EU/3/13/1211(0)
- EU/3/13/1212(0)
- EU/3/13/1213(0)
- EU/3/13/1214(0)
- EU/3/13/1215(0)
- EU/3/13/1216(0)
- EU/3/13/1217(0)
- EU/3/13/1218(0)
- EU/3/13/1219(0)
- EU/3/13/1220(0)
- EU/3/13/1221(0)
- EU/3/13/1222(0)
- EU/3/13/1223(0)
- EU/3/13/1224(0)
- EU/3/13/1225(0)
- EU/3/13/1226(0)
- EU/3/13/1227(0)
- EU/3/13/1228(0)
- EU/3/13/1229(0)
- EU/3/13/1230(0)
- EU/3/13/1231(0)
- EU/3/13/1232(0)
- EU/3/13/1233(0)
- EU/3/13/1234(0)
- EU/3/14/1235(0)
- EU/3/14/1236(0)
- EU/3/14/1237(0)
- EU/3/14/1238(0)
- EU/3/14/1239(0)
- EU/3/14/1240(0)
- EU/3/14/1241(0)
- EU/3/14/1242(0)
- EU/3/14/1243(0)
- EU/3/14/1244(0)
- EU/3/14/1245(0)
- EU/3/14/1246(0)
- EU/3/14/1247(0)
- EU/3/14/1248(0)
- EU/3/14/1249(0)
- EU/3/14/1250(0)
- EU/3/14/1251(0)
- EU/3/14/1252(0)
- EU/3/14/1253(0)
- EU/3/14/1254(0)
- EU/3/14/1255(0)
- EU/3/14/1256(0)
- EU/3/14/1257(0)
- EU/3/14/1258(0)
- EU/3/14/1259(0)
- EU/3/14/1260(0)
- EU/3/14/1261(0)
- EU/3/14/1262(0)
- EU/3/14/1263(0)
- EU/3/14/1264(0)
- EU/3/14/1265(0)
- EU/3/14/1266(0)
- EU/3/14/1267(0)
- EU/3/14/1268(0)
- EU/3/14/1269(0)
- EU/3/14/1270(0)
- EU/3/14/1271(0)
- EU/3/14/1272(0)
- EU/3/14/1273(0)
- EU/3/14/1274(0)
- EU/3/14/1275(0)
- EU/3/14/1276(0)
- EU/3/14/1277(0)
- EU/3/14/1278(0)
- EU/3/14/1279(0)
- EU/3/14/1280(0)
- EU/3/14/1281(0)
- EU/3/14/1282(0)
- EU/3/14/1283(0)
- EU/3/14/1284(0)
- EU/3/14/1285(0)
- EU/3/14/1286(0)
- EU/3/14/1287(0)
- EU/3/14/1288(0)
- EU/3/14/1289(0)
- EU/3/14/1290(0)
- EU/3/14/1291(0)
- EU/3/14/1292(0)
- EU/3/14/1293(0)
- EU/3/14/1294(0)
- EU/3/14/1295(0)
- EU/3/14/1296(0)
- EU/3/14/1297(0)
- EU/3/14/1298(0)
- EU/3/14/1299(0)
- EU/3/14/1300(0)
- EU/3/14/1301(0)
- EU/3/14/1302(0)
- EU/3/14/1303(0)
- EU/3/14/1304(0)
- EU/3/14/1305(0)
- EU/3/14/1306(0)
- EU/3/14/1307(0)
- EU/3/14/1308(0)
- EU/3/14/1309(0)
- EU/3/14/1310(0)
- EU/3/14/1311(0)
- EU/3/14/1312(0)
- EU/3/14/1313(0)
- EU/3/14/1314(0)
- EU/3/14/1315(0)
- EU/3/14/1316(0)
- EU/3/14/1317(0)
- EU/3/14/1318(0)
- EU/3/14/1319(0)
- EU/3/14/1320(0)
- EU/3/14/1321(0)
- EU/3/14/1322(0)
- EU/3/14/1323(0)
- EU/3/14/1324(0)
- EU/3/14/1325(0)
- EU/3/14/1326(0)
- EU/3/14/1327(0)
- EU/3/14/1328(0)
- EU/3/14/1329(0)
- EU/3/14/1330(0)
- EU/3/14/1331(0)
- EU/3/14/1332(0)
- EU/3/14/1333(0)
- EU/3/14/1334(0)
- EU/3/14/1335(0)
- EU/3/14/1336(0)
- EU/3/14/1337(0)
- EU/3/14/1338(0)
- EU/3/14/1339(0)
- EU/3/14/1340(0)
- EU/3/14/1341(0)
- EU/3/14/1342(0)
- EU/3/14/1343(0)
- EU/3/14/1344(0)
- EU/3/14/1345(0)
- EU/3/14/1346(0)
- EU/3/14/1347(0)
- EU/3/14/1348(0)
- EU/3/14/1349(0)
- EU/3/14/1350(0)
- EU/3/14/1351(0)
- EU/3/14/1352(0)
- EU/3/14/1353(0)
- EU/3/14/1354(0)
- EU/3/14/1355(0)
- EU/3/14/1356(0)
- EU/3/14/1357(0)
- EU/3/14/1358(0)
- EU/3/14/1359(0)
- EU/3/14/1360(0)
- EU/3/14/1361(0)
- EU/3/14/1362(0)
- EU/3/14/1363(0)
- EU/3/14/1364(0)
- EU/3/14/1365(0)
- EU/3/14/1366(0)
- EU/3/14/1367(0)
- EU/3/14/1368(0)
- EU/3/14/1369(0)
- EU/3/14/1370(0)
- EU/3/14/1371(0)
- EU/3/14/1372(0)
- EU/3/14/1373(0)
- EU/3/14/1374(0)
- EU/3/14/1375(0)
- EU/3/14/1376(0)
- EU/3/14/1377(0)
- EU/3/14/1378(0)
- EU/3/14/1379(0)
- EU/3/14/1380(0)
- EU/3/14/1381(0)
- EU/3/14/1382(0)
- EU/3/14/1383(0)
- EU/3/14/1384(0)
- EU/3/14/1385(0)
- EU/3/14/1386(0)
- EU/3/14/1387(0)
- EU/3/14/1388(0)
- EU/3/14/1389(0)
- EU/3/14/1390(0)
- EU/3/14/1391(0)
- EU/3/14/1392(0)
- EU/3/14/1393(0)
- EU/3/14/1394(0)
- EU/3/14/1395(0)
- EU/3/14/1396(0)
- EU/3/14/1397(0)
- EU/3/14/1398(0)
- EU/3/14/1399(0)
- EU/3/14/1400(0)
- EU/3/14/1401(0)
- EU/3/14/1402(0)
- EU/3/14/1403(0)
- EU/3/14/1404(0)
- EU/3/14/1405(0)
- EU/3/14/1406(0)
- EU/3/14/1407(0)
- EU/3/14/1408(0)
- EU/3/14/1409(0)
- EU/3/14/1410(0)
- EU/3/14/1411(0)
- EU/3/14/1412(0)
- EU/3/14/1413(0)
- EU/3/14/1414(0)
- EU/3/14/1415(0)
- EU/3/14/1416(0)
- EU/3/14/1417(0)
- EU/3/14/1418(0)
- EU/3/14/1419(0)
- EU/3/14/1420(0)
- EU/3/14/1421(0)
- EU/3/14/1422(0)
- EU/3/14/1423(0)
- EU/3/14/1424(0)
- EU/3/14/1425(0)
- EU/3/14/1426(0)
- EU/3/14/1427(0)
- EU/3/14/1428(0)
- EU/3/14/1429(0)
- EU/3/14/1430(0)
- EU/3/15/1431(0)
- EU/3/15/1432(0)
- EU/3/15/1433(0)
- EU/3/15/1434(0)
- EU/3/15/1435(0)
- EU/3/15/1436(0)
- EU/3/15/1437(0)
- EU/3/15/1438(0)
- EU/3/15/1439(0)
- EU/3/15/1440(0)
- EU/3/15/1441(0)
- EU/3/15/1442(0)
- EU/3/15/1443(0)
- EU/3/15/1444(0)
- EU/3/15/1445(0)
- EU/3/15/1446(0)
- EU/3/15/1447(0)
- EU/3/15/1448(0)
- EU/3/15/1449(0)
- EU/3/15/1450(0)
- EU/3/15/1451(0)
- EU/3/15/1452(0)
- EU/3/15/1453(0)
- EU/3/15/1454(0)
- EU/3/15/1455(0)
- EU/3/15/1456(0)
- EU/3/15/1457(0)
- EU/3/15/1458(0)
- EU/3/15/1459(0)
- EU/3/15/1460(0)
- EU/3/15/1461(0)
- EU/3/15/1462(0)
- EU/3/15/1463(0)
- EU/3/15/1464(0)
- EU/3/15/1465(0)
- EU/3/15/1466(0)
- EU/3/15/1467(0)
- EU/3/15/1468(0)
- EU/3/15/1469(0)
- EU/3/15/1470(0)
- EU/3/15/1471(0)
- EU/3/15/1472(0)
- EU/3/15/1473(0)
- EU/3/15/1474(0)
- EU/3/15/1475(0)
- EU/3/15/1476(0)
- EU/3/15/1477(0)
- EU/3/15/1478(0)
- EU/3/15/1479(0)
- EU/3/15/1480(0)
- EU/3/15/1481(0)
- EU/3/15/1482(0)
- EU/3/15/1483(0)
- EU/3/15/1484(0)
- EU/3/15/1485(0)
- EU/3/15/1486(0)
- EU/3/15/1487(0)
- EU/3/15/1488(0)
- EU/3/15/1489(0)
- EU/3/15/1490(0)
- EU/3/15/1491(0)
- EU/3/15/1492(0)
- EU/3/15/1493(0)
- EU/3/15/1494(0)
- EU/3/15/1495(0)
- EU/3/15/1496(0)
- EU/3/15/1497(0)
- EU/3/15/1498(0)
- EU/3/15/1499(0)
- EU/3/15/1500(0)
- EU/3/15/1501(0)
- EU/3/15/1502(0)
- EU/3/15/1503(0)
- EU/3/15/1504(0)
- EU/3/15/1505(0)
- EU/3/15/1506(0)
- EU/3/15/1507(0)
- EU/3/15/1508(0)
- EU/3/15/1509(0)
- EU/3/15/1510(0)
- EU/3/15/1511(0)
- EU/3/15/1512(0)
- EU/3/15/1513(0)
- EU/3/15/1514(0)
- EU/3/15/1515(0)
- EU/3/15/1516(0)
- EU/3/15/1517(0)
- EU/3/15/1518(0)
- EU/3/15/1519(0)
- EU/3/15/1520(0)
- EU/3/15/1521(0)
- EU/3/15/1522(0)
- EU/3/15/1523(0)
- EU/3/15/1524(0)
- EU/3/15/1525(0)
- EU/3/15/1526(0)
- EU/3/15/1527(0)
- EU/3/15/1528(0)
- EU/3/15/1529(0)
- EU/3/15/1530(0)
- EU/3/15/1531(0)
- EU/3/15/1532(0)
- EU/3/15/1533(0)
- EU/3/15/1534(0)
- EU/3/15/1535(0)
- EU/3/15/1536(0)
- EU/3/15/1537(0)
- EU/3/15/1538(0)
- EU/3/15/1539(0)
- EU/3/15/1540(0)
- EU/3/15/1541(0)
- EU/3/15/1542(0)
- EU/3/15/1543(0)
- EU/3/15/1544(0)
- EU/3/15/1545(0)
- EU/3/15/1546(0)
- EU/3/15/1547(0)
- EU/3/15/1548(0)
- EU/3/15/1549(0)
- EU/3/15/1550(0)
- EU/3/15/1551(0)
- EU/3/15/1552(0)
- EU/3/15/1553(0)
- EU/3/15/1554(0)
- EU/3/15/1555(0)
- EU/3/15/1556(0)
- EU/3/15/1557(0)
- EU/3/15/1558(0)
- EU/3/15/1559(0)
- EU/3/15/1560(0)
- EU/3/15/1561(0)
- EU/3/15/1562(0)
- EU/3/15/1563(0)
- EU/3/15/1564(0)
- EU/3/15/1565(0)
- EU/3/15/1566(0)
- EU/3/15/1567(0)
- EU/3/15/1568(0)
- EU/3/15/1569(0)
- EU/3/15/1570(0)
- EU/3/15/1571(0)
- EU/3/15/1572(0)
- EU/3/15/1573(0)
- EU/3/15/1574(0)
- EU/3/15/1575(0)
- EU/3/15/1576(0)
- EU/3/15/1577(0)
- EU/3/15/1578(0)
- EU/3/15/1579(0)
- EU/3/15/1580(0)
- EU/3/15/1581(0)
- EU/3/15/1582(0)
- EU/3/15/1583(0)
- EU/3/15/1584(0)
- EU/3/15/1585(0)
- EU/3/15/1586(0)
- EU/3/15/1587(0)
- EU/3/15/1588(0)
- EU/3/15/1589(0)
- EU/3/15/1590(0)
- EU/3/15/1591(0)
- EU/3/15/1592(0)
- EU/3/15/1593(0)
- EU/3/15/1594(0)
- EU/3/15/1595(0)
- EU/3/15/1596(0)
- EU/3/15/1597(0)
- EU/3/15/1598(0)
- EU/3/15/1599(0)
- EU/3/15/1600(0)
- EU/3/15/1601(0)
- EU/3/15/1602(0)
- EU/3/15/1603(0)
- EU/3/15/1604(0)
- EU/3/15/1605(0)
- EU/3/15/1606(0)
- EU/3/15/1607(0)
- EU/3/16/1608(0)
- EU/3/16/1609(0)
- EU/3/16/1610(0)
- EU/3/16/1611(0)
- EU/3/16/1612(0)
- EU/3/16/1613(0)
- EU/3/16/1614(0)
- EU/3/16/1615(0)
- EU/3/16/1616(0)
- EU/3/16/1617(0)
- EU/3/16/1618(0)
- EU/3/16/1619(0)
- EU/3/16/1620(0)
- EU/3/16/1621(0)
- EU/3/16/1622(0)
- EU/3/16/1623(0)
- EU/3/16/1624(0)
- EU/3/16/1625(0)
- EU/3/16/1626(0)
- EU/3/16/1627(0)
- EU/3/16/1628(0)
- EU/3/16/1629(0)
- EU/3/16/1630(0)
- EU/3/16/1631(0)
- EU/3/16/1632(0)
- EU/3/16/1633(0)
- EU/3/16/1634(0)
- EU/3/16/1635(0)
- EU/3/16/1636(0)
- EU/3/16/1637(0)
- EU/3/16/1638(0)
- EU/3/16/1639(0)
- EU/3/16/1640(0)
- EU/3/16/1641(0)
- EU/3/16/1642(0)
- EU/3/16/1643(0)
- EU/3/16/1644(0)
- EU/3/16/1645(0)
- EU/3/16/1646(0)
- EU/3/16/1647(0)
- EU/3/16/1648(0)
- EU/3/16/1649(0)
- EU/3/16/1650(0)
- EU/3/16/1651(0)
- EU/3/16/1652(0)
- EU/3/16/1653(0)
- EU/3/16/1654(0)
- EU/3/16/1655(0)
- EU/3/16/1656(0)
- EU/3/16/1657(0)
- EU/3/16/1658(0)
- EU/3/16/1659(0)
- EU/3/16/1660(0)
- EU/3/16/1661(0)
- EU/3/16/1662(0)
- EU/3/16/1663(0)
- EU/3/16/1664(0)
- EU/3/16/1665(0)
- EU/3/16/1666(0)
- EU/3/16/1667(0)
- EU/3/16/1668(0)
- EU/3/16/1669(0)
- EU/3/16/1670(0)
- EU/3/16/1671(0)
- EU/3/16/1672(0)
- EU/3/16/1673(0)
- EU/3/16/1674(0)
- EU/3/16/1675(0)
- EU/3/16/1676(0)
- EU/3/16/1677(0)
- EU/3/16/1678(0)
- EU/3/16/1679(0)
- EU/3/16/1680(0)
- EU/3/16/1681(0)
- EU/3/16/1682(0)
- EU/3/16/1683(0)
- EU/3/16/1684(0)
- EU/3/16/1685(0)
- EU/3/16/1686(0)
- EU/3/16/1687(0)
- EU/3/16/1688(0)
- EU/3/16/1689(0)
- EU/3/16/1690(0)
- EU/3/16/1691(0)
- EU/3/16/1692(0)
- EU/3/16/1693(0)
- EU/3/16/1694(0)
- EU/3/16/1695(0)
- EU/3/16/1696(0)
- EU/3/16/1697(0)
- EU/3/16/1698(0)
- EU/3/16/1699(0)
- EU/3/16/1700(0)
- EU/3/16/1701(0)
- EU/3/16/1702(0)
- EU/3/16/1703(0)
- EU/3/16/1704(0)
- EU/3/16/1705(0)
- EU/3/16/1706(0)
- EU/3/16/1707(0)
- EU/3/16/1708(0)
- EU/3/16/1709(0)
- EU/3/16/1710(0)
- EU/3/16/1711(0)
- EU/3/16/1712(0)
- EU/3/16/1713(0)
- EU/3/16/1714(0)
- EU/3/16/1715(0)
- EU/3/16/1716(0)
- EU/3/16/1717(0)
- EU/3/16/1718(0)
- EU/3/16/1719(0)
- EU/3/16/1720(0)
- EU/3/16/1721(0)
- EU/3/16/1722(0)
- EU/3/16/1723(0)
- EU/3/16/1724(0)
- EU/3/16/1725(0)
- EU/3/16/1726(0)
- EU/3/16/1727(0)
- EU/3/16/1728(0)
- EU/3/16/1729(0)
- EU/3/16/1730(0)
- EU/3/16/1731(0)
- EU/3/16/1732(0)
- EU/3/16/1733(0)
- EU/3/16/1734(0)
- EU/3/16/1735(0)
- EU/3/16/1736(0)
- EU/3/16/1737(0)
- EU/3/16/1738(0)
- EU/3/16/1739(0)
- EU/3/16/1740(0)
- EU/3/16/1741(0)
- EU/3/16/1742(0)
- EU/3/16/1743(0)
- EU/3/16/1744(0)
- EU/3/16/1745(0)
- EU/3/16/1746(0)
- EU/3/16/1747(0)
- EU/3/16/1748(0)
- EU/3/16/1749(0)
- EU/3/16/1750(0)
- EU/3/16/1751(0)
- EU/3/16/1752(0)
- EU/3/16/1753(0)
- EU/3/16/1754(0)
- EU/3/16/1755(0)
- EU/3/16/1756(0)
- EU/3/16/1757(0)
- EU/3/16/1758(0)
- EU/3/16/1759(0)
- EU/3/16/1760(0)
- EU/3/16/1761(0)
- EU/3/16/1762(0)
- EU/3/16/1763(0)
- EU/3/16/1764(0)
- EU/3/16/1765(0)
- EU/3/16/1766(0)
- EU/3/16/1767(0)
- EU/3/16/1768(0)
- EU/3/16/1769(0)
- EU/3/16/1770(0)
- EU/3/16/1771(0)
- EU/3/16/1772(0)
- EU/3/16/1773(0)
- EU/3/16/1774(0)
- EU/3/16/1775(0)
- EU/3/16/1776(0)
- EU/3/16/1777(0)
- EU/3/16/1778(0)
- EU/3/16/1779(0)
- EU/3/16/1780(0)
- EU/3/16/1781(0)
- EU/3/16/1782(0)
- EU/3/16/1783(0)
- EU/3/16/1784(0)
- EU/3/16/1785(0)
- EU/3/16/1786(0)
- EU/3/16/1787(0)
- EU/3/16/1788(0)
- EU/3/16/1789(0)
- EU/3/16/1790(0)
- EU/3/16/1791(0)
- EU/3/16/1792(0)
- EU/3/16/1793(0)
- EU/3/16/1794(0)
- EU/3/16/1795(0)
- EU/3/16/1796(0)
- EU/3/16/1797(0)
- EU/3/16/1798(0)
- EU/3/16/1799(0)
- EU/3/16/1800(0)
- EU/3/16/1801(0)
- EU/3/16/1802(0)
- EU/3/16/1803(0)
- EU/3/16/1804(0)
- EU/3/16/1805(0)
- EU/3/16/1806(0)
- EU/3/16/1807(0)
- EU/3/16/1808(0)
- EU/3/16/1809(0)
- EU/3/16/1810(0)
- EU/3/16/1811(0)
- EU/3/16/1812(0)
- EU/3/16/1813(0)
- EU/3/16/1814(0)
- EU/3/16/1815(0)
- EU/3/16/1816(0)
- EU/3/16/1817(0)
- EU/3/16/1818(0)
- EU/3/16/1819(0)
- EU/3/16/1820(0)
- EU/3/16/1821(0)
- EU/3/16/1822(0)
- EU/3/16/1823(0)
- EU/3/16/1824(0)
- EU/3/16/1825(0)
- EU/3/16/1826(0)
- EU/3/16/1827(0)
- EU/3/17/1828(0)
- EU/3/17/1829(0)
- EU/3/17/1830(0)
- EU/3/17/1831(0)
- EU/3/17/1832(0)
- EU/3/17/1833(0)
- EU/3/17/1834(0)
- EU/3/17/1835(0)
- EU/3/17/1836(0)
- EU/3/17/1837(0)
- EU/3/17/1838(0)
- EU/3/17/1839(0)
- EU/3/17/1840(0)
- EU/3/17/1841(0)
- EU/3/17/1842(0)
- EU/3/17/1843(0)
- EU/3/17/1844(0)
- EU/3/17/1845(0)
- EU/3/17/1846(0)
- EU/3/17/1847(0)
- EU/3/17/1848(0)
- EU/3/17/1849(0)
- EU/3/17/1850(0)
- EU/3/17/1851(0)
- EU/3/17/1852(0)
- EU/3/17/1853(0)
- EU/3/17/1854(0)
- EU/3/17/1855(0)
- EU/3/17/1856(0)
- EU/3/17/1857(0)
- EU/3/17/1858(0)
- EU/3/17/1859(0)
- EU/3/17/1860(0)
- EU/3/17/1861(0)
- EU/3/17/1862(0)
- EU/3/17/1863(0)
- EU/3/17/1864(0)
- EU/3/17/1865(0)
- EU/3/17/1866(0)
- EU/3/17/1867(0)
- EU/3/17/1868(0)
- EU/3/17/1869(0)
- EU/3/17/1870(0)
- EU/3/17/1871(0)
- EU/3/17/1872(0)
- EU/3/17/1873(0)
- EU/3/17/1874(0)
- EU/3/17/1875(0)
- EU/3/17/1876(0)
- EU/3/17/1877(0)
- EU/3/17/1878(0)
- EU/3/17/1879(0)
- EU/3/17/1880(0)
- EU/3/17/1881(0)
- EU/3/17/1882(0)
- EU/3/17/1883(0)
- EU/3/17/1884(0)
- EU/3/17/1885(0)
- EU/3/17/1886(0)
- EU/3/17/1887(0)
- EU/3/17/1888(0)
- EU/3/17/1889(0)
- EU/3/17/1890(0)
- EU/3/17/1891(0)
- EU/3/17/1892(0)
- EU/3/17/1893(0)
- EU/3/17/1894(0)
- EU/3/17/1895(0)
- EU/3/17/1896(0)
- EU/3/17/1897(0)
- EU/3/17/1898(0)
- EU/3/17/1899(0)
- EU/3/17/1900(0)
- EU/3/17/1901(0)
- EU/3/17/1902(0)
- EU/3/17/1903(0)
- EU/3/17/1904(0)
- EU/3/17/1905(0)
- EU/3/17/1906(0)
- EU/3/17/1907(0)
- EU/3/17/1908(0)
- EU/3/17/1909(0)
- EU/3/17/1910(0)
- EU/3/17/1911(0)
- EU/3/17/1912(0)
- EU/3/17/1913(0)
- EU/3/17/1914(0)
- EU/3/17/1915(0)
- EU/3/17/1916(0)
- EU/3/17/1917(0)
- EU/3/17/1918(0)
- EU/3/17/1919(0)
- EU/3/17/1920(0)
- EU/3/17/1921(0)
- EU/3/17/1922(0)
- EU/3/17/1923(0)
- EU/3/17/1924(0)
- EU/3/17/1925(0)
- EU/3/17/1926(0)
- EU/3/17/1927(0)
- EU/3/17/1928(0)
- EU/3/17/1929(0)
- EU/3/17/1930(0)
- EU/3/17/1931(0)
- EU/3/17/1932(0)
- EU/3/17/1933(0)
- EU/3/17/1934(0)
- EU/3/17/1935(0)
- EU/3/17/1936(0)
- EU/3/17/1937(0)
- EU/3/17/1938(0)
- EU/3/17/1939(0)
- EU/3/17/1940(0)
- EU/3/17/1941(0)
- EU/3/17/1942(0)
- EU/3/17/1943(0)
- EU/3/17/1944(0)
- EU/3/17/1945(0)
- EU/3/17/1946(0)
- EU/3/17/1947(0)
- EU/3/17/1948(0)
- EU/3/17/1949(0)
- EU/3/17/1950(0)
- EU/3/17/1951(0)
- EU/3/17/1952(0)
- EU/3/17/1953(0)
- EU/3/17/1954(0)
- EU/3/17/1955(0)
- EU/3/17/1956(0)
- EU/3/17/1957(0)
- EU/3/17/1958(0)
- EU/3/17/1959(0)
- EU/3/17/1960(0)
- EU/3/17/1961(0)
- EU/3/17/1962(0)
- EU/3/17/1963(0)
- EU/3/17/1964(0)
- EU/3/17/1965(0)
- EU/3/17/1966(0)
- EU/3/17/1967(0)
- EU/3/17/1968(0)
- EU/3/17/1969(0)
- EU/3/17/1970(0)
- EU/3/17/1971(0)
- EU/3/18/1972(0)
- EU/3/18/1973(0)
- EU/3/18/1974(0)
- EU/3/18/1975(0)
- EU/3/18/1976(0)
- EU/3/18/1977(0)
- EU/3/18/1978(0)
- EU/3/18/1979(0)
- EU/3/18/1980(0)
- EU/3/18/1981(0)
- EU/3/18/1982(0)
- EU/3/18/1983(0)
- EU/3/18/1984(0)
- EU/3/18/1985(0)
- EU/3/18/1986(0)
- EU/3/18/1987(0)
- EU/3/18/1988(0)
- EU/3/18/1989(0)
- EU/3/18/1990(0)
- EU/3/18/1991(0)
- EU/3/18/1992(0)
- EU/3/18/1993(0)
- EU/3/18/1994(0)
- EU/3/18/1995(0)
- EU/3/18/1996(0)
- EU/3/18/1997(0)
- EU/3/18/1998(0)
- EU/3/18/1999(0)
- EU/3/18/2000(0)
- EU/3/18/2001(0)
- EU/3/18/2002(0)
- EU/3/18/2003(0)
- EU/3/18/2004(0)
- EU/3/18/2005(0)
- EU/3/18/2006(0)
- EU/3/18/2007(0)
- EU/3/18/2008(0)
- EU/3/18/2009(0)
- EU/3/18/2010(0)
- EU/3/18/2011(0)
- EU/3/18/2012(0)
- EU/3/18/2013(0)
- EU/3/18/2014(0)
- EU/3/18/2015(0)
- EU/3/18/2016(0)
- EU/3/18/2017(0)
- EU/3/18/2018(0)
- EU/3/18/2019(0)
- EU/3/18/2020(0)
- EU/3/18/2021(0)
- EU/3/18/2022(0)
- EU/3/18/2023(0)
- EU/3/18/2024(0)
- EU/3/18/2025(0)
- EU/3/18/2026(0)
- EU/3/18/2027(0)
- EU/3/18/2028(0)
- EU/3/18/2029(0)
- EU/3/18/2030(0)
- EU/3/18/2031(0)
- EU/3/18/2032(0)
- EU/3/18/2033(0)
- EU/3/18/2034(0)
- EU/3/18/2035(0)
- EU/3/18/2036(0)
- EU/3/18/2037(0)
- EU/3/18/2038(0)
- EU/3/18/2039(0)
- EU/3/18/2040(0)
- EU/3/18/2041(0)
- EU/3/18/2042(0)
- EU/3/18/2043(0)
- EU/3/18/2044(0)
- EU/3/18/2045(0)
- EU/3/18/2046(0)
- EU/3/18/2047(0)
- EU/3/18/2048(0)
- EU/3/18/2049(0)
- EU/3/18/2050(0)
- EU/3/18/2051(0)
- EU/3/18/2052(0)
- EU/3/18/2053(0)
- EU/3/18/2054(0)
- EU/3/18/2055(0)
- EU/3/18/2056(0)
- EU/3/18/2057(0)
- EU/3/18/2058(0)
- EU/3/18/2059(0)
- EU/3/18/2060(0)
- EU/3/18/2061(0)
- EU/3/18/2062(0)
- EU/3/18/2063(0)
- EU/3/18/2064(0)
- EU/3/18/2065(0)
- EU/3/18/2066(0)
- EU/3/18/2067(0)
- EU/3/18/2068(0)
- EU/3/18/2069(0)
- EU/3/18/2070(0)
- EU/3/18/2071(0)
- EU/3/18/2072(0)
- EU/3/18/2073(0)
- EU/3/18/2074(0)
- EU/3/18/2075(0)
- EU/3/18/2076(0)
- EU/3/18/2077(0)
- EU/3/18/2078(0)
- EU/3/18/2079(0)
- EU/3/18/2080(0)
- EU/3/18/2081(0)
- EU/3/18/2082(0)
- EU/3/18/2083(0)
- EU/3/18/2084(0)
- EU/3/18/2085(0)
- EU/3/18/2086(0)
- EU/3/18/2087(0)
- EU/3/18/2088(0)
- EU/3/18/2089(0)
- EU/3/18/2090(0)
- EU/3/18/2091(0)
- EU/3/18/2092(0)
- EU/3/18/2093(0)
- EU/3/18/2094(0)
- EU/3/18/2095(0)
- EU/3/18/2096(0)
- EU/3/18/2097(0)
- EU/3/18/2098(0)
- EU/3/18/2099(0)
- EU/3/18/2100(0)
- EU/3/18/2101(0)
- EU/3/18/2102(0)
- EU/3/18/2103(0)
- EU/3/18/2104(0)
- EU/3/18/2105(0)
- EU/3/18/2106(0)
- EU/3/18/2107(0)
- EU/3/18/2108(0)
- EU/3/18/2109(0)
- EU/3/18/2110(0)
- EU/3/18/2111(0)
- EU/3/18/2112(0)
- EU/3/18/2113(0)
- EU/3/18/2114(0)
- EU/3/18/2115(0)
- EU/3/18/2116(0)
- EU/3/18/2117(0)
- EU/3/18/2118(0)
- EU/3/18/2119(0)
- EU/3/18/2120(0)
- EU/3/18/2121(0)
- EU/3/18/2122(0)
- EU/3/18/2123(0)
- EU/3/18/2124(0)
- EU/3/18/2125(0)
- EU/3/18/2126(0)
- EU/3/18/2127(0)
- EU/3/18/2128(0)
- EU/3/18/2129(0)
- EU/3/18/2130(0)
- EU/3/18/2131(0)
- EU/3/18/2132(0)
- EU/3/18/2133(0)
- EU/3/19/2134(0)
- EU/3/19/2135(0)
- EU/3/19/2136(0)
- EU/3/19/2137(0)
- EU/3/19/2138(0)
- EU/3/19/2139(0)
- EU/3/19/2140(0)
- EU/3/19/2141(0)
- EU/3/19/2142(0)
- EU/3/19/2143(0)
- EU/3/19/2144(0)
- EU/3/19/2145(0)
- EU/3/19/2146(0)
- EU/3/19/2147(0)
- EU/3/19/2148(0)
- EU/3/19/2149(0)
- EU/3/19/2150(0)
- EU/3/19/2151(0)
- EU/3/19/2152(0)
- EU/3/19/2153(0)
- EU/3/19/2154(0)
- EU/3/19/2155(0)
- EU/3/19/2156(0)
- EU/3/19/2157(0)
- EU/3/19/2158(0)
- EU/3/19/2159(0)
- EU/3/19/2160(0)
- EU/3/19/2161(0)
- EU/3/19/2162(0)
- EU/3/19/2163(0)
- EU/3/19/2164(0)
- EU/3/19/2165(0)
- EU/3/19/2166(0)
- EU/3/19/2167(0)
- EU/3/19/2168(0)
- EU/3/19/2169(0)
- EU/3/19/2170(0)
- EU/3/19/2171(0)
- EU/3/19/2172(0)
- EU/3/19/2173(0)
- EU/3/19/2174(0)
- EU/3/19/2175(0)
- EU/3/19/2176(0)
- EU/3/19/2177(0)
- EU/3/19/2178(0)
- EU/3/19/2179(0)
- EU/3/19/2180(0)
- EU/3/19/2181(0)
- EU/3/19/2182(0)
- EU/3/19/2183(0)
- EU/3/19/2184(0)
- EU/3/19/2185(0)
- EU/3/19/2186(0)
- EU/3/19/2187(0)
- EU/3/19/2188(0)
- EU/3/19/2189(0)
- EU/3/19/2190(0)
- EU/3/19/2191(0)
- EU/3/19/2192(0)
- EU/3/19/2193(0)
- EU/3/19/2194(0)
- EU/3/19/2195(0)
- EU/3/19/2196(0)
- EU/3/19/2197(0)
- EU/3/19/2198(0)
- EU/3/19/2199(0)
- EU/3/19/2200(0)
- EU/3/19/2201(0)
- EU/3/19/2202(0)
- EU/3/19/2203(0)
- EU/3/19/2204(0)
- EU/3/19/2205(0)
- EU/3/19/2206(0)
- EU/3/19/2207(0)
- EU/3/19/2208(0)
- EU/3/19/2209(0)
- EU/3/19/2210(0)
- EU/3/19/2211(0)
- EU/3/19/2212(0)
- EU/3/19/2213(0)
- EU/3/19/2214(0)
- EU/3/19/2215(0)
- EU/3/19/2216(0)
- EU/3/19/2217(0)
- EU/3/19/2218(0)
- EU/3/19/2219(0)
- EU/3/19/2220(0)
- EU/3/19/2221(0)
- EU/3/19/2222(0)
- EU/3/19/2223(0)
- EU/3/19/2224(0)
- EU/3/19/2225(0)
- EU/3/19/2226(0)
- EU/3/19/2227(0)
- EU/3/19/2228(0)
- EU/3/19/2229(0)
- EU/3/19/2230(0)
- EU/3/19/2231(0)
- EU/3/19/2232(0)
- EU/3/19/2233(0)
- EU/3/19/2234(0)
- EU/3/19/2235(0)
- EU/3/19/2236(0)
- EU/3/19/2237(0)
- EU/3/19/2238(0)
- EU/3/19/2239(0)
- EU/3/19/2240(0)
- EU/3/19/2241(0)
- EU/3/19/2242(0)
- EU/3/19/2243(0)
- EU/3/19/2244(0)
- EU/3/19/2245(0)
- EU/3/19/2246(0)
- EU/3/20/2247(0)
- EU/3/20/2248(0)
- EU/3/20/2249(0)
- EU/3/20/2250(0)
- EU/3/20/2251(0)
- EU/3/20/2252(0)
- EU/3/20/2253(0)
- EU/3/20/2254(0)
- EU/3/20/2255(0)
- EU/3/20/2256(0)
- EU/3/20/2257(0)
- EU/3/20/2258(0)
- EU/3/20/2259(0)
- EU/3/20/2260(0)
- EU/3/20/2261(0)
- EU/3/20/2262(0)
- EU/3/20/2263(0)
- EU/3/20/2264(0)
- EU/3/20/2265(0)
- EU/3/20/2266(0)
- EU/3/20/2267(0)
- EU/3/20/2268(0)
- EU/3/20/2269(0)
- EU/3/20/2270(0)
- EU/3/20/2271(0)
- EU/3/20/2272(0)
- EU/3/20/2273(0)
- EU/3/20/2274(0)
- EU/3/20/2275(0)
- EU/3/20/2276(0)
- EU/3/20/2277(0)
- EU/3/20/2278(0)
- EU/3/20/2279(0)
- EU/3/20/2280(0)
- EU/3/20/2281(0)
- EU/3/20/2282(0)
- EU/3/20/2283(0)
- EU/3/20/2284(0)
- EU/3/20/2285(0)
- EU/3/20/2286(0)
- EU/3/20/2287(0)
- EU/3/20/2288(0)
- EU/3/20/2289(0)
- EU/3/20/2290(0)
- EU/3/20/2291(0)
- EU/3/20/2292(0)
- EU/3/20/2293(0)
- EU/3/20/2294(0)
- EU/3/20/2295(0)
- EU/3/20/2296(0)
- EU/3/20/2297(0)
- EU/3/20/2298(0)
- EU/3/20/2299(0)
- EU/3/20/2300(0)
- EU/3/20/2301(0)
- EU/3/20/2302(0)
- EU/3/20/2303(0)
- EU/3/20/2304(0)
- EU/3/20/2305(0)
- EU/3/20/2306(0)
- EU/3/20/2307(0)
- EU/3/20/2308(0)
- EU/3/20/2309(0)
- EU/3/20/2310(0)
- EU/3/20/2311(0)
- EU/3/20/2312(0)
- EU/3/20/2313(0)
- EU/3/20/2314(0)
- EU/3/20/2315(0)
- EU/3/20/2316(0)
- EU/3/20/2317(0)
- EU/3/20/2318(0)
- EU/3/20/2319(0)
- EU/3/20/2320(0)
- EU/3/20/2321(0)
- EU/3/20/2322(0)
- EU/3/20/2323(0)
- EU/3/20/2324(0)
- EU/3/20/2325(0)
- EU/3/20/2326(0)
- EU/3/20/2327(0)
- EU/3/20/2328(0)
- EU/3/20/2329(0)
- EU/3/20/2330(0)
- EU/3/20/2331(0)
- EU/3/20/2332(0)
- EU/3/20/2333(0)
- EU/3/20/2334(0)
- EU/3/20/2335(0)
- EU/3/20/2336(0)
- EU/3/20/2337(0)
- EU/3/20/2338(0)
- EU/3/20/2339(0)
- EU/3/20/2340(0)
- EU/3/20/2341(0)
- EU/3/20/2342(0)
- EU/3/20/2343(0)
- EU/3/20/2344(0)
- EU/3/20/2345(0)
- EU/3/20/2346(0)
- EU/3/20/2347(0)
- EU/3/20/2348(0)
- EU/3/20/2349(0)
- EU/3/20/2350(0)
- EU/3/20/2351(0)
- EU/3/20/2352(0)
- EU/3/20/2353(0)
- EU/3/20/2354(0)
- EU/3/20/2355(0)
- EU/3/20/2356(0)
- EU/3/20/2357(0)
- EU/3/20/2358(0)
- EU/3/20/2359(0)
- EU/3/20/2360(0)
- EU/3/20/2361(0)
- EU/3/20/2362(0)
- EU/3/20/2363(0)
- EU/3/20/2364(0)
- EU/3/20/2365(0)
- EU/3/20/2366(0)
- EU/3/20/2367(0)
- EU/3/20/2368(0)
- EU/3/20/2369(0)
- EU/3/20/2370(0)
- EU/3/20/2371(0)
- EU/3/20/2372(0)
- EU/3/20/2373(0)
- EU/3/20/2374(0)
- EU/3/20/2375(0)
- EU/3/20/2376(0)
- EU/3/20/2377(0)
- EU/3/20/2378(0)
- EU/3/20/2379(0)
- EU/3/20/2380(0)
- EU/3/20/2381(0)
- EU/3/20/2382(0)
- EU/3/20/2383(0)
- EU/3/20/2384(0)
- EU/3/20/2385(0)
- EU/3/20/2386(0)
- EU/3/20/2387(0)
- EU/3/20/2388(0)
- EU/3/20/2389(0)
- EU/3/20/2390(0)
- EU/3/20/2391(0)
- EU/3/20/2392(0)
- EU/3/20/2393(0)
- EU/3/20/2394(0)
- EU/3/20/2395(0)
- EU/3/20/2396(0)
- EU/3/21/2397(0)
- EU/3/21/2398(0)
- EU/3/21/2399(0)
- EU/3/21/2400(0)
- EU/3/21/2401(0)
- EU/3/21/2402(0)
- EU/3/21/2403(0)
- EU/3/21/2404(0)
- EU/3/21/2405(0)
- EU/3/21/2406(0)
- EU/3/21/2407(0)
- EU/3/21/2408(0)
- EU/3/21/2409(0)
- EU/3/21/2410(0)
- EU/3/21/2411(0)
- EU/3/21/2412(0)
- EU/3/21/2413(0)
- EU/3/21/2414(0)
- EU/3/21/2415(0)
- EU/3/21/2416(0)
- EU/3/21/2417(0)
- EU/3/21/2418(0)
- EU/3/21/2419(0)
- EU/3/21/2420(0)
- EU/3/21/2421(0)
- EU/3/21/2422(0)
- EU/3/21/2423(0)
- EU/3/21/2424(0)
- EU/3/21/2425(0)
- EU/3/21/2426(0)
- EU/3/21/2427(0)
- EU/3/21/2428(0)
- EU/3/21/2429(0)
- EU/3/21/2430(0)
- EU/3/21/2431(0)
- EU/3/21/2432(0)
- EU/3/21/2433(0)
- EU/3/21/2434(0)
- EU/3/21/2435(0)
- EU/3/21/2436(0)
- EU/3/21/2437(0)
- EU/3/21/2438(0)
- EU/3/21/2439(0)
- EU/3/21/2440(0)
- EU/3/21/2441(0)
- EU/3/21/2442(0)
- EU/3/21/2443(0)
- EU/3/21/2444(0)
- EU/3/21/2445(0)
- EU/3/21/2446(0)
- EU/3/21/2447(0)
- EU/3/21/2448(0)
- EU/3/21/2449(0)
- EU/3/21/2450(0)
- EU/3/21/2451(0)
- EU/3/21/2452(0)
- EU/3/21/2453(0)
- EU/3/21/2454(0)
- EU/3/21/2455(0)
- EU/3/21/2456(0)
- EU/3/21/2457(0)
- EU/3/21/2458(0)
- EU/3/21/2459(0)
- EU/3/21/2460(0)
- EU/3/21/2461(0)
- EU/3/21/2462(0)
- EU/3/21/2463(0)
- EU/3/21/2464(0)
- EU/3/21/2465(0)
- EU/3/21/2466(0)
- EU/3/21/2467(0)
- EU/3/21/2468(0)
- EU/3/21/2469(0)
- EU/3/21/2470(0)
- EU/3/21/2471(0)
- EU/3/21/2472(0)
- EU/3/21/2473(0)
- EU/3/21/2474(0)
- EU/3/21/2475(0)
- EU/3/21/2476(0)
- EU/3/21/2477(0)
- EU/3/21/2478(0)
- EU/3/21/2479(0)
- EU/3/21/2480(0)
- EU/3/21/2481(0)
- EU/3/21/2482(0)
- EU/3/21/2483(0)
- EU/3/21/2484(0)
- EU/3/21/2485(0)
- EU/3/21/2486(0)
- EU/3/21/2487(0)
- EU/3/21/2488(0)
- EU/3/21/2489(0)
- EU/3/21/2490(0)
- EU/3/21/2491(0)
- EU/3/21/2492(0)
- EU/3/21/2493(0)
- EU/3/21/2494(0)
- EU/3/21/2495(0)
- EU/3/21/2496(0)
- EU/3/21/2497(0)
- EU/3/21/2498(0)
- EU/3/21/2499(0)
- EU/3/21/2500(0)
- EU/3/21/2501(0)
- EU/3/21/2502(0)
- EU/3/21/2503(0)
- EU/3/21/2504(0)
- EU/3/21/2505(0)
- EU/3/21/2506(0)
- EU/3/21/2507(0)
- EU/3/21/2508(0)
- EU/3/21/2509(0)
- EU/3/21/2510(0)
- EU/3/21/2511(0)
- EU/3/21/2512(0)
- EU/3/21/2513(0)
- EU/3/21/2514(0)
- EU/3/21/2515(0)
- EU/3/21/2516(0)
- EU/3/21/2517(0)
- EU/3/21/2518(0)
- EU/3/21/2519(0)
- EU/3/21/2520(0)
- EU/3/21/2521(0)
- EU/3/21/2522(0)
- EU/3/21/2523(0)
- EU/3/21/2524(0)
- EU/3/21/2525(0)
- EU/3/21/2526(0)
- EU/3/21/2527(0)
- EU/3/21/2528(0)
- EU/3/21/2529(0)
- EU/3/21/2530(0)
- EU/3/21/2531(0)
- EU/3/21/2532(0)
- EU/3/21/2533(0)
- EU/3/21/2534(0)
- EU/3/21/2535(0)
- EU/3/21/2536(0)
- EU/3/21/2537(0)
- EU/3/21/2538(0)
- EU/3/21/2539(0)
- EU/3/21/2540(0)
- EU/3/21/2541(0)
- EU/3/21/2542(0)
- EU/3/21/2543(0)
- EU/3/21/2544(0)
- EU/3/21/2545(0)
- EU/3/21/2546(0)
- EU/3/21/2547(0)
- EU/3/21/2548(0)
- EU/3/21/2549(0)
- EU/3/21/2550(0)
- EU/3/21/2551(0)
- EU/3/21/2552(0)
- EU/3/21/2553(0)
- EU/3/21/2554(0)
- EU/3/21/2555(0)
- EU/3/21/2556(0)
- EU/3/21/2557(0)
- EU/3/21/2558(0)
- EU/3/21/2559(0)
- EU/3/21/2560(0)
- EU/3/21/2561(0)
- EU/3/21/2562(0)
- EU/3/21/2563(0)
- EU/3/21/2564(0)
- EU/3/21/2565(0)
- EU/3/21/2566(0)
- EU/3/21/2567(0)
- EU/3/21/2568(0)
- EU/3/21/2569(0)
- EU/3/21/2570(0)
- EU/3/21/2571(0)
- EU/3/22/2572(0)
- EU/3/22/2573(0)
- EU/3/22/2574(0)
- EU/3/22/2575(0)
- EU/3/22/2576(0)
- EU/3/22/2577(0)
- EU/3/22/2578(0)
- EU/3/22/2579(0)
- EU/3/22/2580(0)
- EU/3/22/2581(0)
- EU/3/22/2582(0)
- EU/3/22/2583(0)
- EU/3/22/2584(0)
- EU/3/22/2585(0)
- EU/3/22/2586(0)
- EU/3/22/2587(0)
- EU/3/22/2588(0)
- EU/3/22/2589(0)
- EU/3/22/2590(0)
- EU/3/22/2591(0)
- EU/3/22/2592(0)
- EU/3/22/2593(0)
- EU/3/22/2594(0)
- EU/3/22/2595(0)
- EU/3/22/2596(0)
- EU/3/22/2597(0)
- EU/3/22/2598(0)
- EU/3/22/2599(0)
- EU/3/22/2600(0)
- EU/3/22/2601(0)
- EU/3/22/2602(0)
- EU/3/22/2603(0)
- EU/3/22/2604(0)
- EU/3/22/2605(0)
- EU/3/22/2606(0)
- EU/3/22/2607(0)
- EU/3/22/2608(0)
- EU/3/22/2609(0)
- EU/3/22/2610(0)
- EU/3/22/2611(0)
- EU/3/22/2612(0)
- EU/3/22/2613(0)
- EU/3/22/2614(0)
- EU/3/22/2615(0)
- EU/3/22/2616(0)
- EU/3/22/2617(0)
- EU/3/22/2618(0)
- EU/3/22/2619(0)
- EU/3/22/2620(0)
- EU/3/22/2621(0)
- EU/3/22/2622(0)
- EU/3/22/2623(0)
- EU/3/22/2624(0)
- EU/3/22/2625(0)
- EU/3/22/2626(0)
- EU/3/22/2627(0)
- EU/3/22/2628(0)
- EU/3/22/2629(0)
- EU/3/22/2630(0)
- EU/3/22/2631(0)
- EU/3/22/2632(0)
- EU/3/22/2633(0)
- EU/3/22/2634(0)
- EU/3/22/2635(0)
- EU/3/22/2636(0)
- EU/3/22/2637(0)
- EU/3/22/2638(0)
- EU/3/22/2639(0)
- EU/3/22/2640(0)
- EU/3/22/2641(0)
- EU/3/22/2642(0)
- EU/3/22/2643(0)
- EU/3/22/2644(0)
- EU/3/22/2645(0)
- EU/3/22/2646(0)
- EU/3/22/2647(0)
- EU/3/22/2648(0)
- EU/3/22/2649(0)
- EU/3/22/2650(0)
- EU/3/22/2651(0)
- EU/3/22/2652(0)
- EU/3/22/2653(0)
- EU/3/22/2654(0)
- EU/3/22/2655(0)
- EU/3/22/2656(0)
- EU/3/22/2657(0)
- EU/3/22/2658(0)
- EU/3/22/2659(0)
- EU/3/22/2660(0)
- EU/3/22/2661(0)
- EU/3/22/2662(0)
- EU/3/22/2663(0)
- EU/3/22/2664(0)
- EU/3/22/2665(0)
- EU/3/22/2666(0)
- EU/3/22/2667(0)
- EU/3/22/2668(0)
- EU/3/22/2669(0)
- EU/3/22/2670(0)
- EU/3/22/2671(0)
- EU/3/22/2672(0)
- EU/3/22/2673(0)
- EU/3/22/2674(0)
- EU/3/22/2675(0)
- EU/3/22/2676(0)
- EU/3/22/2677(0)
- EU/3/22/2678(0)
- EU/3/22/2679(0)
- EU/3/22/2680(0)
- EU/3/22/2681(0)
- EU/3/22/2682(0)
- EU/3/22/2683(0)
- EU/3/22/2684(0)
- EU/3/22/2685(0)
- EU/3/22/2686(0)
- EU/3/22/2687(0)
- EU/3/22/2688(0)
- EU/3/22/2689(0)
- EU/3/22/2690(0)
- EU/3/22/2691(0)
- EU/3/22/2692(0)
- EU/3/22/2693(0)
- EU/3/22/2694(0)
- EU/3/22/2695(0)
- EU/3/22/2696(0)
- EU/3/22/2697(0)
- EU/3/22/2698(0)
- EU/3/22/2699(0)
- EU/3/22/2700(0)
- EU/3/22/2701(0)
- EU/3/22/2702(0)
- EU/3/22/2703(0)
- EU/3/22/2704(0)
- EU/3/22/2705(0)
- EU/3/22/2706(0)
- EU/3/22/2707(0)
- EU/3/22/2708(0)
- EU/3/22/2709(0)
- EU/3/22/2710(0)
- EU/3/22/2711(0)
- EU/3/22/2712(0)
- EU/3/22/2713(0)
- EU/3/22/2714(0)
- EU/3/22/2715(0)
- EU/3/22/2716(0)
- EU/3/22/2717(0)
- EU/3/22/2718(0)
- EU/3/22/2719(0)
- EU/3/22/2720(0)
- EU/3/22/2721(0)
- EU/3/22/2722(0)
- EU/3/22/2723(0)
- EU/3/22/2724(0)
- EU/3/22/2725(0)
- EU/3/22/2726(0)
- EU/3/22/2727(0)
- EU/3/22/2728(0)
- EU/3/22/2729(0)
- EU/3/22/2730(0)
- EU/3/22/2731(0)
- EU/3/22/2732(0)
- EU/3/22/2733(0)
- EU/3/22/2734(0)
- EU/3/22/2735(0)
- EU/3/22/2736(0)
- EU/3/22/2737(0)
- EU/3/22/2738(0)
- EU/3/22/2739(0)
- EU/3/22/2740(0)
- EU/3/22/2741(0)
- EU/3/22/2742(0)
- EU/3/22/2743(0)
- EU/3/22/2744(0)
- EU/3/22/2745(0)
- EU/3/22/2746(0)
- EU/3/22/2747(0)
- EU/3/23/2748(0)
- EU/3/23/2749(0)
- EU/3/23/2750(0)
- EU/3/23/2751(0)
- EU/3/23/2752(0)
- EU/3/23/2753(0)
- EU/3/23/2754(0)
- EU/3/23/2755(0)
- EU/3/23/2756(0)
- EU/3/23/2757(0)
- EU/3/23/2758(0)
- EU/3/23/2759(0)
- EU/3/23/2760(0)
- EU/3/23/2761(0)
- EU/3/23/2762(0)
- EU/3/23/2763(0)
- EU/3/23/2764(0)
- EU/3/23/2765(0)
- EU/3/23/2766(0)
- EU/3/23/2767(0)
- EU/3/23/2768(0)
- EU/3/23/2769(0)
- EU/3/23/2770(0)
- EU/3/23/2771(0)
- EU/3/23/2772(0)
- EU/3/23/2773(0)
- EU/3/23/2774(0)
- EU/3/23/2775(0)
- EU/3/23/2776(0)
- EU/3/23/2777(0)
- EU/3/23/2778(0)
- EU/3/23/2779(0)
- EU/3/23/2780(0)
- EU/3/23/2781(0)
- EU/3/23/2782(0)
- EU/3/23/2783(0)
- EU/3/23/2784(0)
- EU/3/23/2785(0)
- EU/3/23/2786(0)
- EU/3/23/2787(0)
- EU/3/23/2788(0)
- EU/3/23/2789(0)
- EU/3/23/2790(0)
- EU/3/23/2791(0)
- EU/3/23/2792(0)
- EU/3/23/2793(0)
- EU/3/23/2794(0)
- EU/3/23/2795(0)
- EU/3/23/2796(0)
- EU/3/23/2797(0)
- EU/3/23/2798(0)
- EU/3/23/2799(0)
- EU/3/23/2800(0)
- EU/3/23/2801(0)
- EU/3/23/2802(0)
- EU/3/23/2803(0)
- EU/3/23/2804(0)
- EU/3/23/2805(0)
- EU/3/23/2806(0)
- EU/3/23/2807(0)
- EU/3/23/2808(0)
- EU/3/23/2809(0)
- EU/3/23/2810(0)
- EU/3/23/2811(0)
- EU/3/23/2812(0)
- EU/3/23/2813(0)
- EU/3/23/2814(0)
- EU/3/23/2815(0)
- EU/3/23/2816(0)
- EU/3/23/2817(0)
- EU/3/23/2818(0)
- EU/3/23/2819(0)
- EU/3/23/2820(0)
- EU/3/23/2821(0)
- EU/3/23/2822(0)
- EU/3/23/2823(0)
- EU/3/23/2824(0)
- EU/3/23/2825(0)
- EU/3/23/2826(0)
- EU/3/23/2827(0)
- EU/3/23/2828(0)
- EU/3/23/2829(0)
- EU/3/23/2830(0)
- EU/3/23/2831(0)
- EU/3/23/2832(0)
- EU/3/23/2833(0)
- EU/3/23/2834(0)
- EU/3/23/2835(0)
- EU/3/23/2836(0)
- EU/3/23/2837(0)
- EU/3/23/2838(0)
- EU/3/23/2839(0)
- EU/3/23/2840(0)
- EU/3/23/2841(0)
- EU/3/23/2842(0)
- EU/3/23/2843(0)
- EU/3/23/2844(0)
- EU/3/23/2845(0)
- EU/3/23/2846(0)
- EU/3/23/2847(0)
- EU/3/23/2848(0)
- EU/3/23/2849(0)
- EU/3/23/2850(0)
- EU/3/23/2851(0)
- EU/3/23/2852(0)
- EU/3/23/2853(0)
- EU/3/23/2854(0)
- EU/3/23/2855(0)
- EU/3/23/2856(0)
- EU/3/23/2857(0)
- EU/3/23/2858(0)
- EU/3/23/2859(0)
- EU/3/23/2860(0)
- EU/3/23/2861(0)
- EU/3/23/2862(0)
- EU/3/23/2863(0)
- EU/3/23/2864(0)
- EU/3/23/2865(0)
- EU/3/23/2866(0)
- EU/3/23/2867(0)
- EU/3/23/2868(0)
- EU/3/23/2869(0)
- EU/3/23/2870(0)
- EU/3/23/2871(0)
- EU/3/23/2872(0)
- EU/3/23/2873(0)
- EU/3/23/2874(0)
- EU/3/23/2875(0)
- EU/3/23/2876(0)
- EU/3/23/2877(0)
- EU/3/23/2878(0)
- EU/3/23/2879(0)
- EU/3/23/2880(0)
- EU/3/23/2881(0)
- EU/3/23/2882(0)
- EU/3/23/2883(0)
- EU/3/23/2884(0)
- EU/3/23/2885(0)
- EU/3/23/2886(0)
- EU/3/23/2887(0)
- EU/3/23/2888(0)
- EU/3/23/2889(0)
- EU/3/24/2890(0)
- EU/3/24/2891(0)
- EU/3/24/2892(0)
- EU/3/24/2893(0)
- EU/3/24/2894(0)
- EU/3/24/2896(0)
- EU/3/24/2897(0)
- EU/3/24/2898(0)
- EU/3/24/2899(0)
- EU/3/24/2900(0)
- EU/3/24/2901(0)
- EU 28 science medicines health a regulatory system fit for the future(0)
- EU actions to support availability of medicines during COVID19 pandemic update #2(0)
- EU actions to support availability of medicines during COVID19 pandemic update #3(0)
- EU actions to support availability of medicines during COVID19 pandemic update #4(0)
- EU actions to support availability of medicines during COVID19 pandemic update #5(0)
- EU actions to support availability of medicines during COVID19 pandemic update #6(0)
- EU actions to support availability of medicines during COVID19 pandemic update #7(0)
- EU agencies consider phenylbutazone detected in horsemeat of low concern for consumers recommend improved horse traceability and monitoring of veterinary medicinal residues(0)
- EU agencies to advise on risks from phenylbutazone in horsemeat(0)
- EU and Japan improve informationsharing in the area of good manufacturing practice using EudraGMDP database(0)
- EU and Japan reinforce their collaboration on inspections of medicine manufacturers(0)
- EU and Swiss regulators sign confidentiality arrangement(0)
- EU and Switzerland to improve informationsharing on good manufacturing practice through use of the EudraGMDP database(0)
- EU and US reach a milestone in mutual recognition of inspections of medicines manufacturers(0)
- EU authorities agree new measures to support availability of medicines used in the COVID19 pandemic(0)
- EU authorities take further action in ongoing review of sartans Zheijiang Huahai placed under increased supervision Aurobindo Pharma stopped from supplying irbesartan to the EU(0)
- EU Big Data Stakeholder Forum(0)
- EU big data stakeholder virtual forum(0)
- Eucalypti aetheroleum(0)
- Eucalypti folium(0)
- EU Clinical Trials Register goes live(0)
- EU Clinical Trials Register information now available through WHOs International Clinical Trials Registry Platform(0)
- EU Clinical Trials Register recognised as primary registry of WHOs International Clinical Trials Registry Platform(0)
- EU collaboration strengthens safety monitoring of medicines(0)
- EU cooperation on rare diseases honoured with new EU Ombudsman prize(0)
- Eucreas(0)
- EudraGMDP database(0)
- EudraGMP 20 gives public access to information about good manufacturing practice GMP(0)
- EudraVigilance(0)
- EudraVigilance access policy for medicines for veterinary use(0)
- EudraVigilance and Signal Management information day(0)
- EudraVigilance and signal management information day(0)
- EudraVigilance electronic reporting(0)
- EudraVigilance Expert Working Group(0)
- EudraVigilance Gateway(0)
- EudraVigilance how to register(0)
- EudraVigilance Information Day(0)
- EudraVigilance information day(0)
- EudraVigilance security principles and responsibilities(0)
- EudraVigilance signal detection methods help detect drug safety issues earlier(0)
- Eudravigilance stakeholders(0)
- EudraVigilance system overview(0)
- EudraVigilance training and support(0)
- EudraVigilance Training in 2006 A joint initiative of the EMEA with DIA acting as the conference organiser(0)
- EudraVigilance training on electronic reporting of ICSRs in the EEA(0)
- EudraVigilance training on electronic reporting of ICSRs in the European Economic Area(0)
- EudraVigilance training on electronic reporting of individual case safety reports(0)
- EudraVigilance training on electronic reporting of individual case safety reports ICSRs in the European Economic Area Madrid(0)
- EudraVigilance training on electronic reporting of individual case safety reports ICSRs in the European Economic Area Vienna(0)
- EudraVigilance training on electronic reporting of Individual Case Safety Reports in the European Economic Area(0)
- EudraVigilance training on electronic reporting of individual case safety reports in the European Economic Area(0)
- EudraVigilance training on the electronic reporting of individual case safety reports ICSRs in the European Economic Area(0)
- EudraVigilance Veterinary(0)
- EU enlargement(0)
- EU enlargement countries to join EMEA as observers from 1 April 2003(0)
- EU flags are up in EMAs new building in Amsterdam(0)
- Eugenia Cogliandro(0)
- Eugenia Di Meco(0)
- Eugenie van Leeuwen(0)
- Eugenio Aiello(0)
- EU Innovation Network EUIN(0)
- EU Innovation Network workshop with academia(0)
- EU inspection finds Zhejiang Huahai site noncompliant for manufacture of valsartan EMA and national authorities considering impact on other active substances produced at the site(0)
- EU Institutions(0)
- EU medicines agencies reflect on lessons learned from COVID19(0)
- EU Member States(0)
- EU Network Training Centre EU NTC(0)
- EU Ombudsman confirms EMAs correct handling of declared interests(0)
- EU partners(0)
- Euphrasiae herba(0)
- Eurartesim(0)
- EU recommendations for 2017/2018 seasonal flu vaccine composition(0)
- EU recommendations for 2018/2019 seasonal flu vaccine composition(0)
- EU recommendations for 2019/2020 seasonal flu vaccine composition(0)
- EU recommendations for 2020/2021 seasonal flu vaccine composition(0)
- EU recommendations for 2024/2025 seasonal flu vaccine composition(0)
- EU recommendations for 20212022 seasonal flu vaccine composition(0)
- EU recommendations for 20222023 seasonal flu vaccine composition(0)
- EU recommendations for 20232024 seasonal flu vaccine composition(0)
- EU regulators develop recommendations to forecast demand of medicines(0)
- EU regulators fully uphold transparency and independence standards for COVID19 treatments and vaccines(0)
- EU Regulatory Network Challenges and Opportunities for Croatia(0)
- EU report more evidence on link between antibiotic use and antibiotic resistance(0)
- EU report provides basis for effective fight against development of resistant bacteria(0)
- EU requirements for batches with maximum and minimum titre or batch potency for developmental safety and efficacy studies Scientific guideline(0)
- Eurican Herpes 205(0)
- Eurican L4(0)
- Eurifel RCP FeLV(0)
- EuroGen Pharmaceuticals withdraws its application for Orathecin(0)
- Euro Nippon Kayaku GmbH withdraws its marketing authorisation application for Spanidin gusperimus(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products 1617 December 2003(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products 1820 November 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products 2021 January 2004(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products 2024 April 2004(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products 2122 November 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products 2324 March 2004(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products 2325 November 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products 2426 February 2004(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products extraordinary meeting 3 September 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 15 to 17 January 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 15 to 17 October 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 17 and 18 December 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 17 and 18 December 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 17 to 19 September 2002(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 18 to 19 March 2003(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 18 to 20 February 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 19 to 21 February 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 19 to 21 March 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 19 to 21 November 2002(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 20 to 22 May 2003(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 21 to 23 January 2003(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 22 to 24 July 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 23 to 25 April 2002(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 23 to 25 April 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 23 to 25 July 2002(0)
- European Agency for the evaluation of medicinal products Committee for Proprietary Medicinal Products meeting of 24 to 26 June 2003(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 25 to 27 June 2002(0)
- European Agency for the Evaluation of Medicinal Products Committee for Proprietary Medicinal Products Meeting of 28 to 30 May 2002(0)
- European Agency for the Evaluation of Medicinal Products EudraLink Launch meeting 2829 January 2003(0)
- European and international experts discuss the way forward in developing ophthalmology medicines(0)
- European and international experts discuss the way forward in stemcell research and development(0)
- European and US regulators agree on mutual recognition of inspections of medicines manufacturers(0)
- European Antibiotic Awareness Day 18 November 2010(0)
- European Antibiotic Awareness Day 18 November 2011(0)
- European Antibiotic Awareness Day 18 November 2012(0)
- European Antibiotic Awareness Day 2013 Everyone is responsible(0)
- European Antibiotic Awareness Day 2014(0)
- European Antibiotic Awareness Day 2015(0)
- European Antibiotic Awareness Day 2022 Preventing antimicrobial resistance together(0)
- European Antibiotic Awareness Day Fighting the silent pandemic(0)
- European Antibiotic Awareness Day Statement by Guido Rasi Executive Director of the European Medicines Agency(0)
- European Commission/European Medicines Agency US Food and Drug Administration bilateral update(0)
- European Commission closes infringement procedure against Roche(0)
- European Commission conference 50 years of European Union Pharma legislation achievements and future perspectives(0)
- European Commission EMA and FDA agree new priorities to strengthen their collaboration on medicines(0)
- European Commissioner for Health and Food Safety visits EMA(0)
- European Commission European Medicines Agency and World Health Organization step up cooperation to better protect global public health(0)
- European Commission European Medicines Agency China Food and Drugs Administration bilateral and International Summit of Heads of Medicines Regulatory Agencies(0)
- European Commission invites feedback on experience with the Paediatric Regulation(0)
- European Commission launches logo for online pharmacies to protect patients from falsified medicines(0)
- European Commission legalisation of EMEA certificates to end(0)
- European Commission report highlights successes of the first five years of the EU Paediatric Regulation(0)
- European conference on rare diseases and orphan products ECRD 2014(0)
- European countries increase commitment to responsible antibiotic use in animals(0)
- European Directorate for the Quality of Medicines and HealthCare EDQM of the Council of Europe(0)
- European expert group proposes reduction of use in animals of last resort antibiotic colistin to manage risk of resistance(0)
- European experts(0)
- European Health Union EU steps up action to prevent shortages of antibiotics for next winter(0)
- European Immunisation Week Statement of Guido Rasi the Executive Director of the European Medicines Agency EMA(0)
- European Immunization Week 2018 Statement of Guido Rasi Executive Director European Medicines Agency(0)
- European Immunization Week 2019 statement by Executive Director Guido Rasi(0)
- European Immunization Week 2022 Statement by Executive Director Emer Cooke Why vaccines contribute to a Long Life for All(0)
- European Immunization Week 2023 Statement by Executive Director Emer Cooke Routine vaccination matters Every dose counts to stay protected(0)
- European Medicine Agency Committee for Medicinal Products for Human Use 2729 July 2004(0)
- European medicines agencies network strategy(0)
- European Medicines Agency / AnimalhealthEurope veterinary medicines info day 2021(0)
- European Medicines Agency/CHMP Working Group with Healthcare Professionals Organisations HCP WG meeting 16 March 2007(0)
- European Medicines Agency/CHMP Working Group with Healthcare Professionals Organisations HCP WG meeting 17 November 2006(0)
- European Medicines Agency/CHMP Working Group with Healthcare Professionals Organisations HCP WG meeting 24 October 2007(0)
- European Medicines Agency/CHMP Working Group with Healthcare Professionals Organisations HCP WG meeting 30 October 2008(0)
- European Medicines Agency/CHMP Working Group with Healthcare Professionals Organisations HCP WG meeting 31 January 2008(0)
- European Medicines Agency / Committee for Medicinal Products for Human Use Working Group with Healthcare Professionals Organisations HCP WG meeting 29 October 2009(0)
- European Medicines Agency / Emergency Task Force and European Commission workshop on lessons learned on clinical trials in public health emergencies(0)
- European Medicines Agency/European Federation of Pharmaceutical Industries and Associations first workshop on adaptive designs in confirmatory clinical trials(0)
- European Medicines Agency/European Federation of Pharmaceutical Industries and Associations second workshop on adaptive design in confirmatory trials(0)
- European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop Integrating pharmacogenomics early into drug development pharmacokinetics as a working example(0)
- European Medicines Agency/European Federation of Pharmaceutical Industries and Associations workshop on the importance of dose finding and dose selection for the successful development licensing and lifecycle management of medicinal products(0)
- European Medicines Agency / healthtechnologyassessmentbody workshop on parallel scientific advice in drug development(0)
- European Medicines Agency/International Federation for Animal Health Europe info day 2014(0)
- European Medicines Agency/International Federation for Animal HealthEurope info day 2015(0)
- European Medicines Agency/International Federation for Animal Health Europe info day 2016(0)
- European Medicines Agency 2009 midyear report shows it is still on target despite influenza pandemic activities(0)
- European Medicines Agency acts on deficiencies in Roche medicinessafety reporting(0)
- European Medicines Agency addresses development of new antibacterials(0)
- European Medicines Agency adopts a positive opinion for the use of Prozac in the treatment of children and adolescents suffering from depression(0)
- European Medicines Agency adopts first positive opinion for a medicinal product derived from transgenic biotechnology(0)
- European Medicines Agency adopts first positive opinion for a similar biological medicinal product(0)
- European Medicines Agency adopts first positive opinion for mockup pandemic influenza vaccine(0)
- European Medicines Agency adopts positive opinion for avian influenza vaccines for use in birds(0)
- European Medicines Agency advises doctors treating patients with nosocomial pneumonia with Doribax(0)
- European Medicines Agency advises of risk of fever in young children following vaccination with Pandemrix(0)
- European Medicines Agency advises on compassionate use of a new combination therapy for chronic hepatitis C(0)
- European Medicines Agency advises on compassionate use of daclatasvir(0)
- European Medicines Agency advises on compassionate use of sofosbuvir(0)
- European Medicines Agency agrees on action plan following the recall of Viracept and recommends suspension of the marketing authorisation(0)
- European Medicines Agency agrees policy on publication of clinical trial data with more userfriendly amendments(0)
- European Medicines Agency agrees to precautionary recall of Advagraf 05 mg capsule batches(0)
- European Medicines Agency agrees to recall of Vimpat 15mg/ml syrup(0)
- European Medicines Agency alerts EU healthcare professionals after vials of falsified Herceptin identified(0)
- European Medicines Agency and COCIR bilateral meeting(0)
- European Medicines Agency and EUnetHTA agree joint work plan(0)
- European Medicines Agency and EUnetHTA Joint Action start collaboration on European Public Assessment Report EPAR contribution to relative effectiveness assessments(0)
- European Medicines Agency and EUnetHTA review progress of their cooperation(0)
- European Medicines Agency and EuropaBio annual bilateral meeting 2020(0)
- European Medicines Agency and EuropaBio annual bilateral meeting 2022(0)
- European Medicines Agency and European Centre for Disease Prevention and Control agree to enhance cooperation(0)
- European Medicines Agency and European Chemicals Agency enhance cooperation(0)
- European Medicines Agency and European Commission extend confidentiality arrangement with Japan(0)
- European Medicines Agency and European Commission renew confidentiality arrangement with Canada(0)
- European Medicines Agency and European Commission renew confidentiality arrangement with Japan(0)
- European Medicines Agency and European Commission start reflection process on way forward for the Agency and the network(0)
- European Medicines Agency and European Food Safety Authority commit to greater cooperation(0)
- European Medicines Agency and European Healthcare Distribution Association GIRP bilateral meeting(0)
- European Medicines Agency and European Monitoring Centre for Drugs and Drug Addiction EMCDDA sign cooperation agreement(0)
- European Medicines Agency and European Network of Centres for Pharmacoepidemiology & Pharmacovigilance ENCePP launch ENCePP studies(0)
- European Medicines Agency and European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ENCePP launch electronic Register of Studies ERegister(0)
- European Medicines Agency and European Union payer community meeting(0)
- European Medicines Agency and FDA announce launch of generic medicines application inspections initiative(0)
- European Medicines Agency and Food and Drug Administration publish implementation plan for confidentiality arrangement(0)
- European Medicines Agency and German Society for Transfusion Medicine and Immunohaematology to coorganise workshop on advanced therapies(0)
- European Medicines Agency and Heads of Medicines Agencies propose measures to make information in application dossiers more transparent(0)
- European Medicines Agency and its international partners complete successful inspection pilots(0)
- European Medicines Agency and Massachusetts Institute of Technology launch joint project on regulatory science(0)
- European Medicines Agency and Medicines for Europe annual bilateral meeting 2017(0)
- European Medicines Agency and payer community meeting(0)
- European Medicines Agency and Swissmedic agree sharing of information on H1N1 pandemic medicines(0)
- European Medicines Agency and Swissmedic extend confidentiality arrangement(0)
- European Medicines Agency and United States Food and Drug Administration seek potential candidate companies for joint goodmanufacturingpractice inspection programme(0)
- European Medicines Agency and United States Food and Drug Administration to share manufacturing site inspections(0)
- European Medicines Agency and US Food and Drug Administration announce pilot programme for parallel assessment of qualitybydesign applications(0)
- European Medicines Agency and US Food and Drug Administration extend confidentiality arrangements indefinitely(0)
- European Medicines Agency and US Food and Drug Administration FDA launch Good Clinical Practice Initiative(0)
- European Medicines Agency and US Food and Drug Administration receive first parallel qualitybydesign application(0)
- European Medicines Agency and US Food and Drug Administration release first conclusions of parallel assessment of qualitybydesign applications(0)
- European Medicines Agency and US Food and Drug Administration release further guidance on qualitybydesign approach(0)
- European Medicines Agency and US Food and Drug Administration release joint proposal to facilitate clinical investigation of new medicines for Gaucher disease in children(0)
- European Medicines Agency and US Food and Drug Administration set up biosimilar cluster and publish first report on interactions(0)
- European Medicines Agency and US Food and Drug Administration strengthen collaboration in pharmacovigilance area(0)
- European Medicines Agency announces next steps for the maintenance of information on medicines in accordance with mandatory Article 572 requirements(0)
- European Medicines Agency announces plan to publish committee agendas and minutes(0)
- European Medicines Agency announces recall of Viracept(0)
- European Medicines Agency announces regulatory action on COX2 inhibitors(0)
- European Medicines Agency announces start of process improvement of core business procedures(0)
- European Medicines Agency annual report for 2006 shows record numbers of applications assessment times in core processes significantly reduced(0)
- European Medicines Agency applies greater feereduction rates for orphan medicines in 2014(0)
- European Medicines Agency appoints Head of International and European Cooperation(0)
- European Medicines Agency appoints new Head of Unit for Veterinary medicines and inspections(0)
- European medicines agency appoints senior medical officer(0)
- European Medicines Agency approves 100th herbal Community monograph(0)
- European Medicines Agency awards first ENCePP study seal for postmarketing study(0)
- European Medicines Agency begins to publish recommendations based on safety signals(0)
- European Medicines Agency bids farewell to CHMP Pharmacovigilance Working Party(0)
- European Medicines Agency boosts EU transparency with online publication of suspected side effect reports(0)
- European Medicines Agency clarifies opinion on pioglitazone and the risk of bladder cancer(0)
- European Medicines Agency clarifies rules on fees(0)
- European Medicines Agency closed 1 May 2012(0)
- European Medicines Agency closed 1 May 2013(0)
- European Medicines Agency closed 1 May 2014(0)
- European Medicines Agency closed 1 May 2015(0)
- European Medicines Agency closed 1 May 2017(0)
- European Medicines Agency closed 1 May 2018(0)
- European Medicines Agency closed 1 May 2019(0)
- European Medicines Agency closed 2 November 2015(0)
- European Medicines Agency closed 5 June 2017(0)
- European Medicines Agency closed 9 June 2014(0)
- European Medicines Agency closed 9 May 2012(0)
- European Medicines Agency closed 9 May 2014(0)
- European Medicines Agency closed 9 May 2017(0)
- European Medicines Agency closed 9 May 2019(0)
- European Medicines Agency closed 12 November 2012(0)
- European Medicines Agency closed 13 June 2011(0)
- European Medicines Agency closed 13 November 2017(0)
- European Medicines Agency closed 16 May 2016(0)
- European Medicines Agency closed 20 May 2013(0)
- European Medicines Agency closed 21 December 2018 to 2 January 2019(0)
- European Medicines Agency closed 21 December 2019 to 5 January 2020(0)
- European Medicines Agency closed 21 May 2018(0)
- European Medicines Agency closed 22 December 2017 to 2 January 2018(0)
- European Medicines Agency closed 23 December 2011 to 2 January 2012(0)
- European Medicines Agency closed 23 December 2013 to 2 January 2014(0)
- European Medicines Agency closed 23 December 2015 to 3 January 2016(0)
- European Medicines Agency closed 23 December 2016 to 2 January 2017(0)
- European Medicines Agency closed 23 June 2011(0)
- European Medicines Agency closed 24 December 2012 to 2 January 2013(0)
- European Medicines Agency closed 24 December 2014 to 4 January 2015(0)
- European Medicines Agency closed 25 August 2014(0)
- European Medicines Agency closed 25 May 2015(0)
- European Medicines Agency closed 26 April 2015(0)
- European Medicines Agency closed 26 August 2013(0)
- European Medicines Agency closed 27 August 2018(0)
- European Medicines Agency closed 28 March 1 April 2013(0)
- European Medicines Agency closed 28 May 2012(0)
- European Medicines Agency closed 29 August 2011(0)
- European Medicines Agency closed 29 August 2016(0)
- European Medicines Agency closed 29 March to 2 April 2018(0)
- European Medicines Agency closed 31 August 2015(0)
- European Medicines Agency closed 31 October 2014(0)
- European Medicines Agency closed 31 October to 2 November 2011(0)
- European Medicines Agency closed 59 April 2012(0)
- European Medicines Agency closed 59 May 2016(0)
- European Medicines Agency closed 910 May 2013(0)
- European Medicines Agency closed 911 May 2018(0)
- European Medicines Agency closed 1317 April 2017(0)
- European Medicines Agency closed 1415 May 2015(0)
- European Medicines Agency closed 1718 May 2012(0)
- European Medicines Agency closed 1721 April 2014(0)
- European Medicines Agency closed 2428 March 2016(0)
- European Medicines Agency closed 2526 May 2017(0)
- European Medicines Agency closed 2930 May 2014(0)
- European Medicines Agency closed Monday 27 August(0)
- European Medicines Agency closed on 1 November 2013(0)
- European Medicines Agency closes PIM project(0)
- European Medicines AgencyCommittee for Advanced Therapies stakeholders workshop(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 13 June 2004(0)
- European Medicines Agency Committee for Medicinal Products for Human Use14 17 March 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 18 21 April 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 18 21 October 2004(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1013 October 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1114 December 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1215 September 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1315 December 2004(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1316 September 2004(0)
- European Medicines Agency Committee for Medicinal Products for Human Use1417 February 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1417 November 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 1518 November 2004(0)
- European Medicines Agency Committee for Medicinal Products for Human Use1720 January 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2023 February 2006(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2023 June 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2023 March 2006(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2223 June 2004(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2326 January 2006(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2326 May 2005(0)
- European Medicines AgencyCommittee for Medicinal Products for Human Use2427 April 2006(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2427 July 2006(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2427 May 2006(0)
- European Medicines Agency Committee for Medicinal Products for Human Use2528 July 2005(0)
- European Medicines Agency Committee for Medicinal Products for Human Use 2628 June 2006(0)
- European Medicines Agency completes its review of Avastin used in breast cancer(0)
- European Medicines Agency completes review of polymyxinbased medicines(0)
- European Medicines Agency completes review of protaminecontaining medicines(0)
- European Medicines Agency concludes action on COX2 inhibitors(0)
- European Medicines Agency concludes class review of bisphosphonates and atypical fractures(0)
- European Medicines Agency concludes first accelerated assessment for a medicine for human use(0)
- European Medicines Agency concludes new advice to doctors and patients for Champix needed(0)
- European Medicines Agency concludes new advice to doctors and patients for Tysabri natalizumab needed(0)
- European Medicines Agency concludes on use of celecoxib in familial adenomatous polyposis(0)
- European Medicines Agency concludes review of dose recommendations for antituberculosis medicines used in children(0)
- European Medicines Agency concludes review of modifiedrelease oral opioids of the WHO level III scale for the management of pain(0)
- European Medicines Agency concludes review of systemic nimesulidecontaining medicines(0)
- European Medicines Agency concludes that benefitrisk balance of angiotensinIIreceptor antagonists remains positive(0)
- European Medicines Agency concludes that benefitrisk balance of Invirase remains positive(0)
- European Medicines Agency concludes that benefitrisk balance of Revlimid remains positive(0)
- European Medicines Agency conference on Environmental Risk Assessment for Human and Veterinary Medicinal Products(0)
- European Medicines Agency confirms positive benefitrisk balance for Champix(0)
- European Medicines Agency confirms positive benefitrisk balance for rosiglitazone and pioglitazone(0)
- European Medicines Agency confirms positive benefitrisk balance of MabThera(0)
- European Medicines Agency confirms positive benefitrisk balance of orlistatcontaining medicines(0)
- European Medicines Agency confirms positive benefitrisk balance of pholcodinecontaining cough medicines(0)
- European Medicines Agency confirms positive benefitrisk balance of Protelos / Osseor but recommends new contraindications and revised warnings(0)
- European Medicines Agency confirms positive benefitrisk balance of Rotarix(0)
- European Medicines Agency confirms positive benefitrisk balance of RotaTeq(0)
- European Medicines Agency confirms positive benefitrisk balance of somatropincontaining medicines(0)
- European Medicines Agency confirms positive benefitrisk balance of topical formulations of ketoprofen(0)
- European Medicines Agency confirms recommendation to suspend Tredaptive Pelzont and Trevaclyn(0)
- European Medicines Agency confirms that presence of unexpected viral DNA in live attenuated vaccines does not raise public health concerns(0)
- European Medicines Agency consulting on a draft guideline on pharmacovigilance for medicines used in children(0)
- European Medicines Agency consults on updates to its policy on access to EudraVigilance(0)
- European Medicines Agency creates Healthcare Professionals Working Party(0)
- European Medicines Agency discusses pharmacovigilance with French General Inspectorate of Social Affairs(0)
- European Medicines Agency EMA / Drug Information Association DIA signal management information day(0)
- European Medicines Agency EMA / Drug Information Association DIA statistics forum The role of observational data in assessing the benefits and risks of medicines(0)
- European Medicines Agency EMA / European Biopharmaceutical Enterprises EBE fifth annual regulatory conference on optimising the development of advanced therapies to meet patient needs(0)
- European Medicines Agency EMA/European Generic medicines Association joint workshop on the impact of the revised EMA guideline on the pharmacokinetic and clinical evaluation of modifiedrelease dosage forms(0)
- European Medicines Agency EMA/European Society for Medical Oncology ESMO Rare Cancers Europe initiative Joint workshop on chordoma as a model for very rare cancers(0)
- European Medicines Agency EMA / Heads of Medicines Agencies HMA / European Commission EC workshop on electronic product information ePI(0)
- European Medicines Agency EMA and Federation of Veterinarians of Europe FVE info session on the UPD public portal(0)
- European Medicines Agency EMA and Federation of Veterinarians of Europe FVE webinar on data collection on sales and use of antimicrobials(0)
- European Medicines Agency EMA and Federation of Veterinarians of Europe FVE webinar on the Union Product Database website(0)
- European Medicines Agency EMA and MedTech Europe bilateral meeting(0)
- European Medicines Agency EMA Healthcare Professionals Working Party HCPWP meeting(0)
- European Medicines Agency EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP(0)
- European Medicines Agency EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting(0)
- European Medicines Agency EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting Session on communication and information on medicines(0)
- European Medicines Agency EMA Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and with Healthcare Professionals Organisations HCPWP(0)
- European Medicines Agency EMA Human Scientific Committees Working Party with Healthcare Professionals Organisations HCPWP(0)
- European Medicines Agency EMA Joint Patients and Consumers PCWP and Healthcare Professionals HCPWP meeting(0)
- European Medicines Agency EMA Patients and Consumers PCWP and Healthcare Professionals HCPWP Working Parties Joint meeting(0)
- European Medicines Agency EMA Patients and Consumers PCWP and Healthcare Professionals HCPWP Working Parties joint meeting(0)
- European Medicines Agency EMA Patients and ConsumersPCWP and Healthcare Professionals HCPWP Working Parties joint meeting(0)
- European Medicines Agency EMA Patients and Consumers PCWP and Healthcare Professionals HCPWP Working Parties Joint Virtual meeting(0)
- European Medicines Agency EMA Patients and Consumers PCWP and Healthcare Professionals HCPWP Working Parties joint virtual meeting(0)
- European Medicines Agency EMA Patients and Consumers PCWP and Healthcare Professionals HCPWP Working Parties meeting with all eligible organisations(0)
- European Medicines Agency EMA Patients and Consumers PCWP Working Party meeting(0)
- European Medicines Agency EMA Patients and Consumers Working Party meeting PCWP(0)
- European Medicines Agency encourages companies to use electronic application tools(0)
- European Medicines Agency encourages submission of quality typeI variations by end of November(0)
- European Medicines Agency enhances cooperation with EU drugmonitoring agency on psychoactive and abused medicines(0)
- European Medicines Agency establishes Geriatric Expert Group(0)
- European Medicines Agency EudraVigilance and signal management information day(0)
- European Medicines AgencyEuropaBio information day(0)
- European Medicines Agency European Commission and Health Canada agree implementation plan for confidentiality arrangement(0)
- European Medicines AgencyEuropean Federation of Pharmaceutical Industries and Associations modelling and simulation workshop(0)
- European Medicines Agency excellence in pharmacovigilance Clinical trials and postmarketing(0)
- European Medicines Agency excellence in pharmacovigilance Clinical trials and postmarketing training course(0)
- European Medicines Agency explains EU incident management plan for human medicines(0)
- European Medicines Agency explores ways to further involve patients in the benefitrisk assessment of medicines(0)
- European Medicines Agency facilitates interaction between small and mediumsized enterprises SMEs(0)
- European Medicines Agency finalises first set of guidelines on good pharmacovigilance practices(0)
- European Medicines Agency finalises guidance on medicines containing monoclonal antibodies(0)
- European Medicines Agency finalises new procedure for EU pharmaceutical guidelines(0)
- European Medicines Agency finalises review of antidepressants in children and adolescents(0)
- European Medicines Agency finalises review of Baxters dialysis solutions(0)
- European Medicines Agency finalises review of medicines concerned by Roche pharmacovigilance inspection(0)
- European Medicines Agency finalises review of recent published data on cardiovascular safety of NSAIDs(0)
- European Medicines Agency finalises set of guidelines on similar biological medicines and publishes two more new concept papers(0)
- European Medicines Agency finalises update to diabetes guideline(0)
- European Medicines Agency finalises update to guideline on renewals(0)
- European Medicines Agency finalises update to Parkinsons disease guideline(0)
- European Medicines Agency finds no signal for decreased effectiveness of HBVAXPRO and Procomvax(0)
- European Medicines Agency focuses on new legislation in 2012 work programme(0)
- European Medicines Agency focuses on new legislation increased efficiency and transparency in 2013 work programme(0)
- European Medicines Agency formalises interaction with healthcare professionals(0)
- European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories(0)
- European Medicines Agency gives first opinion for a vaccine for use outside the EU(0)
- European Medicines Agency gives first opinion on compassionate use(0)
- European Medicines Agency gives first positive opinion for paediatricuse marketing authorisation(0)
- European Medicines Agency gives first positive opinions on medicinal products for use outside the European Union(0)
- European Medicines Agency gives further interim recommendations on dealing with shortcomings in quality assurance at Ben Venue Laboratories(0)
- European Medicines Agency gives guidance for use of antiviral medicines in case of a novel influenza A/H1N1 pandemic(0)
- European Medicines Agency gives interim recommendations to deal with shortcomings in quality assurance at Ben Venue Laboratories(0)
- European Medicines Agency gives new advice to better manage risk of adverse effects on the heart with Gilenya(0)
- European Medicines Agency gives new temporary treatment recommendations for Fabrazyme(0)
- European Medicines Agency gives recommendations on the use of intravenous nicardipine(0)
- European Medicines Agency gives recommendations to deal with sterility assurance concerns for DepoCyte(0)
- European Medicines Agency gives second positive opinion for a paediatricuse marketing authorisation(0)
- European Medicines Agency hears views from stakeholders on its conflictsofinterests policy for scientific experts(0)
- European Medicines Agency holds first meeting of Committee for Advanced Therapies CAT(0)
- European Medicines Agency holds first meeting of expert group on the replacement reduction and refinement of the use of animals(0)
- European Medicines Agency holds first meeting of the Pharmacovigilance Risk Assessment Committee PRAC(0)
- European Medicines Agency holds first scientific workshop on nanomedicines(0)
- European Medicines Agency holds first stakeholder forum on the implementation of the new pharmacovigilance legislation(0)
- European Medicines Agency holds Focus Group meeting on fibrosarcoma occurring at sites of injection of veterinary medicines in cats(0)
- European Medicines Agency holds international workshop on clinical trials in the context of global medicines development(0)
- European Medicines Agency holds workshop on vaccines development against Schmallenberg virus(0)
- European Medicines Agency hosts first workshop on subgroup analysis(0)
- European Medicines Agency hosts global animal health conference on availability of veterinary medicines(0)
- European Medicines Agency hosts meeting with European Parliament representatives(0)
- European Medicines Agency hosts training course for GCP inspectors from countries across the world(0)
- European Medicines Agency hosts workshop on ethics in paediatric clinical trials(0)
- European Medicines Agency Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting(0)
- European Medicines Agency Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting Information session on biosimilars(0)
- European Medicines Agency Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting Workshop on benefitrisk communication(0)
- European Medicines Agency Human Scientific Committees Working Parties with Patients and Consumers Organisations PCWP and Healthcare Professionals Organisations HCPWP joint meeting workshop on risk minimisation measures(0)
- European Medicines Agency Human Scientific Committees Working Party with Healthcare Professionals Organisations HCPWP(0)
- European Medicines Agency Human Scientific Committees Working Party with Healthcare Professionals Organisations HCPWP meeting(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations meeting(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations meeting with all eligible organisations(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP and Healthcare Professionals Working Party HCPWP joint meeting(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP meeting(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP meeting with all eligible organisations(0)
- European Medicines Agency Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP plenary meeting with all eligible organisations(0)
- European Medicines Agency Implementation Working Group Meeting with European Union pharmaceutical industry associations on the implementation of Article 572 second subparagraph of Regulation EC No 726/2004(0)
- European Medicines Agency implements internal reorganisation(0)
- European Medicines Agency improves package leaflets(0)
- European Medicines Agency increases public information on conflicts of interest of experts and management(0)
- European Medicines Agency increases transparency of ongoing applications for human medicines(0)
- European Medicines Agencyindustry stakeholders platform meeting on paediatric medicines(0)
- European Medicines AgencyIndustry Stakeholders Platform second meeting on paediatric medicines(0)
- European Medicines Agency information day on measuring the impact of pharmacovigilance activities(0)
- European Medicines Agency information day on risk management planning implementation of GVP V and RMP template rev 2 guidance(0)
- European Medicines Agency information day on services and systems in pharmacovigilance preparing for business change(0)
- European Medicines Agency informs doctors and patients about drug interaction between Victrelis and ritonavirboosted HIV protease inhibitors(0)
- European Medicines Agency introduces new faster scientific advice procedure(0)
- European Medicines Agency introduces new fee incentives for SMEs for postauthorisation activities(0)
- European Medicines Agency investigates findings on pancreatic risks with GLP1based therapies for type2 diabetes(0)
- European Medicines Agency invites comments on new overarching guidance for the development of influenza vaccines(0)
- European Medicines Agency invites expressions of interest for ophthalmology workshop(0)
- European Medicines Agency invites feedback on plans to revise existing guidelines on biosimilar medicines and influenza vaccines(0)
- European Medicines Agency invites feedback on the draft guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis(0)
- European Medicines Agency invites registrations for eSubmission Gateway(0)
- European Medicines Agency is consulting on the reflection paper on the use offluoroquinolones in foodproducing animals in the European Union development of resistance and impact on human and animal health(0)
- European Medicines Agency issues guidance on prevention of HIV transmission for public consultation(0)
- European Medicines Agency issues recommendations for 2012/2013 seasonal flu vaccine composition(0)
- European Medicines Agency issues recommendations for 2013/2014 seasonal flu vaccine composition(0)
- European Medicines Agency issues reminder on PIP deferral obligations(0)
- European Medicines Agency issues revised guidance on genotoxicity testing of medicines(0)
- European Medicines Agency issues six key recommendations to tackle the issue of medication errors(0)
- European Medicines Agency IT systems unavailable from 16 April to 17 April 2016(0)
- European Medicines Agency IT systems unavailable from 30 October to 3 November 2015(0)
- European Medicines Agency IT systems unavailable Saturday 29 June(0)
- European Medicines Agency launches adaptive licensing pilot project(0)
- European Medicines Agency launches a new version of EudraCT(0)
- European Medicines Agency launches call for expression of interest from healthcare professional organisations(0)
- European Medicines Agency launches consultation on its position on replacement of animal studies(0)
- European Medicines Agency launches consultation on its Road Map to 2015(0)
- European Medicines Agency launches consultation on pharmacovigilance changes to product information(0)
- European Medicines Agency launches database of clinical studies in children completed before 2007(0)
- European Medicines Agency launches electronic application form pilot(0)
- European Medicines Agency launches EudraGMP the Community GMP database(0)
- European Medicines Agency launches EudraPharm the European medicines database(0)
- European Medicines Agency launches new database of European experts(0)
- European Medicines Agency launches new elearning course for Article 572 requirements on submission of information on medicines(0)
- European Medicines Agency launches new electronic form for submission of plasmamasterfile applications(0)
- European Medicines Agency launches new organisational structure and new visual identity(0)
- European Medicines Agency launches new website(0)
- European Medicines Agency launches public catalogue of medicine shortages assessed by the Agency(0)
- European Medicines Agency launches public consultation on ethical and good clinical practice GCP aspects of clinical trials conducted in third countries(0)
- European Medicines Agency launches public consultation on new transparency policy(0)
- European Medicines Agency launches public consultation on rules of procedures for public hearings(0)
- European Medicines Agency launches strategy on medicines for older people(0)
- European Medicines Agency launches survey to gather feedback on SME programme(0)
- European Medicines Agency listens to stakeholder expectations for pharmacovigilance reforms(0)
- European Medicines Agency looks to stimulate better use of genomic data and biomarkers in medicines development and safety monitoring(0)
- European Medicines Agency maintains fee reduction for SMEs developing orphan medicines in 2013(0)
- European Medicines Agency maintains recommendation not to grant a marketing authorisation for Glybera(0)
- European Medicines Agency makes first recommendation for use of a medicine in children based on PIP data(0)
- European Medicines Agency makes recommendations for safer use of Ritalin and other methylphenidatecontaining medicines in the EU(0)
- European Medicines Agency makes recommendations on the use ofantimicrobials in livestock and companion animals in relation to the risk ofMRSA infection in animals(0)
- European Medicines Agency makes recommendations to minimise risk of nephrogenic systemic fibrosis with gadoliniumcontaining contrast agents(0)
- European Medicines Agency Management Board adopt new policies on handling of conflicts of interests and on access to documents(0)
- European Medicines Agency Management Board elects Kent Woods as new chair(0)
- European Medicines Agency Management Board holds its 50th meetingAnnual report 2005 shows a reduction in applications for new medicines but suggests increases in the years to come(0)
- European Medicines Agency Management Board reelects Pat OMahony as chair(0)
- European Medicines Agency Management Board reelects Sir Kent Woods as chair(0)
- European Medicines Agency Management Board strengthens conflicts of interest policies and transparency(0)
- European Medicines Agency marks 40th anniversary of PIC/S(0)
- European Medicines Agency meetings to be held offsite during 2012 Olympics(0)
- European Medicines Agency meeting with interested parties and research centres on the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance(0)
- European Medicines Agency meets with avian flu vaccine manufacturers(0)
- European Medicines Agency notified of recall of swine fever vaccine Porcilis Pesti by Intervet International BV(0)
- European Medicines Agency now publishing meeting agendas for all scientific committees(0)
- European Medicines Agency on track to meet core business targets for 2012(0)
- European Medicines Agency opens public discussion on need for active control in clinical trials(0)
- European Medicines Agency opens SME Office to support small and mediumsized enterprises(0)
- European Medicines Agency organises SME workshop dedicated to veterinary topics(0)
- European Medicines Agency organising workshop on biosimilars(0)
- European Medicines Agency Paediatric Working Party meets for last time ahead of creation of new Paediatric Committee(0)
- European Medicines Agency Parenteral Drug Association PDA bilateral meeting(0)
- European Medicines Agency passes milestone of 40th positive opinion for an orphan medicinal product(0)
- European Medicines Agency Payer Community meeting(0)
- European Medicines Agency phasing out followup measures(0)
- European Medicines Agency plans public access to information on side effects(0)
- European Medicines Agency prepares for approval of pandemic vaccines(0)
- European Medicines Agency prepares for entry into force of new legislation on paediatric medicines(0)
- European Medicines Agency proposes new faster scientific advice procedure(0)
- European Medicines Agency provides plan to help deal with manufacturingrelated medicine shortages(0)
- European Medicines Agency provides update on electronic submission of information on medicines(0)
- European Medicines Agency public statement on Leflunomide Arava Severe and serious hepatic reactions(0)
- European Medicines Agency Public Statement on the lifting of the suspension of the marketing authorisation for Tolcapone Tasmar(0)
- European Medicines Agency public statement on the suspension of the marketing authorisation for bextra valdecoxib in the European Union(0)
- European Medicines Agency public statement on update on hexavalent vaccines Hexavac and Infanrix Hexa(0)
- European Medicines Agency public statement on valdecoxib and parecoxib sodium Cardiovascular risks in coronary artery bypass graft surgery and serious adverse skin reactions(0)
- European Medicines Agency publishes 2012 annual report(0)
- European Medicines Agency publishes active substance list with lead Member State responsible for safety monitoring(0)
- European Medicines Agency publishes agenda for workshop on conflicts of interests on 6 September 2013(0)
- European Medicines Agency publishes a video explaining the concept of medicines under additional monitoring(0)
- European Medicines Agency publishes booklet on European regulatory system for medicines(0)
- European Medicines Agency publishes CVs of experts involved in its activities(0)
- European Medicines Agency publishes final advice from clinicaltrial advisory groups(0)
- European Medicines Agency publishes final Road map to 2015(0)
- European Medicines Agency publishes first public summaries of Paediatric Committee evaluations of paediatric investigation plans(0)
- European Medicines Agency publishes first report on sales of veterinary antimicrobial agents(0)
- European Medicines Agency publishes first review of orphan designation(0)
- European Medicines Agency publishes first summary of a riskmanagement plan for a medicine(0)
- European Medicines Agency publishes first weekly pandemic pharmacovigilance update(0)
- European Medicines Agency publishes format for submission of information on medicines(0)
- European Medicines Agency publishes guidance on preparing and reviewing summaries of product characteristics(0)
- European Medicines Agency publishes guideline on clinical investigation of medicines for depression(0)
- European Medicines Agency publishes guideline on use of pharmacogenetics in evaluating pharmacokinetics of medicines(0)
- European Medicines Agency publishes initial list of medicines under additional monitoring(0)
- European Medicines Agency publishes interim fee advice for bluetonguevaccine manufacturers(0)
- European Medicines Agency publishes list of EU reference dates and frequency of PSUR submission(0)
- European Medicines Agency publishes list of human medicines under evaluation(0)
- European Medicines Agency publishes minutes of CHMP CVMP and CAT meetings for the first time(0)
- European Medicines Agency publishes new document on regulatory procedural advice on similar biological medicines(0)
- European Medicines Agency publishes new strategy on combating antimicrobial resistance(0)
- European Medicines Agency publishes new versions of controlled vocabularies used to comply with Article 57 2 requirements on submission of information on medicines(0)
- European Medicines Agency publishes policy on changing scope of paediatric investigation plans(0)
- European Medicines Agency publishes policy on communicating safety issues for human medicines(0)
- European Medicines Agency publishes public assessment reports for ancillary medicinal substances included in medical devices(0)
- European Medicines Agency publishes reflection paper on general issues for consideration regarding coated nanomedicines(0)
- European Medicines Agency publishes report on conflicts of interests workshop(0)
- European Medicines Agency publishes report on patient recruitment and geographical location of clinical trials(0)
- European Medicines Agency publishes report on sales of veterinary antimicrobial agents in 2010(0)
- European Medicines Agency publishes report on sales of veterinary antimicrobials in 25 countries in 2011(0)
- European Medicines Agency publishes revised Code of Conduct(0)
- European Medicines Agency publishes second work package of benefitrisk methodology project(0)
- European Medicines Agency publishes sources for orphandisease prevalence data(0)
- European Medicines Agency publishes supplementary information on funding for medicine safety studies through Seventh Framework Programme(0)
- European Medicines Agency publishes updated set of mandatory Article 572 requirements for marketing authorisation holders(0)
- European Medicines Agency publishes video explaining pharmacovigilance legislation(0)
- European Medicines Agency reaffirms efficacy and safety of H1N1 pandemic vaccines(0)
- European Medicines Agency receives 1000th application for a Paediatric Investigation Plan or Waiver(0)
- European Medicines Agency receives first pandemic influenza vaccine application(0)
- European Medicines Agency receives interim decisions of the General Court of the EU on access to clinical and nonclinical information(0)
- European Medicines Agency receives second application for human pandemic influenza vaccine(0)
- European Medicines Agency recommendation on the use of Linoladiol N and Linoladiol HN estradiolcontaining creams(0)
- European Medicines Agency recommendation on use of angiotensinIIreceptor antagonists during pregnancy(0)
- European Medicines Agency recommendations on extension of shelf life for Tamiflu(0)
- European Medicines Agency recommends 14 medicines for use in animals in first half of 2014(0)
- European Medicines Agency recommends 39 medicines for human use for marketing authorisation in first half of 2014(0)
- European Medicines Agency recommends Acomplia must not be used in patients on antidepressants or with major depression(0)
- European Medicines Agency recommends action plan to deal with possible presence of endotoxins in Baxter peritoneal dialysis solutions(0)
- European Medicines Agency recommends additional measures to better manage risk of progressive multifocal leukoencephalopathy PML with Tysabri(0)
- European Medicines Agency recommends approval of 44 medicines for human use and six medicines for veterinary use in first half 2013(0)
- European Medicines Agency recommends approval of a locally targeted treatment for ulcerative colitis and Crohns disease(0)
- European Medicines Agency recommends approval of a new medicine for multidrugresistant tuberculosis(0)
- European Medicines Agency recommends approval of combined advancedtherapy product(0)
- European Medicines Agency recommends approval of Daklinza in chronic hepatitis C(0)
- European Medicines Agency recommends approval of first higherstrength insulin for treatment of patients with diabetes mellitus in the EU(0)
- European Medicines Agency recommends approval of firstinclass treatment for metastatic or unresectable melanoma(0)
- European Medicines Agency recommends approval of first radiopharmaceutical for PET imaging of βamyloid neuritic plaque density(0)
- European Medicines Agency recommends approval of first treatment for pseudobulbar affect(0)
- European Medicines Agency recommends approval of first two monoclonalantibody biosimilars(0)
- European Medicines Agency recommends approval of first vaccine for meningitis B(0)
- European Medicines Agency recommends approval of fourth advanced therapy in Europe(0)
- European Medicines Agency recommends approval of Gazyvaro for chronic lymphocytic leukaemia(0)
- European Medicines Agency recommends approval of medicine for reduction of alcohol consumption(0)
- European Medicines Agency recommends approval of medicine for treatment of vitreomacular traction(0)
- European Medicines Agency recommends approval of Mekinist for the treatment of melanoma(0)
- European Medicines Agency recommends approval of new HIV medicine(0)
- European Medicines Agency recommends approval of new medicine for Cushings disease(0)
- European Medicines Agency recommends approval of pomalidomide for the treatment of multiple myeloma(0)
- European Medicines Agency recommends approval of sofosbuvir for the treatment of chronic hepatitis C(0)
- European Medicines Agency recommends approval of Tafinlar for the treatment of metastatic melanoma(0)
- European Medicines Agency recommends approval of two new treatment options for rare cancers(0)
- European Medicines Agency recommends authorisation of additional vaccine for influenza pandemic H1N1 2009(0)
- European Medicines Agency recommends authorisation of first bluetongue vaccine through centralised procedure(0)
- European Medicines Agency recommends authorisation of first generic medicine for human use(0)
- European Medicines Agency recommends authorisation of first medicine for Castlemans disease(0)
- European Medicines Agency recommends authorisation of first medicine specifically for irritable bowel syndrome(0)
- European Medicines Agency recommends authorisation of novel antibiotic agent(0)
- European Medicines Agency recommends authorisation of novel treatment for type2 diabetes(0)
- European Medicines Agency recommends authorisation of two additional Bluetongue vaccines through the centralised procedure(0)
- European Medicines Agency recommends authorisation of two vaccines for influenza pandemic H1N1 2009(0)
- European Medicines Agency recommends authorisation of Vimpat syrup for patients who cannot swallow tablets(0)
- European Medicines Agency recommends cautious use of protopic/protopy and elidel(0)
- European Medicines Agency recommends changes in the product information for Protelos / Osseor due to the risk of severe hypersensitivity reactions(0)
- European Medicines Agency recommends changes in use of leukaemia medicine Iclusig ponatinib in order to minimise risk of blood clots(0)
- European Medicines Agency recommends changes to the use of metoclopramide(0)
- European Medicines Agency recommends conditional approval of Pixuvri pixantrone for relapsed or refractory aggressive nonHodgkins Bcell lymphoma(0)
- European Medicines Agency recommends continued vaccination with Gardasil(0)
- European Medicines Agency recommends contraindication for Regranex in patients with any preexisting cancer(0)
- European Medicines Agency recommends contraindications for suppositories containing terpenic derivatives(0)
- European Medicines Agency recommends discontinuation of Vimpat 15mg/ml syrup(0)
- European Medicines Agency recommends extending use of Abraxane to include treatment of pancreatic cancer(0)
- European Medicines Agency recommends extending use of Nexavar to include treatment of differentiated thyroid cancer(0)
- European Medicines Agency recommends first gene therapy for approval(0)
- European Medicines Agency recommends firstinclass medicine for treatment of cystic fibrosis(0)
- European Medicines Agency recommends firstinclass medicine for treatment of Duchenne muscular dystrophy(0)
- European Medicines Agency recommends first marketing authorisation for an advanced therapy medicinal product(0)
- European Medicines Agency recommends first medical treatment for patients with short bowel syndrome(0)
- European Medicines Agency recommends first medical treatment for removal of eschar from severe burn wounds(0)
- European Medicines Agency recommends first switch from prescriptiononly to nonprescription for a centrally authorised medicine(0)
- European Medicines Agency recommends first vaccine for footandmouth disease for authorisation at EU level(0)
- European Medicines Agency recommends further measures to minimise risk of blood vessel blockage with Iclusig(0)
- European Medicines Agency recommends interim measures for Pandemrix(0)
- European Medicines Agency recommends lifting of supply and treatment restrictions for Neupro(0)
- European Medicines Agency recommends lifting of suspension for Viracept(0)
- European Medicines Agency recommends lifting of suspension of Octagam(0)
- European Medicines Agency recommends lifting suspension of aprotinin(0)
- European Medicines Agency recommends limiting longterm use of calcitonin medicines(0)
- European Medicines Agency recommends measures to manage contamination of heparincontaining medicines(0)
- European Medicines Agency recommends measures to reduce risk of heart problems with Corlentor/Procoralan ivabradine(0)
- European Medicines Agency recommends new advice on safer use of fibrin sealant spray applications(0)
- European Medicines Agency recommends new advice to surgeons on safer use of fibrin sealants Evicel and Quixil(0)
- European Medicines Agency recommends new antimalaria treatment for use outside the European Union(0)
- European Medicines Agency recommends new contraindication and warning for Rasilez and other aliskiren medicines(0)
- European Medicines Agency recommends new contraindication for Fareston toremifene(0)
- European Medicines Agency recommends new contraindication for Velcade bortezomib(0)
- European Medicines Agency recommends new contraindications and warnings for aliskirencontaining medicines(0)
- European Medicines Agency recommends new contraindications and warnings for pioglitazone to reduce small increased risk of bladder cancer(0)
- European Medicines Agency recommends new malaria treatment for approval(0)
- European Medicines Agency recommends no changes for Tamiflu safety information(0)
- European Medicines Agency recommends precautionary recall of batches of clopidogrelcontaining medicines from Acino Pharma GmbH(0)
- European Medicines Agency recommends precautionary recall of remaining batch of Vistide manufactured at Ben Venue Laboratories(0)
- European Medicines Agency recommends restricted use and strengthened warnings for Ketek(0)
- European Medicines Agency recommends restricted use for piroxicam(0)
- European Medicines Agency recommends restricted use of nimesulidecontaining medicinal products(0)
- European Medicines Agency recommends restricting the use of dexrazoxanecontaining medicines(0)
- European Medicines Agency recommends restricting the use of methysergidecontaining medicines(0)
- European Medicines Agency recommends restricting the use of modafinil(0)
- European Medicines Agency recommends restricting the use of oral moxifloxacincontaining medicines(0)
- European Medicines Agency recommends restricting Trobalt to lastline therapy in partial epilepsy(0)
- European Medicines Agency recommends restricting use of cilostazolcontaining medicines(0)
- European Medicines Agency recommends restricting use of Multaq(0)
- European Medicines Agency recommends restricting use of Pandemrix(0)
- European Medicines Agency recommends restricting use of thiocolchicoside by mouth or injection(0)
- European Medicines Agency recommends restricting use of tolperisone medicines(0)
- European Medicines Agency recommends restricting use of trimetazidinecontaining medicines(0)
- European Medicines Agency recommends revaccination for some travellers in need of protection with Ixiaro(0)
- European Medicines Agency recommends revocation of marketing authorisations for bufexamac(0)
- European Medicines Agency recommends revoking authorisations of Caustinerf arsenical and Yranicid arsenical used in dental procedures(0)
- European Medicines Agency recommends suspension of all buflomedilcontaining medicines(0)
- European Medicines Agency recommends suspension of Avandia Avandamet and Avaglim(0)
- European Medicines Agency recommends suspension of classical swine fever vaccine Porcilis Pesti(0)
- European Medicines Agency recommends suspension of Hexavac(0)
- European Medicines Agency recommends suspension of marketing authorisation for sibutramine(0)
- European Medicines Agency recommends suspension of marketing authorisation of aprotinincontaining medicines for systemic use(0)
- European Medicines Agency recommends suspension of marketing authorisations for carisoprodolcontaining medicinal products(0)
- European Medicines Agency recommends suspension of marketing authorisations for meprobamatecontaining medicines in the European Union(0)
- European Medicines Agency recommends suspension of marketing authorisations for oral ketoconazole(0)
- European Medicines Agency recommends suspension of Octagam in all EU Member States(0)
- European Medicines Agency recommends suspension of oral buflomedilcontaining medicines(0)
- European Medicines Agency recommends suspension of the marketing authorisation of Raptiva efalizumab(0)
- European Medicines Agency recommends that Protelos/Osseor remain available but with further restrictions(0)
- European Medicines Agency recommends the approval of thalidomide for the treatment of rare bonemarrow cancer(0)
- European Medicines Agency recommends the suspension of the marketing authorisation of Ionsys fentanyl hydrochloride(0)
- European Medicines Agency recommends transfer of manufacturing sites for Caelyx and Ceplene(0)
- European Medicines Agency recommends two new treatment options for tuberculosis(0)
- European Medicines Agency recommends update of product information of Tysabri and risk of progressive multifocal leukoencephalopathy PML(0)
- European Medicines Agency recommends use of fibrates as secondline treatment(0)
- European Medicines Agency recommends withdrawal of benfluorex from the market in European Union(0)
- European Medicines Agency recommends withdrawal of dextropropoxyphenecontaining medicines(0)
- European Medicines Agency recommends withdrawal of marketing authorisations for cough medicines containing clobutinol(0)
- European Medicines Agency recommends withdrawal of medicinal products containing veralipride(0)
- European Medicines Agency recommends withdrawal of the marketing authorisations for lumiracoxibcontaining medicines(0)
- European Medicines Agency reiterates PRAC recommendation for Diane 35 and generics(0)
- European Medicines Agency reiterates support for staff member(0)
- European Medicines Agency releases best practice guidance on parallel scientific advice with healthtechnologyassessment bodies(0)
- European Medicines Agency releases for public consultation its draft policy on the publication and access to clinicaltrial data(0)
- European Medicines Agency releases good pharmacovigilance practice modules for public consultation(0)
- European Medicines Agency releases guideline on biosimilar interferon beta for public consultation(0)
- European Medicines Agency releases guideline on medicinal products for the treatment of schizophrenia(0)
- European Medicines Agency releases new additional guidance for development of antibacterials for public consultation(0)
- European Medicines Agency releases qualification opinion on diagnosis of predementia Alzheimers for public consultation(0)
- European Medicines Agency releases revised guidance on advancedtherapy classification for public consultation(0)
- European Medicines Agency releases updated guidance on insomnia treatments(0)
- European Medicines Agency reminds companies about arrangements before and during Olympic Games(0)
- European Medicines Agency reminds companies of timeframe to submit productinformation translations in Croatian(0)
- European Medicines Agency reminds marketingauthorisation holders about requirement for paediatric annual reports(0)
- European Medicines Agency reminds marketingauthorisation holders about revised monographs for human normal immunoglobulin(0)
- European Medicines Agency reorganisation(0)
- European Medicines Agency replies to concerns of Sane Vax Inc(0)
- European Medicines Agency responds to concerns on its publication of clinical trial data policy(0)
- European Medicines Agency responds to criticism of staff member(0)
- European Medicines Agency responds to criticism over clinical trial reporting(0)
- European Medicines Agency responds to criticism over transparency in British Medical Journal(0)
- European Medicines Agency response to European Ombudsman letter regarding proactive publication of and access to clinical trial data(0)
- European Medicines Agency reveals new structure(0)
- European Medicines Agency review concludes positive benefitrisk balance for nonselective NSAIDs(0)
- European Medicines Agency review of pandemic vaccines underway(0)
- European Medicines Agency reviews cardiovascular risk of Multaq(0)
- European Medicines Agency reviews further data on narcolepsy and possible association with Pandemrix(0)
- European Medicines Agency reviews hypothesis on Pandemrix and development of narcolepsy(0)
- European Medicines Agency reviews its operations and prepares for reorganisation in 2013(0)
- European Medicines Agency reviews treatment recommendations for Fabrazyme(0)
- European Medicines Agency revises MUMS / limitedmarket policy(0)
- European Medicines Agency revises three guidance documents to include orphanrelated information(0)
- European Medicines Agency roundtable on the small and mediumsized enterprise SME initiative(0)
- European Medicines Agency roundtable with stakeholders on the 10year anniversary of the Micro small and mediumsizedenterprise SME office(0)
- European Medicines Agencys 2009 budget approved(0)
- European Medicines Agencys 2010 accounts approved by European Parliament(0)
- European Medicines Agencys 2010 annual report shows increase in activities(0)
- European Medicines Agency scientific debate(0)
- European Medicines Agencys Committee on Herbal Medicinal Products elects new chair and vicechair(0)
- European Medicines Agencys conflictsofinterests handling recognised in European Court of Auditors report(0)
- European Medicines Agency seeking participants for website userexperience research(0)
- European Medicines Agency seeking participants for website usertesting research(0)
- European Medicines Agency seeks views on genomic markers in medicine development(0)
- European Medicines Agency seeks views on involvement of children and young people in Paediatric Committee(0)
- European Medicines Agency sees benefits of interaction with Japanese regulators(0)
- European Medicines Agency sees no safety concerns with the Rotarix oral vaccine(0)
- European Medicines Agency sees strong level of applications in 2007(0)
- European Medicines Agency selects first two medicines to be included in its adaptive licensing pilot project(0)
- European Medicines Agency sets out next steps on access to clinicaltrial data(0)
- European Medicines Agency signs lease for new office space(0)
- European Medicines Agencys Implementation Working Group IWG with Pharmaceutical Industry Associations meeting on the implementation of the Article 572 second subparagraph of Regulation EC No 726/2004(0)
- European Medicines Agency simplifies processing of fee reductions for orphan medicines(0)
- European Medicines Agency simplifies SME assignment process(0)
- European Medicines Agencys Management Board backs EMEA conflicts of interests policy(0)
- European Medicines Agencys Management Board elects new chair and vicechair(0)
- European Medicines Agencys Management Board emphasises the importance of the European medicines network(0)
- European Medicines Agencys Management Board endorses revised EMA code of conduct(0)
- European Medicines Agencys Management Board endorses revised policy on handling of declarations of interests(0)
- European Medicines Agencys Management Board endorses the work programme 2010 and strengthens the involvement of patients in the work of the Agency(0)
- European Medicines Agencys Management Board endorses work programme 2011 and launches new Road Map to 2015(0)
- European Medicines Agencys Management Board endorses work programme 2012(0)
- European Medicines Agencys Management Board endorses work programme 2013(0)
- European Medicines Agencys Management Board endorses work programme 2014(0)
- European Medicines Agencys Management Board nominates Guido Rasi as Executive Director(0)
- European Medicines Agencys Management Board nominates Guido Rasi as new Executive Director(0)
- European Medicines Agencys Management Board officially appoints Guido Rasi as new Executive Director(0)
- European Medicines Agencys Management Board supports plan to publish agendas and minutes of all committees(0)
- European Medicines Agencys Management Board welcomes new civilsociety members(0)
- European Medicines Agencys Paediatric Committee Elects its first chairand vicechair(0)
- European Medicines Agencys Scientific Coordination Board starts reflection on best cooperation between scientific committees(0)
- European Medicines Agency stakeholder interaction on the development of medicinal products for chronic noninfectious liver diseases PBC PSC NASH(0)
- European Medicines Agency starts consultation on inventory of needs for childrens medicines(0)
- European Medicines Agency starts infringement procedure to investigate Roches alleged noncompliance with pharmacovigilance obligations(0)
- European Medicines Agency starts new review of cardiovascular risks of nonselective NSAIDs(0)
- European Medicines Agency starts review of aliskirencontaining medicines following termination of ALTITUDE study(0)
- European Medicines Agency starts review of Gilenya fingolimod(0)
- European Medicines Agency starts review of ibuprofen medicines(0)
- European Medicines Agency starts review of orlistatcontaining medicines(0)
- European Medicines Agency starts review of Pandemrix(0)
- European Medicines Agency starts review of Protelos / Osseor(0)
- European Medicines Agency starts review of rosiglitazonecontaining medicines(0)
- European Medicines Agency starts review of Tredaptive Pelzont and Trevaclyn(0)
- European Medicines Agency starts safety review of Diane 35 and its generics(0)
- European Medicines Agency statement following seizure of Avandamet tablets by US Food and Drug Administration(0)
- European Medicines Agency statement following withdrawal of Vioxx rofecoxib(0)
- European Medicines Agency statement on celecoxib(0)
- European Medicines Agency statement on Herceptin(0)
- European Medicines Agency statement on new information on Rotarix oral vaccine(0)
- European Medicines Agency statement on recent publication on cardiac safety of rosiglitazone Avandia Avandamet Avaglim(0)
- European Medicines Agency statement on safety of Tamiflu(0)
- European Medicines Agency statement on the safety of Gardasil(0)
- European Medicines Agency statement on the suspension of use of Bextra(0)
- European Medicines Agency strengthens rules on conflicts of interests of its scientific experts(0)
- European Medicines Agencys workshop on conflicts of interests today(0)
- European Medicines Agencys workshop on nanomedicines(0)
- European Medicines Agencys workshop on stem cellbased therapies(0)
- European Medicines Agency takes a further step in its interaction with patients and consumers(0)
- European Medicines Agency tightens conflictsofinterests policies with immediate effect(0)
- European Medicines Agency to accept biosimilar reference medicines sourced outside European Economic Area(0)
- European Medicines Agency to begin PSUR assessment based on active substances in both centrally and nationally authorised medicines(0)
- European Medicines Agency to continue to involve patients in scientific discussions on human medicines(0)
- European Medicines Agency to grant fee waivers to applications for bluetongue vaccines(0)
- European Medicines Agency to host workshop on regulatory options in the fight against antimicrobial resistance(0)
- European Medicines Agency to publish information on ongoing medicine evaluations(0)
- European Medicines Agency to push ahead in 2014 towards publication and access to clinical trial data(0)
- European Medicines Agency to review COX2 inhibitors(0)
- European Medicines Agency to review the safety of somatropincontaining medicines(0)
- European Medicines Agency to review third and fourthgeneration combined oral contraceptives(0)
- European Medicines Agency update on combined contraceptives(0)
- European Medicines Agency update on Diane 35 and generics used in the treatment of acne(0)
- European Medicines Agency update on nonselective NSAIDs(0)
- European Medicines Agency update on ongoing benefitrisk review of Avandia Avandamet and Avaglim(0)
- European Medicines Agency update on progressive multifocal leukoencephalopathy PML and Tysabri(0)
- European Medicines Agency update on review of nonselective NSAIDs(0)
- European Medicines Agency update on safety of insulin glargine(0)
- European Medicines Agency update on safety of insulin glargine Update(0)
- European Medicines Agency update on stolen vials of Herceptin(0)
- European Medicines Agency update on the safety of Tamiflu(0)
- European Medicines Agency updates guidance for annual strain change of seasonal influenza vaccines(0)
- European Medicines Agency updates guideline on drug interactions(0)
- European Medicines Agency updates guideline on evaluation of anticancer medicines(0)
- European Medicines Agency updates on development of its policy on publication and access to clinicaltrial data(0)
- European Medicines Agency updates on ongoing benefitrisk review of Multaq(0)
- European Medicines Agency updates on ongoing benefitrisk review of pioglitazonecontaining medicines(0)
- European Medicines Agency updates on ongoing safety review of sibutramine Weightloss medicine assessed over cardiovascular concerns(0)
- European Medicines Agency updates on pandemic influenza(0)
- European Medicines Agency updates on pandemic medicines(0)
- European Medicines Agency updates on safety of Pradaxa(0)
- European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy(0)
- European Medicines Agency updates patient and prescriber information for Pradaxa(0)
- European Medicines Agency updates procedural guidance in line with new pharmacovigilance legislation(0)
- European Medicines Agency updates productinformation template to label medicines subject to additional monitoring and encourage adversereaction reporting(0)
- European Medicines Agency updates treatment recommendations because of continued Fabrazyme shortage(0)
- European Medicines Agency urges companies to submit Croatian product information for checking(0)
- European Medicines Agency veterinary medicines info day(0)
- European Medicines Agency veterinary medicines info day 2022(0)
- European Medicines Agency veterinary medicines info day 2023(0)
- European Medicines Agency veterinary medicines innovation day(0)
- European Medicines Agency website intermittently offline 2526 February 2012(0)
- European Medicines Agency website on suspected side effect reports now in all 23 EU official languages(0)
- European Medicines Agency website unavailable 89 September(0)
- European Medicines Agency website unavailable 1900 to 2300 Friday 14 September(0)
- European Medicines Agency website unavailable 2000 to 2400 Friday 27 July(0)
- European Medicines Agency website unavailable 2022 September 2013(0)
- European Medicines Agency website unavailable 2325 September 2011(0)
- European Medicines Agency website unavailable 13001730 on 5 April 2012(0)
- European Medicines Agency website unavailable intermittently Saturday 6 October(0)
- European Medicines Agency website unavailable intermittently Saturday 22 September(0)
- European Medicines Agency website unavailable Saturday 4 May(0)
- European Medicines Agency website unavailable Saturday 6 September 2014(0)
- European Medicines Agency website unavailable Saturday 9 November(0)
- European Medicines Agency website unavailable Saturday 11 June 2016(0)
- European Medicines Agency website unavailable Saturday 13 August(0)
- European Medicines Agency website unavailable Saturday 28 September(0)
- European Medicines Agency website unavailable Sunday 1 December 2013(0)
- European Medicines Agency website updated with new pages(0)
- European Medicines Agency website updated with new searching and sharing features(0)
- European Medicines Agency website upgraded with new features(0)
- European Medicines Agency welcomes 1000th orphan designation(0)
- European Medicines Agency welcomes adoption of new pharmacovigilance legislation by European Parliament(0)
- European Medicines Agency welcomes continuation of DAD study(0)
- European Medicines Agency welcomes new Head of Administration(0)
- European Medicines Agency welcomes new Head of Communication Department and new Head of Human Resources(0)
- European Medicines Agency welcomes new Head of Finance and Budget(0)
- European Medicines Agency welcomes new Head of Information and Communications Technology(0)
- European Medicines Agency welcomes new Head of Infrastructure Services(0)
- European Medicines Agency welcomes new Head of IT Development Department(0)
- European Medicines Agency welcomes new Head of Legal Service(0)
- European Medicines Agency welcomes new Head of Safety and Efficacy of Medicines(0)
- European Medicines Agency welcomes new Head of Veterinary Medicines(0)
- European Medicines Agency welcomes new members and observers to its Management Board(0)
- European Medicines Agency welcomes new rules on falsified medicines(0)
- European Medicines Agency welcomes publication of pharmacovigilance fee Regulation in Official Journal of the EU(0)
- European Medicines Agency welcomes publication of the Clinical Trials Regulation(0)
- European Medicines Agency widens public access to documents(0)
- European Medicines Agency workshop for micro small and mediumsized enterprises SMEs Focus on pharmacovigilance(0)
- European Medicines Agency workshop on antibacterials(0)
- European Medicines Agency workshop on extrapolation across age groups(0)
- European Medicines Agency workshop on firstinman clinical trials draft guideline(0)
- European Medicines Agency workshop on medicines for older people(0)
- European Medicines Agency workshop on methodological aspects of clinical trials for efficacy evaluation in small populations(0)
- European Medicines Agency workshop on modelling in paediatric medicines(0)
- European Medicines Agency workshop on multiplicity issues in clinical trials(0)
- European Medicines Agency workshop on pharmacogenomics from science to clinical care(0)
- European Medicines Agency workshop on slowing the progression of neurodegenerative diseases(0)
- European Medicines Agency workshop on the clinical investigation of medicines for the treatment of Alzheimers disease(0)
- European Medicines Agency workshop on the collaboration with general practitioners / family physicians(0)
- European Medicines Agency workshop on the development of new medicinalproducts for the treatment of ulcerative colitis and Crohns disease(0)
- European Medicines Agency workshop on the investigation of subgroups in confirmatory clinical trials(0)
- European Medicines Agency workshop with European Union pharmaceutical industry associations on the implementation of Article 572 second subparagraph of Regulation EC No 726/2004(0)
- European medicines regulators agree a common Europewide approach for the identification of commercially confidential information and personal data(0)
- European medicines regulatory network(0)
- European medicines regulatory network adopts EU common standard for electronic product information(0)
- European medicines regulatory network fully mobilised in fight against COVID19(0)
- European Network for Paediatric Research at the European Medicines Agency EnprEMA awareness webinar(0)
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance(0)
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ENCePP adopts work plan for 20112012(0)
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ENCePP sees rapid growth(0)
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance plenary meeting(0)
- European Network of Centres for Pharmacoepidemiology and Pharmacovigilance scientific convention European Union EU healthcare databases for panEU pharmacoepidemiological research(0)
- European Network of Centres in Pharmacoepidemiology and Pharmacovigilance ENCePP information day(0)
- European Network of Paediatric Research at EMA elects new chair(0)
- European Network of Paediatric Research at the European Medicines Agency EnprEMA(0)
- European network of paediatric research at the European Medicines Agency EnprEMA Coordinating Group and networks meeting(0)
- European networkof paediatric research at the European Medicines Agency EnprEMA Coordinating Group and networks meeting(0)
- European Network of Paediatric Research at the European Medicines Agency introduced to wider audience(0)
- European network of paediatric researchEuropean Medicines Agency meeting on rare gastrointestinal and liver diseases(0)
- European paediatric research network ready to start(0)
- European public assessment reports background and context(0)
- European public health agencies evaluate antibiotic resistance of Staphylococcus aureus(0)
- European quality leader of the year 2006 award goes to EMEA staff member(0)
- European regulators make recommendations drawing on lessons learnt from presence of nitrosamines in sartan medicines(0)
- European regulators propose way forward for publication of full clinicaltrial data(0)
- European Risk Management Strategy 20082009 work programme adopted(0)
- European Risk Management Strategy Achievements to date(0)
- European Risk Management Strategy ERMS(0)
- European Risk Management Strategy Progress to date and next steps(0)
- European Sales and Use of Antimicrobials for Veterinary Medicine Working Group(0)
- European Shortages Monitoring Platform(0)
- European SME Week 39 October 2011(0)
- European SME Week 2012 1521 October(0)
- European SME Week early dialogue with the EMA is key to success(0)
- European SME Week supporting a major driver of innovation(0)
- European Surveillance of Veterinary Antimicrobial Consumption annual network meeting 2012(0)
- European Surveillance of Veterinary Antimicrobial Consumption ESVAC 2009 2023(0)
- European Surveillance of Veterinary Antimicrobial Consumption ESVAC stakeholders annual meeting 2017(0)
- European Surveillance of Veterinary Antimicrobial Consumption ESVAC workshop on testing of system for data collection by species(0)
- European Surveillance of Veterinary Antimicrobial Consumption stakeholders meeting(0)
- European Surveillance of Veterinary Antimicrobial Consumption stakeholders meeting 2015(0)
- European Technology Platform for Global Animal Health(0)
- European Union agencies(0)
- European Union clinical trials portal and Union database Meeting with stakeholders(0)
- European Union clinical trials portal and Union database meeting with stakeholders(0)
- European Union Committee of Experts on Rare Diseases/European Medicines Agency workshop Towards a publicprivate partnership for registries in the field of rare diseases(0)
- European Union EU International Organisation for Standardisation ISO identification of medical products IDMP task force meeting(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting Apr 2020(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting April 2021(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting Dec 2018(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting Dec 2020(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting January 2023(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting Jul 2020(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting May 2019(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting Oct 2019(0)
- European Union EU International Organisation for Standardization ISO for identification of medical products IDMP/Substance Product Organisation and Referential SPOR data Task Force meeting Sept 2020(0)
- European Union EU International Organization for Standardization ISO identification of medicinal products IDMP Task Force meeting(0)
- European Union European Commission and European Medicines Agency and Food and Drug Administration extend confidentiality arrangements for five more years(0)
- European Union European Commission and European Medicines Agency EMEA and Food and Drug Administration FDA agree on guiding principles for joint FDAEMEA voluntary genomic data submission briefing meetings(0)
- European Union EU workshop on ICH Q3D from a quality perspective(0)
- European Union International Organisation for Standardization ISO identification of medicinal products IDMP task force meeting(0)
- European Union International Organization for Standardization ISO for the identification of medicinal products IDMP / Substance Product Organisation and Referential data SPOR task force meeting(0)
- European Union International Organization for Standardization ISO for the identification of medicinal products IDMP / Substance product organisation and referential data SPOR task force meeting(0)
- European Union International Organization for Standardization ISO for the identification of medicinal products IDMP / substance product organisation and referential data SPOR task force meeting(0)
- European Union International Organization for Standardization ISO for the identification of medicinal products IDMP task force meeting(0)
- European Union monographs and list entries(0)
- European Union regulatory workshop on medication errors(0)
- European UnionUnited States Food and Drug Administration bilateral meeting 12 September 2003(0)
- Europe to boost cooperation with international partners on generics(0)
- Europe to boost international cooperation on generics(0)
- EU scientific opinion how to assess progress on reduction of antimicrobial resistance and antimicrobial consumption(0)
- EUUSA strategic meeting on the future of paediatric medicines(0)
- EUUS collaboration to boost medicine development for rare diseases(0)
- EUUS mutual recognition of inspections of medicines manufacturers enters operational phase(0)
- EUwide recall of Raptiva efalizumab to be initiated(0)
- Eva Angela Segovia(0)
- Eva Bizjak(0)
- Eva Cantarero(0)
- Eva Cermakova(0)
- Eva Chobotová(0)
- Eva Hrušková Reinová(0)
- Eva Jirsová(0)
- Eva Jost(0)
- Eva Kjer Heerfordt(0)
- Eva Kolouchova(0)
- Eva Lander Persson(0)
- Evalon(0)
- Evaluation of advanced therapy medicines(0)
- Evaluation of anticancer medicinal products in man addendum on paediatric oncology Scientific guideline(0)
- Evaluation of anticancer medicinal products in man Scientific guideline(0)
- Evaluation of bovine spongiform encephalopathies BSE risk via the use of materials of bovine origin in or during the manufacture of vaccines Scientific guideline(0)
- Evaluation of bovine spongiform encephalopathies BSErisk via the use of materials of bovine origin in or during the manufacture of vaccines Scientific guideline(0)
- Evaluation of bovine spongiform encephalopathy risk via the use of materials of bovine origin in or during the manufacture of vaccines Scientific guideline(0)
- Evaluation of control samples for nonclinical safety studies checking for contamination with the test substance Scientific guideline(0)
- Evaluation of drugs for the treatment of gastroesophageal reflux disease GORD Scientific guideline(0)
- Evaluation of Drugs in rare diseases Eudipharm & EMEA seminar(0)
- Evaluation of medicinal products for cardiovascular disease prevention Scientific guideline(0)
- Evaluation of medicinal products for the treatment of irritable bowel syndrome Scientific guideline(0)
- Evaluation of Medicinal Products in Children Forth European Course(0)
- Evaluation of medicinal products indicated for treatment of bacterial infections Scientific guideline(0)
- Evaluation of new medicinal products in the treatment of primary osteoporosis Scientific guideline(0)
- Evaluation of the pharmacokinetics of medicinal products in patients with decreased renal function Scientific guideline(0)
- Evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function Scientific guideline(0)
- Eva Mählmann(0)
- Eva Maria Bartos Roth(0)
- EvaMaria Jahn(0)
- Eva María Nadal Elduayen(0)
- Eva Mendes(0)
- Eva M Lindberg(0)
- Evangelia Giannaki(0)
- Eva Niklíčková(0)
- Evanovo(0)
- Evant(0)
- Eva Otterstad(0)
- Eva Pomezna(0)
- Eva Rencova(0)
- Evarrest(0)
- Eva Skovlund(0)
- Eva Thessén(0)
- Eva Vernerova(0)
- Eva Wissgott(0)
- Eva ZojerFuchs(0)
- Evelien De Clercq(0)
- Evelien Minten(0)
- Evelien Wynendaele(0)
- Evelina Shumkova(0)
- Evelin Saar(0)
- Evelyn Bach(0)
- Evelyne Pirotte(0)
- Evelyn Olthof(0)
- Evenity(0)
- Everaldo Attard(0)
- Everolimus productspecific bioequivalence guidance(0)
- Evicel(0)
- Evicto(0)
- Eviplera(0)
- Evista(0)
- Evkeeza(0)
- Evoltra(0)
- Evolution to the next step The needs of the future A joint EMEA/TOPRA Meeting(0)
- Evolution to the next step The needs of the future A joint meeting between The Organisation for Professionals in Regulatory Affairs and the European Medicines Agency(0)
- Evotaz(0)
- Evotopin(0)
- Evra(0)
- Evrenzo(0)
- Evrysdi(0)
- Evusheld(0)
- Evy Reviers(0)
- Ewa Antkiewicz(0)
- Ewa Augustynowicz(0)
- Ewa Balkowiec Iskra(0)
- Ewa Goscinska(0)
- Ewa KleczkowskaPlichta(0)
- Ewa Marta Smidova Molska(0)
- Ewa Pieciukiewicz(0)
- Ewa Szydłak(0)
- Ewa WyszeckaKaszuba(0)
- Ewa Zarzycka(0)
- Exalief(0)
- Exblifep(0)
- Excellence in pharmacovigilance Clinical trials and postmarketing(0)
- Excipients in the dossier for application for marketing authorisation for veterinary medicinal products Scientific guideline(0)
- Excipients in the dossier for application for marketing authorisation of a medicinal product Scientific guideline(0)
- Excipients labelling(0)
- Executive Director(0)
- Executive Steering Group on Shortages and Safety of Medicinal Products(0)
- Executive Steering Group on Shortages and Safety of Medicinal Products MSSG meeting April 2024(0)
- Executive Steering Group on Shortages and Safety of Medicinal Products MSSG meetings(0)
- Executive Steering Group on Shortages of Medical Devices(0)
- Executive Steering Group on Shortages of Medical Devices MDSSG meetings(0)
- Exelon(0)
- Exemptions to labelling and packageleaflet obligations(0)
- Exenatide productspecific bioequivalence guidance(0)
- Exforge(0)
- Exforge HCT(0)
- Exjade(0)
- Exkivity(0)
- Exondys(0)
- Exparel liposomal(0)
- Experimental Ebola treatments still at early stage of development(0)
- Expert group meeting on paediatric heart failure(0)
- Expert meeting in familial neurodegenerative disorders(0)
- Expert meeting on clinical investigation of new drugs for the treatment of chronic hepatitis C in the paediatric population(0)
- Expert meeting on gastroenterology and rheumatology(0)
- Expert meeting on genome editing technologies used in medicine development(0)
- Expert meeting on neonatal and paediatric sepsis(0)
- Expert meeting on paediatric asthma(0)
- Expert meeting on paediatric development of fixeddose combinations for the treatment of the human immunodeficiency virus HIV(0)
- Expert meeting on specific immunotherapy(0)
- Expert meeting on the clinical investigation of medicines for the treatment of paediatric hepatitis C(0)
- Experts and regulators discuss role of modelling and simulation in medicine development and regulatory assessment(0)
- Expert workshop on process validation for the manufacture of biotechnologyderived active substances(0)
- Expert workshop on setting specifications for biotechnological products(0)
- Expert workshop on subgroup analysis(0)
- Explanatory note on the withdrawal of the note for guidance on harmonisation of requirements for influenza vaccines Scientific guideline(0)
- Exploring new ways to fight antimicrobial resistance(0)
- Exploring opportunities for collaboration between regulators and healthcare payers(0)
- Expressions of interest invited for membership of European Medicines Agency committees and Management Board(0)
- Expressions of interest invited for transatlantic workshop on drugrelated PML(0)
- Expressions of interest invited for workshop on ethics of clinical trials in children(0)
- Expressions of interest invited for workshop on medicines for older people(0)
- Extavia(0)
- eXtended EudraVigilance Medicinal Product Dictionary facetoface training course(0)
- eXtended EudraVigilance medicinal product dictionary facetoface training course(0)
- eXtended EudraVigilance Medicinal Product Dictionary facetoface training course Amsterdam(0)
- eXtended EudraVigilance Medicinal Product Dictionary facetoface training course Lisbon(0)
- eXtended EudraVigilance Medicinal Product Dictionary facetoface training course London(0)
- eXtended EudraVigilance Medicinal Product Dictionary facetoface training course Lyon(0)
- eXtended EudraVigilance medicinal product dictionary facetoface training course Madrid(0)
- eXtended EudraVigilance medicinal product dictionary facetoface training course Prague(0)
- eXtended EudraVigilance Medicinal Product Dictionary Training Course(0)
- eXtended EudraVigilance Medicinal Product Dictionary training course(0)
- eXtended EudraVigilance Medicinal Product Dictionary training course November 2021(0)
- eXtended EudraVigilance Medicinal Product Dictionary training course October 2021(0)
- eXtended EudraVigilance Medicinal Product Dictionary training course September 2021(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD Information session Industry webinar(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course February 2022(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course February 2023(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors February 2022(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors February 2023(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors June 2022(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors May 2022(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors May 2023(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors November 2022(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors November 2023(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors October 2022(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors October 2023(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for clinical trial sponsors September 2022(0)
- Extended EudraVigilance medicinal product dictionary XEVMPD training course for sponsors(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course July 2023(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course June 2022(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course May 2022(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course May 2023(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course November 2022(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course November 2023(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course October 2022(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course October 2023(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course September 2022(0)
- eXtended EudraVigilance Medicinal Product Dictionary XEVMPD training course September 2023(0)
- Extended mandate First meeting of Executive Steering Group on Shortages and Safety of Medicinal Products MSSG(0)
- Extension of the shelf life for the antigen stocks during the type II variation assessment Scientific guideline(0)
- Extensions of marketing authorisations questions and answers(0)
- External guidance on the implementation of the European Medicines Agency policy on the publication of clinical data for medicinal products for human use(0)
- External whistleblowing policy(0)
- Extra dose from vials of Comirnaty COVID19 vaccine(0)
- Extraordinary Management Board meeting 6 February 2018(0)
- Extraordinary Management Board meeting 25 June 2020(0)
- Extraordinary Management Board meeting 28 February 2018(0)
- Extraordinary Management Board meeting on CTIS audit(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 1 September 2022(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 4 October 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 6 December 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 6 January 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 11 March 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 12 January 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 19 November 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 19 October 2022(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 20 December 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 21 December 2020(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 23 July 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 25 November 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 25 October 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 28 May 2021(0)
- Extraordinary meeting of the Committee for Medicinal Products for Human Use CHMP 29 December 2020(0)
- Extraordinary meeting of the Pharmacovigilance Risk Assessment Committee PRAC 18 March 2021(0)
- Extraordinary meeting of the Pharmacovigilance Risk Assessment Committee PRAC 20 April 2021(0)
- Extraordinary meeting to finalise review of Anorectic Agents(0)
- Extrapolation of data from adults to children can facilitate development of paediatric medicines(0)
- Extrapolation of efficacy and safety in medicine development Scientific guideline(0)
- Extrapolation of efficacy and safety in paediatric medicine development Scientific guideline(0)
- Extrapolation of results from clinical studies conducted outside Europe to the EUpopulation Scientific guideline(0)
- Extra transparency measures for COVID19 vaccines and therapeutics(0)
- Exubera(0)
- Exulett(0)
- Exviera(0)
- Exzolt(0)
- Eye injuries in people and dogs when using Osurnia ear gel for dogs(0)
- Eylea(0)
- Ezetimibe and simvastatin fixed combination(0)
- Ezetimibe productspecific bioequivalence guidance(0)
- F(0)
- Fabhalta(0)
- Fabian van Hoof(0)
- Fabien ALLEMAN(0)
- Fabien Lagarde(0)
- Fabien Lavergne(0)
- Fabienne Gaugaz(0)
- Fabiola Micheletti(0)
- Fabio Ruggiero(0)
- Fabio Scarinci(0)
- Fablyn(0)
- Fabrazyme(0)
- Fabrice Eroukhmanoff(0)
- Fabrice Moore(0)
- Fabrizio Chiodo(0)
- Fabrizio Clarelli(0)
- Fabrizio De Ponti(0)
- Fabrizio Galliccia(0)
- Fabrizio Maggi(0)
- Fabrizio Sacco(0)
- Facilitating applications for paediatric investigation plans(0)
- Facilitating Decentralised Clinical Trials in the EU(0)
- Facilitating development of medicines for autism spectrum disorder(0)
- Facilitating global access to diabetes treatments for nonEU patients(0)
- Facilitating global development of biosimilars(0)
- Facilitating submission of postapproval data(0)
- Facilitating the development of advanced therapies(0)
- Facilitating the development of gene therapies(0)
- Factive(0)
- Factor VIII medicines no clear and consistent evidence of difference in risk of inhibitor development between classes(0)
- Fakhredin Sayed Tabatabaei(0)
- Faldaprevir Boehringer Ingelheim(0)
- Falsified Medicines Directive Imported active substances need written confirmation to guarantee GMP standards(0)
- Falsified medicines overview(0)
- Falsified medicines reporting obligations(0)
- Fampridine(0)
- Fampridine Accord(0)
- Fampridine productspecific bioequivalence guidance(0)
- Fampyra(0)
- Fanaptum(0)
- Fanny Filley(0)
- Fareston(0)
- Farshid Jalalvand(0)
- Farydak(0)
- Farzaneh Mousakhan(0)
- Fasenra(0)
- Faslodex(0)
- Fast track routes for medicines that address unmet medical needs(0)
- Fasturtec(0)
- Fate of veterinary medicinal products in manure Focus Group Meeting(0)
- Fati Kirakoya(0)
- Fátima Ventura(0)
- Fatrovax RHD(0)
- Faustine VIDIL(0)
- Fausto Chiazza(0)
- Fausto Roila(0)
- FDA European Commission and EMA reinforce collaboration to advance medicine development and evaluation(0)
- Febrin Hennemann(0)
- Febseltiq(0)
- Febuxostat Krka(0)
- Febuxostat Viatris previously Febuxostat Mylan(0)
- Federica Aureli(0)
- Federica Bruno(0)
- Federica Chiara(0)
- Federico De Angelis(0)
- Federico Gonnella(0)
- Federico Marighetti(0)
- Federico Prefumo(0)
- Feedback requested on the draft list of EU reference dates for periodic safety update reports in preparation for introduction of the new pharmacovigilance legislation(0)
- Feerelated incentives for advancedtherapy medicines to expire on 30 December 2012(0)
- Fees(0)
- Fees for type IA variations to be due at start of procedure(0)
- Fees payable to the European Medicines Agency(0)
- Fei Fei(0)
- Felice Frey(0)
- Félicien Tosso(0)
- Felicitas Deget(0)
- Felisecto Plus(0)
- Félix Carvalho(0)
- Fellowships(0)
- Felpreva(0)
- Femke Geers(0)
- Femke HodesTaverne(0)
- Fendrix(0)
- Fenflor(0)
- Fentanyl citrate(0)
- Feraccru(0)
- Feraheme(0)
- Ferenc Lukacs(0)
- Fergus Sweeney(0)
- Fernanda Cardoso(0)
- Fernando Blanco(0)
- Fernando Cabanas(0)
- Fernando de Andrés Trelles(0)
- Fernando España González(0)
- Fernando Mendez Hermida(0)
- Fernando Vizcaino Merino(0)
- Ferran Torres(0)
- Ferrer Internacional SA withdraws its marketing authorisation application for Egrifta tesamorelin(0)
- Ferriprox(0)
- Fertavid(0)
- Fetcroja(0)
- Fevaxyn Pentofel(0)
- Fexeric(0)
- Fexinidazole Winthrop(0)
- FGK Representative Service GmbH withdraws its marketingauthorisation application for Memantine FGK memantine(0)
- Fiasp(0)
- Fifteenth Meeting of the Management Board(0)
- Fifth EMAEFPIA annual bilateral meeting(0)
- Fifth EMA workshop for SMEs "Regulatory considerations in initiating clinical trials"(0)
- Fifth European Medicines Agency EMA and the Association of the European SelfMedication Industry AESGP bilateral meeting(0)
- Fifth European Medicines Agency EuropaBio bilateral meeting(0)
- Fifth European Medicines Agency Medicines for Europe bilateral meeting(0)
- Fifth industry stakeholder platform on research and development support(0)
- Fifth Industry Standing Group ISG meeting(0)
- Fifth meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Fifth Meeting of the EMEA Management Board took the form of the Official Inauguration(0)
- Fifth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines(0)
- Fifth Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Fifth Nitrosamine Implementation Oversight Group NIOG meeting with pharmaceutical industry(0)
- Fifth stakeholder forum on the implementation of the new pharmacovigilance legislation(0)
- Fighting antimicrobial resistance globally(0)
- Filgrastim Hexal(0)
- Filgrastim ratiopharm(0)
- Filipendulae ulmariae flos(0)
- Filipendulae ulmariae herba(0)
- Filip Josephson(0)
- Filip Kukulski(0)
- Filippo Capasso(0)
- Filip Van Aelst(0)
- Filip Van Nieuwerburgh(0)
- Filip Van Nuffel(0)
- Filomena Nappi(0)
- Filspari(0)
- Filsuvez(0)
- Final referral decisions(0)
- Finance procedures(0)
- Financial advantages of SME status(0)
- Financial management and budgetary reporting(0)
- Finbarr Leacy(0)
- Fingolimod Accord(0)
- Fingolimod Mylan(0)
- Fingolimod productspecific bioequivalence guidance(0)
- Finlee(0)
- Finn Dag Hjelseth(0)
- Fintepla(0)
- Fiorella Petronzelli(0)
- Fiprex(0)
- Firazyr(0)
- Firdapse previously Zenas(0)
- Firmagon(0)
- First 2017 meeting of the coordinating group of the European network of paediatric research at the European Medicines Agency EnprEMA(0)
- First adapted COVID19 booster vaccines recommended for approval in the EU(0)
- First anniversary of PRIME experience so far(0)
- First anniversary of PRIME experience so far(0)
- First annual bilateral meeting between the European Medicines Agency and the European Generic and Biosimilar Medicines Association(0)
- First antibodydrug conjugate for multiple myeloma patients with limited treatment options(0)
- First antidote for reversal of anticoagulation with factor Xa inhibitors apixaban and rivaroxaban(0)
- First CART cell medicine for mantle cell lymphoma(0)
- First cases of BSE in USA and Canada risk assessment of ruminant materials originating from USA and Canada Scientific guideline(0)
- First cellbased gene therapy to treat adult patients with multiple myeloma(0)
- First clinical biomarker qualification released for public consultation(0)
- First comprehensive overview of global initiatives on medicine regulation published(0)
- First COVID19 treatment recommended for EU authorisation(0)
- First COVID19 vaccine approved for children aged 12 to 15 in EU(0)
- First COVID19 vaccine safety update published(0)
- First DNA vaccine in the EU recommended for use in salmon(0)
- First electronic product information ePI published for selected human medicines(0)
- First EMA regular press briefing on COVID19(0)
- First EMA workshop on nonanimal approaches in support of medicinal product development challenges and opportunities for use of microphysiological systems(0)
- First EMEA Workshop for Micro Small and MediumSized Enterprises SMEs Navigating the Regulatory Maze(0)
- First EMEA Workshop on Advanced Therapy Medicinal Products ATMPs(0)
- First EMEA workshop on ethics in clinical trials Use of placebo in clinical trials(0)
- First EMEA workshop with industry on Orphan Medicinal Products(0)
- First EudraVigilance Information Day(0)
- First European Medicines Agency and Affordable Medicines Europe bilateral meeting(0)
- First European Medicines Agency and Nuclear Medicines Europe bilateral meeting(0)
- First European Medicines Agency EMA and IPFA PPTA bilateral meeting(0)
- First European Medicines AgencyEuropaBio annual bilateral meeting(0)
- First European Medicines Agency European Confederation of Pharmaceutical Entrepreneurs EUCOPE bilateral meeting(0)
- First European Medicines Agency European Federation of Pharmaceutical Industries and Associations annual bilateral meeting(0)
- First European Medicines Agency Vaccines Europe meeting(0)
- First EU treatment for rare sleepwake disorder(0)
- First ever guidance for stem cell therapies in animals published(0)
- First gene editing therapy to treat beta thalassemia and severe sickle cell disease(0)
- First gene therapy to treat children with rare inherited neurological disease(0)
- First gene therapy to treat haemophilia B(0)
- First gene therapy to treat severe haemophilia A(0)
- First Global Animal Health Conference to enhance positive environment for veterinary medicines(0)
- First guidance on monoclonal antibodies for use in animals(0)
- First guidance on new rules for certain medical devices(0)
- First HDAC inhibitor for treatment of multiple myeloma recommended for approval in EU(0)
- First histologyindependent treatment for solid tumours with a specific gene mutation(0)
- First hormone replacement therapy for parathyroid disorder(0)
- Firstinclass medicine recommended for treatment of rare blood vessel inflammation(0)
- Firstinclass medicine to prevent bleeding in haemophilia A patients with inhibitors(0)
- Firstinclass medicine to treat aggressive form of breast cancer(0)
- Firstinclass treatment to lower cholesterol(0)
- First industry standing group ISG meeting(0)
- First information day on periodic safety update reports PSURs International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH E2CR2 periodic benefitrisk evaluation reports(0)
- First information day on the use of the Medical Dictionary for Regulatory Activities MedDRA including medication errors(0)
- Firstinman clinical trials guideline released for public consultation(0)
- First joint DIA/EMA workshop on statistical methodology in clinical R&D(0)
- First joint meeting of the EMA Scientific Committees Working Party with Patients and Consumers Organisations PCWP and the EMA/CHMP Working Group with Healthcare Professionals Organisations HCP WG(0)
- First listenandlearn focus group meeting of the Quality Innovation Group(0)
- First longacting injectable antiretroviral therapy for HIV recommended for approval(0)
- First malaria vaccine receives positive scientific opinion from EMA(0)
- First medicine for HIV preexposure prophylaxis recommended for approval in the EU(0)
- First medicine for rare blood cancer(0)
- First medicine for spinal muscular atrophy(0)
- First medicine recommended for approval for hidradenitis suppurativa(0)
- First medicine to treat neonatal diabetes(0)
- First meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- First meeting of the EMEA Scientific Committees Working Party with with Patients and Consumers Organisations PCWP with all eligible Patients and Consumers organisations(0)
- First meeting of the Modelling and Simulation Working Group(0)
- First monoclonal antibody in veterinary medicine recommended for a marketing authorisation(0)
- First monoclonal antibody therapy for prevention of migraine(0)
- First Nitrosamine Implementation Oversight Group NIOG meeting with pharmaceutical industry(0)
- First noninjectable treatment for severe low blood sugar levels(0)
- First oncolytic immunotherapy medicine recommended for approval(0)
- First oral addon treatment to insulin for treatment of certain patients with type 1 diabetes(0)
- First oral GLP1 treatment for type 2 diabetes(0)
- First oral monotherapy for patients with paroxysmal nocturnal haemoglobinuria(0)
- First oral treatment against residual haemolytic anaemia in patients with paroxysmal nocturnal haemoglobinuria(0)
- First oral treatment for Fabry disease recommended for approval in the EU(0)
- First oral treatment for spinal muscular atrophy SMA recommended for approval(0)
- First paediatric medicine to treat rare hormonal disorder(0)
- First qualification opinion on a statistical methodology for dose finding released for public consultation(0)
- First regulatory workshop on COVID19 facilitates global collaboration on vaccine development(0)
- First RSV vaccine to protect infants up to 6 months of age and older adults(0)
- First specific replacement therapy to treat rare bleeding disorder(0)
- First stakeholder forum on the implementation of the new 2010 pharmacovigilance legislation(0)
- First statistics on PRIME are released(0)
- First stem cellbased veterinary medicine recommended for marketing authorisation(0)
- First stemcell therapy recommended for approval in EU(0)
- First survey on patients involvement in the European Medicines Agencys work reveals high satisfaction levels overall(0)
- First therapy to treat rare genetic nervous system disorder AADC deficiency(0)
- First therapy to treat transplant patients with posttransplant lymphoproliferative disease(0)
- First therapy to treat two types of NiemannPick disease a rare genetic metabolic disorder(0)
- First treatment for acute hepatic porphyria(0)
- First treatment for children with Progeria or progeroid like syndromes rare premature aging syndromes(0)
- First treatment for rare condition primary hyperoxaluria type 1(0)
- First treatment for rare disease characterised by high levels of triglycerides in blood(0)
- First treatment for rare inherited muscle contraction disorders(0)
- First treatment for rare liver disease(0)
- First treatment for rare metabolic disorder alkaptonuria(0)
- First treatment recommended for rare bone disease(0)
- First triple combination therapy for asthma with optional electronic sensor(0)
- First two CART cell medicines recommended for approval in the European Union(0)
- First vaccine for prevention of dengue(0)
- First vaccine to protect against Ebola(0)
- First vaccine to protect older adults from respiratory syncytial virus RSV infection(0)
- First version of the Union list of critical medicines agreed to help avoid potential shortages in the EU(0)
- First webinar on regulatory and procedural aspects of type I variations(0)
- First workshop for the EMEA/CHMP Working Group with Patients Organisations(0)
- Five additional countries to benefit from EUUS mutual recognition agreement for inspections(0)
- Fixed combination products Scientific guideline(0)
- Flavia Mayer(0)
- Flavia Tedesco(0)
- Flebogamma DIF previously Flebogammadif(0)
- Flexicam(0)
- Flixabi(0)
- Flora Musuamba Tshinanu(0)
- Flóra Szabó(0)
- Flore Demay(0)
- Florence HAMANN BURON(0)
- Florence Pillet(0)
- Florence Turcry(0)
- Florentine Baldee Nieuwmeyer(0)
- Florgane(0)
- Floriana DUrso(0)
- Florian Klinglmueller(0)
- Florian Koban(0)
- Flosfluridine tidoxil(0)
- Fluad Paediatric(0)
- Fluad Tetra(0)
- Flucelvax Tetra(0)
- Flucytosine(0)
- Fluenz(0)
- Fluenz Tetra(0)
- Flukicides for which no maximum residue limit has been established in milk and which are intended for use in ruminants producing milk for human consumption(0)
- Fluoroquinolone and quinolone antibiotics PRAC recommends new restrictions on use following review of disabling and potentially longlasting side effects(0)
- Fluoroquinolone antibiotics reminder of measures to reduce the risk of longlasting disabling and potentially irreversible side effects(0)
- Fluoroquinolones(0)
- Fluorouracil / salicylic acid(0)
- Flynpovi(0)
- Focetria(0)
- Foclivia(0)
- Focus group meeting of Committee for Medicinal Products for Veterinary Use experts and interested parties Reflection paper on the use of fluoroquinolones in foodproducing animals(0)
- Focus group meeting of CVMP experts interested parties and member states reflection paper on the use of fluoroquinolones in foodproducing animals(0)
- Focus group meeting on bacteriophages as veterinary medicines(0)
- Focus group meeting on dose optimisation of established veterinary antibiotics in the context of summary of product characteristics harmonisation(0)
- Focus group meeting on the revision of the CVMP guideline for the demonstration of efficacy for veterinary medicinal products containing antimicrobial substances(0)
- Focus group on promotion of pharmacovigilance for food producing animals(0)
- Focus group on veterinary pharmacovigilance reporting in aquaculture(0)
- Focus group on veterinary pharmacovigilance reporting in poultry(0)
- Focus group with invited stakeholders on field efficacy trials in the context of an EU authorisation for veterinary vaccines(0)
- Focus on innovative medicines for animals(0)
- Foeniculi amari fructus(0)
- Foeniculi amari fructus aetheroleum(0)
- Foeniculi dulcis fructus(0)
- Fokaline Vroom(0)
- Folcepri(0)
- Follow up EMA and EORTC multistakeholder workshop on soft tissue and bone sarcoma(0)
- Follow up information session on the TransCelerate initiative(0)
- Followup of patients administered with gene therapy medicinal products Scientific guideline(0)
- Folotyn(0)
- Fons Wesseling(0)
- Food and Drug Administration / European Medicines Agency orphanproduct designation and grant workshop(0)
- Food and Drug Administration and European Medicines Agency agree to accept a single orphan drug designation annual report(0)
- Forcaltonin(0)
- Forceris(0)
- Former EMA policy on minor use / minor species MUMS / limited markets(0)
- Forms and templates(0)
- Formulations of choice for the paediatric population Scientific guideline(0)
- Forodesine hydrochloride(0)
- Forsteo(0)
- Fortacin(0)
- Fortekor(0)
- Fortekor Plus(0)
- Fortovase(0)
- Forxiga(0)
- Fosavance(0)
- Foscan(0)
- Fostering medicines for children(0)
- Fotivda(0)
- Four more EU Member States benefit from EUUS mutual recognition agreement for inspections(0)
- Fournier Laboratories withdraws its marketing authorisation application for Synordia(0)
- Fourteenth Meeting of the Management Board(0)
- Fourth EMA and Association of the European SelfMedication Industry AESGP annual bilateral meeting(0)
- Fourth European Conference for Clinical Nanomedicine CLINAM 2011(0)
- Fourth European Medicines Agency and European Federation of Pharmaceutical Industries and Associations annual bilateral meeting(0)
- Fourth European Medicines Agency Medicines for Europe bilateral meeting(0)
- Fourth industry stakeholder platform on research and development support(0)
- Fourth industry stakeholder platform on the operation of the centralised procedure for human medicines(0)
- Fourth industry stakeholder platform operation of European Union pharmacovigilance legislation(0)
- Fourth Industry Standing Group ISG meeting(0)
- Fourth meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Fourth Meeting of the Management Board of the European Agency for the Evaluation of Medical Products(0)
- Fourth Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Fourth small and mediumsized enterprise workshop for micro small and mediumsized enterprises SMEs Paediatric medicines(0)
- Fourth stakeholder forum on the implementation of the new 2010 pharmacovigilance legislation(0)
- Fourweek limit for use of highstrength estradiol creams(0)
- Fragariae folium(0)
- Fragrances containing allergens(0)
- Framework for a close collaboration with Israel in place(0)
- Franca Gauly(0)
- Francesca Alteni(0)
- Francesca Alunno(0)
- Francesca Ceccarini(0)
- Francesca Galeotti(0)
- Francesca Luciani(0)
- Francesca Ravaioli(0)
- Francesca Renda(0)
- Francesca Rocchi(0)
- Francesca Tittone(0)
- Francesco Giorgino(0)
- Francesco Marino(0)
- Francesco Nonino(0)
- Francesco Onida(0)
- Francesco Rodeghiero(0)
- Francesco Trotta(0)
- Francesco Vairo(0)
- FRANCISCA MOYA(0)
- Francisco Javier Membrillo de Novales(0)
- Francisco LópezMedrano(0)
- Franco Bambi(0)
- Franco Granella(0)
- François Cano(0)
- Francoise Goebel(0)
- Françoise Possémé(0)
- Francoise Wuillaume(0)
- Francois Houyez(0)
- FrançoisXavier MICHON(0)
- Frane Božić(0)
- Frangulae cortex(0)
- Frank Blommaert(0)
- Frank Hamann(0)
- Frank Holtkamp(0)
- Frank Schuler(0)
- Frank Sielaff(0)
- Frank Straßberger(0)
- Frank Van Trimpont(0)
- Frank Verheijen(0)
- Frank Wolters(0)
- Frans Russel(0)
- Frantisek Drafi(0)
- Frantisek Pavlik(0)
- Franziska Brandt(0)
- Franziska Kurz(0)
- Franziska Wolter(0)
- Franz RiederRommer(0)
- Franz Schönfeld(0)
- Franz Xaver Kleber(0)
- Frauke Lukas(0)
- Frauke NaumannWinter(0)
- Fraxini folium(0)
- Frédéric Klein(0)
- Frederic Thalheimer(0)
- Frederika Vermeijvan Nimwegen(0)
- Frederik Beaulieux(0)
- Frederike Lentz(0)
- Frederik Grell(0)
- Frederikke Hillebrand Laustsen(0)
- Frederik Waldo Weijers(0)
- Frédérique MARCHAL(0)
- Fredrik Hultén(0)
- Fredrik Hussenius(0)
- Frequently asked questions(0)
- Frequently asked questions about parallel distribution(0)
- Frida Hasslung Wikström(0)
- Frida Martin(0)
- Friederike Marei Feldmann(0)
- From data to evidence in medicines regulation(0)
- Frontpro previously known as Afoxolaner Merial(0)
- Frouke van Sorgen(0)
- Fructose and sorbitol(0)
- Fruzaqla(0)
- Fucus(0)
- Fulphila(0)
- Fulvestrant Mylan(0)
- FULVIO MARSILIO(0)
- Fumariae herba(0)
- Funding(0)
- Funding for paediatric studies(0)
- Fungitraxx(0)
- Further data needed to determine risk of heart attack with abacavir(0)
- Further guidance on interpretation of the data from VICH GL27 Scientific guideline(0)
- Further measures to identify and address medicine shortages during public health emergencies adopted(0)
- Further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine(0)
- Further questions and answers on the followup to the Viracept recall(0)
- Further resources(0)
- Further review of Iclusig started(0)
- Fuzeon(0)
- Fycompa(0)
- Fyzoclad(0)
- G(0)
- Gábor Kulcsár(0)
- Gabriela Burianová(0)
- Gabriela FischerMayer(0)
- Gabriela Tuchila(0)
- Gabriela Ullio Gamboa(0)
- Gabriele Bachus(0)
- Gabriele Balciunaite Murziene(0)
- Gabriele Eibenstein(0)
- Gabriele Maurer(0)
- Gabriele Reichmann(0)
- Gabriele Rothmueller(0)
- Gabriele RuppertSeipp(0)
- Gabriele SchlosserWeber(0)
- Gabriele Schwarz(0)
- Gabriele Schweyen(0)
- Gabriel Ioan Prada(0)
- Gabriella Alexandersson von Dobeln(0)
- Gabriella Csontos(0)
- Gabriella Passacquale(0)
- Gabriel Westman(0)
- Gaby Wangorsch(0)
- Gaelle De Meyer(0)
- Gaelle Louin(0)
- Gaelle Weiss(0)
- Gaëtan Briffaerts(0)
- Gaetan Philippot(0)
- Gaja Lesnicar Pucko(0)
- Galafold(0)
- Galatia Theophanous(0)
- Gal Christian Zvegelj(0)
- Gallimune Flu H5N9 i(0)
- Galliprant(0)
- Galvus(0)
- Gamifant(0)
- Ganfort(0)
- Ganirelix Gedeon Richter(0)
- Gardasil(0)
- Gardasil 9(0)
- Gardasil 9 offers wider protection against cancers caused by human papillomavirus HPV(0)
- Garenoxacin mesylate(0)
- Gareth Bowen(0)
- Garsun(0)
- Gary Johansson(0)
- Gasper Marc(0)
- Gastromotal(0)
- Gaucher disease a strategic collaborative approach from the European Medicines Agency and Food and Drug Administration Scientific guideline(0)
- Gavin McGauran(0)
- Gavin Ryan(0)
- Gavreto(0)
- Gazyvaro(0)
- Geanne Thole(0)
- Gearoid McGauran(0)
- Geert Dom(0)
- Geert Molenberghs(0)
- Geert Verbeke(0)
- Gefitinib Mylan(0)
- Gefitinib productspecific bioequivalence guidance(0)
- Gefzuris(0)
- GeGant(0)
- Gela Camelia Lazar(0)
- Gema Cortés Ruiz(0)
- Gemesis(0)
- Gemma Sanchez Doral(0)
- Genasense(0)
- Gencebok(0)
- Gender differences in cardiovascular diseases Scientific guideline(0)
- Gendux Molecular Limited withdraws its marketing authorisation application for Advexin contusugene ladenovec(0)
- Gendux Molecular Limited withdraws its marketing authorisation application for Contusugene ladenovec Gendux contusugene ladenovec(0)
- General Court confirms EMA approach to transparency(0)
- General Court finds no fault in 2011 appointment procedure of EMA Executive Director(0)
- General Court upholds European Medicines Agency decision to refuse paediatric waiver for perflubutane(0)
- General procedures(0)
- General Regulatory and procedural guidance(0)
- Generating highquality evidence from registrybased studies(0)
- Generic and biosimilar medicines in the centralised procedure 3rd EMAEGA information day(0)
- Generic and hybrid applications(0)
- Generic and hybrid medicines(0)
- Gene therapy product quality aspects in the production of vectors and genetically modified somatic cells Scientific guideline(0)
- Geneviève Waeterloos(0)
- Genotoxic and carcinogenic potential of phenolphthalein Scientific guideline(0)
- Gentamicin(0)
- Gentianae radix(0)
- Genvoya(0)
- George Aislaitner(0)
- George Patrinos(0)
- George Volikakis(0)
- Georgia Bouziou(0)
- Georgia Gkegka(0)
- Georgia Valsami(0)
- GEORGIOS PALIOURAS(0)
- Georg Neuwirther(0)
- Gerald Fischer(0)
- Gerald Geroldinger(0)
- Gerard Alphonse Schockmel(0)
- GERARD NGUYEN DUC LONG(0)
- Gerardo Priotto(0)
- Gerardus Rongen(0)
- Gerd Maack(0)
- Gergana Kashova(0)
- Gergana Kirkova(0)
- Gergana Lazarova(0)
- Gergana Nikolova(0)
- Gergely Tasi(0)
- Gerhard Beck(0)
- Gerhard Garhöfer(0)
- Geriatric Expert Group(0)
- Gerlienke GeurtsVoerman(0)
- Gerlinde Kugler(0)
- German RamirezOlivencia(0)
- Gernot Hirn(0)
- Gerrit Johannes van Ringen(0)
- Gerrit Johan Schefferlie(0)
- Gerrit Johan Schefferlie elected new Chair of EMA Committee for Veterinary Medicinal Products CVMP(0)
- Gert Laekeman(0)
- Gertraud MarklLaubender(0)
- Getting involved(0)
- Getting ready for EMAs website relaunch on 5 December 2023(0)
- GHRYVELIN previously Macimorelin Aeterna Zentaris(0)
- Giacomina Pugliese(0)
- Giampiero Lorenti(0)
- GianinaNicoleta Andrei(0)
- Gianluca Antonio Romeo(0)
- GIANLUCA MIGLIO(0)
- Giapreza(0)
- Gilenya(0)
- gilles reuter(0)
- Ginkgo folium(0)
- Ginseng radix(0)
- Gintaras Daunoras(0)
- Gintare Dargiene(0)
- Gintare Gilaite(0)
- Giorgio Palù(0)
- Giotrif(0)
- Giovanna Salvatierra Gutiérrez(0)
- GIOVANNI CAMISASCA(0)
- Girolan and its associated name Apralan(0)
- Gisela Kröber(0)
- Gitte BachBreitling(0)
- Gitte Larsen(0)
- Giulia Callegaro(0)
- Giulia Gritti(0)
- Giulio Pisani(0)
- Giuseppa Pistritto(0)
- Giuseppe Fanciulli(0)
- Giuseppe Rosano(0)
- Giuseppina Ialongo(0)
- Givlaari(0)
- GlaxoSmithKline Biologicals withdraws its application for a scientific opinion for Globorix(0)
- GlaxoSmithKline withdraws its application for an extension of the indication for Tyverb lapatinib(0)
- GlaxoSmithKline withdraws its marketing authorisation application for Bosatria mepolizumab(0)
- GlaxoSmithKline withdraws its marketing authorisation application for Zunrisa casopitant mesilate(0)
- Glenn Lastennet(0)
- Glidipion previously Pioglitazone Actavis Group(0)
- Gliolan(0)
- Glivec(0)
- Global Animal Health Conference(0)
- Global animal health conference Global availability of veterinary medicines providing a climate for science and innovation(0)
- Global public meeting on draft ICH guideline on clinical trials(0)
- Global regulators agree on key principles on adapting vaccines to tackle virus variants(0)
- Global regulators agree on way forward to adapt COVID19 vaccines to emerging variants(0)
- Global regulators call for international collaboration to integrate realworld evidence into regulatory decisionmaking(0)
- Global regulators celebrate 10 years of strategic leadership and cooperation(0)
- Global regulators commit to cooperate on observational research in the context of COVID19(0)
- Global regulators confirm good safety profile of COVID19 vaccines(0)
- Global regulators discuss data requirements for phase 3 trials of COVID19 vaccines(0)
- Global regulators discuss observational studies of real world data for COVID19 medicines(0)
- Global regulators discuss path towards regulatory alignment on response to Omicron variant(0)
- Global regulators highlight key role of healthcare professionals in fostering confidence in COVID19 vaccines(0)
- Global regulators map out data requirements for phase 1 COVID19 vaccine trials(0)
- Global regulators strengthen efforts to ensure continuous availability of safe and highquality medicines(0)
- Global regulators stress need for robust evidence on COVID19 treatments(0)
- Global regulators urge continuation of COVID19 vaccine trials for longerterm safety and efficacy followup(0)
- Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID19(0)
- Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID19 update #2(0)
- Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID19 update #3(0)
- Global regulators work towards alignment on policy approaches and regulatory flexibility during COVID19 update #4(0)
- Global regulators work towards strengthening collaboration on observational research beyond COVID19 pandemic(0)
- Global regulatory workshop on COVID19 realworld evidence and observational studies(0)
- Global regulatory workshop on COVID19 therapeutics #2 agreement on acceptable endpoints for clinical trials(0)
- Globorix(0)
- Gloria Maria Palomo Carrasco(0)
- Glossaries(0)
- Glossary of regulatory terms(0)
- Glubrava(0)
- Glucose monohydrate(0)
- Glustin(0)
- Glybera(0)
- Glycini semen(0)
- Glyxambi(0)
- GMP/GDP Inspections Working Party(0)
- GMP/GDP Inspectors Working Group(0)
- Godefroid Libambu Wolaka(0)
- Goedele Louwagie(0)
- GONALf(0)
- Gonazon(0)
- Good agricultural and collection practice for starting materials of herbal origin Scientific guideline(0)
- Goodbye 2023 when optimism came back(0)
- Good clinical practice(0)
- Good clinical practice GCP inspection procedures(0)
- Good Clinical Practice Inspectors Working Group(0)
- Good distribution practice(0)
- Good laboratory practice compliance(0)
- Good manufacturing practice(0)
- Good manufacturing practice training programme for Turkish inspectors(0)
- Good pharmacogenomic practice Scientific guideline(0)
- Good pharmacovigilance practices(0)
- Gorana Perina Lakos(0)
- Goranka Marusic Kontent(0)
- Gordana Gregorović(0)
- GoResp Digihaler previously Budesonide/Formoterol Teva Pharma BV(0)
- Gorkem Tanriover(0)
- Gorm Greisen(0)
- Gorm Herlev Jørgensen(0)
- Gottfried Peter Völk(0)
- Governance and reporting(0)
- Governance procedures(0)
- Grainne Kirwan(0)
- Grainne Mary Power(0)
- Granpidam(0)
- Granupas previously Paraaminosalicylic acid Lucane(0)
- Graspa(0)
- Grastofil(0)
- Grasustek(0)
- Graziella Curtale(0)
- Green light given for new EudraVigilance system for collection and monitoring of suspected adverse reactions(0)
- Greet Musch(0)
- Greger Abrahamsen(0)
- Gregor Gorojans(0)
- Gregor Trstenjak(0)
- GREGORY SCHINDLER(0)
- Grégory Verdier(0)
- Grepid(0)
- Greta Budukeviciute(0)
- Grigoriy Shizgal(0)
- Grindeliae herba(0)
- Gripovac 3(0)
- Grit Barthel(0)
- Gro Dahlseng Hakonsen(0)
- Gro Fossum(0)
- Grouping of variations questions and answers(0)
- Gry Helene Olaussen(0)
- Grzegorz Cessak(0)
- Grzegorz Kubiak(0)
- Gualberto Gussoni(0)
- Guangchao Chen(0)
- Gudrun Fridgeirsdottir(0)
- Gudrun Lind Runarsdottir(0)
- Gudrun Putz(0)
- Gudrun Steinarsdottir(0)
- Guenther Carl(0)
- Guerbet withdraws its marketing authorisation application for Sinerem(0)
- Guglielmo Busiello(0)
- Guidance documents(0)
- Guidance documents related to data submission for authorised medicines(0)
- Guidance for companies seeking scientific support and advice on traditional herbal medicinal products(0)
- Guidance for individual laboratories for transfer of quality control methods validated in collaborative trials with a view to implementing 3Rs Scientific guideline(0)
- Guidance for industry to prevent and mitigate medicine shortages(0)
- Guidance for medicine developers and other stakeholders on COVID19(0)
- Guidance for pharmaceutical companies to prepare for UKs withdrawal from EU(0)
- Guidance for the application of Article 34 of Regulation EU 2019/6 prescription status(0)
- Guidance for the publication of clinical data(0)
- Guidance on good manufacturing practice and good distribution practice Questions and answers(0)
- Guidance on regulatory requirements in the context of the COVID19 pandemic(0)
- Guidance on statistical principles for clinical trials for immunological veterinary medicinal products Scientific guideline(0)
- Guidance on submission of single assessment PSURs published(0)
- Guidance to sponsors on how to manage clinical trials during the COVID19 pandemic(0)
- Guideline on clinical trials with immunological veterinary medicinal products Scientific guideline(0)
- Guideline on core SmPC labelling and package leaflet for advanced therapy medicinal products ATMPs containing genetically modified cells Scientific guideline(0)
- Guideline on data requirements for authorisation of immunological veterinary medicinal products in exceptional circumstances Scientific guideline(0)
- Guideline on determination of the need for an MRL evaluation for biological substances Scientific guideline(0)
- Guideline on medicines for the treatment of amyotrophic lateral sclerosis released for a sixmonth public consultation(0)
- Guideline on medicines for the treatment of irritable bowel syndrome released for a sixmonth public consultation(0)
- Guideline on quality nonclinical and clinical requirements for investigational advanced therapy medicinal products in clinical trials Scientific guideline(0)
- Guideline on registrybased studies(0)
- Guideline on registrybased studies launch of public consultation(0)
- Guideline on registrybased studies Scientific guideline(0)
- Guideline on safety and efficacy followup and risk management of advanced therapy medicinal products Scientific guideline(0)
- Guideline on the acceptability of names for human medicinal products processed through the centralised procedure Scientific guideline(0)
- Guideline on the clinical development of medicines for the treatment of pain released for public consultation(0)
- Guideline on the documentation to be submitted for inclusion into the community list of herbal substances preparations and combinations thereof for use in traditional herbal medicinal products(0)
- Guideline on the scientific application and the practical arrangements necessary to implement Regulation EC No 507/2006 on the conditional marketing authorisation for medicinal products for human use falling within the scope of Regulation EC No (0)
- Guideline on the scientific application and the practical arrangements necessary to implement the procedure for accelerated assessment pursuant to Article 149 of Regulation EC No 726/2004(0)
- Guideline on the summary of product characteristics SPC for veterinary medicinal products containing antimicrobial substances Scientific guideline(0)
- Guideline on the use of the CTD format in the preparation of a registration application for traditional herbal medicinal products(0)
- Guidelines Consistency Group(0)
- Guidelines relevant for advanced therapy medicinal products(0)
- Guide on methodological standards in pharmacoepidemiology revised to include pharmacogenetic studies(0)
- Guido Rasi begins as new head of European Medicines Agency(0)
- Guido Rasi elected chair of International Coalition of Medicines Regulatory Authorities ICMRA(0)
- Guido Rasi takes office as head of EMA(0)
- Guillaume Belliard(0)
- Guillaume Dionkre(0)
- Guillaume Grach(0)
- Guillaume Jean(0)
- Guillaume Vaquer(0)
- Guillaume ZIMNY(0)
- Gulf Cooperation Council GCC Biosimilar Medicinal Products Workshop(0)
- Gülru Gürdemir(0)
- Gumbohatch(0)
- Gunilla AndrewNielsen(0)
- Gunilla Johansson(0)
- Gunilla SjölinForsberg(0)
- Gunnar Thor Gunnarsson(0)
- Gunn Kisen(0)
- Gunta Pauksena(0)
- Günter Waxenecker(0)
- Gunther Boos(0)
- Gunther Speichert(0)
- Guoda Radaviciute(0)
- Guri Wilhelmsen(0)
- Gus Baker(0)
- Gutal(0)
- Guy Fonck(0)
- Guðbjörg Guttormsdóttir(0)
- Guðrún Stefánsdóttir(0)
- Guðrún Þengilsdóttir(0)
- GVK Biosciences European Medicines Agency confirms recommendation to suspend medicines over flawed studies(0)
- GVK Biosciences European Medicines Agency recommends suspending medicines over flawed studies(0)
- GVK Biosciences review some Member States suspend marketing authorisations for concerned medicines(0)
- Gwenael Cirefice(0)
- Gwenaelle Nouail(0)
- Gwenaelle Veyrac(0)
- Gwenda Pirk(0)
- Gwylim Janssens(0)
- Gyöngyi Petró(0)
- Gyorgy Medgyesi(0)
- H(0)
- Haakon Meyer(0)
- Haematology European Specialised Expert Community(0)
- Haematology Working Party(0)
- Haematology Working Party documents(0)
- Haemophilia registries workshop(0)
- Hafdis Birna Baldursdottir(0)
- Hakan Cetin(0)
- Håkan Persson(0)
- Halagon(0)
- Halaven(0)
- Halimatoz(0)
- Halocur(0)
- Hamamelidis cortex(0)
- Hamamelidis folium(0)
- Hamamelidis folium et cortex aut ramunculus destillatum(0)
- Hampus Hällbom(0)
- Hana Boudová(0)
- Hanane Belhouari(0)
- Handling competing interests(0)
- Handling competing interests revised rules for Management Board members(0)
- Hang Le THuy Pham(0)
- Hanh Trung Ung(0)
- Hanja de Kooter(0)
- Hanna Belcik Christensen(0)
- Hanna Bremer(0)
- Hanna Haataja(0)
- Hannah Münch(0)
- Hanna Holst(0)
- Hanna Kankkonen(0)
- Hanna Leskinen(0)
- Hanna SekitaStocka(0)
- Hanna Wootz(0)
- Hanna Zeime(0)
- Hanne Bergendahl(0)
- Hanne Debergh(0)
- Hanneke Mulder(0)
- Hanne Lomholt Larsen(0)
- Hannelore Samyn(0)
- Hanne Marie Norseth(0)
- Hannes Eintrei(0)
- Hannes Todt(0)
- HansHermann Thulke(0)
- HansJürgen Kammler(0)
- Hans Kristian Ostensen(0)
- Hans Scheurer(0)
- Harald Bernsteiner(0)
- Harald Enzmann(0)
- Harald Sitte(0)
- Harald Weninger(0)
- Hardy Mitdank(0)
- Harmonisation and update of the clinical aspects in the authorised conditions of use for radiopharmaceuticals and other diagnostic medicinal products Scientific guideline(0)
- Harmonisation of requirements for influenza vaccines(0)
- Harmonising the approach to VeDDRA coding workshop(0)
- Harnessing the potential of real world data through a learning healthcare system(0)
- Harpagophyti radix(0)
- Harriët Hafkamp(0)
- Harry J M Groen(0)
- Harry Verbunt(0)
- Haru Kroneis(0)
- Harvoni(0)
- Harvoni recommended for the treatment of chronic hepatitis C(0)
- Hatice Canan Bayar(0)
- Have your say on EMAs communications how are we doing(0)
- Hazel Hummels(0)
- HBVaxPro(0)
- Head of International Affairs Emer Cooke to leave European Medicines Agency(0)
- Head of Veterinary Medicines Unit to leave European Medicines Agency(0)
- Heads of Medicines Agencies(0)
- Heads of Medicines Agencies / European Medicines Agency technical meeting on availability of authorised human medicines(0)
- Heads of Medicines Agencies HMA / European Medicines Agency EMA Joint Big Data Task Force meeting identifying solutions for big data challenges(0)
- Healthcare professionals(0)
- Healthcare professionals Key documents(0)
- Healthcare Professionals Organisations Working Group HCP WG(0)
- Healthcare Professionals Organisations Working Party HCPWP workshop with academia(0)
- Healthcare Professionals Working Group HCPWG(0)
- Healthcare Professionals Working Party(0)
- Healthcare professionals working party elects cochair(0)
- Healthcare Professionals Working Party meetings(0)
- Health technology assessment bodies(0)
- Hederae helicis folium(0)
- Hedvig Marie Egeland Nordeng(0)
- Hedwig Enzmann(0)
- Hefiya(0)
- Heidemarie Schindl(0)
- Heide Muckenfuß(0)
- Heidi Foth(0)
- Heidi Mestl(0)
- Heidi Meyer(0)
- Heidi Mustalammi(0)
- Heike Gyra(0)
- Heike Kaspar(0)
- Heike Knöß(0)
- Heike Rabe(0)
- Heiko Keller(0)
- Heiko Preusser(0)
- Heili Tikk(0)
- Heinrich Scheiblauer(0)
- Helena Back(0)
- HELENA CALERO GARNACHO(0)
- Helena Faust(0)
- Helena Fonseca(0)
- Helena Fridborg(0)
- Helena Hazizaj(0)
- Helena Kimleová(0)
- Helena Lindberg(0)
- Helena Malm(0)
- Helena Panayiotopoulou(0)
- Helena Rorby(0)
- Helene Blok(0)
- Hélène Bruguera(0)
- Helene Godiksen(0)
- Helene Ly(0)
- Helene Paarup(0)
- Helene Stenbaek Hansen(0)
- Helen Gatling(0)
- Helen MeyerMartin(0)
- Helen RochfordBrennan(0)
- Helen Vella(0)
- Helerin Eiche(0)
- Helga Cassar(0)
- Helga Eyjolfsdottir(0)
- Helga Gardarsdottir(0)
- Helga Sgardelli(0)
- Helge Joa(0)
- Helichrysi flos(0)
- Helicobacter Test INFAI(0)
- Heli Suila(0)
- Helixate NexGen(0)
- Helle Gerda Olsen(0)
- Helle Mulvad(0)
- Helmut Keck(0)
- Helve Vestman(0)
- Hemangiol(0)
- HemAryo(0)
- Hemgenix(0)
- Hemlibra(0)
- Hemme Hijma(0)
- Hemoprostol(0)
- Henning Brohmann(0)
- Henning Locht(0)
- Henning Willads Petersen(0)
- Henrica Ria Nibbeling(0)
- Henriette Rau(0)
- Henrik Bengtsson(0)
- Henrike Buehl(0)
- Henrik Harms(0)
- Henrik Holst(0)
- Henrik Wahlstrom(0)
- Henrique Ramos da Costa(0)
- Hepacare(0)
- Heparesc(0)
- Hepcludex(0)
- Heplisav(0)
- Heplisav B(0)
- Hepsera(0)
- Herbal medicinal products(0)
- Herbal medicinal products containing cimicifugae racemosae rhizoma serious hepatic reactions Scientific guideline(0)
- Herbal medicinal products questions and answers(0)
- Herbal medicinal products Regulatory and procedural guidance(0)
- Herbal medicinal products scientific guidelines(0)
- Herbal medicinal products working group Executive summary of adhoc meetings(0)
- Herbal medicines 2004 2014(0)
- Herbal medicines regulatory and scientific support(0)
- Herbal medicines strengthening assessment methodology and improved communication for the public(0)
- Herbert Lenicker(0)
- Herceptin(0)
- Herceptin Alimta and Remicade batches concerned by ongoing investigation(0)
- Herniariae herba(0)
- Hervelous(0)
- Herwenda(0)
- Herzuma(0)
- Hester Peltenburg(0)
- Hetlioz(0)
- Hexacima(0)
- Hexal AG withdraws its marketing authorisation application for Ibandronic acid Hexal ibandronic acid(0)
- Hexavac(0)
- Hexaxim(0)
- Hexyon(0)
- Hieronyma Schell(0)
- Highertier testing of veterinary medicinal products to dung fauna Scientific guideline(0)
- Higher tier testing to investigate the effects of parasiticidal veterinary medicinal products on dung fauna Scientific guideline(0)
- Highgrade glioma expert group(0)
- Highlights of 100th Management Board meeting June 2018(0)
- Highlights of Management Board June 2020 meeting(0)
- Highlights of Management Board June 2021 meeting(0)
- Highlights of Management Board meeting June 2019(0)
- Highlights of Management Board October 2020 meeting(0)
- Highlights of Management Board October 2021 meeting(0)
- Highquality data to empower datadriven medicines regulation in the European Union(0)
- Hila Wardak(0)
- Hilda Kuin(0)
- Hilde Nelis(0)
- Hilke Zander(0)
- Hinke Johanna Van der Woude(0)
- Hinta Meijerink(0)
- Hippocastani cortex(0)
- Hippocastani semen(0)
- Hiprabovis IBR Marker Live(0)
- Hiprabovis Pneumos(0)
- Hipralona EnroS(0)
- Hirobriz Breezhaler(0)
- History of EMA(0)
- HIV and AIDS(0)
- Hizentra(0)
- Hjalti Kristinsson(0)
- HMA/EMA Big Data Stakeholder Forum 2023(0)
- HMA/EMA multistakeholder workshop on shortages(0)
- HMA/EMA statement on approval of vaccines(0)
- HMA / EMA Task Force on the Availability of Authorised Medicines for Human and Veterinary Use(0)
- HMPC Documents(0)
- HMPC meeting archive 20042011(0)
- HMPC meeting archive 20122014(0)
- HMPC members(0)
- HMPC status report(0)
- HMPC Working parties and other groups(0)
- Holger Bachus(0)
- Holger Loessner(0)
- Holoclar(0)
- Homeopathic Workshop(0)
- HopGuard Gold(0)
- Hopveus(0)
- Horizon 2020 research funding(0)
- Horse Allo 20(0)
- HorStem(0)
- Housam Eidi(0)
- How access to full clinicaltrial data sets will benefit medicines developers(0)
- How are new medicines approved by EMA(0)
- How big data can be used for the development and regulation of medicines(0)
- How EMA evaluates medicines for human use(0)
- How incidents with medicines are managed in the EU a tenyear analysis(0)
- How the committees work(0)
- How the EU regulates medicines(0)
- How to better apply the paediatric legislation to boost development of medicines for children(0)
- How to develop vaccines and medicines that prevent and treat respiratory syncytial virus RSV infection(0)
- How to ensure that novel analytic methods are fit for decisionmaking(0)
- How to facilitate development of cancer immunotherapies(0)
- How to facilitate development of cancer treatment based on genetically modified Tcells(0)
- How to find us(0)
- How to improve product lifecycle management(0)
- How to improve the availability of veterinary vaccines in Europe(0)
- How to make better use of patient registries to collect highquality data on medicines(0)
- How to pay(0)
- How to prepare and review a summary of product characteristics(0)
- How to submit information on authorised and investigational medicines(0)
- How we work(0)
- How will pharmacovigilance look in 2030(0)
- HPV vaccines EMA confirms evidence does not support that they cause CRPS or POTS(0)
- Hrefna Gudmundsdottir(0)
- Hristina Georgieva(0)
- Hrvoje Pavasovic(0)
- HsiaoTzu Chien(0)
- Hubertina Johanna Ineke Maria Josephina Crijns(0)
- HugoJan Jansen(0)
- Hugo Tavares(0)
- Hugues Malonne(0)
- Hukyndra(0)
- Hulio(0)
- Humalog(0)
- Human & Veterinary Medicinal Products Regulation Turkeys Road to EU Membership(0)
- Human and veterinary pharmaceuticals regulation towards EU accession Serbias regulatory challenges expectations and opportunities(0)
- Human autologous mesenchymal adult stem cells extracted from adipose tissue(0)
- Human cellbased medicinal products Scientific guideline(0)
- Human dietary exposure assessments(0)
- Human IGG1 monoclonal antibody specific for human interleukin1 alpha XBiotech(0)
- Human Medicines(0)
- Human medicines highlights of 2015(0)
- Human medicines highlights of 2016(0)
- Human medicines highlights of 2017(0)
- Human medicines highlights of 2018(0)
- Human medicines highlights of 2019(0)
- Human medicines highlights of 2020(0)
- Human medicines highlights of 2021(0)
- Human medicines highlights of 2022(0)
- Human medicines highlights of 2023(0)
- Human normal immunoglobulin(0)
- Human Papillomavirus1 Type 6 L1 protein / Human Papillomavirus1 Type 11 L1 protein / Human Papillomavirus1 Type 16 L1 protein / Human Papillomavirus1 Type 18 L1 protein(0)
- Human Papillomavirus type 16 L1 protein / Human Papillomavirus type 18 L1 protein(0)
- Human plasma proteins(0)
- Human regulatory overview(0)
- Human Variations eAF DADI golive Q&A session(0)
- Human variations eAF Form DADI training session(0)
- Human variations electronic Application Form eAF & Product Management Service PMS Q&A clinics Session 1(0)
- Human variations electronic Application Form eAF & Product Management Service PMS Q&A clinics Session 2(0)
- Human variations electronic application form eAF public training(0)
- Human variations electronic application form eAF Q&A clinics session 6(0)
- Human variations electronic application form eAF Q&A clinics session 7(0)
- Human variations electronic application forms public training(0)
- Human Variations electronic application forms Q&A Clinics Session 1(0)
- Human Variations electronic application forms Q&A Clinics Session 2(0)
- Human Variations electronic application forms Q&A Clinics Session 3 focus access management(0)
- Human variations electronic application forms Q&A clinics session 4(0)
- Human variations electronic application forms Q&A clinics session 5(0)
- HumaSPECT(0)
- Humenza(0)
- Humira(0)
- Hyalograft C autograft(0)
- Hycamtin(0)
- Hydrocortisone aceponate Ecuphar previously Cortacare(0)
- hydroxyethyl starch(0)
- Hydroxyethyl starch solutions CMDh introduces new measures to protect patients(0)
- Hydroxyethylstarch solutions for infusion recommended for suspension from the market(0)
- Hydroxyethylstarch solutions for infusion to be suspended CMDh endorses PRAC recommendation(0)
- Hydroxyethylstarch solutions HES should no longer be used in patients with sepsis or burn injuries or in critically ill patients CMDh endorses PRAC recommendations(0)
- Hyftor(0)
- Hyperici herba(0)
- HyQvia(0)
- Hyrimoz(0)
- I(0)
- Iasibon(0)
- Ibaflin(0)
- Ib Alstrup(0)
- Ibandronic acid Accord(0)
- Ibandronic Acid Hexal(0)
- Ibandronic Acid Sandoz(0)
- Ibandronic Acid Teva(0)
- Iblias(0)
- Ibrance(0)
- Ibrutinib productspecific bioequivalence guidance(0)
- Ibuprofen/Diphenhydramine Hydrochloride Wyeth(0)
- Ibuprofen / Famotidine(0)
- Ibuprofen diphenhydramine hydrochloride(0)
- Ibuprofen GenOrph(0)
- Ibuprofen productspecific bioequivalence guidance(0)
- Icandra previously Vildagliptin / metformin hydrochloride Novartis(0)
- Icatibant Accord(0)
- ICH / Global Cooperation Group Association of Southeast Asian Nations workshop ICH Q5C Stability testing for biotechnological/biological products(0)
- ICH 4 QB Annex 9 Tablet friability Scientific guideline(0)
- ICH considerations(0)
- ICH Considerations general principles to address the risk of inadvertent germline integration of gene therapy vectors Scientific guideline(0)
- ICH Considerations general principles to address virus and vector shedding Scientific guideline(0)
- ICH Considerations oncolytic viruses Scientific guideline(0)
- ICH E1 Population exposure the extent of population exposure to assess clinical safety Scientific guideline(0)
- ICH E2A Clinical safety data management definitions and standards for expedited reporting Scientific guideline(0)
- ICH E2B R3 Electronic transmission of individual case safety reports ICSRs data elements and message specification implementation guide Scientific guideline(0)
- ICH E2C R2 Periodic benefitrisk evaluation report Scientific guideline(0)
- ICH E2D Postapproval safety data management Scientific guideline(0)
- ICH E2E Pharmacovigilance planning Pvp Scientific guideline(0)
- ICH E2F Development safety update report Scientific guideline(0)
- ICH E3 Structure and content of clinical study reports Scientific guideline(0)
- ICH E4 Dose response information to support drug registration Scientific guideline(0)
- ICH E5 R1 Ethnic factors in the acceptability of foreign clinical data Scientific guideline(0)
- ICH E5R1 Ethnic factors in the acceptability of foreign clinical data questions and answers Scientific guideline(0)
- ICH E6 R2 Good clinical practice Scientific guideline(0)
- ICH E6R3 good clinical practice workshop with Patients and Consumers PCWP and Healthcare Professionals HCPWP Working Parties(0)
- ICH E7 Studies in support of special populations geriatrics questions and answers Scientific guideline(0)
- ICH E7 Studies in support of special populations geriatrics Scientific guideline(0)
- ICH E8 General considerations for clinical studies Scientific guideline(0)
- ICH E9 statistical principles for clinical trials Scientific guideline(0)
- ICH E10 Choice of control group in clinical trials Scientific guideline(0)
- ICH E11R1 step 5 guideline on clinical investigation of medicinal products in the pediatric population Scientific guideline(0)
- ICH E12 Principles for clinical evaluation of new antihypertensive drugs Scientific guideline(0)
- ICH E14 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs Scientific guideline(0)
- ICH E14 R3 Clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for nonantiarrhythmic drugs questions and answers Scientific guideline(0)
- ICH E15 Definitions for genomic biomarkers pharmacogenomics pharmacogenetics genomic data and sample coding categories Scientific guideline(0)
- ICH E16 Genomic biomarkers related to drug response context structure and format of qualification submissions Scientific guideline(0)
- ICH E18 Guideline on genomic sampling and management of genomic data Scientific guideline(0)
- ICH efficacy(0)
- ICH guideline E11A on pediatric extrapolation Scientific guideline(0)
- ICH guideline E17 on general principles for planning and design of multiregional clinical trials Scientific guideline(0)
- ICH guideline E19 on a selective approach to safety data collection in specific latestage preapproval or postapproval clinical trials Scientific guideline(0)
- ICH Guideline M13A on bioequivalence for immediaterelease solid oral dosage forms Scientific guideline(0)
- ICH guideline Q13 on continuous manufacturing of drug substances and drug products Scientific guideline(0)
- ICH guidelines(0)
- ICH guideline S1BR1 on testing for carcinogenicity of pharmaceuticals Scientific guideline(0)
- ICH guideline S11 on nonclinical safety testing in support of development of paediatric pharmaceuticals Step 5 Scientific guideline(0)
- ICH guideline S12 on nonclinical biodistribution considerations for gene therapy products Step 2b Scientific guideline(0)
- ICH M2 Business requirements Scientific guideline(0)
- ICH M2 Electronic common technical document eCTD file format criteria Scientific guideline(0)
- ICH M2 Electronic common technical document eCTD Scientific guideline(0)
- ICH M3 R2 Nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals Scientific guideline(0)
- ICH M4 Common technical document CTD for the registration of pharmaceuticals for human use organisation of CTD Scientific guideline(0)
- ICH M 4 Common technical document for the registration of pharmaceuticals for human use Organisation of CTD Scientific guideline(0)
- ICH M4 Common technical document for the registration of pharmaceuticals for human use questions and answers Scientific guideline(0)
- ICH M 4 E Common technical document for the registration of pharmaceuticals for human use Efficacy Scientific guideline(0)
- ICH M 4 Q Common technical document for the registration of pharmaceuticals for human use Quality Scientific guideline(0)
- ICH M 4 S Common technical document for the registration of pharmaceuticals for human use Safety Scientific guideline(0)
- ICH M4E Common technical document for the registration of pharmaceuticals for human use efficacy questions and answers Scientific guideline(0)
- ICH M4E Common technical document for the registration of pharmaceuticals for human use efficacy Scientific guideline(0)
- ICH M4Q Common technical document for the registration of pharmaceuticals for human use quality Scientific guideline(0)
- ICH M4Q Location issues for common technical document for the registration of pharmaceuticals for human use quality questions and answers Scientific guideline(0)
- ICH M4S Common technical document for the registration of pharmaceuticals for human use safety questions and answers Scientific guideline(0)
- ICH M4S Common technical document for the registration of pharmaceuticals for human use safety Scientific guideline(0)
- ICH M5 Data elements and standards for drug dictionaries Scientific guideline(0)
- ICH M5 EWG Routes of administration controlled vocabulary Scientific guideline(0)
- ICH M5 EWG Units and measurements controlled vocabulary Scientific guideline(0)
- ICH M7 Assessment and control of DNA reactive mutagenic impurities in pharmaceuticals to limit potential carcinogenic risk Scientific guideline(0)
- ICH M8 Electronic common technical document eCTD v40 draft ICH implementation guide v20 Scientific guideline(0)
- ICH M9 on biopharmaceutics classification system based biowaivers Scientific guideline(0)
- ICH M10 on bioanalytical method validation Scientific guideline(0)
- ICH M11 guideline clinical study protocol template and technical specifications Scientific guideline(0)
- ICH M12 on drug interaction studies Scientific guideline(0)
- ICH multidisciplinary(0)
- ICH Q1A R2 Stability testing of new drug substances and drug products Scientific guideline(0)
- ICH Q1B Photostability testing of new active substances and medicinal products Scientific guideline(0)
- ICH Q1C Stability testing requirements for new dosage forms Scientific guideline(0)
- ICH Q1D Bracketing and matrixing designs for stability testing of drug substances and drug products Scientific guideline(0)
- ICH Q1E Evaluation of stability data Scientific guideline(0)
- ICH Q1F Stability data package for registration in climatic zones III and IV Scientific guideline(0)
- ICH Q2R2 Validation of analytical procedures Scientific guideline(0)
- ICH Q3A R2 Impurities in new drug substances Scientific guideline(0)
- ICH Q3B R2 Impurities in new drug products Scientific guideline(0)
- ICH Q3C R8 Residual solvents Scientific guideline(0)
- ICH Q3D Elemental impurities Scientific guideline(0)
- ICH Q4B Annex 1 Residue on ignition/sulphated ash Scientific guideline(0)
- ICH Q4B Annex 2 Test for extractable volume in parenteral preparations Scientific guideline(0)
- ICH Q4B Annex 3 Test for particulate contamination subvisible particles Scientific guideline(0)
- ICH Q4B Annex 4A Microbiological examination of nonsterile products microbial enumeration tests Scientific guideline(0)
- ICH Q4B Annex 4B Test for microbiological examination of nonsterile products tests for specified microorganisms Scientific guideline(0)
- ICH Q4B Annex 4C Test for microbiological examination of nonsterile products acceptance criteria for pharmaceutical preparations and substances for pharmaceutical use Scientific guideline(0)
- ICH Q4B Annex 5 Disintegration test Scientific guideline(0)
- ICH Q4B Annex 6 Uniformity of dosage unites general chapter Scientific guideline(0)
- ICH Q4B Annex 7 Dissolution test Scientific guideline(0)
- ICH Q4B Annex 8 Sterility test Scientific guideline(0)
- ICH Q4B Annex 10 Polyacrylamide gel electrophoresis Scientific guideline(0)
- ICH Q4B Annex 11 Capillary electrophoresis Scientific guideline(0)
- ICH Q4B Annex 12 Analytical sieving Scientific guideline(0)
- ICH Q4B Annex 13 Bulk density and tapped density of powders Scientific guideline(0)
- ICH Q4B Annex 14 Bacterial endotoxins tests Scientific guideline(0)
- ICH Q4B Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions Scientific guideline(0)
- ICH Q5AR2 Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin Scientific guideline(0)
- ICH Q5B Analysis of the expression construct in cell lines used for production of rDNAderived protein products Scientific guideline(0)
- ICH Q5C Stability testing of biotechnological/biological products Scientific guideline(0)
- ICH Q5D Derivation and characterisation of cell substrates used for production of biotechnological/biological products Scientific guideline(0)
- ICH Q5E Biotechnological/biological products subject to changes in their manufacturing process comparability of biotechnological/biological products Scientific guideline(0)
- ICH Q6A specifications test procedures and acceptance criteria for new drug substances and new drug products chemical substances Scientific guideline(0)
- ICH Q6B Specifications test procedures and acceptance criteria for biotechnological/biological products Scientific guideline(0)
- ICH Q7 Good manufacturing practice for active pharmaceutical ingredients Scientific guideline(0)
- ICH Q8 Q9 and Q10 questions and answers Scientific guideline(0)
- ICH Q8 R2 Pharmaceutical development Scientific guideline(0)
- ICH Q9 Quality risk management Scientific guideline(0)
- ICH Q10 Pharmaceutical quality system Scientific guideline(0)
- ICH Q11 Development and manufacture of drug substances chemical entities and biotechnological/biological entities Scientific guideline(0)
- ICH Q12 Technical and regulatory considerations for pharmaceutical product lifecycle management Scientific guideline(0)
- ICH Q14 Analytical procedure development Scientific guideline(0)
- ICH quality(0)
- ICH Quality Implementation Working Group points to consider for ICH Q8/Q9/Q10 guidelines Scientific guideline(0)
- ICH S1 Regulatory notice on changes to core guideline on rodent carcinogenicity testing of pharmaceuticals Scientific guideline(0)
- ICH S1A Need for carcinogenicity studies of pharmaceuticals Scientific guideline(0)
- ICH S1C R2 Dose selection for carcinogenicity studies of pharmaceuticals Scientific guideline(0)
- ICH S2 R1 Genotoxicity testing and data interpretation for pharmaceuticals intended for human use Scientific guideline(0)
- ICH S3A Toxicokinetics the assessment of systemic exposure in toxicity studies questions and answers Scientific guideline(0)
- ICH S3A Toxicokinetics the assessment of systemic exposure in toxicity studies Scientific guideline(0)
- ICH S3B Pharmacokinetics repeated dose tissue distribution studies Scientific guideline(0)
- ICH S4 Duration of chronic toxicity testing in animals rodent and nonrodent toxicity testing Scientific guideline(0)
- ICH S5 R3 Guideline on detection of reproductive and developmental toxicity for human pharmaceuticals Scientific guideline(0)
- ICH S6 R1 Preclinical safety evaluation of biotechnologyderived pharmaceuticals Scientific guideline(0)
- ICH S7A Safety pharmacology studies for human pharmaceuticals Scientific guideline(0)
- ICH S7B Nonclinical evaluation of the potential for delayed ventricular repolarization QT interval prolongation by human pharmaceuticals Scientific guideline(0)
- ICH S8 Immunotoxicity studies for human pharmaceuticals Scientific guideline(0)
- ICH S9 Nonclinical evaluation for anticancer pharmaceuticals Scientific guideline(0)
- ICH S10 Photosafety evaluation of pharmaceuticals Scientific guideline(0)
- ICH safety(0)
- ICMRA and WHO map out flexibilities used by regulators to respond to the COVID19 pandemic(0)
- ICMRA highlevel meeting on global health emergencies and regulatory approaches(0)
- Ida Bergva Aas(0)
- Ida Bruun Kristensen(0)
- Idacio(0)
- Idea AG withdraws its marketing authorisation application for Diractin ketoprofen(0)
- Idefirix(0)
- Idelvion(0)
- Identification of medicines EU task force to implement new international standards(0)
- Identifying research priorities for the study of drugrelated progressive multifocal leukoencephalopathy PML(0)
- IDflu(0)
- Idhifa(0)
- Ieva Ausrotaite(0)
- Ieva Rutkovska(0)
- Ifirmacombi(0)
- Ifirmasta previously Irbesartan Krka(0)
- Iftekhar Khan(0)
- Ignacio Laorga(0)
- Igor Aurer(0)
- Igor Guljasevic(0)
- Igor Stojkov(0)
- Ikervis(0)
- Ilaria Baldelli(0)
- Ilaria Passarani(0)
- Ilaris(0)
- Ilga Bubula(0)
- Iliana Ionkova(0)
- Ilkka Reenilä(0)
- Ilko Getov(0)
- Illiana Meurs(0)
- Ilmar Casimir Kruis(0)
- Ilona Anna Kopyta(0)
- Ilona Bruinsma(0)
- Ilona Czajka(0)
- Ilona G Reischl(0)
- Ilona Ivanoviene(0)
- Ilpo Lundberg(0)
- Ilse Boekhoud(0)
- Ilse Vincke(0)
- Ilumetri(0)
- Ilze Kalve(0)
- Ilze Treibaha(0)
- Ilze Zonenberga(0)
- Imagify(0)
- Imatinib Accord(0)
- Imatinib Actavis(0)
- Imatinib Koanaa(0)
- Imatinib medac(0)
- Imatinib productspecific bioequivalence guidance(0)
- Imatinib Teva(0)
- Imatinib Teva BV(0)
- Imbarkyd(0)
- Imbruvica(0)
- Imcivree(0)
- Imfinzi(0)
- IMI ADAPT SMART IMI GetReal and MIT NEW Drug Development ParadIGmS NEWDIGS Adaptive Design Laboratory workshop(0)
- Imjudo(0)
- Imke Jenniches(0)
- Imlygic(0)
- Immanuel Barth(0)
- Immunesystem diseases(0)
- Immune tolerance induction in haemophilia A patients with inhibitors Scientific guideline(0)
- ImmunoGam(0)
- Immunogenicity assessment of biotechnologyderived therapeutic proteins Scientific guideline(0)
- Immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use Scientific guideline(0)
- Immunologicals general(0)
- Immunologicals guidelines(0)
- Immunologicals multidisciplinary(0)
- Immunologicals stability(0)
- Immunologicals Working Party(0)
- Imnovid previously Pomalidomide Celgene(0)
- Imoxat(0)
- Impact of brain immaturity when investigating medicinal products intended for neonatal use Scientific guideline(0)
- Impact of liver immaturity when investigating medicinal products intended for neonatal use Scientific guideline(0)
- Impact of lung and heart immaturity when investigating medicinal products intended for neonatal use Scientific guideline(0)
- Impact of renal immaturity when investigating medicinal products intended for paediatric use Scientific guideline(0)
- Impact of the war in Ukraine on methodological aspects of ongoing clinical trials Scientific guideline(0)
- Implementation of the pharmacovigilance legislation(0)
- Implementing ISO IDMP introduction to SPOR data services(0)
- Implications of coronavirus disease COVID19 on methodological aspects of ongoing clinical trials Scientific guideline(0)
- Important new pharmacokinetic data demonstrating that REYATAZ atazanavirsulfate combined with NORVIR ritonavir and omeprazole should not be coadministered(0)
- Imprida(0)
- Imprida HCT(0)
- Improvac(0)
- Improved electronic reporting of suspected adverse reactions for better health protection(0)
- Improving bioequivalence studies(0)
- Improving patient safety through more proactive risk management(0)
- Improving quality of submissions(0)
- Improving safety of firstinhuman clinical trials(0)
- Improving safety of medicines across Europe(0)
- Improving the availability of vaccines for animals within the EU(0)
- Improving understanding of biosimilars in the EU(0)
- Impulsor(0)
- Imraldi(0)
- Imrestor(0)
- Imvanex(0)
- Ina Ebert(0)
- Ina GeorgievaIlieva(0)
- Inaqovi(0)
- Inaugural meeting of the Committee for Orphan Medicinal Products(0)
- Inauguration of the new committee on herbal medicinal products(0)
- Inbrija(0)
- Incellipan(0)
- Incident management plan(0)
- Incident management plan veterinary medicines(0)
- Incivo(0)
- Inclusion of antioxidants and antimicrobial preservatives in medicinal products Scientific guideline(0)
- Inclusion of appendices to clinical study reports in marketing authorisation applications Scientific guideline(0)
- Increased fees coming into effect on 1 April 2011(0)
- Increased fees coming into effect on 1 April 2012(0)
- Increased fees coming into effect on 1 April 2013(0)
- Increased fees coming into effect on 1 April 2014(0)
- Increased manufacturing capacity and supply for Spikevax(0)
- Increased manufacturing capacity for COVID19 Vaccine Janssen(0)
- Increased reporting of side effects of veterinary medicines helps to protect animal and human health(0)
- Increased risk of blood clots in lungs and death with higher dose of Xeljanz tofacitinib for rheumatoid arthritis(0)
- Increase in manufacturing capacity for COVID19 vaccine from AstraZeneca(0)
- Increase in manufacturing capacity for COVID19 vaccine from BioNTech/Pfizer(0)
- Increase in manufacturing capacity for COVID19 vaccines from Janssen Moderna and BioNTech/Pfizer(0)
- Increase in manufacturing capacity for Vaxzevria previously COVID19 Vaccine AstraZeneca(0)
- Increase in vaccine manufacturing capacity and supply for COVID19 vaccines from AstraZeneca BioNTech/Pfizer and Moderna(0)
- Increase in vaccine manufacturing capacity and supply for COVID19 vaccines from BioNTech/Pfizer and Moderna(0)
- Increase in vaccine manufacturing capacity for COVID19 vaccines from BioNTech / Pfizer and Moderna(0)
- Increasing access to reports on adverse reactions to medicines(0)
- Increasing oversight of API manufacturing through international collaboration(0)
- Increasing the availability of veterinary medicines(0)
- Increasing the availability of veterinary vaccines in the EU(0)
- Increlex(0)
- Incresync(0)
- Increxxa(0)
- Incruse Ellipta previously Incruse(0)
- Incurin(0)
- India(0)
- Indications for veterinary vaccines Scientific guideline(0)
- Indimacis 125(0)
- Individual case safety report ICSR information day(0)
- Individual case safety report information day(0)
- Indrek Soosaar(0)
- Indre SveikauskaiteRadučienė(0)
- Inductos to be suspended in the EU(0)
- Industry annual bilateral meetings(0)
- Industry associations webinar update on the implementation of European Medicines Agency policy on publication of clinical data Policy 0070(0)
- Industry stakeholder meeting on Brexit and operation of centralised procedure for human and veterinary medicines(0)
- Industry stakeholder meeting on Brexit and operation of the centralised procedure for human and veterinary medicine products(0)
- Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicinal products(0)
- Industry stakeholder meeting on Brexit and operation of the centralised procedure for human medicines(0)
- Industry stakeholder platform meetings(0)
- Industry stakeholder platform on research and development support(0)
- Industry stakeholder platform on the operation of the centralised procedure(0)
- Industry stakeholder teleconference on Brexit and operation of the centralised procedure for veterinary medicines(0)
- Industry stakeholder webinar on the UK withdrawal from the European Union End of transition period(0)
- Industry Standing Group(0)
- Industry Standing Group meetings(0)
- Industry Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRI(0)
- Ineke Havinga(0)
- Inés Almendros López(0)
- Ines Alves(0)
- Inés Contreras(0)
- Ines Dias(0)
- Ines Flugge(0)
- Ines Jurac(0)
- Ine Skottheim Rusten(0)
- ines Lacchetti(0)
- Ines Lindner(0)
- Ines Martins de Almeida(0)
- Ines Ottersbach(0)
- Inés VidalPardo Pardo(0)
- Ineta Popena(0)
- INFAI withdraws its marketing authorisation application for Gastromotal(0)
- Infanrix HepB(0)
- Infanrix Hexa(0)
- Infanrix Penta(0)
- Infectious Diseases Working Party(0)
- Infergen(0)
- Infinia(0)
- Inflacam(0)
- Inflectra(0)
- Infliximab(0)
- Influenza vaccines nonclinical and clinical module Scientific guideline(0)
- Influenza vaccines prepared from viruses with the potential to cause a pandemic and intended for use outside of the core dossier context Scientific guideline(0)
- Influenza vaccines quality module Scientific guideline(0)
- Influenza vaccines submission and procedural requirements Scientific guideline(0)
- Info day for micro small and mediumsized enterprises SMEs EMA support for SMEs under the new Veterinary Medicinal Products Regulation(0)
- Info day for micro small and mediumsized enterprises SMEs regulatory toolbox for medicines and combined devices developers(0)
- Info day for micro small and mediumsized enterprises supporting innovative medicines development and early access(0)
- Information and Q&A session on updated CAPs in webbased eAF(0)
- Information day on medication errors(0)
- Information day on new services and systems in pharmacovigilance preparing for business change(0)
- Information day on risk management planning and postauthorisation studies(0)
- Information day on the new identification of medicinal products international standards and International Conference on Harmonisation ICH M5/M2 and implementation of electronic submission of medicinal product information in the European Union(0)
- Information day on the new individual case safety report international standard and ICH E2B/M2(0)
- Information Management(0)
- Information management(0)
- Information meeting on participation of Croatia and Turkey in EMEA activities in 2006 and 2007(0)
- Information on suspected side effects of nationally authorised medicines now available through a single website(0)
- Information on transitional arrangements for pharmacovigilance legislation published(0)
- Information session on the pilot for expert panels scientific advice to manufacturers of highrisk medical devices(0)
- Information systems(0)
- Infrastructure procedures(0)
- Infringement procedure against Roche EMA update(0)
- Inga Salomon(0)
- Inga Sile(0)
- Inga Soveri(0)
- Ingeborg Barisic(0)
- Ingeborg Gerngross(0)
- Inge Holsappel(0)
- Inge Krabbendam(0)
- Ingela ThorsonKaija(0)
- Ingelvac CircoFLEX(0)
- Ingelvac PCV FLEX(0)
- Inger Ekman(0)
- IngerMargrethe Stavdal Paulsen(0)
- Inger Muldervan Dam(0)
- Inge Vandenbulcke(0)
- Inge van Geijlswijk(0)
- Inge van Gompel(0)
- Inge Verfaillie(0)
- Inge Zomerdijk(0)
- Ingo SchmidtWolf(0)
- Ingrid Ackermann(0)
- Ingrid Bijsmans(0)
- Ingrid Bolstad Eri(0)
- Ingrid Bourges(0)
- Ingrid Landberg(0)
- Ingrid Langner(0)
- Ingrid Lund(0)
- Ingrid Schellens(0)
- Ingrid Wang(0)
- Ingun Lemke(0)
- Ingvild Aaløkken(0)
- Inhixa(0)
- Initial evaluation procedures(0)
- Initiation of DARWIN EU® Coordination Centre advances integration of realworld evidence into assessment of medicines in the EU(0)
- Injectable veterinary medicinal products containing vitamin A for use in food producing species(0)
- Injectionsite residues considerations for risk assessment and residue surveillance Scientific guideline(0)
- Injectionsite residues Scientific guideline(0)
- Inke Reimer(0)
- Inlyta(0)
- Inmaculada Corrales(0)
- INMACULADA HERNANDEZ(0)
- INMACULADA MONTANUY(0)
- Inne Crèvecoeur(0)
- Innovation and Biomarkers in Cancer Drug Development IBCD 2015(0)
- Innovation and biomarkers in cancer drug development IBCD 2018(0)
- Innovation in veterinary medicines(0)
- Innovative Medicines Initiative WEBRADR workshop(0)
- Innovative Medicines Initiative WEBRADR workshop mobile technologies and social media as new tools in pharmacovigilance(0)
- InnovaxILT(0)
- InnovaxILTIBD(0)
- InnovaxNDH5(0)
- InnovaxNDIBD(0)
- InnovaxNDILT(0)
- INOmax(0)
- Inovelon(0)
- Inpremzia(0)
- Inrebic(0)
- Insmed withdraws its marketing authorisation application for IPLEX(0)
- Inspection activities procedures(0)
- Inspections procedures(0)
- Instanyl(0)
- Instrument for Preaccession Assistance project 20112013(0)
- Insufficient data on use of inhaled corticosteroids to treat COVID19(0)
- Insulatard(0)
- Insulin aspart Sanofi(0)
- Insulin glargine(0)
- Insulin human(0)
- Insulin Human 30/70 Mix Marvel(0)
- Insulin Human Long Marvel(0)
- Insulin Human Rapid Marvel(0)
- Insulin Human Winthrop(0)
- Insulin lispro Sanofi(0)
- Insuman(0)
- Intanza(0)
- Integrated management system(0)
- Integrating patients views in clinical studies of anticancer medicines(0)
- Integration of EudraGMDP and OMS Webinar for industry(0)
- Integrilin(0)
- Intelence(0)
- InterCommittee Scientific Advisory Group on Oncology(0)
- Interested in joining the Committee for Advanced Therapies CAT to represent patients associations or clinicians(0)
- Interested Parties to the HMPC(0)
- Interim guidance on enhanced safety surveillance for seasonal influenza vaccines in the EU Scientific guideline(0)
- Internal error(0)
- International activities(0)
- International agreements(0)
- International Clinical Trials Day(0)
- International Clinical Trials Day 20 May 2012(0)
- International Clinical Trials Day 20 May 2013(0)
- International Coalition of Medicines Regulatory Authorities ICMRA(0)
- International collaboration on GMP inspections(0)
- International collaboration on good manufacturing practice inspections expanded(0)
- International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Quality Implementation Working Group QIWG Integrated Implementation Training Workshops for ICH Q8 Q9 and Q10(0)
- International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products VICH(0)
- International cooperation to align approaches for regulation of COVID19 vaccines and medicines(0)
- International coordination needed to encourage conduct of large decisionrelevant COVID19 clinical trials(0)
- International Council on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH(0)
- International Pharmaceutical Regulators Programme IPRP(0)
- International regulators align positions on phase 3 COVID19 vaccine trials(0)
- International regulators and WHO address need to boost COVID19 vaccine confidence(0)
- International regulators and WHO call for wider public access to clinical data(0)
- International regulators and WHO join forces to address COVID19 challenges(0)
- International regulators and WHO support healthcare professionals to enhance public confidence in COVID19 vaccines(0)
- International regulators discuss available knowledge supporting COVID19 medicine development(0)
- International regulators pledge collective support to combat COVID19 pandemic(0)
- International regulators provide guiding principles for COVID19 clinical trials(0)
- International regulators recommendations on COVID19 vaccines and the Omicron variant(0)
- International regulators reflections on remote approaches to GCP and GMP regulatory oversight during COVID19 pandemic(0)
- International regulators stress continued need for COVID19 therapeutics(0)
- International regulators stress value of safe and effective vaccines(0)
- International regulators working together to enhance collaboration on COVID19 observational research(0)
- International regulators work towards alignment on development and authorisation of secondgeneration COVID19 vaccines(0)
- International workshop on the ethical and goodclinicalpractice aspects of clinical trials conducted in third countries(0)
- Interoperability of track and trace systems key to public health protection(0)
- Interpretation of Article 72 of Regulation EU 2019/6 Environmental safety documentation and environmental risk assessment of certain veterinary medicinal products Scientific guideline(0)
- Interpretation of Article 187 of Regulation EU 2019/6 Scientific guideline(0)
- Intrarosa(0)
- Intrinsa(0)
- Introducing a review and update of existing EU guidelines on residues studies to bring these into line with the VICH metabolism and residues guidelines GL46 to 49 Scientific guideline(0)
- Introducing DADI webinar on the digital application dataset integration DADI network project to replace electronic application forms(0)
- Introduction to Organisation Management Service OMS / Referentials Management Service RMS services and activities Industry webinar(0)
- Introduction to Organisation Management Service OMS and Referentials Management Service RMS services and activities Industry webinar(0)
- Introduction to Organisation Management Service OMS Industry webinar(0)
- Introduction to pharmacovigilance and rules for expedited reporting of Individual Case Safety Reports in Europe(0)
- Introduction to pharmacovigilance and rules for expedited reporting of individual case safety reports in Europe(0)
- Introduction to Referentials Management Service RMS Industry webinar(0)
- Introduction to Substance Management Service SMS Industry webinar(0)
- Introduction to the European Union regulatory system and European Medicines Agency for international regulators and nongovernmental organisations(0)
- IntronA(0)
- Intse Romein(0)
- Intuniv(0)
- Inuse stability testing of human medicinal products Scientific guideline(0)
- Inuse stability testing of veterinary medicinal products excluding immunological veterinary medicinal products Scientific guideline(0)
- Invanz(0)
- Invega(0)
- Invented Name Review Group(0)
- Investigation into GLP1based diabetes therapies concluded(0)
- Investigation into reports of serious adverse events following use of Fluad(0)
- Investigation of bioequivalence Scientific guideline(0)
- Investigation of chiral active substances human Scientific guideline(0)
- Investigation of chiral active substances veterinary Scientific guideline(0)
- Investigation of COVID19 Vaccine AstraZeneca and thromboembolic events continues(0)
- Investigation of drug interactions Scientific guideline(0)
- Investigation of manufacturing processes for plasmaderived medicinal products with regard to variant CreutzfeldtJakob disease risk Scientific guideline(0)
- Investigation of medicinal products in the term and preterm neonate Scientific guideline(0)
- Investigation of subgroups in confirmatory clinical trials Scientific guideline(0)
- Invirase(0)
- Invitation to EMEA 10th anniversary celebrations 11 March 2005(0)
- Invitro cultured chondrocyte containing products for cartilage repair of the knee Scientific guideline(0)
- In vitro investigation of mitochondrial toxicity of antiHIV nucleoside reverse transcriptase inhibitors Scientific guideline(0)
- Invokana(0)
- Involvement of children and young people at the Paediatric Committee Scientific guideline(0)
- Involving general practitioners in regulatory decisions on medicines(0)
- Involving patients in discussions on benefits and risks of medicines(0)
- Involving young people in EMA activities(0)
- Ioa(0)
- Ioana Agache(0)
- Ioana Tene(0)
- IOANNA ANGELOPOULOU(0)
- Ioanna Chinou(0)
- Ioannis Argyropoulos(0)
- IOANNIS IAKOVOU(0)
- Ioannis Kkolos(0)
- Ionsys(0)
- IPA programme Introductory meeting(0)
- Ipique(0)
- Iplex(0)
- Ipreziv(0)
- Ipsen Ltd withdraws its application for an extension of indication for NutropinAq(0)
- Ira Koval(0)
- Irbesartan/Hydrochlorothiazide Teva(0)
- Irbesartan BMS(0)
- Irbesartan Hydrochlorothiazide BMS(0)
- Irbesartan Hydrochlorothiazide Zentiva previously Irbesartan Hydrochlorothiazide Winthrop(0)
- Irbesartan Teva(0)
- Irbesartan Zentiva previously Irbesartan Winthrop(0)
- Irena Rogovska(0)
- Irena SenecicCala(0)
- Irena Vaketaite(0)
- Irene Arkesteijn(0)
- Irene Bachmann(0)
- Irene Bidault(0)
- Irene Bosselaers(0)
- Irene de Celis Cantera(0)
- Irene de la Casa Resino(0)
- Irene Izquierdo(0)
- Irene Mandrup Krüger(0)
- Irene Nowotny(0)
- Irene Promussas(0)
- Irene Ruiz de Diego(0)
- Irene Saugar Gomez(0)
- Iressa(0)
- Irina Csender(0)
- Irina Sandu(0)
- Irini Chrysafi Fanidou(0)
- IRIS for Good Pharmacovigilance practice GVP inspections training session for industry users(0)
- Iris Geussens(0)
- Iris Lauer(0)
- Irmeli Happonen(0)
- Irmgard Resch(0)
- Irmtraud Held(0)
- Iryna Vlasenko(0)
- Isabella Salzer(0)
- Isabelle DaoustMaleval(0)
- Isabelle Delneuville(0)
- Isabelle Pellanne(0)
- Isabelle PUFF(0)
- Isabelle Strépenne(0)
- Isabelle Yoldjian(0)
- Isabel Marques(0)
- ISABEL OLMOS(0)
- Isabel Proano Gomez(0)
- Isabel Rodrigo Castro(0)
- Is an orphan medicine still an orphan once it gets on the market(0)
- Isavella Kyriakidou(0)
- Iscover(0)
- Is diclofenac a threat to European vultures(0)
- Isemid(0)
- Isentress(0)
- Iska Lehmann(0)
- Iskra Pechijareva Sadikarijo(0)
- Ismail Rafik(0)
- Ismail Zor(0)
- ISO/ICH E2BR3 Individual case safety report ICSR in the EU Virtual live handson training course using the EudraVigilance system 28 Sept 2 Oct 2020(0)
- ISO/ICH E2BR3 Individual case safety report ICSR in the EU Virtual live handson training course using the EudraVigilance system 711 Dec 2020(0)
- ISO/ICH E2BR3 Individual case safety report ICSR in the EU Virtual live handson training course using the EudraVigilance system 711 Sept 2020(0)
- ISO/ICH E2BR3 Individual case safety report ICSR in the EU Virtual live handson training course using the EudraVigilance system 1216 Oct 2020(0)
- ISO/ICH E2BR3 Individual case safety report ICSR in the EU Virtual live handson training course using the EudraVigilance system 1620 Nov 2020(0)
- ISO/ICH E2BR3 Individual case safety reporting in the EU Handson training course using the EudraVigilance system(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Amsterdam(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Basel(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Berlin(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Bucharest(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Lisbon(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System London(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Madrid(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Munich(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Paris(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Prague(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System San Marino(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson training course using the EudraVigilance System Vienna(0)
- ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Virtual live handson training course using the EudraVigilance System(0)
- Isomarv medium(0)
- Israel(0)
- Issarlos(0)
- ISTA Pharma Ltd withdraws its marketing authorisation application for Vitragan(0)
- Istodax(0)
- Isturisa(0)
- Istvan Szatmari(0)
- Istvan Varkonyi MD(0)
- Its time to reduce replace and rethink the use of antimicrobials in animals(0)
- IT systems intermittently unavailable from 16 to 18 April 2021(0)
- IT systems temporarily unavailable from 18 to 20 June 2021(0)
- IT systems temporarily unavailable from 31 December 2020 to 1 January 2021(0)
- IT systems unavailable from 15 to 18 June 2018(0)
- IT systems unavailable from 18 to 20 September 2020(0)
- IT systems unavailable from 27 to 30 July 2018(0)
- IT systems unavailable from 28 October to 1 November 2016(0)
- IT systems unavailable from 30 March to 1 April 2019(0)
- IT systems unavailable from 30 November to 3 December 2018(0)
- IT systems unavailable from 30 October to 3 November 2015(0)
- Ivabradine Accord(0)
- Ivabradine Anpharm(0)
- Ivabradine JensonR(0)
- Ivabradine Zentiva(0)
- Iva Gruden Zdunic(0)
- Iva Klarica Domjanovic(0)
- Iva Kuliš(0)
- Iva Markovic(0)
- Ivana Bazina(0)
- Ivana Golabova(0)
- Ivana Jović(0)
- Ivana Kosier Mihalic(0)
- Ivana Ljubicic(0)
- Ivana Povrazníková(0)
- Ivana Pravdova(0)
- Ivana Sagud(0)
- Ivana Tasevska(0)
- Ivan Bernat(0)
- Ivan Kosalec(0)
- Ivan Mestrovic(0)
- Iva Strnadova(0)
- Ivelina Ivanova(0)
- Ivelina Terzieva(0)
- Ivemend(0)
- Ivermectin(0)
- Iveta Eglite(0)
- Iveta Obrovska(0)
- Iveta Sincakova(0)
- Iveta Vilcane(0)
- Ivica Malnar(0)
- Ivona Jukic(0)
- Ivozall(0)
- Iwona KorzeniewskaRybicka(0)
- Iwona Malinowska(0)
- Iwona MietusPastuszek(0)
- Ixempra(0)
- Ixense(0)
- Ixiaro(0)
- IXinity(0)
- IZABELA GRABOWSKAPlAZA(0)
- Izabela Jemielity(0)
- Izba(0)
- Jaana Hautala(0)
- Jaana Palomäki(0)
- Jaana Santaholma(0)
- Jacinta Hastings(0)
- Jacoba Jacqueline van Kuijk(0)
- Jacob Alsbæk Olsen(0)
- Jacob Haaber Christensen(0)
- Jacobus Romme(0)
- Jacqueline Daly(0)
- Jacqueline Masterson(0)
- Jacqueline Poot(0)
- Jacqueline Wiesner(0)
- Jacques Bietrix(0)
- Jaime García Sánchez(0)
- Jakavi(0)
- Jaka Zavasnik(0)
- Jakob Christensen(0)
- Jakob Paur(0)
- Jakub Szumilo(0)
- Jakub Velik(0)
- Jalra(0)
- James Mount(0)
- Janacti(0)
- Jana Danilovits(0)
- Jana Dubnova(0)
- Jana Fluksová(0)
- Jana Grobarcik Ballekova(0)
- Jana Hundt(0)
- Jana Jandlova(0)
- Jana Klimasová(0)
- Jana Kopecká(0)
- Jana Kundert(0)
- Jana Lass(0)
- Jana Lukacisinova(0)
- Jana Mazelova(0)
- Jana Pelouchova(0)
- Jana Schimanski(0)
- Jana Schweigertova(0)
- Jana Sipkova(0)
- Jana Zizkovska(0)
- Jan Bogaerts(0)
- Jan Brosda(0)
- Jan De Belie(0)
- Janet Koenig(0)
- Janet Mifsud(0)
- Jan HasselPflugh(0)
- Janica Mizzi(0)
- Janice Cassar Giacomotto(0)
- Janine Ezendam(0)
- JANINE MAHUNGU(0)
- Janis Kurlovics(0)
- Janis Ositis(0)
- Janja Mikuz(0)
- Janja Zagar(0)
- Jan Joseph(0)
- Janka SchulteMichels(0)
- Jan Krouzelka(0)
- Jan Mihule(0)
- Jan Mol(0)
- Jan MuellerBerghaus(0)
- Janneke van Leeuwen(0)
- Janneke van Oirschot(0)
- Janne Komi(0)
- Jan Nemecek(0)
- Jan Neuhauser(0)
- Jannik HelwegLarsen(0)
- JanOliver Karo(0)
- Janos Porszasz(0)
- Jan Pridöhl(0)
- Jan Saevels(0)
- JanssenCilag International NV withdraws its application for an extension of indication for Invega paliperidone(0)
- JanssenCilag International NV withdraws its application for an extension of the indication for Velcade bortezomib(0)
- JanssenCilag International NV withdraws its marketing authorisation application for Comfyde carisbamate(0)
- Jan Staessen(0)
- Jan Szulc(0)
- Janumet(0)
- Janusz Szyndler(0)
- Januvia(0)
- Jan Van Meerbeeck(0)
- Jan Velík(0)
- Jan Vosatka(0)
- Jan Welink(0)
- Jan Willem van der Laan(0)
- Jan Wolf(0)
- Japan(0)
- Jardiance(0)
- Jaroslav Kollárik(0)
- Jaroslav Maxa(0)
- Jaroslav Sterba(0)
- Jaroslav Tóth(0)
- Jascha Johann Hörnisch(0)
- Jasmin BarmanAksozen(0)
- Jasmin Bruckner(0)
- Jasper Brian Zantvoord(0)
- Jaume Vidal(0)
- Javad Mohammadnejad(0)
- Javier Alonso Naveda(0)
- Javier De Cristobal(0)
- Javier Espíldora Hernández(0)
- Javier Gisbert(0)
- Javlor(0)
- Jayempi(0)
- Jayne Crowe(0)
- Jaypirca(0)
- Jcovden previously COVID19 Vaccine Janssen(0)
- Jean Bachmann(0)
- JeanBaptiste Trancheveux(0)
- JeanChristophe Faucon(0)
- JeanClaude Rouby(0)
- Jean Emmanuel Severin(0)
- Jeanette Birgitta Johansson(0)
- Jeanette Charlton(0)
- Jeanette Devane(0)
- JeanLouis Robert(0)
- JeanLuc Golnez(0)
- JeanMarc PHILIPPE(0)
- JeanMichel Dogné(0)
- JeanMichel Race(0)
- Jeanne Jungclaus Majland(0)
- JeanNicolas Tournier(0)
- JeanNoël Talbot(0)
- JeanPaul Pirnay(0)
- JeanYves Reginster(0)
- Jehanara Korimbocus(0)
- Jelena Andjelic(0)
- Jelena Celutkiene(0)
- Jelena Katic(0)
- Jelena Pilic(0)
- Jelena Rakocevic(0)
- Jelle Demeestere(0)
- Jemperli(0)
- Jennie Sandberg(0)
- Jennifer Neubert(0)
- Jenni Keskitalo(0)
- Jenni Lehtisalo(0)
- Jenny Akke Wijbenga(0)
- Jenny Louise Lunt(0)
- Jenny Lund(0)
- JennyMaria Jönsson(0)
- Jenny Zhiyi You(0)
- Jens Barthel(0)
- Jens Bate(0)
- Jens Lindman(0)
- Jens Peter Hartmann(0)
- Jens Reinhardt(0)
- Jens Rotthauwe(0)
- Jens Schönfeld(0)
- Jens Stegers(0)
- JensUwe Bleich(0)
- Jentadueto(0)
- Jenzyl(0)
- Jeppe Larsen(0)
- Jeraygo(0)
- Jeremiah Gabriel Beechinor(0)
- Jeroen Koomen(0)
- Jeroen Poels(0)
- Jeroen Van Der Meijde(0)
- Jesduvroq(0)
- Jessica Harskamp(0)
- Jessica Hartmann(0)
- Jessica Mwinyi(0)
- Jessica van Montfoort(0)
- Jessica Zarb(0)
- Jess Skrydstrup Petersen(0)
- Jesus Alberto Sanchez Rodriguez(0)
- Jetrea(0)
- Jevtana(0)
- JiaWei Chen(0)
- Jinarc(0)
- Jinarc recommended for approval in rare kidney disease(0)
- Jiří Bureš(0)
- Jiri Dobias(0)
- Jiri Haman(0)
- Jiri Kaderabek(0)
- Jirina Koudelkova(0)
- Jitka Chumchalova(0)
- Jitka Soukupova(0)
- Jitka Vokrouhlická(0)
- Jitske de Vries(0)
- Jitske Jettinghoff(0)
- Jivadco(0)
- Jivi(0)
- JMJ Schipper(0)
- Joachim Ludwig(0)
- Joanna Kornacka(0)
- Joanna Kubisa(0)
- Joanna MorganNowak(0)
- Joanna Nurkowska(0)
- João Fernandes(0)
- Joao Jose Sousa(0)
- João Manuel Lopes de Oliveira(0)
- Joao Manuel Valente Nabais(0)
- João Pedro Duarte Da Silva(0)
- Joao Rocha(0)
- João Simões(0)
- Joaquim Bobi i Gibert(0)
- JoBirger Schmeing(0)
- Jobst Limberg(0)
- Joelle Warlin(0)
- Joël Mossong(0)
- Joep Bergers(0)
- Joerg Kahle(0)
- Joerg Kirberg(0)
- Joerg Zinserling(0)
- Johan Forsell(0)
- Johan Heldemar(0)
- Johanna Degerman(0)
- Johanna de Groot(0)
- Johanna Henriksnäs(0)
- Johanna KuhlmannGottke(0)
- Johanna Kuusisto(0)
- Johanna Lähteenvuo(0)
- Johanna Linnolahti(0)
- Johanna Reul(0)
- Johanna Wernsperger(0)
- Johanne Juhl Korsbæk(0)
- Johannes Blümel(0)
- Johannes Hendrikus Ovelgonne(0)
- Johannes Petrus Theodorus Span(0)
- Johannes Pietilainen(0)
- Johannes Schmidramsl(0)
- Johannes Taminiau(0)
- Johannes van Cruchten(0)
- Johan Nilvebrant(0)
- Johan Sällström(0)
- John Aspegren(0)
- John Boutelje(0)
- John Joseph Borg(0)
- Joicela(0)
- Joint Audit Programme(0)
- Joint Biologics Working Party/ Quality Working Party/ Good Manufacturing and Distributing Practice Inspectors Working Group European industry workshop on lifecycle management(0)
- Joint Biologics Working Party / Quality Working Party workshop with stakeholders in relation to prior knowledge and its use in regulatory applications(0)
- Joint DIA/EFGCP/EMA better medicines for children conference 2016 on optimisation of drug development for the benefit of children(0)
- Joint DIA EMEA CMDh workshop on user testing(0)
- Joint Drug Information Association/European Forum for Good Clinical Practice/European Medicines Agency paediatric forum 2011 The paediatric regulation in its 5th year Transition from toddler to school age(0)
- Joint Drug Information Association/European Medicines Agency/Food and Drug Administration orphandrug designation workshop(0)
- Joint Drug Information Association/European Medicines Agency information day on postauthorisation studies PAS(0)
- Joint Drug Information Association DIA / European Forum for Good Clinical Practice EFGCP /European Medicines Agency EMA conference on how to optimise childrens access to innovative medicines(0)
- Joint EMA / European Directorate for the Quality of Medicines and Healthcare EDQM event on biosimilars(0)
- Joint EMA / European Directorate for the Quality of Medicines and Healthcare workshop on characterisation of new clottingfactor concentrates with respect to potency assays used for labelling and testing of postinfusion samples(0)
- Joint EMA/FDA/MHLWPMDA orphan medicinal product workshop takes place today(0)
- Joint EMAECDC press briefing on current state of respiratory diseases and treatments in the EU/EEA(0)
- Joint EMAFDA workshop Efficacy of monoclonal antibodies in the context of rapidly evolving SARSCoV2 variants(0)
- Joint EMEA/IFAHEurope Info Day(0)
- Joint EMEANRG/EFPIA Workshop on Invented Names(0)
- Joint EMEANRG/Interested Parties Meeting(0)
- Joint European Forum for Good Clinical Practice / Drug Information Association / European Medicines Agency Better medicines for children conference(0)
- Joint European Medicines Agency/Drug Information Association information day on International Organization for Standardization identification of medicinal products standards achieving compliance(0)
- Joint European Medicines Agency/Drug Information Association information day on risk management planning(0)
- Joint European Medicines Agency/European Directorate for the Quality of Medicines and Healthcare workshop on improved potency assays for inactivated influenza vaccines(0)
- Joint European Medicines Agency / Food and Drug Administration workshop for paediatric Gaucher disease type I exploring the way forward(0)
- Joint European Medicines Agency / Heads of Medicines Agencies workshop on requirements for the authorisation of veterinary vaccines in the European Union(0)
- Joint European Medicines Agency/Parenteral Drug Association qualitybydesign workshop(0)
- Joint European Medicines Agency EMA / European Organisation for Research and Treatment of Cancer EORTC workshop on novel patientreported outcomes PRO and quality of life QoL approaches in cancer clinical research(0)
- Joint European Medicines Agency EMA US Food and Drug Administration FDA and Japanese Ministry of Health Labour and Welfare MHLW and Pharmaceuticals and Medical Devices Agency PMDA orphan medicinal product workshop(0)
- Joint Heads of Medicines Agencies/European Medicines Agency meeting on promoting prudent and responsible use of antimicrobials in veterinary medicine(0)
- Joint Heads of Medicines Agencies HMA/European Medicines Agency EMA AI workshop Smart regulation in a rapidly evolving world(0)
- Joint Heads of Medicines Agencies HMA/European Medicines Agency EMA Multistakeholder workshop on Patient Registries(0)
- Joint HMA/EMA Big Data Steering Group workshop on RWE methods(0)
- Joint HMA/EMA workshop on artificial intelligence in medicines regulation(0)
- Joint meeting of Goodclinicalpractice compliance Inspectors Working Group and eClinical Forum representatives on electronic data capture systems and investigator site eSource readiness(0)
- Joint meeting of Patients and Consumers Organisations PCO and Committee on Herbal Medicinal Products HMPC(0)
- Joint meeting of the EMA Scientific Committees Working Party with Patients and Consumers Organisations PCWP and the EMA/CHMP Working Group with Healthcare Professionals Organisations HCP WG(0)
- Joint meeting with all interested parties on a continuity policy for orphan medicinal products in the European Union(0)
- Joint press briefing The Clinical Trial Regulation enters into application in the EU(0)
- Joint scientific report of the European Centre for Disease Prevention and Control ECDC the European Food Safety Authority EFSA and the European Medicines Agency on meticillinresistant Staphylococcus aureus MRSA in livestock companion animals(0)
- Joint statement by Executive Steering Group on Shortages and Safety of Medicinal Products MSSG on shortages of antibiotic medicines(0)
- Joint strategy sets direction for EMA and EU medicines regulatory agencies to 2025(0)
- Joint TAIEX/EMEA Central Eastern European Countries Forum on the regulation of veterinary medicinal products(0)
- Joint TOPRA/EMA meeting The annual European Medicines Agency review of the year and outlook for 2011 and beyond(0)
- Joint workshop with representatives from patients consumers and healthcare professionals organisations Regulatory and methodological standards to improve benefitrisk evaluation of medicines(0)
- Joke Dols(0)
- Joke Jaarsma(0)
- Joke Sybesma(0)
- Jolanta Gulbinovic(0)
- Jolanta Karavackaite(0)
- Jolita Pancere(0)
- Jonas Bøje Nielsen(0)
- Jonathan Bergman(0)
- Jonathan Clark(0)
- Jonathan Ewbank(0)
- Jonna Kumpulainen(0)
- Joost Swart(0)
- Jordi López Ramon(0)
- Jordi Remon(0)
- Jorge Batista(0)
- Jorge Martinez Fernandez(0)
- Jörg Engelbergs(0)
- Jorge Núñez Baz(0)
- Jörg Richstein(0)
- Jorie Versmissen(0)
- Joris van Loenhout(0)
- Jorn Mulder(0)
- Jo Robays(0)
- Jorveza(0)
- Josa Preuss(0)
- José A Jonis(0)
- José Antonio Navarro Alonso(0)
- Jose Daniel de Vicente Corbeira(0)
- Jose Drabwell(0)
- Josef Suchy(0)
- Jose Ignacio Garcia(0)
- Jose Ignacio Malagon Calle(0)
- José Javier Sawchik Monegal(0)
- Jose Luis Cobos Serrano(0)
- JOSE MANUEL GARCIAPINILLA(0)
- Jose Manuel Zubeldia(0)
- Jose María Rodríguez Pachón(0)
- José Morais(0)
- Joseph Christian Abela(0)
- Joseph De Courcey(0)
- JOSEP VERGES MILANO(0)
- Jose Ramon Franco Minguell(0)
- José Willemse(0)
- Josipa Cvek(0)
- Jostein Hatlelid(0)
- Jos van der Ven(0)
- Joulferon(0)
- Jovana Radovanovic(0)
- Juan Carlos Baiges Salvado(0)
- Juan Fernando Martínez Leal(0)
- Juan Pablo Horcajada(0)
- Jubbonti(0)
- Judgement by European Union Civil Service Tribunal on appointment procedure of EMA Executive Director(0)
- Judita Skladaná(0)
- Judit Bedekovics(0)
- Judit Fehér(0)
- Judith Romberg(0)
- Judith Secklehner(0)
- Judit Juhász(0)
- Juglandis folium(0)
- Juha Hakulinen(0)
- Juha Jarvi(0)
- Juha Kolehmainen(0)
- JuhaMatti Juntunen(0)
- Juhan Ruut(0)
- Juha Sinnemäki(0)
- Juha Vakkilainen(0)
- Jukka Leppänen(0)
- Jukka Pakkanen(0)
- Jukka Sallinen(0)
- Julia Djonova(0)
- Julia Högler(0)
- Julia Katharina Maier(0)
- Julia Kreß(0)
- Julia Lehtinen(0)
- Juliane Bauch(0)
- Julian Eftimov(0)
- Juliane Jaekel(0)
- Juliane Meissner(0)
- Juliane Rau(0)
- Juliane Schäfer(0)
- Juliane Teubel(0)
- Julian Fearne(0)
- Julian Isla(0)
- Julian Paesler(0)
- Julia Pallos(0)
- Julia Ruiz Gutierrez(0)
- Julia Stiles(0)
- Julia Wadoux(0)
- Julia Zimmer(0)
- Julie Dallemagne(0)
- Julie Duquesne(0)
- Julien Laporte(0)
- Juliette Maupu(0)
- Julija Lohina(0)
- Juline Meinhold(0)
- Julio Delgado Gonzalez(0)
- Julius Pollinger(0)
- Julius Uber(0)
- Juluca(0)
- Juniperi aetheroleum(0)
- Juniperi galbulus pseudofructus(0)
- Jurate Antanaviciene(0)
- Jurgen Grimm(0)
- Jürgen Scherer(0)
- Jürgen Wolf(0)
- Justina Creppy(0)
- Justine Etscheid(0)
- Justine van Tongeren(0)
- Justyna Dziewiatka(0)
- Justyna KozikJaromin(0)
- Juta Kraav(0)
- Jutta Dedorath(0)
- Juvenile animal studies JAS and impact on anticancer medicine development and use in children Scientific guideline(0)
- Jylamvo(0)
- Jyseleca(0)
- Kaatje Smits(0)
- Kadcyla(0)
- Kaftrio(0)
- KahJee Li(0)
- Kai Liang(0)
- Kairi Kasemets(0)
- Kairi Laius(0)
- Kairi Rooma(0)
- Kaisa Immonen elected as new cochair of Patients and Consumers Working Party(0)
- Kaisa Kärberg(0)
- Kaisa Mari Hämäläinen(0)
- Kaisa Paldanius(0)
- Kaisa Sunela(0)
- KaiUwe Eckardt(0)
- KaiUwe Riedel(0)
- Kaja Jantson(0)
- KAJA LUND(0)
- Kalbitor(0)
- Kaletra(0)
- Kalydeco(0)
- Kamilla Josefsdottir(0)
- Kanjinti(0)
- Kanuma(0)
- Kapruvia(0)
- Karel Allegaert(0)
- Karen Cristiano(0)
- Karen De Smet(0)
- Karen Ekkelund Petersen(0)
- Karen Goetz(0)
- Karen Mary Keely(0)
- Karen Millet(0)
- Karen Pilgaard(0)
- Karen RösnerFriese(0)
- Karen Van Malderen(0)
- Kari Grave(0)
- Karijn PijnenburgKleizen(0)
- Kari Lönnberg(0)
- Karima Adamo(0)
- Karima Ourdache(0)
- Kari Mette Engh(0)
- Karina SuciuSubert(0)
- Karina van Wonderen(0)
- Karin Bolin(0)
- Karine Le Dortz(0)
- Karine Meunier(0)
- Karin Erika Svedlund(0)
- Karin Erneholm(0)
- Karin Fawkner(0)
- Karin Fjordén(0)
- Karin Gröndahl(0)
- Karin Hellgren(0)
- Karin Janssen van Doorn(0)
- Karin Krogars(0)
- Karin Kundler(0)
- Karin Mathold(0)
- Karin Nordenankar(0)
- Karin Nylén(0)
- Karin Poellitzer(0)
- Karin Seifert(0)
- Karin Sjöström(0)
- Karin Weisser(0)
- Kari Olli Helgesen(0)
- Kari Punnonen(0)
- Kari Salmela(0)
- Karl Bo Anders Lindahl(0)
- Karl Broich(0)
- Karl de Marco(0)
- Karl Högström(0)
- Karlijne Geijtenbeek(0)
- Karl Katholnig(0)
- Karl Mikael Kälkner(0)
- Karl Weigand(0)
- Karmela Kopcic(0)
- Karmin Saadat(0)
- Karolien Goffin(0)
- Karolina Ditrych Hvid(0)
- Karolina Kwiatek(0)
- Karolína Pestova(0)
- Karolina Törneke(0)
- Karolina Westin(0)
- Karoline Buhre(0)
- Karolin Volkmann(0)
- Karri Penttila(0)
- Karvea(0)
- Karvezide(0)
- Kassandra Walluks(0)
- Katalina Mettke(0)
- Katalin Szalay(0)
- Katariina KivilahtiMantyla(0)
- Katarina Albreht(0)
- Katarina Dathe(0)
- Katarina Ekholm Selling(0)
- Katarina Glogoški(0)
- Katarína Kollarova(0)
- Katarina Lindahl(0)
- Katarína Massányiová(0)
- Katarina Sjogreen Gleisner(0)
- Katarina Straus(0)
- Katarina Sundberg(0)
- Katarina Tepsic Stupica(0)
- Katarzyna Chrobak(0)
- Katarzyna Glowacka(0)
- Katarzyna Lastawska(0)
- Katarzyna PostekKaczmarczyk(0)
- Katarzyna Ziolkowska(0)
- Katarzyna Zywiec(0)
- Kate Kelly(0)
- Katelijne De Swert(0)
- Katerina Pospisilova(0)
- Katerina Saitzova(0)
- KATERINA SAVVIDOU(0)
- Katharina Beck(0)
- Katharina Dirmeier(0)
- Katharina GazdaPleban(0)
- Katharina Habel(0)
- Katharina Hees(0)
- Katharina Hoenigl(0)
- Katharina Hofmann(0)
- Katharina Högdin(0)
- Katharina Weber(0)
- Kathrin Bayanga(0)
- Kathrin Dietze(0)
- Kathrine Ask Asmussen(0)
- Kathrine Just Andersen(0)
- Kathrine Rose(0)
- Kathrin Schirmann(0)
- Kathrin Schmidt(0)
- Kathrin Zeller(0)
- Kathryn Elun Morgan(0)
- Katia Carvalho Alves(0)
- Katia Chemala(0)
- Katia Pauwels(0)
- Katie Corrigan(0)
- Katja Ableiter(0)
- Katja Belt(0)
- Katja Boxberger(0)
- Katja Breznik Divjak(0)
- Katja Findeisen(0)
- Katja HeitinkPolle(0)
- Katja Kaulich(0)
- Katja Pihlainen(0)
- Katja Sliva(0)
- Katja Valent(0)
- Katleen Nicolaï(0)
- Katrien Bernaert(0)
- Katrien Oude Rengerink(0)
- Katrien Van Landuyt(0)
- Katrin Buss(0)
- Katrine Damkjær Madsen(0)
- Katrine Heier(0)
- Katrin Féchir(0)
- Katrin Jeeger(0)
- Katrin Kirsch(0)
- Katrin Krach(0)
- Katrin Kurvits(0)
- Katrin Schlager(0)
- Katrin Tagel(0)
- Kauliv(0)
- KayMartin Hanschmann(0)
- Keeping medicines safe(0)
- Keith Baptiste(0)
- Keiu Heinla(0)
- Kelly Underwood(0)
- Kendra Schafti(0)
- Kengrexal(0)
- Kenichi Tamiya(0)
- Kenneth Brett(0)
- Kenneth Nieleboch(0)
- Kenny Glæsner(0)
- Kentera previously Oxybutynin Nicobrand(0)
- Kepivance(0)
- Kepnetic(0)
- Keppra(0)
- Kerendia(0)
- Kerstin Brakmann(0)
- Kerstin Cramer(0)
- Kerstin Elisabeth Sollerbrant Melefors(0)
- Kerstin Franke(0)
- Kerstin Loschcke(0)
- Kerstin Stephan(0)
- Kerstin Wickström(0)
- Kersti Oselin(0)
- Kesimpta(0)
- Ketabel 100 mg/ml solution for injection and associated names(0)
- Ketek(0)
- Ketoconazole AIDSCFM(0)
- Ketoconazole HRA(0)
- Ketoconazole HRA recommended for approval in Cushings syndrome(0)
- Kevin Arien(0)
- Kevin Gauci(0)
- Kevin James ODonnell(0)
- Kevin Keohane(0)
- Kevin van de Wiel(0)
- Kevzara(0)
- Kexxtone(0)
- Key aspects for the use of pharmacogenomic methodologies in the pharmacovigilance evaluation of medicinal products Scientific guideline(0)
- Key deliverable of Falsified Medicines Directive achieved(0)
- Key principles for the use of electronic product information for EU medicines(0)
- Keytruda(0)
- Khadija Selouaoui(0)
- Kheira Hamadi(0)
- Khoa Huynh(0)
- Khodor Chatila(0)
- Kiacta(0)
- Kieran Breen(0)
- Kigabeq(0)
- Kimberley Sherwood(0)
- Kimberly Vanthuyne(0)
- Kim Boerkamp(0)
- Kimmo Jaakkola(0)
- Kimmtrak(0)
- Kim Sherwood(0)
- Kine Marita Knudsen Sand(0)
- Kineret(0)
- Kinga Csecsei(0)
- Kinga NowickaMatus(0)
- Kinpeygo(0)
- Kinzalkomb(0)
- Kinzalmono previously Telmisartan Boehringer Ingelheim Pharma KG(0)
- Kiovig(0)
- Kira Blankenbach(0)
- Kira Fiedermutz(0)
- Kira Rosenkilde Underbjerg(0)
- Kirsi Luoto(0)
- Kirsten Egebjerg Juul(0)
- Kirsten Hornberg(0)
- Kirsten Martin(0)
- Kirsten Thomsen(0)
- Kirsti Villikka(0)
- Kirsty previously Kixelle(0)
- Kisplyx(0)
- Kisqali(0)
- Kivexa(0)
- Klara Hammarström(0)
- Klara Saar(0)
- Klara Siroka(0)
- Klaudia Dudarewicz(0)
- Klaudia Hettinger(0)
- KlausHeinrich Zimlich(0)
- Klaus Neumuller(0)
- Klaus Stüwe(0)
- Klaus Uhlenhut(0)
- KLEANTHI SAPKA(0)
- Klisyri(0)
- Knud Sveen Torjesen(0)
- Knut Almgren(0)
- KNUT MAGNE SKAAR(0)
- Kobe Dewilde(0)
- Koenraad Brusselmans(0)
- Kogenate Bayer(0)
- Kolbam(0)
- Komboglyze(0)
- Kommerie Hendrik(0)
- Konstantia Tasioudi(0)
- Konstantina Alexopoulou(0)
- Konstantinos Ghirtis(0)
- Konstantinos Konstantopoulos(0)
- Konstantinos Markopoulos(0)
- Konstantin WeberLassalle(0)
- Kora Doorduyn van der Stoep(0)
- Koraljka Meštrović(0)
- Kornelia Flämig(0)
- Koselugo(0)
- Kovaltry(0)
- Krasimir Zlatkov(0)
- Krazati(0)
- Kriptazen(0)
- Krista Ress(0)
- Kristian Aagaard(0)
- Kristianne Kok(0)
- Kristian Wennmalm(0)
- Kristiina Järvinen(0)
- Kristiina Karro(0)
- Kristina Almasiova(0)
- Kristina Bech Jensen(0)
- Kristina Brundziene(0)
- Kristina Dunder(0)
- Kristina Hoffmann(0)
- Kristina Kluge(0)
- kristina kozikova(0)
- Kristina Laursen(0)
- Kristina Lehmann(0)
- Kristina Magnusson Lundqvist(0)
- Kristina MalinovskajaGomez(0)
- Kristina Martinell(0)
- Kristina Nadrah(0)
- Kristina Raczova(0)
- Kristina Vavruskova(0)
- Kristine EdolfaKalnina(0)
- Kristine Hvolby(0)
- Kristine Kazaka(0)
- Kristin Elf(0)
- Kristine Moltu(0)
- Kristine OndrupeKirilova(0)
- Kristine Plensnere(0)
- Kristine Supe(0)
- Kristin Karlsson(0)
- Kristin Skougaard(0)
- Kristin Thorseng Kvande(0)
- Kristofer Olofsson(0)
- Kristyna Pruchova(0)
- Kristyna Rehorova Hradilkova(0)
- Kristýna Veselá(0)
- Krisztina Ella(0)
- Krka dd Novo mesto withdraws its marketing authorisation application for Desloratadine Krka desloratadine(0)
- Kromeya(0)
- Krõõt Aab(0)
- Krystexxa(0)
- Krystyna CegielskaPerun(0)
- Krzysztof Podhorec(0)
- Ksenija Sandor(0)
- kuberaka mariampillai(0)
- Kuelli Laur(0)
- Kuvan(0)
- Kymriah(0)
- Kynamro(0)
- Kyndrisa(0)
- Kyntheum(0)
- Kyomarc(0)
- Kyprolis(0)
- Kyriaki Fakinou(0)
- Kyrre Eeg Emblem(0)
- Labazenit(0)
- Lacosamide Accord(0)
- Lacosamide Adroiq(0)
- Lacosamide Pain UCB Pharma(0)
- Lacosamide UCB(0)
- Lactose(0)
- Laetitia Le Letty(0)
- Lagae Lieven(0)
- Lagevrio(0)
- Laila Matveja(0)
- Laivi Saaremäel(0)
- La Jolla Limited withdraws its marketing authorisation application for Riquent(0)
- Lakhdar Badis Bensaad(0)
- Lamivudine/Zidovudine Teva(0)
- Lamivudine / Zidovudine ViiV previously Lamivudine / Zidovudine GSK(0)
- Lamivudine Teva(0)
- Lamivudine Teva Pharma BV(0)
- Lamivudine ViiV(0)
- Lamzede(0)
- Languages on this website(0)
- Lanreotide acetate productspecific bioequivalence guidance(0)
- Lantus(0)
- Lapatinib ditosylate monohydrate(0)
- Lapatinib productspecific bioequivalence guidance(0)
- Lara Consani(0)
- Lara Miletić(0)
- Lara Quiroga Gonzalez(0)
- Larisa Aragon Castro(0)
- Larisa Gorobets(0)
- Larissa de Lannoy(0)
- Larissa Engel(0)
- Larissa Higgins(0)
- Larissa Kopp(0)
- Lars Bo Nielsen(0)
- Lars Christoph Nickel(0)
- Lars Krueger(0)
- Lars Peter Engeset Austdal(0)
- Lasofoxifene tartrate(0)
- László Péter Drimba(0)
- László Tóthfalusi(0)
- Latanoprost(0)
- Latest data support continued use of ACE inhibitors and ARB medicines during COVID19 pandemic(0)
- Latuda(0)
- Launch of enhanced monitoring system for availability of medicines used for treating COVID19(0)
- Launch of European project for monitoring benefits and risks of vaccines throughout their lifecycle(0)
- Launch of international pilot programme on inspection of manufacturers of sterile medicines(0)
- Launch of new HMAEMA catalogues of realworld data sources and studies(0)
- Launch of PRIME Paving the way for promising medicines for patients(0)
- Launch of public consultation on joint network strategy to 2025(0)
- Launch of public consultation to start discussion on clinical studies of herbal medicines in children(0)
- Laura Andreoli(0)
- Laura Braghiroli(0)
- Laura Campitelli(0)
- Laura Díez Alonso(0)
- Laura Ebbing(0)
- Laura Fazzolari(0)
- Laura Galatti(0)
- Laura Ivett Varga(0)
- Laura Jimenez Hernando(0)
- Laura Macek(0)
- Laura Marrero Ortiz(0)
- Laura Mie Jensen(0)
- Laura Oggianu(0)
- Laura Quintas Lorenzo(0)
- Laura Rodriguez Garcia(0)
- Laura Rodwell(0)
- Laura Sottosanti(0)
- Laura Tejedor(0)
- Laura Van Hoyweghen(0)
- Laure BADUEL(0)
- Laure de Ligniville(0)
- Laurence Baril(0)
- Laurence de Fays(0)
- Laurence GirodGerin(0)
- Laurence Odwyer(0)
- Lauren Myles(0)
- Laurens de Leur(0)
- Laurens Verscheijden(0)
- Laurent Fabry(0)
- Lauren Vareslija(0)
- Laure Tiquet(0)
- Lauro Cascia(0)
- Lavandulae aetheroleum(0)
- Lavandulae flos(0)
- Laventair Ellipta previously Laventair(0)
- Leaflets(0)
- Learnings initiative webinar for optimal use of big data for regulatory purpose(0)
- Lecithinum ex soya(0)
- Ledaga(0)
- Ledipasvir/sofosbuvir productspecific bioequivalence guidance(0)
- Leena Valmu(0)
- Leen De Vuyst(0)
- Leflunomide medac(0)
- Leflunomide ratiopharm(0)
- Leflunomide Teva(0)
- Leflunomide Zentiva previously Leflunomide Winthrop(0)
- Legal framework(0)
- Legal framework Advanced therapies(0)
- Legal framework orphan designation(0)
- Legal framework Pharmacovigilance(0)
- Legal notice(0)
- Leganto(0)
- Legislative issues(0)
- Leire Aguado(0)
- Leire Solis Garate(0)
- Lembe Kullamaa(0)
- Lena Eroukhmanoff(0)
- Lena Hedman(0)
- Lenalidomide Accord(0)
- Lenalidomide Celgene Europe(0)
- Lenalidomide Krka dd(0)
- Lenalidomide Krka dd Novo mesto previously Lenalidomide Krka(0)
- Lenalidomide Krka previously Lenalidomide Krka dd Novo mesto(0)
- Lenalidomide Mylan(0)
- Lenalidomide productspecific bioequivalence guidance(0)
- Lena Strindelius(0)
- Lena Tencic(0)
- Lene Birgitte Grejs Petersen(0)
- Lene Hansen(0)
- Lenka Cincerova(0)
- Lenka Karaszova(0)
- Lenka Kralova(0)
- Lenka Maresova(0)
- Lenka Maxová(0)
- Lenka Simova(0)
- Lennart Rusch(0)
- Lenvima(0)
- Leona Nepejchalová(0)
- Leonhard Held(0)
- LeonhardKey Mien(0)
- Leonidas Klironomos(0)
- Leonie Zimmermann(0)
- Leonore Aubry(0)
- Leonuri cardiacae herba(0)
- Leon van Aerts(0)
- Leopoldina de Sousa(0)
- Leqvio(0)
- Lesley Verley(0)
- Leticia Martinez Peyrat(0)
- Leticia Ribeiro(0)
- Letifend(0)
- Leucofeligen FeLV/RCP(0)
- Leucogen(0)
- LeukoScan(0)
- Leuprorelin(0)
- Leuprorelin depot medicines PRAC recommends new measures to avoid handling errors(0)
- Level of purification of extracts to be considered as herbal preparations Scientific guideline(0)
- Levemir(0)
- Levetiracetam Accord(0)
- Levetiracetam Actavis(0)
- Levetiracetam Actavis Group(0)
- Levetiracetam Hospira(0)
- Levetiracetam ratiopharm(0)
- Levetiracetam Sun(0)
- Levetiracetam Teva(0)
- Levistici radix(0)
- Levitra(0)
- Levodopa/Carbidopa/Entacapone Orion(0)
- Levodopa/carbidopa/entacapone productspecific bioequivalence guidance(0)
- Levonorgestrel(0)
- Levonorgestrel and ulipristal remain suitable emergency contraceptives for all women regardless of bodyweight(0)
- Levothyroxine productspecific bioequivalence guidance(0)
- Levviax(0)
- Lextemy(0)
- Lexylan(0)
- Leyre Sanchez Sanchez de Rojas(0)
- Liam Childs(0)
- Liam McDonough(0)
- Liana Martirosyan(0)
- Liane van HoutePluimgraaff(0)
- Libertek(0)
- Libmeldy(0)
- Libmyris(0)
- Librela(0)
- Libtayo(0)
- Lichen islandicus(0)
- Lidija Cizmovic(0)
- Lidija Makarova(0)
- Lidija Prka(0)
- Lidocaine/tetracaine(0)
- Lieke Sandberg Smits(0)
- Lieke van der Velden(0)
- Liene Luce(0)
- Liesbeth Bogaert(0)
- Liesbeth Van Nieuwenhove(0)
- Lies Elizabeth Van Vlijmen(0)
- Lifmior(0)
- Liga Kalnina(0)
- Liga Kunrade(0)
- Liga Mitrike(0)
- Ligia Elena Dutu(0)
- Liina Salur(0)
- Liisa Jutila(0)
- Liisa Pylkkanen(0)
- Liisa Saare(0)
- Liisa Tenkanen(0)
- Liliane Mbiye Mutekemena(0)
- Lilija Miller(0)
- Liliya Rostomyan(0)
- Lily Cannon(0)
- Limin Liu(0)
- Limitations to the use of ethylene oxide in the manufacture of medicinal products human Scientific guideline(0)
- Lina Čačić(0)
- Lina Laze(0)
- Lina Seibokiene(0)
- Linas Mazeika(0)
- Lincocin and its associated names(0)
- LincoSpectin 100 and associated names(0)
- Linda Dalin(0)
- Linda Gallais(0)
- Linda Holtkamp(0)
- Linda Marchioro(0)
- Linda Sufrica(0)
- Linda van Orsouw(0)
- Line Caroe Sorensen(0)
- Line Marie Nordstrand(0)
- Line Michan(0)
- Line Praest Lauridsen(0)
- Linguistic review Human(0)
- Linguistic review Veterinary(0)
- Linhaliq(0)
- Lini semen(0)
- LinkedIn Live interview with Ivo Claassen Tomorrows veterinary medicines for healthy animals and humans(0)
- LinkedIn Live interview with Peter Arlett Realworld evidence in medicines regulation(0)
- Linnea Willdén Melin(0)
- Lioba Helfgen(0)
- lionel piroth(0)
- Liora Brunel(0)
- Liposomal amphotericin B productspecific bioequivalence guidance(0)
- Liprolog(0)
- Liquiritiae radix(0)
- Lisa Agerholm Larsen(0)
- Lisa Englert(0)
- Lisa Hanquet(0)
- Lisa Heltzel(0)
- Lisa Jost(0)
- Lisa Nika(0)
- Lisbeth Bregnhoj(0)
- Lise Laborieux(0)
- Lise Rudbæk Christensen(0)
- Listening to the publics views on the safety of medicines(0)
- List of medicines under additional monitoring(0)
- Litak(0)
- Litfulo(0)
- Liva Jakovele(0)
- Live bacterium B thetaiotaomicron(0)
- Livensa(0)
- Live recombinant vector vaccines for veterinary use Scientific guideline(0)
- Livia Puljak(0)
- Liviu Nitulescu(0)
- Livmarli(0)
- Liv Merete Wiik(0)
- Livogiva(0)
- Livtencity(0)
- Lixiana(0)
- Ljubica Hodak(0)
- Loargys(0)
- Local tolerance of intramammary preparations in cows Scientific guideline(0)
- Locametz(0)
- Locatim previously Serinucoli(0)
- Lodipressin(0)
- Loes den Otter(0)
- Loes Maton(0)
- Logo and visual identity(0)
- Lojuxta(0)
- Lokelma(0)
- Lollita Sanda Camelia Taban(0)
- Longacting formulations for injection containing barium selenate for all food producing species(0)
- Longrange(0)
- Lonquex(0)
- Lonsurf(0)
- Looking back at 2013 from Guido Rasi Executive Director(0)
- Lopinavir/Ritonavir Mylan(0)
- Lora Ruth Wogu(0)
- Loredana Candela(0)
- Lorella Chiappinelli(0)
- Lorenzo Brunetti(0)
- Lorenzo Tesolin(0)
- Loreto Carmona(0)
- Loreto Fernández Rodríguez(0)
- Lorraine Nolan(0)
- Lorviqua(0)
- Lothar Bergmann(0)
- Lotilaner Elanco(0)
- Lotimax(0)
- Lotte Dahl Nissen(0)
- Lotte Skoulund Laursen(0)
- Louisa Braun Exner(0)
- Louise Claessen(0)
- Louise Lykke Karlsson(0)
- Louise WenzelPetersen(0)
- Loulla(0)
- Lourdes Fernandez Martn(0)
- Lourens Bloem(0)
- Loxicom(0)
- Loxitab(0)
- Luana Mifsud Buhagiar(0)
- Lubica Jezova(0)
- Luca Busani(0)
- Luca Fancsalszky(0)
- Luca Massacesi(0)
- Luca Roberti(0)
- Luca Romanelli(0)
- Luca Santi(0)
- Lucas Mevius(0)
- Lucas Moreno Martin Retortillo(0)
- Lucas Rems(0)
- Luc Baeyens(0)
- Lucentis(0)
- Lucia Kovářová(0)
- Lucia Krskova(0)
- Lucia Kuráková(0)
- Lucía LópezAnglada Fernández(0)
- Luciana Labanca(0)
- Lucie Bouzidová(0)
- Lucie Moulisová(0)
- Lucie Pallagy(0)
- Lucie Pokludová(0)
- Lucie Skalova(0)
- Lucija Fasalek(0)
- Lucija Kusar(0)
- Lucy Wyse(0)
- Ludger Klimek(0)
- Ludivine MARTIN(0)
- Luela Fröhlich(0)
- Luisa Arreaza Lopez(0)
- Luisa Becedas(0)
- Luisa Cordova(0)
- Luis Agote Casado(0)
- Luisa Maria Martin Cabrejas(0)
- Luisa Stoppa(0)
- Luisa Valer(0)
- Luis González Rivas(0)
- Luis Gouveia(0)
- Luis Ignacio Gonzalez Granado(0)
- Luis Ignacio PerezOrdoyo Garcia(0)
- LuJie FERRE(0)
- Luka Kosec(0)
- Lukas Malte Aguirre Davila(0)
- Lukas Slovak(0)
- Lukas Stahuliak(0)
- Lukasz Japtok(0)
- Lukasz Kutner(0)
- Lukasz Montewka(0)
- Lukasz Olak(0)
- Luke Bowden(0)
- Lumark(0)
- Lumeblue previously known as Methylthioninium chloride Cosmo(0)
- Lumevoq(0)
- Lumigan(0)
- Luminity(0)
- Lumoxiti(0)
- Lumykras(0)
- Lunivia(0)
- Lunsumio(0)
- Lupkynis(0)
- Lupuli flos(0)
- Lurasidone productspecific bioequivalence guidance(0)
- Lusduna(0)
- Lutathera(0)
- Lutetium 177Lu chloride Billev previously Illuzyce(0)
- Lutholaz(0)
- Lutz Wiesner(0)
- Luveniq(0)
- Luveris(0)
- Lux Biosciences GmbH withdraws its marketing authorisation application for Luveniq voclosporin(0)
- Luxceptar(0)
- Luxturna(0)
- LUZ MARIA MEDRANO DE DIOS(0)
- Luz VethTello(0)
- Lydaxx(0)
- Lydia Antalics(0)
- Lydisilka(0)
- Lyfnua(0)
- Lymphoseek(0)
- Lympreva(0)
- Lynparza(0)
- Lynparza recommended for approval in ovarian cancer(0)
- Lyrica(0)
- LysaKare(0)
- Lysodren(0)
- Lytenava(0)
- Lytgobi(0)
- Lyubina Racheva Todorova(0)
- Lyubomir Malamov(0)
- Lyudmil Antonov(0)
- Lyumjev previously Liumjev(0)
- Lyxumia(0)
- Lærke Skov Nilausen(0)
- M(0)
- Maaike Cronenberg(0)
- Maaike van Dartel(0)
- Maaret Nummi(0)
- Maarit Gustafsson(0)
- Maartje Roskams(0)
- MabCampath(0)
- MabThera(0)
- Macarena Gajardo Alvarez(0)
- Macarena Rodriguez Mendizabal(0)
- Macugen(0)
- Madalina Doru(0)
- Madeleine Berendsen(0)
- Mads Bo Jørnung Wellendorph(0)
- Maëlle Lebrun(0)
- Maëva Robin(0)
- Maeve Cusack(0)
- Magdalena Bellido Samaniego(0)
- Magdalena Dunajewska(0)
- Magdalena Galster(0)
- Magdalena Leszczynska(0)
- Magdalena Nakielska(0)
- Magdalena PajewskaLewandowska(0)
- Magdalena Rychter(0)
- Magdalena Schilling(0)
- Magdalena Senkyrova(0)
- Magdalena Sliczniak(0)
- Magdalena Szymaniak(0)
- Magdalena Wojtynska(0)
- Magda Pedro(0)
- Magdolna Keszég(0)
- Magnus Backelin(0)
- Magnus IngelmanSundberg(0)
- Mahdi Ben Cheikh(0)
- Maheninasy Rakotondrainipiana(0)
- Maia Uusküla(0)
- Maie Palmeos(0)
- Maija Cirkina(0)
- Maija Tarkkanen(0)
- Maike Goemmel(0)
- Maike Sophie Gömmel(0)
- Maini Kukkonen(0)
- Mair Powell(0)
- Maja Lovrek Romcevic(0)
- Maja Lusina Kregar(0)
- Maja Mlakar(0)
- Maja Puklek(0)
- Maja Sommerfelt Grønvold(0)
- Maja TabakSlošić(0)
- Major European research project on monitoring and evaluation of medicines concludes(0)
- Major update of the SME user guide(0)
- Making a difference to human and animal health(0)
- Making best use of big data for public health publication of the Big Data Steering Group workplan for 202021(0)
- Making IT services for medicine regulation in Europe more efficient(0)
- Malak Abou Taam(0)
- Malene Weis(0)
- Malgorzata Berska(0)
- Malgorzata Gralec(0)
- Malgorzata KobierskaSzeliga(0)
- Malgorzata Mikulska(0)
- Malgorzata Piasecka(0)
- Malgorzata PlochGlapinska(0)
- Malgorzata Skiba(0)
- Małgorzata Staninska(0)
- malgorzata wisniewska(0)
- Malin Ålander(0)
- Malin Johansen(0)
- Malin Kyllikki Hobro Soderberg(0)
- Malin Ohlund(0)
- Malvae folium(0)
- Malvae sylvestris flos(0)
- Management Board(0)
- Management Board completes framework for conflicts of interests(0)
- Management Board delays formal adoption of European Medicines Agency publication of clinicaltrialdata policy to October 2014(0)
- Management Board expected to nominate EMA Executive Director on 1 October 2015(0)
- Management Board finalises its longterm plan and adopts workprogramme and budget for 2005(0)
- Management Board initiates building approval process for EMA premises in Amsterdam(0)
- Management Board meeting 1 October 2009(0)
- Management Board meeting 1 October 2020(0)
- Management Board meeting 2 October 2014(0)
- Management Board meeting 3 October 2013(0)
- Management Board meeting 3 October 2019(0)
- Management Board meeting 3 October 2024(0)
- Management Board meeting 4 October 2012(0)
- Management Board meeting 4 October 2018(0)
- Management Board meeting 5 May 2011(0)
- Management Board meeting 5 October 2017(0)
- Management Board meeting 5 October 2023(0)
- Management Board meeting 6 October 2011(0)
- Management Board meeting 6 October 2022(0)
- Management Board meeting 7 June 2012(0)
- Management Board meeting 7 October 2010(0)
- Management Board meeting 7 October 2021(0)
- Management Board meeting 8 June 2011(0)
- Management Board meeting 9 June 2011(0)
- Management Board meeting 10 December 2009(0)
- Management Board meeting 10 June 2010(0)
- Management Board meeting 11 12 December 2024(0)
- Management Board meeting 11 June 2009(0)
- Management board meeting 11 June 2009(0)
- Management Board meeting 11 June 2015(0)
- Management Board meeting 11 June 2020(0)
- Management Board meeting 11 March 2021(0)
- Management Board meeting 12 13 June 2024(0)
- Management Board meeting 12 June 2014(0)
- Management Board meeting 12 October 2015(0)
- Management Board meeting 13 December 2012(0)
- Management Board meeting 13 June 2013(0)
- Management Board meeting 15 December 2011(0)
- Management Board meeting 15 March 2018(0)
- Management Board meeting 16 December 2010(0)
- Management Board meeting 16 June 2016(0)
- Management Board meeting 16 March 2017(0)
- Management Board meeting 16 March 2023(0)
- Management Board meeting 17 June 2021(0)
- Management Board meeting 17 March 2016(0)
- Management Board meeting 18 December 2014(0)
- Management Board meeting 19 March 2015(0)
- Management Board meeting 19 March 2020(0)
- Management Board meeting 21 March 2019(0)
- Management Board meeting 21 March 2024(0)
- Management Board meeting 45 March 2009(0)
- Management Board meeting 56 October 2016(0)
- Management Board meeting 67 June 2018(0)
- Management Board meeting 78 June 2023(0)
- Management Board meeting 1112 December 2013(0)
- Management Board meeting 1213 December 2018(0)
- Management Board meeting 1213 June 2019(0)
- Management Board meeting 1314 December 2017(0)
- Management Board meeting 1314 December 2023(0)
- Management Board meeting 1415 December 2016(0)
- Management Board meeting 1415 December 2022(0)
- Management Board meeting 1415 June 2017(0)
- Management Board meeting 1516 December 2021(0)
- Management Board meeting 1516 June 2022(0)
- Management Board meeting 1617 December 2015(0)
- Management Board meeting 1617 December 2020(0)
- Management Board meeting 1617 March 2011(0)
- Management Board meeting 1617 March 2022(0)
- Management Board meeting 1718 March 2010(0)
- Management Board meeting 1819 December 2019(0)
- Management Board meeting 1920 March 2014(0)
- Management Board meeting 2021 March 2013(0)
- Management Board meeting 2122 March 2012(0)
- Management Board meetings(0)
- Management Board Meetings 2009(0)
- Management Board Meetings 2010(0)
- Management Board Meetings 2011(0)
- Management Board Meetings 2012(0)
- Management Board Meetings 2013(0)
- Management Board Meetings 2014(0)
- Management Board Meetings 2015(0)
- Management Board Meetings 2016(0)
- Management Board Meetings 2017(0)
- Management Board Meetings 2018(0)
- Management Board members(0)
- Management Board prepares groundwork in anticipation of a busy 2006(0)
- Management Board reelects Christa WirthumerHoche as chair(0)
- Management Board reelects Vicechair and starts budget discussions for 2010(0)
- Management Board started building approval process of EMA premises in Amsterdam(0)
- Management of clinical risks deriving from insertional mutagenesis Scientific guideline(0)
- Mandatory use of CTIS from 31 January 2023 for all new clinical trial applications(0)
- Mandatory use of international standard for the reporting of side effects to improve safety of medicines(0)
- Mandatory use of ISO/ICH E2BR3 individual case safety reporting in the EU Handson training course on using the EudraVigilance system(0)
- Mandatory use of ISO/ICH E2BR3 individual case safety reporting in the EU handson training course on using the EudraVigilance system(0)
- Mandatory use of ISO/ICH E2BR3 Individual Case Safety Reporting in the EU Handson Training Course using the EudraVigilance System(0)
- Mandatory use of ISO/ICH E2BR3 individual case safety reporting in the EU handson training course using the EudraVigilance system(0)
- Mandy Catherine Daly(0)
- Manfred Franck(0)
- Manfred Schuster(0)
- Manos Papadakis(0)
- Mantas Malinauskas(0)
- Manuela Leitner(0)
- manuela lepre(0)
- Manuela Messelhaeusser(0)
- Manuela Mura(0)
- Manuel Campos Toimil(0)
- Manuel Ibarra Lorente(0)
- Manuel Wedemeyer(0)
- Manufacture of the finished dosage form human Scientific guideline(0)
- Manufacture of the finished dosage form veterinary Scientific guideline(0)
- Marc Dhenain(0)
- Marcela Beková(0)
- Marcela Vostarkova(0)
- Marcel Günther(0)
- Marcel HN Hoefnagel(0)
- Marcello Frigerio(0)
- Marcel Maliepaard(0)
- Marcel Prax(0)
- Marcel SG Kwa(0)
- Marc Ferrante(0)
- Marcia Sofia Sanches de Castro Lopes Silva(0)
- Marcin Gladysz(0)
- Marcin Glanda(0)
- Marcin Kolakowski(0)
- Marcin Koszewski(0)
- Marcin RodzinkaVerhelle(0)
- Marcin Rynkiewicz(0)
- Marcin Wisniewski(0)
- Marc Maliepaard(0)
- Marco Cavaleri(0)
- Marco Di Girolamo(0)
- Marco Felici(0)
- Marco Franceschin(0)
- Marco Fulfaro(0)
- Marco Greco(0)
- Marco Panero Bertucci(0)
- MARCOS MADRUGA(0)
- Marcos Timón(0)
- Marco van Teijlingen(0)
- Marc Schmit(0)
- Marc Schulte(0)
- Marcus Savsek(0)
- Marek Chlustik(0)
- Marek Jutel(0)
- Marek Migdal(0)
- Marek Ubraniak(0)
- Marek Wisniewski(0)
- Maren Frederking(0)
- Maren Hammann(0)
- Maren Osmers(0)
- Margareta Bego(0)
- Margaréta Fogelová(0)
- Margareta Ramstrom Jonsson(0)
- Margaret Maguire(0)
- Margaret Walker(0)
- Margarida Machado(0)
- Margarita Kovachka(0)
- Margarita Majem(0)
- margherita parziale(0)
- Margit Salzmann(0)
- Margje MonsterSimons(0)
- Margot Amoureus(0)
- Margrét Lilja Heiðarsdóttir(0)
- Margriet de SpirtBezuijen(0)
- marguerite friconneau(0)
- Maria Amparo Haro(0)
- Maria Bäärnhielm(0)
- Maria Bartolo(0)
- Maria Brito(0)
- Maria Bruun(0)
- Maria Carmen Bravo(0)
- Maria Carmen Garganese(0)
- Maria Cavaller Bellaubi(0)
- Maria Chamorro Somoza DiazSarmiento(0)
- Maria Chiara Astuto(0)
- MARIA COLAMONICO(0)
- Maria Concepcion Payares(0)
- Maria Criado(0)
- María Cristina Ballesteros Tercero(0)
- Maria Cristina Piattella(0)
- Maria da Graca Ribeiro Campos(0)
- Maria Daniel Loureiro(0)
- María del Mar Fuentes González(0)
- MARÍA DEL PILAR EVIA PÉREZ(0)
- Maria del Pilar Rayon(0)
- Maria Del Val Bermejo Sanz(0)
- Maria Di Marzo(0)
- MariaDimokleia Ziotopoulou(0)
- Maria Dimopoulou(0)
- Maria Dolores Vazquez Novelle(0)
- Maria Dominguez Nicolas(0)
- Maria Eleni Avraamidou(0)
- Maria Elisabeth Kalland(0)
- Maria Esperanza Herreros Avila(0)
- María Esplugues(0)
- María Estela Moreno Martín(0)
- Maria Estrella Moya Sanchez(0)
- Maria Eugenia Abad Abad(0)
- Maria Eugenia Golino(0)
- Maria Fernanda Ralha Henriques Matos(0)
- Maria Formosa Cassar(0)
- Maria Francesca Cometa(0)
- Maria Franden(0)
- MARIA GALIULO(0)
- Maria Gazouli(0)
- Maria Gemma Fernandez Miguel(0)
- Maria Gomes Da Silva(0)
- Maria Grazia Evandri(0)
- Maria Grünewald(0)
- Maria Hazuchova(0)
- Maria Helena Pinto Ferreira(0)
- Maria Helena Ponte(0)
- Maria Ingevaldsson(0)
- Maria Inmaculada Plaza Chaves(0)
- Maria Isabel Borba Vieira(0)
- Maria Jesús Fernández Cortizo(0)
- María Jesús Lamas Díaz(0)
- Maria J Gomez Miguel(0)
- Maria Jose AguilellaVizcaino(0)
- Maria Jose Ferrer(0)
- Maria Jose Gonzalez Fernandez(0)
- Maria Jose Otero Lopez(0)
- Maria Judit Molnar(0)
- Maria Kladi(0)
- Maria Kovacova(0)
- Maria Kukk(0)
- Marialessia Marvulli(0)
- Maria Letizia Fabrizi(0)
- Maria Linnea Asp(0)
- Maria Luisa Bencetti(0)
- Maria Luisa Casini(0)
- Maria Luisa DAmore(0)
- Maria Luisa Palanca Sanchez(0)
- Maria Luttgen(0)
- Marialuz Septien(0)
- Maria Martinez Gonzalez(0)
- Maria Mathilde Haugaard(0)
- Maria Morais(0)
- Maria Nabais(0)
- Marian Hjortlund Allon(0)
- Marianne Depreter(0)
- Marianne Højsgaard Rasmussen(0)
- Marianne Klanker(0)
- Marianne Løiten Dalhus(0)
- Marianne Lunzer(0)
- Marianne Patt(0)
- Marianne Schmidt(0)
- Marianne Solsvik(0)
- Marianne Weisner(0)
- Mariann Viranyi(0)
- Marian Verbruggen(0)
- Maria Orfanou(0)
- Maria Paile Hyvarinen(0)
- Maria Paola Trotta(0)
- Maria Papachristou(0)
- Maria Papageorgiou(0)
- Maria Pettersson(0)
- Maria PopovaKiradjieva(0)
- Maria Riehl(0)
- Maria SkiffardHolm(0)
- Maria Stavrou(0)
- Maria Teresa Herdeiro(0)
- Maria Teresa Martin Fuentes(0)
- Maria Victoria Tudanca Pacios(0)
- Maria von Karpowitz(0)
- Maria Winqvist(0)
- Maria Zachou(0)
- Maribavir(0)
- Marie Åkerman(0)
- MarieCaroline Pesquidous(0)
- Marie Chantal ZwaanBaltus(0)
- MarieChristine Annequin(0)
- Marie Gadeyne(0)
- Marie GRANDCOLLOTCHABOT(0)
- MarieHélène Sabinotto(0)
- Marie Heroutova(0)
- Mariela Chilingirova(0)
- MarieLaure Veyries(0)
- Mariëlle Bouma(0)
- Marielle Svensson(0)
- Marie Louise Schougaard Christiansen(0)
- Mariem Loukil(0)
- Marie Pauline J Evers(0)
- Marie Tardieu(0)
- Marie Tauszig(0)
- MarieThérèse Duffour(0)
- Mariette Saléry(0)
- Marija Gintaliene(0)
- Marija Kristina Josipovic(0)
- Marija Malesevic(0)
- Marija Pekas(0)
- Marija Vella(0)
- Marijke Valstar(0)
- Marijke van de Beek(0)
- Marika Doucet(0)
- Marika Harz(0)
- Marika Ruponen(0)
- Marika van Leeuwen(0)
- Marilena Paola Etna(0)
- Marina Lesičar(0)
- Marina Saiz Sabater(0)
- Marina Senek(0)
- Marina van der Meijde(0)
- Marina Vidovic(0)
- Marine Martin(0)
- Marinus Christianus van den Heuvel(0)
- Mario Carere(0)
- Mario Miguel Coelho da Silva Rosa(0)
- Marion Haberkamp(0)
- Marion Moller(0)
- Marion Perrin(0)
- Marion van den Bosch(0)
- Marios Genakritis(0)
- Mari Pirttimaki(0)
- Marisa Delbò elected as new chair of herbal medicines committee(0)
- Maris Kuningas(0)
- Marita Fedcenko(0)
- Marita Kailajarvi(0)
- Mari Thorn(0)
- Marit Hovde Sonsteby(0)
- Marit Hystad(0)
- Marixino previously Maruxa(0)
- Marjan van Hooft(0)
- MarjaRiitta Taskinen(0)
- Marja van de Bovenkamp(0)
- Marjeta Jordan(0)
- Marjetka Plementas(0)
- Marje Zernant(0)
- Marjolein Wintzen(0)
- Marjolijn Schalk(0)
- Marjo Mannisto(0)
- Marjukka Aarni(0)
- Marju Sammul(0)
- Mark Branschofsky(0)
- Mark Cilia(0)
- Mark Denny(0)
- Markers used for quantitative and qualitative analysis of herbal medicinal products and traditional herbal medicinal products Scientific guideline(0)
- Marketa Beranova(0)
- Marketa Kalmarova(0)
- Markéta Příhodová(0)
- Marketa Vankova(0)
- Market exclusivity orphan medicines(0)
- Marketing and cessation notification Regulatory and procedural guidance(0)
- Marketing authorisation(0)
- Marketing authorisation guidance documents(0)
- Marketingauthorisation procedures for advancedtherapy medicinal products(0)
- Marketing authorisation templates(0)
- Marketing authorisation veterinary medicines(0)
- Mark Konijnenberg(0)
- Markku Mård(0)
- Mark Lawrence Zammit(0)
- Marko Korenjak(0)
- Marko Kuosmanen(0)
- Marko Mikulin(0)
- Marko Pesu(0)
- Mark Thompson(0)
- Mark Turner(0)
- Markus Braun(0)
- Markus Forslund(0)
- Markus Hansson(0)
- Markus Paulmichl(0)
- Markus PeckRadosavljevic(0)
- Markus Pongratz(0)
- Markus Tomek(0)
- Markus Varheenmaa(0)
- Markus Weber(0)
- Markus Weidendorfer(0)
- Markus Zeitlinger(0)
- Mark van Bussel(0)
- Marleen Renard(0)
- Marlena Sychowicz(0)
- Marlene Wessel Larsen(0)
- Marlies Kubbinga(0)
- Marlinda Hupkes(0)
- Marloes Bazelier(0)
- Marrubii herba(0)
- Marta Camacho Artacho(0)
- Marta Casalengua Domínguez(0)
- Marta Diaz Menendez(0)
- Marta Giovanna Toma(0)
- Marta Koziarska(0)
- Marta Lafuente Gonzalez(0)
- Marta Marcelino(0)
- Marta Martin Juárez(0)
- Marta Mate(0)
- Marta Monreal(0)
- Marta Moreno(0)
- Marta Mosca(0)
- Marta Reining(0)
- Marta Romano(0)
- Marta Velasco Gonzalez(0)
- Marta Wagnerová(0)
- Marte Fergestad(0)
- MarteHelene Bjork(0)
- Marten Wendt(0)
- Martijn Baeten(0)
- Martijn Bruysters(0)
- Martijn Sen(0)
- Martijn van Gils(0)
- Martina Bencetic Marijanovic(0)
- Martina Cesani(0)
- Martina Fedačková(0)
- Martina Joseph(0)
- Martina Kern(0)
- Martina Klapf(0)
- Martina Kotulkova(0)
- Martina Madarasova(0)
- Martina Perini(0)
- Martina Raud(0)
- Martina Rejtharová(0)
- Martina Sabotin(0)
- Martina SchuesslerLenz(0)
- Martina SchüsslerLenz elected as new chair of Committee for Advanced Therapies(0)
- Martina SchüsslerLenz reelected as chair of Committee for Advanced Therapies(0)
- Martina Unteregger(0)
- Martina Weise(0)
- Martina ZündorfReich(0)
- Martin Bjerregaard Pedersen(0)
- Martine Muusse(0)
- Martine Puhl(0)
- Martine Redureau(0)
- Martine Reidiboym(0)
- Martin Erik Nyeland(0)
- Martine Sabbe(0)
- Martine Sernetz(0)
- Martine Trauffler(0)
- Martin Huber(0)
- Martin Kinberg(0)
- Martin Landray(0)
- Martin Machyna(0)
- Martin Mengel(0)
- Martin Oleksiewicz(0)
- Martin Piffet(0)
- Martin Posch(0)
- Martin Rakusa(0)
- Martin Renhardt(0)
- Martin Schlesinger(0)
- Martin Spruth(0)
- Martin Stricker(0)
- Martin Strobl(0)
- Martin Tobias Speth(0)
- Martin Walter(0)
- Martin Zahle Larsen(0)
- Marvel LifeSciences Ltd withdraws its marketing authorisation applications for Insulin Human Rapid Marvel Insulin Human Long Marvel and Insulin Human 30/70 Mix Marvel(0)
- Marvel LifeSciences Ltd withdraws its marketingauthorisation applications for Solumarv Isomarv medium and Combimarv human insulin(0)
- Marvin Gaspar Quarenta(0)
- Maryam Mehmandoust(0)
- Maryline BUGGINDAUBIE(0)
- Mary Lynne Van PoelgeestPomfret(0)
- Mary McCarthy(0)
- Mary OGrady(0)
- Maryse Arendt(0)
- Marzia Zambon(0)
- Masa Kusar(0)
- Masican(0)
- Masipro(0)
- Masivet(0)
- Masiviera(0)
- Massimiliano Filosto(0)
- Massimo Nicolò(0)
- Massimo Siciliano(0)
- Massimo Tempestilli(0)
- Mastic(0)
- Matea Cartolano(0)
- Mate folium(0)
- Mateo Oresic(0)
- Matever(0)
- Mathieu LE DEM(0)
- Mathilde Geynet Kovacs(0)
- Mathilde Harvey(0)
- Mathilde Kouwenhoven(0)
- Mathilde Moe Moeldrup(0)
- Mathilde Skaarup Larsen(0)
- Matias Huhtala(0)
- Matija Radovanovic(0)
- Matilde Moreno Garcia(0)
- Matjaz Cizej(0)
- Matjaz Marc(0)
- Matricariae aetheroleum(0)
- Matricariae flos(0)
- Mats Jernberg(0)
- Mats Ökvist(0)
- Mats Welin(0)
- Mattheus Ouwerkerk(0)
- Matthew Camilleri(0)
- Matthias Braun(0)
- Matthias Renner(0)
- Matthias Schyns(0)
- Matthieu Lechallier(0)
- Matthieu Meslin(0)
- Matti Karvanen(0)
- Maud ANFOSSO(0)
- Maura ODonovan(0)
- Maura Olechnovic(0)
- Maurizio Massella(0)
- Maurizio Volterrani(0)
- Mavenclad(0)
- Maviret(0)
- Max Groenhart(0)
- Max Hilz(0)
- maxime salade(0)
- Maxim Frizler(0)
- Maximilian Ehrhardt(0)
- Maximilian Koblischke(0)
- Maximum inuse shelflife for medicated drinking water Scientific guideline(0)
- Maximum residue limit assessment reports(0)
- Maximum residue limit MRL evaluation for biological substances Scientific guideline(0)
- Maximum residue limit opinions(0)
- Maximum residue limits MRL(0)
- Maximum residue limits procedures(0)
- Maximum Residue Limits Q&A Introduction(0)
- Maximum shelflife for sterile medicinal products after first opening or following reconstitution Scientific guideline(0)
- Maximum shelflife for sterile products for human use after first opening or following reconstitution Scientific guideline(0)
- Max van Noesel(0)
- Maydis stigma(0)
- Mayzent(0)
- MEA002958PIP0121(0)
- MEA002970PIP0121(0)
- Measures to help protect patients from falsified medicines(0)
- Measures to minimise risk of serious side effects of multiple sclerosis medicine Lemtrada(0)
- Media(0)
- Medical Device Regulation comes into application(0)
- Medical devices(0)
- Medical Device Shortages Single Point of Contact SPOC Working Party(0)
- Medical Device Shortages SPOC Working Party meetings(0)
- Medical literature monitoring(0)
- Medical literature monitoring workshop(0)
- Medication errors(0)
- Medicinal gases pharmaceutical documentation including recommendation on nonclinical safety requirements for well established medicinal gases Scientific guideline(0)
- Medicinal Oxygen Air Liquide Sante(0)
- Medicinal products for the treatment of insomnia Scientific guideline(0)
- Medicinal products nonsteroidal antiinflammatory compounds for the treatment of chronic disorders Scientific guideline(0)
- Medicine evaluation figures(0)
- Medicine evaluation figures archive 20102015(0)
- Medicines(0)
- Medicines and Healthcare Products Regulatory Agency information day Medical Dictionary for Regulatory Activities in the pharmacovigilance regulatory process(0)
- Medicines assessed under the EUM4all procedure(0)
- Medicines authorised during pandemic(0)
- Medicines containing nomegestrol or chlormadinone PRAC recommends new measures to minimise risk of meningioma(0)
- Medicines for human use under evaluation(0)
- Medicines for human use under evaluation 20142012(0)
- Medicines for human use under evaluation 20172015(0)
- Medicines for human use under evaluation 20202018(0)
- Medicines for older people(0)
- Medicines for the treatment of pain in children EMEA workshop28 october 2004(0)
- Medicines for use outside the European Union(0)
- Medicine shortages and availability issues(0)
- Medicine shortages and availability issues guidance for companies(0)
- Medicine shortages and availability issues guidance for patients and healthcare professionals(0)
- Medicine shortages and availability issues guidance for regulators(0)
- Medicine shortages EU network takes steps to improve reporting and communication(0)
- Medicine Shortages Single Point of Contact SPOC Working Party(0)
- Medicine Shortages SPOC Working Party meetings(0)
- Medicines regulators on both sides of the Atlantic confirm commitment to cooperation on medicines(0)
- Medicines regulators to work together internationally to find innovative solutions to facilitate evaluation of and access to potential new medicines to counter Ebola outbreaks(0)
- Medicines under additional monitoring(0)
- Meera Varma(0)
- Meeting highlights from EMAs safety committee PRAC 2629 November 2018(0)
- Meeting highlights from EMAs safety committee PRAC 2931 October 2018(0)
- Meeting highlights from ICMRA global regulatory workshop on COVID19 observational studies and real world data(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1013 December 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1114 December 2006(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1215 November 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1316 November 2006(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1518 December 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1518 October 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1618 October 2006(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1619 February 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1619 July 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1619 March 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1719 March 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1720 November 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1720 September 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1821 February 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1821 June 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use 1821 September 2006(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1922 February 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1922 January 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1922 March 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use1922 October 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use 2023 April 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2023 July 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2023 October 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2124 April 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2124 January 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2124 July 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2124 May 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2124 September 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2224 January 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2225 June 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2225 September 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2326 April 2007(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2326 June 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use 2629 May 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use2730 May 2008(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 11 to 14 September 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 20 23 February 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 24 26 April 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 27 30 March 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 29 March 1 April 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 69 November 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 69 November 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 710 December 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 710 November 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 710 November 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 811 November 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 912 December 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 912 November 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 912 October 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 912 October 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1013 December 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1013 December 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1013 October 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1013 October 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1114 April 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1114 December 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1114 December 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1114 November 2019 updated(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1114 October 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1114 September 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 December 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 December 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 December 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 March 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 November 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 November 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 October 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 September 2016 corrected(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1215 September 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1316 December 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1316 December 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1316 February 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1316 September 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 December 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 December 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 February 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 January 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 March 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 November 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 October 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1417 September 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 December 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 February 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 March 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 May 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 November 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 October 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1518 October 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 April 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 December 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 January 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 July 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 May 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 May 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 November 2009(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 November 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 September 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1619 September 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 February 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 January 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 July 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 July 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 March 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 May 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 May 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 November 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 October 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 September 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1720 September 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 April 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 February 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 January 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 July 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 July 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 July 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 June 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 March 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 March 2024(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 May 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 November 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1821 October 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 April 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 April 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 April 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 February 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 February 2024(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 January 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 July 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 July 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 June 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 June 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 March 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 May 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 October 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 1922 September 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 April 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 February 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 January 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 July 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 July 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP2023 June 2011(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 June 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 June 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 March 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 October 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2023 September 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 February 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 July 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 June 2010(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 June 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 March 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 May 2012(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 October 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2124 September 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 April 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 April 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 April 2024(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 February 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 February 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 January 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 January 2024(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 July 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 July 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 June 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 June 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 March 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 May 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2225 September 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 April 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 April 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 February 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 January 2017(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 January 2023(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 July 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 June 2014(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 March 2015(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 March 2020 updated(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2326 May 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2427 February 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2427 January 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2427 June 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2427 June 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2528 April 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2528 February 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2528 January 2016(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2528 June 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2528 March 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2528 May 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2529 January 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2729 May 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2730 January 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2730 May 2013(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2830 April 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2831 January 2019(0)
- Meeting highlights from the Committee for Medicinal Products for Human Use CHMP 2831 May 2018(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 34 November 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 35 November 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 57 October 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 67 October 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 79 December 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 79 September 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 89 September 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 810 December 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1012 May 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1315 April 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1315 July 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1416 July 2020(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1517 June 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1617 February 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1618 March 2021(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1819 January 2022(0)
- Meeting highlights from the Committee for Medicinal Products for Veterinary Use CVMP 1920 January 2021(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 35 October 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 46 October 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 57 December 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 57 September 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 68 December 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 68 September 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 79 November 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 810 November 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1012 May 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1113 April 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1113 July 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1213 March 2024(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1214 July 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1314 February 2024(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1315 June 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1415 June 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1416 February 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1516 February 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1516 March 2022(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1516 May 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1617 January 2024(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1618 April 2024(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1718 January 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 1820 April 2023(0)
- Meeting highlights from the Committee for Veterinary Medicinal Products CVMP 2122 March 2023(0)
- Meeting highlights from the Paediatric Committee 09 11 December 2009(0)
- Meeting highlights from the Paediatric Committee 1 2 August 2007(0)
- Meeting highlights from the Paediatric Committee 1 3 April 2009(0)
- Meeting highlights from the Paediatric Committee 2 4 July 2008(0)
- Meeting highlights from the Paediatric Committee 2 4 June 2008(0)
- Meeting highlights from the Paediatric Committee 4 6 February 2009(0)
- Meeting highlights from the Paediatric Committee 4 6 March 2009(0)
- Meeting highlights from the Paediatric Committee 6 8 May 2008(0)
- Meeting highlights from the Paediatric Committee 7 9 January 2009(0)
- Meeting highlights from the Paediatric Committee 9 11 April 2008(0)
- Meeting highlights from the Paediatric Committee 10 12 December 2008(0)
- Meeting highlights from the Paediatric Committee 11 13 November 2009(0)
- Meeting highlights from the Paediatric Committee 12 14 March 2008(0)
- Meeting highlights from the Paediatric Committee12 14 November 2008(0)
- Meeting highlights from the Paediatric Committee 13 15 February 2008(0)
- Meeting highlights from the Paediatric Committee 14 16 October 2009(0)
- Meeting highlights from the Paediatric Committee 15 17 October 2008(0)
- Meeting highlights from the Paediatric Committee 16 18 January 2008(0)
- Meeting highlights from the Paediatric Committee 16 18 September 2009(0)
- Meeting highlights from the Paediatric Committee 17 19 September 2008(0)
- Meeting highlights from the Paediatric Committee 18 20 December 2007(0)
- Meeting highlights from the Paediatric Committee 21 23 November 2007(0)
- Meeting highlights from the Paediatric Committee 22 24 July 2009(0)
- Meeting highlights from the Paediatric Committee 24 26 June 2009(0)
- Meeting highlights from the Paediatric Committee 24 26 October 2007(0)
- Meeting highlights from the Paediatric Committee 26 28 September 2007(0)
- Meeting highlights from the Paediatric Committee 27 29 August 2008(0)
- Meeting highlights from the Paediatric Committee27 29 May 2009(0)
- Meeting highlights from the Paediatric Committee 28 30 April 2009(0)
- Meeting highlights from the Paediatric Committee 29 31 August 2007(0)
- Meeting highlights from the Paediatric Committee 29 31 July 2008(0)
- Meeting highlights from the Paediatric Committee 2729 May 2009(0)
- Meeting highlights from the Paediatric Committee held by written procedure 19 21 August 2009(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 3 6 July 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 5 8 June 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 5 August 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 6 9 February 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 7 10 February 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 9 12 January 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 10 12 May 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 10 13 January 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 13 16 March 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 13 October 2012(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 14 December 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 14 October 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 24 27 October 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 25 December 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 25 May 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 25 May 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 25 September 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 25 September 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 28 November 1 December 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 28 November 1 December 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 28 September 1 October 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 29 August1 September 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 29 August 1 September 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 29 November 2 December 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 30 August 2 September 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 30 August 2 September 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 30 November 3 December 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 30 September3 October 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 31 August 3 September 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 35 November 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 April 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 February 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 July 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 March 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 May 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 November 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 36 September 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 April 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 February 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 July 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 March 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 March 2024(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 May 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 47 November 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 48 July 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 58 February 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 58 February 2024(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 58 July 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 58 March 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 58 May 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 58 October 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 April 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 February 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 January 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 January 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 July 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 July 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 June 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 June 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 March 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 69 October 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 April 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 April 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 January 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 July 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 June 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 June 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 March 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 October 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 710 September 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 April 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 April 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 April 2024(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 February 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 February 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 January 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 January 2024(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 July 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 July 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 June 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 June 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 March 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 811 September 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 912 April 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 912 February 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 912 January 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 912 July 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 912 March 2015(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 912 March 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1013 February 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1013 June 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1013 June 2014(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1013 May 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 April 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 April 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 February 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 January 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 January 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 June 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 June 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1114 May 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1215 March 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1316 January 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1316 May 2013(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1316 May 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1417 April 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1417 January 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1417 March 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 1417 May 2018(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2326 November 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2326 October 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2326 October 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2427 October 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2528 November 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2528 October 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2528 September 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2529 September 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2629 November 2012(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2629 October 2020(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2629 September 2016(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2629 September 2022(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2730 November 2017(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2730 November 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2730 September 2021(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2831 August 2023(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2831 October 2019(0)
- Meeting highlights from the Pharmacovigilance Risk Assessment Committee PRAC 2931 October 2012(0)
- Meeting management procedures(0)
- Meeting of the CTTI/FDA Patient Engagement Collaborative PEC and EMA Patients and Consumers Working Party PCWP(0)
- Meeting of the EMEA working party on herbal medicinal products 1 2 April 2004(0)
- Meeting of the EMEA working party on herbal medicinal products 2 3 February 2004(0)
- Meeting of the EMEA working party on herbal medicinal products 3 4 November 2003(0)
- Meeting of the EMEA Working Party on Herbal Medicinal Products 3 and 4 June 2004(0)
- Meeting of the EMEA working party on herbal medicinal products 4 and 5 November 2002(0)
- Meeting of the EMEA working party on herbal medicinal products 11 and 12 March 2002(0)
- Meeting of the EMEA working party on herbal medicinal products 13 14 March 2001(0)
- Meeting of the EMEA working party on herbal medicinal products 24 25 February 2003(0)
- Meeting of the EMEA working party on herbal medicinal products 28 and 29 October 1999(0)
- Meeting of the EMEA working party on herbal medicinal products 29 and October 2001(0)
- Meeting of the EMEA working party on herbal medicinal products 30 and 31 October 2000(0)
- Meeting of the EMEA working party on herbal medicinal products 30 June 1 July 2003(0)
- Meeting of the EMEA working party on herbal medicinal products 31 May 1 June 1999(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG April 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG April 2024(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG December 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG February 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG February 2024(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG January 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG January 2024(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG July 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG June 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG March 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG March 2024(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG May 2024(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG November 2023(0)
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products MSSG September 2023(0)
- Meeting of the Executive Steering Group on Shortages of Medical Devices MDSSG(0)
- Meeting of the Medical Device Shortages Single Point of Contact SPOC Working Party(0)
- Meeting of the Medicine Shortages Single Point of Contact SPOC Working Party(0)
- Meeting of the paediatric diabetes mellitus expert group(0)
- Meeting of the paediatric human immunodeficiency virus HIV expert group(0)
- Meeting on lessons learnt from sartan medicines containing Nnitrosamine impurities(0)
- Meeting on monitoring of sales of veterinary antimicrobial agents in Europe(0)
- Meeting on redacting commercially confidential information CCI in clinical reports and anonymising clinical reports for the purpose of publication(0)
- Meeting report of the Seventh EMEA/FEDESA Joint Info Day at the European Agency in London(0)
- Meetings management procedures(0)
- Meetings with stakeholders and other organisations(0)
- Meeting with Alliance for Regenerative Medicine(0)
- Meeting with stakeholders on monitoring sales of veterinary antimicrobial agents in Europe(0)
- Megestrol Alkermes(0)
- Meggy Van NuenenCox(0)
- Mehtap Ozturk(0)
- Meike Stemmler(0)
- Mekinist(0)
- Mektovi(0)
- Melaleucae aetheroleum(0)
- Melanie Bald(0)
- Melanie Cachet(0)
- Melanie Diane Klok(0)
- Melanie Gräf(0)
- Melanie Hamann(0)
- Melanie Ramberger(0)
- Melatonin Circadin(0)
- Melatonin Neurim(0)
- Melchior de Bruin(0)
- Meliloti herba(0)
- Melinda Palfi(0)
- Melinda Sobor(0)
- Melissae folium(0)
- Melita Tovornik(0)
- Melosolute(0)
- Melosus(0)
- Melovem(0)
- Meloxidolor(0)
- Meloxidyl(0)
- Meloxivet(0)
- Meloxoral(0)
- Melvin Faber(0)
- Memantine Accord(0)
- Memantine FGK(0)
- Memantine LEK(0)
- Memantine Merz(0)
- Memantine Mylan(0)
- Memantine productspecific bioequivalence guidance(0)
- Memantine ratiopharm(0)
- Menarini International Operations Luxembourg withdraws its marketing authorisation application for Factive gemifloxacin(0)
- Mencia de Lemus Belmonte(0)
- Menno van der Elst(0)
- Menotropin(0)
- MenQuadfi(0)
- Menthae piperitae aetheroleum(0)
- Menthae piperitae folium(0)
- Menveo(0)
- Menyanthidis trifoliatae folium(0)
- Mepact(0)
- Mepsevii(0)
- Mercaptopurine monohydrate(0)
- Mercedes Ureña Montilla(0)
- Merck KGaA withdraws its application for an extension of the indication for Erbitux cetuximab(0)
- Merck Serono Europe Limited withdraws its marketing authorisation application for Movectro cladribine(0)
- Merck Sharp & Dohme Europe Inc withdraws its marketing authorisation application for Janacti sitagliptin and pioglitazone and related trade names(0)
- Merck Sharp & Dohme Ltd withdraws its marketing authorisation application for Vorinostat MSD(0)
- Merck Sharp and Dohme Ltd withdraws its marketingauthorisation application for Jenzyl ridaforolimus(0)
- Merel Hennink(0)
- Merete BlixenkroneMøller(0)
- Merete Hermann(0)
- Mersarex(0)
- Mervi Saukkosaari(0)
- Meryem Köycü Basoda(0)
- Message from EMAs outgoing Executive Director Guido Rasi(0)
- Messoud Ashina(0)
- Metabolic and cardiovascular complications of antiretroviral combination therapy in HIVinfected patients(0)
- Metacam(0)
- Metalyse(0)
- metamizole(0)
- Metformin productspecific bioequivalence guidance(0)
- Methodological issues in confirmatory clinical trials planned with an adaptive design Scientific guideline(0)
- Methodological issues with pharmacogenomic biomarkers in relation to clinical development and patient selection Scientific guideline(0)
- Methodology European Specialised Expert Community(0)
- Methodology Working Party(0)
- Methodology Working Party stakeholder interaction meeting(0)
- Methods found suitable within the European Union for demonstrating freedom from extraneous agents of the seeds used for the production of immunological veterinary medicinal products Scientific guideline(0)
- MethoxasolT(0)
- Methylprednisolone injection for cattle(0)
- Methylthioninium chloride Proveblue(0)
- Meticillinresistant Staphylococcus aureus in foodproducing and companion animals in the European Union epidemiology and control options for human and animal health Scientific guideline(0)
- Meticillinresistant Staphylococcus pseudintermedius Scientific guideline(0)
- Metoda LipnikStangelj(0)
- Mette Bjørn(0)
- Mette Hjorslev Knudgaard(0)
- Mette Linnert Jensen(0)
- Mette Riedel(0)
- Mette Toftegaard Madsen(0)
- Mette Tranholm(0)
- Mette Wikkelsø(0)
- Metty Staal(0)
- Mevlyq(0)
- Mhyosphere PCV ID(0)
- Micardis(0)
- MicardisPlus(0)
- Michaela Dlouhá(0)
- Michaela Jung(0)
- Michaela Kosová(0)
- Michael Alexa(0)
- Michael Benning(0)
- Michael Bühlen(0)
- Michael Chiorazzo(0)
- Michael Denkinger(0)
- Michael Eddleston(0)
- Michael Etscheid(0)
- Michael Jirout(0)
- Michael John(0)
- Michael Lassmann(0)
- Michael Marleaux(0)
- Michael McDonald(0)
- Michael Muehlebach(0)
- Michael Nauck(0)
- Michael Schramm(0)
- Michael Skaarup Pedersen(0)
- Michael Wolzt(0)
- Michael Zieschang(0)
- Michael Zwitkovits(0)
- Michal Bencze(0)
- Michal Czarnogórski(0)
- Michal Gryz(0)
- Michal Pirozynski(0)
- Michal Rataj(0)
- Michal Zwiewka(0)
- Michela Palmisano(0)
- Michela Piezzo(0)
- Michel Collart(0)
- Michèle Forner(0)
- Michel Goret(0)
- Michel Hoffmann(0)
- Michel Kooijman(0)
- Michelle Heib(0)
- Michelle Mulchrone(0)
- Michelle van der Grift(0)
- Michelle Wegrad(0)
- Michiel van den Heuvel(0)
- Michiel van der Eijk(0)
- Mickaelle Sachet(0)
- Micotil 300 and its associated names(0)
- Micotil 300 Injectie(0)
- Microbiological aspects of herbal medicinal products and traditional herbal medicinal products Scientific guideline(0)
- Micro small and mediumsizedenterprise SME workshop Focus on chemistry manufacturing and controls CMC regulatory compliance for biopharmaceuticals and advanced therapies(0)
- Midterm report on 2025 network strategy highlights good progress during critical period of the pandemic(0)
- Mieke Wuyts(0)
- Miglena Goranova(0)
- Miglena Mitova(0)
- Miglustat Dipharma(0)
- Miglustat GenOrph(0)
- Miglustat productspecific bioequivalence guidance(0)
- Miguel Bley(0)
- Miguel del Rey Cristóbal(0)
- Mihkel Plaas(0)
- Mikaela Kolaci Kotmilo(0)
- Mikael Andersson(0)
- Mikaela Odemyr(0)
- Mikael Le Bihan(0)
- Miki Hew(0)
- Mikkel Kjelkvist Calum(0)
- Mikko Jokisalo(0)
- Milaxyn Plus(0)
- MILENA ATANASOVA(0)
- Milena Peraita Ezcurra(0)
- Milica Mitrevski(0)
- Millefolii flos(0)
- Millefolii herba(0)
- Milnacipran Pierre Fabre Medicament(0)
- MilouDaniel Drici(0)
- Mimpara(0)
- Minimising the risk of transmitting animal spongiform encephalopathy agents via human and veterinary medicinal products Scientific guideline(0)
- Minjuvi(0)
- Minna Kurronen(0)
- Minna Leppänen(0)
- Minna Myllyntausta(0)
- Minne Casteels(0)
- Minoska Valli(0)
- Mioara Andrei(0)
- MiPet Easecto(0)
- Miplyffa(0)
- Mira Kontic(0)
- Mirapexin(0)
- Mirataz(0)
- Mircera(0)
- Mirei IGUCHI(0)
- Mirela Jonson(0)
- Mirela Tavakol(0)
- Miriam AlexanderKatz(0)
- Miriama Rothova(0)
- Miriam Bartolo(0)
- Miriam FuerstWilmes(0)
- Miriam Schrader(0)
- Miriam Taekema(0)
- Mirijam Krehbiehl(0)
- Mirjam Crul(0)
- Mirjam Hinterleitner(0)
- Mirjam Smeets(0)
- Mirka Laavola(0)
- Mirko Petrovic(0)
- Mirna Galovic(0)
- Mirna Golemovic(0)
- Miroslava Gocova(0)
- Miroslava Horváth Petriková(0)
- Miroslava Laukova(0)
- Miroslava Mercová(0)
- Miroslav Andrišić(0)
- Miroslav Georgiev(0)
- Miroslav Weiss(0)
- Mirvaso(0)
- Mirza Catibusic(0)
- Missing data in confirmatory clinical trials Scientific guideline(0)
- Mitigating risk aversion in medicines regulation in the interest of public health(0)
- Mitigating risks due to the use of antibiotics in animals(0)
- Mixtard(0)
- MMRVaxPro(0)
- Moa Moritz(0)
- Mockups and specimens(0)
- Mockups for veterinary medicines(0)
- Modelling and simulation in the development and regulatory review of medicines(0)
- Modelling and simulation in the development of medicines(0)
- Modelling and simulation questions and answers(0)
- Modernising the orphan designation process(0)
- Modification of seasonal flu vaccines(0)
- Modifications to templates Paediatrics(0)
- Modified live porcine respiratory and reproductive syndrome PRRS virus vaccines(0)
- Modifiedrelease paracetamolcontaining products to be suspended from EU market(0)
- Modigraf(0)
- Mogens Westergaard(0)
- Mohamad Mohty(0)
- Mohammed Alali(0)
- Mohit Khera(0)
- Mojca Lunder(0)
- Mojca Ogriz(0)
- Mojca Pust(0)
- Mometamax Ultra(0)
- Momir Radulovic(0)
- Mona ElSayed Hervig(0)
- Mona KassemYoussef(0)
- Mona Opsata(0)
- Mónica Beteta Robles(0)
- Monica Costa(0)
- Mónica Estevão(0)
- Monica Fernandez Gozalo(0)
- Monica Martinez Redondo(0)
- MÓNICA SALDAÑAVALDERAS(0)
- Monika Ciszewska(0)
- Monika Hofmann(0)
- Monika JarockaWierzba(0)
- Monika Kaczmarska(0)
- Monika Kyselicova(0)
- Monika Mennicken(0)
- Monika Oracz(0)
- Monika PetrajtisGolobow(0)
- Monika Petruláková(0)
- Monika Posega(0)
- Monika Trojan(0)
- Monique Al(0)
- Monique van Raamsdonk(0)
- Monique Wakelkamp(0)
- Monitoring of COVID19 medicines(0)
- Monitoring of products originating from Japan for the possibility of radioactivity(0)
- Monitoring the safety of medicines European Medicines Agency presents first report on implementation of pharmacovigilance legislation to the European Commission(0)
- Monkeypox EMA starts review for Imvanex(0)
- Monoclonal antibodies for veterinary use specific questions to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies ADVENT Scientific guideline(0)
- Monotard(0)
- Morana Pavicic(0)
- Mor Dickman(0)
- More flexible storage conditions for BioNTech/Pfizers COVID19 vaccine(0)
- Morgane Souchal(0)
- Moritz Graf(0)
- Moritz Sander(0)
- Mosquirix(0)
- Mouna Houdon(0)
- Mounjaro(0)
- Movectro(0)
- Moventig(0)
- Movymia(0)
- Moxidectincontaining veterinary medicines used in cattle sheep and horses(0)
- Mozobil(0)
- Mpox(0)
- Mpox monkeypox(0)
- MSH Vaccine(0)
- Mulpleo previously Lusutrombopag Shionogi(0)
- Mulsevo(0)
- Multaq(0)
- Multiagency report highlights importance of reducing antibiotic use(0)
- Multidisciplinary artificial intelligence AI(0)
- Multidisciplinary biosimilar(0)
- Multidisciplinary cell therapy and tissue engineering(0)
- Multidisciplinary gene therapy(0)
- Multidisciplinary guidelines(0)
- Multidisciplinary nanomedicines(0)
- Multidisciplinary orally inhaled products(0)
- Multidisciplinary pharmacogenomics(0)
- Multidisciplinary vaccines(0)
- Multilateral coalitions and initiatives(0)
- Multiple sclerosis workshop Registries initiative(0)
- Multiplicity issues in clinical trials Scientific guideline(0)
- Multistakeholder advanced therapy medicinal products ATMPs expert meeting exploring solutions to foster ATMPs development and patient access in Europe(0)
- Multistakeholder paediatric oncology strategy workshop cancers with anaplastic lymphoma kinase aberrations(0)
- Multistakeholder webinar on the HMAEMA Catalogues of realworld data sources and studies(0)
- Multistakeholder webinar to support implementation of the Medical Devices Regulation on drugdevice combinations(0)
- Multistakeholder workshop on Data Quality Framework for Adverse Drug Reaction reporting(0)
- Multistakeholder workshop on draft Regulatory Science to 2025 strategy stakeholders for human medicines(0)
- Multistakeholder workshop on draft Regulatory Science to 2025 strategy stakeholders for veterinary medicines(0)
- Multistakeholder workshop on EMAs extended mandate(0)
- Multistakeholder workshop on Real World Data RWD quality and Real World Evidence RWE use(0)
- Multistakeholder workshop on the guideline on clinical investigation of medicinal products in the treatment of epileptic disorders(0)
- Multistakeholder workshop Patient experience data in medicines development and regulatory decisionmaking(0)
- Multistakeholder workshop to further improve the implementation of the Paediatric Regulation(0)
- Multistakeholder workshop to launch consultation on European Medicines Agency EMA human regulatory science to 2025(0)
- Multistakeholder workshop to launch consultation on European Medicines Agency EMA veterinary regulatory science to 2025(0)
- Multistakeholder workshop to support implementation of the Medical Devices Regulation on drugdevice combinations(0)
- Multistakeholder workshop with the HMA/EMA task force on availability of authorised medicines(0)
- Muriel DURAN CORDOBES(0)
- Muriel Echemann(0)
- Muriel Pasco(0)
- Muriel Uzzan(0)
- Mutual recognition agreements MRA(0)
- Mutual reliance between the United States Food and Drug Administration and the European Union on goodmanufacturingpractice inspections(0)
- Mvabea(0)
- Mvasi(0)
- Myalepta(0)
- Mycamine(0)
- Mycapssa(0)
- Myclausen(0)
- Mycograb(0)
- Mycophenolate mofetil Teva(0)
- Mycophenolate updated recommendations for contraception for men and women(0)
- Myfenax(0)
- Mylan SAS withdraws its marketing authorisation application for Docetaxel Mylan docetaxel(0)
- Mylene Ferrier(0)
- Mylene Hübecker(0)
- Mylotarg(0)
- Myocet liposomal previously Myocet(0)
- Myozyme(0)
- Myriam Kessler(0)
- Myrrha(0)
- Myrtilli fructus recens(0)
- Myrtilli fructus siccus(0)
- Mysildecard(0)
- Mysimba recommended for approval in weight management in adults(0)
- Mª Angeles Fernández Fernández(0)
- N(0)
- N/A(0)
- Nabil Bezzenine(0)
- Nadia Martin Blanco(0)
- Nadine Binai(0)
- Nadine Matzmohr(0)
- Nadine Petitpain(0)
- Nadine Sider(0)
- Nadire Lleshi(0)
- Nadja Grujic(0)
- Nadya Ognyanova Vladimirova(0)
- Naglazyme(0)
- Naime MorinaShaqiri(0)
- Naissant Gwladys(0)
- Name Review Group form(0)
- Names of liposomal medicines to be changed to avoid medication errors(0)
- Namuscla(0)
- Nancy De Bremaeker(0)
- Nancy Postma(0)
- Nanna Aaby Thirstrup(0)
- Nanna Lundgaard Rasmussen(0)
- Nanneke Hendricks(0)
- Nannette Groß(0)
- Naomi Barak(0)
- Narcolepsy treatment recommended for approval(0)
- Narvina Sinani(0)
- Nasym(0)
- Natacha Bolanos(0)
- Natalia Formigo(0)
- Natalia WąsowiczŻendzian(0)
- Natalie Krueger(0)
- Natalie Welter(0)
- Natalizumab Elan Pharma(0)
- Natasa Kiza(0)
- Natasa SEKULIC(0)
- Nathalie Bridoux(0)
- Nathalie DEREUDDREBOSQUET(0)
- Nathalie Dumarcet(0)
- Nathalie Gault(0)
- Nathalie Jung(0)
- Nathalie Legrand(0)
- Nathalie Morgensztejn(0)
- Nathalie Parij(0)
- Nathiana Smit(0)
- National competent authorities human(0)
- National competent authorities veterinary(0)
- National registers of authorised medicines(0)
- Natividad Galiana LLorca(0)
- Natpar(0)
- Naveruclif(0)
- Naxcel(0)
- Nazanin Orouji(0)
- Nebojsa Mihajlica(0)
- Necessity of initiatives to stimulate the conduct of clinical studies with herbal medicinal products in the paediatric population Scientific guideline(0)
- Nectaroula Cooper(0)
- Need for active control in therapeutic areas where use of placebo is deemed ethical and one or more established medicines are available Scientific guideline(0)
- Need for a guideline on process validation of medicinal products containing biotechnology derived proteins as active substance(0)
- Need for a guideline on the clinical development of thrombopoetin receptor agonists for the treatment of chronic immune idiopathic thrombocytopenic purpura Scientific guideline(0)
- Need for an addendum on the clinical investigation of medicinal products intended for treatment of glucocorticoidinduced osteoporosis Scientific guideline(0)
- Need for a paediatric addendum of the guideline on clinical investigation of medicinal products for the treatment and prophylaxis of venous thromboembolic disease Scientific guideline(0)
- Need for assessment of reproduction toxicity of human insulin analogues Scientific guideline(0)
- Need for nonclinical testing in juvenile animals on human pharmaceuticals for paediatric indications Scientific guideline(0)
- Needs for paediatric medicines(0)
- Neffy(0)
- Nele Alders(0)
- Nele Berthels(0)
- Nele Maenhaut(0)
- Nele Steens(0)
- Nemdatine(0)
- Nenad(0)
- Neoatricon(0)
- Neocepri(0)
- Neoclarityn(0)
- Neocolipor(0)
- Neofordex(0)
- Neoleish(0)
- NeoRecormon(0)
- NeoSpect(0)
- Neparvis(0)
- Nepexto(0)
- Neptra(0)
- Nerina Pflanz(0)
- Neringa Kalinauskaitė(0)
- Nerlynx(0)
- Nerventra(0)
- Nespo(0)
- Netvax(0)
- Network Portfolio(0)
- Networks(0)
- Network Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS(0)
- Network users training for Regulatory Procedure Management 1st rollout on IRIS(0)
- Neulasta(0)
- Neupopeg(0)
- Neupro(0)
- Neuraceq(0)
- NeuroBloc(0)
- Neurochem withdraws its marketing authorisation application for Kiacta eprodisate disodium(0)
- Neurodegenerative diseases(0)
- Nevanac(0)
- Nevenka Prpar(0)
- Nevirapine Teva(0)
- New action plan to foster development of advanced therapies(0)
- New action plan to support SMEs as drivers of pharmaceutical innovation(0)
- New addon treatment for patients with severe asthma(0)
- New addon treatment for rare autoimmune inflammatory disorder(0)
- New addon treatment to insulin for treatment of certain patients with type 1 diabetes(0)
- New advanced therapy to repair cartilage defects in the knee(0)
- New antibiotic to fight infections caused by multidrugresistant bacteria(0)
- New antiretrovirals improve quality of life of HIV/AIDS patients(0)
- New approach developed by the Joint Food and Agriculture Organization/World Health Organization Expert Committee on Food Additives for exposure and maximum residue limit assessment of residues of veterinary medicinal products Scientific guideline(0)
- New call for patient and healthcareprofessional representatives on European Medicines Agency committees(0)
- New cellbased therapy to support stem cell transplantation in patients with highrisk blood cancer(0)
- New cochairs elected for working parties for healthcare professionals and for patients and consumers(0)
- New EMA guidance on development of antibacterials to help in the fight against multidrugresistant pathogens(0)
- New EMEA human medicines units announced(0)
- New enzyme replacement therapy to treat rare genetic disorder alphamannosidosis in children and adults(0)
- New EudraVigilance system improves reporting of side effects and detection of safety signals(0)
- New EudraVigilance system is live(0)
- New EU rules for safe and highquality medicines for animals become effective(0)
- New features further strengthen Priority Medicines scheme PRIME(0)
- New fees for marketing authorisation applications in force(0)
- Newflend ND H9(0)
- New gene therapy for rare inherited disorder causing vision loss recommended for approval(0)
- New gene therapy for the treatment of children with ultrarare immune disorder recommended for approval(0)
- New gene therapy to treat adult patients with multiple myeloma(0)
- New gene therapy to treat rare genetic disorder metachromatic leukodystrophy(0)
- New gene therapy to treat rare inherited blood condition(0)
- New gene therapy to treat spinal muscular atrophy corrected(0)
- New gene therapy treatment for patients with relapsed or refractory large Bcell lymphoma(0)
- New guidance to speed up development of antibiotics(0)
- New guidelines on good manufacturing practices for advanced therapies(0)
- New guide on biosimilar medicines for healthcare professionals(0)
- New international standard to improve safety of medicines(0)
- New judicial decisions at odds with EMAs efforts to allow access to documents on medicines(0)
- New layout for EMA scientific guidelines(0)
- New legislation for veterinary medicines(0)
- New longlasting implant to treat opioid dependence(0)
- New Management Board elects its chairman and approves composition of new scientific committees(0)
- New manufacturing sites and new formulation approved for COVID19 vaccine from BioNTech/Pfizer(0)
- New measures to avoid potentially fatal dosing errors with methotrexate for inflammatory diseases(0)
- New measures to avoid valproate exposure in pregnancy endorsed(0)
- New measures to facilitate conduct of ENCePP studies(0)
- New measures to minimise risk of meningioma with medicines containing nomegestrol or chlormadinone(0)
- New medicine for cystic fibrosis patients(0)
- New medicine for hereditary angioedema a rare disease causing swelling beneath the skin(0)
- New medicine for hereditary rare disease(0)
- New medicine for multiple myeloma patients with limited treatment options(0)
- New medicine for multiple sclerosis(0)
- New medicine for rare bone disease(0)
- New medicine for rare chronic liver disease(0)
- New medicine for rare eye disease(0)
- New medicine for rare form of eye allergy in children and teenagers(0)
- New medicine for rare inflammatory condition of the oesophagus(0)
- New medicine for rare neurodegenerative disorder in children(0)
- New medicine for rare type of eye cancer(0)
- New medicine for the prevention of migraine(0)
- New medicine to help in the fight against antimicrobial resistance(0)
- New medicine to prevent cytomegalovirus disease in stem cell transplant patients(0)
- New medicine to protect babies and infants from respiratory syncytial virus RSV infection(0)
- New medicine to protect honey bees against Varroa mites(0)
- New medicine to treat heart failure recommended for approval(0)
- New medicine to treat infections in adults(0)
- New medicine to treat perianal fistulas in patients with Crohns disease(0)
- New membership list published for the European Network of Paediatric Research at the European Medicines Agency EnprEMA(0)
- New online platform for parallel distribution(0)
- New online platform for scientific advice(0)
- New oral treatment for moderate to severe atopic dermatitis(0)
- New oral treatment for rheumatoid arthritis(0)
- New Paediatric Committee holds its first meeting(0)
- New pharmaceutical legislation enters into force on 20 May 2004(0)
- New pharmacovigilance legislation comes into operation(0)
- New platform for collection of sales and use data of antimicrobials in animals(0)
- New Quality Innovation Expert Group QIG supports medicine innovation(0)
- New recommendations for terlipressincontaining medicines in the treatment of hepatorenal syndrome(0)
- New recommendations on the use of phthalates and parabens as excipients in human medicines released for public consultation(0)
- New recommendations to manage risk of allergic reactions with intravenous ironcontaining medicines(0)
- New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya(0)
- New recommendations to strengthen supply chains of critical medicines(0)
- New restrictions on use of medicines containing ergot derivatives(0)
- New restrictions to minimise the risks of effects on heart rhythm with hydroxyzinecontaining medicines(0)
- News(0)
- New safety advice for diclofenac CMDh endorses PRAC recommendation(0)
- New safety features for medicines sold in the EU(0)
- News and events(0)
- New search page for periodic safety update report single assessments PSUSAs(0)
- Newsletter archive(0)
- Newsletters(0)
- New strategy to fight antimicrobial resistance(0)
- New study suggests risk of birth defects in babies born to women on HIV medicine dolutegravir(0)
- News update from veterinary unit 14 April 1997 centralised procedure for authorisation of veterinary medicinal products in the EU(0)
- New tracking tool for EMAs relocation to Amsterdam(0)
- New treatment for advanced form of kidney cancer(0)
- New treatment for advanced melanoma(0)
- New treatment for breast cancer(0)
- New treatment for children with chronic kidney disease(0)
- New treatment for children with type 2 diabetes(0)
- New treatment for obesity caused by rare genetic disorders(0)
- New treatment for patients with multiple myeloma(0)
- New treatment for patients with soft tissue sarcoma(0)
- New treatment for people with dwarfism(0)
- New treatment for rare autoimmune disease of nerve cells(0)
- New treatment for rare motor neurone disease recommended for approval(0)
- New treatment for rare white blood cell cancer(0)
- New treatment for sickle cell disease(0)
- New treatment for young children with parasitic disease schistosomiasis(0)
- New treatment option for heavily pretreated multiple myeloma patients(0)
- New treatment option for patients with advanced lung cancer(0)
- New treatment option for patients with rare blood cancer(0)
- New treatment option for rare inflammatory disease(0)
- New treatment option recommended for patients with advanced melanoma(0)
- New treatment to enable kidney transplant in highly sensitised patients(0)
- New vaccine for prevention of Ebola virus disease recommended for approval in the European Union(0)
- New vaccine to protect people in the EU and worldwide against dengue(0)
- New validation criteria for electronic submissions from 1 September 2011(0)
- New version of EudraGMP allows access to information from all Member States(0)
- New video launched How does EMA support SMEs(0)
- New Zealand(0)
- Nexavar(0)
- NexGard(0)
- NexGard Combo(0)
- Nexgard Spectra(0)
- Nexium Control(0)
- NexoBrid(0)
- Nexpovio(0)
- Nexviadyme(0)
- Nezglyal(0)
- Ngenla(0)
- Niall Fanning(0)
- Niamh Buckley(0)
- Niamh Ennis(0)
- Niapelf(0)
- Nick Jindrisek(0)
- Nicklas Hasselblad Lundstrøm(0)
- Niclas Falk(0)
- Nicola Lewis(0)
- Nicolas Beix(0)
- Nicolas Camhaji(0)
- Nicolas Glasser(0)
- Nicolas Lee(0)
- Nicolas Mortier(0)
- Nicolas Nyssen(0)
- Nicole Bethge(0)
- Nicole Bick(0)
- Nicole Jaspers(0)
- Nicole Kavanagh(0)
- Nicole Keil(0)
- Nicole Leitner(0)
- Nicole Thiele(0)
- Nicole Visser(0)
- NicOx SA withdraws its marketing authorisation application for Beprana naproxcinod(0)
- Niels Christian Kyvsgaard(0)
- Niels Paulsen(0)
- Nienke Rodenhuis(0)
- Nigel Olisa(0)
- Niina Makkonen(0)
- Niina Savolainen(0)
- Niklas Ekman(0)
- Niklas Walther(0)
- Niko Costantino(0)
- Nikola Lange(0)
- Nikolaus Zehetmayer(0)
- Nikolay Nikolaev(0)
- Nikolina Bolander(0)
- Nikolina Torti(0)
- Nikos Dedes(0)
- Nilemdo(0)
- Nils Jost(0)
- Nils Lilienthal(0)
- Nils Peter Lönn(0)
- Nimenrix(0)
- Nimet Filiz(0)
- Nimvastid(0)
- Nina Alex(0)
- Nina Benedicte Tuxen(0)
- Nina Hessvik(0)
- Nina Hulin(0)
- Nina Lalic(0)
- Nina Malvik(0)
- Nina Pannwitz(0)
- Nina Ruso(0)
- Nina SonneckTernes(0)
- Nineteenth Meeting of the Management Board(0)
- Ninlaro(0)
- Nintedanib Accord(0)
- Ninth industry stakeholder platform on research and development support(0)
- Ninth industry stakeholder platform on the operation of EU pharmacovigilance legislation(0)
- Ninth meeting of the EMA Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP(0)
- Ninth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicine(0)
- Ninth Meeting of the Management Board(0)
- Ninth Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Ninth stakeholder forum on the pharmacovigilance legislation(0)
- Nisamox Lactating Cow(0)
- Nitisinone MDK previously Nitisinone MendeliKABS(0)
- Nitrosamine Implementation Oversight Group NIOG Kickoff meeting(0)
- Nitrosamine impurities(0)
- Nitrosamines EMA aligns recommendations for sartans with those for other medicines(0)
- Nitrosamines Safety Operational Expert Group(0)
- Nityr(0)
- Nivéditha Dévie Le Bonheur(0)
- Nives Bebek Bestvina(0)
- Nivestim(0)
- Nivolumab BMS(0)
- Nobilis IB 491(0)
- Nobilis IB Primo QX(0)
- Nobilis Influenza H5N2(0)
- Nobilis Influenza H5N6(0)
- Nobilis Influenza H7N1(0)
- Nobilis Multriva RT+IBm+ND+Gm+REOm+EDS(0)
- Nobilis OR Inac(0)
- Nobivac Bb(0)
- Nobivac DP Plus(0)
- Nobivac L4(0)
- Nobivac LeuFel(0)
- Nobivac LoVo L4(0)
- Nobivac MyxoRHD(0)
- Nobivac MyxoRHD Plus(0)
- Nobivac Piro(0)
- No change is needed in use of direct oral anticoagulants following EMAfunded study(0)
- No change to product information for breast cancer medicine Tyverb following reassessment of data(0)
- No consistent evidence of an increased risk of heart problems with testosterone medicines(0)
- Nodetrip previously Xeristar(0)
- No evidence that Fluad vaccine caused deaths in Italy(0)
- Nomegestrol / chlormadinone(0)
- Nonafact(0)
- Nonclinical and clinical development for oral and topical HIV preexposure prophylaxis PrEP Scientific guideline(0)
- Nonclinical and clinical development of medicinal products for the treatment of nausea and vomiting associated with cancer chemotherapy Scientific guideline(0)
- Nonclinical and clinical development of similar biological medicinal products containing lowmolecularweight heparins Scientific guideline(0)
- Nonclinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues Scientific guideline(0)
- Nonclinical and clinical development of similar biological medicinal products containing recombinant interferon alpha or pegylated recombinant interferon alpha Scientific guideline(0)
- Nonclinical and clinical evaluation of antiviral medicinal products and monoclonal antibodies for the prevention and treatment of COVID19 Scientific guideline(0)
- NonClinical and New Approach Methodologies European Specialised Expert Community(0)
- Nonclinical assessment of the carcinogenic potential of human insulin analogues Scientific guideline(0)
- Nonclinical development(0)
- Nonclinical development of fixed combinations of medicinal products Scientific guideline(0)
- Nonclinical documentation for mixed marketing authorisation applications Scientific guideline(0)
- Nonclinical documentation in applications for marketing authorisation / registration of wellestablished and traditional herbal medicinal products Scientific guideline(0)
- Nonclinical environmental risk assessment(0)
- Nonclinical evaluation of druginduced liver injury DILI Scientific guideline(0)
- Nonclinical guidelines(0)
- Nonclinical investigation of the dependence potential of medicinal products Scientific guideline(0)
- Nonclinical local tolerance testing of medicinal products Scientific guideline(0)
- Nonclinical pharmacokinetics and toxicokinetics(0)
- Nonclinical pharmacology and safety pharmacology(0)
- Nonclinical requirements for radiopharmaceuticals Scientific guideline(0)
- Nonclinical studies required before first clinical use of gene therapy medicinal products Scientific guideline(0)
- Nonclinical testing for inadvertent germline transmission of gene transfer vectors Scientific guideline(0)
- Nonclinical toxicology(0)
- Nonclinical Working Party(0)
- Nonclinical Working Party documents(0)
- No new patients should start treatment with Lartruvo after study shows cancer medicine does not prolong life(0)
- Noninferiority and equivalence comparisons in clinical trials Scientific guideline(0)
- Nonpharmaceutical products(0)
- Nonpharmacopoeial reference standards for herbal substances herbal preparations and herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Nonremunerated and remunerated donors safety and supply of plasmaderived medicinal products Scientific guideline(0)
- Noora Ihala(0)
- Norah Cassidy(0)
- Norbert Benda(0)
- Norbert Brockmeyer(0)
- Norbert Moller(0)
- Norbert Müller(0)
- Norbonex 5 mg/ml pouron solution for beef and dairy cattle(0)
- Nordimet(0)
- Norontsoa Rasolondramanitra(0)
- Norvir(0)
- Note on the removal of the target animal batch safetytest TABST from European Pharmacopoeia monographs Scientific guideline(0)
- Notifications Regulatory and procedural guidance(0)
- Notifying a change of marketing status(0)
- Notifying a change of marketing status and sunset clause veterinary medicines(0)
- Notifying EMA of changes to contact persons veterinary medicines(0)
- nour kammar(0)
- Nouryant(0)
- Novagali Pharma SA withdraws its marketing authorisation application for Vekacia ciclosporin(0)
- Novaquin(0)
- Novartis Europharm Ltd withdraws its application for an extension of indication for Zometa zoledronic acid(0)
- Novartis Europharm Ltd withdraws its applications for an extension of the indication for Exelon and Prometax rivastigmine(0)
- Novartis Europharm Ltd withdraws its marketing authorisation application for Joulferon albinterferon alfa2b(0)
- Novartis Europharm Ltd withdraws its marketing authorisation application for Rasival aliskiren/valsartan(0)
- Novartis Europharm Ltd withdraws its marketingauthorisation application for Ruvise imatinib mesilate(0)
- Novartis Vaccines and Diagnostics Srl withdraws its application for paediatric use marketing authorisation for Fluad Paediatric influenza vaccine(0)
- Novartis Vaccines and Diagnostics Srl withdraws its marketing authorisation application for the prepandemic vaccine Aflunov(0)
- Novartis withdraws its application to extend the marketing authorisation for Glivec(0)
- Novartis withdraws its application to extend the marketing authorisation for Zometa(0)
- Novartis withdraws its marketing authorisation application for Joicela lumiracoxib(0)
- Novel therapies(0)
- Novel Therapies and Technologies Working Party(0)
- Novel veterinary medicines how to make use of stem cells and monoclonal antibodies(0)
- Novem(0)
- NovoEight(0)
- NovoMix(0)
- Novo Nordisk withdraws its application to extend the marketing authorisations for NovoNorm and Prandin(0)
- Novo Nordisk withdraw their application to extend the marketing authorisation for NovoSeven(0)
- NovoNorm(0)
- NovoRapid(0)
- NovoSeven(0)
- NovoThirteen(0)
- Noxafil(0)
- Nplate(0)
- Nubeqa(0)
- Nucala(0)
- Nuceiva(0)
- Nuedexta(0)
- Nuflor(0)
- Nuflor Swine Once(0)
- Nulibry(0)
- Nulojix(0)
- Numeta G13%E to be suspended and new riskminimisation measures to be introduced for Numeta G16%E(0)
- Numient(0)
- Nuno Janeiro(0)
- Nuno Miguel Elvas Neves Silva(0)
- Nuno RochaPereira(0)
- Nuno Simões(0)
- Nuno Sousa(0)
- nunzia sanarico(0)
- Nunzio Guido Mangano(0)
- Nuria Doñamayor Alonso(0)
- Nuria Garcia Sainz(0)
- Nuria Roldán(0)
- Nuria Sanchez Ranchel(0)
- Nuria Teresa Sols Cueto(0)
- Nustendi(0)
- NutropinAq(0)
- Nuvaxovid(0)
- Nuwiq(0)
- Nuzyra(0)
- Nynke Brouwer(0)
- Nynke ZandstraHosper(0)
- Nyracta(0)
- Nyvepria(0)
- Nyxoid(0)
- Nyxthracis previously Obiltoxaximab SFL(0)
- O(0)
- Obgemsa(0)
- Obizur(0)
- Obtaining and maintaining a scientific opinion on a medicine for use outside the European Union(0)
- Obtaining an EU marketing authorisation stepbystep(0)
- Ocrevus(0)
- Octocog alfa(0)
- Octreotide acetate productspecific bioequivalence guidance(0)
- Odefsey(0)
- Odoardo Maria Olimpieri(0)
- Odomzo(0)
- Odrun Havneras(0)
- Oenotherae oleum(0)
- Ofev(0)
- Offlabel use of antimicrobials in veterinary medicine in the European Union Scientific guideline(0)
- Ogivri(0)
- Ogluo(0)
- Okedi(0)
- Olaf Klungel(0)
- Olaf Ludek(0)
- Olaf Schnurbusch(0)
- Ola Martinelle(0)
- Olansek(0)
- Olanzapine Apotex(0)
- Olanzapine Cipla previously Olanzapine Neopharma(0)
- Olanzapine Glenmark(0)
- Olanzapine Glenmark Europe(0)
- Olanzapine Mylan(0)
- Olanzapine Teva(0)
- Olaparib productspecific bioequivalence guidance(0)
- Olazax(0)
- Olazax Disperzi(0)
- Oldouz Majidi(0)
- Oleae folium(0)
- Ole Henrik Myrdal(0)
- Ole Weis Bjerrum(0)
- Olga Chatzis(0)
- OLGA GRECIANO GRECIANO(0)
- Olga Kamp(0)
- Olga Kholmanskikh(0)
- Olga KolajRobin(0)
- Olga Maria Palomino(0)
- Olga Rogelsperger(0)
- Olga Tcheremenskaia(0)
- Olga Teresa Esteban(0)
- Olimpia Neagu(0)
- Oliver Semler(0)
- Oliver Walisko(0)
- Olive Smyth(0)
- Olivia Dzwonkowski(0)
- Olivier Clement(0)
- Olivier FERRARIS(0)
- Olivier Garinot(0)
- Olivier Gorgé(0)
- Olivier Le Blaye(0)
- Olivier Moes(0)
- Olli Tenhunen(0)
- Olmesartan medoxomil / amlodipine besilate / hydrochlorothiazide(0)
- Olumiant(0)
- Olysio(0)
- Omacetaxine mepesuccinate(0)
- Omblastys(0)
- Omega3 fatty acid ethyl esters(0)
- Omega3 fatty acid medicines no longer considered effective in preventing heart disease(0)
- Omega3acid 85% ethyl esters of eicosapentaenoic acid EPA and docosahexaenoic acid DHA in a ratio of 0915 simvastatin(0)
- Omidria(0)
- Omjjara(0)
- Omlyclo(0)
- Omnitrope(0)
- Omontys(0)
- Omvoh(0)
- Onbevzi(0)
- Onbrez Breezhaler(0)
- Oncaspar(0)
- Oncept IL2(0)
- Oncept Melanoma(0)
- Oncology European Specialised Expert Community(0)
- Oncology Working Party(0)
- Oncophage(0)
- Oncoscience AG withdraws its application for Theraloc nimotuzumab(0)
- Ondexxya(0)
- Ondrej Duben(0)
- Onduarp(0)
- One additional country to benefit from EUUS mutual recognition agreement for inspections(0)
- Ongentys(0)
- Onglyza(0)
- Onivyde pegylated liposomal previously known as Onivyde(0)
- Online training course for bioequivalence inspectors(0)
- Online training how to register for access to IRIS what research product identifiers RPI are and how we use them(0)
- Online training How to submit initial and followup scientific advice applications human using IRIS(0)
- Online training How to submit Initial and followup scientific advice applications veterinary using IRIS(0)
- Only For Children Pharmaceuticals withdraws its marketingauthorisation application for Loulla mercaptopurine(0)
- Onno Kaandorp(0)
- Ononidis radix(0)
- Onpattro(0)
- Onsenal(0)
- Onsior(0)
- Ontilyv(0)
- Ontozry(0)
- Ontruzant(0)
- Onureg(0)
- Onzeald(0)
- Opatanol(0)
- Opaxio(0)
- Opdivo(0)
- Opdualag(0)
- Open consultations(0)
- OPEN framework extended to a wider range of medicines(0)
- Opening procedures at EMA to nonEU authorities OPEN initiative(0)
- Opening up clinical data on new medicines(0)
- Open letters(0)
- Operation of the Clinical Trials Directive Directive 2001/20/EC and Perspectives for the Future A joint conference of the European Commission and the European Medicines Agency(0)
- Opfolda(0)
- Opgenra(0)
- Opinions and letters of support on the qualification of novel methodologies for medicine development(0)
- Oportuzumab monatox DLRC Pharma Services(0)
- Oprymea(0)
- Opsiria(0)
- Opsumit(0)
- Optaflu(0)
- Optimark(0)
- Optimising safety information for medicines in Europe throughout product lifecycle(0)
- Optison(0)
- Optruma(0)
- Opulis(0)
- Opzelura(0)
- Oral almitrine to be withdrawn by EU Member States(0)
- OraNera(0)
- Orathecin(0)
- Orbax(0)
- orBec(0)
- Orencia(0)
- Orepaxam(0)
- Orfadin(0)
- Orgalutran(0)
- Organisational Matters Drafting Group(0)
- Organisation Management Service OMS(0)
- Organisation Management System OMS Trouble Shooting Session for CTIS users July 2022(0)
- Organisation Management System OMS Trouble Shooting Session for CTIS users June 2022(0)
- Organisation Management System OMS Trouble Shooting Session for CTIS users November 2022(0)
- Organisation Management System OMS Trouble Shooting Session for CTIS users October 2022(0)
- Organisation Management System OMS Trouble Shooting Session for CTIS users September 2022(0)
- Organisations Management Services OMS data quality standards webinar with OMS users(0)
- Orgovyx(0)
- Origani dictamni herba(0)
- Origani majoranae herba(0)
- Orion Corporation withdraws its application for an extension of indication for Stalevo levodopa/carbidopa/entacapone(0)
- Orkambi(0)
- Orlaam(0)
- Orladeyo(0)
- Ornella Tinelli(0)
- Orn Gudmundsson(0)
- Orphacol(0)
- Orphan designation marketing authorisation(0)
- Orphan designation Overview(0)
- Orphan designation postauthorisation(0)
- Orphan designation research and development(0)
- Orphan drug and paediatric clinical trials EMEA workshop on methodological aspects of clinical trials for efficacy evaluation in small populations(0)
- Orphan incentives(0)
- Orphan medicines development ask the European regulator(0)
- Orphan medicines development in Europe and Japan(0)
- Orphan medicines in the EU leaving noone behind(0)
- Orphan medicines procedures(0)
- Orphans Regulatory and procedural guidance and forms(0)
- Orplatna(0)
- Orserdu(0)
- Orsolya Juhász(0)
- Orthosiphonis folium(0)
- Oscar Cruciani(0)
- Oscar Ljungberg(0)
- Oseltamivir productspecific bioequivalence guidance(0)
- Osigraft(0)
- Oskar Nilsson(0)
- Oskar Skog(0)
- Oslif Breezhaler(0)
- Osseor(0)
- Osurnia(0)
- Otezla(0)
- Othmar Engelhardt(0)
- Otsuka Pharmaceutical Europe Ltd withdraws its application for an extension of indication for Abilify aripiprazole(0)
- Ott Laius(0)
- Our commitment to patients welfare will continue to guide our work in 2016(0)
- Outcome report on first European collaboration between regulators and HTA organisations improving the contribution of regulatory assessment reports to health technology assessment(0)
- Outcomes of imposed noninterventional postauthorisation safety studies(0)
- OUTDATED PRAC meetings(0)
- Outi Honkanen(0)
- Outi Kimmo(0)
- Outi MäkiIkola(0)
- Ovaleap(0)
- Over 1000 SMEs now registered with European Medicines Agency SME office(0)
- Over 1000 studies now recorded in EU register of postauthorisation studies(0)
- Overview of the current regulatory testing requirements for medicinal products for human use and opportunities for implementation of the 3Rs Scientific guideline(0)
- Overview of the current regulatory testing requirements for veterinary medicinal products and opportunities for implementation of the 3Rs Scientific guideline(0)
- Ovitrelle(0)
- OvuGel(0)
- Oxapex(0)
- Oxbryta(0)
- Oxervate(0)
- Oxlumo(0)
- Oxmax(0)
- Oxybee(0)
- Oxyglobin(0)
- Oyavas(0)
- Oyvind Holte(0)
- Ozawade(0)
- Ozempic(0)
- Ozempic / Victoza(0)
- Ozespa(0)
- Ozurdex(0)
- P(0)
- P/0096/2023 EMA decision of 10 March 2023 on the granting of a product specific waiver for pembrolizumab Keytruda EMEA001474PIP0322(0)
- P/0273/2022 EMA on the granting of a product specific waiver for tramadol hydrochloride / magnesium lactate dihydrate EMEA003216PIP0122(0)
- P/0289/2015(0)
- P/0321/2014(0)
- P/0323/2014(0)
- P/0325/2014(0)
- P/0341/2014(0)
- P/0343/2014(0)
- P/0451/2022 EMA decision of 28 October 2022 on the granting of a product specific waiver for trilaciclib dihydrochloride EMEA002534PIP0322(0)
- P/3/2010(0)
- P/4/2010(0)
- P/5/2010(0)
- P/9/2010(0)
- P/12/2009(0)
- P/13/2010(0)
- P/16/2011(0)
- P/17/2011(0)
- P/22/2011(0)
- P/23/211(0)
- P/25/2011(0)
- P/36/2011(0)
- P/80/2010(0)
- P/82/2010(0)
- P/86/2010(0)
- P/87/2010(0)
- P/90/2010(0)
- P/91/2010(0)
- P/93/2010(0)
- P/111/2010(0)
- P/116/2010(0)
- P/117/2010(0)
- P/118/2010(0)
- P/149/2011(0)
- P/198/2011(0)
- Pablo Centeno(0)
- Pablo de Felipe(0)
- Pablo Guisado Vasco(0)
- Pablo Mínguez Gabiña(0)
- PABLO OTERO PAZOS(0)
- Paccal Vet(0)
- Padcev(0)
- Padraig Keane(0)
- Paediatric addendum on the CHMP guideline on clinical investigation of medicinal products for the treatment of acute heart failure Scientific guideline(0)
- Paediatric addendum to the guideline on clinical investigation of medicinal products for the treatment of pulmonary arterial hypertension Scientific guideline(0)
- Paediatric addendum to the guideline on clinical investigation of medicinal products in the treatment of lipid disorders Scientific guideline(0)
- Paediatric addendum to the guideline on clinical investigation on medicinal products in the treatment of hypertension Scientific guideline(0)
- Paediatric anticoagulation therapy expert meeting(0)
- Paediatric clinical trials(0)
- Paediatric Commitee PDCO 46 July 2012(0)
- Paediatric Committee elects Koenraad Norga as its new chair(0)
- Paediatric Committee elects new Chair and ViceChair(0)
- Paediatric Committee PDCO(0)
- Paediatric Committee PDCO 14 September 2020(0)
- Paediatric Committee PDCO 26 February1 March 2019(0)
- Paediatric Committee PDCO 29 January1 February 2019(0)
- Paediatric Committee PDCO 29 May 1 June 2018(0)
- Paediatric Committee PDCO 30 March 1 April 2016(0)
- Paediatric Committee PDCO 35 October 2012(0)
- Paediatric Committee PDCO 36 September 2024(0)
- Paediatric Committee PDCO 46 December 2013(0)
- Paediatric Committee PDCO 57 December 2012(0)
- Paediatric Committee PDCO 57 September 2012(0)
- Paediatric Committee PDCO 58 September 2023(0)
- Paediatric Committee PDCO 68 February 2013(0)
- Paediatric Committee PDCO 68 June 2012(0)
- Paediatric Committee PDCO 68 November 2013(0)
- Paediatric Committee PDCO 68 October 2010(0)
- Paediatric Committee PDCO 69 September 2022(0)
- Paediatric Committee PDCO 79 August 2013(0)
- Paediatric Committee PDCO 79 December 2011(0)
- Paediatric Committee PDCO 79 March 2012(0)
- Paediatric Committee PDCO 79 November 2012(0)
- Paediatric Committee PDCO 79 October 2015(0)
- Paediatric Committee PDCO 79 September 2011(0)
- Paediatric Committee PDCO 710 November 2017(0)
- Paediatric Committee PDCO 710 November 2023(0)
- Paediatric Committee PDCO 710 September 2021(0)
- Paediatric Committee PDCO 810 December 2010(0)
- Paediatric Committee PDCO 810 February 2012(0)
- Paediatric Committee PDCO 810 October 2014(0)
- Paediatric Committee PDCO 810 September 2010(0)
- Paediatric Committee PDCO 811 December 2020(0)
- Paediatric Committee PDCO 811 December 2026(0)
- Paediatric Committee PDCO 811 November 2016(0)
- Paediatric Committee PDCO 811 November 2022(0)
- Paediatric Committee PDCO 811 September 2026(0)
- Paediatric Committee PDCO 911 December 2015(0)
- Paediatric Committee PDCO 911 December 2019(0)
- Paediatric Committee PDCO 911 January 2013(0)
- Paediatric Committee PDCO 911 June 2010(0)
- Paediatric Committee PDCO 911 November 2011(0)
- Paediatric Committee PDCO 911 October 2013(0)
- Paediatric Committee PDCO 911 September 2015(0)
- Paediatric Committee PDCO 912 December 2025(0)
- Paediatric Committee PDCO 912 November 2021(0)
- Paediatric Committee PDCO 912 September 2025(0)
- Paediatric Committee PDCO 1012 April 2013(0)
- Paediatric Committee PDCO 1012 August 2011(0)
- Paediatric Committee PDCO 1012 December 2014(0)
- Paediatric Committee PDCO 1012 November 2010(0)
- Paediatric Committee PDCO 1012 September 2014(0)
- Paediatric Committee PDCO 1013 December 2024(0)
- Paediatric Committee PDCO 1013 November 2020(0)
- Paediatric Committee PDCO 1013 November 2026(0)
- Paediatric Committee PDCO 1013 October 2017(0)
- Paediatric Committee PDCO 1013 October 2023(0)
- Paediatric Committee PDCO 1113 April 2012(0)
- Paediatric Committee PDCO 1113 February 2015(0)
- Paediatric Committee PDCO 1113 January 2012(0)
- Paediatric Committee PDCO 1113 November 2015(0)
- Paediatric Committee PDCO 1113 September 2013(0)
- Paediatric Committee PDCO 1114 December 2018(0)
- Paediatric Committee PDCO 1114 November 2025(0)
- Paediatric Committee PDCO 1114 October 2022(0)
- Paediatric Committee PDCO 1214 August 2015(0)
- Paediatric Committee PDCO 1214 February 2014(0)
- Paediatric Committee PDCO 1214 January 2011(0)
- Paediatric Committee PDCO 1214 June 2013(0)
- Paediatric Committee PDCO 1214 November 2014(0)
- Paediatric Committee PDCO 1214 October 2011(0)
- Paediatric Committee PDCO 1214 October 2016(0)
- Paediatric Committee PDCO 1215 December 2017(0)
- Paediatric Committee PDCO 1215 December 2023(0)
- Paediatric Committee PDCO 1215 November 2019(0)
- Paediatric Committee PDCO 1215 November 2024(0)
- Paediatric Committee PDCO 1215 October 2021(0)
- Paediatric Committee PDCO 1215 September 2017(0)
- Paediatric Committee PDCO 1315 August 2014(0)
- Paediatric Committee PDCO 1315 January 2010(0)
- Paediatric Committee PDCO 1315 July 2011(0)
- Paediatric Committee PDCO 1315 March 2013(0)
- Paediatric Committee PDCO 1316 December 2016(0)
- Paediatric Committee PDCO 1316 December 2022(0)
- Paediatric Committee PDCO 1316 November 2018(0)
- Paediatric Committee PDCO 1316 October 2020(0)
- Paediatric Committee PDCO 1316 October 2026(0)
- Paediatric Committee PDCO 1416 April 2010(0)
- Paediatric Committee PDCO 1416 January 2015(0)
- Paediatric Committee PDCO 1416 July 2010(0)
- Paediatric Committee PDCO 1416 May 2012(0)
- Paediatric Committee PDCO 1416 September 2016(0)
- Paediatric Committee PDCO 1417 December 2021(0)
- Paediatric Committee PDCO 1417 October 2025(0)
- Paediatric Committee PDCO 1517 April 2015(0)
- Paediatric Committee PDCO 1517 August 2012(0)
- Paediatric Committee PDCO 1517 January 2014(0)
- Paediatric Committee PDCO 1517 July 2015(0)
- Paediatric Committee PDCO 1517 June 2011(0)
- Paediatric Committee PDCO 1517 May 2013(0)
- Paediatric Committee PDCO 1518 August 2017(0)
- Paediatric Committee PDCO 1518 October 2019(0)
- Paediatric Committee PDCO 1518 October 2024(0)
- Paediatric Committee PDCO 1618 February 2011(0)
- Paediatric Committee PDCO 1618 July 2014(0)
- Paediatric Committee PDCO 1618 March 2011(0)
- Paediatric Committee PDCO 1619 January 2024(0)
- Paediatric Committee PDCO 1619 May 2017(0)
- Paediatric Committee PDCO 1619 October 2018(0)
- Paediatric Committee PDCO 1719 August 2016(0)
- Paediatric Committee PDCO 1719 February 2010(0)
- Paediatric Committee PDCO 1719 July 2013(0)
- Paediatric Committee PDCO 1719 June 2015(0)
- Paediatric Committee PDCO 1719 March 2010(0)
- Paediatric Committee PDCO 1720 January 2023(0)
- Paediatric Committee PDCO 1720 June 2025(0)
- Paediatric Committee PDCO 1720 May 2022(0)
- Paediatric Committee PDCO 1720 September 2019(0)
- Paediatric Committee PDCO 1820 April 2011(0)
- Paediatric Committee PDCO 1820 June 2014(0)
- Paediatric Committee PDCO 1820 March 2015(0)
- Paediatric Committee PDCO 1820 May 2011(0)
- Paediatric Committee PDCO 1821 April 2017(0)
- Paediatric Committee PDCO 1821 January 2022(0)
- Paediatric Committee PDCO 1821 July 2017(0)
- Paediatric Committee PDCO 1821 July 2023(0)
- Paediatric Committee PDCO 1821 May 2021(0)
- Paediatric Committee PDCO 1821 September 2018(0)
- Paediatric Committee PDCO 1921 March 2014(0)
- Paediatric Committee PDCO 1921 May 2010(0)
- Paediatric Committee PDCO 1922 April 2022(0)
- Paediatric Committee PDCO 1922 July 2022(0)
- Paediatric Committee PDCO 1922 March 2024(0)
- Paediatric Committee PDCO 1922 May 2026(0)
- Paediatric Committee PDCO 2022 July 2016(0)
- Paediatric Committee PDCO 2022 May 2015(0)
- Paediatric Committee PDCO 2023 April 2021(0)
- Paediatric Committee PDCO 2023 February 2018(0)
- Paediatric Committee PDCO 2023 February 2024(0)
- Paediatric Committee PDCO 2023 July 2021(0)
- Paediatric Committee PDCO 2023 June 2017(0)
- Paediatric Committee PDCO 2023 June 2023(0)
- Paediatric Committee PDCO 2023 March 2018(0)
- Paediatric Committee PDCO 2023 May 2025(0)
- Paediatric Committee PDCO 2123 May 2014(0)
- Paediatric Committee PDCO 2124 April 2026(0)
- Paediatric Committee PDCO 2124 August 2018(0)
- Paediatric Committee PDCO 2124 February 2017(0)
- Paediatric Committee PDCO 2124 February 2023(0)
- Paediatric Committee PDCO 2124 July 2020(0)
- Paediatric Committee PDCO 2124 July 2026(0)
- Paediatric Committee PDCO 2124 June 2022(0)
- Paediatric Committee PDCO 2124 March 2017(0)
- Paediatric Committee PDCO 2224 June 2016(0)
- Paediatric Committee PDCO 2225 April 2025(0)
- Paediatric Committee PDCO 2225 February 2022(0)
- Paediatric Committee PDCO 2225 July 2025(0)
- Paediatric Committee PDCO 2225 June 2021(0)
- Paediatric Committee PDCO 2225 March 2022(0)
- Paediatric Committee PDCO 2325 April 2014(0)
- Paediatric Committee PDCO 2326 April 2019(0)
- Paediatric Committee PDCO 2326 April 2024(0)
- Paediatric Committee PDCO 2326 February 2021(0)
- Paediatric Committee PDCO 2326 January 2018(0)
- Paediatric Committee PDCO 2326 July 2019(0)
- Paediatric Committee PDCO 2326 July 2024(0)
- Paediatric Committee PDCO 2326 June 2020(0)
- Paediatric Committee PDCO 2326 June 2026(0)
- Paediatric Committee PDCO 2326 March 2021(0)
- Paediatric Committee PDCO 2326 May 2023(0)
- Paediatric Committee PDCO 2426 April 2023(0)
- Paediatric Committee PDCO 2426 February 2016(0)
- Paediatric Committee PDCO 2427 April 2018(0)
- Paediatric Committee PDCO 2427 February 2026(0)
- Paediatric Committee PDCO 2427 January 2017(0)
- Paediatric Committee PDCO 2427 July 2018(0)
- Paediatric Committee PDCO 2427 March 2020(0)
- Paediatric Committee PDCO 2427 March 2026(0)
- Paediatric Committee PDCO 2527 May 2016(0)
- Paediatric Committee PDCO 2528 February 2020(0)
- Paediatric Committee PDCO 2528 February 2025(0)
- Paediatric Committee PDCO 2528 June 2019(0)
- Paediatric Committee PDCO 2528 June 2024(0)
- Paediatric Committee PDCO 2528 March 2025(0)
- Paediatric Committee PDCO 2629 January 2021(0)
- Paediatric Committee PDCO 2629 June 2018(0)
- Paediatric Committee PDCO 2629 March 2019(0)
- Paediatric Committee PDCO 2629 May 2020(0)
- Paediatric Committee PDCO 2729 April 2016(0)
- Paediatric Committee PDCO 2729 January 2016(0)
- Paediatric Committee PDCO 2729 May 2019(0)
- Paediatric Committee PDCO 2730 January 2026(0)
- Paediatric Committee PDCO 2830 April 2020(0)
- Paediatric Committee PDCO 2831 January 2020(0)
- Paediatric Committee PDCO 2831 January 2025(0)
- Paediatric Committee PDCO 2831 March 2023(0)
- Paediatric Committee PDCO 2831 May 2024(0)
- Paediatric Committee reelects chair(0)
- Paediatric development and juvenile animal studies assessors meeting(0)
- Paediatric Epilepsy Experts Group Meeting(0)
- Paediatric Formulation Operational Expert Group(0)
- Paediatric formulations(0)
- Paediatric investigation plans(0)
- Paediatric investigation plans submitting documents(0)
- Paediatric investigation plans Templates forms and submission dates(0)
- Paediatric medicines Marketing authorisation(0)
- Paediatric medicines Overview(0)
- Paediatric medicines Postauthorisation(0)
- Paediatric medicines procedures(0)
- Paediatric medicines Research and development(0)
- Paediatric medicines Workshops(0)
- Paediatric Oncology Strategy Forum 2425 October 2024(0)
- Paediatric osteoporosis expert meeting(0)
- Paediatric Regulation(0)
- Paediatric requirements for marketingauthorisation applications(0)
- Paediatric requirements for variations and extensions to marketing authorisations(0)
- Paediatric rheumatology expert group meeting(0)
- Paediatrics Regulatory and procedural guidance(0)
- Paediatric strategy forum for medicinal product development for acute myeloid leukaemia in children and adolescents(0)
- Paediatric strategy forum for medicinal product development for epigenetic modifiers in children and adolescents(0)
- Paediatric strategy forum for medicinal product development of checkpoint inhibitors for use in combination therapy in paediatric patients(0)
- Paediatricuse marketing authorisations(0)
- Paeoniae radix alba(0)
- Paeoniae radix rubra(0)
- Paglitaz(0)
- Päivi Luhtanen(0)
- Palbociclib productspecific bioequivalence guidance(0)
- Palforzia(0)
- Paliperidone palmitate productspecific bioequivalence guidance(0)
- Paliperidone productspecific bioequivalence guidance(0)
- Palladia(0)
- Palonosetron Accord(0)
- Palonosetron Hospira(0)
- Palynziq(0)
- Panacur AquaSol(0)
- Panagiota Tsantili(0)
- Panagiotis Psaras(0)
- Pandemic influenza(0)
- Pandemic influenza news archive(0)
- Pandemic influenza pharmacovigilance updates(0)
- Pandemic influenza vaccine H5N1 AstraZeneca previously Pandemic influenza vaccine H5N1 Medimmune(0)
- Pandemic Influenza Vaccine H5N1 Baxter AG(0)
- Pandemrix(0)
- Panexcell Clinical Laboratories suspension of medicines over flawed studies(0)
- Panos Mytides(0)
- Panretin(0)
- Pantecta Control(0)
- Pantoloc Control(0)
- Pantozol Control(0)
- Paola Aita(0)
- Paola di Basilio(0)
- Paola Elena Kruger(0)
- Paola Morandi(0)
- Paola Mosillo(0)
- Paola Spinsanti(0)
- Paolo Antonio Ascierto(0)
- Paolo Foggi(0)
- Paolo Gasparini(0)
- Paolo Martelletti(0)
- Paolo Petracci(0)
- Paolo Porcelli(0)
- Paolo Sbraccia(0)
- Paper calls for continued support for development of advanced therapies(0)
- Paquita Cornelissen(0)
- Paracetamol productspecific bioequivalence guidance(0)
- Parallel distribution(0)
- Parallel distribution human medicines procedures(0)
- Parallel distribution Regulatory and procedural guidance(0)
- Parallel joint scientific consultation with regulators and health technology assessment bodies(0)
- Parametric release Scientific guideline(0)
- Parareg(0)
- Parenteral Drug Association / European Medicines Agency joint conference Ensuring patient safety through supplychain control and good manufacturing practice(0)
- Parsabiv(0)
- Parsaclisib Incyte Biosciences Distribution BV(0)
- Partners & networks(0)
- Parvoduk(0)
- Pascal Di Donato(0)
- Pascale Macours(0)
- Pascal Giloteau(0)
- Pasquale Marchione(0)
- Passiflorae herba(0)
- Patient registries(0)
- Patient registries workshop(0)
- Patients/Consumers Working Party PCWP and Healthcare Professionals Working Group HCP WG joint meeting(0)
- Patients and carers(0)
- Patients and consumers(0)
- Patients and consumers Key documents(0)
- Patients and Consumers Working Party(0)
- Patients and Consumers Working Party/Healthcare Professionals Working Group joint meeting(0)
- Patients and Consumers Working Party and Healthcare Professionals Working Party joint meeting(0)
- Patients and Consumers Working Party elects new cochair(0)
- Patients and Consumers Working Party meetings(0)
- Patients and Consumers Working Party PCWP and Healthcare Professionals Working Group HCPWG joint meeting(0)
- Patients and Consumers Working Party PCWP and Healthcare Professionals Working Party HCPWP joint meeting(0)
- Patients and Consumers Working Party PCWP and Healthcare Professionals Working Party HCPWP joint meeting Workshop on the patients voice in the evaluation of medicines(0)
- Patients and Consumers Working Party PCWP and Healthcare Professionals Working Party HCPWP joint workshop on personalised medicines(0)
- Patients and healthcare professionals organisations updated on EMAs response to COVID19(0)
- Patients to discuss benefitrisk evaluation of medicines with the Committee for Medicinal Products for Human Use(0)
- Patrex(0)
- Patricia Bodart(0)
- Patricia Catalao(0)
- Patricia Córdoba Freire(0)
- Patricia Felgueiras Seabra Durao(0)
- Patricia Havet(0)
- Patricia Maria Tabernero Estevez(0)
- Patricia McGettigan(0)
- Patricia OttoTerlouw(0)
- Patricia Rodríguez(0)
- Patricia Vera Luque(0)
- Patrick Baudru(0)
- Patrick Rühl(0)
- Patrick Schröder(0)
- Patrick Vrijlandt(0)
- Patrick Weydt(0)
- Patrik Rosker(0)
- Patrizia Apollonio(0)
- Patrizia Felicetti(0)
- Patrizia Iacovacci(0)
- Patryk Neska(0)
- Paula Cardona Xuereb(0)
- Paula Contreras Alarcón(0)
- Paula Grönroos(0)
- Paula Kajaste(0)
- Paula Koivumäki(0)
- Paula Loekemeijer(0)
- Paula Lumme(0)
- Paula Rio(0)
- Paula Rubio Marques(0)
- PAULA SUEIRO JANZA(0)
- Paul Broertjes(0)
- Paul Declerck(0)
- Paul Houeto(0)
- Pauliina Ikäheimo(0)
- Pauliina LehtolainenDalkilic(0)
- Pauline Dayani(0)
- Pauline Keena(0)
- Pauline Marck(0)
- Paul Knoebl(0)
- Paul Knoop(0)
- Paulliniae semen(0)
- Paul McNeill(0)
- Paul Monteiro(0)
- Paulo Paixão(0)
- Paul Pirson(0)
- Paul Sexton(0)
- Paul Ten Berg(0)
- Paulus Bakx(0)
- Pavel Mohr(0)
- Pavel Shubin(0)
- Pavel Simek(0)
- Paving the way towards coordinated clinical trials in public health emergencies in the EU(0)
- Pavla Trejbalova(0)
- Pavla Zemanová(0)
- Pavlína Chladová(0)
- Pawel Pawlowski(0)
- Pawel Szoka(0)
- Paxene(0)
- Paxlovid(0)
- Pazenir(0)
- Pazopanib productspecific bioequivalence guidance(0)
- PCWP/HCPWP meeting with all eligible organisations COVID19 pandemic update(0)
- PDA/EMA 2011 Conference(0)
- PDCO Committee meeting report archive 20072011(0)
- PDCO Documents(0)
- PDCO meeting archive 20122014(0)
- PDCO meeting archive 20152017(0)
- PDCO meeting archive 20182020(0)
- PDCO members(0)
- PDCO Working parties and other groups(0)
- PecFent(0)
- Pedea(0)
- Pedmarqsi(0)
- Pegasys(0)
- PegIntron(0)
- Pegylated liposomal doxorubicin hydrochloride productspecific bioequivalence guidance(0)
- Pelargonii radix(0)
- Pelgraz(0)
- Pelmeg(0)
- Pelzont(0)
- Pemazyre(0)
- Pemetrexed Accord(0)
- Pemetrexed Baxter(0)
- Pemetrexed ditromethamine Hospira(0)
- Pemetrexed Fresenius Kabi(0)
- Pemetrexed Krka(0)
- Pemetrexed Lilly(0)
- Pemetrexed medac(0)
- Pemetrexed Pfizer previously known as Pemetrexed Hospira UK Limited(0)
- Pemetrexed Pfizer previously Pemetrexed Hospira(0)
- Pemetrexed Sandoz(0)
- Pending EC decisions on maximum residue limits(0)
- Penny Gilberts(0)
- Pepaxti(0)
- Per Albertsson(0)
- Pere Soler Palacin(0)
- Perflubutane(0)
- Performance enhancers Scientific guideline(0)
- Pergoveris(0)
- Periodic safety update report information day(0)
- Periodic safety update reports PSURs(0)
- Perjeta(0)
- Pernilla Örtqvist(0)
- Pernille Harg(0)
- Pernille Kaae Holm(0)
- Pernille Sterling(0)
- Perrine GoguetRubio(0)
- Per Sindahl(0)
- Personalised medicines focus on patients and healthcare professionals(0)
- Personal Message from Mr Fernand Sauer EMEA Executive Director 29 June 2000(0)
- Per Spindler(0)
- Pertti Pellinen(0)
- Petar Mas(0)
- Peter Bachmann(0)
- Peter Bay(0)
- Peter Caspers(0)
- Peter Egbert Hermann Schwarz(0)
- Peter Gozzi(0)
- Peter Jan Hooikaas(0)
- Peter Jongen(0)
- Peter Julian Sandler(0)
- Peter Mayer(0)
- Peter Mol(0)
- Peter Munch Andersen(0)
- Peter Oliver Murphy(0)
- Peter Platzer(0)
- Peter Riis Hansen(0)
- Peter Sisovsky(0)
- Peter Szitanyi(0)
- Peter Theunissen(0)
- Peter van de Ven(0)
- Peter Van Meer(0)
- Peter Van Vlaardingen(0)
- Peter Voitl(0)
- Peter Zsolt Fekete(0)
- Petra Arndt(0)
- Petra Brugmann(0)
- Petra Falb(0)
- Petra Gubova(0)
- Petra Jamnik(0)
- Petra Kaftanová(0)
- Petra Kubová(0)
- Petra Minder(0)
- Petra Müllerová(0)
- Petra Prent(0)
- Petra Prouzova(0)
- Petra Schlick(0)
- Petra Sokol(0)
- Petra TeklenburgTodt(0)
- Petra Vacková(0)
- Petra Wiesinger(0)
- Petri Kaheinen(0)
- Petr Soukup(0)
- Petrus Luijsterburg(0)
- Petrus Schonken Steyn(0)
- Petr Vrbata(0)
- Pexion(0)
- Peyona previously Nymusa(0)
- Pfizer Limited withdraws its application for an extension of the indication for Macugen pegaptanib sodium(0)
- Pfizer withdraws its application to change the marketing authorisation for Viagra 50 mg sildenafil from prescriptiononly to nonprescription(0)
- Pfizer withdraws its marketing authorisation application for Exulett dalbavancin(0)
- Pharmaceutical development of intravenous medicinal products containing active substances solubilised in micellar systems nonpolymeric surfactants Scientific guideline(0)
- Pharmaceutical development of medicines for paediatric use Scientific guideline(0)
- Pharmaceutical development of medicines for use in the older population Scientific guideline(0)
- Pharmaceutical industry(0)
- Pharmaceutical quality of inhalation and nasal products Scientific guideline(0)
- Pharmaceuticals Regulation Croatias Road to EU Membership(0)
- Pharmaceutics International Inc US supply of noncritical medicines to EU to be stopped due to manufacturing failings(0)
- Pharmacogenetics briefing meeting Scientific guideline(0)
- Pharmacogenomic samples testing and data handling Scientific guideline(0)
- Pharmacogenomics in oncology Scientific guideline(0)
- Pharmacogenomics Working Party(0)
- Pharmacokinetic and clinical evaluation of modifiedrelease dosage forms Scientific guideline(0)
- Pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products Scientific guideline(0)
- Pharmacokinetic studies in man Scientific guideline(0)
- Pharmacokinetics Working Party(0)
- Pharmacovigilance assessments challenges and solutions for pharmacovigilance assessors(0)
- Pharmacovigilance fees Information for companies on fees for safety monitoring of medicines(0)
- Pharmacovigilance fees payable to the European Medicines Agency(0)
- Pharmacovigilance fees questions and answers(0)
- Pharmacovigilance for advanced therapies(0)
- Pharmacovigilance guidelines(0)
- Pharmacovigilance inspection procedures human(0)
- Pharmacovigilance inspections for veterinary medicines(0)
- Pharmacovigilance Inspectors Working Group(0)
- Pharmacovigilance in the paediatric population workshop(0)
- Pharmacovigilance marketing authorisation(0)
- Pharmacovigilance Overview(0)
- Pharmacovigilance postauthorisation(0)
- Pharmacovigilance procedures(0)
- Pharmacovigilance procedures for human medicines(0)
- Pharmacovigilance procedures for veterinary medicines(0)
- Pharmacovigilance Regulatory and procedural guidance(0)
- Pharmacovigilancerelated recommendations to product information for centrally authorised veterinary medicines(0)
- Pharmacovigilance research and development(0)
- Pharmacovigilance Risk Assessment Committee confirms Chair and Vicechair for new three year mandate(0)
- Pharmacovigilance Risk Assessment Committee one year of publichealth promotion and protection(0)
- Pharmacovigilance Risk Assessment Committee PRAC(0)
- Pharmacovigilance Risk Assessment Committee PRAC 5 August 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 13 October 2012(0)
- Pharmacovigilance Risk Assessment Committee PRAC 14 December 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 14 October 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 28 November 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 December 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 May 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 May 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 September 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 September 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 25 September 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 28 31 October 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 28 November 1 December 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 28 November 1 December 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 28 September1 October 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 29 August1 September 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 29 August 1 September 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 29 November2 December 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 30 August 2 September 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 30 August2 September 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 30 November3 December 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 30 September3 October 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 30 September 3 October 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 31 August3 September 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 31 July 3 August 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 35 September 2012(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 April 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 August 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 February 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 July 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 July 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 March 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 May 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 November 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 November 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 36 September 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 April 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 February 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 July 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 March 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 March 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 May 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 47 November 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 48 July 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 August 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 August 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 February 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 February 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 July 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 June 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 March 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 May 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 58 October 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 April 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 August 2012(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 February 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 February 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 January 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 January 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 July 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 July 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 June 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 June 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 March 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 69 October 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 April 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 April 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 February 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 January 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 July 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 June 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 June 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 March 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 October 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 710 September 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 April 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 April 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 April 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 February 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 February 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 January 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 January 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 July 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 July 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 July 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 June 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 June 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 March 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 811 September 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 April 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 February 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 January 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 January 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 July 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 March 2015(0)
- Pharmacovigilance Risk Assessment Committee PRAC 912 March 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1012 May 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1013 February 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1013 January 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1013 June 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1013 June 2014(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1013 June 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1013 May 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 April 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 April 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 February 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 January 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 January 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 June 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 June 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1114 May 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1215 March 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1316 January 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1316 March 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1316 May 2013(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1316 May 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1316 May 2024(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1417 April 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1417 January 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1417 March 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1417 May 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 1920 July 2012(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2326 November 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2326 October 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2326 October 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2427 October 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2427 October 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2528 November 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2528 October 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2528 September 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2529 September 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2629 November 2012(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2629 November 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2629 October 2020(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2629 September 2016(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2629 September 2022(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2730 November 2017(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2730 November 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2730 September 2021(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2831 August 2023(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2831 October 2019(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2931 October 2012(0)
- Pharmacovigilance Risk Assessment Committee PRAC 2931 October 2018(0)
- Pharmacovigilance Risk Assessment Committee PRAC elects chair and vicechair(0)
- Pharmacovigilance Risk Assessment Committee PRAC invites stakeholders feedback in review of Diane 35 and its generics(0)
- Pharmacovigilance system questions and answers(0)
- Pharmacovigilance system veterinary medicines(0)
- Pharmacovigilance training materials(0)
- Pharmacovigilance veterinary medicines(0)
- Pharmacovigilance Working Party(0)
- Pharmasin(0)
- Pharmion Ltd withdraws its marketing authorisation application forOrplatna satraplatin(0)
- Pharm Research Associates UK Ltd withdraws marketing authorisation application for Surfaxin(0)
- Phaseoli fructus sine semine(0)
- Phasing out of extraordinary COVID19 regulatory flexibilities(0)
- Pheburane(0)
- Phelinun(0)
- Phesgo(0)
- Philipp Berg(0)
- Philippe Berny(0)
- Philippe CHAUMETRIFFAUD(0)
- Philippe Delahaut(0)
- Philipp Janesch(0)
- Phosphates(0)
- PhotoBarr(0)
- Physical frailty instruments for baseline characterisation of older populations in clinical trials Scientific guideline(0)
- Pia Lahti(0)
- Pia Pihlavisto(0)
- Pia Rivetti di Val Cervo(0)
- Picrorhizae kurroae rhizoma et radix(0)
- Piera Polidori(0)
- Piero Luigi OLLIARO(0)
- Pierre Demolis(0)
- Pierre Duez(0)
- Pieter Colin(0)
- Pieter Glerum(0)
- Pieter Postema(0)
- Pieter Sonneveld(0)
- Pieter Van de Vijver(0)
- PietHein Overhaus(0)
- Pifeltro(0)
- Piia Salo(0)
- Piia Vuorela(0)
- Pilar Blanco Martinez(0)
- Pille Saalik(0)
- Pilosellae herba cum radice(0)
- Pilot Signal Management Expert Group(0)
- Pilots of multistakeholder consultations in earlystage drug development(0)
- Pina Guido(0)
- Pinar Kartal(0)
- Pioglitazone Accord(0)
- Pioglitazone Actavis(0)
- Pioglitazone Krka(0)
- Pioglitazone ratio(0)
- Pioglitazone ratiopharm(0)
- Pioglitazone ratiopharm GmbH(0)
- Pioglitazone Teva(0)
- Pioglitazone Teva Generics(0)
- Pioglitazone Teva Pharma(0)
- Piotr Falkowski(0)
- Piotr Juniewicz(0)
- Piotr Szymanski(0)
- Piperis methystici rhizoma(0)
- Piqray(0)
- Pirfenidone(0)
- Pirfenidone axunio previously Pirfenidone AET(0)
- Pirfenidone productspecific bioequivalence guidance(0)
- Pirfenidone Viatris(0)
- Pirjo Hanninen(0)
- Pirjo Inki(0)
- Pirjo Rosenberg(0)
- Pirkko Lepola(0)
- Pirsue(0)
- Pisana Maria Ferrari(0)
- Pixuvri(0)
- Piyush Jain(0)
- Plantaginis lanceolatae folium(0)
- Plantaginis ovatae semen(0)
- Plantaginis ovatae seminis tegumentum(0)
- Plant testing strategy for veterinary medicinal products(0)
- Plant testing strategy in the risk assessment for veterinary medicinal products Scientific guideline(0)
- Plasmaderived medicinal products ALT testing Scientific guideline(0)
- Plasmaderived medicinal products Scientific guideline(0)
- Plasma master file certificates(0)
- Plasma Master File dossier format and submission requirements(0)
- Plasma master file epidemiology(0)
- Plasma Master File PMF background documents(0)
- Plasma master file PMF certification(0)
- Plasma Master File PMF procedural guidelines(0)
- Plasma Master File PMF submissions(0)
- Plasma master files application form(0)
- Plasmid DNA vaccines for veterinary use Scientific guideline(0)
- Plastic primary packaging materials Scientific guideline(0)
- Platform for postauthorisation studies registered as EU trade mark(0)
- Platform trials Scientific guideline(0)
- Plavix(0)
- Plegridy(0)
- Plenadren(0)
- Plerixafor Accord(0)
- Plivensia(0)
- Pluvicto(0)
- Po Chi Lee(0)
- Points to consider for assessors New factor VIII and factor IX products potency determination for labelling and assays for testing postinfusion samples Scientific guideline(0)
- Poleta Luga(0)
- Policies and procedures(0)
- Policy on veterinary medicines for minor use minor species / limited market revised(0)
- Polivy(0)
- Polona Golmajer(0)
- Polona Pogacnik(0)
- Polycyclic Aromatic Hydrocarbons in herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Polygoni avicularis herba(0)
- Polypodii rhizoma(0)
- Polysorbate 80 Scientific guideline(0)
- Polysorbates(0)
- Pomalidomide Viatris(0)
- Pombiliti(0)
- Ponvory(0)
- Poorly extractable and/or non radiolabelled substances Scientific guideline(0)
- Porcilis ART DF(0)
- Porcilis ColiClos(0)
- Porcilis M Hyo(0)
- Porcilis PCV(0)
- Porcilis PCV ID(0)
- Porcilis PCV M Hyo(0)
- Porcilis Pesti(0)
- Porcilis Porcoli Diluvac Forte previously Porcilis Porcoli(0)
- Porcilis PRRS(0)
- Porcimectin Injection and its associated names(0)
- Portrazza(0)
- Portugal to also benefit from EUUS mutual recognition agreement for inspections(0)
- Posaconazole Accord(0)
- Posaconazole AHCL(0)
- Posaconazole productspecific bioequivalence guidance(0)
- Posaconazole SP(0)
- Posatex(0)
- Position paper on the risks associated with the use of herbal products containing aristolochia species(0)
- Possia(0)
- Postassessment guidance(0)
- Postauthorisation(0)
- Postauthorisation Background information(0)
- Postauthorisation efficacy studies questions and answers(0)
- Postauthorisation measures questions and answers(0)
- Postauthorisation measures recommendations conditions and specific obligations(0)
- Postauthorisation procedures(0)
- Postauthorisation safety studies PASS(0)
- Postauthorisation veterinary medicines(0)
- Posting of clinical trial summary results in European Clinical Trials Database EudraCT to become mandatory for sponsors as of 21 July 2014(0)
- Postmarketing surveillance studies for metered dose inhalers with new propellant Scientific guideline(0)
- Post opinion Regulatory and procedural guidance(0)
- Potactasol(0)
- Poteligeo(0)
- Potency declaration/labelling for biological medicinal products which contain modified proteins as active substance Scientific guideline(0)
- Potency labelling for insulin analogue containing products with particular reference to the use of "international units" or "units" Scientific guideline(0)
- Potency testing of cell based immunotherapy medicinal products for the treatment of cancer(0)
- Potency testing of cellbased immunotherapy medicinal products for the treatment of cancer Scientific guideline(0)
- Potential medication errors in the context of benefit risk balance and risk minimisation measures Scientific guideline(0)
- Potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines PRAC recommends precautionary measures(0)
- Poulvac Bursa Plus(0)
- Poulvac E coli(0)
- Poulvac Flufend H5N3 RG(0)
- Poulvac Procerta HVTIBD(0)
- Poul Vibholm Petersen(0)
- PRAC Committee agendas minutes and meeting highlights report archive 20122013(0)
- PRAC concludes assessment of gadolinium agents used in body scans and recommends regulatory actions including suspension for some marketing authorisations(0)
- PRAC concludes review of Zydelig and issues updated recommendations for use(0)
- PRAC concludes there is no evidence of a change in known risk of neutropenic enterocolitis with docetaxel(0)
- PRAC confirms fourweek limit for use of highstrength estradiol creams(0)
- PRAC confirms that benefits of all combined hormonal contraceptives CHCs continue to outweigh risks(0)
- PRAC confirms that hydroxyethylstarch solutions HES should no longer be used in patients with sepsis or burn injuries or in critically ill patients(0)
- PRAC considers benefits of Kogenate Bayer/Helixate NexGen outweigh risks in previously untreated patients(0)
- PRAC considers risk of severe allergic reactions with ambroxol and bromhexinecontaining medicines to be small(0)
- PRAC meeting archive 20122014(0)
- PRAC meeting archive 20152017(0)
- PRAC members(0)
- PRAC recommendations on safety signals(0)
- PRAC recommendations on safety signals monthly overviews Archive(0)
- PRAC recommends against combined use of medicines affecting the reninangiotensin RAS system(0)
- PRAC recommends further measures to minimise risk of blood vessel blockage with Iclusig(0)
- PRAC recommends further measures to minimise risk of osteonecrosis of the jaw with bisphosphonate medicine(0)
- PRAC recommends further restrictions for multiple sclerosis medicine Zinbryta due to risk of serious liver damage(0)
- PRAC recommends measures to reduce risk of heart problems with Corlentor/Procoralan ivabradine(0)
- PRAC recommends new measures to avoid dosing errors with methotrexate(0)
- PRAC recommends new measures to avoid topiramate exposure in pregnancy(0)
- PRAC recommends new measures to avoid valproate exposure in pregnancy(0)
- PRAC recommends new measures to minimise known heart risks of hydroxyzinecontaining medicines(0)
- PRAC recommends new measures to minimise risk of rare but serious liver injury with Esmya for fibroids(0)
- PRAC recommends product information of zolpidem be updated with new advice to minimise the risk of nextmorning impaired driving ability and mental alertness(0)
- PRAC recommends restricting the use of codeine when used for pain relief in children(0)
- PRAC recommends restricting the use of flupirtinecontaining medicines(0)
- PRAC recommends restricting use of domperidone(0)
- PRAC recommends restrictions on the use of codeine for cough and cold in children(0)
- PRAC recommends revoking marketing authorisation of ulipristal acetate for uterine fibroids(0)
- PRAC recommends strengthening the restrictions on the use of valproate in women and girls(0)
- PRAC recommends suspending hydroxyethylstarch solutions for infusion from the market(0)
- PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl starch(0)
- PRAC recommends suspending use of Protelos/Osseor(0)
- PRAC recommends suspension of diacereincontaining medicines(0)
- PRAC recommends that fusafungine nose and mouth sprays are no longer marketed(0)
- PRAC recommends the same cardiovascular precautions for diclofenac as for selective COX2 inhibitors(0)
- PRAC recommends updating advice on use of highdose ibuprofen(0)
- PRAC recommends using acipimox only as additional or alternative treatment to lower high triglyceride levels(0)
- PRAC reexamines diacerein and recommends that it remain available with restrictions(0)
- PRAC review does not confirm increase in heart problems with testosterone medicines(0)
- PRAC reviews known risk of pneumonia with inhaled corticosteroids for chronic obstructive pulmonary disease(0)
- PRAC starts review of topiramate use in pregnancy and women of childbearing potential(0)
- PRAC starts safety review of pseudoephedrinecontaining medicines(0)
- Practic(0)
- Practical guidance on implementation of pharmacovigilance legislation published(0)
- Practical guidelines relating to noneCTD electronic submissions Scientific guideline(0)
- PRAC updates on the risks of serious vascular occlusive events associated with cancer medicine Iclusig(0)
- PRAC warns of risk of hepatitis B reactivation with directacting antivirals for hepatitis C(0)
- Pradaxa(0)
- Praluent(0)
- Praluent recommended for approval to lower cholesterol(0)
- Pramipexole Accord(0)
- Pramipexole dihydrochloride monohydrate(0)
- Pramipexole Teva(0)
- Prandin(0)
- Prasugrel productspecific bioequivalence guidance(0)
- Prasugrel Viatris previously Prasugrel Mylan(0)
- Pravafenix(0)
- Pravastatin sodium / Fenofibrate(0)
- Praxbind(0)
- Preaccession linguistic check for Croatian underway(0)
- Preauthorisation guidance(0)
- Preauthorisation guidance under the Veterinary Medicinal Products Regulation Regulation EU 2019/6(0)
- Precautionary marketing suspension of thalassaemia medicine Zynteglo(0)
- Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines(0)
- Preclinical pharmacological and toxicological testing of vaccines Scientific guideline(0)
- Preclinical safety evaluation of biotechnologyderived pharmaceuticals ICH S6 R1(0)
- Predictive biomarkerbased assay development in the context of drug development and lifecycle(0)
- Pregabalin Accord(0)
- Pregabalin Mylan(0)
- Pregabalin Mylan Pharma(0)
- Pregabalin Pfizer(0)
- Pregabalin Sandoz(0)
- Pregabalin Sandoz GmbH(0)
- Pregabalin Zentiva(0)
- Pregabalin Zentiva ks(0)
- Pregsure BVD(0)
- PreHevbri(0)
- Preliminary data indicate COVID19 vaccines remain effective against severe disease and hospitalisation caused by the Omicron variant(0)
- Premixes for medicated feeding stuffs for veterinary use versus powders/granules for oral use or use in drinking water Scientific guideline(0)
- Preotact(0)
- Prepandemic Influenza Vaccine H5N1 Split Virion Inactivated Adjuvanted GlaxoSmithKline Biologicals(0)
- Prepandemic influenza vaccine H5N1 surface antigen inactivated adjuvanted Novartis Vaccines and Diagnostics(0)
- Prepandrix(0)
- Press and social media(0)
- Press briefing on EU recommendation for COVID19 Vaccine AstraZeneca(0)
- Press briefing on EU recommendation on first COVID19 vaccine(0)
- Press briefing on PRAC conclusions on signal of thromboembolic events with COVID19 Vaccine Janssen(0)
- Press briefing on the conclusion of the assessment of the Pharmacovigilance Risk Assessment Committee PRAC of Vaxzevria previously COVID19 Vaccine AstraZeneca and thromboembolic events(0)
- Press briefing on the conclusion of the investigation of COVID19 Vaccine AstraZeneca and thromboembolic events by the Pharmacovigilance Risk Assessment Committee PRAC(0)
- Press briefings and stakeholder meetings(0)
- Press Release on COMTESS/COMTAN Entacapone Update of Product Information(0)
- Press Release on the cardiovascular safety of nonselective NSAIDs(0)
- Presubmission request form(0)
- Prevenar(0)
- Prevenar 13(0)
- Prevenar 20 previously Apexxnar(0)
- Preventing medication errors in the European Union(0)
- Prevexxion RN(0)
- Prevexxion RN+HVT(0)
- Prevexxion RN+HVT+IBD(0)
- Previcox(0)
- Prevomax(0)
- Prevymis(0)
- Prezista(0)
- Prialt(0)
- Prilocaine Lidocaine(0)
- Primavax(0)
- PRIME enables earlier availability of lifechanging medicines(0)
- PRIME priority medicines(0)
- Primulae flos(0)
- Primulae radix(0)
- Priority access for children during Myozyme supply shortage(0)
- priscilla nibi(0)
- Priscilla Schoondermark(0)
- Pristiqs(0)
- Pritor(0)
- PritorPlus(0)
- Privigen(0)
- Proactive publication of clinicaltrial data discussing the way forward(0)
- Procaine benzylpenicillin(0)
- Procedural advice for vaccine platform technology master file vPTMF certification Procedural Guidance(0)
- Procedural advice for veterinary vaccine antigen master file VAMF certification Procedural Guidance(0)
- Procedural advice on the submission of variations for annual update of human influenza inactivated vaccines applications in the centralised procedure(0)
- Procedural announcements(0)
- Procedural guidance to help pharma companies prepare for Brexit(0)
- Procedural information EMA goes electronic for PDCO opinions and subsequent EMA decisions(0)
- Procedural timetables(0)
- Procedural update on submission of Type I variations to EMA in March April and May 2019(0)
- Procedure for the review and revision of European Union herbal monographs and European Union list entries(0)
- Procedure on management of proposals from interested parties for Community list entries or Community herbal monographs(0)
- Procedure on the publication of Committee on Herbal Medicinal Products public statements when European Union herbal monographs on herbal substances preparations and/or combinations thereof are not established(0)
- Procedures(0)
- Procedures for monograph and list entry establishment(0)
- Processing joint FDA and EMA voluntary genomic data submissions within the framework of the confidentiality arrangement Scientific guideline(0)
- Process validation for finished products information and data to be provided in regulatory submissions Scientific guideline(0)
- Process validation for the manufacture of biotechnologyderived active substances and data to be provided in the regulatory submission Scientific guideline(0)
- Procomvax(0)
- Procoralan(0)
- Procox(0)
- Procurement(0)
- Procurement activities 2016(0)
- Procurement activities 2017(0)
- Procurement activities 2018(0)
- Procurement activities 2019(0)
- Procurement activities 2020(0)
- Procurement activities 2021(0)
- Procurement activities 2022(0)
- Procurement archive(0)
- Procysbi(0)
- Product authorisation lifecycle procedures(0)
- Product defects and recalls(0)
- Product development procedures(0)
- Product information(0)
- Product information Reference documents and guidelines(0)
- Productinformation requirements(0)
- Productinformation requirements for veterinary medicines(0)
- Productinformation templates Human(0)
- Production and quality control of animal immunoglobins and immunosera for human use Scientific guideline(0)
- Production and quality control of medicinal products derived by recombinant DNA technology Scientific guideline(0)
- Production of tallow derivatives for use in pharmaceuticals Scientific guideline(0)
- Product Lifecycle Management PLM Portal Access Management Training Session(0)
- Product Lifecycle Management PLM Value Stream DeepDive Webinar(0)
- Product Management Service PMS InfoDay(0)
- Product Management Service PMS Product UI and API training access & navigation(0)
- Product Management Service PMS progress webinar(0)
- Product Management Service PMS Webinar on Data Migration(0)
- Product Management Services PMS deepdive webinar(0)
- Product Management Services PMS SubGroups SG Webinar(0)
- Productspecific bioequivalence guidance(0)
- Profender(0)
- Progress in science medicine and health(0)
- Progress in science medicines health(0)
- Progress in the area of antimicrobial resistance veterinary medicines(0)
- Progress made in the operation of EU pharmacovigilance legislation(0)
- Progress on science medicines and health(0)
- Progress update on pilot for academic and nonprofit developers of advanced therapy medicines(0)
- Progress with EUUS mutual recognition agreement for inspections for veterinary medicines(0)
- Prohippur(0)
- Prolevare(0)
- Prolia(0)
- Proline Scientific guideline(0)
- ProMeris(0)
- ProMeris Duo(0)
- Prometax(0)
- Promoting highquality clinical research in children through strengthened international collaboration(0)
- Promoting highquality clinical research to develop more and better medicines for children(0)
- Promoting high quality scientific research in paediatric medicines(0)
- Promoting the authorisation of alternatives to antimicrobial veterinary medicinal products in the EU Scientific guideline(0)
- Prontax 5 mg/ml pouron solution for cattle(0)
- Prontax 10 mg/ml solution for injection for cattle sheep and pigs(0)
- Proposals to revise guidance on firstinhuman clinical trials(0)
- Propylene glycol and esters(0)
- ProQuad(0)
- Prospective dialogue between developers and regulators makes for better evidence generation(0)
- Prostate cancer medicine Xofigo must not be used with Zytiga and prednisone/prednisolone(0)
- Protaphane(0)
- Protection of personal data and commercially confidential information CCI for documents uploaded and published in the Clinical Trials Information System CTIS Workshop on draft guidance(0)
- PROTECT symposium(0)
- Protelos(0)
- ProteqFlu(0)
- ProteqFluTe(0)
- Proteq West Nile(0)
- Protherics withdraws its marketing authorisation application for Voraxaze(0)
- Protopic(0)
- Protopy(0)
- Provenge(0)
- ProZinc(0)
- Pruban(0)
- Pruni africanae cortex(0)
- Prunus avium peduncle(0)
- Przemyslaw Salanski(0)
- pseudoephedrine(0)
- PSUR roadmap joint industry/assessor training(0)
- PSURs Regulatory and procedural guidance(0)
- PSUSA/00000007/201412(0)
- PSUSA/00000007/201712(0)
- PSUSA/00000007/202012(0)
- PSUSA/00000008/201505(0)
- PSUSA/00000008/201805(0)
- PSUSA/00000008/202105(0)
- PSUSA/00000016/202207(0)
- PSUSA/00000017/201503(0)
- PSUSA/00000018/201712(0)
- PSUSA/00000022/201703(0)
- PSUSA/00000022/202003(0)
- PSUSA/00000022/202303(0)
- PSUSA/00000026/201805(0)
- PSUSA/00000027/202107(0)
- PSUSA/000000330/202206(0)
- PSUSA/00000034/201509(0)
- PSUSA/00000034/201809(0)
- PSUSA/00000039/201602(0)
- PSUSA/00000039/201902(0)
- PSUSA/00000039/202202(0)
- PSUSA/00000048/201806(0)
- PSUSA/00000048/202306(0)
- PSUSA/00000050/201512(0)
- PSUSA/00000050/201805(0)
- PSUSA/00000050/202105(0)
- PSUSA/00000051/201510(0)
- PSUSA/00000051/201610(0)
- PSUSA/00000051/201710(0)
- PSUSA/00000051/201810(0)
- PSUSA/00000051/201910(0)
- PSUSA/00000051/202010(0)
- PSUSA/00000051/202110(0)
- PSUSA/00000051/202210(0)
- PSUSA/00000059/201409(0)
- PSUSA/00000059/201709(0)
- PSUSA/00000059/202009(0)
- PSUSA/00000062/201708(0)
- PSUSA/00000062/202208(0)
- PSUSA/00000072/201608(0)
- PSUSA/00000073/202007(0)
- PSUSA/00000076/201712(0)
- PSUSA/00000078/201601(0)
- PSUSA/00000078/202101(0)
- PSUSA/00000080/202006(0)
- PSUSA/00000082/201509(0)
- PSUSA/00000082/201809(0)
- PSUSA/00000082/202109(0)
- PSUSA/00000084/201711(0)
- PSUSA/00000084/202211(0)
- PSUSA/00000091/202101(0)
- PSUSA/00000095/201512(0)
- PSUSA/00000095/201612(0)
- PSUSA/00000095/201712(0)
- PSUSA/00000095/202012(0)
- PSUSA/00000097/201505(0)
- PSUSA/00000101/201706(0)
- PSUSA/00000101/202006(0)
- PSUSA/00000101/202306(0)
- PSUSA/00000108/201412(0)
- PSUSA/00000108/201912(0)
- PSUSA/00000109/201603(0)
- PSUSA/00000109/201903(0)
- PSUSA/00000109/202203(0)
- PSUSA/00000110/201601(0)
- PSUSA/00000110/202101(0)
- PSUSA/00000111/201707(0)
- PSUSA/00000111/202207(0)
- PSUSA/00000112/201705(0)
- PSUSA/00000112/202205(0)
- PSUSA/00000124/202202(0)
- PSUSA/00000125/202202(0)
- PSUSA/00000126/201801(0)
- PSUSA/00000130/201609(0)
- PSUSA/00000130/201909(0)
- PSUSA/00000130/202209(0)
- PSUSA/00000131/201609(0)
- PSUSA/00000131/201909(0)
- PSUSA/00000131/202209(0)
- PSUSA/00000138/202006(0)
- PSUSA/00000143/201706(0)
- PSUSA/00000143/202206(0)
- PSUSA/00000165/201610(0)
- PSUSA/00000165/201910(0)
- PSUSA/00000165/202210(0)
- PSUSA/00000166/201412(0)
- PSUSA/00000166/201712(0)
- PSUSA/00000166/202012(0)
- PSUSA/00000167/201501(0)
- PSUSA/00000167/201701(0)
- PSUSA/00000167/202001(0)
- PSUSA/00000167/202301(0)
- PSUSA/00000168/201501(0)
- PSUSA/0000017/201803(0)
- PSUSA/00000170/201501(0)
- PSUSA/00000170/201801(0)
- PSUSA/00000170/202101(0)
- PSUSA/00000171/201602(0)
- PSUSA/00000171/201702(0)
- PSUSA/00000171/201802(0)
- PSUSA/00000171/201902(0)
- PSUSA/00000171/202002(0)
- PSUSA/00000171/202102(0)
- PSUSA/00000174/201603(0)
- PSUSA/00000174/201703(0)
- PSUSA/00000174/202203(0)
- PSUSA/00000177/201601(0)
- PSUSA/00000177/202201(0)
- PSUSA/00000179/201610(0)
- PSUSA/00000179/202110(0)
- PSUSA/00000181/201503(0)
- PSUSA/00000181/201803(0)
- PSUSA/00000185/201706(0)
- PSUSA/00000185/202206(0)
- PSUSA/00000187/201703(0)
- PSUSA/00000187/202203(0)
- PSUSA/00000188/201703(0)
- PSUSA/00000188/202203(0)
- PSUSA/00000197/201502(0)
- PSUSA/00000197/201802(0)
- PSUSA/00000197/202102(0)
- PSUSA/00000199/201906(0)
- PSUSA/00000210/201708(0)
- PSUSA/00000210/202208(0)
- PSUSA/00000210/202308(0)
- PSUSA/00000212/201412(0)
- PSUSA/00000227/201505(0)
- PSUSA/00000227/201511(0)
- PSUSA/00000227/201611(0)
- PSUSA/00000227/201911(0)
- PSUSA/00000227/202211(0)
- PSUSA/00000230/201602(0)
- PSUSA/00000230/202202(0)
- PSUSA/00000236/201610(0)
- PSUSA/00000236/201910(0)
- PSUSA/00000236/202210(0)
- PSUSA/00000255/202006(0)
- PSUSA/00000260/201409(0)
- PSUSA/00000260/201909(0)
- PSUSA/00000262/201411(0)
- PSUSA/00000262/201511(0)
- PSUSA/00000265/201411(0)
- PSUSA/00000266/201710(0)
- PSUSA/00000266/202210(0)
- PSUSA/00000267/202212(0)
- PSUSA/00000275/201812(0)
- PSUSA/00000277/201412(0)
- PSUSA/00000277/201712(0)
- PSUSA/00000277/202012(0)
- PSUSA/00000284/201611(0)
- PSUSA/00000284/201911(0)
- PSUSA/00000284/202211(0)
- PSUSA/00000293/201601(0)
- PSUSA/00000293/202101(0)
- PSUSA/00000294/201609(0)
- PSUSA/00000294/201809(0)
- PSUSA/00000294/202009(0)
- PSUSA/00000295/201712(0)
- PSUSA/00000295/202212(0)
- PSUSA/00000303/201803(0)
- PSUSA/00000303/202303(0)
- PSUSA/00000304/201803(0)
- PSUSA/00000306/201612(0)
- PSUSA/00000306/202112(0)
- PSUSA/00000309/201701(0)
- PSUSA/00000312/201604(0)
- PSUSA/00000312/201904(0)
- PSUSA/00000312/202204(0)
- PSUSA/00000313/201511(0)
- PSUSA/00000313/202011(0)
- PSUSA/00000314/201605(0)
- PSUSA/00000314/202105(0)
- PSUSA/00000330/201706(0)
- PSUSA/00000375/201510(0)
- PSUSA/00000375/201810(0)
- PSUSA/00000375/202110(0)
- PSUSA/00000378/201901(0)
- PSUSA/00000383/202006(0)
- PSUSA/00000384/201510(0)
- PSUSA/00000384/202010(0)
- PSUSA/00000389/201712(0)
- PSUSA/00000389/202012(0)
- PSUSA/00000391/202101(0)
- PSUSA/00000394/202101(0)
- PSUSA/00000398/202101(0)
- PSUSA/00000399/202101(0)
- PSUSA/00000401/201705(0)
- PSUSA/00000401/202205(0)
- PSUSA/00000402/202006(0)
- PSUSA/00000405/201901(0)
- PSUSA/00000407/201702(0)
- PSUSA/00000407/202302(0)
- PSUSA/00000414/201901(0)
- PSUSA/00000415/201608(0)
- PSUSA/00000415/201908(0)
- PSUSA/00000415/202208(0)
- PSUSA/00000419/201509(0)
- PSUSA/00000419/202009(0)
- PSUSA/00000420/201511(0)
- PSUSA/00000420/201811(0)
- PSUSA/00000420/202111(0)
- PSUSA/00000421/202009(0)
- PSUSA/00000422/202203(0)
- PSUSA/00000426/201812(0)
- PSUSA/00000426/202112(0)
- PSUSA/00000427/201512(0)
- PSUSA/00000427/201812(0)
- PSUSA/00000427/202112(0)
- PSUSA/00000430/201609(0)
- PSUSA/00000430/202109(0)
- PSUSA/00000431/201609(0)
- PSUSA/00000431/202109(0)
- PSUSA/00000434/201907(0)
- PSUSA/00000435/201708(0)
- PSUSA/00000435/202008(0)
- PSUSA/00000435/202308(0)
- PSUSA/00000437/201609(0)
- PSUSA/00000437/202209(0)
- PSUSA/00000438/201510(0)
- PSUSA/00000438/201810(0)
- PSUSA/00000439/201711(0)
- PSUSA/00000439/202211(0)
- PSUSA/00000444/201612(0)
- PSUSA/00000444/201912(0)
- PSUSA/00000444/202212(0)
- PSUSA/00000449/201604(0)
- PSUSA/00000449/202104(0)
- PSUSA/00000450/201608(0)
- PSUSA/00000459/201707(0)
- PSUSA/00000461/201512(0)
- PSUSA/00000461/201812(0)
- PSUSA/00000461/202112(0)
- PSUSA/00000462/201608(0)
- PSUSA/00000462/202108(0)
- PSUSA/00000463/201704(0)
- PSUSA/00000471/201602(0)
- PSUSA/00000471/202102(0)
- PSUSA/00000477/201503(0)
- PSUSA/00000477/201803(0)
- PSUSA/00000477/201903(0)
- PSUSA/00000477/202203(0)
- PSUSA/00000482/201707(0)
- PSUSA/00000485/201511(0)
- PSUSA/00000485/201811(0)
- PSUSA/00000485/202111(0)
- PSUSA/00000485/202211(0)
- PSUSA/00000491/202106(0)
- PSUSA/00000491/202206(0)
- PSUSA/00000494/201506(0)
- PSUSA/00000494/201806(0)
- PSUSA/00000494/202106(0)
- PSUSA/00000495/201501(0)
- PSUSA/00000495/201801(0)
- PSUSA/00000495/202101(0)
- PSUSA/00000527/201704(0)
- PSUSA/00000527/202204(0)
- PSUSA/00000535/201504(0)
- PSUSA/00000535/202004(0)
- PSUSA/00000536/201604(0)
- PSUSA/00000536/202104(0)
- PSUSA/00000539/202012(0)
- PSUSA/00000546/201706(0)
- PSUSA/00000546/202206(0)
- PSUSA/00000548/201610(0)
- PSUSA/00000548/201910(0)
- PSUSA/00000548/202210(0)
- PSUSA/00000557/201701(0)
- PSUSA/00000557/202201(0)
- PSUSA/00000559/201601(0)
- PSUSA/00000559/201901(0)
- PSUSA/00000559/202201(0)
- PSUSA/00000560/201601(0)
- PSUSA/00000560/202101(0)
- PSUSA/00000574/201903(0)
- PSUSA/00000575/201704(0)
- PSUSA/00000575/202204(0)
- PSUSA/00000582/201908(0)
- PSUSA/00000584/201707(0)
- PSUSA/00000584/202207(0)
- PSUSA/00000589/201611(0)
- PSUSA/00000589/202111(0)
- PSUSA/00000593/201506(0)
- PSUSA/00000593/201806(0)
- PSUSA/00000593/202106(0)
- PSUSA/00000595/201703(0)
- PSUSA/00000597/201601(0)
- PSUSA/00000597/202101(0)
- PSUSA/00000598/201601(0)
- PSUSA/00000598/202101(0)
- PSUSA/00000599/201512(0)
- PSUSA/00000599/201812(0)
- PSUSA/00000605/201712(0)
- PSUSA/00000605/202212(0)
- PSUSA/00000608/201510(0)
- PSUSA/00000608/201810(0)
- PSUSA/00000611/201707(0)
- PSUSA/00000613/201505(0)
- PSUSA/00000613/201805(0)
- PSUSA/00000613/202305(0)
- PSUSA/00000615/201704(0)
- PSUSA/00000615/202204(0)
- PSUSA/00000616/201412(0)
- PSUSA/00000616/201712(0)
- PSUSA/00000616/202012(0)
- PSUSA/00000617/202001(0)
- PSUSA/00000625/202204(0)
- PSUSA/00000628/201711(0)
- PSUSA/00000628/202211(0)
- PSUSA/00000629/201608(0)
- PSUSA/00000629/202108(0)
- PSUSA/00000677/201611(0)
- PSUSA/00000679/201611(0)
- PSUSA/00000685/201508(0)
- PSUSA/00000685/202104(0)
- PSUSA/00000715/201705(0)
- PSUSA/00000715/202005(0)
- PSUSA/00000715/202305(0)
- PSUSA/00000717/201803(0)
- PSUSA/00000742/201508(0)
- PSUSA/00000742/201808(0)
- PSUSA/00000742/202108(0)
- PSUSA/00000745/201512(0)
- PSUSA/00000745/201812(0)
- PSUSA/00000745/202112(0)
- PSUSA/00000748/201706(0)
- PSUSA/00000748/202206(0)
- PSUSA/00000749/201502(0)
- PSUSA/00000749/201802(0)
- PSUSA/00000749/202102(0)
- PSUSA/00000755/201801(0)
- PSUSA/00000769/201912(0)
- PSUSA/00000771/201612(0)
- PSUSA/00000771/202112(0)
- PSUSA/00000774/201411(0)
- PSUSA/00000774/201711(0)
- PSUSA/00000774/202011(0)
- PSUSA/00000775/201801(0)
- PSUSA/00000775/202304(0)
- PSUSA/00000776/201801(0)
- PSUSA/00000777/201507(0)
- PSUSA/00000777/202007(0)
- PSUSA/00000778/201712(0)
- PSUSA/00000779/201612(0)
- PSUSA/00000779/202112(0)
- PSUSA/00000788/201704(0)
- PSUSA/00000788/202004(0)
- PSUSA/00000788/202304(0)
- PSUSA/00000789/201906(0)
- PSUSA/00000794/201809(0)
- PSUSA/00000794/201909(0)
- PSUSA/00000794/202209(0)
- PSUSA/00000795/201510(0)
- PSUSA/00000795/201810(0)
- PSUSA/00000795/202110(0)
- PSUSA/00000798/202002(0)
- PSUSA/00000799/201502(0)
- PSUSA/00000799/202002(0)
- PSUSA/00000804/201702(0)
- PSUSA/00000812/201506(0)
- PSUSA/00000812/202006(0)
- PSUSA/00000827/201505(0)
- PSUSA/00000827/202005(0)
- PSUSA/00000858/201807(0)
- PSUSA/00000858/202307(0)
- PSUSA/00000876/201410(0)
- PSUSA/00000876/201910(0)
- PSUSA/00000883/201702(0)
- PSUSA/00000883/202202(0)
- PSUSA/00000902/201412(0)
- PSUSA/00000902/201712(0)
- PSUSA/00000902/202012(0)
- PSUSA/00000905/202307(0)
- PSUSA/00000906/201705(0)
- PSUSA/00000906/202005(0)
- PSUSA/00000906/202305(0)
- PSUSA/00000911/202103(0)
- PSUSA/00000911/202303(0)
- PSUSA/00000914/201601(0)
- PSUSA/00000914/202101(0)
- PSUSA/00000919/201802(0)
- PSUSA/00000919/202302(0)
- PSUSA/00000922/201508(0)
- PSUSA/00000922/202008(0)
- PSUSA/00000923/201812(0)
- PSUSA/00000928/201412(0)
- PSUSA/00000928/201712(0)
- PSUSA/00000928/202012(0)
- PSUSA/00000936/201506(0)
- PSUSA/00000936/202106(0)
- PSUSA/00000946/201501(0)
- PSUSA/00000958/201709(0)
- PSUSA/00000958/202009(0)
- PSUSA/00000964/201412(0)
- PSUSA/00000964/201712(0)
- PSUSA/00000964/202012(0)
- PSUSA/00000966/201607(0)
- PSUSA/00000966/202107(0)
- PSUSA/00000967/201509(0)
- PSUSA/00000967/202009(0)
- PSUSA/00000973/201601(0)
- PSUSA/00000973/202101(0)
- PSUSA/00000979/202103(0)
- PSUSA/00000986/201709(0)
- PSUSA/00000986/201809(0)
- PSUSA/00000986/201909(0)
- PSUSA/00000986/202009(0)
- PSUSA/00000986/202109(0)
- PSUSA/00000986/202209(0)
- PSUSA/00000986/202309(0)
- PSUSA/00000989/201506(0)
- PSUSA/00000989/201806(0)
- PSUSA/00000989/202106(0)
- PSUSA/00000996/201708(0)
- PSUSA/00000996/202008(0)
- PSUSA/00000997/201510(0)
- PSUSA/00000997/202110(0)
- PSUSA/00001009/201511(0)
- PSUSA/00001009/201811(0)
- PSUSA/00001009/202111(0)
- PSUSA/00001026/201612(0)
- PSUSA/00001026/201712(0)
- PSUSA/00001026/202012(0)
- PSUSA/000010290/201507(0)
- PSUSA/000010330/202301(0)
- PSUSA/00001040/201707(0)
- PSUSA/00001040/202207(0)
- PSUSA/00001040/202307(0)
- PSUSA/00001041/202001(0)
- PSUSA/00001048/201509(0)
- PSUSA/00001048/201809(0)
- PSUSA/00001048/202109(0)
- PSUSA/00001054/201510(0)
- PSUSA/00001054/201810(0)
- PSUSA/00001057/201803(0)
- PSUSA/00001057/202303(0)
- PSUSA/00001071/201504(0)
- PSUSA/00001074/201507(0)
- PSUSA/00001075/201504(0)
- PSUSA/00001075/201804(0)
- PSUSA/00001075/202104(0)
- PSUSA/00001079/201504(0)
- PSUSA/00001084/201705(0)
- PSUSA/00001084/202205(0)
- PSUSA/00001104/201609(0)
- PSUSA/00001104/201909(0)
- PSUSA/00001104/202209(0)
- PSUSA/00001121/201710(0)
- PSUSA/00001124/201411(0)
- PSUSA/00001124/201711(0)
- PSUSA/00001124/202011(0)
- PSUSA/00001125/201703(0)
- PSUSA/00001125/202203(0)
- PSUSA/00001126/201507(0)
- PSUSA/00001126/202007(0)
- PSUSA/00001127/201708(0)
- PSUSA/00001127/202208(0)
- PSUSA/00001128/201505(0)
- PSUSA/00001128/202005(0)
- PSUSA/00001151/201503(0)
- PSUSA/00001151/201803(0)
- PSUSA/00001151/202103(0)
- PSUSA/00001158/201501(0)
- PSUSA/00001158/201611(0)
- PSUSA/00001158/201911(0)
- PSUSA/00001160/201611(0)
- PSUSA/00001160/202111(0)
- PSUSA/00001164/201709(0)
- PSUSA/00001164/202209(0)
- PSUSA/00001166/201602(0)
- PSUSA/00001166/201902(0)
- PSUSA/00001169/201512(0)
- PSUSA/00001169/202012(0)
- PSUSA/00001174/201704(0)
- PSUSA/00001174/202304(0)
- PSUSA/00001184/201412(0)
- PSUSA/00001184/201912(0)
- PSUSA/00001191/201805(0)
- PSUSA/00001191/202305(0)
- PSUSA/00001195/201711(0)
- PSUSA/00001195/202211(0)
- PSUSA/00001204/201602(0)
- PSUSA/00001204/202102(0)
- PSUSA/00001211/201803(0)
- PSUSA/00001211/202303(0)
- PSUSA/00001212/201707(0)
- PSUSA/00001213/201501(0)
- PSUSA/00001213/201801(0)
- PSUSA/00001213/202301(0)
- PSUSA/00001231/201710(0)
- PSUSA/00001231/202210(0)
- PSUSA/00001232/202007(0)
- PSUSA/00001233/202009(0)
- PSUSA/00001234/201706(0)
- PSUSA/00001234/202006(0)
- PSUSA/00001234/202306(0)
- PSUSA/00001236/201703(0)
- PSUSA/00001236/202203(0)
- PSUSA/00001242/201703(0)
- PSUSA/00001242/202203(0)
- PSUSA/00001243/201704(0)
- PSUSA/00001243/202204(0)
- PSUSA/00001244/201704(0)
- PSUSA/00001244/202204(0)
- PSUSA/00001248/201602(0)
- PSUSA/00001257/201903(0)
- PSUSA/00001259/201610(0)
- PSUSA/00001259/202110(0)
- PSUSA/00001263/201507(0)
- PSUSA/00001263/202007(0)
- PSUSA/00001265/201612(0)
- PSUSA/00001266/201608(0)
- PSUSA/00001266/202108(0)
- PSUSA/00001270/201704(0)
- PSUSA/00001270/202204(0)
- PSUSA/00001275/201703(0)
- PSUSA/00001278/201703(0)
- PSUSA/00001278/202203(0)
- PSUSA/00001307/202007(0)
- PSUSA/00001308/201603(0)
- PSUSA/00001308/202103(0)
- PSUSA/00001309/201604(0)
- PSUSA/00001309/201904(0)
- PSUSA/00001309/202204(0)
- PSUSA/00001312/201708(0)
- PSUSA/00001313/201610(0)
- PSUSA/00001313/202110(0)
- PSUSA/00001316/202003(0)
- PSUSA/00001316/202303(0)
- PSUSA/00001320/201709(0)
- PSUSA/00001320/202209(0)
- PSUSA/00001321/201410(0)
- PSUSA/00001321/201710(0)
- PSUSA/00001321/202010(0)
- PSUSA/00001330/201709(0)
- PSUSA/00001330/202209(0)
- PSUSA/00001331/201509(0)
- PSUSA/00001331/201809(0)
- PSUSA/00001331/202109(0)
- PSUSA/00001333/201602(0)
- PSUSA/00001333/201708(0)
- PSUSA/00001333/202302(0)
- PSUSA/00001334/201703(0)
- PSUSA/00001334/202203(0)
- PSUSA/00001344/201601(0)
- PSUSA/00001345/201512(0)
- PSUSA/00001346/201710(0)
- PSUSA/00001346/202210(0)
- PSUSA/00001347/201903(0)
- PSUSA/00001348/201605(0)
- PSUSA/00001349/201712(0)
- PSUSA/00001349/202012(0)
- PSUSA/00001350/201709(0)
- PSUSA/00001350/202209(0)
- PSUSA/00001351/201409(0)
- PSUSA/00001351/201709(0)
- PSUSA/00001356/201712(0)
- PSUSA/00001356/202212(0)
- PSUSA/00001357/201712(0)
- PSUSA/00001358/201803(0)
- PSUSA/00001362/201707(0)
- PSUSA/00001362/202007(0)
- PSUSA/00001362/202307(0)
- PSUSA/00001366/201709(0)
- PSUSA/00001366/202209(0)
- PSUSA/00001367/201802(0)
- PSUSA/00001367/202302(0)
- PSUSA/00001368/201704(0)
- PSUSA/00001368/201804(0)
- PSUSA/00001370/201504(0)
- PSUSA/00001370/201804(0)
- PSUSA/00001370/202104(0)
- PSUSA/00001370/202204(0)
- PSUSA/00001370/202304(0)
- PSUSA/00001382/202306(0)
- PSUSA/00001388/201703(0)
- PSUSA/00001388/202203(0)
- PSUSA/00001392/201508(0)
- PSUSA/00001392/201608(0)
- PSUSA/00001392/201708(0)
- PSUSA/00001392/201808(0)
- PSUSA/00001392/201908(0)
- PSUSA/00001392/202108(0)
- PSUSA/00001392/202308(0)
- PSUSA/00001396/201706(0)
- PSUSA/00001396/202206(0)
- PSUSA/00001400/201702(0)
- PSUSA/00001402/202003(0)
- PSUSA/00001404/201703(0)
- PSUSA/00001404/202003(0)
- PSUSA/00001404/202303(0)
- PSUSA/00001406/201708(0)
- PSUSA/00001406/202208(0)
- PSUSA/00001413/201512(0)
- PSUSA/00001413/202112(0)
- PSUSA/00001416/201505(0)
- PSUSA/00001416/201805(0)
- PSUSA/00001416/202105(0)
- PSUSA/00001418/201601(0)
- PSUSA/00001418/201901(0)
- PSUSA/00001418/202201(0)
- PSUSA/00001437/201410(0)
- PSUSA/00001437/201411(0)
- PSUSA/00001437/201711(0)
- PSUSA/00001442/201709(0)
- PSUSA/00001442/202209(0)
- PSUSA/00001450/201611(0)
- PSUSA/00001450/201911(0)
- PSUSA/00001450/202211(0)
- PSUSA/00001453/201810(0)
- PSUSA/00001454/201702(0)
- PSUSA/00001454/202202(0)
- PSUSA/00001455/201410(0)
- PSUSA/00001455/201910(0)
- PSUSA/00001457/202208(0)
- PSUSA/00001458/201707(0)
- PSUSA/00001458/202207(0)
- PSUSA/00001459/201706(0)
- PSUSA/00001469/201705(0)
- PSUSA/00001469/202005(0)
- PSUSA/00001472/201803(0)
- PSUSA/00001474/201507(0)
- PSUSA/00001475/201507(0)
- PSUSA/00001476/202008(0)
- PSUSA/00001484/201703(0)
- PSUSA/00001484/202203(0)
- PSUSA/00001491/201501(0)
- PSUSA/00001491/201801(0)
- PSUSA/00001491/202301(0)
- PSUSA/00001493/201512(0)
- PSUSA/00001493/201612(0)
- PSUSA/00001493/202303(0)
- PSUSA/00001499/201602(0)
- PSUSA/00001499/201902(0)
- PSUSA/00001499/202202(0)
- PSUSA/00001500/201504(0)
- PSUSA/00001500/202004(0)
- PSUSA/00001500/202108(0)
- PSUSA/00001500/202304(0)
- PSUSA/00001502/201504(0)
- PSUSA/00001502/202108(0)
- PSUSA/00001502/202304(0)
- PSUSA/00001503/201504(0)
- PSUSA/00001503/202004(0)
- PSUSA/00001504/201504(0)
- PSUSA/00001504/202004(0)
- PSUSA/00001504/202108(0)
- PSUSA/00001504/202304(0)
- PSUSA/00001505/202004(0)
- PSUSA/00001506/201504(0)
- PSUSA/00001506/202004(0)
- PSUSA/00001506/202108(0)
- PSUSA/00001506/202304(0)
- PSUSA/00001507/201504(0)
- PSUSA/00001507/202004(0)
- PSUSA/00001507/202108(0)
- PSUSA/00001507/202304(0)
- PSUSA/00001509/201504(0)
- PSUSA/00001509/202004(0)
- PSUSA/00001509/202108(0)
- PSUSA/00001509/202304(0)
- PSUSA/00001512/201603(0)
- PSUSA/00001512/202003(0)
- PSUSA/00001516/201606(0)
- PSUSA/00001516/201906(0)
- PSUSA/00001516/202206(0)
- PSUSA/00001519/201801(0)
- PSUSA/00001519/202301(0)
- PSUSA/00001529/201411(0)
- PSUSA/00001529/201711(0)
- PSUSA/00001529/202011(0)
- PSUSA/00001532/201602(0)
- PSUSA/00001532/202102(0)
- PSUSA/00001534/201706(0)
- PSUSA/00001534/202206(0)
- PSUSA/00001535/201901(0)
- PSUSA/00001535/202201(0)
- PSUSA/00001539/201703(0)
- PSUSA/00001539/202203(0)
- PSUSA/00001552/202007(0)
- PSUSA/00001556/201509(0)
- PSUSA/00001557/201509(0)
- PSUSA/00001562/201605(0)
- PSUSA/00001562/202105(0)
- PSUSA/00001568/201602(0)
- PSUSA/00001568/202102(0)
- PSUSA/00001582/201712(0)
- PSUSA/00001583/201702(0)
- PSUSA/00001583/202002(0)
- PSUSA/00001583/202302(0)
- PSUSA/00001584/201702(0)
- PSUSA/00001584/202002(0)
- PSUSA/00001584/202302(0)
- PSUSA/00001586/201705(0)
- PSUSA/00001594/201706(0)
- PSUSA/00001594/202006(0)
- PSUSA/00001594/202306(0)
- PSUSA/00001596/201901(0)
- PSUSA/00001606/201409(0)
- PSUSA/00001614/201503(0)
- PSUSA/00001614/202103(0)
- PSUSA/00001617/201907(0)
- PSUSA/00001617/202207(0)
- PSUSA/00001619/201610(0)
- PSUSA/00001619/202210(0)
- PSUSA/00001620/201411(0)
- PSUSA/00001620/201911(0)
- PSUSA/00001621/201510(0)
- PSUSA/00001621/201810(0)
- PSUSA/00001622/202206(0)
- PSUSA/00001624/201506(0)
- PSUSA/00001629/201605(0)
- PSUSA/00001629/201705(0)
- PSUSA/00001629/201805(0)
- PSUSA/00001629/201905(0)
- PSUSA/00001629/202005(0)
- PSUSA/00001629/202105(0)
- PSUSA/00001635/201702(0)
- PSUSA/00001635/202302(0)
- PSUSA/00001638/201604(0)
- PSUSA/00001638/202104(0)
- PSUSA/00001639/201704(0)
- PSUSA/00001639/202204(0)
- PSUSA/00001642/201409(0)
- PSUSA/00001642/201709(0)
- PSUSA/00001642/202009(0)
- PSUSA/00001654/201602(0)
- PSUSA/00001655/201802(0)
- PSUSA/00001660/201501(0)
- PSUSA/00001660/201801(0)
- PSUSA/00001662/201501(0)
- PSUSA/00001662/201801(0)
- PSUSA/00001662/202101(0)
- PSUSA/00001686/201511(0)
- PSUSA/00001686/201811(0)
- PSUSA/00001686/202111(0)
- PSUSA/00001688/201703(0)
- PSUSA/00001693/202104(0)
- PSUSA/00001694/201501(0)
- PSUSA/00001694/201703(0)
- PSUSA/00001694/201803(0)
- PSUSA/00001694/201903(0)
- PSUSA/00001694/202003(0)
- PSUSA/00001694/202203(0)
- PSUSA/00001694/202303(0)
- PSUSA/00001696/201411(0)
- PSUSA/00001696/201605(0)
- PSUSA/00001696/201711(0)
- PSUSA/00001696/202011(0)
- PSUSA/00001701/201801(0)
- PSUSA/00001701/202301(0)
- PSUSA/00001708/202007(0)
- PSUSA/00001711/201507(0)
- PSUSA/00001711/201607(0)
- PSUSA/00001711/201707(0)
- PSUSA/00001711/201807(0)
- PSUSA/00001711/201907(0)
- PSUSA/00001711/202007(0)
- PSUSA/00001711/202107(0)
- PSUSA/00001711/202207(0)
- PSUSA/00001711/202307(0)
- PSUSA/00001713/201712(0)
- PSUSA/00001713/202212(0)
- PSUSA/00001720/201611(0)
- PSUSA/00001720/202211(0)
- PSUSA/00001721/201409(0)
- PSUSA/00001721/201709(0)
- PSUSA/00001721/202009(0)
- PSUSA/00001723/202007(0)
- PSUSA/00001728/202007(0)
- PSUSA/00001731/201511(0)
- PSUSA/00001731/202011(0)
- PSUSA/00001734/202107(0)
- PSUSA/00001736/201705(0)
- PSUSA/00001738/202007(0)
- PSUSA/00001738/202307(0)
- PSUSA/00001740/201809(0)
- PSUSA/00001744/201504(0)
- PSUSA/00001744/201508(0)
- PSUSA/00001744/201603(0)
- PSUSA/00001744/201703(0)
- PSUSA/00001744/201903(0)
- PSUSA/00001744/202003(0)
- PSUSA/00001744/202103(0)
- PSUSA/00001744/202203(0)
- PSUSA/00001744/202303(0)
- PSUSA/00001746/201504(0)
- PSUSA/00001746/201508(0)
- PSUSA/00001756/201410(0)
- PSUSA/00001760/201601(0)
- PSUSA/00001760/201901(0)
- PSUSA/00001764/201505(0)
- PSUSA/00001764/202105(0)
- PSUSA/00001766/202004(0)
- PSUSA/00001768/202006(0)
- PSUSA/00001769/202004(0)
- PSUSA/00001771/201912(0)
- PSUSA/00001773/202006(0)
- PSUSA/00001777/201802(0)
- PSUSA/00001780/201701(0)
- PSUSA/00001780/202301(0)
- PSUSA/00001781/202001(0)
- PSUSA/00001781/202301(0)
- PSUSA/00001783/201705(0)
- PSUSA/00001783/202005(0)
- PSUSA/00001783/202305(0)
- PSUSA/00001786/201610(0)
- PSUSA/00001786/201910(0)
- PSUSA/00001786/202211(0)
- PSUSA/00001789/201411(0)
- PSUSA/00001789/201911(0)
- PSUSA/00001792/201605(0)
- PSUSA/00001792/201905(0)
- PSUSA/00001795/201505(0)
- PSUSA/00001796/201508(0)
- PSUSA/00001798/201703(0)
- PSUSA/00001798/202203(0)
- PSUSA/00001804/201512(0)
- PSUSA/00001804/201812(0)
- PSUSA/00001804/202112(0)
- PSUSA/00001807/202005(0)
- PSUSA/00001809/201707(0)
- PSUSA/00001809/202201(0)
- PSUSA/00001810/201707(0)
- PSUSA/00001810/202207(0)
- PSUSA/00001811/201707(0)
- PSUSA/00001812/201706(0)
- PSUSA/00001812/202206(0)
- PSUSA/00001813/201410(0)
- PSUSA/00001813/201710(0)
- PSUSA/00001813/202010(0)
- PSUSA/00001814/202002(0)
- PSUSA/00001815/201610(0)
- PSUSA/00001815/202110(0)
- PSUSA/00001819/201509(0)
- PSUSA/00001819/202009(0)
- PSUSA/00001821/201605(0)
- PSUSA/00001821/202105(0)
- PSUSA/00001825/201711(0)
- PSUSA/00001825/202211(0)
- PSUSA/00001826/201705(0)
- PSUSA/00001826/202005(0)
- PSUSA/00001826/202105(0)
- PSUSA/00001826/202205(0)
- PSUSA/00001826/202305(0)
- PSUSA/00001827/201612(0)
- PSUSA/00001827/202112(0)
- PSUSA/00001832/201604(0)
- PSUSA/00001832/202104(0)
- PSUSA/00001833/201706(0)
- PSUSA/00001833/202206(0)
- PSUSA/00001834/201504(0)
- PSUSA/00001834/201510(0)
- PSUSA/00001834/201604(0)
- PSUSA/00001834/201610(0)
- PSUSA/00001834/201704(0)
- PSUSA/00001834/201710(0)
- PSUSA/00001834/201804(0)
- PSUSA/00001834/202304(0)
- PSUSA/00001839/201610(0)
- PSUSA/00001839/201910(0)
- PSUSA/00001839/202210(0)
- PSUSA/00001841/201908(0)
- PSUSA/00001842/201510(0)
- PSUSA/00001842/201610(0)
- PSUSA/00001842/201810(0)
- PSUSA/00001842/202110(0)
- PSUSA/00001844/201707(0)
- PSUSA/00001848/201712(0)
- PSUSA/00001848/202212(0)
- PSUSA/00001849/201711(0)
- PSUSA/00001849/202211(0)
- PSUSA/00001850/201707(0)
- PSUSA/00001850/202307(0)
- PSUSA/00001854/201510(0)
- PSUSA/00001854/201810(0)
- PSUSA/00001855/201905(0)
- PSUSA/00001855/202205(0)
- PSUSA/00001856/201412(0)
- PSUSA/00001856/201712(0)
- PSUSA/00001856/201905(0)
- PSUSA/00001858/201609(0)
- PSUSA/00001858/201909(0)
- PSUSA/00001860/201601(0)
- PSUSA/00001860/201901(0)
- PSUSA/00001860/202201(0)
- PSUSA/00001861/202009(0)
- PSUSA/00001867/201703(0)
- PSUSA/00001867/202203(0)
- PSUSA/00001868/202006(0)
- PSUSA/00001869/202006(0)
- PSUSA/00001879/202008(0)
- PSUSA/00001888/201704(0)
- PSUSA/00001888/202204(0)
- PSUSA/00001894/201509(0)
- PSUSA/00001896/201411(0)
- PSUSA/00001902/201801(0)
- PSUSA/00001902/202301(0)
- PSUSA/00001903/201605(0)
- PSUSA/00001907/201702(0)
- PSUSA/00001907/202202(0)
- PSUSA/00001908/201702(0)
- PSUSA/00001908/202202(0)
- PSUSA/00001909/201601(0)
- PSUSA/00001909/201801(0)
- PSUSA/00001909/202001(0)
- PSUSA/00001909/202201(0)
- PSUSA/00001910/201412(0)
- PSUSA/00001910/201712(0)
- PSUSA/00001910/202012(0)
- PSUSA/00001912/201709(0)
- PSUSA/00001921/201709(0)
- PSUSA/00001921/202209(0)
- PSUSA/00001924/201605(0)
- PSUSA/00001924/201905(0)
- PSUSA/00001924/202205(0)
- PSUSA/00001926/201610(0)
- PSUSA/00001926/202110(0)
- PSUSA/00001932/201506(0)
- PSUSA/00001932/201806(0)
- PSUSA/00001938/201905(0)
- PSUSA/00001955/201702(0)
- PSUSA/00001955/202002(0)
- PSUSA/00001955/202302(0)
- PSUSA/00001970/201602(0)
- PSUSA/00001971/201510(0)
- PSUSA/00001971/201810(0)
- PSUSA/00001971/202110(0)
- PSUSA/00001979/201803(0)
- PSUSA/00001979/202303(0)
- PSUSA/00001986/202001(0)
- PSUSA/00001989/201508(0)
- PSUSA/00001989/201808(0)
- PSUSA/00001990/201502(0)
- PSUSA/00001990/202002(0)
- PSUSA/00001990/202202(0)
- PSUSA/00001996/201711(0)
- PSUSA/00001996/202101(0)
- PSUSA/00001997/201504(0)
- PSUSA/00001997/201804(0)
- PSUSA/00001997/202003(0)
- PSUSA/00001997/202103(0)
- PSUSA/00001999/202001(0)
- PSUSA/00002001/201504(0)
- PSUSA/00002001/201804(0)
- PSUSA/00002001/202104(0)
- PSUSA/00002002/201506(0)
- PSUSA/00002002/201806(0)
- PSUSA/00002002/202106(0)
- PSUSA/00002004/201905(0)
- PSUSA/00002004/202205(0)
- PSUSA/00002019/201706(0)
- PSUSA/00002019/202206(0)
- PSUSA/00002024/201510(0)
- PSUSA/00002024/201710(0)
- PSUSA/00002024/201810(0)
- PSUSA/00002024/201910(0)
- PSUSA/00002024/202110(0)
- PSUSA/00002025/201803(0)
- PSUSA/00002025/202303(0)
- PSUSA/00002026/201411(0)
- PSUSA/00002026/201711(0)
- PSUSA/00002026/202011(0)
- PSUSA/00002030/201502(0)
- PSUSA/00002036/201510(0)
- PSUSA/00002036/201811(0)
- PSUSA/00002036/202111(0)
- PSUSA/00002046/201806(0)
- PSUSA/00002052/201410(0)
- PSUSA/00002057/201709(0)
- PSUSA/00002057/202209(0)
- PSUSA/00002060/201705(0)
- PSUSA/00002060/202005(0)
- PSUSA/00002060/202305(0)
- PSUSA/00002061/201807(0)
- PSUSA/00002063/201504(0)
- PSUSA/00002063/201804(0)
- PSUSA/00002063/202104(0)
- PSUSA/00002064/201510(0)
- PSUSA/00002064/201810(0)
- PSUSA/00002064/202110(0)
- PSUSA/00002065/201708(0)
- PSUSA/00002065/202208(0)
- PSUSA/00002066/202010(0)
- PSUSA/00002067/201510(0)
- PSUSA/00002067/201710(0)
- PSUSA/00002068/201808(0)
- PSUSA/00002068/202308(0)
- PSUSA/00002076/201606(0)
- PSUSA/00002076/201906(0)
- PSUSA/00002076/202206(0)
- PSUSA/00002077/201801(0)
- PSUSA/00002078/201711(0)
- PSUSA/00002079/201704(0)
- PSUSA/00002079/202204(0)
- PSUSA/00002082/201706(0)
- PSUSA/00002085/201705(0)
- PSUSA/00002085/202005(0)
- PSUSA/00002085/202305(0)
- PSUSA/00002087/201507(0)
- PSUSA/00002087/201807(0)
- PSUSA/00002087/202107(0)
- PSUSA/00002094/201605(0)
- PSUSA/00002094/202105(0)
- PSUSA/00002095/201701(0)
- PSUSA/00002095/202201(0)
- PSUSA/00002096/201703(0)
- PSUSA/00002096/202203(0)
- PSUSA/00002101/201703(0)
- PSUSA/00002102/201605(0)
- PSUSA/00002102/202105(0)
- PSUSA/00002104/201503(0)
- PSUSA/00002104/201803(0)
- PSUSA/00002104/202103(0)
- PSUSA/00002105/201502(0)
- PSUSA/00002105/201802(0)
- PSUSA/00002105/202102(0)
- PSUSA/00002109/202008(0)
- PSUSA/00002117/201511(0)
- PSUSA/00002117/201811(0)
- PSUSA/00002117/202211(0)
- PSUSA/00002125/201708(0)
- PSUSA/00002125/202008(0)
- PSUSA/00002126/201702(0)
- PSUSA/00002126/202202(0)
- PSUSA/00002129/201803(0)
- PSUSA/00002131/201603(0)
- PSUSA/00002131/201903(0)
- PSUSA/00002131/202203(0)
- PSUSA/00002149/201605(0)
- PSUSA/00002150/201505(0)
- PSUSA/00002150/202005(0)
- PSUSA/00002151/202008(0)
- PSUSA/00002151/202308(0)
- PSUSA/00002152/201602(0)
- PSUSA/00002152/202202(0)
- PSUSA/00002156/201508(0)
- PSUSA/00002156/202008(0)
- PSUSA/00002157/201512(0)
- PSUSA/00002157/201812(0)
- PSUSA/00002157/202112(0)
- PSUSA/00002160/201908(0)
- PSUSA/00002160/202108(0)
- PSUSA/00002163/201807(0)
- PSUSA/00002165/201506(0)
- PSUSA/00002165/202306(0)
- PSUSA/00002166/201811(0)
- PSUSA/00002170/201503(0)
- PSUSA/00002170/201803(0)
- PSUSA/00002171/201503(0)
- PSUSA/00002171/201803(0)
- PSUSA/00002171/202103(0)
- PSUSA/00002174/201502(0)
- PSUSA/00002174/201802(0)
- PSUSA/00002174/202102(0)
- PSUSA/00002181/201501(0)
- PSUSA/00002181/201801(0)
- PSUSA/00002181/202101(0)
- PSUSA/00002188/201708(0)
- PSUSA/00002188/202208(0)
- PSUSA/00002190/202306(0)
- PSUSA/00002192/201803(0)
- PSUSA/00002192/202303(0)
- PSUSA/00002199/201701(0)
- PSUSA/00002201/201706(0)
- PSUSA/00002201/202006(0)
- PSUSA/00002201/202306(0)
- PSUSA/00002203/201504(0)
- PSUSA/00002203/201804(0)
- PSUSA/00002203/202104(0)
- PSUSA/00002203/202304(0)
- PSUSA/00002204/201504(0)
- PSUSA/00002204/201804(0)
- PSUSA/00002204/202104(0)
- PSUSA/00002207/201610(0)
- PSUSA/00002207/202110(0)
- PSUSA/00002208/201704(0)
- PSUSA/00002208/202204(0)
- PSUSA/00002209/201610(0)
- PSUSA/00002209/202110(0)
- PSUSA/00002210/201704(0)
- PSUSA/00002210/202204(0)
- PSUSA/00002213/201705(0)
- PSUSA/00002213/202205(0)
- PSUSA/00002215/201704(0)
- PSUSA/00002215/202204(0)
- PSUSA/00002217/201502(0)
- PSUSA/00002217/201802(0)
- PSUSA/00002217/202102(0)
- PSUSA/00002229/201504(0)
- PSUSA/00002229/201804(0)
- PSUSA/00002229/202104(0)
- PSUSA/00002233/201701(0)
- PSUSA/00002235/201608(0)
- PSUSA/00002235/201908(0)
- PSUSA/00002235/202008(0)
- PSUSA/00002235/202108(0)
- PSUSA/00002254/201804(0)
- PSUSA/00002254/202104(0)
- PSUSA/00002254/202204(0)
- PSUSA/00002254/202304(0)
- PSUSA/00002256/202307(0)
- PSUSA/00002258/202008(0)
- PSUSA/00002263/201706(0)
- PSUSA/00002263/202006(0)
- PSUSA/00002264/201512(0)
- PSUSA/00002269/201505(0)
- PSUSA/00002269/201805(0)
- PSUSA/00002269/202105(0)
- PSUSA/00002275/201912(0)
- PSUSA/00002307/201806(0)
- PSUSA/00002307/202306(0)
- PSUSA/00002310/201508(0)
- PSUSA/00002310/201808(0)
- PSUSA/00002311/201505(0)
- PSUSA/00002311/201605(0)
- PSUSA/00002311/201705(0)
- PSUSA/00002311/201805(0)
- PSUSA/00002311/202105(0)
- PSUSA/00002316/201608(0)
- PSUSA/00002316/201908(0)
- PSUSA/00002316/202208(0)
- PSUSA/00002319/201712(0)
- PSUSA/00002319/202212(0)
- PSUSA/00002320/201804(0)
- PSUSA/00002320/202304v(0)
- PSUSA/00002322/202008(0)
- PSUSA/00002322/202308(0)
- PSUSA/00002329/201806(0)
- PSUSA/00002329/202306(0)
- PSUSA/00002333/201608(0)
- PSUSA/00002333/202108(0)
- PSUSA/00002338/201706(0)
- PSUSA/00002338/202206(0)
- PSUSA/00002345/201812(0)
- PSUSA/00002351/201612(0)
- PSUSA/00002354/201510(0)
- PSUSA/00002354/202010(0)
- PSUSA/00002355/201707(0)
- PSUSA/00002355/201808(0)
- PSUSA/00002355/202008(0)
- PSUSA/00002357/202008(0)
- PSUSA/00002359/202001(0)
- PSUSA/00002368/202003(0)
- PSUSA/00002370/202001(0)
- PSUSA/00002378/201501(0)
- PSUSA/00002392/202008(0)
- PSUSA/00002392/202308(0)
- PSUSA/00002396/201505(0)
- PSUSA/00002396/201905(0)
- PSUSA/00002396/202105(0)
- PSUSA/00002408/201607(0)
- PSUSA/00002408/202107(0)
- PSUSA/00002409/201707(0)
- PSUSA/00002409/202207(0)
- PSUSA/00002410/201608(0)
- PSUSA/00002410/202108(0)
- PSUSA/00002411/201503(0)
- PSUSA/00002411/201603(0)
- PSUSA/00002411/201703(0)
- PSUSA/00002411/201803(0)
- PSUSA/00002411/202303(0)
- PSUSA/00002425/201709(0)
- PSUSA/00002425/202209(0)
- PSUSA/00002427/201806(0)
- PSUSA/00002429/201704(0)
- PSUSA/00002429/202204(0)
- PSUSA/00002433/201510(0)
- PSUSA/00002433/201810(0)
- PSUSA/00002433/202110(0)
- PSUSA/00002436/201703(0)
- PSUSA/00002436/202003(0)
- PSUSA/00002436/202303(0)
- PSUSA/00002438/201704(0)
- PSUSA/00002438/202004(0)
- PSUSA/00002438/202304(0)
- PSUSA/00002449/202104(0)
- PSUSA/00002454/202009(0)
- PSUSA/00002458/201607(0)
- PSUSA/00002460/201507(0)
- PSUSA/00002472/202010(0)
- PSUSA/00002472/202110(0)
- PSUSA/00002472/202210(0)
- PSUSA/00002492/201409(0)
- PSUSA/00002492/201909(0)
- PSUSA/00002500/201703(0)
- PSUSA/00002500/202003(0)
- PSUSA/00002500/202303(0)
- PSUSA/00002503/201804(0)
- PSUSA/00002503/202104(0)
- PSUSA/00002506/202308(0)
- PSUSA/00002525/202006(0)
- PSUSA/00002537/202205(0)
- PSUSA/00002550/201601(0)
- PSUSA/00002550/202101(0)
- PSUSA/00002555/201711(0)
- PSUSA/00002555/202211(0)
- PSUSA/00002569/201410(0)
- PSUSA/00002569/201710(0)
- PSUSA/00002569/202010(0)
- PSUSA/00002589/201707(0)
- PSUSA/00002589/202006(0)
- PSUSA/00002590/201707(0)
- PSUSA/00002591/201604(0)
- PSUSA/00002591/202104(0)
- PSUSA/00002592/201604(0)
- PSUSA/00002592/202104(0)
- PSUSA/00002598/201611(0)
- PSUSA/00002598/202111(0)
- PSUSA/00002601/201510(0)
- PSUSA/00002601/201610(0)
- PSUSA/00002601/202110(0)
- PSUSA/00002602/201703(0)
- PSUSA/00002602/202003(0)
- PSUSA/00002602/202303(0)
- PSUSA/00002610/201505(0)
- PSUSA/00002610/201805(0)
- PSUSA/00002610/202105(0)
- PSUSA/00002615/201504(0)
- PSUSA/00002615/202004(0)
- PSUSA/00002634/201501(0)
- PSUSA/00002643/201508(0)
- PSUSA/00002643/201808(0)
- PSUSA/00002643/202108(0)
- PSUSA/00002647/201510(0)
- PSUSA/00002648/201603(0)
- PSUSA/00002648/202103(0)
- PSUSA/00002649/201705(0)
- PSUSA/00002649/202205(0)
- PSUSA/00002655/201806(0)
- PSUSA/00002655/202306(0)
- PSUSA/00002656/201602(0)
- PSUSA/00002656/201902(0)
- PSUSA/00002661/201607(0)
- PSUSA/00002661/201907(0)
- PSUSA/00002661/202207(0)
- PSUSA/00002662/201709(0)
- PSUSA/00002662/202209(0)
- PSUSA/00002664/201711(0)
- PSUSA/00002664/202211(0)
- PSUSA/00002669/201412(0)
- PSUSA/00002669/201612(0)
- PSUSA/00002669/201812(0)
- PSUSA/00002669/202112(0)
- PSUSA/00002670/201501(0)
- PSUSA/00002673/201506(0)
- PSUSA/00002673/201512(0)
- PSUSA/00002673/201612(0)
- PSUSA/00002673/201712(0)
- PSUSA/00002673/202012(0)
- PSUSA/00002681/201510(0)
- PSUSA/00002681/202010(0)
- PSUSA/00002695/201507(0)
- PSUSA/00002695/201601(0)
- PSUSA/00002695/201701(0)
- PSUSA/00002695/201801(0)
- PSUSA/00002695/201901(0)
- PSUSA/00002695/202001(0)
- PSUSA/00002695/202301(0)
- PSUSA/00002696/201703(0)
- PSUSA/00002696/202203(0)
- PSUSA/00002698/201501(0)
- PSUSA/00002698/202001(0)
- PSUSA/00002702/202009(0)
- PSUSA/00002709/201704(0)
- PSUSA/00002709/202004(0)
- PSUSA/00002753/201703(0)
- PSUSA/00002767/201704(0)
- PSUSA/00002767/202204(0)
- PSUSA/00002769/201706(0)
- PSUSA/00002769/202006(0)
- PSUSA/00002774/201908(0)
- PSUSA/00002780/201503(0)
- PSUSA/00002780/201803(0)
- PSUSA/00002780/202103(0)
- PSUSA/00002781/201501(0)
- PSUSA/00002781/201801(0)
- PSUSA/00002781/202101(0)
- PSUSA/00002786/201603(0)
- PSUSA/00002786/202103(0)
- PSUSA/00002795/201705(0)
- PSUSA/00002800/201611(0)
- PSUSA/00002800/201911(0)
- PSUSA/00002828/201604(0)
- PSUSA/00002828/202204(0)
- PSUSA/00002829/201511(0)
- PSUSA/00002829/202011(0)
- PSUSA/00002832/201409(0)
- PSUSA/00002832/201909(0)
- PSUSA/00002834/201708(0)
- PSUSA/00002834/202008(0)
- PSUSA/00002834/202308(0)
- PSUSA/00002843/201504(0)
- PSUSA/00002843/201804(0)
- PSUSA/00002843/202104(0)
- PSUSA/00002846/201504(0)
- PSUSA/00002846/202004(0)
- PSUSA/00002847/201607(0)
- PSUSA/00002847/202107(0)
- PSUSA/00002849/201411(0)
- PSUSA/00002849/201711(0)
- PSUSA/00002849/201811(0)
- PSUSA/00002849/202111(0)
- PSUSA/00002856/201610(0)
- PSUSA/00002861/201511(0)
- PSUSA/00002866/201603(0)
- PSUSA/00002866/201703(0)
- PSUSA/00002868/201706(0)
- PSUSA/00002870/201705(0)
- PSUSA/00002878/201611(0)
- PSUSA/00002878/202111(0)
- PSUSA/00002893/201502(0)
- PSUSA/00002893/201802(0)
- PSUSA/00002893/202102(0)
- PSUSA/00002895/201511(0)
- PSUSA/00002895/201811(0)
- PSUSA/00002896/201709(0)
- PSUSA/00002896/202209(0)
- PSUSA/00002897/201612(0)
- PSUSA/00002897/202112(0)
- PSUSA/00002905/201504(0)
- PSUSA/00002905/201804(0)
- PSUSA/00002905/202104(0)
- PSUSA/00002907/201512(0)
- PSUSA/00002908/201512(0)
- PSUSA/00002908/201812(0)
- PSUSA/00002908/202112(0)
- PSUSA/00002909/201708(0)
- PSUSA/00002910/201501(0)
- PSUSA/00002910/201801(0)
- PSUSA/00002910/202301(0)
- PSUSA/00002911/201410(0)
- PSUSA/00002911/201510(0)
- PSUSA/00002911/201610(0)
- PSUSA/00002911/202010(0)
- PSUSA/00002921/201706(0)
- PSUSA/00002921/202206(0)
- PSUSA/00002925/201505(0)
- PSUSA/00002925/201805(0)
- PSUSA/00002925/202305(0)
- PSUSA/00002927/201507(0)
- PSUSA/00002929/201603(0)
- PSUSA/00002942/201506(0)
- PSUSA/00002942/201806(0)
- PSUSA/00002942/202106(0)
- PSUSA/00002943/201506(0)
- PSUSA/00002943/201806(0)
- PSUSA/00002943/202106(0)
- PSUSA/00002944/201507(0)
- PSUSA/00002944/201807(0)
- PSUSA/00002944/202107(0)
- PSUSA/00002947/201612(0)
- PSUSA/00002947/201912(0)
- PSUSA/00002951/201701(0)
- PSUSA/00002952/201505(0)
- PSUSA/00002952/202005(0)
- PSUSA/00002959/201502(0)
- PSUSA/00002972/201610(0)
- PSUSA/00002972/202110(0)
- PSUSA/00002974/201605(0)
- PSUSA/00002974/201905(0)
- PSUSA/00002974/202205(0)
- PSUSA/00002977/201412(0)
- PSUSA/00002977/201912(0)
- PSUSA/00002991/201906(0)
- PSUSA/00002991/202206(0)
- PSUSA/00002993/201609(0)
- PSUSA/00002996/201701(0)
- PSUSA/00002997/201505(0)
- PSUSA/00003002/201705(0)
- PSUSA/00003002/202005(0)
- PSUSA/00003002/202306(0)
- PSUSA/00003004/201902(0)
- PSUSA/00003005/201503(0)
- PSUSA/00003005/202003(0)
- PSUSA/00003012/202308(0)
- PSUSA/00003013/201511(0)
- PSUSA/00003013/201605(0)
- PSUSA/00003013/201611(0)
- PSUSA/00003013/201711(0)
- PSUSA/00003013/201805(0)
- PSUSA/00003013/201905(0)
- PSUSA/00003015/201703(0)
- PSUSA/00003015/202203(0)
- PSUSA/00003016/201708(0)
- PSUSA/00003016/202208(0)
- PSUSA/00003017/201707(0)
- PSUSA/00003017/202207(0)
- PSUSA/00003023/201707(0)
- PSUSA/00003023/202207(0)
- PSUSA/00003043/201508(0)
- PSUSA/00003043/201608(0)
- PSUSA/00003043/201708(0)
- PSUSA/00003043/202008(0)
- PSUSA/00003047/201412(0)
- PSUSA/00003047/201712(0)
- PSUSA/00003047/202012(0)
- PSUSA/00003048/201703(0)
- PSUSA/00003048/202203(0)
- PSUSA/00003063/201609(0)
- PSUSA/00003063/202109(0)
- PSUSA/00003065/201708(0)
- PSUSA/00003065/202008(0)
- PSUSA/00003067/201707(0)
- PSUSA/00003067/202112(0)
- PSUSA/00003078/201507(0)
- PSUSA/00003078/201807(0)
- PSUSA/00003078/202107(0)
- PSUSA/00003082/201703(0)
- PSUSA/00003084/201611(0)
- PSUSA/00003086/201512(0)
- PSUSA/00003086/201812(0)
- PSUSA/00003086/202112(0)
- PSUSA/00003089/201603(0)
- PSUSA/00003089/202103(0)
- PSUSA/00003090/201501(0)
- PSUSA/00003090/201801(0)
- PSUSA/00003090/202101(0)
- PSUSA/00003097/201501(0)
- PSUSA/00003097/202001(0)
- PSUSA/00003102/201611(0)
- PSUSA/00003102/202011(0)
- PSUSA/00003104/201705(0)
- PSUSA/00003104/202205(0)
- PSUSA/00003104/202305(0)
- PSUSA/00003105/202001(0)
- PSUSA/00003112/201409(0)
- PSUSA/00003112/201709(0)
- PSUSA/00003124/201704(0)
- PSUSA/00003124/202204(0)
- PSUSA/00003134/202005(0)
- PSUSA/00003134/202305(0)
- PSUSA/00003135/201612(0)
- PSUSA/00003135/201812(0)
- PSUSA/00003135/202012(0)
- PSUSA/00003135/202212(0)
- PSUSA/00003138/201512(0)
- PSUSA/00003140/201907(0)
- PSUSA/00003141/201701(0)
- PSUSA/00003141/202201(0)
- PSUSA/00003143/201703(0)
- PSUSA/00003143/202109(0)
- PSUSA/00003146/201507(0)
- PSUSA/00003146/202007(0)
- PSUSA/00003150/201703(0)
- PSUSA/00003151/202308(0)
- PSUSA/00003155/202305(0)
- PSUSA/00003158/201603(0)
- PSUSA/00003158/202103(0)
- PSUSA/00003159/201512(0)
- PSUSA/00003159/201612(0)
- PSUSA/00003159/201712(0)
- PSUSA/00003159/202012(0)
- PSUSA/00003161/201508(0)
- PSUSA/00003161/201808(0)
- PSUSA/00003161/202108(0)
- PSUSA/00003162/201601(0)
- PSUSA/00003162/201701(0)
- PSUSA/00003162/201801(0)
- PSUSA/00003162/202001(0)
- PSUSA/00003162/202201(0)
- PSUSA/00003163/201603(0)
- PSUSA/00003163/201703(0)
- PSUSA/00003167/201612(0)
- PSUSA/00003167/201912(0)
- PSUSA/00003167/202212(0)
- PSUSA/00003168/201602(0)
- PSUSA/00003168/201902(0)
- PSUSA/00003168/202202(0)
- PSUSA/00003170/201508(0)
- PSUSA/00003170/202008(0)
- PSUSA/00003175/201703(0)
- PSUSA/00003175/202103(0)
- PSUSA/00003178/201606(0)
- PSUSA/00003185/201502(0)
- PSUSA/0000389/201412(0)
- PSUSA/00009004/201707(0)
- PSUSA/00009004/202007(0)
- PSUSA/00009057/201501(0)
- PSUSA/00009057/201801(0)
- PSUSA/ 00009057/202101(0)
- PSUSA/00009060/201510(0)
- PSUSA/00009076/201506(0)
- PSUSA/00009084/201512(0)
- PSUSA/00009084/201812(0)
- PSUSA/00009084/202112(0)
- PSUSA/00009099/201704(0)
- PSUSA/00009099/202204(0)
- PSUSA/00009153/201704(0)
- PSUSA/00009153/202004(0)
- PSUSA/00009159/201703(0)
- PSUSA/00009159/202003(0)
- PSUSA/00009159/202303(0)
- PSUSA/00009162/201503(0)
- PSUSA/00009162/201803(0)
- PSUSA/00009174/201602(0)
- PSUSA/00009174/201702(0)
- PSUSA/00009174/201802(0)
- PSUSA/00009174/202102(0)
- PSUSA/00009182/201612(0)
- PSUSA/00009182/201712(0)
- PSUSA/00009182/202012(0)
- PSUSA/00009182/202212(0)
- PSUSA/00009190/201501(0)
- PSUSA/00009190/201801(0)
- PSUSA/00009190/202101(0)
- PSUSA/00009191/202007(0)
- PSUSA/00009197/201706(0)
- PSUSA/00009201/202308(0)
- PSUSA/00009205/201509(0)
- PSUSA/00009205/201609(0)
- PSUSA/00009205/201901(0)
- PSUSA/00009205/202201(0)
- PSUSA/00009225/201506(0)
- PSUSA/00009225/202006(0)
- PSUSA/00009231/201605(0)
- PSUSA/00009231/201905(0)
- PSUSA/00009231/202305(0)
- PSUSA/00009236/201506(0)
- PSUSA/00009236/201806(0)
- PSUSA/00009236/202106(0)
- PSUSA/00009251/201510(0)
- PSUSA/00009256/202004(0)
- PSUSA/00009271/201503(0)
- PSUSA/00009271/201603(0)
- PSUSA/00009271/201703(0)
- PSUSA/00009271/201803(0)
- PSUSA/00009271/202103(0)
- PSUSA/00009272/201509(0)
- PSUSA/00009272/201609(0)
- PSUSA/00009272/201909(0)
- PSUSA/00009277/201603(0)
- PSUSA/00009277/202103(0)
- PSUSA/00009284/201702(0)
- PSUSA/00009284/202002(0)
- PSUSA/00009284/202302(0)
- PSUSA/00009316/201712(0)
- PSUSA/00009316/202012(0)
- PSUSA/00009317/201603(0)
- PSUSA/00009317/202103(0)
- PSUSA/00009318/202009(0)
- PSUSA/00009319/201708(0)
- PSUSA/00009319/202208(0)
- PSUSA/0000936/201806(0)
- PSUSA/0000958/201409(0)
- PSUSA/00010000/201412(0)
- PSUSA/00010000/201712(0)
- PSUSA/00010000/201901(0)
- PSUSA/00010000/202301(0)
- PSUSA/00010001/201509(0)
- PSUSA/00010002/201803(0)
- PSUSA/00010002/202103(0)
- PSUSA/00010003/201508(0)
- PSUSA/00010005/201702(0)
- PSUSA/00010005/202002(0)
- PSUSA/00010007/202307(0)
- PSUSA/00010012/201504(0)
- PSUSA/00010012/202004(0)
- PSUSA/00010021/201507(0)
- PSUSA/00010021/201807(0)
- PSUSA/00010021/202107(0)
- PSUSA/00010030/202005(0)
- PSUSA/00010051/201607(0)
- PSUSA/00010051/202107(0)
- PSUSA/00010067/201510(0)
- PSUSA/00010067/201810(0)
- PSUSA/00010067/202110(0)
- PSUSA/00010068/201607(0)
- PSUSA/00010068/201907(0)
- PSUSA/00010068/202207(0)
- PSUSA/00010070/201611(0)
- PSUSA/00010070/202111(0)
- PSUSA/00010072/201409(0)
- PSUSA/00010072/201909(0)
- PSUSA/00010078/201703(0)
- PSUSA/00010078/202203(0)
- PSUSA/00010080/201707(0)
- PSUSA/00010080/202207(0)
- PSUSA/00010092/202104(0)
- PSUSA/00010109/201701(0)
- PSUSA/00010117/201704(0)
- PSUSA/00010130/201502(0)
- PSUSA/00010130/202002(0)
- PSUSA/00010137/202009(0)
- PSUSA/00010145/201502(0)
- PSUSA/00010145/201508(0)
- PSUSA/00010145/201608(0)
- PSUSA/00010145/201702(0)
- PSUSA/00010145/201708(0)
- PSUSA/00010145/201802(0)
- PSUSA/00010155/201609(0)
- PSUSA/00010155/201909(0)
- PSUSA/00010155/202209(0)
- PSUSA/00010161/201411(0)
- PSUSA/00010161/201512(0)
- PSUSA/00010161/201612(0)
- PSUSA/00010163/201608(0)
- PSUSA/00010163/202108(0)
- PSUSA/00010163/202308(0)
- PSUSA/00010178/201808(0)
- PSUSA/00010178/202308(0)
- PSUSA/00010184/201412(0)
- PSUSA/00010184/201506(0)
- PSUSA/00010187/201901(0)
- PSUSA/00010190/201506(0)
- PSUSA/00010190/201512(0)
- PSUSA/00010190/201612(0)
- PSUSA/00010190/201712(0)
- PSUSA/00010190/201812(0)
- PSUSA/00010191/201704(0)
- PSUSA/00010191/202204(0)
- PSUSA/00010192/201612(0)
- PSUSA/00010199/201505(0)
- PSUSA/00010199/201605(0)
- PSUSA/00010199/201705(0)
- PSUSA/00010199/201805(0)
- PSUSA/00010199/202105(0)
- PSUSA/00010206/201411(0)
- PSUSA/00010206/201505(0)
- PSUSA/00010206/201805(0)
- PSUSA/00010206/202105(0)
- PSUSA/00010207/201611(0)
- PSUSA/00010207/201911(0)
- PSUSA/00010209/201502(0)
- PSUSA/00010209/201508(0)
- PSUSA/00010209/201602(0)
- PSUSA/00010209/201702(0)
- PSUSA/00010209/201802(0)
- PSUSA/00010209/201902(0)
- PSUSA/00010209/202002(0)
- PSUSA/00010217/201609(0)
- PSUSA/00010217/201909(0)
- PSUSA/00010217/202209(0)
- PSUSA/00010223/201702(0)
- PSUSA/00010224/201502(0)
- PSUSA/00010224/201508(0)
- PSUSA/00010224/201602(0)
- PSUSA/00010224/201608(0)
- PSUSA/00010224/201708(0)
- PSUSA/00010224/201808(0)
- PSUSA/00010224/202008(0)
- PSUSA/00010224/202108(0)
- PSUSA/00010224/202308(0)
- PSUSA/00010225/201501(0)
- PSUSA/00010225/201710(0)
- PSUSA/00010226/201605(0)
- PSUSA/00010226/201905(0)
- PSUSA/00010226/202205(0)
- PSUSA/00010230/201611(0)
- PSUSA/00010230/202111(0)
- PSUSA/00010236/201701(0)
- PSUSA/00010236/201801(0)
- PSUSA/00010236/201901(0)
- PSUSA/00010236/202001(0)
- PSUSA/00010239/201502(0)
- PSUSA/00010239/201508(0)
- PSUSA/00010239/201602(0)
- PSUSA/00010239/201608(0)
- PSUSA/00010239/201708(0)
- PSUSA/00010239/201808(0)
- PSUSA/00010241/201704(0)
- PSUSA/00010242/201708(0)
- PSUSA/00010242/202008(0)
- PSUSA/00010242/202108(0)
- PSUSA/00010242/202308(0)
- PSUSA/00010243/201510(0)
- PSUSA/00010243/201605(0)
- PSUSA/00010245/201503(0)
- PSUSA/00010245/201509(0)
- PSUSA/00010245/201603(0)
- PSUSA/00010245/201703(0)
- PSUSA/00010245/201803(0)
- PSUSA/00010245/202103(0)
- PSUSA/00010252/201806(0)
- PSUSA/00010252/202106(0)
- PSUSA/0001026/201512(0)
- PSUSA/00010266/201612(0)
- PSUSA/00010266/201912(0)
- PSUSA/00010269/201507(0)
- PSUSA/00010269/201807(0)
- PSUSA/00010269/202107(0)
- PSUSA/00010271/201707(0)
- PSUSA/00010271/202007(0)
- PSUSA/00010271/202307(0)
- PSUSA/00010280/201702(0)
- PSUSA/00010280/202002(0)
- PSUSA/00010283/201501(0)
- PSUSA/00010283/201507(0)
- PSUSA/00010283/201601(0)
- PSUSA/00010283/201701(0)
- PSUSA/00010283/202001(0)
- PSUSA/00010285/201507(0)
- PSUSA/00010285/201807(0)
- PSUSA/00010285/202107(0)
- PSUSA/00010287/201505(0)
- PSUSA/00010287/201511(0)
- PSUSA/00010287/201811(0)
- PSUSA/00010287/202111(0)
- PSUSA/00010288/201505(0)
- PSUSA/00010288/201511(0)
- PSUSA/00010288/201605(0)
- PSUSA/00010288/201611(0)
- PSUSA/00010288/201705(0)
- PSUSA/00010288/201711(0)
- PSUSA/00010288/201805(0)
- PSUSA/00010288/201811(0)
- PSUSA/00010288/201905(0)
- PSUSA/00010288/201911(0)
- PSUSA/00010288/202005(0)
- PSUSA/00010288/202011(0)
- PSUSA/00010288/202105(0)
- PSUSA/00010288/202111(0)
- PSUSA/00010288/202211(0)
- PSUSA/00010289/201502(0)
- PSUSA/00010289/201508(0)
- PSUSA/00010289/201702(0)
- PSUSA/00010289/201802(0)
- PSUSA/00010289/201902(0)
- PSUSA/00010289/202002(0)
- PSUSA/00010289/202102(0)
- PSUSA/00010289/202202(0)
- PSUSA/00010290/201601(0)
- PSUSA/00010290/201607(0)
- PSUSA/00010290/201701(0)
- PSUSA/00010290/201801(0)
- PSUSA/00010291/201506(0)
- PSUSA/00010291/201606(0)
- PSUSA/00010291/201706(0)
- PSUSA/00010291/201806(0)
- PSUSA/00010291/202006(0)
- PSUSA/00010291/202306(0)
- PSUSA/00010292/201503(0)
- PSUSA/00010292/201603(0)
- PSUSA/00010292/201703(0)
- PSUSA/00010292/201903(0)
- PSUSA/00010292/202103(0)
- PSUSA/00010292/202303(0)
- PSUSA/00010298/201504(0)
- PSUSA/00010298/201508(0)
- PSUSA/00010298/201603(0)
- PSUSA/00010298/201703(0)
- PSUSA/00010298/201803(0)
- PSUSA/00010298/201903(0)
- PSUSA/00010298/202003(0)
- PSUSA/00010298/202103(0)
- PSUSA/00010298/202203(0)
- PSUSA/00010298/202303(0)
- PSUSA/00010299/201504(0)
- PSUSA/00010299/201508(0)
- PSUSA/00010299/201603(0)
- PSUSA/00010299/201703(0)
- PSUSA/00010299/201803(0)
- PSUSA/00010299/201903(0)
- PSUSA/00010299/202003(0)
- PSUSA/00010300/201504(0)
- PSUSA/00010300/201508(0)
- PSUSA/00010300/201603(0)
- PSUSA/00010300/201703(0)
- PSUSA/00010300/201803(0)
- PSUSA/00010300/201903(0)
- PSUSA/00010300/202003(0)
- PSUSA/00010308/201512(0)
- PSUSA/00010312/201701(0)
- PSUSA/00010312/202001(0)
- PSUSA/00010324/201712(0)
- PSUSA/00010324/202012(0)
- PSUSA/00010326/201607(0)
- PSUSA/00010326/201907(0)
- PSUSA/00010326/202207(0)
- PSUSA/00010328/201908(0)
- PSUSA/00010330/201701(0)
- PSUSA/00010330/202001(0)
- PSUSA/00010332/201704(0)
- PSUSA/00010332/202004(0)
- PSUSA/00010332/202304(0)
- PSUSA/00010333/201611(0)
- PSUSA/00010333/201911(0)
- PSUSA/00010333/202211(0)
- PSUSA/00010336/201907(0)
- PSUSA/00010336/202207(0)
- PSUSA/00010339/201507(0)
- PSUSA/00010339/201607(0)
- PSUSA/00010339/201707(0)
- PSUSA/00010339/201807(0)
- PSUSA/00010339/202107(0)
- PSUSA/00010342/201509(0)
- PSUSA/00010342/201809(0)
- PSUSA/00010345/201702(0)
- PSUSA/00010346/201611(0)
- PSUSA/00010346/202111(0)
- PSUSA/00010347/201710(0)
- PSUSA/00010348/201509(0)
- PSUSA/00010348/201809(0)
- PSUSA/00010348/202109(0)
- PSUSA/00010349/201504(0)
- PSUSA/00010349/202104(0)
- PSUSA/00010353/201505(0)
- PSUSA/00010353/201605(0)
- PSUSA/00010353/201705(0)
- PSUSA/00010353/201805(0)
- PSUSA/00010353/201905(0)
- PSUSA/00010353/202005(0)
- PSUSA/00010353/202105(0)
- PSUSA/00010354/201505(0)
- PSUSA/00010354/201705(0)
- PSUSA/00010354/202005(0)
- PSUSA/00010354/202305(0)
- PSUSA/00010355/201509(0)
- PSUSA/00010355/201809(0)
- PSUSA/00010355/202109(0)
- PSUSA/00010358/201711(0)
- PSUSA/00010358/202211(0)
- PSUSA/00010361/201805(0)
- PSUSA/00010364/201509(0)
- PSUSA/00010364/201603(0)
- PSUSA/00010364/201609(0)
- PSUSA/00010364/201703(0)
- PSUSA/00010364/201803(0)
- PSUSA/00010364/201903(0)
- PSUSA/00010364/202203(0)
- PSUSA/00010374/201801(0)
- PSUSA/00010374/202101(0)
- PSUSA/00010376/201510(0)
- PSUSA/00010376/201604(0)
- PSUSA/00010376/201610(0)
- PSUSA/00010376/201704(0)
- PSUSA/00010376/201804(0)
- PSUSA/00010376/201904(0)
- PSUSA/00010376/202004(0)
- PSUSA/00010376/202104(0)
- PSUSA/00010377/201604(0)
- PSUSA/00010377/201904(0)
- PSUSA/00010377/202204(0)
- PSUSA/00010378/201705(0)
- PSUSA/00010378/202005(0)
- PSUSA/00010378/202305(0)
- PSUSA/00010381/201604(0)
- PSUSA/00010381/201804(0)
- PSUSA/00010381/202004(0)
- PSUSA/00010381/202304(0)
- PSUSA/00010382/201704(0)
- PSUSA/00010385/201807(0)
- PSUSA/00010386/201610(0)
- PSUSA/00010386/201910(0)
- PSUSA/00010390/2018(0)
- PSUSA/00010390/201601(0)
- PSUSA/00010390/201607(0)
- PSUSA/00010390/201701(0)
- PSUSA/00010390/201707(0)
- PSUSA/00010390/201801(0)
- PSUSA/00010390/201907(0)
- PSUSA/00010390/202007(0)
- PSUSA/00010390/202107(0)
- PSUSA/00010392/201605(0)
- PSUSA/00010392/201905(0)
- PSUSA/00010392/202205(0)
- PSUSA/00010396/201704(0)
- PSUSA/00010396/202004(0)
- PSUSA/00010396/202204(0)
- PSUSA/00010402/202001(0)
- PSUSA/00010406/201910(0)
- PSUSA/00010414/201909(0)
- PSUSA/00010415/201707(0)
- PSUSA/00010416/201902(0)
- PSUSA/00010417/201901(0)
- PSUSA/00010425/201808(0)
- PSUSA/00010425/202308(0)
- PSUSA/00010430/201711(0)
- PSUSA/00010430/202011(0)
- PSUSA/00010431/202010(0)
- PSUSA/00010432/201610(0)
- PSUSA/00010432/201910(0)
- PSUSA/00010433/201811(0)
- PSUSA/00010433/202211(0)
- PSUSA/00010434/201807(0)
- PSUSA/00010434/202107(0)
- PSUSA/00010436/202005(0)
- PSUSA/00010437/201804(0)
- PSUSA/00010437/202104(0)
- PSUSA/00010439/201607(0)
- PSUSA/00010439/202107(0)
- PSUSA/00010440/201608(0)
- PSUSA/00010440/202108(0)
- PSUSA/00010441/201704(0)
- PSUSA/00010441/202004(0)
- PSUSA/00010441/202304(0)
- PSUSA/00010442/201607(0)
- PSUSA/00010442/201701(0)
- PSUSA/00010442/201707(0)
- PSUSA/00010442/201801(0)
- PSUSA/00010442/201807(0)
- PSUSA/00010442/201901(0)
- PSUSA/00010442/202001(0)
- PSUSA/00010442/202101(0)
- PSUSA/00010443/201606(0)
- PSUSA/00010443/201906(0)
- PSUSA/00010444/201809(0)
- PSUSA/00010444/202309(0)
- PSUSA/00010461/201809(0)
- PSUSA/00010461/202109(0)
- PSUSA/00010462/202010(0)
- PSUSA/00010463/201807(0)
- PSUSA/00010463/202107(0)
- PSUSA/00010465/201612(0)
- PSUSA/00010465/201912(0)
- PSUSA/00010465/202212(0)
- PSUSA/00010466/201610(0)
- PSUSA/00010468/201901(0)
- PSUSA/00010468/202201(0)
- PSUSA/00010473/201903(0)
- PSUSA/00010473/202203(0)
- PSUSA/00010474/201607(0)
- PSUSA/00010474/202207(0)
- PSUSA/00010475/201607(0)
- PSUSA/00010475/201907(0)
- PSUSA/00010475/202203(0)
- PSUSA/00010483/201806(0)
- PSUSA/00010483/202106(0)
- PSUSA/00010484/201611(0)
- PSUSA/00010484/201705(0)
- PSUSA/00010484/201711(0)
- PSUSA/00010484/201805(0)
- PSUSA/00010484/201811(0)
- PSUSA/00010484/201905(0)
- PSUSA/00010484/202005(0)
- PSUSA/00010484/202105(0)
- PSUSA/00010484/202205(0)
- PSUSA/00010486/201801(0)
- PSUSA/00010486/202301(0)
- PSUSA/00010487/201808(0)
- PSUSA/00010488/201611(0)
- PSUSA/00010488/201705(0)
- PSUSA/00010488/201805(0)
- PSUSA/00010488/201905(0)
- PSUSA/00010488/202005(0)
- PSUSA/00010488/202105(0)
- PSUSA/00010488/202205(0)
- PSUSA/00010488/202305(0)
- PSUSA/00010489/201705(0)
- PSUSA/00010489/201805(0)
- PSUSA/00010489/202105(0)
- PSUSA/00010491/201704(0)
- PSUSA/00010491/202004(0)
- PSUSA/00010491/202304(0)
- PSUSA/00010492/201704(0)
- PSUSA/00010492/202004(0)
- PSUSA/00010492/202304(0)
- PSUSA/00010496/201706(0)
- PSUSA/00010496/202206(0)
- PSUSA/00010502/201707(0)
- PSUSA/00010502/201807(0)
- PSUSA/00010502/201907(0)
- PSUSA/00010502/202207(0)
- PSUSA/00010506/201711(0)
- PSUSA/00010506/202211(0)
- PSUSA/00010508/201709(0)
- PSUSA/00010508/202009(0)
- PSUSA/00010510/201701(0)
- PSUSA/00010510/202001(0)
- PSUSA/00010511/202107(0)
- PSUSA/00010512/201901(0)
- PSUSA/00010521/201706(0)
- PSUSA/00010525/201704(0)
- PSUSA/00010525/201710(0)
- PSUSA/00010525/201804(0)
- PSUSA/00010525/202004(0)
- PSUSA/00010525/202104(0)
- PSUSA/00010532/202009(0)
- PSUSA/00010542/201912(0)
- PSUSA/00010542/202212(0)
- PSUSA/00010543/201912(0)
- PSUSA/00010549/201710(0)
- PSUSA/00010551/201901(0)
- PSUSA/00010551/202201(0)
- PSUSA/00010558/201706(0)
- PSUSA/00010558/201806(0)
- PSUSA/00010558/201906(0)
- PSUSA/00010558/202006(0)
- PSUSA/00010558/202106(0)
- PSUSA/00010560/201804(0)
- PSUSA/00010560/201904(0)
- PSUSA/00010561/201706(0)
- PSUSA/00010561/202206(0)
- PSUSA/00010565/202106(0)
- PSUSA/00010566/202106(0)
- PSUSA/00010569/201812(0)
- PSUSA/00010570/201708(0)
- PSUSA/00010570/201802(0)
- PSUSA/00010570/201808(0)
- PSUSA/00010570/201902(0)
- PSUSA/00010570/202002(0)
- PSUSA/00010570/202302(0)
- PSUSA/00010572/201706(0)
- PSUSA/00010572/201806(0)
- PSUSA/00010572/202006(0)
- PSUSA/00010572/202206(0)
- PSUSA/00010579/201803(0)
- PSUSA/00010579/202103(0)
- PSUSA/00010582/201709(0)
- PSUSA/00010582/201803(0)
- PSUSA/00010582/201909(0)
- PSUSA/00010582/202109(0)
- PSUSA/00010582/202209(0)
- PSUSA/00010584/201803(0)
- PSUSA/00010584/202303(0)
- PSUSA/00010586/201711(0)
- PSUSA/00010586/201904(0)
- PSUSA/00010593/201903(0)
- PSUSA/00010599/202208(0)
- PSUSA/00010600/202303(0)
- PSUSA/00010602/201803(0)
- PSUSA/00010605/201907(0)
- PSUSA/00010606/201906(0)
- PSUSA/00010606/202206(0)
- PSUSA/00010613/201710(0)
- PSUSA/00010613/201810(0)
- PSUSA/00010613/202110(0)
- PSUSA/00010622/202301(0)
- PSUSA/00010628/202203(0)
- PSUSA/00010631/201812(0)
- PSUSA/00010631/202112(0)
- PSUSA/00010642/201807(0)
- PSUSA/00010648/202106(0)
- PSUSA/00010649/202002(0)
- PSUSA/00010649/202302(0)
- PSUSA/00010650/202202(0)
- PSUSA/00010651/201805(0)
- PSUSA/00010651/201905(0)
- PSUSA/00010651/201911(0)
- PSUSA/00010651/202005(0)
- PSUSA/00010651/202105(0)
- PSUSA/00010651/202205(0)
- PSUSA/00010656/202201(0)
- PSUSA/00010658/202204(0)
- PSUSA/00010665/201805(0)
- PSUSA/00010665/202105(0)
- PSUSA/00010667/201806(0)
- PSUSA/00010667/202306(0)
- PSUSA/00010670/201808(0)
- PSUSA/00010670/201909(0)
- PSUSA/00010670/202009(0)
- PSUSA/00010670/202109(0)
- PSUSA/00010679/202010(0)
- PSUSA/00010693/201901(0)
- PSUSA/00010693/201904(0)
- PSUSA/00010693/202110(0)
- PSUSA/00010696/202101(0)
- PSUSA/00010706/202211(0)
- PSUSA/00010707/202110(0)
- PSUSA/00010710/201901(0)
- PSUSA/00010710/202001(0)
- PSUSA/00010710/202101(0)
- PSUSA/00010710/202201(0)
- PSUSA/00010721/202207(0)
- PSUSA/00010722/202207(0)
- PSUSA/00010734/202111(0)
- PSUSA/00010735/201910(0)
- PSUSA/00010735/202210(0)
- PSUSA/00010748/201907(0)
- PSUSA/00010748/202007(0)
- PSUSA/00010749/202103(0)
- PSUSA/00010751/202003(0)
- PSUSA/00010751/202203(0)
- PSUSA/00010752/202308(0)
- PSUSA/00010771/201912(0)
- PSUSA/00010771/202012(0)
- PSUSA/00010774/202103(0)
- PSUSA/0001079/201804(0)
- PSUSA/00010790/202108(0)
- PSUSA/00010791/202106(0)
- PSUSA/00010801/202207(0)
- PSUSA/00010806/202010(0)
- PSUSA/00010806/202110(0)
- PSUSA/00010806/202210(0)
- PSUSA/00010808/202203(0)
- PSUSA/00010810/202304(0)
- PSUSA/00010813/202211(0)
- PSUSA/00010814/202202(0)
- PSUSA/00010815/202007(0)
- PSUSA/00010815/202101(0)
- PSUSA/00010815/202107(0)
- PSUSA/00010815/202201(0)
- PSUSA/00010815/202207(0)
- PSUSA/00010815/202307(0)
- PSUSA/00010827/202205(0)
- PSUSA/00010828/202105(0)
- PSUSA/00010844/202304(0)
- PSUSA/00010846/202010(0)
- PSUSA/00010846/202110(0)
- PSUSA/00010853/202111(0)
- PSUSA/00010853/202211(0)
- PSUSA/00010854/202104(0)
- PSUSA/00010864/202101(0)
- PSUSA/00010867/202101(0)
- PSUSA/00010877/202107(0)
- PSUSA/00010881/202106(0)
- PSUSA/00010881/202206(0)
- PSUSA/00010883/202204(0)
- PSUSA/00010913/202306(0)
- PSUSA/00010929/202210(0)
- PSUSA/00010956/202207(0)
- PSUSA/00010956/202307(0)
- PSUSA/00010957/202204(0)
- PSUSA/00010957/202304(0)
- PSUSA/00011039/202307(0)
- PSUSA/0002066/201510(0)
- PSUSA/0009060/201504(0)
- PSUSA/0009162202103(0)
- PSUSA/0058/201807(0)
- PSUSA/0464/201907(0)
- PSUSA/10381/201704(0)
- PSUSA/10510/202301(0)
- PSUSA 00000048/201506(0)
- PSUSA00000230201802(0)
- PSUSA00000778202212(0)
- PSUSA00001457201708(0)
- PSUSA00001694202103(0)
- PSUSA00001781201701(0)
- PSUSA00001811202207(0)
- PSUSA00002067202010(0)
- PSUSA00002110202305(0)
- PSUSA00002152201902(0)
- PSUSA00002641202304(0)
- PSUSA00002656202202(0)
- PSUSA00002993202109(0)
- PSUSA00009182201812(0)
- PSUSA 00010239202108(0)
- PSUSA00010291202106(0)
- PSUSA00010312202301(0)
- PSUSA00010583201801(0)
- Psychedelics and their therapeutic use Linkedin Live interview with Steffen Thirstrup EMAs Chief Medical Officer(0)
- Psyllii semen(0)
- Public access to suspected side effect reports of veterinary medicines(0)
- Publication of clinical reports(0)
- Publications(0)
- Public consultation concerning the European Union template for good manufacturing practice GMP noncompliance statement(0)
- Public consultation Draft report on the development of a harmonised approach to exposure assessment methodologies for residues from veterinary medicinal products feed additives and pesticides in food of animal origin(0)
- Public consultation on a multistakeholder platform to improve clinical trials in the EU(0)
- Public consultation on application of transparency rules of EU Clinical Trial Regulation(0)
- Public consultation on key principles for the electronic product information of EU medicines(0)
- Public consultation on reflection paper on prophylactic use of antimicrobials in animals(0)
- Public consultation on the publication and access to clinicaltrial data now closed(0)
- Public consultation open on concept paper on pharmacogenomics in evaluation of authorised medicines(0)
- Public consultation open on guideline on the acceptability of names for human medicines(0)
- Public consultation open on phasingin of black symbol for medicines under additional monitoring(0)
- Public consultation opens on draft guideline on biosimilars containing lowmolecularweight heparins(0)
- Public consultation opens on draft guideline on clinical investigation of medicinal products for treatment of acute heart failure(0)
- Public consultation opens on European Medicines Agencys draft guide on monitoring of medical literature(0)
- Public consultation opens on standard paediatric investigation plans for two types of cancer in children(0)
- Public consultation opens on the revised guideline on good distribution practice of medicinal products for human use(0)
- Public consultation opens on the revised guideline on the evaluation of human anticancer medicines(0)
- Public consultation starts on first guideline on medicines for the treatment of lupus erythematous(0)
- Public consultation starts on PRIME a new scheme to optimise development of priority medicines and facilitate patients access(0)
- Public data from Article 57 database(0)
- Publicfriendly information on herbal medicines now available(0)
- Publichealth advice during COVID19 pandemic(0)
- Public health threats(0)
- Public hearing on 13 June 2018(0)
- Public hearing on quinolones and fluoroquinolones 23 speakers from 11 EU countries to share experience(0)
- Public hearings(0)
- Public information on medicine shortages(0)
- Public register of parallel distribution now available(0)
- Public stakeholder meeting approval safety monitoring and impact of COVID19 vaccines in the EU(0)
- Public stakeholder meeting development and authorisation of safe and effective COVID19 vaccines in the EU(0)
- Public stakeholder meeting on COVID19 vaccines and therapeutics in the EU(0)
- Public stakeholder meeting on the approval and rollout of COVID19 vaccines in the EU(0)
- Public statement Baraclude entecavir Occurrence of a resistant HIV variant in a patient coinfected with HIV and HBV(0)
- Public Statement Epoetins and the risk of tumour growth progression and thromboembolic events in cancer patients and cardiovascular risks in patients with chronic kidney disease(0)
- Public statement European Medicines Agency announces regulatory action on COX2 inhibitors(0)
- Public Statement European Medicines Agency starts review of the safety of epoetins(0)
- Public Statement on Benefix Nonacog alfa Intensive Postmarketing Surveillance for all New patients + New Clinical Trials(0)
- Public statement on concerns over unregulated medicinal products containing stem cells(0)
- Public Statement on Fee Reductions for Designated Orphan Medicinal Products(0)
- Public Statement on HerceptinNTrastuzumab New Pharmacokinetic Data(0)
- Public statement on infliximab Remicade on the increased incidence of mortality and hospitalisation for worsening congestive heart failure(0)
- Public statement on infliximab Remicade Update on safety concerns(0)
- Public statement on Insuman Infusat 100IU/ml solution for injection in cartridges of 315 ml insulin human Risk of leakage during use(0)
- Public statement on interaction between clopidogrel and protonpump inhibitors(0)
- Public Statement on Leflunomide Arava Pancytopenia and Serious Skin Reactions(0)
- Public Statement on Levacetylmethadol Orlaam Life Threatening Cardiac Rhythm Disorders(0)
- Public Statement on Metalyse Tenecteplase importance of correct product handling syringevial assembly(0)
- Public Statement on Orlaam Levacetylmethadol Life threatening Ventricular Rhythm Disorders(0)
- Public statement on Parecoxib Sodium Dynastat/Rayzon/Xapit on the risk of serious hypersensitivity and skin reactions(0)
- Public statement on possible interaction between clopidogrel and proton pump inhibitors(0)
- Public Statement on Rapilysin Reteplase Incompatibility with Heparin and Precipitation following the Reconstitution Important New Instructions for Use(0)
- Public statement on Remicade infliximab Reports of tuberculosis infections(0)
- Public Statement on Sifrol Daquiran Mirapexin Pramipexole Recommendation to Reinforce the Warningon the sudden onset of sleep(0)
- Public Statement onSifrol Daquiran Mirapexin Pramipexole Sudden onset of sleep(0)
- Public statement on supply of Norvir hard capsules(0)
- Public statement on the cessation of marketing of exubera Insulin human(0)
- Public statement on the current shortage of radiopharmaceuticals in the European Union(0)
- Public statement on the increased risk of serious infection and neutropenia in patients treated concurrently with Kineret anakinra and Enbrel etanercept(0)
- Public statement on the recommendation to lift the suspension of the marketing authorisation for Optison perflutren(0)
- Public Statement on the risk of drug interactions with Hypericum perforatum St Johns Wort and antiretroviral medicinal products(0)
- Public statement on the use of herbal medicinal products containing toxic unsaturated pyrrolizidine alkaloids PAs including recommendations regarding contamination of herbal medicinal products with PAs(0)
- Public Statement on Trovan / Trovan IV / Turvel / Turvel IV Trovafloxacin/Alatrofloxacin recommendation to suspend the marketing authorisation in the European Union(0)
- Public Statement on Trovan/Trovan IV/Turvel/Turvel IV Trovafloxacin/Alatrofloxacin Serious severe and unpredictable liver injuries(0)
- Public Statement on Trovan IV and Turvel IV(0)
- Public Statement on Viagra and Patrex(0)
- Public Statement on Viramune Nevirapine Severe and LifeThreatening Cutaneous and Hepatic Reactions(0)
- Public Statement on Ziagen Abacavir Abacavir hypersensitivity cases following an interruption of therapy(0)
- Public Statement on Ziagen Abacavir Important safety Information on Hypersensitivity Reactions and Respiratory Symptoms(0)
- Public statement Risk of peripheral neuropathy with Sebivo telbivudine(0)
- Public statement Vasovist and nephrogenic systemic fibrosis NSF(0)
- Puldysa(0)
- Pulmotil AC(0)
- Pulmotil Premix(0)
- Pulsaflox(0)
- Pumarix(0)
- Puregon(0)
- Purevax FeLV(0)
- Purevax Rabies(0)
- Purevax RC(0)
- Purevax RCCh(0)
- Purevax RCP(0)
- Purevax RCPCh(0)
- Purevax RCPCh FeLV(0)
- Purevax RCP FeLV(0)
- Purified antigen fractions of inactivated split virion Influenza A/Indonesia/5/05 H5N1(0)
- Pylclari(0)
- Pylobactell(0)
- PyloriChek(0)
- Pyramax(0)
- Pyrukynd(0)
- Pyry Valitalo(0)
- Pyzchiva(0)
- Q&A Article 20 pharmacovigilance procedures(0)
- Q&A Extension applications(0)
- Q&A Good clinical practice GCP(0)
- Q&A Grouping of variations(0)
- Q&A Type II variations(0)
- Q&A Type II variations vs Extension applications(0)
- Q&A Worksharing of variations(0)
- Qaialdo(0)
- Qalsody(0)
- Qarziba previously Dinutuximab beta EUSA and Dinutuximab beta Apeiron(0)
- Qdenga(0)
- Qinlock(0)
- Qinprezo(0)
- Qizenday(0)
- QRD guidance on the use of approved pictograms on the packaging of veterinary medicinal products authorised via the centralised mutual recognition and decentralised procedures Species pictograms(0)
- Qsiva(0)
- Qtern(0)
- Qtrilmet(0)
- Quadramet(0)
- Quadrisol(0)
- Qualification of nongenotoxic impurities Scientific guideline(0)
- Qualification of novel methodologies for medicine development(0)
- Quality active substance(0)
- Quality and equivalence of topical products Scientific guideline(0)
- Quality and safety assessment for the plasma master file PMF certification with regard to donor deferral criteria for sexual risk behaviour Scientific guideline(0)
- Quality aspects included in the product information for vaccines for human use Scientific guideline(0)
- Quality aspects of pharmaceutical veterinary medicines for administration via drinking water Scientific guideline(0)
- Quality aspects of singledose veterinary spoton products Scientific guideline(0)
- Quality aspects on the isolation of candidate influenza vaccine viruses in cell culture Scientific guideline(0)
- Quality assessors training(0)
- Quality availability limited markets(0)
- Quality availability minor uses/minor species(0)
- Quality by design(0)
- Quality by design questions and answers(0)
- Quality data requirements for applications for biological veterinary medicinal products intended for limited markets Scientific guideline(0)
- Quality data requirements for applications for veterinary medicinal products other than biologicals intended for limited markets Scientific guideline(0)
- Quality defects and recalls(0)
- Quality documentation for medicinal products when used with a medical device Scientific guideline(0)
- Quality Drafting Group(0)
- Quality excipients(0)
- Quality guidelines(0)
- Quality impurities(0)
- Quality Innovation Group(0)
- Quality lifecycle management(0)
- Quality manufacturing(0)
- Quality Multidisciplinary(0)
- Quality nonclinical and clinical aspects of live recombinant viral vectored vaccines Scientific guideline(0)
- Quality nonclinical and clinical aspects of medicinal products containing genetically modified cells Scientific guideline(0)
- Quality nonclinical and clinical issues relating specifically to recombinant adenoassociated viral vectors Scientific guideline(0)
- Quality nonimmunologicals(0)
- Quality of biological active substances produced by stable transgene expression in higher plants Scientific guideline(0)
- Quality of biological active substances produced by transgene expression in animals Scientific guideline(0)
- Quality of combination herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Quality of essential oils as active substances in herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Quality of herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Quality of medicines Q&A Introduction(0)
- Quality of medicines Q&A Introduction(0)
- Quality of medicines questions and answers Part 1(0)
- Quality of medicines questions and answers Part 2(0)
- Quality of modified release dosage forms for veterinary use Scientific guideline(0)
- Quality of oral modified release products Scientific guidelines(0)
- Quality of transdermal patches Scientific guideline(0)
- Quality of water for pharmaceutical use Scientific guideline(0)
- Quality of water used in the production of vaccines for parenteral use Scientific guideline(0)
- Quality packaging(0)
- Quality pharmaceutical development(0)
- Quality post approval change management protocols(0)
- Quality preclinical and clinical aspects of gene therapy medicinal products Scientific guideline(0)
- Quality Quality by Design QbD(0)
- Quality safety and efficacy of bacteriophages as veterinary medicines Scientific guideline(0)
- Quality specifications analytical procedures and analytical validation(0)
- Quality specific types of products(0)
- Quality stability(0)
- Quality Working Party(0)
- Quality Working Party questions and answers on API mix Scientific guideline(0)
- Quarterly system demo Q1 2022(0)
- Quarterly system demo Q1 2023(0)
- Quarterly System Demo Q1 2024(0)
- Quarterly system demo Q2 2022(0)
- Quarterly system demo Q2 2023(0)
- Quarterly system demo Q3 2022(0)
- Quarterly system demo Q3 2023(0)
- Quarterly system demo Q4 2022(0)
- Quarterly system demo Q4 2023(0)
- Quercus cortex(0)
- Questions & answers EU actions to prevent medicine shortages due to Brexit(0)
- Questions and answers Article 13 referral procedures(0)
- Questions and answers Article 20 nonpharmacovigilance procedures(0)
- Questions and answers Article 30 referral procedures(0)
- Questions and answers Article 31 nonpharmacovigilance referrals(0)
- Questions and answers Article 31 pharmacovigilance referrals(0)
- Questions and answers Article 35 veterinary referral procedures(0)
- Questions and answers Article 294 referral procedures(0)
- Questions and answers for biological medicinal products(0)
- Questions and answers on bovine spongiform encephalopathies BSE and vaccines Scientific guideline(0)
- Questions and answers on comparability considerations for advanced therapy medicinal products ATMP Scientific guideline(0)
- Questions and answers on data requirements when transitioning to low global warming potential LGWP propellants in oral pressurised metered dose inhalers Scientific guideline(0)
- Questions and answers on gene therapy Scientific guideline(0)
- Questions and Answers on how to use a CEP in the context of a Marketing Authorisation Application or a Marketing Authorisation Variation(0)
- Questions and Answers on ketoprofen ketorolac and piroxicam(0)
- Questions and answers on management of extraneous agents in immunological veterinary medicinal products IVMPs Scientific guideline(0)
- Questions and answers on post approval change management protocols Scientific guideline(0)
- Questions and answers on quality of herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Questions and answers on requirements for preclinical studies submitted in support of a marketing authorisation application for a veterinary medicinal product Scientific guideline(0)
- Questions and answers on the CHMP recommendation to allow Viracept back onto the market(0)
- Questions and answers on the guideline on the clinical investigation of corticosteroids intended for use on the skin Scientific guideline(0)
- Questions and answers on the guideline on the environmental risk assessment of medicinal products for human use(0)
- Questions and answers on the Haemagglutination Inhibition HI test for qualification of influenza vaccine inactivated seed preparations Scientific guideline(0)
- Questions and answers on the possibility to extrapolate preinactivation titres as part of validation of an inactivation process Scientific guideline(0)
- Questions and answers on the withdrawal of the note for guidance on single dose toxicity Scientific guideline(0)
- Questions and answers Orphandesignation application(0)
- Questions and answers Urgent Union procedures Article 107i(0)
- Quinolones(0)
- Quinsair(0)
- Quintanrix(0)
- Quirine Fillekes(0)
- Quirin Werthner(0)
- Quixidar(0)
- Quofenix(0)
- Quofenix / Quinsair(0)
- Qutavina(0)
- Qutenza(0)
- Quviviq(0)
- Quynh Nguyen(0)
- R(0)
- Rabigen SAG2(0)
- Rabitec(0)
- Radhakrishnan Rajaratnam(0)
- Radicava(0)
- Radina Dimitrova(0)
- Radiopharmaceuticals Scientific guideline(0)
- Radka Cerychova(0)
- Radka Smítalová(0)
- Radoslav Ruitchev(0)
- Radost Asenova(0)
- Radu Tanasescu(0)
- Rafael Delgado(0)
- Rafael Delgado y Palacios(0)
- Rafaella Pontou(0)
- Rafael Olecki(0)
- Raffaele Badolato(0)
- Raffaella Sardelli(0)
- Ragnhild Mehli(0)
- Ragnhildur Heidarsdottir(0)
- Raimondas Benetis(0)
- Rainer Gnibl(0)
- Rainer Kahlich(0)
- Raising awareness of the perils of antimicrobial resistance(0)
- Ralf Gerwers(0)
- Ralf Meyer(0)
- Ralf Rest(0)
- Ralf Sanzenbacher(0)
- Raligize(0)
- Raloxifene Teva(0)
- Raltegravir Viatris(0)
- Raltitrexed(0)
- Raluca Mihaela Andreescu(0)
- Raman Velayudhan(0)
- Ramelteon(0)
- Ramiro Casimiro(0)
- Ramla Hamada(0)
- Ramona Mirzaei(0)
- Ramon Lorenzo Gomez(0)
- Ramon van Poppel(0)
- Ramvocid(0)
- Ranbaxy Toansa assessment concluded no risk to public health(0)
- Randi Ingebjørg Krontveit(0)
- Ranexa previously Latixa(0)
- Ranivisio(0)
- Rapamune(0)
- Rapilysin(0)
- Rapiscan(0)
- Raplixa(0)
- Raptiva(0)
- RAQUEL GARCIA NAVARRO(0)
- Raquel Gutiérrez Machín(0)
- Raquel Martin Palomeque(0)
- Rare Disease Day 28 February 2011(0)
- Rare Disease Day 29 February 2012(0)
- Rare Disease Day 2014 twelve new orphan medicines available to patients over the past year(0)
- Rare Disease Day 2015(0)
- Rasagiline Mylan(0)
- Rasagiline ratiopharm(0)
- Rasa Judickiene(0)
- Rasilamlo(0)
- Rasilez(0)
- Rasilez HCT(0)
- Rasitrio(0)
- Rasival(0)
- Rasmus Henninger(0)
- Ratioepo(0)
- Ratiograstim(0)
- Raul Belmar Liberato(0)
- Raute Kallin(0)
- Ravicti(0)
- Raxone(0)
- Raylumis(0)
- Raymond Anderson(0)
- Rayoqta(0)
- Rayvow(0)
- Rayzon(0)
- Razvan Cioc(0)
- R Braham(0)
- RDACTION / EMA / DG SANTE workshop how European Reference Networks can add value to clinical research(0)
- Reagila(0)
- Real time release testing Scientific guideline(0)
- Real world research on medicines contribution of the European Network of Centres in Pharmacoepidemiology and Pharmacovigilance ENCePP(0)
- Reanalysis of data on use of breast cancer medicine Tyverb following treatment with trastuzumab(0)
- Reasanz(0)
- REBECA GIL(0)
- Rebeca Gonzalez Gregori(0)
- Rebecca BarlowNoone(0)
- Rebecca Bromley(0)
- Rebecca Faresjö Melander(0)
- Rebecca Moore(0)
- Rebetol(0)
- Rebif(0)
- Reblozyl(0)
- Recarbrio(0)
- Recocam(0)
- Recommendation on the evaluation of the benefitrisk balance of veterinary medicinal products(0)
- Recommendations for use of aminoglycosides in animals to reduce risk of antimicrobial resistance(0)
- Recommendations issued for 2011/2012 seasonal flu vaccine composition(0)
- Recommendations on labelling and packaging for nonprescription medicines released for consultation(0)
- Recommendations on medication errors(0)
- Recommendations to restrict use of fosfomycin antibiotics(0)
- Recommendation to restrict the use of Protelos / Osseor strontium ranelate(0)
- Recommendation to suspend tetrazepamcontaining medicines endorsed by CMDh(0)
- Reconcile(0)
- Record number of medicines for rare diseases recommended for approval in 2014(0)
- Recothrom(0)
- Recruitment procedure for new Executive Director of the European Medicines Agency started(0)
- Recuvyra(0)
- Redistribution of UKs portfolio of centrally authorised products(0)
- Redmer Van Leeuwen(0)
- Reducing offlabel use of antimicrobials in veterinary medicine to reduce risk of resistance(0)
- Reducing risks to human and animal health from exposure to Nmethyl pyrrolidone in veterinary medicines(0)
- Reducing the use of antimicrobial agents in animal husbandry(0)
- Reduction elimination or substitution of thiomersal in vaccines Scientific guideline(0)
- Reestablishment of working seeds and working cell banks using TSE compliant materials Scientific guideline(0)
- ReFacto AF(0)
- Referentials Management Service RMS(0)
- Referral opinions pending EC decision(0)
- Referral procedures human medicines(0)
- Referral procedures Regulatory and procedural guidance(0)
- Referral procedures veterinary medicines(0)
- Referrals procedures(0)
- Refixia(0)
- Reflection paper on classification of advanced therapies released for public consultation(0)
- Reflection paper on investigation of pharmacokinetics in the obese population Scientific guideline(0)
- Reflection paper on resistance in ectoparasites Scientific guideline(0)
- Reflection paper on the application of Regulation EU 2019/6 for certain categories of variations(0)
- Reflection paper on the reasons and timelines for revision of final European Union herbal monographs and list entries(0)
- Reflection paper on the use of artificial intelligence in the lifecycle of medicines(0)
- Reflection paper on the use of measurable residual disease as a clinical endpoint in multiple myeloma studies Scientific guideline(0)
- Reflection papers on regulatory requirements for the development of medicinal products for chronic noninfectious liver diseases PBC PSC NASH Scientific guideline(0)
- Refludan(0)
- Regina GassnerOber(0)
- Regina Wolf(0)
- Regine Magdalene Lehnert(0)
- Registration(0)
- Registration open for Committee for Advanced Therapies stakeholders workshop(0)
- Registration open for conference on advanced therapies(0)
- Registration open for EMA/EFPIA Info Day 23 May 2011(0)
- Registration open for EMA/IFAHEurope Info Day 1011 March 2011(0)
- Registration open for orphanproductdesignation and grant workshop(0)
- Registration open for PDA/EMA 2011 Conference 35 May 2011(0)
- Registration open for workshop on access to clinicaltrial data and transparency(0)
- Registration open for workshop on the clinical investigation of medicines for the treatment of multiple sclerosis(0)
- Registration opens for EMA workshop on the clinical investigation of medicines for the treatment of Alzheimers disease(0)
- Registration opens for FDA/EMA orphan product designation and grant workshop(0)
- Registration opens for joint EMA/FDA/MHLWPMDA orphan medicinal product workshop(0)
- Registration opens for workshop of the European Network of Paediatric Research at the European Medicines Agency(0)
- Registration opens for workshop on clinical trial design in neuromyelitis optica to facilitate global medicine development in a rare and serious disease(0)
- Registration opens for workshop on conflicts of interests(0)
- Registration opens for workshop on dose finding at the European Medicines Agency(0)
- Registration opens for workshop on EMAHTA parallel scientific advice in drug development(0)
- Regkirona(0)
- Regranex(0)
- Regula Johner(0)
- Regulation of advanced therapy medicines(0)
- Regulation of Human medicines(0)
- Regulation of Human medicines News(0)
- Regulation on EMAs extended mandate becomes applicable(0)
- Regulators advice can make a difference for faster patient access to highly innovative therapies(0)
- Regulators in EU Japan and US take steps to facilitate development of new antibiotics(0)
- Regulatory acceptance of 3R replacement reduction refinement testing approaches Scientific guideline(0)
- Regulatory and scientific virtual conference on RNAbased medicines(0)
- Regulatory awareness session on medical devices Webinar(0)
- Regulatory Cooperation Expanded(0)
- Regulatory cooperation to improve global health(0)
- Regulatory flexibility to ensure availability of veterinary medicines during COVID19 pandemic(0)
- Regulatory guidance for industry to prepare for the UKs withdrawal from the EU(0)
- Regulatory guidance for pharmaceutical companies to prepare for UKs withdrawal from EU(0)
- Regulatory guidance for the use of healthrelated quality of life HRQL measures in the evaluation of medicinal products Scientific guideline(0)
- Regulatory harmonisation of clinical trials in the EU Clinical Trials Regulation to enter into application and new Clinical Trials Information System to be launched(0)
- Regulatory information 03% and 53% increase in general fees from 1 April 2022(0)
- Regulatory information 16% increase in fees from 1 April 2020(0)
- Regulatory information 17% and 16% increase of pharmacovigilance fees from 1 November 2020(0)
- Regulatory information 17% increase of fees from 1 April 2018(0)
- Regulatory information 17% increase of fees from 1 April 2019(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2016(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2017(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2018(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2019(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2020(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2023(0)
- Regulatory information adjusted fees for applications to EMA from 1 April 2024(0)
- Regulatory information adjusted fees for applications to European Medicines Agency from 1 April 2014(0)
- Regulatory information Adjusted fees for applications to European Medicines Agency from 1 April 2015(0)
- Regulatory information adjusted fees for applications to European Medicines Agency from 1 April 2016(0)
- Regulatory information adjusted fees for pharmacovigilance applications from 3 October 2022(0)
- Regulatory information adjusted fees for pharmacovigilance applications from 18 October 2018(0)
- Regulatory information adjusted fees for pharmacovigilance applications to EMA from 12 February 2018(0)
- Regulatory information adjusted fees for pharmacovigilance applications to EMA from January 2018(0)
- Regulatory information adjustment of linguistic review timetable for opinions adopted at December CHMP meeting(0)
- Regulatory information A new operating model for procedure management to improve support for evaluation procedures(0)
- Regulatory information application deadline for participation in informationsharing pilot project for generics extended(0)
- Regulatory information Changes in SME registration procedures to reduce administrative burden(0)
- Regulatory information Committee chairs handwritten signatures no longer included in opinion documents from March 2015(0)
- Regulatory information Companies now required to update complete and improve quality of information on authorised medicines submitted to the European Medicines Agency(0)
- Regulatory information Electronic application becomes mandatory today(0)
- Regulatory information EMA announces next steps for the maintenance of information on authorised medicines by marketingauthorisation holders(0)
- Regulatory information EMA clarifies interpretation of new variation classification categories(0)
- Regulatory information EMA encourages companies to submit quality typeI variations for 2013 by end of November(0)
- Regulatory information EMA encourages companies to submit type I variations and transfer of marketing authorisation applications for 2015 by end of November(0)
- Regulatory information EMA improves its guidance for postauthorisation activities(0)
- Regulatory information EMA introduces product numbers to track medicines through preauthorisation procedures(0)
- Regulatory information EMA introduces weekly start dates for the assessment of type II variations from March 2015(0)
- Regulatory information EMA issues recommendations for 2014/2015 seasonal flu vaccine composition(0)
- Regulatory information EMA provides advice notes on pharmacovigilance annual fees(0)
- Regulatory information EMA releases practical guidance on accesstodocuments requests(0)
- Regulatory information eSubmission Gateway or web client mandatory for all eCTD submissions through the centralised procedure from 1 March 2014(0)
- Regulatory information EU recommendations for 2015/2016 seasonal flu vaccine composition(0)
- Regulatory information EU recommendations for composition of 2016/2017 seasonal influenza vaccines(0)
- Regulatory information European Medicines Agency introduces digital signatures for selected procedures(0)
- Regulatory information European Medicines Agency organises training sessions on eSubmission Gateway and web client for PSUR singleassessment submissions(0)
- Regulatory information European Medicines Agency publishes guidance on validation process for initial marketing authorisation(0)
- Regulatory information European Medicines Agency revises rules on fees(0)
- Regulatory information European Medicines Agency updates guidance on European Union periodicsafetyupdatereport single assessment for nationally authorised medicines(0)
- Regulatory information Further guidance on adaptive licensing pilot project available(0)
- Regulatory information Green light for reliance on Article 57 database for key pharmacovigilance information on medicines for human use in Europe(0)
- Regulatory information Management of changes to risk management plans and certain quality aspects simplified(0)
- Regulatory information Mandatory use of common repository for human centralised procedures as of today(0)
- Regulatory information new formatted table template to be used in selected veterinary procedural submission cover letters(0)
- Regulatory information New guidance on type II variations and marketing authorisation extensions for orphandesignated medicines(0)
- Regulatory information New tool for companies to facilitate maintenance of information on authorised medicines(0)
- Regulatory information Paediatric guidance revised to reflect changes to European Commission guideline(0)
- Regulatory information reflection on chemical structure and properties to be considered for the evaluation of new active substance status(0)
- Regulatory information Replacement of GCP noncompliant pivotal studies in centralised marketingauthorisation applications not accepted(0)
- Regulatory information Revised dossiersubmission requirements for activesubstance master files(0)
- Regulatory information revised guideline on acceptability of names for human medicines is published(0)
- Regulatory information Revision of procedural guidance to reflect update of variations guidelines from the European Commission(0)
- Regulatory information Rules on fees are revised(0)
- Regulatory information Simplification of submission of product information updates in periodic safety update reports for nationally authorised products(0)
- Regulatory information Transitioning to mandatory use of electronic application forms(0)
- Regulatory information Updated SME user guide now available(0)
- Regulatory information Updated variations application form for human and veterinary medicines(0)
- Regulatory information Update of EMA recommendations for 2015/2016 seasonal flu vaccine composition(0)
- Regulatory information Updates to product information templates for all medicines for human use(0)
- Regulatory information use of eSubmission Gateway and web client extended to new procedure types from 1 April 2014(0)
- Regulatory information User testing of electronic application forms underway(0)
- Regulatory requirements for the authorisation of lowdose modifiedrelease acetylsalicylicacid formulations in the secondary prevention of cardiovascular events Scientific guideline(0)
- Regulatory requirements for the development of medicinal products for Acute Kidney Injury AKI Scientific guideline(0)
- Regulatory requirements for vaccines intended to provide protection against variant strains of SARSCoV2 Scientific guideline(0)
- Regulatory science research(0)
- Regulatory science research needs(0)
- Regulatory science research needs launch event(0)
- Regulatory science strategy(0)
- Regulatory Science to 2025 launch of sixmonth public consultation(0)
- Regulatory science to 2025 live broadcast of postconsultation workshop(0)
- Regulatory science to 2025 live broadcast of postconsultation workshop on veterinary medicines(0)
- Regulatory update All referral procedures to be sent via eSubmission Gateway / Web Client from 1 November 2014(0)
- Regulatory update Changes to scientific advice procedures as of 17 November 2014(0)
- Regulatory update EMA encourages companies to submit quality type I variations for 2014 by end of November(0)
- Regulatory update EMA encourages companies to submit typeI variations for 2014 by end of November(0)
- Regulatory update EMA encourages companies to submit type I variations for 2015 by end of November(0)
- Regulatory update EMA encourages companies to submit Type I variations for 2016 by end of November(0)
- Regulatory update EMA encourages companies to submit type I variations for 2017 by end of November(0)
- Regulatory update EMA encourages companies to submit type I variations for 2018 by end of November 2018(0)
- Regulatory update EMA encourages companies to submit type I variations for 2019 by end of November 2019(0)
- Regulatory update EMA encourages companies to submit type I variations for 2020 by end of November(0)
- Regulatory update EMA encourages companies to submit type I variations for 2021 in November 2021(0)
- Regulatory update EMA encourages companies to submit type I variations for 2022 by end of November(0)
- Regulatory workshop for Parallel Distributors(0)
- Regulatory workshop on clinical trials designs in neuromyelitis optica and spectrum disorders(0)
- Reinforced EU/US collaboration on medicines(0)
- Reinforcing communication with patients and healthcare professionals(0)
- Reinforcing patient safety in Europe(0)
- Reinhard Länger(0)
- Rekambys(0)
- Rekovelle(0)
- Relaunched EMA website now live(0)
- Release of documents on two medicines temporarily halted(0)
- Relenza(0)
- Reliance GeneMedix Plc withdraws its marketing authorisation application for Epostim erythropoietin(0)
- Relistor(0)
- Relocation to Amsterdam(0)
- Relvar Ellipta(0)
- Remco Merkx(0)
- Remicade(0)
- Remicade / Flixabi / Inflectra / Remsima / Zessly(0)
- Reminder to applicants regarding requirements for all future eCTD submissions(0)
- Reminder to applicants regarding requirements for future eCTD submissions(0)
- Remote connection to EMA IT Systems(0)
- Removab(0)
- Removing an orphan designation(0)
- Remsima(0)
- Renaat Peleman(0)
- Renagel(0)
- Renana Rabe(0)
- Renata Golasikova(0)
- Renata Kovacova(0)
- Renata Rupcic(0)
- Renata Skalska(0)
- Renate Kuske(0)
- René Anour(0)
- Rene Gieling(0)
- René Thürmer(0)
- René van Herwijnen(0)
- Renewal and annual reassessment of marketing authorisation(0)
- Renewals Regulatory and procedural guidance(0)
- RenuTend(0)
- Renvela(0)
- Renz Streit(0)
- Repaglinide Accord(0)
- Repaglinide Krka(0)
- Repaglinide productspecific bioequivalence guidance(0)
- Repaglinide Sun(0)
- Repaglinide Teva(0)
- Repatha(0)
- Repeated dose toxicity Scientific guideline(0)
- Replacement of cell lines used for the production of immunological veterinary medicinal products IVMPs Scientific guideline(0)
- Replacement of chlorofluorocarbons CFC in metered dose inhalation products Scientific guideline(0)
- Replacement of rabbit pyrogen testing by an alternative test for plasma derived medicinal products Scientific guideline(0)
- Replagal(0)
- RepliGen Europe Limited withdraws its marketing authorisation application for SecreFlo secretin human(0)
- Report and videos available from EnprEMA launch(0)
- Report available on activities on medicines for children during 2011(0)
- Report from the ADHOC working group meeting on herbal medicinal products 1997 1998(0)
- Report How EU ensured safety of medicines during COVID19(0)
- Reporting a falsified product to EMA(0)
- Reporting a quality defect to EMA(0)
- Reporting irregularities that may affect medicines(0)
- Reporting of physiologically based pharmacokinetic PBPK modelling and simulation Scientific guideline(0)
- Reporting requirements for marketingauthorisation holders(0)
- Reporting safety information on clinical trials(0)
- Reporting side effects of medicines(0)
- Reporting suspected side effects of medicines in patients with COVID19(0)
- Reporting the results of population pharmacokinetic analyses Scientific guideline(0)
- Report on EFPIA infoday 22 october 1999(0)
- Report on origins of clinical trial participants updated(0)
- Report published from workshop on ethics and GCP in clinical trials outside the European Union(0)
- Report published on the uses of medicines for children in the European Union(0)
- ReproCyc ParvoFLEX(0)
- Repso(0)
- Republic of Korea(0)
- Repurposing of authorised medicines pilot to support notforprofit organisations and academia(0)
- Repurposing of medicines pilot project webinar(0)
- Requesting certificates(0)
- Requesting scientific advice or protocol assistance from EMA(0)
- Requirements and controls applied to bovine serum used in the production of immunological veterinary medicinal products Scientific guideline(0)
- Requirements for an authorisation under exceptional circumstances for vaccines for emergency use against bluetongue(0)
- Requirements for an authorisation under exceptional circumstances for vaccines for use in birds against avian influenza(0)
- Requirements for clinical documentation for orally inhaled products including requirements for demonstration of therapeutic equivalence between 2 inhaled products for use in treatment of asthma & chronic obstructive pulmonary disease Scientific guideline(0)
- Requirements for combined vaccines and associations of immunological veterinary medicinal products IVMPs Scientific guideline(0)
- Requirements for concurrent administration of immunological veterinary medicinal products(0)
- Requirements for demonstrating therapeutic equivalence between orally inhaled products OIP for asthma and chronic obstructive pulmonary disease COPD(0)
- Requirements for demonstrating therapeutic equivalence between orally inhaled products OIP for asthma and chronic obstructive pulmonary disease COPD Scientific guideline(0)
- Requirements for plasma master file certification Scientific guideline(0)
- Requirements for quality documentation concerning biological investigational medicinal products in clinical trials Scientific guideline(0)
- Requirements for the production and control of immunological veterinary medicinal products Scientific guideline(0)
- Requirements for the quality production and control safety and efficacy of allergen products for use in horses dogs and cats Scientific guideline(0)
- Requirements for vaccine antigen master file certification Scientific guideline(0)
- Requirements for vaccines against footandmouth disease Scientific guideline(0)
- Requirements to the chemical and pharmaceutical quality documentation concerning investigational medicinal products in clinical trials Scientific guideline(0)
- Research and development(0)
- Research and development veterinary medicines(0)
- Resflor solution injectable and associated names(0)
- Reshma Autar(0)
- Resolor(0)
- Resources for academia(0)
- Resources for healthcare professionals(0)
- Respiporc Flu3(0)
- Respiporc FLUpan H1N1(0)
- Respivac TRT(0)
- Responding to emerging health threats in the EU(0)
- Respreeza(0)
- Restaysis(0)
- Restrictions in the use of flupirtinecontaining medicines CMDh endorses PRAC recommendation(0)
- Restrictions in use of cyproterone due to meningioma risk(0)
- Restrictions in use of Xeljanz while EMA reviews risk of blood clots in lungs(0)
- Restrictions on use of codeine for pain relief in children CMDh endorses PRAC recommendation(0)
- Restrictions on use of shortacting betaagonists in obstetric indications CMDh endorses PRAC recommendations(0)
- Retaane(0)
- Retacrit(0)
- Retisert(0)
- Retsevmo(0)
- Revasc(0)
- Revatio(0)
- Revestive(0)
- Review concludes evidence does not support that HPV vaccines cause CRPS or POTS(0)
- Review of Corlentor/Procoralan started(0)
- Review of emergency contraceptives started(0)
- Review of field safety data by the European Medicines Agency finds a goodsafety record for inactivated bluetongue emergency vaccines(0)
- Review of flupirtinecontaining medicines started(0)
- Review of hydroxyzinecontaining medicines started(0)
- Review of oral methadone medicines containing povidone started(0)
- Review of pholcodine medicines started(0)
- Review of testosteronecontaining medicines started(0)
- Review of the manufacture of Baxters peritoneal dialysis solutions initiated over potential presence of endotoxins in some batches(0)
- Review of transparency rules for the EU Clinical Trials Information System CTIS(0)
- Revinty Ellipta(0)
- Revised framework for development of influenza vaccines(0)
- Revised guideline aims to strengthen global approach to development of new antibacterial medicines(0)
- Revised guideline on biosimilars containing biotechnologyderived proteins published for public consultation(0)
- Revised guideline on clinical studies for Alzheimers disease medicines(0)
- Revised guideline on firstinhuman clinical trials(0)
- Revised guideline on quality of biosimilar medicines open for comments(0)
- Revised guidelines to encourage development of veterinary medicines for minor uses and minor species(0)
- Revised guideline to assess risk of human medicines for the environment(0)
- Revised public statement on Enbrel etanercept Serious haematological reactions(0)
- Revised timelines for certificates of pharmaceutical products CPPs and temporary arrangements during EMAs relocation(0)
- Revised transparency rules for the EU Clinical Trials Information System CTIS(0)
- Revised version of application form for initial evaluation of human medicines available(0)
- Revising the guideline on firstinhuman clinical trials(0)
- Revision of paediatricinvestigationplan guideline stakeholder comments sought by European Commission(0)
- RevitaCAM(0)
- Revlimid(0)
- Revocation of authorisation for sickle cell disease medicine Adakveo(0)
- Revolade(0)
- Rewards and incentives for paediatric medicines(0)
- Rexxolide(0)
- Reyataz(0)
- Rezolsta(0)
- Rezzayo(0)
- Rhamni purshianae cortex(0)
- Rhea Fitzgerald(0)
- Rhei radix(0)
- Rheumatology/Immunology Working Party(0)
- Rheumocam(0)
- Rhiniseng(0)
- Rhodiolae roseae rhizoma et radix(0)
- Rhokiinsa(0)
- Rhona McHugh(0)
- Rhucin(0)
- Rianne Opstelten(0)
- Riarify previously CHF 5993 Chiesi Farmaceutici SpA(0)
- Ribavirin(0)
- Ribavirin BioPartners(0)
- Ribavirin Mylan previously Ribavirin Three Rivers(0)
- Ribavirin Teva(0)
- Ribavirin Teva Pharma BV(0)
- Ribis nigri folium(0)
- Ricardo Carapeto García(0)
- Ricardo Cubedo(0)
- Riccardo Schiavo(0)
- Riccardo Serafini(0)
- Richard Carroll(0)
- Richard CejkaScheidl(0)
- Richard IJzerman(0)
- Richard OSullivan(0)
- Richard Wanko(0)
- Ricini oleum(0)
- Rickard Johannisson(0)
- Rick Greupink(0)
- Rienso(0)
- Riitta Niittyvuopio(0)
- Riitta Svahn(0)
- Rilonacept Regeneron previously Arcalyst(0)
- Rilpivirine productspecific bioequivalence guidance(0)
- Riltrava Aerosphere(0)
- Rilutek(0)
- Riluzole Zentiva(0)
- Rimmyrah(0)
- Rinvoq(0)
- Riprazo(0)
- Riprazo HCT(0)
- Riquent(0)
- Rise in applications for medicines in 2006 concerns over budget situation for 2007 and new transparency measures(0)
- Riskanalysis approach for residues of VMPs in food of animal origin Scientific guideline(0)
- Risk and regulatory assessment of lactose and other products prepared using calf rennet Scientific guideline(0)
- Risk assessment guideline focus group meeting(0)
- Risk assessment of medicinal products on human reproduction and lactation from data to labelling Scientific guideline(0)
- Riskbased approach according to Annex I part IV of Directive 2001/83/EC applied to Advanced Therapy Medicinal Products Scientific guideline(0)
- Risk based quality management in clinical trials workshop(0)
- Risk characterisation and assessment of maximum residue limits MRL for biocides Scientific guideline(0)
- Risk classification of antimicrobials used in animals opens for public consultation(0)
- Risk management(0)
- Risk management information day 2021(0)
- Risk management information day 2022(0)
- Risk management plan information day(0)
- Risk management plans(0)
- Risk management plans RMP in postauthorisation phase questions and answers(0)
- Risk management requirements for elemental impurities in veterinary medicinal products including immunological veterinary medicinal products Scientific guideline(0)
- Riskmitigation measures related to the environmental risk assessment of veterinary medicinal products Scientific guideline(0)
- Risk of antimicrobial resistance transfer from companion animals Scientific guideline(0)
- Risks associated with furocoumarins contained in preparations of Angelica archangelica L Scientific guideline(0)
- Risks associated with the use of herbal products containing Aristolochia species Scientific guideline(0)
- Risks of Picato for actinic keratosis outweigh benefits(0)
- Ristaben(0)
- Ristempa(0)
- Ristfor(0)
- Rita Lokiene(0)
- Rita MirzBierbaum(0)
- Rita Nemeth(0)
- Rita Offermann(0)
- Rita Pacello(0)
- Rita Quondam Giandomenico(0)
- Rita Rom(0)
- Ritemvia(0)
- Ritonavir Mylan(0)
- Rituximab Mabion(0)
- Rituzena previously Tuxella(0)
- Rivaroxaban Accord(0)
- Rivaroxaban productspecific bioequivalence guidance(0)
- Rivaroxaban Viatris previously Rivaroxaban Mylan(0)
- Rivastigmine 1 A Pharma(0)
- Rivastigmine 3M Health Care Ltd(0)
- Rivastigmine Actavis(0)
- Rivastigmine Hexal(0)
- Rivastigmine Sandoz(0)
- Rivastigmine Teva(0)
- Rixathon(0)
- Riximyo(0)
- Rixubis(0)
- Rizmoic(0)
- RoActemra(0)
- RoActemra / Hemlibra / Herceptin / Kadcyla / MabThera / Phesgo / Tecentriq(0)
- Roberta Agius(0)
- Roberta Ranalli(0)
- Robertas Lazauskas(0)
- Robert Burman(0)
- Robert Hoffmann(0)
- Robert Nistico(0)
- Roberto Cauda(0)
- Roberto Delogu(0)
- Roberto Frontini(0)
- Roberto Villa(0)
- Robert Perneczky(0)
- Robert Pollmann(0)
- Robert Porszasz(0)
- Robert Tomsin(0)
- Robin Doeswijk(0)
- Robine Donken(0)
- Robin Ristl(0)
- Robin Svensson(0)
- Robin Vos(0)
- Robrecht Dockx(0)
- Rob van Marum(0)
- Rocío Fernández Granda(0)
- Rocio Garcia Rodriguez(0)
- Roclanda(0)
- Roctavian(0)
- Roderick Houwen(0)
- Roeland Martijn Van der Plas(0)
- Roelie Marinus(0)
- Roelof Mol(0)
- Roel Van Loock(0)
- Roflumilast(0)
- Roger Pally(0)
- Roland Froetschl(0)
- Roland Pochet(0)
- Role of big data for evaluation and supervision of medicines in the EU(0)
- Role of pharmacokinetics in the development of medicinal products in the paediatric population Scientific guideline(0)
- Rolf Beckmann(0)
- Rolf Gedeborg(0)
- Rolufta Ellipta previously Rolufta(0)
- Romana Dorn(0)
- Roman Dorčík(0)
- Roman Górecki(0)
- Romano Danesi(0)
- Roman Polacek(0)
- Roman RomeroOrtuno(0)
- Roman Vangoitsenhoven(0)
- Ronald Bauer(0)
- ronan kilbride(0)
- Ronapreve(0)
- Ronaxan and its associated names(0)
- Ron Bijleveld(0)
- Ronnie Jansson(0)
- Rory Breathnach(0)
- Rosa Castro(0)
- Rosae flos(0)
- Rosa Giuliani(0)
- Rosalía Ruano Camps(0)
- Rosalie de Vries(0)
- Rosalinde Bot(0)
- Rosanne Meijboom(0)
- Rosa Pérez Antona(0)
- Rosario Bullido(0)
- Rosa Virto(0)
- Roselien Poppe(0)
- Rosemarie Potisk(0)
- Rosemary Heneghan(0)
- Rosemary Maher(0)
- Rosi Puniyani(0)
- Rosmarini aetheroleum(0)
- Rosmarini folium(0)
- Rosuvastatin calcium(0)
- Roswitha Merkel(0)
- Rotana AlShammari(0)
- Rotarix(0)
- Rotashield(0)
- RotaTeq(0)
- Roteas(0)
- Rotigotine Mylan(0)
- RouAfza Gunput(0)
- Routes of administration of vaccines to poultry Scientific guideline(0)
- Roxana Dondera(0)
- Roxana Stefania Udrescu(0)
- Roxane Fornacciari(0)
- Rozalina Kulaksazova(0)
- Rozlytrek(0)
- RSS feeds(0)
- Rubi idaei folium(0)
- Rucaparib camsylate(0)
- Ruchika Sharma(0)
- Ruchira Engel(0)
- Ruconest(0)
- Rudolf Schranz(0)
- Rugile Morkuniene(0)
- Rugile Pilviniene(0)
- Rui Castro(0)
- Rui Pedro da Costa Vilar(0)
- Rui Pinto(0)
- Rui Santos Ivo(0)
- Rukobia(0)
- Runa Hauksdottir Hvannberg(0)
- Rune Kjeken(0)
- Rusci rhizoma(0)
- Russell Wheeler(0)
- Russia(0)
- Ruta Buckiunaite(0)
- Ruta Jasote(0)
- Ruta Mameniskiene(0)
- Ruta Minderyte(0)
- Rut AnnaLena Axelson(0)
- Rutger de Vries(0)
- Rutger van den Bor(0)
- Rutger van den Broek(0)
- Ruth Demarco(0)
- Ruth Hoenow(0)
- Ruth Offergeld(0)
- Ruvise(0)
- Ruxience(0)
- Rxulti(0)
- ryan aliabarghooi(0)
- Ryan Kim(0)
- Rybelsus(0)
- Rybrevant(0)
- Rydapt(0)
- Ryeqo(0)
- Rystiggo(0)
- Ryte Giedrikaite(0)
- Ryzneuta(0)
- Ryzodeg(0)
- S(0)
- Sabalis serrulatae fructus(0)
- Sabervel(0)
- Sabina Ahlgren Porthén(0)
- Sabina Uzeirbegović(0)
- Sabine Elke Nußbaumer(0)
- Sabine Engel(0)
- Sabine Ernestine HeinzStempel(0)
- Sabine Linn(0)
- Sabine Mayrhofer(0)
- Sabine Ring(0)
- Sabine Scherer(0)
- Sabine Sereinig(0)
- Sabine Straus(0)
- Sabine Suenkler(0)
- Sabine Tannert(0)
- Sabine van der Putten de Brouwer(0)
- Sabrina Giacomelli(0)
- Sabrina Jenull(0)
- Sabrina Kneissl(0)
- Saccharomyces cerevisiae CBS 5926(0)
- Safer use of medicines by preventing medication errors(0)
- Safety and efficacy data requirements for applications for immunological VMPs intended for limited markets but not eligible for authorisation under Art 23 of Reg EU 20196 Scientific guideline(0)
- Safety and residue data requirements for applications for nonimmunological veterinary medicinal products intended for limited markets but not eligible for authorisation under Article 23 of Regulation EU 2019/6 Scientific guideline(0)
- Safety and residue data requirements for applications for nonimmunological veterinary medicinal products intended for limited markets submitted under Article 23 of Regulation EU 2019/6 Scientific guideline(0)
- Safety and residue data requirements for the establishment of maximum residue limits in minor species Scientific guideline(0)
- Safety and residue data requirements for veterinary medicinal products intended for minor use or minor species MUMS/limited market Scientific guideline(0)
- Safety and residues guidelines(0)
- Safety and residues multidisciplinary(0)
- Safety and residues pharmaceuticals(0)
- Safety monitoring of medicines EMA to screen medical literature for 400 active substance groups(0)
- Safety of COVID19 vaccines(0)
- Safety signals recommendations now available in all EU languages(0)
- Safety veterinary limited markets(0)
- Safety Working Party(0)
- Safety Working Party SWPV(0)
- Saila Antila(0)
- Sales of antibiotics for animal use decrease by 13% in Europe between 2011 and 2015(0)
- Sales of antibiotics for animal use have almost halved between 20112021(0)
- Sales of antibiotics for use in foodproducing animals drop across the EU(0)
- Sales of veterinary antibiotics continue to decline in most European countries(0)
- Salicis cortex(0)
- Sally Baylis(0)
- Sally Hofmeister(0)
- Salvatore Antonio Giuseppe Messana(0)
- Salvatore Tranchina(0)
- Salviae miltiorrhizae radix et rhizoma(0)
- Salviae officinalis aetheroleum(0)
- Salviae officinalis folium(0)
- Salviae trilobae folium(0)
- Sambuci flos(0)
- Sambuci fructus(0)
- Sami Paaskoski(0)
- Samira Alina Marx(0)
- Samo Jeverica(0)
- Sampling and testing(0)
- Sampling and testing questions and answers(0)
- Samsca(0)
- Samuel CROMMELYNCK(0)
- Samuel Silkestrand(0)
- Sancuso(0)
- Sandra Bertulat(0)
- Sandra Bright(0)
- Sandra De Boever(0)
- Sandra Frankemoell(0)
- Sandra Holt(0)
- Sandra Kress(0)
- Sandra Lopes(0)
- SandraMaria Wienhold(0)
- Sandra Mavoungou(0)
- Sandra Monteiro(0)
- Sandra Petraglia(0)
- Sandra Rieger(0)
- Sandra Schack(0)
- Sandra Schmidt(0)
- Sandra ten Voorde(0)
- Sandrine CHIAPPINI(0)
- Sandrine Graff de Faget(0)
- Sandrine Rougier(0)
- Sandrine Tinton(0)
- Sandy Vermout(0)
- Sanna Gevers(0)
- Sanne ten Dam(0)
- SanofiAventis Pharma SA withdraws its application for an extension of indication for Taxotere and Docetaxel Winthrop docetaxel(0)
- Sanofiaventis withdraws its marketing authorisation application forAquilda satavaptan(0)
- Sanofiaventis withdraws its marketing authorisation application for Mulsevo semuloparin sodium(0)
- Sanofi Aventis withdraws its marketing authorisation application for Sliwens eplivanserin(0)
- SanofiAventis withdraws marketing authorisation application for MULTAQ(0)
- Sanofi Pasteur withdraws its marketing authorisation application for Emerflu pandemic influenza vaccine H5N1 split virion inactivated adjuvanted(0)
- Sanofi Pharma BristolMyers Squibb SNC withdraws its marketing authorisation application for DuoPlavin(0)
- SanPo Pan(0)
- Santa Zirnite(0)
- Saphnelo(0)
- Sapropterin Dipharma(0)
- Sara Ambrosino(0)
- Sara ArenasLopez(0)
- Sara Brandel(0)
- Sara Brebbia Dirksen(0)
- Sara Camilleri(0)
- Sarada Das(0)
- Sara Franco(0)
- Sara Galluzzo(0)
- Sarah Abela Hili(0)
- Sarah AdlerFlindt(0)
- Sarah Beesley(0)
- Sarah Bendahou(0)
- Sarah Bolda(0)
- Sarah Brøgger Kristiansen(0)
- Sarah Brophy(0)
- Sarah Buckley(0)
- Sarah Collen(0)
- Sara Henry(0)
- Sarah Gadkarim(0)
- Sarah Gilgunn(0)
- Sarah Goossens(0)
- Sarah Hamels(0)
- Sarah Hanley(0)
- Sarah Kehr(0)
- Sarah Kellaghan(0)
- Sarah Lang(0)
- Sarah Pfaff(0)
- Sarah TKindt(0)
- Sarai Mestre(0)
- Sara Jagric Munih(0)
- Sara Luize Bangiere(0)
- Sara Sacristan Alvarez(0)
- Sara Tognarelli(0)
- Sara Vennberg(0)
- Sara Villa(0)
- Sara Vilske(0)
- Sarclisa(0)
- Sargi Caizergues Lama(0)
- Sarianne Paivike(0)
- Sari Koski(0)
- Sari Tähtiharju(0)
- Sari Tiitinen(0)
- Sarmite Kupca(0)
- Sartan medicines companies to review manufacturing processes to avoid presence of nitrosamine impurities(0)
- Sasa Martinc(0)
- Sashko Arsov(0)
- Saskia Bergervoet(0)
- Saskia Blonk(0)
- Satoko Hirokawa(0)
- Satu Suvanto(0)
- Saul Faust(0)
- Savene(0)
- Sawssen ELOUISI(0)
- Saxagliptin / metformin(0)
- Saxenda(0)
- Saxenda recommended for approval in weight management in adults(0)
- Sayeh Ahrabi(0)
- Scemblix(0)
- Scenesse(0)
- Scenesse recommended for rare disease that causes intolerance to sunlight(0)
- ScheringPlough Europe withdraws its marketing authorisation application for Cylatron peginterferon alfa2b(0)
- ScheringPlough Europe withdraws its marketing authorisation applicationfor Garenoxacin mesylate(0)
- ScheringPlough Europe withdraws its marketing authorisation application for Zenhale mometasone furoate/formoterol fumarate(0)
- Science and innovation for better medicines(0)
- Science Medicines Health Patients at the heart of future innovation(0)
- Science Medicines Health Patients at the heart of future innovation conference(0)
- Scientific advice(0)
- Scientific advice and protocol assistance(0)
- Scientific advice leads to stronger applications from industry(0)
- Scientific advice procedures(0)
- Scientific Advice Working Party(0)
- Scientific Advisory Group on Cardiovascular Issues(0)
- Scientific Advisory Group on Infectious Diseases(0)
- Scientific Advisory Group on Neurology(0)
- Scientific Advisory Group on Vaccines(0)
- Scientific and regulatory meetings procedures(0)
- Scientific and technical recommendations Veterinary Medicines Regulation(0)
- Scientific data requirements for a vaccine antigen master file Scientific guideline(0)
- Scientific data requirements for plasma master file Scientific guideline(0)
- Scientific guidance on postauthorisation efficacy studies Scientific guideline(0)
- Scientific guidelines(0)
- Scientific guidelines for limited market products deemed not eligible for authorisation under Article 23 of Regulation 2019/6(0)
- Scientific guidelines for veterinary medicines(0)
- Scientific guidelines paediatrics(0)
- Scientific publications(0)
- Scientific recommendations on classification of advanced therapy medicinal products(0)
- Scientific requirements for the environmental risk assessment of genetherapy medicinal products Scientific guideline(0)
- Scientific workshop on serology assays and correlates of protection for influenza vaccines(0)
- Scintimun(0)
- Scott Maurits(0)
- Seamus Cotter(0)
- Seamus Doyle(0)
- Sean Barry(0)
- Search tips(0)
- Sebastiaan Engelborghs(0)
- Sebastiaan Hoekema(0)
- Sebastian Mielcarek(0)
- Sebastian Wicha(0)
- Sebastien Hermant(0)
- Sebastjan Kralj(0)
- Sebivo(0)
- Second 2017 meeting of the coordinating group of the European network of paediatric research at the European Medicines Agency EnprEMA(0)
- Second annual scientific workshop at EMA Applying regulatory science to neonates(0)
- Second biannual Big Data Steering Group and industry stakeholders meeting(0)
- Second bilateral meeting between European Medicines Agency and Vaccines Europe(0)
- Second EMAEFPIA annual bilateral meeting(0)
- Second EMEA EGA Info Day Generic and Biosimilar Medicines in the Centralised Procedure(0)
- Second EMEA Workshop for Micro Small and MediumSized Enterprises SMEs Focus on Quality(0)
- Second European Medicines Agency & MedTech Europe bilateral meeting(0)
- Second European Medicines Agency and Affordable Medicines Europe bilateral meeting(0)
- Second European Medicines Agency and Nuclear Medicines Europe bilateral meeting(0)
- Second European Medicines Agency EMA and European Confederation of Pharmaceutical Entrepreneurs EUCOPE bilateral meeting(0)
- Second European Medicines Agency workshop on neurodegenerative diseases focus on dementia(0)
- Second European Network of Centres for Pharmacoepidemiology and Pharmacovigilance meeting with centres at the European Medicines Agency(0)
- Second industry stakeholder platform on research and development support(0)
- Second industry stakeholder platform on the operation of European Union pharmacovigilance legislation(0)
- Second industry stakeholder platform on the operation of the centralised procedure for human medicinal products(0)
- Second Industry Standing Group ISG meeting(0)
- Second information day on the new individual case safety report ICSR international standard and ICH E2B/M2(0)
- Second international awareness session for international regulators academia and nongovernmental organisations(0)
- Second international symposium on biopharmaceutical statistics(0)
- Second joint Drug Information Association/European Medicines Agency European Network of Centres for Pharmacoepidemiology and Pharmacovigilance ENCePP information day(0)
- Second joint Drug Information Association/European Medicines Agency statistics workshop(0)
- Second joint meeting of the EMA Scientific Committees Working Party with Patients and Consumers Organisations PCWP and the EMA/CHMP Working Group with Healthcare Professionals Organisations HCP WG(0)
- Second listenandlearn focus group meeting of the Quality Innovation Group(0)
- Second meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Second Meeting of the Management Board of the European Agency for the Evaluation of Medicinal Products(0)
- Second Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Second Nitrosamine Implementation Oversight Group NIOG meeting with pharmaceutical industry(0)
- Second paediatric strategy forum on medicine development for mature B cell malignancies in children(0)
- Second Patients and Consumers Working Party PCWP meeting with all eligible patients and consumers organisations(0)
- Second periodic safety update report information day(0)
- Second phase of public SME register goes live(0)
- Second stakeholder forum on the implementation of the new 2010 pharmacovigilance legislation(0)
- Second stakeholder meeting on the implementation of the European Medicines Agencys policy on publication of clinical data for human medicines(0)
- Second tripartite meeting held between EMA PMDA and FDA to discuss regulatory approaches for the evaluation of antibacterial agents(0)
- Second Veterinary Big Data stakeholder forum(0)
- Second veterinary esubmission workshop(0)
- Second workshop for the EMEA/CHMP Working Group with Patients Organisations(0)
- SecreFlo(0)
- Sedadex(0)
- Seebri Breezhaler(0)
- Seffalair Spiromax(0)
- Segluromet(0)
- Sejdë Tolaj(0)
- Selection of test materials for genotoxicity testing for traditional herbal medicinal products/herbal medicinal products Scientific guideline(0)
- Selincro(0)
- Seline KnuettelGustavsen(0)
- Selma Arapovic Dzakula(0)
- Semglee(0)
- Seminar on preclinical evaluation of vaccines current experience new adjuvants and future challenges(0)
- Seminar on recent developments in European Pharmacovigilance and Risk Management(0)
- Semintra(0)
- Sem Runge(0)
- Send a question form not working(0)
- Send a question form working again(0)
- Send a question to the European Medicines Agency(0)
- Sennae folium(0)
- Sennae fructus(0)
- Senshio(0)
- Senstend(0)
- Senvelgo(0)
- Sepioglin(0)
- Sepracor Pharmaceuticals Ltd withdraws its marketing authorisation application for Lunivia eszopiclone(0)
- Serena Marchetti(0)
- Serena Zamponi(0)
- Seresto and its associated name Foresto(0)
- Serge Bakchine(0)
- Sergejs Akulics(0)
- Sergio Todde(0)
- Serife Guenay Winter(0)
- Services and databases(0)
- Setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities Scientific guideline(0)
- Setting specifications for related impurities in antibiotics Scientific guideline(0)
- SEVDIJE RUSHITI(0)
- Sevelamer carbonate Winthrop previously Sevelamer carbonate Zentiva(0)
- Seventeenth Meeting of the Management Board(0)
- Seventh Framework Programme FP7 smallpopulation research methods projects and regulatory application workshop(0)
- Seventh industry stakeholder platform on research and development support(0)
- Seventh industry stakeholder platform operation of European Union pharmacovigilance legislation(0)
- Seventh Industry Standing Group ISG meeting(0)
- Seventh meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Seventh meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicine(0)
- Seventh Meeting of the Management Board(0)
- Seventh Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Seventh stakeholders forum on the implementation of the new pharmacovigilance legislation(0)
- SevoFlo(0)
- Sevohale previously known as Sevocalm(0)
- Sevsury(0)
- SGLT2 inhibitors information on potential risk of toe amputation to be included in prescribing information(0)
- SGLT2 inhibitors PRAC makes recommendations to minimise risk of diabetic ketoacidosis(0)
- Shaping a European innovation ecosystem EUInnovation network multistakeholder meeting(0)
- Shaping regulatory science to 2025(0)
- Shaping the future of human and animal health in the EU(0)
- Sharon Essink(0)
- Sharon Murphy(0)
- Shawgi Fiseifis(0)
- Sheila Killalea(0)
- Sheila Mc Nally(0)
- Shingrix(0)
- Shivani Chatterjee(0)
- Shotaflor(0)
- Sialanar(0)
- SIAMED 2000 speeding up drug regulation in Europe(0)
- Sibel Söker(0)
- Sibnayal(0)
- Sideritis herba(0)
- Sieglinde Zahorszki(0)
- Sif Ormarsdóttir(0)
- Sifrol(0)
- Signal detection and management information day(0)
- Signal management(0)
- Signal Management Review Technical SMART Working Group(0)
- Signal management veterinary medicines(0)
- signe Hertz Hansen(0)
- Signe Spanner(0)
- Signifor(0)
- Sigridur Kristinsdottir(0)
- Sigríður Erla Jonsdóttir(0)
- Sigurros Sigmarsdottir(0)
- Siklos(0)
- Silapo(0)
- Sildenafil Actavis(0)
- Sildenafil FGK(0)
- Sildenafil ratiopharm(0)
- Sildenafil Teva(0)
- Sileo(0)
- Silgard(0)
- Silke Bechlars(0)
- Silke Dorner(0)
- Silke Hickmann(0)
- Silke Schuele(0)
- Sille Graa Andreasen(0)
- Silodosin Recordati(0)
- Silodyx(0)
- Silvia Berkner(0)
- Silvia Borioni(0)
- Silvia Cârstoiu(0)
- Silvia Concolino(0)
- Silvia Francisci(0)
- Silvia Lommel(0)
- Silvia Panetta(0)
- Silvia Perez Lopez(0)
- Silvia Ravera(0)
- Silvia Vogl(0)
- Silvie Netopilova(0)
- Silvijus Abramavicius(0)
- Silviu Istrate(0)
- Silybi mariani fructus(0)
- Sima Naujokiene(0)
- Simbrinza(0)
- Similar biological medicinal products containing biotechnologyderived proteins as active substance nonclinical and clinical issues Scientific guideline(0)
- Similar biological medicinal products containing biotechnologyderived proteins as active substance quality issues Scientific guideline(0)
- Similar biological medicinal products containing interferon beta Scientific guideline(0)
- Similar biological medicinal products containing monoclonal antibodies nonclinical and clinical issues Scientific guideline(0)
- Similar biological medicinal products containing recombinant erythropoietins Scientific guideline(0)
- Similar biological medicinal products containing recombinant folliclestimulating hormone Scientific guideline(0)
- Similar biological medicinal products Scientific guideline(0)
- Similar medicinal products containing somatropin Annex to guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance nonclinical and clinical issues Scientific guideline(0)
- Simin OVEISI(0)
- Simona Badoi(0)
- Simona De Robertis(0)
- Simona Humar(0)
- Simona Raluca Manole(0)
- Simona Russo(0)
- Simona Teodosiu(0)
- Simon Degand(0)
- Simone Bergner(0)
- Simone Lehmann(0)
- Simonetta Filippi(0)
- Simonetta Pupella(0)
- Simone van der Meer(0)
- Simon Rögner(0)
- Simon Serge(0)
- Simparica(0)
- Simparica Trio(0)
- Simpler website navigation for regulatory information on human medicines(0)
- Simpler website navigation for regulatory information on veterinary medicines(0)
- Simplification of submission of applications for centrally authorised medicines(0)
- Simponi(0)
- Simulect(0)
- Simultaneous National Scientific Advice information and training webinar(0)
- Simvastatin / fenofibrate(0)
- Simvastatin / sitagliptin phosphate monohydrate(0)
- Sindri Kristjánsson(0)
- Sinead Harrington(0)
- Sinead Hewson(0)
- Sine Buhl NaessSchmidt(0)
- Sinerem(0)
- Singlearm trials as pivotal evidence for the authorisation of medicines in the EU(0)
- Single central platform now mandatory for all periodic safety update reports(0)
- Siniša Tomić(0)
- Siona Slob(0)
- Siri Wang(0)
- Sirlin ValgiTann(0)
- Sirolimus productspecific bioequivalence guidance(0)
- Sirturo(0)
- Sissela Soon Ae Liljeqvist(0)
- Sisymbrii officinalis herba(0)
- Sitagliptin / Metformin hydrochloride Accord(0)
- Sitagliptin / Metformin hydrochloride Mylan(0)
- Sitagliptin / Metformin hydrochloride Sun(0)
- Sitagliptin Accord(0)
- Sitagliptin phosphate monohydrate(0)
- Sitagliptin phosphate monohydrate / simvastatin(0)
- Sitagliptin phosphate monohydrate metformin hydrochloride(0)
- Sitagliptin productspecific bioequivalence guidance(0)
- Sitagliptin SUN(0)
- Sitoiganap(0)
- Sivextro(0)
- Siv Lundström(0)
- Sixmo(0)
- Sixmonth countdown to golive for the Clinical Trials Information System CTIS(0)
- Sixteenth Meeting of the Management Board(0)
- Sixth annual workshop of the European Network of Paediatric Research at the European Medicines Agency EnprEMA(0)
- Sixth EMAMedicines for Europe bilateral meeting(0)
- Sixth EMEA/FEDESA Joint Info Day at the European Agency in London(0)
- Sixth European Medicines Agency EMA and EFPIA bilateral meeting(0)
- Sixth industry stakeholder platform on research and development support(0)
- Sixth Industry Standing Group ISG meeting(0)
- Sixth International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use E2B R3 individualcasesafetyreport information day(0)
- Sixth meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Sixth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines(0)
- Sixth meeting of the Management Board of the European Agency for the Evaluation of Medicinal Products(0)
- Sixth Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Sixth Nitrosamine Implementation Oversight Group NIOG meeting with pharmaceutical industry(0)
- Sixth stakeholder forum on the implementation of the new pharmacovigilance legislation(0)
- Sixth workshop for micro small and mediumsized enterprises SMEs Focus on scientific and regulatory advice(0)
- Sixyear review shows success of the EU signal management system in improving safe use of medicines(0)
- Sjors Van Klaveren(0)
- Skaiste Kasciuskeviciute(0)
- Skilarence(0)
- Skimmed cows milk powder(0)
- Skyclarys(0)
- Skycovion(0)
- Skye Pharma PLC withdraws its application to extend the marketing authorisation for DepoCyte(0)
- Skyrizi(0)
- Skysona(0)
- Skytrofa previously Lonapegsomatropin Ascendis Pharma(0)
- Sladjana Jokic(0)
- Slentrol(0)
- Slenyto(0)
- Sliwens(0)
- Small and mediumsized enterprises driving innovation in medicines(0)
- SME and academia Clinical Trials Information System CTIS twopart training webinar Day 1(0)
- SME and academia Clinical Trials Information System CTIS twopart training webinar Day 2(0)
- SME info day on the new clinical trial regulation(0)
- SME office outcomes of seven years of active support to small and mediumsize businesses(0)
- SME Office wins award for Most significant contribution to mediscience sector(0)
- SME Regulation and reports(0)
- SME workshop for micro small and mediumsized enterprises Focus on quality for medicines containing chemical entities(0)
- SME workshop on quality of medicines takes place this Friday(0)
- Snezana Djurisic(0)
- Snezana Mugosa(0)
- Snieguole Trumpickaite Dzekcioriene(0)
- Sodium laurilsulfate(0)
- Sodium Salicylate(0)
- Sodium used as an excipient in medicinal products for human use(0)
- Sofia Attelind(0)
- Sofia Borges(0)
- Sofia Håkansson(0)
- Sofia Kapanadze(0)
- Sofia Persson(0)
- Sofia Trantza(0)
- Sofi Björklöf(0)
- Sofie Hägervik Sinani(0)
- Sofie Peirs(0)
- Sofie Termont(0)
- Software development companies invited to express interest in workshop on electronic prescribing(0)
- Sogroya(0)
- Sohonos(0)
- Soiae oleum raffinatum(0)
- Soile Peltokangas(0)
- Solacyl(0)
- Solamocta 697 mg/g powder for use in drinking water for chickens ducks and turkeys(0)
- Solani dulcamarae stipites(0)
- Solène Maitenaz(0)
- Solene Villanova(0)
- Solensia(0)
- Solfrid Toftum(0)
- Solidaginis virgaureae herba(0)
- Soline Berend(0)
- Soliris(0)
- Solithromycin Triskel EU Services(0)
- Sol Ruiz(0)
- Soluble yeast beta13/16glucan(0)
- Soludox(0)
- Solumarv(0)
- Solymbic(0)
- Somac Control(0)
- SomaKit TOC(0)
- Somatropin Biopartners(0)
- Somavert(0)
- So Min Lee(0)
- Somnena(0)
- sona fundarkova(0)
- Sonata(0)
- Sondelbay(0)
- Sonia Chambel(0)
- Sonia Garcia Perez(0)
- Sonia Gil Morales(0)
- Sonia Klinger(0)
- Sonia Roldan Munoz(0)
- Sonja Beken(0)
- Sonja Haase(0)
- Sonja Hrabcik(0)
- Sonja Kwadijkde Gijsel(0)
- Sonja Matt(0)
- Sonja Neimanis(0)
- Sonja Otten(0)
- Sonny Larsson(0)
- SonoVue(0)
- SONOVUE 1 sulphur hexafluoride New contraindication in patients with heart disease Restriction of use to noncardiac imaging(0)
- Sophia AustermannBusch(0)
- Sophia Venzke(0)
- Sophie Barreteau(0)
- Sophie Blavier(0)
- Sophie Colyn(0)
- Sophie Dufaÿ(0)
- Sophie Fichter(0)
- Sophie Goethals(0)
- Sophie Mompelat(0)
- sophie skorjanec(0)
- Sophie Teng(0)
- Sorafenib Accord(0)
- Sorafenib productspecific bioequivalence guidance(0)
- Søren Troels Christensen(0)
- Sotirios Nedios(0)
- Sotyktu(0)
- Souzi Makri(0)
- Sovaldi(0)
- Sovrima(0)
- Spanidin(0)
- Speakers confirmed for European Medicines Agency workshop on clinicaltrial data and transparency(0)
- Species amarae(0)
- Species digestivae(0)
- Species diureticae(0)
- Species sedativae(0)
- Specifications and control tests on the finished product Scientific guideline(0)
- Specifications for additional efficacy studies for medicines published in the Official Journal of the EU(0)
- Specifications test procedures and acceptance criteria for herbal substances herbal preparations and herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Specific efficacy requirements for ectoparasiticides in cattle Scientific guideline(0)
- Specific efficacy requirements for ectoparasiticides in sheep Scientific guideline(0)
- Spectrila(0)
- Spedra(0)
- Speeding up development of Ebola treatments and vaccines(0)
- Spevigo(0)
- Spexotras(0)
- Spherox(0)
- Spikevax EMA recommendation on booster(0)
- Spikevax EMA recommends approval of adapted COVID19 vaccine targeting Omicron XBB15(0)
- Spikevax previously COVID19 Vaccine Moderna(0)
- Spinal muscular atrophy workshop(0)
- Spinraza(0)
- Spironolactone Ceva(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars EMA Account Management(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars Organisation Management Service OMS(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars Product Management Service XEVMPD(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars Referentials Management Service RMS(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars Service Desk for SPOR and XEVMPD(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars SPOR Data Governance(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars Substance Management Service SMS(0)
- SPOR and xEVMPD Stakeholder Engagement Webinars Substance product organisation and referential SPOR application programming interface API SPOR API(0)
- SPOR and XEVMPD Week(0)
- SPOR data services questions and answers webinar with industry(0)
- SPOR ISO IDMP Task Force(0)
- SPOR Status Update(0)
- SPOR user registration(0)
- SPOR webinar How to access and use the SPOR API(0)
- Spravato(0)
- Sprimeo(0)
- Sprimeo HCT(0)
- Sprycel(0)
- Spyridon Farlopoulos(0)
- Stability and traceability requirements for vaccine intermediates Scientific guideline(0)
- Stability testing for applications for variations to a marketing authorisation for veterinary medicinal products Scientific guideline(0)
- Stability testing for applications for variations to marketing authorisation Scientific guideline(0)
- Stability testing of existing active ingredients and related finished products Scientific guideline(0)
- Stability testing of existing active substances and related finished products Scientific guideline(0)
- Stability testing of herbal medicinal products and traditional herbal medicinal products Scientific guideline(0)
- Stability testing requirements for new dosage forms ICH Q1C(0)
- Stakeholder focus group meeting on availability of lumpy skin disease LSD vaccines authorised to European Union EU standards(0)
- Stakeholder meeting on product shortages due to manufacturing and quality problems developing a proactive approach to prevention(0)
- Stakeholder meetings pharmacovigilance legislation(0)
- Stakeholder participation in information management(0)
- Stakeholders and Communication(0)
- Stakeholder workshop on support to quality development in early access approaches such as PRIME and Breakthrough Therapies(0)
- Stalevo(0)
- Standardised units of measurement(0)
- Standardised units of measurement for veterinary antimicrobials(0)
- Standard paediatric investigation plans(0)
- Staquis(0)
- Starlix(0)
- Start of review of ambroxol and bromhexine(0)
- Start of review of codeinecontaining medicines when used for cough and cold in children(0)
- Start of review of medicines manufactured at Pharmaceutics International Inc USA(0)
- Start of rolling review for adapted Comirnaty COVID19 vaccine(0)
- Start of rolling review for adapted Spikevax COVID19 vaccine(0)
- Start of shelflife of the finished dosage form Annex to the note for guidance on the manufacture of the finished dosage form Scientific guideline(0)
- Startvac(0)
- Statement by Executive Director Guido Rasi in The Hague(0)
- Statement from Emer Cooke on the end of the COVID19 public health emergency(0)
- Statement on British Biotech Pharmaceuticals Ltds ZACUTEX Application of the 5th May 1998(0)
- Statement on the outcome of the UK referendum(0)
- Statements of noncompliance with GMP now publicly available in EudraGMDP(0)
- Statistical methodology for the comparative assessment of quality attributes in drug development Scientific guideline(0)
- Statistical principles for clinical trials for veterinary medicinal products pharmaceuticals Scientific guideline(0)
- Status of the adaptive pathways pilot project(0)
- Stavros Nikolakopoulos(0)
- Stavroula Mamoucha(0)
- Staying safe when buying medicines online(0)
- Stayveer(0)
- Stefan Bonné(0)
- Stefan De Vos(0)
- Stefan George(0)
- Stefan Grosek(0)
- Stefania Bellino(0)
- Stefania Dalfra(0)
- Stefanie Bodemann(0)
- Stefanie Farrugia(0)
- Stefanie Rindler(0)
- Stefanie Roesler(0)
- Stefanie Scheerlinck(0)
- Stefan Nilsson(0)
- Stefano del Giacco(0)
- Stefan Strasser(0)
- Stefan Teipel(0)
- Stefan Verweij(0)
- Stefan Vieths(0)
- Steffen Buchholz(0)
- Steffen Feustel(0)
- Steffen Gross(0)
- Steglatro(0)
- Steglujan(0)
- Stelara(0)
- Stelfonta(0)
- Stella Attia(0)
- Stella Blackburn appointed president of the International Society for Pharmacoepidemiology(0)
- Stella Dioritou(0)
- Stem cellbased medicinal products Scientific guideline(0)
- Stem cellbased products for veterinary use Specific question on target animal safety addressed by CVMP/ADVENT Scientific guideline(0)
- Stem cellbased products for veterinary use Specific questions on extraneous agents to be addressed by Ad Hoc Expert Group on Veterinary Novel Therapies ADVENT Scientific guideline(0)
- Stem cell based products for veterinary use Specific questions on extraneous agents to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies ADVENT(0)
- Stem cellbased products for veterinary use specific questions on sterility to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies ADVENT Scientific guideline(0)
- Stem cellbased products for veterinary use specific questions on target animal safety to be addressed by the Ad Hoc Expert Group on Veterinary Novel Therapies ADVENT(0)
- Stemcelltherapy treatments(0)
- Stephane Personne(0)
- Stephane Steurbaut(0)
- Stephanie Hueber(0)
- Stephanie Jambon(0)
- Stephanie Kohl(0)
- Stephanie Liane Cini(0)
- Stephanie TuinenburgHoogerwerf(0)
- Stephanie Zeitouni(0)
- Stephan Klösel(0)
- Stephany Suoth(0)
- Stephen Spiteri(0)
- Stergiani Giannakou(0)
- Sterilisation of the medicinal product active substance excipient and primary container Scientific guideline(0)
- Steven Teerenstra(0)
- Steven Van Cruchten(0)
- Stimufend(0)
- Stimulating the development of medicines for children(0)
- Stina Wahlin(0)
- Stine Buchholdt(0)
- Stine Geisler(0)
- Stine Gregers Hørsøe(0)
- Stine Grondal Skifte(0)
- Stine Hasling Mogensen(0)
- Stine Ulsø(0)
- Stivarga(0)
- Stocrin(0)
- Stolen vials of medicine in Italy(0)
- Strangvac(0)
- Strategies to identify and mitigate risks for firstinhuman and early clinical trials with investigational medicinal products Scientific guideline(0)
- Strengthened guidance on followup and risk management for ATMP developers(0)
- Strengthening engagement between EMA and general practitioners(0)
- Strengthening EUUS cooperation in medicine inspections(0)
- Strengthening global collaboration on COVID19 realworld evidence and observational studies(0)
- Strengthening interaction with academia(0)
- Strengthening lifesciences innovation across Europe EUInnovation Network conference(0)
- Strensiq(0)
- Strenzen 500/125mg/g powder(0)
- Stresnil 40 mg/ml solution for injection for pigs and associated names and generic products thereof(0)
- Striascan(0)
- Stribild(0)
- Strimvelis(0)
- Stronghold(0)
- Stronghold Plus(0)
- Strontium ranelate(0)
- Structure of the list of herbal substances preparations and combinations thereof(0)
- Studies assessed by the European Medicines Agency indicate no increased risk of developing cancer for patients who have taken Viracept contaminated with ethyl mesilate(0)
- Studies from Alkem Laboratories Ltd cannot be used to support medicines approval in the EU(0)
- Studies to evaluate the safety of residues of veterinary drugs in human food General approach to establish an acute reference dose ARfD(0)
- Study provides recommendations on European Medicines Agencys communication on medicines(0)
- Suanovil 20 / Captalin associated names and generic products thereof(0)
- Submission dates(0)
- Submission dates veterinary medicines(0)
- Submission deadlines for orphan designations(0)
- Submission of marketingauthorisation applications for pandemic influenza vaccines through the centralised procedure(0)
- Submission of referentials management services RMS and organisations management services OMS change requests(0)
- Submitting annual reports on medicine development(0)
- Submitting a postauthorisation application(0)
- Submitting results of paediatric studies(0)
- Suboxone(0)
- Substance and product data management services(0)
- Substance product organisation and referential data SPOR impact on veterinary stakeholders(0)
- Substance product organisation and referential SPOR master data(0)
- Successful Rijeka conference strengthens EUCroatian cooperation on medicines regulation(0)
- Success rate for marketing authorisation applications from SMEs doubles between 2016 and 2020(0)
- Sue Jordan(0)
- Sugammadex Adroiq(0)
- Sugammadex Amomed(0)
- Sugammadex Fresenius Kabi(0)
- Sugammadex Lorien(0)
- Sugammadex Mylan(0)
- Sugammadex Piramal(0)
- Suifertil 4mg/ml oral solution for pigs and associated names(0)
- Suiseng Diff/A(0)
- Suitability of the graduation of delivery devices for liquid dosage forms Scientific guideline(0)
- Suliqua(0)
- Sumatriptan Galpharm(0)
- Summary of Product Characteristics Advisory Group(0)
- Summary of product characteristics for antiparasitic veterinary medicinal products Scientific guideline(0)
- Summary of requirements for active substances in the quality part of the dossier Scientific guideline(0)
- Sunitinib Accord(0)
- Sunitinib productspecific bioequivalence guidance(0)
- Sunlenca(0)
- Sunosi(0)
- Sun Pharmaceutical Industries Europe BV withdraws its marketing authorisation application for Doxorubicin Sun doxorubicin hydrochloride(0)
- Sun Pharmaceutical Industries Europe BV withdraws its marketing authorisation application for Repaglinide SUN repaglinide(0)
- Sun Pharmaceutical Industries Europe BV withdraws its marketing authorisation application for Topotecan SUN topotecan(0)
- Supemtek(0)
- Superseded Conduct of pharmacovigilance for medicines used by the paediatric population Scientific guideline(0)
- Superseded pharmacovigilance guidance documents(0)
- Supply shortage of Cerezyme updated treatment recommendations required(0)
- Supply shortage of Fabrazyme updated treatment recommendations required for adult male patients(0)
- Supply shortages of Cerezyme and Fabrazyme priority access for patients most in need of treatment recommended(0)
- Support for advancedtherapy developers(0)
- Support for early access(0)
- Support for industry on clinical data publication(0)
- Supporting better use of medicines(0)
- Supporting information(0)
- Supporting innovation(0)
- Supporting innovative SMEs as major drivers of new pharmaceutical developments(0)
- Supporting medicine developers in generating quality data packages in early access approaches PRIME and breakthrough therapies workshop report published(0)
- Supporting responsible use of veterinary antibiotics in Europe(0)
- Support services(0)
- Support to research(0)
- Support to SMEs(0)
- Suprelorin(0)
- Suramox(0)
- Suramox 15 % LA and its associated name Stabox 15 % LA(0)
- Surface coatings general issues for consideration regarding parenteral administration of coated nanomedicine products Scientific guideline(0)
- Surfaxin(0)
- Survey launched for veterinarians on prescribing habits for antimicrobials(0)
- SUSA/00009316/201412(0)
- Susana Ayesa Alvarez(0)
- Susana Casado(0)
- Susana Esteves(0)
- Susana López Hernández(0)
- Susana MoralesAlcelay(0)
- Susana Penedo Alves(0)
- Susan Erichsen(0)
- Susan Flanagan(0)
- Susanna Georgi(0)
- Susanna Hausmann(0)
- Susanna Peltoniemi(0)
- Susanne Breedijkvan den Ende(0)
- Susanne BrendlerSchwaab(0)
- Susanne Bruun(0)
- Susanne Dertz(0)
- Susanne Flemisch(0)
- Susanne Gruber(0)
- Susanne Havn Aamand(0)
- Susanne Høpner Rasmussen(0)
- Susanne Kaul(0)
- Susanne Lerch(0)
- Susanne Liebig(0)
- Susanne Marhold(0)
- Susanne Mueller(0)
- Susanne MuellerEgert(0)
- Susanne PoleyOchmann(0)
- Susanne Schmitz(0)
- Susanne Schust(0)
- Susanne Steinecker(0)
- Susanne Urach(0)
- Susanne van BurgBouwman(0)
- Susanne van Laarhoven(0)
- Susanne Winterscheid(0)
- Susanne Wolf(0)
- Susann Weise(0)
- Susan Reid(0)
- Susan Uiterwaal(0)
- Suspension of fenspiride medicines due to potential risk of heart rhythm problems(0)
- Suspension of ranitidine medicines in the EU(0)
- Suspension of ulipristal acetate for uterine fibroids during ongoing EMA review of liver injury risk(0)
- Sustiva(0)
- Susvimo(0)
- Susy Yeshika OlaveQuispe(0)
- Sutent(0)
- Suvaxyn Aujeszky 783 + O/W(0)
- Suvaxyn Circo(0)
- Suvaxyn Circo+MH RTU(0)
- Suvaxyn CSF Marker(0)
- Suvaxyn Ery(0)
- Suvaxyn Parvo/E(0)
- Suvaxyn PCV(0)
- Suvaxyn PRRS MLV(0)
- Suzana Jukic(0)
- Suzana Vidic(0)
- Suzanila Sanches Silva(0)
- Suzanne Gordon(0)
- Svein Rune Andersen(0)
- Sven Back(0)
- Svend Ladefoged Nielsen(0)
- Svenja Braner(0)
- Svenja Dierkes(0)
- Svenja Esther Sander(0)
- Svenja Rieke(0)
- Svenja Stock(0)
- Svetlana Seiter(0)
- Svetoslav Georgiev(0)
- Svjetlana Krnic(0)
- Switching between superiority and noninferiority Scientific guideline(0)
- Switzerland(0)
- Sybille Schotte(0)
- Sycrest(0)
- Syfovre(0)
- Sylvant(0)
- Sylvia Kuehn(0)
- Sylvia Maurer(0)
- Sylvie Armel(0)
- Sylvie Benchetrit(0)
- Sylvie Louet(0)
- Sylvie Morgeaux(0)
- Sylvie Vanderick(0)
- Symkevi(0)
- Symphyti radix(0)
- Symtuza(0)
- Synagis(0)
- Synapse Labs Pvt Ltd EMA recommends suspension of medicines over flawed studies(0)
- Synchron Research Service suspension of medicines over flawed studies(0)
- Synflorix(0)
- Synjardy(0)
- Synordia(0)
- Synulox Lactating Cow(0)
- Syvazul BTV(0)
- Szilvia Florutane dr Toth(0)
- T(0)
- Taavo Tähtjärv(0)
- Tabrecta(0)
- Tacforius(0)
- TachoSil(0)
- Tackling medication errors European Medicines Agency workshop calls for coordinated EU approach(0)
- Taco Monster(0)
- Tacrolimus granules productspecific bioequivalence guidance(0)
- Tadalafil Lilly(0)
- Tadalafil Mylan(0)
- Tadalafil productspecific bioequivalence guidance(0)
- Tafinlar(0)
- Tagrisso(0)
- Tailored scientific advice to support stepbystep development of new biosimilars(0)
- Taina Mattila(0)
- Taina Methuen(0)
- Takeda withdraws its marketing authorisation application for Ramelteon(0)
- Takhzyro(0)
- Taliglucerase alfa(0)
- Talip Eroglu(0)
- Talmanco previously Tadalafil Generics(0)
- Taltz(0)
- Taluvian(0)
- Talvey(0)
- Talzenna(0)
- Tamara Mandusic Nazor(0)
- Tamara Scheidt(0)
- Tamas Laszlo Balazsa(0)
- Tamás Tóth(0)
- Tamiflu(0)
- Tanaceti parthenii herba(0)
- Tandemact(0)
- Tania Masmas(0)
- Tania Meier(0)
- Tania Schink(0)
- Tanja Hadberg Nielsen(0)
- Tanja Spanic(0)
- Tanja Trbojevic Krpanic(0)
- Tanja Zahlner(0)
- Taraxaci folium(0)
- Taraxaci officinalis radix(0)
- Taraxaci radix cum herba(0)
- Tarceva(0)
- Tarec Christoffer ElGalaly(0)
- Targanta Netherlands BV withdraws its marketing authorisation application for Ramvocid oritavancin(0)
- Targeted consultation on the guideline for development of new medicinal products for the treatment of rheumatoid arthritis(0)
- Targretin(0)
- Tarja SissalaAiraksinen(0)
- Tartaric acid(0)
- Tasermity(0)
- Tasigna(0)
- Task Forces(0)
- Tasmar(0)
- Tatiana Balaskova(0)
- Tatiana Holková(0)
- Tatjana Ivaskiene(0)
- Tatyana Devine(0)
- Tavlesse(0)
- Tavneos(0)
- Taxespira previously Docetaxel Hospira UK Limited (0)
- Taxotere(0)
- Tea Linhola(0)
- Tecartus(0)
- Tecentriq(0)
- Tecfidera(0)
- Technical anonymisation group(0)
- Technical Anonymisation Group TAG First meeting(0)
- Technical Webinar Regulatory Procedure Management for PLM in IRIS for Network Users(0)
- Technical workshop on realworld metadata for regulatory purposes(0)
- Tecnemab K1(0)
- Tecovirimat SIGA(0)
- Tecvayli(0)
- Teea Vainionpaa(0)
- Tegsedi(0)
- Teja Drofelnik(0)
- Tekinex(0)
- Tekturna(0)
- Telcagepant(0)
- Telithromycin productspecific bioequivalence guidance(0)
- Telmisartan Actavis(0)
- Telmisartan Teva(0)
- Telmisartan Teva Pharma(0)
- Telzir(0)
- Temodal(0)
- Temomedac(0)
- Temozolomide Accord(0)
- Temozolomide Hexal(0)
- Temozolomide Sandoz(0)
- Temozolomide Sun(0)
- Temozolomide Teva(0)
- Template and recommended format for list of references(0)
- Template for a European Union herbal monograph(0)
- Template for a European Union list entry(0)
- Template for a public statement when no European Union herbal monograph is established(0)
- Template for assessment report for the development of European Union herbal monographs and list entries(0)
- Template for information exchange for the preparation of the assessment report supporting the establishment of European Union monographs and European Union list entries(0)
- Template for submission by Committee on Herbal Medicinal Products HMPC members or national competent authorities of questions for discussion by the HMPC(0)
- Template for submission of a request for scientific support and advice on a traditional herbal medicinal product(0)
- Template for the qualified persons QP declaration concerning good manufacturing practice compliance of active substance manufacture "The QP declaration template" Scientific guideline(0)
- Templates for assessors(0)
- Templates for industry(0)
- Temybric Ellipta(0)
- Tenecteplase Boehringer Ingelheim Pharma GmbH Co KG(0)
- TENE MIHAIMARIUS(0)
- Tenkasi previously Orbactiv(0)
- Tenofovir disoproxil Mylan(0)
- Tenofovir disoproxil Zentiva(0)
- Ten recommendations to unlock the potential of big data for public health in the EU(0)
- Tenth EMA Human Scientific Committees Working Party with Patients and Consumers Organisations PCWP meeting(0)
- Tenth industry stakeholder platform on research and development support(0)
- Tenth industry stakeholder platform on the operation of pharmacovigilance in the European Union(0)
- Tenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines(0)
- Tenth Meeting of the Management Board(0)
- Tenth Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Tenth stakeholder forum on the pharmacovigilance legislation(0)
- Ten years of MUMS 22 new veterinary medicines authorised for minor uses and minor species(0)
- Ten years of orphan medicines legislation in Europe European Medicines Agency reviews success and looks ahead(0)
- Ten years of the Orphan Regulation in Europe(0)
- Ten years promoting highquality scientific research in paediatric medicines(0)
- Teodora Bodea(0)
- Teodor Nikolov(0)
- Teofil Zizek(0)
- Teo Kolonic(0)
- Tepadina(0)
- Tepkinly(0)
- Tepmetko(0)
- Teresa Cejalvo(0)
- Teresa Jansson(0)
- Teresa Llacer Delicado(0)
- Teresa Lluch Armell(0)
- Teresa Magán Martinez(0)
- Teresa Merino Ramos(0)
- Tereza Bazantova(0)
- Tereza Havelkova(0)
- Tereza Vojackova(0)
- Terhi Lehtinen(0)
- Teriflunomide Accord(0)
- Teriflunomide Mylan(0)
- Teriparatide Cinnagen(0)
- Teriparatide Sun(0)
- Terlipressin(0)
- Terminology in pharmacogenetics Scientific guideline(0)
- Terrosa(0)
- Terry McElvaney(0)
- Tesavel(0)
- Teslascan(0)
- Tessie(0)
- Testing and evaluation of the efficacy of antiparasitic substances for the treatment and prevention of tick and flea infestations in dogs and cats Scientific guideline(0)
- Testing for simian virus 40 SV40 in polio virus vaccines Scientific guideline(0)
- Testosterone(0)
- Tevagrastim(0)
- Teva Pharma BV withdraws its marketing authorisation application for Clopidogrel Teva Pharma clopidogrel hydrobromide(0)
- Tevimbra(0)
- Teysuno(0)
- Tezspire(0)
- Thadeus Bao Quan Nguyen(0)
- Thalia Marie Estrup Blicher(0)
- Thalidomide BMS previously Thalidomide Celgene(0)
- Thalidomide Followup meeting with patients and victims organisations(0)
- Thalidomide Lipomed(0)
- Thank you for submitting your request(0)
- The adequacy of the Mahalanobis distance to assess the comparability of drug dissolution profiles Scientific guideline(0)
- Thea Neumann(0)
- The annual European Medicines Agency review of the year and outlook for 2012(0)
- The annual European Medicines Agency review of the year and outlook for 2013(0)
- The annual European Medicines Agency review of the year and outlook for 2014(0)
- The annual European Medicines Agency review of the year and outlook for 2015(0)
- The annual European Medicines Agency review of the year and outlook for 2016(0)
- The annual European Medicines Agency review of the year and outlook for 2017(0)
- The annual European Surveillance of Veterinary Antimicrobial Consumption ESVAC stakeholders annual meeting 2016(0)
- The bacterial challenge Time to react a call to narrow the gap between multidrugresistant bacteria in the EU and development of new antibacterial agents(0)
- The EMEA and the CMDh review Europewide experience with user consultation in the readability testing of package leaflets(0)
- The European Commission launches a public consultation on the Paediatric Regulation(0)
- The European Medicines Agency and the Netherlands agree on Seat Agreement(0)
- The European Medicines Agency mourns the passing of Jordi Llinares Garcia(0)
- The European Medicines Agency recommends suspension of the marketing authorisation of Acomplia(0)
- The European Medicines Agency recommends that estradiolcontaining creams Linoladiol N and Linoladiol HN remain available(0)
- The European Union and the Food and Drug Administration working together to create common application for orphan designation for Medicines(0)
- The evaluation of medicines stepbystep(0)
- The first conference for medicines regulatory authorities in Sudan and neighbouring countries(0)
- Theis Jacobsen(0)
- Theis Moeslund Jensen(0)
- Thelin(0)
- Thelin sitaxentan to be withdrawn due to cases of unpredictable serious liver injury(0)
- Themis Kyprianou(0)
- The new EudraVigilance system and electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Paris(0)
- The New EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH 2BR3 format handson training course(0)
- The new EudraVigilance System and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Amsterdam(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Amsterdam The Netherlands(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Athens(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Berlin Germany(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Lisbon(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Lisbon Portugal(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Madrid(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Madrid Spain(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Paris(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Paris France(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Prague(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course San Marino(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course San Marino Republic of San Marino(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Vienna(0)
- The new EudraVigilance system and the electronic reporting of ICSRs in the ISO/ICH E2BR3 format handson training course Vienna Austria(0)
- The new EudraVigilance system and the electronic reporting of individual case safety reports ICSRs in the ISO/ICH E2BR3 format handson training course(0)
- The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2BR3 format Handson training course(0)
- The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2BR3 format handson training course(0)
- The new EudraVigilance system and the electronic reporting of individual case safety reports in the ISO/ICH E2BR3 format handson training course Berlin(0)
- The new EudraVigilance System and the electronic reporting of the individual case safety in the ISO/ICH E2BR3 format handson training course(0)
- The number of tests required to control for complete inactivation in inactivated vaccines(0)
- Theo de Reijke(0)
- Theodoros Karampinas(0)
- THEOGNOSIA PATSALIDOU(0)
- Théo Henriet(0)
- Theoni Kousteni(0)
- The Pharmaceutical Inspection Cooperation Scheme(0)
- The procedure to be followed when a batch of a vaccine finished product is suspected to be contaminated with bovine viral diarrhoea virus Scientific guideline(0)
- The PROTECT project on pharmacovigilance achieves key objectives(0)
- Theraloc(0)
- Therapeutic areas latest updates(0)
- Therésa Dao(0)
- Therese Klamer(0)
- Therese Le Rimul(0)
- The role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants DOACs(0)
- The role of regulators in establishing added benefit of novel therapies(0)
- The role of singlearm trials in the authorisation of new cancer medicines(0)
- Theryttrex(0)
- The use of Artificial Intelligence AI in the medicinal product lifecycle(0)
- Thibault Roguet(0)
- Thierry Godard(0)
- Thijs Ambagts(0)
- Thi Le(0)
- Thiomersal implementation of the warning statement relating to sensitisation Scientific guideline(0)
- Thiomersal in vaccines for human use recent evidence supports safety of thiomersalcontaining vaccines Scientific guideline(0)
- Thiotepa Riemser(0)
- Third EMA and Association of the European SelfMedication Industry AESGP annual bilateral meeting(0)
- Third EMAEFPIA annual bilateral meeting(0)
- Third EMEA Workshop for Micro Small and MediumSized Enterprises SMEs Focus on Nonclinical Aspects(0)
- Third European Medicines Agency and Affordable Medicines Europe bilateral meeting(0)
- Third European Medicines Agency and Nuclear Medicines Europe bilateral meeting(0)
- Third European Medicines Agency EMA and MedTech Europe bilateral meeting(0)
- Third European Medicines Agency EuropaBio bilateral meeting(0)
- Third European Medicines AgencyMedicines for Europe bilateral meeting(0)
- Third industry stakeholder platform on research and development support(0)
- Third industry stakeholder platform on the operation of the centralised procedure for human medicinal products(0)
- Third industry stakeholder platform operation of European Union pharmacovigilance legislation(0)
- Third Industry Standing Group ISG meeting(0)
- Third international awareness session on science and regulation for animal health and welfare public health and the environment(0)
- Third joint meeting of the EMA Scientific Committees Working Party with Patients and Consumers Organisations PCWP and the EMA/CHMP Working Group with Healthcare Professionals Organisations HCP WG(0)
- Third listenandlearn focus group meeting of the Quality Innovation Group(0)
- Third meeting of the EMEA Human Scientific Committees Working Party with with Patients and Consumers Organisations PCWP(0)
- Third Meeting of the Management Board of the European Agency for the Evaluation of Medicinal Products(0)
- Third Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Third Nitrosamine Implementation Oversight Group NIOG meeting with pharmaceutical industry(0)
- Third stakeholder forum on the implementation of the new 2010 pharmacovigilance legislation(0)
- Third tripartite meeting held between EMA PMDA and FDA to discuss regulatory approaches for the evaluation of antibacterial agents(0)
- Third Veterinary Big Data Stakeholder Forum(0)
- Thirteenth Meeting of the Management Board(0)
- Thirtieth meeting of the Management Board(0)
- Thirtyfifth meeting of the Management Board(0)
- Thirtyfirst meeting of the Management Board(0)
- Thirtysecond meeting of the Management Board(0)
- Thirtythird meeting of the Management Board(0)
- Thomas Berbain(0)
- Thomas Brouwers(0)
- Thomas Drapier(0)
- Thomas Eucker(0)
- Thomas Grüger(0)
- Thomas Heberer(0)
- Thomas Hecker(0)
- Thomas Hinz(0)
- Thomas Holzhauser(0)
- Thomas Kocar(0)
- Thomas Lang(0)
- Thomas Lönngren reappointed as Executive Director of the European Medicines Agency(0)
- Thomas Lucotte(0)
- Thomas Nagel(0)
- Thomas Pedersen(0)
- Thomas Reichhart(0)
- Thomas Sassen(0)
- Thomas Schochat(0)
- Thomas Stock(0)
- Thomas Sudhop(0)
- Thorinane(0)
- Thorsten Gnad(0)
- Thrombin alfa(0)
- Thurid Buch(0)
- Thuy Hoang Nguyen(0)
- Thymanax(0)
- Thymi aetheroleum(0)
- Thymi herba(0)
- Thymi herba and Primulae radix(0)
- Thyrogen(0)
- Tia Erika Hirvonen(0)
- Tiago Villanueva(0)
- Tiago Vistulo De Abreu(0)
- Tiamulin hydrogen fumarate presented as premix for medicated feeding stuff and oral powder for infeed use to be administered to pigs(0)
- Tiamutin(0)
- Tibor Soós(0)
- Tibsovo(0)
- Ticagrelor productspecific bioequivalence guidance(0)
- Tick and flea control agent Bravecto continues to be acceptably safe to use(0)
- Tidhesco(0)
- Tigecycline Accord(0)
- Tiina Asikainen(0)
- Tiina Gyllenberg(0)
- Tiina Jaakkola(0)
- Tiina Karonen(0)
- Tiina Reinivuori(0)
- Tijana Micovic(0)
- Tikosyn(0)
- Tildren(0)
- Tiliae flos(0)
- Tiliae tomentosae flos(0)
- Till Winkler(0)
- Tilo Moede(0)
- Tímea Kahlesz(0)
- Time allowed for applicants to respond to questions and issues raised during the assessment of new marketing authorisation applications in the centralised procedure(0)
- Tim Leest(0)
- Tim Niehues(0)
- Timo Grimmer(0)
- Timo Mauriala(0)
- Timo Wille(0)
- Tim Vanuytsel(0)
- Tina Pasciuto(0)
- TINA SETNIKAR(0)
- Tina Soon Engraff(0)
- Tina Visholm Jensen(0)
- Tine Broløs(0)
- Ting Lu(0)
- Tinneke Pletinckx(0)
- Tin Sandl(0)
- Tiphaine de Jouvencel(0)
- Tiphaine MoreacPesselier(0)
- Tiphaine Vaillant(0)
- Tirdad Seifi Ala(0)
- TitaMaria Muhonen(0)
- Titina Alina Iordache(0)
- title>(0)
- Tivicay(0)
- Tizveni(0)
- Tjasa Pustoslemsek(0)
- Tjerk Feenstra(0)
- Tobias Fellinger(0)
- Tobias Gluexam(0)
- Tobias Lamkemeyer(0)
- Tobias Siefen(0)
- Tobi Podhaler(0)
- Todor Darakchiev(0)
- Tofidence(0)
- Toivo Maimets(0)
- Toltrazuril(0)
- Tolucombi(0)
- Tolura(0)
- Tolvaptan Accord(0)
- Toma Mikalauskaite(0)
- Tomas Arroyo Perez(0)
- Tomas Boran(0)
- Tomas Eriksson(0)
- Tomas Nilsson(0)
- Tomas Radimersky(0)
- Tomas Rasi(0)
- Tomasz Grybek(0)
- Tom Bschor(0)
- Tom Gaulton(0)
- Tom Hillary(0)
- Tom Lams(0)
- Tommaso Eliseo(0)
- Tom Meyerson Goldschmidt(0)
- Tommi Nurminen(0)
- Tom Van Der Heijden(0)
- Tone Agasøster(0)
- Tonje Høy(0)
- Tookad(0)
- Toolbox guidance on scientific elements and regulatory tools to support quality data packages for PRIME and certain marketing authorisation applications targeting an unmet medical need Scientific guideline(0)
- Toomas Tiirats(0)
- Topiramate / phentermine(0)
- Topotecan Actavis(0)
- Topotecan Eagle(0)
- Topotecan Hospira(0)
- Topotecan SUN(0)
- Topotecan Teva(0)
- Tora Gauslaa(0)
- Torbjörn Callréus(0)
- Torgny Undin(0)
- Torisel(0)
- Tormentillae rhizoma(0)
- Torsten Feldt(0)
- Torsten Holm Nielsen(0)
- Torsten Stemmler(0)
- Torunn Lisbeth Wangen(0)
- Torunn Thuv Volden(0)
- Toujeo previously Optisulin(0)
- Tovanor Breezhaler(0)
- Tove Frisch(0)
- Tove Lill Stendal(0)
- Toviaz(0)
- Towards a permanent collaboration framework for EMA and Health Technology Assessment bodies(0)
- Towards a robust global framework for conduct and oversight of clinical trials(0)
- Towards a single development programme for new antibiotics in EU Japan and US(0)
- Towards better prevention of medicine shortages in the EU(0)
- Towards electronic product information for EU medicines(0)
- Towards improved safety monitoring of veterinary medicines(0)
- Towards improving the availability of medicines in the EU(0)
- Towards more ethical use of animals in medicine testing(0)
- Tracleer(0)
- Tractocile(0)
- Tracy Keane(0)
- Training and resources for patients and consumers(0)
- Training on electronic reporting of individual case safety reports ICSRs to EudraVigilance in the European Economic Area(0)
- Training on electronic submission of information on medicines new pharmacovigilance legislation Art 57 paragraph 2 2nd subparagraph Regulation EC No 726/2004(0)
- Training on electronic submission of information on medicines new pharmacovigilance legislation Article 57 paragraph 2 second subparagraph Regulation EC No 726/2004(0)
- Training opportunities for nonEU regulators(0)
- Training session for patients and consumers interested in EMA activities(0)
- Training session for patients and consumers interested in European Medicines Agency activities(0)
- Training session for patients and consumers involved in European Medicines Agency activities(0)
- Training session for patients and consumers involved in European Medicines Agency EMA activities(0)
- Training session for patients consumers and healthcare professionals interested in EMA activities(0)
- Training session for patients consumers and healthcare professionals interested in European Medicines Agency activities(0)
- Training session for patients consumers and healthcare professionals involved in medicine regulatory activities(0)
- Training session on the new pharmaceutical legislation(0)
- Training session on the review of product information for patient and consumer organisations(0)
- Training webinar on the use of Scientific Explorer in scientific advice regulatory procedures(0)
- Trajenta(0)
- Tramadol / paracetamol(0)
- Tramadol hydrochloride Paracetamol(0)
- Transatlantic Taskforce continues international fight against antimicrobial resistance(0)
- Transatlantic Taskforce on Antimicrobial Resistance reports progress and outcomes of 17 recommendations(0)
- Transatlantic workshop drugrelated progressive multifocal leukoencephalopathy(0)
- Transfer of MA Regulatory and procedural guidance(0)
- Transfer of marketing authorisation questions and answers(0)
- Transfer of orphan designation(0)
- Transferring an orphan designation(0)
- Transferring a veterinary marketing authorisation(0)
- Transferring quality control methods validated in collaborative trials to a product/laboratory specific context Scientific guideline(0)
- Translarna(0)
- Transparency(0)
- Transparency exceptional measures for COVID19 medicines(0)
- Transparency in drug regulation(0)
- Transparency questions and answers(0)
- Transparency Regulatory and procedural guidance(0)
- Transparency veterinary medicines(0)
- Travatan(0)
- Trazec(0)
- Trazimera(0)
- Treatment and prophylaxis of respiratory syncytial virus RSV disease Scientific guideline(0)
- Treatment of premenstrual dysphoric disorder Scientific guideline(0)
- TREATNMD workshop on the development of antisense oligonucleotide therapies for Duchenne muscular dystrophy(0)
- Trecondi(0)
- Tredaptive(0)
- Trelegy Ellipta(0)
- Tremelimumab AstraZeneca(0)
- Tremfya(0)
- Trends in initial evaluation of veterinary medicines by EMA in 2013(0)
- Treprostinil SciPharm Sàrl(0)
- Trepulmix(0)
- Tresiba(0)
- Trevaclyn(0)
- Trevicta previously Paliperidone Janssen(0)
- Triacelluvax(0)
- Tribrissen(0)
- Tribuli terrestris herba(0)
- Trifexis(0)
- Trigonellae foenugraeci semen(0)
- Triin Maesalu(0)
- Triin Suvi(0)
- Triin Teppor(0)
- Trijntje van der VeldeKoerts(0)
- Trilocur(0)
- Trilorale(0)
- Trimbow(0)
- Trine Aalund Rasmussen(0)
- Trine Jensen(0)
- Tripartite meeting between EMA PMDA and FDA on regulatory approaches for the evaluation of antibacterial agents(0)
- Tripartite meeting held between the EMA Food and Drug Administration FDA and Pharmaceuticals and Medical Devices Agency PMDA to discuss regulatory approaches for the evaluation of antibacterial agents(0)
- Tripartite Meeting JPMA/PhRMA/EBCPC hosted by EMEA Approving Innovative Medicines in 21st Century(0)
- Trisenox(0)
- Tritanrix HB(0)
- Tritanrix HepB(0)
- Triumeq(0)
- Trixeo Aerosphere(0)
- Trizivir(0)
- Trobalt(0)
- Trocoxil(0)
- Trodelvy(0)
- Trogarzo(0)
- Trond Kristoffer Nybruket(0)
- Trovan(0)
- Trovan IV(0)
- Truberzi(0)
- Trudexa(0)
- Trulicity(0)
- Trumenba(0)
- Truqap(0)
- TruScient(0)
- Truvada(0)
- Truvelog Mix 30(0)
- Truxima(0)
- Trydonis(0)
- TSUYOSHI ANDO(0)
- Tsvetanka Valova(0)
- Tuija Kainulainen(0)
- Tukysa(0)
- Tulatrixx(0)
- Tulaven(0)
- Tulinovet(0)
- Tulissin(0)
- Turalio(0)
- Turvel(0)
- Turvel IV(0)
- Tuuli Metsvaht(0)
- Tuznue(0)
- Twelfth industry stakeholder platform on the operation of pharmacovigilance in the European Union(0)
- Twelfth joint European Medicines Agency/European network for Health Technology Assessment dialogue meeting(0)
- Twelfth Meeting of the Management Board(0)
- Twelfth Nitrosamine Implementation Oversight Group NIOG meeting(0)
- Twelfth Paediatric Oncology Strategy Forum for Medicinal Product Development of CDK4/6 CDK7 and CDK9 Inhibitors in children and adolescents(0)
- Twentieth Meeting of the Management Board(0)
- Twentyeighth meeting of the Management Board(0)
- TwentyFirst Meeting of the Management Board(0)
- Twentyfourth Meeting of the Management Board(0)
- Twentyninth meeting of the Management Board(0)
- Twentysecond Meeting of the Management Board(0)
- Twentyseventh meeting of the Management Board(0)
- Twentysixth meeting of the Management Board(0)
- Twentythird Joint European Medicines Agency / European network for Health Technology Assessment dialogue meeting(0)
- Twentythird Meeting of the Management Board(0)
- Twinrix Adult(0)
- Twinrix Paediatric(0)
- Two additional countries to benefit from EUUS mutual recognition agreement for inspections(0)
- Two additional manufacturing sites for BioNTech/Pfizers COVID19 vaccine(0)
- Two further modules on good pharmacovigilance practices released for public consultation(0)
- Two modules of guideline on good pharmacovigilance practices released for public consultation(0)
- Two more EU Member States benefit from EUUS mutual recognition agreement for inspections(0)
- Two new combination therapies against chronic hepatitis C(0)
- Two new medicines for advanced kidney cancer(0)
- Two new medicines recommended for the treatment of chronic hepatitis C(0)
- Two new paediatricuse marketing authorisations recommended by CHMP(0)
- Two years of PRIME(0)
- Twynsta(0)
- Tybost(0)
- Tyenne(0)
- Tygacil(0)
- Tylosin injection for mastitis(0)
- TypeIA variations questions and answers(0)
- TypeIB variations questions and answers(0)
- TypeII variations questions and answers(0)
- Type II variations Regulatory and procedural guidance(0)
- Type II Variations vs Extension applications Regulatory and procedural guidance(0)
- Types of contract(0)
- Tyruko(0)
- Tyvaso(0)
- Tyverb(0)
- U(0)
- Ubac(0)
- UCB Pharma withdraws its marketing authorisation application for Lacosamide Pain UCB Pharma(0)
- Ucedane(0)
- Udenyca(0)
- UK withdrawal from the EU on 31 January 2020(0)
- Ulf Peter Schuett(0)
- Ulipristal acetate(0)
- Ulipristal acetate for uterine fibroids EMA recommends restricting use(0)
- Ulipristal Acetate Gedeon Richter(0)
- Ulla Wändel Liminga(0)
- Ulpt Kirchner(0)
- Ulrica Brunsberg(0)
- Ulrich Jaeger(0)
- Ulrich Rohr(0)
- Ulrike Heissenberger(0)
- Ulrike Hermes(0)
- Ulrike Muus(0)
- Ulrike Rehberger(0)
- Ulrike ScharaSchmidt(0)
- Ultibro Breezhaler(0)
- Ultifend ND IBD(0)
- Ultomiris(0)
- Ultratard(0)
- Ulunar Breezhaler(0)
- Umberto CASALEGNO(0)
- Umbipro(0)
- Ummahan Cakin(0)
- Una Moore(0)
- Una Riekstina(0)
- Una Zilbere(0)
- Uncariae tomentosae cortex(0)
- Union Pharmacovigilance Database follow up webinar on collection and recording of suspected adverse events for veterinary medicinal products(0)
- Union Pharmacovigilance Database follow up webinar on signal detection evaluation and yearly reporting(0)
- Union Pharmacovigilance Database refresher webinar on signal management overview(0)
- Union Pharmacovigilance Database webinar on adverse event collection and recording(0)
- Union Pharmacovigilance Database webinar on signal detection and analysis(0)
- Union Product Database(0)
- Union Product Database follow up webinar for marketing authorisation holders(0)
- Union Product Database Product grouping and 3rd country product names Webinar for UPD Industry users(0)
- Union Product Database release notes(0)
- Union Product Database Volume of sales webinar for UPD industry users(0)
- Union Product Database webinar for marketing authorisation holders(0)
- Union Product Database webinar on variations not requiring assessment VNRAs for marketing authorisation holders(0)
- Unisol(0)
- United States(0)
- United Therapeutics Europe Ltd withdraws its marketing authorisation application for Tyvaso(0)
- Unituxin(0)
- Unparalleled access to clinical data one year on(0)
- UpCard(0)
- Updated advice on body fat changes and lactic acidosis with HIV medicines(0)
- Updated advice on use of highdose ibuprofen(0)
- Updated formatted table template for dossier submission available(0)
- Updated guidance on good clinical practice released for consultation(0)
- Updated measures for pregnancy prevention during retinoid use(0)
- Updated recommendations to minimise the risk of the rare brain infection PML with Tecfidera(0)
- Updated recommendations to minimise the risk of the rare brain infection PML with Tysabri(0)
- Updated restrictions for Gilenya multiple sclerosis medicine not to be used in pregnancy(0)
- Updated rules for clinical development of vaccines(0)
- Updated statement from European Medicines Agency on celecoxib(0)
- Updated temporary treatment recommendations for Cerezyme(0)
- Update from the European Medicines Agency on COX2 inhibitors(0)
- Update of EMA recommendations for 2017/2018 seasonal flu vaccine composition(0)
- Update of EU recommendations for 2018/2019 seasonal flu vaccine composition(0)
- Update of EU recommendations for 2019/2020 seasonal flu vaccine composition(0)
- Update of EU recommendations for 2020/2021 seasonal flu vaccine composition(0)
- Update of EU recommendations for 20192020 seasonal flu vaccine composition(0)
- Update of EU recommendations for 20212022 seasonal flu vaccine composition(0)
- Update on assessment of marketing authorisation application for Modernas mRNA1273 COVID19 vaccine(0)
- Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application(0)
- Update on EMA relocation preparedness(0)
- Update on EMAs Brexit preparedness(0)
- Update on EU actions to support availability of medicines during COVID19 pandemic(0)
- Update on human variations webbased electronic application form implementation on product lifecycle management portal(0)
- Update on infringement procedure against Roche Registration Ltd(0)
- Update on investigation by Italian authorities into the supply of stolen medicines(0)
- Update on medicines containing valsartan from Zhejiang Tianyu company no longer authorised to manufacture valsartan active substance for EU medicines due to presence of NDMA(0)
- Update on nitrosamines in EU medicines(0)
- Update on ongoing European review of pioglitazonecontaining medicines(0)
- Update on publication of clinical data(0)
- Update on remdesivir EMA will evaluate new data from Solidarity trial(0)
- Update on reshaping the organisation of the European Medicines Agency(0)
- Update on review of recalled valsartan medicines preliminary assessment of possible risk to patients(0)
- Update on review of valsartan medicines due to detection of NDMA EMA reviewing valsartan produced by another company Zhejiang Tianyu(0)
- Update on review of valsartan medicines following detection of impurity in active substance assessing potential impact on patients is priority(0)
- Update on review of valsartan medicines risk from NDMA remains low a related substance NDEA also being investigated(0)
- Update on rolling review of AstraZenecas COVID19 vaccine(0)
- Update on seasonalinfluenza vaccines produced by Novartis Vaccines(0)
- Update on somatropincontaining medicines(0)
- Update on the implementation of EMA policy on publication of clinical data Policy 0070 and draft revisions guidance to industry industry associations webinar(0)
- Update on the implementation of EMA policy on publication of clinical data Policy 0070 and draft revisions to the guidance to industry industry associations webinar(0)
- Update on the implementation of policy on publication of clinical data Policy 0070 Industry associations webinar(0)
- Update on the withdrawal of Thelin(0)
- Update on treatments and vaccines against COVID19 under development(0)
- Update to guidance on regulatory expectations in the context of COVID19 pandemic(0)
- Update webinar on Regulatory Procedure Management for Product Lifecycle Management on IRIS(0)
- Upkanz(0)
- Uplizna(0)
- Uprima(0)
- Upstaza(0)
- Uptravi(0)
- Urorec(0)
- Ursel Fürstenau(0)
- Urska Hajnrih(0)
- Urska Peunik(0)
- Ursodeoxycholic acid productspecific bioequivalence guidance(0)
- Ursula DrechselBäuerle(0)
- Ursula Ladstaedter(0)
- Ursula Vetter(0)
- Ursula WeissFuchs(0)
- Ursula Wippo(0)
- Urszula Borkowska(0)
- Urticae folium(0)
- Urticae herba(0)
- Urticae radix(0)
- Use of aminoglycosides in animals in the European Union development of resistance and impact on human and animal health Scientific guideline(0)
- Use of aminopenicillins and their betalactamase inhibitor combinations in animals in the European Union development of resistance and impact on human and animal health Scientific guideline(0)
- Use of antibiotics in animals European Medicines Agency to give advice to European Commission on public and animalhealth impact(0)
- Use of antibiotics in animals is decreasing(0)
- Use of antimicrobials in animals public consultations on two guidelines(0)
- Use of antiretroviral treatment in HIVpatients with hepatic impairment and/or HBV/HCV coinfection(0)
- Use of big data to improve human and animal health(0)
- Use of bovine serum in the manufacture of human biological medicinal products Scientific guideline(0)
- Use of Clinical Trials Information System becomes mandatory for new clinical trial applications in the EU(0)
- Use of cocrystals of active substances in medicinal products Scientific guideline(0)
- Use of fluoroquinolones in foodproducing animals in the European Union development of resistance and impact on human and animal health Scientific guideline(0)
- Use of fumigants Scientific guideline(0)
- Use of genomics in cardiovascular clinical trials(0)
- Use of heat treatment to inactivate endogenous retroviruses in live immunological veterinary medicinal products Scientific guideline(0)
- Use of herbal medicinal products containing asarone Scientific guideline(0)
- Use of herbal medicinal products containing estragole Scientific guideline(0)
- Use of herbal medicinal products containing methyleugenol Scientific guideline(0)
- Use of herbal medicinal products containing pulegone and menthofuran Scientific guideline(0)
- Use of herbal medicinal products containing thujone Scientific guideline(0)
- Use of herbal medicinal products containing toxic unsaturated pyrrolizidine alkaloids PAs Scientific guideline(0)
- Use of ionizing radiation in the manufacture of medicinal products Scientific guideline(0)
- Use of macrolides lincosamides and streptogramins in foodproducing animals in the European Union development of resistance and impact on human and animal health Scientific guideline(0)
- Use of metformin to treat diabetes now expanded to patients with moderately reduced kidney function(0)
- Use of methyl and propylparaben as excipients in human medicinal products for oral use Scientific guideline(0)
- Use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies Scientific guideline(0)
- Use of multiple sclerosis medicine Lemtrada restricted while EMA review is ongoing(0)
- Use of near infrared spectroscopy NIRS by the pharmaceutical industry and the data requirements for new submissions and variations Scientific guideline(0)
- Use of pharmacogenetic methodologies in the pharmacokinetic evaluation of medicinal products Scientific guideline(0)
- Use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products Scientific guideline(0)
- Use of phthalates as excipients in human medicinal products Scientific guideline(0)
- Use of pleuromutilins in foodproducing animals in the European Union development of resistance and impact on human and animal health Scientific guideline(0)
- Use of porcine trypsin used in the manufacture of human biological medicinal products Scientific guideline(0)
- Use of realworld evidence in regulatory decision making EMA publishes review of its studies(0)
- Use of recovered/recycled solvents in the manufacture of herbal preparations for use in herbal medicinal products/traditional herbal medicinal products Scientific guideline(0)
- Use of starting materials and intermediates collected from different sources in the manufacturing of nonrecombinant biological medicinal products Scientific guideline(0)
- Use of third and fourthgeneration cephalosporins in foodproducing animals in the European Union development of resistance and impact on human and animal health Scientific guideline(0)
- Use of tumorigenic cells of human origin for the production of biological and biotechnological medicinal products Scientific guideline(0)
- User safety for immunological veterinary medicinal products Scientific guideline(0)
- User safety for pharmaceutical veterinary medicinal products Scientific guideline(0)
- User safety of topically administered products Scientific guideline(0)
- Using Organisations Management Service OMS data in electronic application forms eAF(0)
- Using Organisations Management Services OMS and Referentials Management Service RMS data in electronic application forms eAF SPOR webinar(0)
- Uta BuckpeschHeberer(0)
- Uta Herbst(0)
- Ute Brandt(0)
- Ute Fischer(0)
- Ute Friedel(0)
- Ute Kühnen(0)
- Ute Vahlensieck(0)
- Uvae ursi folium(0)
- Uwe Lipke(0)
- Uwe Meier(0)
- Uzpruvo(0)
- V(0)
- Vaborem(0)
- Vabysmo(0)
- Vaccine availability survey(0)
- Vaccine Monitoring Platform(0)
- Vaccines for pandemic influenza(0)
- Vaccines Working Party(0)
- Vaccines Working Party closed workshop on correlates for the protection and serological assays for influenza vaccines(0)
- Vaccines Working Party documents(0)
- Vaccinii macrocarpi fructus(0)
- Vafseo(0)
- Vaginal ring to reduce the risk of HIV infection for women in nonEU countries with high disease burden(0)
- Vahid Taravati(0)
- Vaida Kurapkiene(0)
- Vaida Palakauske(0)
- Vaida Ribokaitė(0)
- Valbazen 100 mg/ml Total Spectrum Wormer oral suspension and associated names including its generic/hybrid products(0)
- Valdas Liukaitis(0)
- Valdemaras Brusokas(0)
- Valdoxan(0)
- Valdyn(0)
- Valdyn previously Kudeq(0)
- Valentina Blahova(0)
- Valentina Conti(0)
- Valentina Di Giovanni(0)
- Valentina Lorenzi(0)
- Valentina Salvati(0)
- Valentina Vivod(0)
- Valeria Di Muzio(0)
- Valerianae aetheroleum(0)
- Valerianae radix(0)
- Valerianae radix and Lupuli flos(0)
- Valeria Zoccano(0)
- Valerie Colin(0)
- Valérie Darmon(0)
- Valerie DENUX(0)
- Valerie Lescrainier(0)
- Valerie Lievre(0)
- Valerie Nataf(0)
- Valerie Niederwieser(0)
- Valerie Willox(0)
- Valeska Reichel(0)
- Valgerdur Gudrun Gunnarsdottir(0)
- Validation of immunoassay for the detection of antibody to human immunodeficiency virus in plasma pools Scientific guideline(0)
- Validation of immunoassay for the detection of hepatitis B virus surface antigen in plasma pools Scientific guideline(0)
- Validity of a marketing authorisation veterinary medicines(0)
- Vallo Tillmann(0)
- valproate(0)
- Valsartan from Mylan laboratories in India can no longer be used in EU medicines due to NDEA impurity(0)
- Valsartan review of impurities extended to other sartan medicines(0)
- Valtropin(0)
- Vanda Pharmaceuticals Ltd withdraws its marketingauthorisation application for Fanaptum iloperidone(0)
- Vanda Randi(0)
- Vandetanib productspecific bioequivalence guidance(0)
- Vanditi Rajan(0)
- VANESA GUILLEN CASLA(0)
- Vanessa Grima(0)
- Vanessa Respondek(0)
- Vanflyta(0)
- Van Hoc Nguyen(0)
- Vaniqa(0)
- Vanja Kilibarda(0)
- Vantavo previously Alendronate sodium and colecalciferol MSD(0)
- Vantobra(0)
- Vantobra previously Tobramycin PARI(0)
- Vargatef(0)
- Variations for veterinary medicines(0)
- Variations guidance under Regulation EC No 1234/2008 and Regulation EU No 712/2012(0)
- Variations including extensions of marketing authorisations(0)
- Variations not already listed veterinary medicines(0)
- Variations not requiring assessment veterinary medicines(0)
- Variations regulation regulatory and procedural guidance(0)
- Variations requiring assessment veterinary medicines(0)
- VarroMed(0)
- Varuby(0)
- Vasileios Loutas(0)
- Vasileios Sakalis(0)
- VASILIKI NIKOU(0)
- VASILIKI PANTELEON(0)
- VasilikiRafaela Vakouftsi(0)
- Vasiliki Styliani Barmpatsalou(0)
- Vasotop P(0)
- Vassilis Violakis(0)
- vasvija zubcevic kobilic(0)
- Vaxchora(0)
- Vaxelis(0)
- Vaxneuvance(0)
- Vaxxitek HVT+IBD(0)
- Vaxzevria EMA advises against use in people with history of capillary leak syndrome(0)
- Vaxzevria further advice on blood clots and low blood platelets(0)
- Vaxzevria previously COVID19 Vaccine AstraZeneca(0)
- Vazkepa(0)
- Vectibix(0)
- Vectormune FP ILT(0)
- Vectormune FP ILT + AE(0)
- Vectormune ND(0)
- Vectra 3D(0)
- Vectra Felis(0)
- Vedrop(0)
- Veera Vaharautio(0)
- Vegzelma(0)
- Veikko Ulvi(0)
- Vekacia(0)
- Veklury(0)
- Velactis(0)
- Velcade(0)
- Vello Thomasson(0)
- Velmetia(0)
- Velosulin(0)
- Velphoro(0)
- Velsipity(0)
- Veltassa(0)
- Vemlidy(0)
- Vemurafenib productspecific bioequivalence guidance(0)
- Venclyxto(0)
- Venke Skibeli(0)
- Ventavis(0)
- Venvia(0)
- Veoza(0)
- Vepacel(0)
- Vepured(0)
- Vera Branquinho(0)
- Veraflox(0)
- Vera Mahler(0)
- VeraSeal(0)
- Veraseal(0)
- Verbasci flos(0)
- Verbenae citriodorae folium(0)
- Verena Brand(0)
- Verena Jakel(0)
- Verena Kluempers(0)
- Verena Plattner(0)
- Verena Scheer(0)
- Verkazia(0)
- Vernakalant hydrochloride(0)
- Veronica Devesa(0)
- Veronica Fridh(0)
- VERONICA GARCIA GIL(0)
- Verónica García Morales(0)
- Veronica Krogstad(0)
- veronika bártová(0)
- Veronika Descikova(0)
- Veronika Horvath(0)
- Veronika Kunstekova(0)
- Veronika Pisazka(0)
- Veronika Pós(0)
- Veronique Deffarges(0)
- Verquvo(0)
- Versican Plus DHPPi(0)
- Versican Plus DHPPi/L4(0)
- Versican Plus DHPPi/L4R(0)
- Versican Plus L4(0)
- Versican Plus Pi(0)
- Versican Plus Pi/L4(0)
- Versican Plus Pi/L4R(0)
- Versiguard SARS CoV2(0)
- Verzenios(0)
- Vesa Kiviniemi(0)
- Vesa Lund(0)
- Vesa Mustalammi(0)
- Veselina SkrinskaKirilova(0)
- Veselinka Vukicevic(0)
- Veterinary big data(0)
- Veterinary Big Data stakeholder forum(0)
- Veterinary esubmission workshop(0)
- Veterinary focus group meeting Committee for Medicinal Products for Veterinary Use bioequivalence guideline revision(0)
- Veterinary Focus group Meeting PK/PD modelling(0)
- Veterinary focus group meeting with stakeholders revision of the reflection paper on anthelmintic resistance(0)
- Veterinary good pharmacovigilance practices VGVP(0)
- Veterinary limited markets(0)
- Veterinary medicinal products containing a combination of lincomycin and spectinomycin to be administered orally to pigs and or poultry(0)
- Veterinary medicinal products containing gentamicin presented as solutions for injection to be administered to cattle and pigs(0)
- Veterinary medicinal products containing Nmethyl pyrrolidone as an excipient(0)
- Veterinary medicinal products containing paromomycin to be administered parenterally to pigs(0)
- Veterinary medicinal products containing toltrazuril to be administered orally to chickens(0)
- Veterinary medicinal products containing tylosin base as a single active substance presented as solutions for injection for intramuscular use in pigs(0)
- Veterinary medicinal products containing tylosin presented as solution for injection to be administered to sheep(0)
- Veterinary medicinal products containing tylosin to be administered orally via feed or the drinking water to pigs(0)
- Veterinary medicinal products controlling Varroa destructor parasitosis in bees Scientific guideline(0)
- Veterinary medicinal products for fluid therapy in case of diarrhoea Scientific guideline(0)
- Veterinary medicinal products for zootechnical purposes Scientific guideline(0)
- Veterinary Medicinal Products Regulation(0)
- Veterinary Medicines(0)
- Veterinary Medicines Availability minor uses/minor species(0)
- Veterinary medicines containing enrofloxacin to be administered via the drinking water to chickens and/or turkeys(0)
- Veterinary medicines highlights of 2015(0)
- Veterinary medicines highlights of 2016(0)
- Veterinary medicines highlights of 2017(0)
- Veterinary medicines highlights of 2018(0)
- Veterinary medicines highlights of 2019(0)
- Veterinary medicines highlights of 2020(0)
- Veterinary medicines highlights of 2021(0)
- Veterinary medicines highlights of 2022(0)
- Veterinary medicines Highlights of 2023(0)
- Veterinary pharmacovigilance inspections Q&As(0)
- Veterinary postauthorisation guidance updated with new sections and questions(0)
- Veterinary preauthorisation guidance(0)
- Veterinary preauthorisation guidance under Directive 2001/82/EC and Regulation EU 726/2004(0)
- Veterinary presubmission Q&A 120(0)
- Veterinary presubmission Q&A 2140(0)
- Veterinary product information templates(0)
- Veterinary regulatory overview(0)
- Veterinary Scientific Advice Workshop(0)
- Vey Tosal 100 mg/ml + 005 mg/ml solution for injection for horses cattle dogs and cats and associated names(0)
- Veyvondi(0)
- Vfend(0)
- Viagra(0)
- Vibativ(0)
- Vibeke Lindberg(0)
- VICH GL1 Validation of analytical procedures definition and terminology Scientific guideline(0)
- VICH GL2 Validation of analytical procedures methodology Scientific guideline(0)
- VICH GL3 Stability testing of new veterinary drug substances and medicinal products Scientific guideline(0)
- VICH GL4 Stability testing for new veterinary dosage forms Scientific guideline(0)
- VICH GL5 Stability testing photostability testing of new veterinary drug substances and medicinal products Scientific guideline(0)
- VICH GL6 Environmental impact assessment EIAS for veterinary medicinal products Phase I Scientific guideline(0)
- VICH GL7 Efficacy of anthelmintics general requirements Scientific guideline(0)
- VICH GL8 Stability testing for medicated premixes Scientific guideline(0)
- VICH GL9 Good clinical practices Scientific guideline(0)
- VICH GL10 Impurities in new veterinary drug substances Scientific guideline(0)
- VICH GL11 Impurities in new veterinary medicinal products Scientific guideline(0)
- VICH GL12 Efficacy of anthelmintics specific recommendations for bovines Scientific guideline(0)
- VICH GL13 Efficacy of anthelmintics specific requirements for ovines Scientific guideline(0)
- VICH GL14 Efficacy of anthelmintics specific requirements for caprines Scientific guideline(0)
- VICH GL15 Efficacy of anthelmintics specific recommendations for equines Scientific guideline(0)
- VICH GL16 Efficacy of anthelmintics specific requirements for porcines Scientific guideline(0)
- VICH GL17 Stability testing of biotechnological/biological veterinary medicinal products Scientific guideline(0)
- VICH GL18R2 impurities residual solvents in new veterinary medicinal products active substances and excipients Scientific guideline(0)
- VICH GL19 Efficacy of anthelmintics specific recommendations for canines Scientific guideline(0)
- VICH GL20 Efficacy of anthelmintics specific recommendations for felines Scientific guideline(0)
- VICH GL21 Efficacy of anthelmintics specific recommendations for chickens Scientific guideline(0)
- VICH GL22 Safety studies for veterinary drug residues in human food reproduction studies Scientific guideline(0)
- VICH GL23 Studies to evaluate the safety of residues of veterinary drugs in human food genotoxicity testing Scientific guideline(0)
- VICH GL25 Biologicals testing of residual formaldehyde Scientific guideline(0)
- VICH GL26 Biologicals testing of residual moisture Scientific guideline(0)
- VICH GL27 Guidance on the preapproval information for registration of new veterinary medicinal products for foodproducing animals with respect to antimicrobial resistance Scientific guideline(0)
- VICH GL28 Studies to evaluate the safety of veterinary drugs in human carcinogenicity testing Scientific guideline(0)
- VICH GL31 Safety studies for veterinary drug residues in human food repeatdose 90 toxicity testing Scientific guideline(0)
- VICH GL32 Studies to evaluate the safety of residues of veterinary drugs in human food developmental toxicity testing Scientific guideline(0)
- VICH GL33 Safety studies for veterinary drug residues in human food general approach to testing Scientific guideline(0)
- VICH GL34 Biologicals testing for the detection of Mycoplasma contamination Scientific guideline(0)
- VICH GL36 Studies to evaluate the safety of residues of veterinary drugs in human food General approach to establish a microbiological ADI Scientific guideline(0)
- VICH GL37 Safety of veterinary drugs in human food repeatdose chronic toxicity testing Scientific guideline(0)
- VICH GL38 Environmental impact assessments for veterinary medicinal products Phase II Scientific guideline(0)
- VICH GL39 Test procedures and acceptance criteria for new veterinary drug substances and new medicinal products chemical substances Scientific guideline(0)
- VICH GL40 Test procedures and acceptance criteria for new biotechnological/biological veterinary medicinal products Scientific guideline(0)
- VICH GL41 Target animal safety examination of live veterinary vaccines in target animals for absence of reversion to virulence Scientific guideline(0)
- VICH GL43 Target animal safety pharmaceuticals Scientific guideline(0)
- VICH GL44 Target animal safety for veterinary live and inactivated vaccines Scientific guideline(0)
- VICH GL45 Bracketing and matrixing designs for stability testing of new veterinary drug substances and medicinal products Scientific guideline(0)
- VICH GL46 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in foodproducing animals metabolism study to determine the quantity and identify the nature of residues Scientific guideline(0)
- VICH GL47 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in foodproducing animals laboratory animal comparative metabolism studies Scientific guideline(0)
- VICH GL48 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in foodproducing animals Markerresiduedepletion studies to establish product withdrawal periods Scientific guideline(0)
- VICH GL49 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in foodproducing animals validation of analytical methods used in residue depletion studies Scientific guideline(0)
- VICH GL50 Harmonisation of criteria to waive target animal batch safety testing for inactivated vaccines for veterinary use Scientific guideline(0)
- VICH GL51 Quality statistical evaluation of stability data Scientific guideline(0)
- VICH GL52 Bioequivalence blood level bioequivalence study Scientific guideline(0)
- VICH GL54 Studies to evaluate the safety of residues of veterinary drugs in human food general approach to establish an acute reference dose ARfD Scientific guideline(0)
- VICH GL55 Harmonisation of criteria to waive target animal batch safety testing for live vaccines for veterinary use Scientific guideline(0)
- VICH GL56 Studies to evaluate the metabolism and residue kinetics of veterinary drugs in foodproducing species study design recommendations for residue studies in honey for establishing MRLs and withdrawal periods Scientific guideline(0)
- VICH GL57 on studies to evaluate the metabolism and residue kinetics of veterinary drugs in foodproducing species marker residue depletion studies to establish product withdrawal periods in aquatic species Scientific guideline(0)
- VICH GL58 stability testing of new veterinary drug substances and medicinal products in climatic zones III and IV Scientific guideline(0)
- VICH GL60 Good manufacturing practice for active ingredients used in veterinary medicinal products Scientific guideline(0)
- VICH GL61 Pharmaceutical Development Scientific guideline(0)
- Vicki Shimizu(0)
- Vicriviroc maleate(0)
- Víctor Fuentes(0)
- Victoria Hamelinck(0)
- Victoria Romero Pazos(0)
- Victor Mangas Sanjuan(0)
- Victoza(0)
- Victrelis(0)
- Vida Kevaliene(0)
- Vidaza(0)
- VidPrevtyn Beta(0)
- Viekirax(0)
- Vihuma(0)
- Vijoice(0)
- Viktor Billes(0)
- Viktoriia Starokozhko(0)
- Viktorija Pruse(0)
- Viktor Rognås(0)
- Vildagliptin / Metformin hydrochloride Accord(0)
- Vilma Dosedlova(0)
- Vilma Petrikaite(0)
- Vimizim(0)
- Vimpat(0)
- Vincent CLAUS(0)
- Vincent Debruycker(0)
- Vincent Gazin(0)
- Vincent Neuviale(0)
- Vincenza Giuseppina Azzarà(0)
- Viola Bardoczy(0)
- Violae herba cum flore(0)
- Violaine Closson Carella(0)
- Violaine FRANCOIS(0)
- Violaine Vermillard(0)
- Viola Middelhauve(0)
- Violeta Georgieva Tsonkova(0)
- Violeta StoyanovaBeninska(0)
- Violeta Tamasdan(0)
- Violette Dirix(0)
- Vipdomet(0)
- Vipidia(0)
- Viracept(0)
- Viraferon(0)
- ViraferonPeg(0)
- Viral diseases(0)
- Viral safety of oral poliovirus vaccine OPV Scientific guideline(0)
- Viral safety of plasmaderived medicinal products with respect to hepatitis E virus Scientific guideline(0)
- Viramune(0)
- Virbagen Omega(0)
- Viread(0)
- Virgilio Donini(0)
- Virginia Cuconato(0)
- Virginia Safra(0)
- Virginie Hivert(0)
- Virginie Pithon(0)
- Virtual live handson training course for Clinical Trials Sponsors using EudraVigilance System(0)
- Virtual live handson training course for Clinical Trials Sponsors using EudraVigilance system(0)
- Virtual live handson training course for clinical trials sponsors using EudraVigilance system(0)
- Virus safety evaluation of biotechnological investigational medicinal products Scientific guideline(0)
- Virus validation studies the design contribution and interpretation of studies validating the inactivation and removal of viruses Scientific guideline(0)
- Virve Aromaa(0)
- Visci albi herba(0)
- Visit of GIRP European Association of Pharmaceutical Fullline Wholesalers(0)
- Visit of IberoAmerican regulatory authorities to the Spanish Ministry of Health and Consumer Affairs Madrid and to the EMEA London(0)
- Visit of the Danish Association of the Pharmaceutical Industry(0)
- Visit of the East African Community EAC(0)
- Vismodegib productspecific bioequivalence guidance(0)
- Visnja Drinovac Vlah(0)
- Vistide(0)
- Visudyne(0)
- Vitalis Briedis(0)
- Vita SimonyteVerbickiene(0)
- Vitekta(0)
- Vitis viniferae folium(0)
- Vitragan(0)
- Vitrakvi(0)
- Vitrasert Implant(0)
- Vitravene(0)
- Vittorio Del Grosso(0)
- Vittorio Simeon(0)
- Vivanza(0)
- VIVIANA ANGHEL(0)
- Viviana Giannuzzi(0)
- Vivien Molitor(0)
- Vivika Peets(0)
- Vivjoa(0)
- Vizamyl(0)
- Vizarsin(0)
- Vizimpro(0)
- Vladimir Bulatovic(0)
- Vladislav Petkov(0)
- Vladlena Pfeifer(0)
- Vlasta Zavadova(0)
- Vocabria(0)
- Voinka Dimitrova(0)
- Vokanamet(0)
- Volibris(0)
- Volker Vieth(0)
- Volker Windeisen(0)
- Voncento(0)
- Voraxaze(0)
- Voriconazole Accord(0)
- Voriconazole Hikma previously Voriconazole Hospira(0)
- Voriconazole productspecific bioequivalence guidance(0)
- Vorinostat MSD(0)
- Vortioxetine hydrobromide / vortioxetine lactate productspecific bioequivalence guidance(0)
- Vosevi(0)
- Votrient(0)
- Votubia(0)
- Voxzogo(0)
- Voydeya(0)
- Vpriv(0)
- Vueway(0)
- Vumerity(0)
- Vydura(0)
- Vyepti(0)
- Vylaer Spiromax(0)
- Vyndaqel(0)
- Vynfinit(0)
- Vynpenta previously AvacopanChemoCentryx(0)
- Vytautas Alseika(0)
- Vytautas Jakutis(0)
- Vyvgart(0)
- Vyxeos liposomal previously known as Vyxeos(0)
- W(0)
- wafa RAJHI(0)
- Wakix(0)
- Walburga Lutkehermolle(0)
- Walid OUMESSAD(0)
- Walter Johannes Beiersdorf(0)
- Walter Marrocco(0)
- Walter Matheis(0)
- Walther Honscha(0)
- Warner Chilcott UK Ltd withdraws its application for an extension of indication for Intrinsa(0)
- Warning on transmissible agents in summary of product characteristics and package leaflets for plasmaderived medicinal products Scientific guideline(0)
- Watch the live broadcast of EMAs workshop on bacteriophages on Monday 8 June from 0900(0)
- Water for injection prepared by reverse osmosis(0)
- Waylivra(0)
- Webinar for small and mediumsized enterprises SMEs and academia on the Clinical Trials Regulation and the Clinical Trials Information System CTIS(0)
- Webinar How can clinical research networks support developers of medicines for children(0)
- Webinar on EMAs categorisation of antibiotics used in animals(0)
- Webinar on Nationally Authorised Products NAPs release on Product Lifecycle Management PLM Portal electronic Application Forms eAFs(0)
- Webinar on regulatory and procedural aspects of applications for type I variations(0)
- Webinar on Regulatory Procedure Management for Product Lifecycle Management 1st rollout on IRIS(0)
- Webinar on reporting suspected side effects following administration of veterinary medicines(0)
- Webinar on requesting access to and using EMAs substance product organisation and referential SPOR application programming interface API(0)
- Webinar on submissions of parallel distribution notifications for centrally authorised products CAPs(0)
- Webinar on the draft Data Quality Framework for EU medicines regulation(0)
- Webinar on the Union Product Database Data Quality Framework(0)
- Webinar on veterinary pharmacovigilance PhV inspections and systems their quality management systems and PhV system master files Introduction and principles(0)
- Website outages and upgrades(0)
- Wegovy(0)
- Wendy van Loon(0)
- Wendy Yared(0)
- Werner Knöss(0)
- Werner Terhalle(0)
- West Nile virus and plasmaderived medicinal products Scientific guideline(0)
- Wezenla(0)
- What we do(0)
- What we publish on medicines and when(0)
- Wheat starch containing gluten(0)
- Who are the originators of innovative medicines in the EU(0)
- WHO collaborative procedure for registering medicines through reliance(0)
- WHO declares influenza pandemic European Medicines Agency initiates crisismanagement plan(0)
- Who we are(0)
- Why EMA matters to European citizens(0)
- Wiebke Godow(0)
- Wiebke Kirsten SeemannRoch(0)
- Wiebke Loebker(0)
- Wiebke Marie Luise Hoppensack(0)
- Wiebke Weiher(0)
- Wieslawa Kondracka(0)
- Wilfried De Backer(0)
- Wilhelm Johan de Waard(0)
- Wilhelmus Simons(0)
- Willem de Boode(0)
- Willemijn Ekkenbus(0)
- Willem Verweij(0)
- William FitzGerald(0)
- William Kenneth Casler(0)
- Wilma FischerBarth(0)
- Wilma Knol(0)
- Wilzin(0)
- Wim Oyen(0)
- Wim Penninckx(0)
- Wim Van Linden(0)
- Wim Van Molle(0)
- Wim Van Paesschen(0)
- Winfried Rütz(0)
- Winfuran(0)
- Withaniae somniferae radix(0)
- Withdrawal of marketing authorisations for fenspiride medicines(0)
- Withdrawal of pain medicine flupirtine endorsed(0)
- Withdrawn applications and products(0)
- Wojciech Dymowski(0)
- Wolfgang Herzog(0)
- Wolfgang Jacquet(0)
- Wolfgang Löscher(0)
- Wolfgang Sipos(0)
- Wolfgang Willenbacher(0)
- Women taking Esmya for uterine fibroids to have regular liver tests while EMA review is ongoing(0)
- Wording of Helicobacter pylori eradication therapy in selected summaryofproductcharacteristics sections Scientific guideline(0)
- Working Group on Quality Review of Documents(0)
- Working parties and other groups(0)
- Working parties for healthcare professionals and for patients and consumers elect new cochairs(0)
- Working Party on European Union Monographs and European Union List(0)
- Working together for people with rare and complex diseases(0)
- Working together for safe medicines in the EU(0)
- Working with stakeholders(0)
- Working with stakeholders to improve availability of medicines in the EU(0)
- Work programmes(0)
- Worksharing of variations veterinary medicines(0)
- Worksharing questions and answers(0)
- Workshop addressing unmet needs of children with pulmonary arterial hypertension(0)
- Workshop advancing regulatory science to 2025 for veterinary medicines(0)
- Workshop for micro small and mediumsized enterprises SMEs European Medicines Agency regulatory support pre and postauthorisation(0)
- Workshop for micro small and mediumsized enterprises statistical perspectives in regulatory clinical development programmes(0)
- Workshop In vitro cytokinerelease assays(0)
- Workshop measuring the impact of pharmacovigilance activities(0)
- Workshop on access to clinicaltrial data and transparency kicks off process towards proactive publication of data(0)
- Workshop on adaptive pathways discussing a concept for development of medicines addressing unmet medical needs(0)
- Workshop on adaptive pathways discussion on development approach for medicines addressing unmet medical needs(0)
- Workshop on benefitrisk of medicines used during pregnancy and breastfeeding(0)
- Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies(0)
- Workshop on biosimilars(0)
- Workshop on biosimilars takes place today(0)
- Workshop on clinical development and scientific advice in ophthalmology(0)
- Workshop on clinical investigation of new medicines for the treatment of multiple sclerosis takes place today(0)
- Workshop on clinical outcome measures and endpoints for efficacy assessment in spinal muscular atrophy(0)
- Workshop on clinicaltrial data and transparency(0)
- Workshop on clinicaltrial data and transparency this afternoon(0)
- Workshop on conflicts of interests deadline for registration extended(0)
- Workshop on demonstrating significant benefit of orphan medicines concepts methodology and impact on access(0)
- Workshop on development of new antibacterial medicines(0)
- Workshop on development pathways for advancedtherapy medicinal products(0)
- Workshop on draft guideline on requirements for firstinman clinical trials for potential highrisk medicinal products(0)
- Workshop on endpoints for cystic fibrosis clinical trials(0)
- Workshop on firstline acute promyelocytic leukaemia treatment European Union cooperative groups and the pharmaceutical industry(0)
- Workshop on FP7 and offpatent medicines developed for children(0)
- Workshop on generating clinical evidence for treatment and prevention options for longCOVID / postacute sequelae condition PASC(0)
- Workshop on generation and use of Health Based Exposure Limits HBEL(0)
- Workshop on good clinical practice for bioequivalence trials/generics(0)
- Workshop on haemophilia registries(0)
- Workshop on healthrelated quality of life in oncology(0)
- Workshop on how to better support medicine developers in the generation and preparation of quality data packages for PRIME and Breakthrough Therapy applications(0)
- Workshop on identifying opportunities for big data in medicines development and regulatory science(0)
- Workshop on immunogenicity assessment of biotechnologyderived therapeutic proteins(0)
- Workshop on making Article 58 and other European Medicines Agency outputs more relevant for nonEU regulators(0)
- Workshop on measuring the impact of pharmacovigilance activities(0)
- Workshop on medicines for bees What the European Medicines Agency can do to increase availability(0)
- Workshop on methods for efficacy studies in everyday medical practice(0)
- Workshop on Neonates(0)
- Workshop on paediatric formulations for assessors in national regulatory agencies(0)
- Workshop on paediatric investigation plans in type2 diabetes mellitus(0)
- Workshop on Paediatric pain(0)
- Workshop on Paediatric Regulation stakeholders to discuss how to boost development of medicines for children(0)
- Workshop on patientsupport programmes PSPs and marketresearch programmes MSPs Understanding the diversity of such programmes and the management of safety information(0)
- Workshop on product shortages due to manufacturing and quality problems Developing a proactive approach to prevention(0)
- Workshop on qualification and reporting of physiologicallybased pharmacokinetic PBPK modelling and simulation(0)
- Workshop on regulatory options in fight against antimicrobial resistance takes place today(0)
- Workshop on regulatory support for development of orphan medicines(0)
- Workshop on revising the guideline on strategies to identify and mitigate risks for firstinhuman clinical trials with investigational medicines(0)
- Workshop on singlearm trials in oncology(0)
- Workshop on site and histology Independent indications in oncology(0)
- Workshop on support for orphan medicines development(0)
- Workshop on the application of the General Data Protection Regulation GDPR in the area of health and Secondary Use of Data for Medicines and Public Health Purposes(0)
- Workshop on the challenges for the approval of anticancer immunotherapeutic drugs(0)
- Workshop on the clinical investigation of new medicines for the treatment of multiple sclerosis(0)
- Workshop on the development of an EMEA transparency policy(0)
- Workshop on the development of antimicrobial medicinal products for paediatric patients(0)
- Workshop on the development of new medicines to treat tuberculosis(0)
- Workshop on the draft guideline on registrybased studies(0)
- Workshop on the General Data Protection Regulation GDPR and secondary use of data for medicines and public health purposes(0)
- Workshop on the Guideline on pharmaceutical development of medicines for paediatric use(0)
- Workshop on the implementation of ISO standard for individual case safety reports ICSRs(0)
- Workshop on the reflection paper on statistical methodology for the comparative assessment of quality attributes in drug development(0)
- Workshop on the role of registries in the monitoring of cancer therapies based on genetic and molecular features(0)
- Workshop on the therapeutic use of bacteriophages(0)
- Workshop on the use of pharmacokinetics and pharmacodynamics in the development of antibacterial medicinal products(0)
- Workshop on transparency and access to documents of the EMEA of the 30 October 1997(0)
- Workshop on vaccine development against the Schmallenberg virus(0)
- Workshop on veterinary regulatory support for micro small and mediumsized enterprises SMEs(0)
- Workshop on viral safety of plasmaderived medicinal products with respect to hepatitis E virus(0)
- Workshop safe use of medicines during pregnancy and breastfeeding(0)
- Workshops for micro small and mediumsized enterprises focus on nonclinical aspects(0)
- Workshop significant benefit of orphan drugs concepts and future developments(0)
- Workshop towards new treatments for tuberculosis(0)
- Workshop User testing and how to review the data(0)
- Workshop Veterinary pharmacovigilance question time better regulation for electronic reporting and periodic safety update reports PSURs(0)
- Workshop working towards new therapies for spinal muscular atrophy(0)
- World AIDS Day 1 December 2010(0)
- World AIDS Day 1 December 2011(0)
- World AIDS Day 1 December 2012(0)
- World AIDS Day 2013 Revised guidance to facilitate development of new medicines(0)
- World Alzheimers Day 21 September 2011(0)
- World Alzheimers Month September 2012(0)
- World Alzheimers Month Supporting development of medicines by qualification of biomarkers(0)
- World Arthritis Day(0)
- World Arthritis Day 12 October 2011(0)
- World Arthritis Day 12 October 2012(0)
- World Arthritis Day 12 October 2013(0)
- World Cancer Day 4 February 2011(0)
- World Cancer Day 4 February 2012(0)
- World Cancer Day 4 February 2013(0)
- World Diabetes Day 14 November 2011(0)
- World Diabetes Day 14 November 2012(0)
- World Diabetes Day more treatment options to meet needs of growing patient numbers(0)
- World Health Day 7 April 2012(0)
- World Health Day 2014 focus on diseases transmitted by vectors(0)
- World Health Day 2015(0)
- World Health Day on 7 April 2013 focus on high blood pressure(0)
- World Health Organization international consultation on regulatory systems strengthening(0)
- World Health Organization WHO(0)
- World Heart Day 29 September 2011(0)
- World Heart Day 29 September 2012(0)
- World Heart Day more guidance for medicines developers(0)
- World Hepatitis Day 28 July 2012(0)
- World Hepatitis Day 28 July 2013(0)
- World Hepatitis Day European Medicines Agency uses regulatory tools to facilitate patient access to innovative medicines(0)
- World Hypertension Day 17 May 2012(0)
- World Hypertension Day 17 May 2013(0)
- World Kidney Day 8 March 2012(0)
- World Mental Health Day 10 October 2012(0)
- World Mental Health Day 10 October 2013(0)
- World Organisation for Animal Health OIE(0)
- World TB Day three new medicines recommended in last six months for patients with multidrugresistant tuberculosis(0)
- World Veterinary Day 28 April 2012(0)
- World Veterinary Day 2014 focus on animal welfare(0)
- World Veterinary Day on 27 April 2013 Vaccination to prevent and protect(0)
- Wouter Hoogenboom(0)
- Wouter Iwema Bakker(0)
- Wouter Jasper Van Brussel(0)
- Wyeth Consumer Healthcare withdraws its marketing authorisation application for Ibuprofen/Diphenhydramine Hydrochloride Wyeth(0)
- Wyeth Europa Limited withdraws its marketing authorisation application for Brilence(0)
- Wyeth Europa Ltd withdraws its marketing authorisation application for Ellefore(0)
- Wyeth Europa Ltd withdraws its marketing authorisation application forPristiqs desvenlafaxine(0)
- Wyeth withdraws its application to extend the marketing authorisation for Tygacil(0)
- Wyost(0)
- Xadago(0)
- Xagrid(0)
- Xalkori(0)
- Xaluprine previously Mercaptopurine Nova Laboratories(0)
- Xapit(0)
- Xarelto(0)
- Xavier Chenivesse(0)
- Xavier Fritel(0)
- Xavier Goossens(0)
- Xavier Kurz(0)
- Xavier Pepermans(0)
- Xavier Vantyghem(0)
- Xegafri(0)
- Xelevia(0)
- Xeloda(0)
- Xeloda / Capecitabine Accord / Capecitabine Medac / Capecitabine Teva / Ecansya previously Capecitabine Krka / Teysuno(0)
- Xenia Dimont(0)
- Xenia Patricia von Kruger(0)
- Xenical(0)
- Xenleta(0)
- Xenogeneic cellbased medicinal products Scientific guideline(0)
- Xenpozyme(0)
- Xeplion(0)
- Xerava(0)
- Xermelo(0)
- Xevudy(0)
- Xgeva(0)
- Xiaofei Liu(0)
- Xiaoyu Niu(0)
- Xiapex(0)
- Xigduo(0)
- Xigris(0)
- Xigris drotrecogin alfa activated to be withdrawn due to lack of efficacy(0)
- Xiidra(0)
- Xiliarx(0)
- Ximelagatran 36 mg film coated tablets(0)
- Ximluci(0)
- Xofluza(0)
- Xolair(0)
- Xospata(0)
- Xoterna Breezhaler(0)
- Xromi(0)
- Xtandi(0)
- Xultophy(0)
- Xydalba(0)
- Xyndari(0)
- Xyrem(0)
- Yalchin Mammadov(0)
- YANICA CASSAR(0)
- YannaMarina Chevalme(0)
- Yannis Azzopardi(0)
- Yann Le Cam(0)
- Yanourishka Jansen(0)
- Yargesa(0)
- Yarvitan(0)
- Yasemin Suzer(0)
- Yasmina Vodenicharska(0)
- Yasmín Douhal Fernández(0)
- Yasmin Molter(0)
- Yasuhiro Araki(0)
- Yellox(0)
- Yen Pham(0)
- Yentreve(0)
- Yervoy(0)
- Yesafili(0)
- Yescarta(0)
- YIANNOULA KOULLA(0)
- YiFang Cheng(0)
- Yioryos Evangelides(0)
- Yolanda Varas(0)
- Yorvipath(0)
- Youssef SHAIM(0)
- Ypozane(0)
- Yselty(0)
- Yseult Brun(0)
- Ytracis(0)
- Yttriga(0)
- Yuansheng Sun(0)
- Yuflyma(0)
- Yuliya Viskachkene(0)
- YURVAC RHD(0)
- Yvonne Dorothea Palmer(0)
- Yvonne Lao(0)
- Yvonne Looney(0)
- Yvonne Mein(0)
- Yvonne Odekerken Rombouts(0)
- Zabdeno(0)
- Zactima(0)
- Zactran(0)
- Zafiride(0)
- Zaiga Neidere(0)
- Zakariás El Koulali(0)
- Zalasta(0)
- Zalmoxis(0)
- Zaltrap(0)
- Zalviso(0)
- Zanda Auce(0)
- Zane Kalnina(0)
- Zane Neikena(0)
- Zane Stade(0)
- Zane Valškēvica(0)
- Zanil and associated names and generic products thereof(0)
- Zartra(0)
- Zarzio(0)
- Zavesca(0)
- Zavicefta(0)
- Zdeňka Malanova(0)
- Zdenka Maskova(0)
- Zdenka Mertova(0)
- Zebinix(0)
- Zeffix(0)
- Zeftera previously Zevtera(0)
- Zefylti(0)
- Zejula(0)
- Zektayos Hepjuvo(0)
- Zelboraf(0)
- Zeleris(0)
- Željka Davosir Klarić(0)
- Zelnorm(0)
- Zemdri(0)
- Zemfirza(0)
- Zena Gunther(0)
- Zenalpha(0)
- Zenapax(0)
- Zenhale(0)
- Zepatier(0)
- Zeposia(0)
- Zerbaxa(0)
- Zercepac(0)
- Zerene(0)
- Zerit(0)
- Zessly(0)
- Zevalin(0)
- Zhiyi You(0)
- Ziagen(0)
- Ziextenzo(0)
- Zika(0)
- Zika virus infection plasma and urinederived medicines safe to use(0)
- Zilbrysq(0)
- Zimbus Breezhaler(0)
- Zimulti(0)
- Zinc oxide(0)
- Zinforo(0)
- Zingiberis rhizoma(0)
- Zinplava(0)
- Zioxtenzo(0)
- Zirabev(0)
- Zoely(0)
- Zoe Waibler(0)
- Zokinvy(0)
- Zoledronic Acid Accord(0)
- Zoledronic acid Actavis(0)
- Zoledronic Acid Hospira(0)
- Zoledronic acid medac(0)
- Zoledronic acid Mylan(0)
- Zoledronic acid Teva(0)
- Zoledronic acid Teva Generics(0)
- Zoledronic acid Teva Pharma(0)
- Zolgensma(0)
- Zolsketil pegylated liposomal(0)
- Zoltan Szaller(0)
- Zolvix(0)
- Zomarist(0)
- Zometa(0)
- Zonegran(0)
- Zonisamide Mylan(0)
- Zonisamide productspecific bioequivalence guidance(0)
- Zontivity(0)
- Zoonotic Influenza Vaccine Seqirus(0)
- Zostavax(0)
- Zsófia BALLA(0)
- Zsofia Gyulai(0)
- Zsuzsanna Birone Dr Sandor(0)
- Zsuzsanna Gonda(0)
- Ztalmy(0)
- Zubrin(0)
- Zubsolv(0)
- Zuleika Michelini(0)
- Zulvac 1 Bovis(0)
- Zulvac 1 Ovis(0)
- Zulvac 1+8 Bovis(0)
- Zulvac 1+8 Ovis(0)
- Zulvac 8 Bovis(0)
- Zulvac 8 Ovis(0)
- Zulvac BTV(0)
- Zulvac SBV(0)
- Zunrisa(0)
- Zuprevo(0)
- Zurampic(0)
- Zutectra(0)
- Zuzana Barathova(0)
- Zuzana Chaloupková(0)
- Zuzana Dobiášová(0)
- Zuzana Dzupinova(0)
- zuzana egyud(0)
- Zuzana Fliegerová(0)
- Zuzana Porubska(0)
- Zvjezdana Rehorovic(0)
- Zyclara(0)
- Zycortal(0)
- Zydax(0)
- Zykadia(0)
- Zykadia recommended for approval in advanced non small cell lung cancer(0)
- Zyllt(0)
- Zynlonta(0)
- Zynquista(0)
- Zynrelef(0)
- Zynyz(0)
- Zypadhera(0)
- Zyprexa(0)
- Zyprexa Velotab(0)
- Zytiga(0)
- Article 31 referrals
- Article 29(4) referrals
- Article 30 referrals
- Article 20 procedures
- Article 6(12) referrals (prior to January 2010)
- Article 107 procedures (prior to July 2012)
- Article 29 paediatrics
- Article 36 referrals (prior to July 2012)
- Article 107i procedures
- Article 13 referrals
- Article 6(13) referrals (prior to January 2010)
- Article 5(11) referrals (prior to January 2010)
- Article 13
- Article 33
- Article 34
- Article 35
- Article 78
- Article 82
- Articles 39 and 40
- CHMP/289490/05(2)
- CPMP/2852/02(2)
- EMEA/H/A-30/1300, EMEA/H/A-30/1320(2)
- EMEA/H/A-31/1337(2)
- EMEA/H/A-107(2)
- CHMP/40502/08(1)
- CHMP/45404/2009(1)
- CHMP/45405/2009(1)
- CHMP/46089/06(1)
- CHMP/75066/07(1)
- CHMP/75285/07(1)
- CHMP/80270/06, CHMP/262776/05(1)
- CHMP/85200/2009(1)
- CHMP/85997/06(1)
- CHMP/94618/05(1)
- CHMP/97898/2009(1)
- CHMP/106563/06(1)
- CHMP/113861/2009(1)
- CHMP/137577/2009(1)
- CHMP/142335/06(1)
- CHMP/144030/07(1)
- CHMP/145829/05(1)
- CHMP/150525/2009(1)
- CHMP/151554/08(1)
- CHMP/169383/06(1)
- CHMP/173455/2009(1)
- CHMP/173797/2009(1)
- CHMP/187488/04(1)
- CHMP/194784/2009(1)
- CHMP/194790/2009(1)
- CHMP/204584/2009(1)
- CHMP/212107/08(1)
- CHMP/212114/08(1)
- CHMP/212746/06(1)
- CHMP/233264/2009(1)
- CHMP/239500/2009(1)
- CHMP/247760/07(1)
- CHMP/248862/07(1)
- CHMP/262776/05(1)
- CHMP/283378/07(1)
- CHMP/287837/05(1)
- CHMP/296484/08(1)
- CHMP/306065/06(1)
- CHMP/306351/06(1)
- CHMP/306421/06(1)
- CHMP/306455/06(1)
- CHMP/308176/05(1)
- CHMP/308522/05(1)
- CHMP/319054/08(1)
- CHMP/323166/05(1)
- CHMP/324317/05(1)
- CHMP/324332/05(1)
- CHMP/331678/07(1)
- CHMP/332403/08(1)
- CHMP/336144/08(1)
- CHMP/336151/08(1)
- CHMP/336158/08(1)
- CHMP/338591/07(1)
- CHMP/350251/07(1)
- CHMP/350278/07(1)
- CHMP/373061/05(1)
- CHMP/373083/05(1)
- CHMP/373108/05(1)
- CHMP/378451/07(1)
- CHMP/380454/08(1)
- CHMP/380917/07(1)
- CHMP/384874/08(1)
- CHMP/384875/2008(1)
- CHMP/384876/2008(1)
- CHMP/384877/2008(1)
- CHMP/384879/08(1)
- CHMP/393579/2009(1)
- CHMP/405628/06(1)
- CHMP/407636/06(1)
- CHMP/408150/05(1)
- CHMP/422351/06(1)
- CHMP/423308/06(1)
- CHMP/423384/06(1)
- CHMP/423591/06(1)
- CHMP/423796/06(1)
- CHMP/428671/08(1)
- CHMP/430988/07(1)
- CHMP/432352/07(1)
- CHMP/433691/07(1)
- CHMP/438258/08(1)
- CHMP/454809/2009(1)
- CHMP/471052/07(1)
- CHMP/477258/06(1)
- CHMP/495795/07(1)
- CHMP/495840/07(1)
- CHMP/498198/07(1)
- CHMP/508212/07(1)
- CHMP/512295/08(1)
- CHMP/515890/06(1)
- CHMP/520140/07(1)
- CHMP/524135/08(1)
- CHMP/524251/08(1)
- CHMP/524284/08(1)
- CHMP/633842/2008(1)
- CHMP/634674/08(1)
- CHMP/675340/2009(1)
- CHMP/681374/2009(1)
- CHMP/683039/2009(1)
- CPMP/101-109/96, CPMP/111-112/96, CPMP/113-114/96(1)
- CPMP/375/97(1)
- CPMP/423/04(1)
- CPMP/459/04(1)
- CPMP/538/04(1)
- CPMP/540/04(1)
- CPMP/578/95(1)
- CPMP/600/02(1)
- CPMP/867/04(1)
- CPMP/869/04(1)
- CPMP/886/04/Final(1)
- CPMP/902/00(1)
- CPMP/931/95(1)
- CPMP/990/99(1)
- CPMP/1154/98(1)
- CPMP/1333/03(1)
- CPMP/1357/99(1)
- CPMP/1361/00(1)
- CPMP/1390/04(1)
- CPMP/1416/98(1)
- CPMP/1493/01(1)
- CPMP/1500/98(1)
- CPMP/1724/04(1)
- CPMP/1747/04(1)
- CPMP/1748/04(1)
- CPMP/1749/04(1)
- CPMP/1988/00(1)
- CPMP/2011/00(1)
- CPMP/2020/02(1)
- CPMP/2811/03(1)
- CPMP/2846/03(1)
- CPMP/3122/04(1)
- CPMP/3175/03(1)
- CPMP/3256/03(1)
- CPMP/3257/03(1)
- CPMP/3258/03(1)
- CPMP/3263/03(1)
- CPMP/3346/02(1)
- CPMP/3477/03(1)
- CPMP/3478/03(1)
- CPMP/3736/03(1)
- CPMP/3962/02(1)
- CPMP/4060/03(1)
- CPMP/4082/00(1)
- CPMP/4260/03(1)
- CPMP/4362/00(1)
- CPMP/4514/02(1)
- CPMP/4620/02(1)
- CPMP/4717/02(1)
- CPMP/4786/02(1)
- CPMP/6034/02(1)
- CPMP/6214/03(1)
- CPMP/6236/04(1)
- CPMP/24844/02(1)
- CPMP/32703/03(1)
- CPMP/34168/98(1)
- EMA-H-A-29(4)-1472(1)
- EMA/288359/2011(1)
- EMA/311974/2010(1)
- EMA/808179/2009, EMA/H/A-107/1256(1)
- EMA/811097/2009 Rev. 1(1)
- EMA/CHMP/763180/2011(1)
- EMA/H/A-13/1475(1)
- EMA/H/A-31/1361(1)
- EMEA-H-A-31-1528(1)
- EMEA/329177/2008, CHMP/542169/08(1)
- EMEA/533599/07(1)
- EMEA/658285/2008(1)
- EMEA/CHMP/416317/2005(1)
- EMEA/CPMP/539/04(1)
- EMEA/H-A20/1517/C/004214/0048; EMEA/H-A20/1517/C/005452/0003; EMEA/H-A20/1517/C/004085/0032; EMEA/H-A20/1517/C/004760/0017; EMEA/H-A20/1517/C/005113/0014(1)
- EMEA/H/6(13)/001188(1)
- EMEA/H/A-6(12)/1147(1)
- EMEA/H/A-6(12)/1312(1)
- EMEA/H/A-6(12)/1313(1)
- EMEA/H/A-13/1304(1)
- EMEA/H/A-13/1350(1)
- EMEA/H/A-13/1402(1)
- EMEA/H/A-13/1427(1)
- EMEA/H/A-13/1453(1)
- EMEA/H/A-20/1416/C/000603/0083(1)
- EMEA/H/A-20/1419(1)
- EMEA/H/A-20/1421(1)
- EMEA/H/A-20/1422/C/0408/0082(1)
- EMEA/H/A-20/1438(1)
- EMEA/H/A-20/1439/C/3843/0023(1)
- EMEA/H/A-20/1442(1)
- EMEA/H/A-20/1456/C/003862/0010(1)
- EMEA/H/A-20/1459/C/002653/0028(1)
- EMEA/H/A-20/1460/C/2041/0043(1)
- EMEA/H/A-20/1462/C/003862/0018(1)
- EMEA/H/A-20/1479/C/4216/015(1)
- EMEA/H/A-20/1483/C/3718/0028(1)
- EMEA/H/A-20/1485(1)
- EMEA/H/A-20/1489/C/002275/0030(1)
- EMEA/H/A-20/1493/C/0773/0060(1)
- EMEA/H/A-20/1504/C/003691/0023(1)
- EMEA/H/A-20/1518/C/4272/0033(1)
- EMEA/H/A-20/1525/C/4874/0013(1)
- EMEA/H/A-20/1530/C/3687/0065(1)
- EMEA/H/A-20/1531/C/004093/0045(1)
- EMEA/H/A-29 PAD/1022(1)
- EMEA/H/A-29 PAD/1219(1)
- EMEA/H/A-29 PAD/1253(1)
- EMEA/H/A-29 PAD/1254(1)
- EMEA/H/A-29 PAD/1255(1)
- EMEA/H/A-29 PAE/1270(1)
- EMEA/H/A-29(4)/1447(1)
- EMEA/H/A-29(4)/1451(1)
- EMEA/H/A-29(4)/1466(1)
- EMEA/H/A-29(4)/1467(1)
- EMEA/H/A-29(4)/1473(1)
- EMEA/H/A-29(4)/1474(1)
- EMEA/H/A-29(4)/1487(1)
- EMEA/H/A-29(4)/1492(1)
- EMEA/H/A-29(4)/1497(1)
- EMEA/H/A-29(4)/1498(1)
- EMEA/H/A-29(4)/1506(1)
- EMEA/H/A-29(4)/1511(1)
- EMEA/H/A-29(4)/1516(1)
- EMEA/H/A-29(4)/1519(1)
- EMEA/H/A-29(4)/1522(1)
- EMEA/H/A-29(4)/1533(1)
- EMEA/H/A-29(4)/1535(1)
- EMEA/H/A-29-PAE/1378(1)
- EMEA/H/A-29/001248(1)
- EMEA/H/A-29/001268(1)
- EMEA/H/A-29/001272(1)
- EMEA/H/A-29/001273(1)
- EMEA/H/A-29/001276(1)
- EMEA/H/A-29/001277(1)
- EMEA/H/A-29/001326(1)
- EMEA/H/A-29/001327(1)
- EMEA/H/A-29/139(1)
- EMEA/H/A-29/1060(1)
- EMEA/H/A-29/1062(1)
- EMEA/H/A-29/1082(1)
- EMEA/H/A-29/1084(1)
- EMEA/H/A-29/1094(1)
- EMEA/H/A-29/1105(1)
- EMEA/H/A-29/1123(1)
- EMEA/H/A-29/1169(1)
- EMEA/H/A-29/1170(1)
- EMEA/H/A-29/1216(1)
- EMEA/H/A-29/1238(1)
- EMEA/H/A-29/1246(1)
- EMEA/H/A-29/1247(1)
- EMEA/H/A-29/1258(1)
- EMEA/H/A-29/1286(1)
- EMEA/H/A-29/1294(1)
- EMEA/H/A-29/1308(1)
- EMEA/H/A-29/1325(1)
- EMEA/H/A-29/1328(1)
- EMEA/H/A-29/1330(1)
- EMEA/H/A-29/1331(1)
- EMEA/H/A-29/1332(1)
- EMEA/H/A-29/1334(1)
- EMEA/H/A-29/1338(1)
- EMEA/H/A-29/1358(1)
- EMEA/H/A-29/1359(1)
- EMEA/H/A-29/1360(1)
- EMEA/H/A-29/1364(1)
- EMEA/H/A-29/1367(1)
- EMEA/H/A-29/1368(1)
- EMEA/H/A-29/1375(1)
- EMEA/H/A-29/1386(1)
- EMEA/H/A-29/1389 and EMEA/H/A-29/1390(1)
- EMEA/H/A-29/1411(1)
- EMEA/H/A-29/1411 EMEA/H/A-29/1412(1)
- EMEA/H/A-29/1428(1)
- EMEA/H/A-29/1434(1)
- EMEA/H/A-30/001005(1)
- EMEA/H/A-30/001006(1)
- EMEA/H/A-30/001149(1)
- EMEA/H/A-30/001150(1)
- EMEA/H/A-30/001151(1)
- EMEA/H/A-30/001152(1)
- EMEA/H/A-30/001153(1)
- EMEA/H/A-30/001154(1)
- EMEA/H/A-30/001187(1)
- EMEA/H/A-30/001263(1)
- EMEA/H/A-30/001266(1)
- EMEA/H/A-30/001354(1)
- EMEA/H/A-30/001355(1)
- EMEA/H/A-30/1001(1)
- EMEA/H/A-30/1002(1)
- EMEA/H/A-30/1003(1)
- EMEA/H/A-30/1004(1)
- EMEA/H/A-30/1078(1)
- EMEA/H/A-30/1155(1)
- EMEA/H/A-30/1156(1)
- EMEA/H/A-30/1157(1)
- EMEA/H/A-30/1158(1)
- EMEA/H/A-30/1231(1)
- EMEA/H/A-30/1262(1)
- EMEA/H/A-30/1264(1)
- EMEA/H/A-30/1283(1)
- EMEA/H/A-30/1288(1)
- EMEA/H/A-30/1299(1)
- EMEA/H/A-30/1301(1)
- EMEA/H/A-30/1302(1)
- EMEA/H/A-30/1362(1)
- EMEA/H/A-30/1372(1)
- EMEA/H/A-30/1374(1)
- EMEA/H/A-30/1380(1)
- EMEA/H/A-30/1385(1)
- EMEA/H/A-30/1388(1)
- EMEA/H/A-30/1393(1)
- EMEA/H/A-30/1399(1)
- EMEA/H/A-30/1405(1)
- EMEA/H/A-30/1406(1)
- EMEA/H/A-30/1413(1)
- EMEA/H/A-30/1417(1)
- EMEA/H/A-30/1418(1)
- EMEA/H/A-30/1425(1)
- EMEA/H/A-30/1429(1)
- EMEA/H/A-30/1430(1)
- EMEA/H/A-30/1455(1)
- EMEA/H/A-30/1461(1)
- EMEA/H/A-30/1499(1)
- EMEA/H/A-30/1527(1)
- EMEA/H/A-31/001232(1)
- EMEA/H/A-31/001238(1)
- EMEA/H/A-31/001261(1)
- EMEA/H/A-31/001281(1)
- EMEA/H/A-31/001340(1)
- EMEA/H/A-31/1097(1)
- EMEA/H/A-31/1163, EMEA/H/A-6(12)/1147(1)
- EMEA/H/A-31/1186(1)
- EMEA/H/A-31/1267(1)
- EMEA/H/A-31/1275(1)
- EMEA/H/A-31/1290(1)
- EMEA/H/A-31/1291(1)
- EMEA/H/A-31/1292(1)
- EMEA/H/A-31/1305(1)
- EMEA/H/A-31/1306(1)
- EMEA/H/A-31/1311(1)
- EMEA/H/A-31/1314(1)
- EMEA/H/A-31/1318(1)
- EMEA/H/A-31/1321(1)
- EMEA/H/A-31/1322(1)
- EMEA/H/A-31/1325(1)
- EMEA/H/A-31/1333(1)
- EMEA/H/A-31/1335(1)
- EMEA/H/A-31/1336(1)
- EMEA/H/A-31/1339(1)
- EMEA/H/A-31/1342(1)
- EMEA/H/A-31/1344(1)
- EMEA/H/A-31/1346(1)
- EMEA/H/A-31/1347(1)
- EMEA/H/A-31/1348(1)
- EMEA/H/A-31/1349(1)
- EMEA/H/A-31/1356(1)
- EMEA/H/A-31/1365(1)
- EMEA/H/A-31/1366(1)
- EMEA/H/A-31/1370(1)
- EMEA/H/A-31/1377(1)
- EMEA/H/A-31/1379(1)
- EMEA/H/A-31/1382(1)
- EMEA/H/A-31/1383(1)
- EMEA/H/A-31/1387(1)
- EMEA/H/A-31/1391(1)
- EMEA/H/A-31/1394(1)
- EMEA/H/A-31/1396(1)
- EMEA/H/A-31/1397(1)
- EMEA/H/A-31/1398(1)
- EMEA/H/A-31/1400(1)
- EMEA/H/A-31/1401(1)
- EMEA/H/A-31/1408(1)
- EMEA/H/A-31/1415(1)
- EMEA/H/A-31/1420(1)
- EMEA/H/A-31/1432(1)
- EMEA/H/A-31/1435(1)
- EMEA/H/A-31/1436(1)
- EMEA/H/A-31/1437(1)
- EMEA/H/A-31/1440(1)
- EMEA/H/A-31/1441(1)
- EMEA/H/A-31/1443(1)
- EMEA/H/A-31/1444(1)
- EMEA/H/A-31/1445(1)
- EMEA/H/A-31/1446(1)
- EMEA/H/A-31/1448(1)
- EMEA/H/A-31/1449(1)
- EMEA/H/A-31/1450(1)
- EMEA/H/A-31/1452(1)
- EMEA/H/A-31/1454(1)
- EMEA/H/A-31/1458(1)
- EMEA/H/A-31/1463(1)
- EMEA/H/A-31/1464(1)
- EMEA/H/A-31/1465(1)
- EMEA/H/A-31/1469(1)
- EMEA/H/A-31/1471(1)
- EMEA/H/A-31/1476(1)
- EMEA/H/A-31/1481(1)
- EMEA/H/A-31/1482(1)
- EMEA/H/A-31/1484(1)
- EMEA/H/A-31/1486(1)
- EMEA/H/A-31/1488(1)
- EMEA/H/A-31/1491(1)
- EMEA/H/A-31/1494(1)
- EMEA/H/A-31/1495(1)
- EMEA/H/A-31/1496(1)
- EMEA/H/A-31/1501(1)
- EMEA/H/A-31/1509(1)
- EMEA/H/A-31/1510(1)
- EMEA/H/A-31/1514(1)
- EMEA/H/A-31/1515(1)
- EMEA/H/A-31/1520(1)
- EMEA/H/A-31/1526(1)
- EMEA/H/A-31/1529(1)
- EMEA/H/A-31/1532(1)
- EMEA/H/A-36/1295(1)
- EMEA/H/A-36/1296(1)
- EMEA/H/A-36/1297(1)
- EMEA/H/A-36/1298(1)
- EMEA/H/A-36/1323(1)
- EMEA/H/A-107/001259(1)
- EMEA/H/A-107/001260(1)
- EMEA/H/A-107/001278(1)
- EMEA/H/A-107/001287(1)
- EMEA/H/A-107/1293(1)
- EMEA/H/A-107/1316(1)
- EMEA/H/A-107i/1357(1)
- EMEA/H/A-107i/1363(1)
- EMEA/H/A-107i/1373(1)
- EMEA/H/A-107i/1376(1)
- EMEA/H/A-107i/1395(1)
- EMEA/H/A-107i/1457(1)
- EMEA/H/A-107i/1480(1)
- EMEA/H/A-107i/1521(1)
- EMEA/H/A/-29 PAD/1220(1)
- EMEA/H/A20/1371/C/00560-561/0039-0034(1)
- EMEA/H/A20/1404/C/000598/0031 EMEA/H/A20/1404/C/000597/0032(1)
- EMEA/H/A20/1409/C/002522/0004(1)
- EMEA/H/A107i/1352(1)
- EMEA/H/C/275/A20/150, EMEA/H/C/276/A20/143(1)
- EMEA/H/C/889/A20/37, EMEA/H/C/903/A20/38, EMEA/H/C/897/A20/38(1)
- EMEA/H/C/2695/A20/0003(1)
- EMEA/H/C/A-6(12)/001251(1)
- Salmeterol and fluticasone(1)
- CVMP/209536/08(0)
- CVMP/301122/07(0)
- CVMP/344321/08(0)
- CVMP/455918/08(0)
- CVMP/457286/08(0)
- CVMP/458933/08(0)
- CVMP/459391/08(0)
- CVMP/495339/07(0)
- CVMP/532160/07(0)
- CVMP/532206/07(0)
- CVMP/532222/07(0)
- CVMP/532233/07(0)
- CVMP/532267/07(0)
- CVMP/532271/07(0)
- CVMP532090/07(0)
- EMA/186029/2010(0)
- EMA/189829/2010(0)
- EMA/190025/2010(0)
- EMA/193771/2010(0)
- EMA/214243/2009(0)
- EMA/344861/2010(0)
- EMA/345914/2010(0)
- EMA/434219/2010(0)
- EMA/507899/2011(0)
- EMA/512470/2011(0)
- EMA/512798/2011(0)
- EMA/698942/2009(0)
- EMA/839689/2009(0)
- EMA/V/A/061(0)
- EMA/V/A/062(0)
- EMA/V/A/063(0)
- EMA/V/A/131(0)
- EMEA-V-A-121(0)
- EMEA-V-A-122(0)
- EMEA-V-A-136(0)
- EMEA-V-A-140(0)
- EMEA-V-A-142(0)
- EMEA/214378/2009(0)
- EMEA/215198/2009(0)
- EMEA/313849/2009(0)
- EMEA/313852/2009(0)
- EMEA/402698/2008(0)
- EMEA/436209/2008(0)
- EMEA/471056/2009(0)
- EMEA/608931/2009(0)
- EMEA/608943/2009(0)
- EMEA/681319/2008(0)
- EMEA/V/074(0)
- EMEA/V/A-34/82(0)
- EMEA/V/A-73(0)
- EMEA/V/A/001(0)
- EMEA/V/A/002(0)
- EMEA/V/A/003(0)
- EMEA/V/A/004(0)
- EMEA/V/A/008(0)
- EMEA/V/A/009(0)
- EMEA/V/A/010(0)
- EMEA/V/A/012(0)
- EMEA/V/A/014(0)
- EMEA/V/A/023b/001(0)
- EMEA/V/A/051(0)
- EMEA/V/A/055(0)
- EMEA/V/A/067(0)
- EMEA/V/A/068(0)
- EMEA/V/A/069(0)
- EMEA/V/A/070(0)
- EMEA/V/A/071(0)
- EMEA/V/A/072(0)
- EMEA/V/A/076(0)
- EMEA/V/A/077(0)
- EMEA/V/A/078(0)
- EMEA/V/A/079(0)
- EMEA/V/A/080(0)
- EMEA/V/A/081(0)
- EMEA/V/A/083(0)
- EMEA/V/A/084(0)
- EMEA/V/A/085(0)
- EMEA/V/A/086(0)
- EMEA/V/A/087(0)
- EMEA/V/A/088(0)
- EMEA/V/A/089(0)
- EMEA/V/A/090(0)
- EMEA/V/A/091(0)
- EMEA/V/A/093(0)
- EMEA/V/A/094(0)
- EMEA/V/A/095(0)
- EMEA/V/A/096(0)
- EMEA/V/A/097(0)
- EMEA/V/A/098(0)
- EMEA/V/A/099(0)
- EMEA/V/A/20/002(0)
- EMEA/V/A/100(0)
- EMEA/V/A/101(0)
- EMEA/V/A/104(0)
- EMEA/V/A/106(0)
- EMEA/V/A/108(0)
- EMEA/V/A/109(0)
- EMEA/V/A/110(0)
- EMEA/V/A/111(0)
- EMEA/V/A/112(0)
- EMEA/V/A/113(0)
- EMEA/V/A/114(0)
- EMEA/V/A/115(0)
- EMEA/V/A/116(0)
- EMEA/V/A/117(0)
- EMEA/V/A/118(0)
- EMEA/V/A/119(0)
- EMEA/V/A/123(0)
- EMEA/V/A/124(0)
- EMEA/V/A/125(0)
- EMEA/V/A/126(0)
- EMEA/V/A/129(0)
- EMEA/V/A/130(0)
- EMEA/V/A/132(0)
- EMEA/V/A/133(0)
- EMEA/V/A/134(0)
- EMEA/V/A/135(0)
- EMEA/V/A/137(0)
- EMEA/V/A/138(0)
- EMEA/V/A/141(0)
- EMEA/V/A/144(0)
- EMEA/V/A/145(0)
- EMEA/V/A/146(0)
- EMEA/V/A/147(0)
- EMEA/V/A/148(0)
- V-A-042(0)
- Ebymect(3)
- Synjardy(3)
- Xigduo(3)
- Aprovel(2)
- CoAprovel(2)
- Copalia HCT(2)
- Dafiro HCT(2)
- Edistride(2)
- Esmya(2)
- Exforge HCT(2)
- Forxiga(2)
- Ifirmacombi(2)
- Ifirmasta (previously Irbesartan Krka)(2)
- Invokana(2)
- Irbesartan/Hydrochlorothiazide Teva(2)
- Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)(2)
- Irbesartan Teva(2)
- Irbesartan Zentiva (previously Irbesartan Winthrop)(2)
- Jardiance(2)
- Karvea(2)
- Karvezide(2)
- Vokanamet(2)
- Xeljanz(2)
- Zinbryta(2)
- Actelsar HCT(1)
- Adakveo(1)
- Advate(1)
- Aerinaze(1)
- Amlodipine / Valsartan Mylan(1)
- Ammonaps(1)
- Capecitabine Accord(1)
- Capecitabine Medac(1)
- Capecitabine Teva(1)
- Cibinqo(1)
- Colobreathe(1)
- Competact(1)
- Copalia(1)
- Dafiro(1)
- Daklinza(1)
- Ecansya (previously Capecitabine Krka)(1)
- Edarbi(1)
- Efficib(1)
- Elocta(1)
- Entresto(1)
- Eucreas(1)
- Exforge(1)
- Exviera(1)
- Glubrava(1)
- Harvoni(1)
- Helixate NexGen(1)
- Iblias(1)
- Icandra (previously Vildagliptin / metformin hydrochloride Novartis)(1)
- Iclusig(1)
- Inductos(1)
- Ipreziv(1)
- Janumet(1)
- Jentadueto(1)
- Jylamvo(1)
- Jyseleca(1)
- Kinzalkomb(1)
- Kinzalmono (previously Telmisartan Boehringer Ingelheim Pharma KG)(1)
- Kogenate Bayer(1)
- Komboglyze(1)
- Kovaltry(1)
- Lartruvo(1)
- Lemtrada(1)
- Maci(1)
- Micardis(1)
- MicardisPlus(1)
- Mysimba(1)
- Neparvis(1)
- Nordimet(1)
- NovoEight(1)
- Nuwiq(1)
- Obizur(1)
- Ocaliva(1)
- Olumiant(1)
- Olysio(1)
- Onduarp(1)
- Optimark(1)
- Panretin(1)
- Picato(1)
- Pritor(1)
- PritorPlus(1)
- Quinsair(1)
- Rasilamlo(1)
- Rasilez(1)
- Rasilez HCT(1)
- Rasitrio(1)
- ReFacto AF(1)
- Rinvoq(1)
- Ristfor(1)
- Rubraca(1)
- Sabervel(1)
- Sovaldi(1)
- Targretin(1)
- Telmisartan Actavis(1)
- Telmisartan Teva(1)
- Telmisartan Teva Pharma(1)
- Teysuno(1)
- Tolucombi(1)
- Tolura(1)
- Twynsta(1)
- Tysabri(1)
- Ulipristal Acetate Gedeon Richter(1)
- Velmetia(1)
- Viekirax(1)
- Vipdomet(1)
- Voncento(1)
- Xeljanz(1)
- Xeloda(1)
- Xofigo(1)
- Yondelis(1)
- Zoely(1)
- Zydelig(1)
- Zynteglo(1)
- Anemia, Sickle Cell(1)
- Arthritis(1)
- Arthritis, Juvenile Rheumatoid(1)
- Arthritis, Psoriatic(1)
- Arthritis, Rheumatoid(3)
- beta-Thalassemia(1)
- Breast Neoplasms(1)
- Carbamoyl-Phosphate Synthase I Deficiency Disease(1)
- Citrullinemia(1)
- Colonic Neoplasms(1)
- Colorectal Neoplasms(1)
- Contraception(1)
- Cystic Fibrosis(2)
- Dermatitis, Atopic(1)
- Diabetes Mellitus, Type 2(3)
- Essential Hypertension(1)
- Fracture Fixation, Internal(1)
- Fractures, Cartilage(1)
- Heart Failure(3)
- Heart Failure, Systolic(2)
- Hemophilia A(1)
- Hepatitis C, Chronic(1)
- Hypertension(2)
- Keratosis, Actinic(1)
- Leiomyoma(2)
- Leukemia, Lymphocytic, Chronic, B-Cell(1)
- Leukemia, Lymphoid(1)
- Leukemia, Myeloid(1)
- Liver Cirrhosis, Biliary(1)
- Lymphoma, Non-Hodgkin(1)
- Lymphoma, T-Cell, Cutaneous(1)
- Magnetic Resonance Imaging(1)
- Multiple Sclerosis(4)
- Obesity(1)
- Ornithine Carbamoyltransferase Deficiency Disease(1)
- Ovarian Neoplasms(2)
- Overweight(1)
- Precursor Cell Lymphoblastic Leukemia-Lymphoma(1)
- Prostatic Neoplasms(1)
- Psoriasis(1)
- Renal Insufficiency, Chronic(2)
- Respiratory Tract Infections(1)
- Rhinitis, Allergic, Seasonal(1)
- Sarcoma(2)
- Sarcoma, Kaposi(1)
- Spinal Fusion(1)
- Stomach Neoplasms(1)
- Tibial Fractures(1)
- von Willebrand Diseases(1)
- Agenda(0)
- Annex to CHMP highlights(0)
- Annual Report(0)
- Application withdrawal assessment report(0)
- Committee meeting report(0)
- COVID-19 vaccine safety update(0)
- Direct healthcare professional communication(0)
- EPAR - All authorised presentations(0)
- EPAR - Amended Product Information(0)
- EPAR - Assessment report - Variation(0)
- EPAR - Assessment report on maintenance of orphan designation - Initial authorisation(0)
- EPAR - Assessment report on maintenance of orphan designation - Post-authorisation(0)
- EPAR - Conditions imposed on member states for safe and effective use(0)
- EPAR - Overview(0)
- EPAR - Paediatric investigation plan compliance statement(0)
- EPAR - Procedural steps taken and scientific information after authorisation(0)
- EPAR - Procedural steps taken before authorisation(0)
- EPAR - Product Information(0)
- EPAR - Public assessment report(0)
- EPAR - Risk-management-plan summary(0)
- EPAR - Scientific conclusion(0)
- EPAR - Scientific Discussion(0)
- EPAR - Scientific Discussion - Variation(0)
- EPAR - Steps taken after authorisation when a cutoff date has been used(0)
- Herbal - Call for data(0)
- Herbal - Herbal monograph(0)
- Herbal - HMPC assessment report(0)
- Herbal - HMPC opinion on a European Union herbal monograph(0)
- Herbal - List of references supporting the assessment report(0)
- Herbal - Overview of comments received during consultation(0)
- Herbal - Summary of assessment report for the public(0)
- Herbal – European Union herbal monograph(0)
- Herbal – European Union list entry(0)
- Leaflet(0)
- Maximum Residue Limits - Divergent opinion(0)
- Maximum Residue Limits - Opinion(0)
- Maximum Residue Limits - Report(0)
- Maximum Residue Limits - Summary of opinion(0)
- Medicine QA(0)
- Medicines under additional monitoring(0)
- Minutes(0)
- Newsletter(0)
- Opinion outside EU - All presentations(0)
- Opinion outside EU - Assessment report - Variation(0)
- Opinion outside EU - Medicine questions and answers(0)
- Opinion outside EU - Procedural steps taken and scientific information after opinion(0)
- Opinion outside EU - Procedural steps taken before opinion(0)
- Opinion outside EU - Product information(0)
- Opinion outside EU - Public assessment report(0)
- Opinion outside EU - Risk-management-plan summary(0)
- Opinion outside EU - Scientific discussion(0)
- Opinion outside EU - Summary for the public(0)
- Opinion outside EU - Summary of opinion(0)
- Opinion outside EU - Summary of opinion - Initial authorisation(0)
- Opinion outside EU - Withdrawal assessment report(0)
- Orphan designation(0)
- Orphan review(0)
- Other(0)
- Overview of comments(0)
- Parallel distribution(0)
- Periodic safety update single assessment(0)
- PIP - Notification of discontinuation of a paediatric development which is covered by an agreed PIP decision(0)
- PIP - Paediatric-investigation-plan summary(0)
- PIP decision(0)
- Position statement(0)
- PRAC recommendation on signal(0)
- Presentation(0)
- Press Release(0)
- Procurement(0)
- Public Statement(0)
- Recommendation on medication errors(0)
- Recruitment(0)
- Referrals document(0)
- Regulatory and procedural guideline(0)
- Report(0)
- Scientific guideline(0)
- Standard Operating Procedure - SOP(0)
- Summary of opinion(0)
- Summary of opinion - Initial authorisation(0)
- Supply shortage(0)
- Template or form(0)
- Withdrawal letter(0)
- Work Instruction - WIN(0)
- Work programme(0)
- Advanced therapies(1)
- Antimicrobial resistance(1)
- Biologicals(1)
- Biosimilars(0)
- Brexit(0)
- Careers(0)
- Clinical trials(0)
- Compassionate use(0)
- Compliance and inspections(12)
- Corporate(0)
- COVID-19(0)
- Data on medicines(0)
- Early access(0)
- Fees(0)
- Generic and hybrid medicines(4)
- Governance(0)
- Innovation(0)
- Maximum residue limit(0)
- Medication error(0)
- Medicines(397)
- Medicines for use outside the EU(0)
- Medicine shortages(0)
- Mpox(0)
- Paediatrics(36)
- Parallel distribution(0)
- Pharmacovigilance(133)
- Procurement(0)
- Product information(0)
- Quality of medicines(2)
- Rare diseases(0)
- Referrals(127)
- Regulatory and procedural guidance(0)
- Research and development(1)
- Scientific advice(0)
- Scientific guidelines(0)
- SME(0)
- Vaccines(1)
- Veterinary limited markets(0)
Search results (448)
pseudoephedrine
Article 31 referrals
Status:
European Commission final decision
Opinion/position date:
EC decision date:
Last updated:
ReferralHuman
naltrexone
bupropion
Article 20 procedures
Status:
Under evaluation
Last updated:
ReferralHuman
porcine pancreas enzymes
Article 29(4) referrals
Status:
CHMP opinion
Opinion/position date:
Last updated:
ReferralHuman
Article 31 referrals
Status:
CHMP opinion
Opinion/position date:
Last updated:
ReferralHuman
hepatitis A virus (inactivated, adsorbed)
Article 30 referrals
Associated names:
Havrix and associated names
Status:
Under evaluation
Last updated:
ReferralHuman
obeticholic acid
Article 20 procedures
Status:
Under evaluation
Last updated:
ReferralHuman
ibuprofen
Article 29(4) referrals
Status:
Procedure started
Opinion/position date:
Last updated:
ReferralHuman
hydroxyprogesterone
Article 31 referrals
Associated names:
Lentogest
Progesterone Retard Pharlon
Proluton Depot
Status:
Under evaluation
Last updated:
ReferralHuman
topiramate
Article 31 referrals
Status:
CMDh final position
Opinion/position date:
Last updated:
ReferralHuman
azithromycin
Article 31 referrals
Status:
Under evaluation
Last updated:
ReferralHuman